<SEC-DOCUMENT>0000719135-22-000091.txt : 20221110
<SEC-HEADER>0000719135-22-000091.hdr.sgml : 20221110
<ACCEPTANCE-DATETIME>20221110152021
ACCESSION NUMBER:		0000719135-22-000091
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		65
CONFORMED PERIOD OF REPORT:	20220930
FILED AS OF DATE:		20221110
DATE AS OF CHANGE:		20221110

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Apyx Medical Corp
		CENTRAL INDEX KEY:			0000719135
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				112644611
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-31885
		FILM NUMBER:		221376675

	BUSINESS ADDRESS:	
		STREET 1:		5115 ULMERTON ROAD
		CITY:			CLEARWATER
		STATE:			FL
		ZIP:			33760
		BUSINESS PHONE:		7273842323

	MAIL ADDRESS:	
		STREET 1:		5115 ULMERTON ROAD
		CITY:			CLEARWATER
		STATE:			FL
		ZIP:			33760

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BOVIE MEDICAL Corp
		DATE OF NAME CHANGE:	20150319

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BOVIE MEDICAL CORP
		DATE OF NAME CHANGE:	19990216

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AN CON GENETICS INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>apyx-20220930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:90964edb-9ed2-4911-9f65-50e8b3fbc396,g:6dc5a8ef-7d14-451f-bd94-08d276b52e31,d:e9788c72f4874edca78c1c4f307fec05--><html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:srt="http://fasb.org/srt/2022" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:apyx="http://apyxmedical.com/20220930" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>apyx-20220930</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80L2ZyYWc6NmIzMjRlNjZkZjZmNGNjMjk2N2ZkYmViZDM5ZjhlYTYvdGFibGU6ZjNjNzgwMjhiMzJkNGFlYWI3NmI2ZGY5YjMzYTVmMTMvdGFibGVyYW5nZTpmM2M3ODAyOGIzMmQ0YWVhYjc2YjZkZjliMzNhNWYxM18xLTEtMS0xLTE3NDEw_40339711-f057-4def-856e-ee826e87bcec">0000719135</ix:nonNumeric><ix:nonNumeric contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80L2ZyYWc6NmIzMjRlNjZkZjZmNGNjMjk2N2ZkYmViZDM5ZjhlYTYvdGFibGU6ZjNjNzgwMjhiMzJkNGFlYWI3NmI2ZGY5YjMzYTVmMTMvdGFibGVyYW5nZTpmM2M3ODAyOGIzMmQ0YWVhYjc2YjZkZjliMzNhNWYxM18yLTEtMS0xLTE3NDEw_78649979-5c95-4d59-8723-7aebc0d8d4a4">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80L2ZyYWc6NmIzMjRlNjZkZjZmNGNjMjk2N2ZkYmViZDM5ZjhlYTYvdGFibGU6ZjNjNzgwMjhiMzJkNGFlYWI3NmI2ZGY5YjMzYTVmMTMvdGFibGVyYW5nZTpmM2M3ODAyOGIzMmQ0YWVhYjc2YjZkZjliMzNhNWYxM18zLTEtMS0xLTE3NDEw_8a4ff273-3aa3-49c6-b9f0-372cec333a40">December 31</ix:nonNumeric><ix:nonNumeric contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80L2ZyYWc6NmIzMjRlNjZkZjZmNGNjMjk2N2ZkYmViZDM5ZjhlYTYvdGFibGU6ZjNjNzgwMjhiMzJkNGFlYWI3NmI2ZGY5YjMzYTVmMTMvdGFibGVyYW5nZTpmM2M3ODAyOGIzMmQ0YWVhYjc2YjZkZjliMzNhNWYxM180LTEtMS0xLTE3NDEw_b6b0fee9-cba9-4f45-a437-6bb604496eaf">Q3</ix:nonNumeric><ix:nonNumeric contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80L2ZyYWc6NmIzMjRlNjZkZjZmNGNjMjk2N2ZkYmViZDM5ZjhlYTYvdGFibGU6ZjNjNzgwMjhiMzJkNGFlYWI3NmI2ZGY5YjMzYTVmMTMvdGFibGVyYW5nZTpmM2M3ODAyOGIzMmQ0YWVhYjc2YjZkZjliMzNhNWYxM181LTEtMS0xLTE3NDEw_d59df853-57ad-4d50-b8c2-13519d12ece3">2022</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="apyx-20220930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id27600d5964346308b9afb6a5de31f45_I20221109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-11-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="ic42af16cc8974cebbc452370076f22e5_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i6366ccfc5be94d939469c44eee70e010_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="id6ada2596cf84b118b49af7a6561fb79_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9b0b6a3c69447bf8f151dfd98c14ac9_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0915370fdc66433087f61be1a6429895_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6bd5470a522440896a96cb114d94bc9_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1602e279f8a54d59a4619d5751091e77_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70c60e5ef978483d94930f1744a9d3af_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i138bdba832374d1f808c394db84be422_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iecb0fed55763430baf6093ea22f40d87_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica2773a2e5304f8480d1f69944277492_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i102d87338ba6454f85cc738690cc4358_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ad330e6cdd442be8bf971667788ba23_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6078f16f5134a2e9e175491969aa315_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d63a53f125c4acd96a77b7410be5951_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6459bdf630814b27874dad87632c646a_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia98a748ab05948eda52b8c8873f240ed_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i524cd9c9acd4440f8d2e862dbb84f261_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b3b8a89480b4a8680824601cb0552b9_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i02b00de331904fcebd2e5c7c0add0881_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d3946eaa70742e3a1d7332eacba51a6_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9d5039cab3a4fa5a3b9b29f5d4f1ce0_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic1a290f8b3eb4985ac22e7ccb81b66e5_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2682ba64e91149fb8218158d95782bd3_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1211ee2c038f40b8b5feff5fd9d6fe4c_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87921e2d34bd4d828c5d4930daeb8fc8_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b2ac4e7bb8a4fab90de0f2a2f18a839_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3a4f0fb7c0d44a8a286050fe422e630_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96687d732f8d4567ad6f8406cd1293e3_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id08f3d38045d4418a182b5f9988d3e34_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i229d9ac95648412aa95ce5178946ae89_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac6178b585a24bdd9c611d8f43b21488_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4281c98f6d154bc0bbdaa5ef88536da4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41802e9d47eb481aabfdd816c5c9fa7b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62a88fb8485b4d7fb2c08fb2266ed449_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e93d5bb9951458aa70810e8b5e84de2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19cfd321237247ab9bd9651da54e7476_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f055e88f44443e39bd36692989fa841_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6310af3213b546f996d5b2f97fb70bfd_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66bc1f8757d7488a99f1a6c5eb9a7e4c_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10702330b75541919ad22c7f751db016_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f0faf73be0941df9ec5505291b94bde_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec03140df24341ec90f156ca4aeabce3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d002bf5ac274c73b635110b5036d873_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia7123184de4141839ab376b29683134c_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic739a97c17164277aa8cc3fa9ffb8bf3_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2fc708898034815a0206b71148a8cb0_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95ac060f75d24601ad4fd05a8f4e64e7_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a26c2238772410b9c632db89dc2f95f_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10095f0cb8c949fbb4f3d9e2b6c90b20_D20180830-20180830"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-08-30</xbrli:startDate><xbrli:endDate>2018-08-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c47d3c9d755423bac06c8de9bc6733a_D20180830-20180830"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apyx:SymmetrySurgicalInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">apyx:ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-08-30</xbrli:startDate><xbrli:endDate>2018-08-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4df01ef2deb2470eab833fab1b386632_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apyx:SymmetrySurgicalInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">apyx:ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i715d6d3cb64a4d328a61c8e29b09eeb1_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apyx:SymmetrySurgicalInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">apyx:ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10540b8b8766421e91ac2cc3944b3109_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apyx:SymmetrySurgicalInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">apyx:ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="iee62c576cfc14937a01701621d37dc74_I20220430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9be5f375baba4295ace9fc48f09fe8dc_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">apyx:ChineseSupplierMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84408c5278f544ccb03b5314b28177f5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d492a2b0cb940b3a3efba0a8c74f3b2_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifefbd2b1828e478481b4e147440bb47b_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i614389ddffc7468ba138bf2516c6c05f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i971483142d77406c8234c4a4370fd3f7_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ca81802bedf4dd7b618a8b1cd8ffd83_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iacbe89d9dab74e6990b6f064b9754ea4_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61baec36978a4160b66435f0f2416149_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic03ac90c24194c2181a21dd8933c788e_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia7bdc42847614ed88ba35dd3d0f7643c_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia08951cf06e540858ba8bf177ab2b743_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42b97828049d4ebdaf08135fff616832_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5e3c2254a1e4a9db8e760889439789b_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87a2f188443846f38dac55f8e2d32c45_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee9cabca77f2439a98f1d745e8aa8fbf_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i569c520a81a0408e8dcae24590fd7f45_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb875bc28ba541afbdc97bd369d0b276_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">apyx:ContractWithInternationalDistributorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e86764ca7f24ce6a39afdcc54d3ea31_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">apyx:ContractWithInternationalDistributorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1887856679e9469f916771312e57a2e9_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">apyx:ContractWithInternationalDistributorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc81989264bf4729990e5332a7d926ff_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">apyx:SuitAgainstGoodwinAndSimbMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i47884c866bfd4b0bb5978e741a32ff7a_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">apyx:SuitAgainstGoodwinAndSimbMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d8aee9372fb4f169e0a8eb66390bb67_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">apyx:SuitAgainstGoodwinAndSimbMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if06767f062cc44ada17fa9800b45b707_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:CoVenturerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if24822e015bf406fa7a58fe352a3de87_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:CoVenturerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1cce60115e9e4b31be367f868dcccb14_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:CoVenturerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10d9cc88ef7f4a2cb54fd0ce01238148_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:CoVenturerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if76fe4dedddf40aca527d7e4b7a2654c_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:CoVenturerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8f8d460633b499797d344045f093397_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:CoVenturerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>apyx:segment</xbrli:measure></xbrli:unit><xbrli:context id="ib86c17a29ad64fff8b4f5645ccc11575_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">apyx:AdvancedEnergyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaaa11755febd4f87a4971e2cdb19bccd_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">apyx:OEMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12ee9d61be8f4dc6a652027fc6bd93b9_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14808dab5a9a44dda4de75eaaebf7f2c_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">apyx:AdvancedEnergyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35bc95fa11524622b8a7f5abe7f7a8d0_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">apyx:OEMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id24ea483328641d39abd6bbf5097a73b_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic79a2007f9024641a9822f1b84d5f8cd_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">apyx:AdvancedEnergyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i859943e8321b4443a613d8938534494e_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">apyx:OEMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i042c28c1eeda4c15bb204324175550d5_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab38511a317c44aa9f0dc79521e2a6d5_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">apyx:AdvancedEnergyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7bfacb65a9e6459ea08bf4947d3b9c2b_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">apyx:OEMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6944c3767530469d9f26618cb4e807e6_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c92311eeeba414cba8eeea9eae36a73_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1cbcf0bb6950436780b8711457cab3c0_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36f2a37affac45d0a14e5ea2173cf5e1_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4cf11e8a8ad24223ab309b02dcedcecb_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd22960d67cd4d7fadc9314e44177757_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6227c7fe3e8c479d92f2f099128bd674_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d94b2111aef41dfb83851bf1579dc6e_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idbb33a02347e4099b5d0a31dcb304fdb_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ie9788c72f4874edca78c1c4f307fec05_1"></div><div style="min-height:31.5pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.282%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.283%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:22pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:22pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:22pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xL2ZyYWc6MzZiOWVmNTdlMzc0NDI0NDhlZTU0ODZhZTEwYzdkMDAvdGV4dHJlZ2lvbjozNmI5ZWY1N2UzNzQ0MjQ0OGVlNTQ4NmFlMTBjN2QwMF8xNTM1_6153605e-f607-4cd3-85c2-894558f2ed1e">10-Q</ix:nonNumeric> </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:1.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.805%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.806%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xL2ZyYWc6MzZiOWVmNTdlMzc0NDI0NDhlZTU0ODZhZTEwYzdkMDAvdGFibGU6Y2I2YjY3ZmVmYmE4NGJkMzg5ZWJlNjZmZmYxM2Q5YzcvdGFibGVyYW5nZTpjYjZiNjdmZWZiYTg0YmQzODllYmU2NmZmZjEzZDljN18wLTItMS0xLTE3NDEw_cead7bb7-bcf9-476c-adea-12382c74b36c">&#9746;</ix:nonNumeric></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">For the quarterly period ended</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xL2ZyYWc6MzZiOWVmNTdlMzc0NDI0NDhlZTU0ODZhZTEwYzdkMDAvdGFibGU6Y2I2YjY3ZmVmYmE4NGJkMzg5ZWJlNjZmZmYxM2Q5YzcvdGFibGVyYW5nZTpjYjZiNjdmZWZiYTg0YmQzODllYmU2NmZmZjEzZDljN18xLTQtMS0xLTE3NDEw_0266a46a-2d9a-483b-9dac-1bae6773ba1d">September 30, 2022</ix:nonNumeric></span></td></tr><tr style="height:3pt"><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">or</span></td></tr><tr style="height:3pt"><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xL2ZyYWc6MzZiOWVmNTdlMzc0NDI0NDhlZTU0ODZhZTEwYzdkMDAvdGFibGU6Y2I2YjY3ZmVmYmE4NGJkMzg5ZWJlNjZmZmYxM2Q5YzcvdGFibGVyYW5nZTpjYjZiNjdmZWZiYTg0YmQzODllYmU2NmZmZjEzZDljN181LTItMS0xLTE3NDEw_de1f9b69-215e-4b31-9cc6-c408a9229574">&#9744;</ix:nonNumeric></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">For the transition period from _____ to _____</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Commission File Number: </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xL2ZyYWc6MzZiOWVmNTdlMzc0NDI0NDhlZTU0ODZhZTEwYzdkMDAvdGFibGU6Y2I2YjY3ZmVmYmE4NGJkMzg5ZWJlNjZmZmYxM2Q5YzcvdGFibGVyYW5nZTpjYjZiNjdmZWZiYTg0YmQzODllYmU2NmZmZjEzZDljN183LTQtMS0xLTE3NDEw_3624ad49-34a6-473e-a5d5-237fc912bd96">0-12183</ix:nonNumeric></span></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:114pt"><td colspan="3" style="padding:0 1pt"><div style="text-align:center"><img src="apyx-20220930_g1.jpg" alt="apyx-20220930_g1.jpg" style="height:145px;margin-bottom:5pt;vertical-align:text-bottom;width:223px"/></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xL2ZyYWc6MzZiOWVmNTdlMzc0NDI0NDhlZTU0ODZhZTEwYzdkMDAvdGFibGU6MjU5NTFiMWVhMGRhNGMwMTlhNjBiYmEzZjJjNGU1YjAvdGFibGVyYW5nZToyNTk1MWIxZWEwZGE0YzAxOWE2MGJiYTNmMmM0ZTViMF8xLTAtMS0xLTE3NDEw_e2bf45ee-3e8e-46a4-b454-df5f8d64ba96">APYX MEDICAL CORPORATION</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Exact name of registrant as specified in its charter)</span></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.987%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.724%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.989%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xL2ZyYWc6MzZiOWVmNTdlMzc0NDI0NDhlZTU0ODZhZTEwYzdkMDAvdGFibGU6NGQ2ODBjMzk5ZTg1NGUyOGJhNWMxMGI5OTY5NTBjYjIvdGFibGVyYW5nZTo0ZDY4MGMzOTllODU0ZTI4YmE1YzEwYjk5Njk1MGNiMl8wLTAtMS0xLTE3NDEw_455d69a4-cb55-46d3-ae12-62280262b4eb">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xL2ZyYWc6MzZiOWVmNTdlMzc0NDI0NDhlZTU0ODZhZTEwYzdkMDAvdGFibGU6NGQ2ODBjMzk5ZTg1NGUyOGJhNWMxMGI5OTY5NTBjYjIvdGFibGVyYW5nZTo0ZDY4MGMzOTllODU0ZTI4YmE1YzEwYjk5Njk1MGNiMl8wLTItMS0xLTE3NDEw_c437b952-aaa1-40e0-b6e7-0bb54c008719">11-2644611</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xL2ZyYWc6MzZiOWVmNTdlMzc0NDI0NDhlZTU0ODZhZTEwYzdkMDAvdGV4dHJlZ2lvbjozNmI5ZWY1N2UzNzQ0MjQ0OGVlNTQ4NmFlMTBjN2QwMF8xNTM4_f9ecd1da-35ef-42b8-9be9-eee7075eb1de">5115 Ulmerton Road,</ix:nonNumeric> <ix:nonNumeric contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xL2ZyYWc6MzZiOWVmNTdlMzc0NDI0NDhlZTU0ODZhZTEwYzdkMDAvdGV4dHJlZ2lvbjozNmI5ZWY1N2UzNzQ0MjQ0OGVlNTQ4NmFlMTBjN2QwMF8xNTM5_400378f4-ccdb-4400-be35-ae67ff86d69b">Clearwater</ix:nonNumeric>, <ix:nonNumeric contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xL2ZyYWc6MzZiOWVmNTdlMzc0NDI0NDhlZTU0ODZhZTEwYzdkMDAvdGV4dHJlZ2lvbjozNmI5ZWY1N2UzNzQ0MjQ0OGVlNTQ4NmFlMTBjN2QwMF8xNTQw_b74882fe-819b-48b4-8038-27182358df3a">FL</ix:nonNumeric> <ix:nonNumeric contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xL2ZyYWc6MzZiOWVmNTdlMzc0NDI0NDhlZTU0ODZhZTEwYzdkMDAvdGV4dHJlZ2lvbjozNmI5ZWY1N2UzNzQ0MjQ0OGVlNTQ4NmFlMTBjN2QwMF8xNTQx_a9c2a3da-19e6-4259-b3c0-68c956f422db">33760</ix:nonNumeric> </span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Address of principal executive offices, zip code)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xL2ZyYWc6MzZiOWVmNTdlMzc0NDI0NDhlZTU0ODZhZTEwYzdkMDAvdGV4dHJlZ2lvbjozNmI5ZWY1N2UzNzQ0MjQ0OGVlNTQ4NmFlMTBjN2QwMF8xNTM2_7de06702-8366-4927-adb5-7f7c86c44c3e">727</ix:nonNumeric>) <ix:nonNumeric contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xL2ZyYWc6MzZiOWVmNTdlMzc0NDI0NDhlZTU0ODZhZTEwYzdkMDAvdGV4dHJlZ2lvbjozNmI5ZWY1N2UzNzQ0MjQ0OGVlNTQ4NmFlMTBjN2QwMF8xNTM3_403a339c-8293-4c46-86bb-5f1f87c2f568">384-2323</ix:nonNumeric> </span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number)</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Securities Registered Pursuant to Section 12 (b) of the Act:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:34.478%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.254%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.968%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xL2ZyYWc6MzZiOWVmNTdlMzc0NDI0NDhlZTU0ODZhZTEwYzdkMDAvdGFibGU6N2MwZGIxOTIxN2JiNDE2MGIwYjcyNjlkYThiOTkyOTgvdGFibGVyYW5nZTo3YzBkYjE5MjE3YmI0MTYwYjBiNzI2OWRhOGI5OTI5OF8xLTAtMS0xLTE3NDEw_26308608-e3e8-490f-8daf-70ebb85e7019">Common Stock</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xL2ZyYWc6MzZiOWVmNTdlMzc0NDI0NDhlZTU0ODZhZTEwYzdkMDAvdGFibGU6N2MwZGIxOTIxN2JiNDE2MGIwYjcyNjlkYThiOTkyOTgvdGFibGVyYW5nZTo3YzBkYjE5MjE3YmI0MTYwYjBiNzI2OWRhOGI5OTI5OF8xLTEtMS0xLTE3NDEw_f7c5d4e6-0e5e-4116-a8d1-5608be04ca76">APYX</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xL2ZyYWc6MzZiOWVmNTdlMzc0NDI0NDhlZTU0ODZhZTEwYzdkMDAvdGFibGU6N2MwZGIxOTIxN2JiNDE2MGIwYjcyNjlkYThiOTkyOTgvdGFibGVyYW5nZTo3YzBkYjE5MjE3YmI0MTYwYjBiNzI2OWRhOGI5OTI5OF8xLTItMS0xLTE3NDEw_8563be23-aaa9-47bc-a8ac-d94d2740aceb">Nasdaq Stock Market, LLC</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:6pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xL2ZyYWc6MzZiOWVmNTdlMzc0NDI0NDhlZTU0ODZhZTEwYzdkMDAvdGV4dHJlZ2lvbjozNmI5ZWY1N2UzNzQ0MjQ0OGVlNTQ4NmFlMTBjN2QwMF8xNTQy_bbeaeeed-647f-486f-a41d-cbabf6337f94">Yes</ix:nonNumeric>: </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xL2ZyYWc6MzZiOWVmNTdlMzc0NDI0NDhlZTU0ODZhZTEwYzdkMDAvdGV4dHJlZ2lvbjozNmI5ZWY1N2UzNzQ0MjQ0OGVlNTQ4NmFlMTBjN2QwMF8xNTQz_b9d168f5-48d1-430d-84bd-8c1dbf59ec48">Yes</ix:nonNumeric>: </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer&#8221;, &#8220;accelerated filer&#8221;, &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.560%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.584%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.707%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.726%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#9744;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#9744;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xL2ZyYWc6MzZiOWVmNTdlMzc0NDI0NDhlZTU0ODZhZTEwYzdkMDAvdGFibGU6ZGJiMTZjMTgzZmVjNDBkZGI4NWI5YTI5ZGZkNmI4ODcvdGFibGVyYW5nZTpkYmIxNmMxODNmZWM0MGRkYjg1YjlhMjlkZmQ2Yjg4N18xLTAtMS0xLTE3NDEw_7d363f0c-46e0-4080-ad3c-8898edaae595">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xL2ZyYWc6MzZiOWVmNTdlMzc0NDI0NDhlZTU0ODZhZTEwYzdkMDAvdGFibGU6ZGJiMTZjMTgzZmVjNDBkZGI4NWI5YTI5ZGZkNmI4ODcvdGFibGVyYW5nZTpkYmIxNmMxODNmZWM0MGRkYjg1YjlhMjlkZmQ2Yjg4N18xLTQtMS0xLTE3NDEw_d8f29d2d-70f0-4d8b-8787-ce05436677ee">&#9746;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xL2ZyYWc6MzZiOWVmNTdlMzc0NDI0NDhlZTU0ODZhZTEwYzdkMDAvdGFibGU6ZGJiMTZjMTgzZmVjNDBkZGI4NWI5YTI5ZGZkNmI4ODcvdGFibGVyYW5nZTpkYmIxNmMxODNmZWM0MGRkYjg1YjlhMjlkZmQ2Yjg4N18yLTQtMS0xLTE3NDEw_a2f3d99f-9aee-400c-aef1-d735c039a940">&#9744;</ix:nonNumeric></span></div></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#9744;</span></div></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes: </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xL2ZyYWc6MzZiOWVmNTdlMzc0NDI0NDhlZTU0ODZhZTEwYzdkMDAvdGV4dHJlZ2lvbjozNmI5ZWY1N2UzNzQ0MjQ0OGVlNTQ4NmFlMTBjN2QwMF8xNTQ0_98a8e928-b06c-4a80-865d-dc375112588d">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-bottom:6pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">A</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">s of November&#160;9, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">, <ix:nonFraction unitRef="shares" contextRef="id27600d5964346308b9afb6a5de31f45_I20221109" decimals="0" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xL2ZyYWc6MzZiOWVmNTdlMzc0NDI0NDhlZTU0ODZhZTEwYzdkMDAvdGV4dHJlZ2lvbjozNmI5ZWY1N2UzNzQ0MjQ0OGVlNTQ4NmFlMTBjN2QwMF8xNDU3_b680c738-5ed3-4ab3-9b5d-706aeab5f52a">34,597,822</ix:nonFraction> s</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">hares </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">of the registrant&#8217;s $0.001 par value common stock were outstanding.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.282%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.283%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:13.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ie9788c72f4874edca78c1c4f307fec05_7"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie9788c72f4874edca78c1c4f307fec05_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO QUARTERLY REPORT ON FORM 10-Q</span></div></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended September 30, 2022</span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.775%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part I.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#ie9788c72f4874edca78c1c4f307fec05_10">Financial Information</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#ie9788c72f4874edca78c1c4f307fec05_10">2</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Condensed Consolidated <a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie9788c72f4874edca78c1c4f307fec05_13">Financial Statements</a> (Unaudited)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie9788c72f4874edca78c1c4f307fec05_13">2</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Condensed <a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie9788c72f4874edca78c1c4f307fec05_16">Consolidated Balance Sheets at </a>September&#160;30, 2022 and December&#160;31, 2021</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie9788c72f4874edca78c1c4f307fec05_16">2</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Condensed <a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie9788c72f4874edca78c1c4f307fec05_19">Consolidated Statements of Operations for the three </a>and nine months ended September 30, 2022 and 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie9788c72f4874edca78c1c4f307fec05_19">3</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Condensed <a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie9788c72f4874edca78c1c4f307fec05_22">Consolidated Statements of Changes in Equity for the </a>three and nine months ended September 30, 2022 and 2021</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie9788c72f4874edca78c1c4f307fec05_22">4</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2022 and 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie9788c72f4874edca78c1c4f307fec05_25">5</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie9788c72f4874edca78c1c4f307fec05_28">Notes to Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie9788c72f4874edca78c1c4f307fec05_28">6</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie9788c72f4874edca78c1c4f307fec05_70">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie9788c72f4874edca78c1c4f307fec05_70">20</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie9788c72f4874edca78c1c4f307fec05_79">Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie9788c72f4874edca78c1c4f307fec05_79">28</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie9788c72f4874edca78c1c4f307fec05_82">Controls and Procedures</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie9788c72f4874edca78c1c4f307fec05_82">29</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part II.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#ie9788c72f4874edca78c1c4f307fec05_85">Other Information</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie9788c72f4874edca78c1c4f307fec05_85">30</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie9788c72f4874edca78c1c4f307fec05_88">Legal Proceedings</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie9788c72f4874edca78c1c4f307fec05_88">30</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie9788c72f4874edca78c1c4f307fec05_91">Risk Factors</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie9788c72f4874edca78c1c4f307fec05_91">31</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie9788c72f4874edca78c1c4f307fec05_97">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie9788c72f4874edca78c1c4f307fec05_97">32</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie9788c72f4874edca78c1c4f307fec05_100">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie9788c72f4874edca78c1c4f307fec05_100">32</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie9788c72f4874edca78c1c4f307fec05_103">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie9788c72f4874edca78c1c4f307fec05_103">32</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 5.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie9788c72f4874edca78c1c4f307fec05_106">Other Information</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie9788c72f4874edca78c1c4f307fec05_106">32</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 6.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie9788c72f4874edca78c1c4f307fec05_109">Exhibits</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie9788c72f4874edca78c1c4f307fec05_109">33</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie9788c72f4874edca78c1c4f307fec05_112">Signatures</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie9788c72f4874edca78c1c4f307fec05_112">34</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="ie9788c72f4874edca78c1c4f307fec05_10"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie9788c72f4874edca78c1c4f307fec05_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I. &#160;&#160;&#160;&#160;Financial Information</span></div><div><span><br/></span></div><div id="ie9788c72f4874edca78c1c4f307fec05_13"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. Condensed Consolidated Financial Statements</span></div><div><span><br/></span></div><div id="ie9788c72f4874edca78c1c4f307fec05_16"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(In thousands, except share and per share data)</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:70.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.516%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.517%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September&#160;30, 2022</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Unaudited)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMy0xLTEtMS0xNzQxMA_1c85159b-ac31-4a76-bfe4-b8c05b87f3f9">14,833</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMy0zLTEtMS0xNzQxMA_166564e4-3c5a-4d2e-8f1b-e9f8c75ca101">30,870</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Trade accounts receivable, net of allowance of $<ix:nonFraction unitRef="usd" contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfNC0wLTEtMS0xNzQxMC90ZXh0cmVnaW9uOjIyNzdiYTA2MmQ4MjRhZTRiNTgwODQxNGMyZGNlZjI1XzU0_2ef072d4-cddc-43d5-9977-a4a64a8d2267">634</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfNC0wLTEtMS0xNzQxMC90ZXh0cmVnaW9uOjIyNzdiYTA2MmQ4MjRhZTRiNTgwODQxNGMyZGNlZjI1XzYx_b7848692-02e2-49e6-bde2-fc0fee519cdf">430</ix:nonFraction></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfNC0xLTEtMS0xNzQxMA_f79cfd6e-9786-4261-86e8-6bd51e6e068f">9,094</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfNC0zLTEtMS0xNzQxMA_53ddd200-c236-459c-bdb2-304e1637024e">13,038</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930" decimals="-3" name="us-gaap:IncomeTaxesReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfNS0xLTEtMS0xNzQxMA_86f39a34-b3c2-44b2-97a3-6e4364345d3f">7,545</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231" decimals="-3" name="us-gaap:IncomeTaxesReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfNS0zLTEtMS0xNzQxMA_850cb3ba-e01b-4ec4-b616-56e24493a376">7,642</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfNi0xLTEtMS0xNzQxMA_a93ea1c1-1f8f-4d4a-9501-3a36625be742">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfNi0zLTEtMS0xNzQxMA_e6887cc7-0c31-42d5-aaf6-e9ecb42f4ec4">483</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories, net of provision for obsolescence of $<ix:nonFraction unitRef="usd" contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930" decimals="-3" name="apyx:ProvisionForObsolescenceInventory" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfNy0wLTEtMS0xNzQxMC90ZXh0cmVnaW9uOjYxNDNmZjdiZjhhZjQ4NmY5NjFiYWQ0YTE5Zjk5MjYzXzU0_ba570541-9fc1-4c6d-84c4-a390e3efe064">379</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231" decimals="-3" name="apyx:ProvisionForObsolescenceInventory" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfNy0wLTEtMS0xNzQxMC90ZXh0cmVnaW9uOjYxNDNmZjdiZjhhZjQ4NmY5NjFiYWQ0YTE5Zjk5MjYzXzYx_d3383b79-fffc-42f9-9d54-2a0b006249c0">263</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfNy0xLTEtMS0xNzQxMA_2fc8ad41-9fc4-4db8-a37a-4b0db8f7990b">12,042</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfNy0zLTEtMS0xNzQxMA_9ead2ffe-802d-4699-944d-35e9879390fd">6,778</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfOC0xLTEtMS0xNzQxMA_edd7a1fc-032e-4e51-8e7f-5c0a259bd7ac">2,774</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfOC0zLTEtMS0xNzQxMA_1428d36b-07d2-408a-94aa-5de5548dbe84">1,926</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfOS0xLTEtMS0xNzQxMA_20a09c21-155f-40b0-aef2-2f7d8d9a7d94">46,307</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfOS0zLTEtMS0xNzQxMA_5fc0a08e-aa07-4086-8591-a2ce67929dbb">60,737</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net of accumulated depreciation and amortization of $<ix:nonFraction unitRef="usd" contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMTAtMC0xLTEtMTc0MTAvdGV4dHJlZ2lvbjo5ZTgxMzI0ZDA5OWY0ZWZiYWMxYWQ5ZDlmNjZhZjlmYV84MA_48474e5d-9c22-4ae2-b4c1-60209cf4c6e2">5,335</ix:nonFraction> and </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;$<ix:nonFraction unitRef="usd" contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMTAtMC0xLTEtMTc0MTAvdGV4dHJlZ2lvbjo5ZTgxMzI0ZDA5OWY0ZWZiYWMxYWQ5ZDlmNjZhZjlmYV85MQ_b12b75de-b67c-4305-acf5-fbfc1eb9727a">5,316</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMTAtMS0xLTEtMTc0MTA_f6f4e0f3-598c-445e-9f0e-66c2ac5d7843">6,810</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMTAtMy0xLTEtMTc0MTA_74984c0b-6bb5-43e8-8a9f-44f134c63846">6,575</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMTEtMS0xLTEtMTc0MTA_786cfcb5-2029-4009-af3a-df49f12e60dc">774</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMTEtMy0xLTEtMTc0MTA_bc91ae96-9062-4c76-8404-bda707fa452e">121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMTItMS0xLTEtMTc0MTA_9348d839-47b9-4fc9-aac0-6b76384b78f6">124</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMTItMy0xLTEtMTc0MTA_32e71505-932b-4d1f-8648-d251c08749e3">178</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMTQtMS0xLTEtMTc0MTA_896a9aca-28a9-4f5f-ae2a-a837aa294b2e">1,253</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMTQtMy0xLTEtMTc0MTA_431060ff-6e63-4106-9717-0e9b9cd4b33d">1,110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMTUtMS0xLTEtMTc0MTA_50376d42-1235-4ea6-b546-339711a79ea6">55,268</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMTUtMy0xLTEtMTc0MTA_cc2d6262-09d9-43e6-ba95-1c0dbc49f9ff">68,721</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND EQUITY</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMjEtMS0xLTEtMTc0MTA_0e47683c-bc8f-48b9-bb32-30a499b91655">2,070</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMjEtMy0xLTEtMTc0MTA_0961e7a7-ced1-482e-bd89-fa99f95ee6d0">2,631</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930" decimals="-3" name="apyx:AccruedLiabilitiesAndOtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMjItMS0xLTEtMTc0MTA_754368be-40af-4832-93a4-bd9aeaeab247">8,842</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231" decimals="-3" name="apyx:AccruedLiabilitiesAndOtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMjItMy0xLTEtMTc0MTA_a39f1773-2ef7-4a08-a6b1-e5ae852348d3">10,287</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMjMtMS0xLTEtMTc0MTA_7208b769-9ba1-40b8-9598-c2614c6d9f6b">240</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMjMtMy0xLTEtMTc0MTA_65e81184-ba07-476e-a50e-bf375c0d03d1">122</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of finance lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMjQtMS0xLTEtMTc0MTA_40cd20b2-95ff-4f2d-8326-0cd4d9772bf3">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMjQtMy0xLTEtMTc0MTA_34ed69f8-e872-43c3-87e3-d0980a43833d">165</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMjYtMS0xLTEtMTc0MTA_dc9286e4-985d-4177-85a3-f645dd90e35c">11,194</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMjYtMy0xLTEtMTc0MTA_f4b194e5-ade3-45f8-8d96-4523431d8ec1">13,205</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMjctMS0xLTEtMTc0MTA_260d366f-79ab-43da-9a20-bcd6c866d7fb">454</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMjctMy0xLTEtMTc0MTA_2ac5fe04-88f1-4e67-84b5-4a72adfb3383">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term finance lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMjgtMS0xLTEtMTc0MTA_a3ae713c-75cd-4118-ba30-4ebb202af6e7">78</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMjgtMy0xLTEtMTc0MTA_3fcfa8ec-bf18-42b8-8023-5f2ad8896e82">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term contract liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMjktMS0xLTEtMTc0MTA_9e45a79c-18ae-4264-946a-661d2ca26aad">1,192</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMjktMy0xLTEtMTc0MTA_77fef9f1-6f5f-4364-8fdd-75550846ef3d">1,323</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMzAtMS0xLTEtMTc0MTA_ce26a9f3-1c44-4f76-8dd2-b746e81d827f">133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMzAtMy0xLTEtMTc0MTA_fe9f18fe-56c8-43d7-86a4-ab02dfe26430">166</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMzEtMS0xLTEtMTc0MTA_095ae7bd-2e18-48af-9410-5d313e9d1f4f">13,051</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMzEtMy0xLTEtMTc0MTA_27a1e819-5196-4675-8fd2-bafacc458f95">14,712</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EQUITY</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMzMtMC0xLTEtMTc0MTAvdGV4dHJlZ2lvbjo3NjcxZjE3MzU1YzI0ZDgxOTVhZTAwOTFlNWMzNDZjYl8xOA_b7973ed2-83e9-40f1-ad38-667bfeab5bad"><ix:nonFraction unitRef="usdPerShare" contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMzMtMC0xLTEtMTc0MTAvdGV4dHJlZ2lvbjo3NjcxZjE3MzU1YzI0ZDgxOTVhZTAwOTFlNWMzNDZjYl8xOA_e71dafa9-90b6-4bd1-937d-c94465a35805">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMzMtMC0xLTEtMTc0MTAvdGV4dHJlZ2lvbjo3NjcxZjE3MzU1YzI0ZDgxOTVhZTAwOTFlNWMzNDZjYl8zMg_53da56ad-5c73-4669-80fa-d008fcb941a4"><ix:nonFraction unitRef="shares" contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMzMtMC0xLTEtMTc0MTAvdGV4dHJlZ2lvbjo3NjcxZjE3MzU1YzI0ZDgxOTVhZTAwOTFlNWMzNDZjYl8zMg_dea71242-fca9-49e3-9b7e-e57ef96ab681">75,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMzMtMC0xLTEtMTc0MTAvdGV4dHJlZ2lvbjo3NjcxZjE3MzU1YzI0ZDgxOTVhZTAwOTFlNWMzNDZjYl81NA_7e5c9750-9351-4635-815c-bbfe1a2b7dba"><ix:nonFraction unitRef="shares" contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMzMtMC0xLTEtMTc0MTAvdGV4dHJlZ2lvbjo3NjcxZjE3MzU1YzI0ZDgxOTVhZTAwOTFlNWMzNDZjYl81NA_906d36bb-fb47-47c7-abd3-c6e08e278e6b">34,588,398</ix:nonFraction></ix:nonFraction> issued and outstanding as of September&#160;30, 2022, and <ix:nonFraction unitRef="shares" contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMzMtMC0xLTEtMTc0MTAvdGV4dHJlZ2lvbjo3NjcxZjE3MzU1YzI0ZDgxOTVhZTAwOTFlNWMzNDZjYl85NA_a2d0efc5-6717-4505-9008-5278a0f94e5a"><ix:nonFraction unitRef="shares" contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMzMtMC0xLTEtMTc0MTAvdGV4dHJlZ2lvbjo3NjcxZjE3MzU1YzI0ZDgxOTVhZTAwOTFlNWMzNDZjYl85NA_c2b910f4-aa2b-4bab-b8c0-662a362d9148">34,409,912</ix:nonFraction></ix:nonFraction> issued and outstanding as of December 31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMzMtMS0xLTEtMTc0MTA_812efc43-4864-4b7c-a0e8-7a2559c527e0">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMzMtMy0xLTEtMTc0MTA_f59484b2-ecee-48fe-a15b-7f91ecda4de8">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMzQtMS0xLTEtMTc0MTA_1a703c19-82cb-4934-9757-d35b182caced">71,641</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMzQtMy0xLTEtMTc0MTA_4297a77a-8966-47a0-a098-3f704ee72059">66,221</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMzUtMS0xLTEtMTc0MTA_204af99e-45aa-4b78-bcb2-508d34469fb9">29,686</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMzUtMy0xLTEtMTc0MTA_780313d0-0f10-4f92-a06f-4449945f0ba0">12,551</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total stockholders&#8217; equity</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMzYtMS0xLTEtMTc0MTA_5fb361ad-8dbb-4545-b86a-eaba3858f868">41,990</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMzYtMy0xLTEtMTc0MTA_26d7d5f8-b99c-4f48-805a-39aa2374befb">53,704</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-controlling interest </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930" decimals="-3" name="us-gaap:MinorityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMzctMS0xLTEtMTc0MTA_1cd3072b-1184-4ffd-a6c7-41a3dda547bf">227</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231" decimals="-3" name="us-gaap:MinorityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMzctMy0xLTEtMTc0MTA_795f08cb-9297-484f-a851-fcf39d0e75c8">305</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMzgtMS0xLTEtMTc0MTA_aec5e40f-9fa3-46a4-aa3d-9031f9318dc1">42,217</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMzgtMy0xLTEtMTc0MTA_e673aacf-b639-4f2d-94f3-8b02c388cdb9">54,009</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities and equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMzktMS0xLTEtMTc0MTA_c221fd73-1c2c-4e69-ad26-4c0e6b95775e">55,268</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMzktMy0xLTEtMTc0MTA_c36fb7c7-4088-4aaa-85cf-7f9f2f16866a">68,721</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of the condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="ie9788c72f4874edca78c1c4f307fec05_19"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie9788c72f4874edca78c1c4f307fec05_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(In thousands, except per share data) </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6ada2596cf84b118b49af7a6561fb79_D20220701-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMi0xLTEtMS0xNzQxMA_db506cbc-1dfc-4ec7-b0a7-1600356e1b8e">9,114</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9b0b6a3c69447bf8f151dfd98c14ac9_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMi0zLTEtMS0xNzQxMA_6f4318cb-5999-4436-ad6c-a641f2a36ce5">11,831</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMi01LTEtMS0xNzQxMA_47b9c36c-bcb8-4b98-8de7-8c8abc4b2765">31,899</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMi03LTEtMS0xNzQxMA_43ab1d24-6e35-4ff7-8919-b0d3f2ceacbb">31,693</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6ada2596cf84b118b49af7a6561fb79_D20220701-20220930" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMy0xLTEtMS0xNzQxMA_fd184a9a-a48c-496c-a779-0cb97fbb4ca6">3,357</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9b0b6a3c69447bf8f151dfd98c14ac9_D20210701-20210930" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMy0zLTEtMS0xNzQxMA_1c72bb0f-9c5a-4db2-8f14-6cbb3182ab72">3,775</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMy01LTEtMS0xNzQxMA_75f197e7-3881-4d98-88bd-d1b9819ba180">11,009</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMy03LTEtMS0xNzQxMA_a2b81290-33d4-4fa5-97ee-eebfe71f192f">10,243</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross profit</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6ada2596cf84b118b49af7a6561fb79_D20220701-20220930" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfNC0xLTEtMS0xNzQxMA_8dd7ce71-7b8a-4685-b6b7-5f9ed214b7ca">5,757</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9b0b6a3c69447bf8f151dfd98c14ac9_D20210701-20210930" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfNC0zLTEtMS0xNzQxMA_a49f9497-dfe1-43cc-93f9-449bddfc8e59">8,056</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfNC01LTEtMS0xNzQxMA_bfb4327f-b1ad-4c3b-9f2b-b49dd87dc383">20,890</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfNC03LTEtMS0xNzQxMA_473a4422-a682-41f9-a237-27100c4e4f76">21,450</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other costs and expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6ada2596cf84b118b49af7a6561fb79_D20220701-20220930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfNi0xLTEtMS0xNzQxMA_9420f3f2-72b2-408a-904d-29aa9652ee81">1,061</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9b0b6a3c69447bf8f151dfd98c14ac9_D20210701-20210930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfNi0zLTEtMS0xNzQxMA_4b0a4faf-2c34-4b10-a613-561a3a265817">1,175</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfNi01LTEtMS0xNzQxMA_3d8883dd-8dde-4475-a2ae-73e833b5d5d0">3,289</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfNi03LTEtMS0xNzQxMA_fce27f91-a19f-41f6-a084-6f4516840894">3,374</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6ada2596cf84b118b49af7a6561fb79_D20220701-20220930" decimals="-3" name="us-gaap:ProfessionalFees" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfNy0xLTEtMS0xNzQxMA_ac387865-f122-4f14-916f-0e595ff5f2d1">1,936</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9b0b6a3c69447bf8f151dfd98c14ac9_D20210701-20210930" decimals="-3" name="us-gaap:ProfessionalFees" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfNy0zLTEtMS0xNzQxMA_ce339846-e802-49b7-99c9-a7b905a52e63">2,032</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" decimals="-3" name="us-gaap:ProfessionalFees" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfNy01LTEtMS0xNzQxMA_c5c99628-b9a3-4231-97af-9e8fa56716ab">6,611</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930" decimals="-3" name="us-gaap:ProfessionalFees" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfNy03LTEtMS0xNzQxMA_72214844-88a5-40e3-b0e6-54c3c84f4a5f">5,442</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries and related costs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6ada2596cf84b118b49af7a6561fb79_D20220701-20220930" decimals="-3" name="us-gaap:SalariesAndWages" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfOC0xLTEtMS0xNzQxMA_a231f3ff-20c4-4ea7-aab7-097d54069dfa">3,871</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9b0b6a3c69447bf8f151dfd98c14ac9_D20210701-20210930" decimals="-3" name="us-gaap:SalariesAndWages" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfOC0zLTEtMS0xNzQxMA_67bbfd7b-e645-49e1-9a25-2ddb90064764">4,206</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" decimals="-3" name="us-gaap:SalariesAndWages" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfOC01LTEtMS0xNzQxMA_774899a9-a5f7-470d-bd00-e42b7969eafb">13,944</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930" decimals="-3" name="us-gaap:SalariesAndWages" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfOC03LTEtMS0xNzQxMA_2c3b8d11-8750-464c-9104-8bae708778a3">12,794</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6ada2596cf84b118b49af7a6561fb79_D20220701-20220930" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfOS0xLTEtMS0xNzQxMA_a950c113-d5da-43cb-b12c-cc8fbe7d1630">4,671</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9b0b6a3c69447bf8f151dfd98c14ac9_D20210701-20210930" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfOS0zLTEtMS0xNzQxMA_15c4dc28-2270-44c5-b1a3-e932da592e42">4,611</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfOS01LTEtMS0xNzQxMA_1116405d-95d9-472c-a601-c393b2e6c359">14,675</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfOS03LTEtMS0xNzQxMA_1cf28576-29e9-48a5-8849-d24fa629635d">12,596</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total other costs and expenses</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6ada2596cf84b118b49af7a6561fb79_D20220701-20220930" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMTAtMS0xLTEtMTc0MTA_bd0dab55-1895-4356-bb6c-829803a4a95d">11,539</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9b0b6a3c69447bf8f151dfd98c14ac9_D20210701-20210930" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMTAtMy0xLTEtMTc0MTA_4ecbd706-ef97-4509-ad0e-31a502a5e54d">12,024</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMTAtNS0xLTEtMTc0MTA_e214b0db-d469-4361-b4d8-56910a6b4e01">38,519</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMTAtNy0xLTEtMTc0MTA_c877225d-dbff-491b-b6fb-8182e0622a1f">34,206</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6ada2596cf84b118b49af7a6561fb79_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMTEtMS0xLTEtMTc0MTA_4da79582-222f-4106-971a-a914fa811f74">5,782</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic9b0b6a3c69447bf8f151dfd98c14ac9_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMTEtMy0xLTEtMTc0MTA_5cc8b389-fa5a-4900-8e47-731ca8d7dd94">3,968</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMTEtNS0xLTEtMTc0MTA_0f24df18-f17e-41b5-9f94-763d37f5f9ed">17,629</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMTEtNy0xLTEtMTc0MTA_858526e6-b410-476d-b2f0-79138d5d4c6b">12,756</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6ada2596cf84b118b49af7a6561fb79_D20220701-20220930" decimals="-3" name="us-gaap:InterestIncomeOperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMTItMS0xLTEtMTc0MTA_69aeda59-2237-4db2-a8bd-73f8682db494">73</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9b0b6a3c69447bf8f151dfd98c14ac9_D20210701-20210930" decimals="-3" name="us-gaap:InterestIncomeOperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMTItMy0xLTEtMTc0MTA_181d1dd5-722d-40a1-b637-709134295dd0">2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" decimals="-3" name="us-gaap:InterestIncomeOperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMTItNS0xLTEtMTc0MTA_990202e6-2838-4422-8511-176a9f720203">93</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930" decimals="-3" name="us-gaap:InterestIncomeOperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMTItNy0xLTEtMTc0MTA_5a8ac1ad-f147-4f04-ae1d-56dc48ba70ed">9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6ada2596cf84b118b49af7a6561fb79_D20220701-20220930" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMTMtMS0xLTEtMTc0MTA_9461e78b-5dc1-476f-be37-308d4f143fd4">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic9b0b6a3c69447bf8f151dfd98c14ac9_D20210701-20210930" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMTMtMy0xLTEtMTc0MTA_6188d003-7fd9-4558-99b0-1d109a9a56ce">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMTMtNS0xLTEtMTc0MTA_a61d4ba5-385e-4064-98bf-f6772dd86fc7">12</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMTMtNy0xLTEtMTc0MTA_15f2d749-c611-4165-956a-7e0e62d6afd0">9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (loss) income, net</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6ada2596cf84b118b49af7a6561fb79_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMTQtMS0xLTEtMTc0MTA_b8d75bc4-67f2-4f7c-96ec-dcc2f08cbcea">35</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic9b0b6a3c69447bf8f151dfd98c14ac9_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMTQtMy0xLTEtMTc0MTA_991a5b02-c569-4618-aa02-507482907e96">192</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" decimals="-3" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMTQtNS0xLTEtMTc0MTA_a28ead73-4acb-4c98-8865-9ac55f753090">551</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMTQtNy0xLTEtMTc0MTA_11eb9701-1fa1-4a1f-8abc-07f94f008507">188</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total other income (loss), net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6ada2596cf84b118b49af7a6561fb79_D20220701-20220930" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMTUtMS0xLTEtMTc0MTA_95af418f-66bb-4cfb-b6f0-362a36d78f70">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic9b0b6a3c69447bf8f151dfd98c14ac9_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMTUtMy0xLTEtMTc0MTA_ef6d7f63-2820-42a8-ae86-035559af5424">193</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMTUtNS0xLTEtMTc0MTA_f5d69c57-7bd4-49d1-9f85-fcecef232e18">632</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMTUtNy0xLTEtMTc0MTA_375c0e0f-b461-4c1f-89f2-e945b1cc1a15">188</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss before income taxes</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6ada2596cf84b118b49af7a6561fb79_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMTYtMS0xLTEtMTc0MTA_5a3f7805-9607-46e9-b1e3-0133c4c0698f">5,745</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic9b0b6a3c69447bf8f151dfd98c14ac9_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMTYtMy0xLTEtMTc0MTA_2ea1e02b-46f2-44a7-ad8b-054135f33f6c">4,161</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMTYtNS0xLTEtMTc0MTA_6ab036e4-e017-4659-a0ab-03d8c5d456b9">16,997</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMTYtNy0xLTEtMTc0MTA_494b41d5-86a8-4bdf-8cae-f8310dff26d4">12,944</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6ada2596cf84b118b49af7a6561fb79_D20220701-20220930" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMTctMS0xLTEtMTc0MTA_f69729c5-db75-4e35-b874-1ccee52c4149">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9b0b6a3c69447bf8f151dfd98c14ac9_D20210701-20210930" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMTctMy0xLTEtMTc0MTA_6dc3b75f-5027-419d-b3b9-ebe87b7ab17c">73</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMTctNS0xLTEtMTc0MTA_a4726fad-f30f-44c5-ad4b-081107690181">216</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMTctNy0xLTEtMTc0MTA_e1f853e0-fabb-42bb-8c74-394eb06e854e">246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6ada2596cf84b118b49af7a6561fb79_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMTgtMS0xLTEtMTc0MTA_7da3fdd7-5c53-47bf-ab42-70fac6662fda">5,795</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic9b0b6a3c69447bf8f151dfd98c14ac9_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMTgtMy0xLTEtMTc0MTA_6db9c690-188c-4a31-814e-1f38e7298307">4,234</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMTgtNS0xLTEtMTc0MTA_290617b7-babf-40dd-9961-e89c619cd75a">17,213</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMTgtNy0xLTEtMTc0MTA_3b06e07b-2561-4f36-8df0-a798d51a5f9b">13,190</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Net loss attributable to non-controlling interest</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6ada2596cf84b118b49af7a6561fb79_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMTktMS0xLTEtMTc0MTA_65dcc184-756e-4dda-aa5f-29a695a0087e">31</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic9b0b6a3c69447bf8f151dfd98c14ac9_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMTktMy0xLTEtMTc0MTA_0d0bf830-62fa-4a49-925f-3c43d50edb41">12</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMTktNS0xLTEtMTc0MTA_15f049a6-e1e9-424f-82f5-eb30b87b1a5e">78</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMTktNy0xLTEtMTc0MTA_3b9dcdbe-fcbf-47d4-80b8-9941ed6ec988">21</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss attributable to stockholders</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6ada2596cf84b118b49af7a6561fb79_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMjAtMS0xLTEtMTc0MTA_bf353b51-01c2-435e-90e6-bf5a9b76374f">5,764</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic9b0b6a3c69447bf8f151dfd98c14ac9_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMjAtMy0xLTEtMTc0MTA_0267997a-c009-45da-a994-f6e63ad3a616">4,222</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMjAtNS0xLTEtMTc0MTA_8fae707b-42cf-4fb6-a7be-8913daf102d1">17,135</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMjAtNy0xLTEtMTc0MTA_215875f0-d710-455b-b8f2-85b92b71bb67">13,169</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss per share:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="id6ada2596cf84b118b49af7a6561fb79_D20220701-20220930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMjQtMS0xLTEtMTc0MTA_06487251-ea0a-407e-a1b7-12b83c717f0b"><ix:nonFraction unitRef="usdPerShare" contextRef="id6ada2596cf84b118b49af7a6561fb79_D20220701-20220930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMjQtMS0xLTEtMTc0MTA_ca7abe26-b0d2-4991-9b50-a2e00e1d6840">0.17</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ic9b0b6a3c69447bf8f151dfd98c14ac9_D20210701-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMjQtMy0xLTEtMTc0MTA_77f20804-9876-47a8-bc2e-bf8f0f23c71c"><ix:nonFraction unitRef="usdPerShare" contextRef="ic9b0b6a3c69447bf8f151dfd98c14ac9_D20210701-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMjQtMy0xLTEtMTc0MTA_d8e9c6c8-2c66-4d1e-b334-ba05318f6f43">0.12</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMjQtNS0xLTEtMTc0MTA_810b2514-2695-4f61-aa66-76180ed3aeb7"><ix:nonFraction unitRef="usdPerShare" contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMjQtNS0xLTEtMTc0MTA_cc781c32-042a-4dbe-bf1b-f519d2f53c47">0.50</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMjQtNy0xLTEtMTc0MTA_e225f3ec-92c2-4761-bac7-9dcc2af13f03"><ix:nonFraction unitRef="usdPerShare" contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMjQtNy0xLTEtMTc0MTA_eaa74bb1-be3a-4800-9c90-a29ef24b53fb">0.38</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:12.719%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of the condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="ie9788c72f4874edca78c1c4f307fec05_22"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie9788c72f4874edca78c1c4f307fec05_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(In thousands)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.671%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.850%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2022 and 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Additional Paid-In Capital</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-controlling Interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Equity</span></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Par Value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0915370fdc66433087f61be1a6429895_I20210630" decimals="-3" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMy0xLTEtMS0xNzQxMA_f593a5a6-4ce8-40b6-bea0-c20ae0f4c038">34,323</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0915370fdc66433087f61be1a6429895_I20210630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMy0zLTEtMS0xNzQxMA_234438b1-af5f-43be-baae-a3bbea26181c">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6bd5470a522440896a96cb114d94bc9_I20210630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMy01LTEtMS0xNzQxMA_bec9dd10-94df-40a8-a050-2b3e0494f9d6">63,650</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1602e279f8a54d59a4619d5751091e77_I20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMy03LTEtMS0xNzQxMA_1b4ce6b5-f8e9-4c44-be6b-1e0f6ae75a10">6,326</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70c60e5ef978483d94930f1744a9d3af_I20210630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMy05LTEtMS0xNzQxMA_7f834d7a-60cb-4aa8-9378-caefca870a16">324</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i138bdba832374d1f808c394db84be422_I20210630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMy0xMS0xLTEtMTc0MTA_ea37ecb9-1fe7-46ea-bc4b-1b0eba460c5a">57,682</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issued on stock options exercises for cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iecb0fed55763430baf6093ea22f40d87_D20210701-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfNS0xLTEtMS0xNzQxMA_5b25e102-df4a-4ccb-a054-6d9c4dbfc6b1">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica2773a2e5304f8480d1f69944277492_D20210701-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfNS01LTEtMS0xNzQxMA_6a68d1b1-3499-419b-aac6-dc05a648241b">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9b0b6a3c69447bf8f151dfd98c14ac9_D20210701-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfNS0xMS0xLTEtMTc0MTA_fea6daed-9b67-4633-826a-5c689d694738">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica2773a2e5304f8480d1f69944277492_D20210701-20210930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfNi01LTEtMS0xNzQxMA_b417c403-e363-4729-96ac-a2a815bd87a0">1,184</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9b0b6a3c69447bf8f151dfd98c14ac9_D20210701-20210930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfNi0xMS0xLTEtMTc0MTA_de01cf3e-9527-4bfb-84a7-ead3be6148bd">1,184</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issued on net settlement of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iecb0fed55763430baf6093ea22f40d87_D20210701-20210930" decimals="-3" name="apyx:StockSwapToAcquireOptionsShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfNy0xLTEtMS0xNzQxMA_24202e88-b7d5-4aca-b5ac-aee3ec9eaa00">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i102d87338ba6454f85cc738690cc4358_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfOS03LTEtMS0xNzQxMA_816fc5b0-32f5-439a-b756-daaf21921e58">4,222</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2ad330e6cdd442be8bf971667788ba23_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfOS05LTEtMS0xNzQxMA_8a65cadd-d27a-43bc-a714-40cc8f64426e">12</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic9b0b6a3c69447bf8f151dfd98c14ac9_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfOS0xMS0xLTEtMTc0MTA_97287cee-3eea-4303-95c7-d5dd4e7cd0a1">4,234</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib6078f16f5134a2e9e175491969aa315_I20210930" decimals="-3" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMTAtMS0xLTEtMTc0MTA_e5d571c1-185e-47d7-923d-5acd9447384d">34,340</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6078f16f5134a2e9e175491969aa315_I20210930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMTAtMy0xLTEtMTc0MTA_68348507-69b7-4c1c-945c-0a19e2bec6f9">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d63a53f125c4acd96a77b7410be5951_I20210930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMTAtNS0xLTEtMTc0MTA_c3e23b1b-b73a-4048-8bcd-9d18b03111e1">64,862</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6459bdf630814b27874dad87632c646a_I20210930" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMTAtNy0xLTEtMTc0MTA_6f8a3344-8366-4226-8b38-8f610f32eeb0">10,548</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia98a748ab05948eda52b8c8873f240ed_I20210930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMTAtOS0xLTEtMTc0MTA_f713234d-11c3-4cb0-b770-9398181e8e55">312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i524cd9c9acd4440f8d2e862dbb84f261_I20210930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMTAtMTEtMS0xLTE3NDEw_6aa9e41f-bd7c-457e-86b3-afefd3e8fee7">54,660</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6b3b8a89480b4a8680824601cb0552b9_I20220630" decimals="-3" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMTItMS0xLTEtMTc0MTA_b0ebc734-b37f-4151-b939-d53e6a24e199">34,493</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b3b8a89480b4a8680824601cb0552b9_I20220630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMTItMy0xLTEtMTc0MTA_24d116a1-0579-4e3a-b08c-9faf748d4385">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02b00de331904fcebd2e5c7c0add0881_I20220630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMTItNS0xLTEtMTc0MTA_abdcf884-cab0-4193-bf6d-7eff63ee8622">69,793</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3d3946eaa70742e3a1d7332eacba51a6_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMTItNy0xLTEtMTc0MTA_b4fe53c2-ecb3-4676-a68b-6bbd7a11db1e">23,922</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9d5039cab3a4fa5a3b9b29f5d4f1ce0_I20220630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMTItOS0xLTEtMTc0MTA_6088373d-8d8a-4ec9-912a-2eeaaee83e76">258</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1a290f8b3eb4985ac22e7ccb81b66e5_I20220630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMTItMTEtMS0xLTE3NDEw_90f19f1e-932b-4554-99d4-2cad217f1e77">46,163</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issued on stock options exercises for cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2682ba64e91149fb8218158d95782bd3_D20220701-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMTQtMS0xLTEtMTc0MTA_7cf06426-3d37-492e-8799-0b42098cb088">62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2682ba64e91149fb8218158d95782bd3_D20220701-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMTQtMy0xLTEtMTc0MTA_3b61db59-b50c-4af4-a157-69b9d3ffc1fa">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1211ee2c038f40b8b5feff5fd9d6fe4c_D20220701-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMTQtNS0xLTEtMTc0MTA_9b460541-8074-4871-bd5b-b104bb1eda9b">156</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6ada2596cf84b118b49af7a6561fb79_D20220701-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMTQtMTEtMS0xLTE3NDEw_e6f3ea82-78a1-4ce7-bd33-764c21da0d7f">157</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1211ee2c038f40b8b5feff5fd9d6fe4c_D20220701-20220930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMTUtNS0xLTEtMTc0MTA_8ab1eca8-d2da-4646-bbdf-d215ac525dd5">1,692</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6ada2596cf84b118b49af7a6561fb79_D20220701-20220930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMTUtMTEtMS0xLTE3NDEw_5ed7155c-6f9c-46e4-a901-75d3a372161d">1,692</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issued on net settlement of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2682ba64e91149fb8218158d95782bd3_D20220701-20220930" decimals="-3" name="apyx:StockSwapToAcquireOptionsShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMTYtMS0xLTEtMTc0MTA_186f2992-a538-40a8-a7bc-564d28d685f8">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i87921e2d34bd4d828c5d4930daeb8fc8_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMTgtNy0xLTEtMTc0MTA_685304b7-9195-4714-a503-7d5681d17555">5,764</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b2ac4e7bb8a4fab90de0f2a2f18a839_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMTgtOS0xLTEtMTc0MTA_50a95a2a-1ae6-40da-9bf9-8ef6f9c501fa">31</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6ada2596cf84b118b49af7a6561fb79_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMTgtMTEtMS0xLTE3NDEw_b0854b16-98df-4264-951b-e4efbff5ec28">5,795</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie3a4f0fb7c0d44a8a286050fe422e630_I20220930" decimals="-3" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMTktMS0xLTEtMTc0MTA_50d37219-35db-4fbc-92d9-99742411b115">34,588</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3a4f0fb7c0d44a8a286050fe422e630_I20220930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMTktMy0xLTEtMTc0MTA_a0846286-9e9d-4986-b62b-60ee80488f24">35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96687d732f8d4567ad6f8406cd1293e3_I20220930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMTktNS0xLTEtMTc0MTA_9ffffeef-85de-434e-8d89-58673d827b36">71,641</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id08f3d38045d4418a182b5f9988d3e34_I20220930" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMTktNy0xLTEtMTc0MTA_4c08c3df-97d5-4d4e-8b7a-22f264788a00">29,686</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i229d9ac95648412aa95ce5178946ae89_I20220930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMTktOS0xLTEtMTc0MTA_df88a3cb-dc1e-45df-b12c-f1ad26af626d">227</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMTktMTEtMS0xLTE3NDEw_7efb9f6a-be09-4b5a-b93e-fc4a2505b679">42,217</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2022 and 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Additional Paid-In Capital</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Retained Earnings (Accumulated Deficit)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-controlling Interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Par Value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iac6178b585a24bdd9c611d8f43b21488_I20201231" decimals="-3" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMjQtMS0xLTEtMTc0MTA_24a8ee41-6ad2-47c6-8057-6bc0a636f80d">34,289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac6178b585a24bdd9c611d8f43b21488_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMjQtMy0xLTEtMTc0MTA_b9eb4365-b91b-4bdb-ab5e-9fd971ae6c2d">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4281c98f6d154bc0bbdaa5ef88536da4_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMjQtNS0xLTEtMTc0MTA_ee6f806f-1224-41bd-ab07-c305ee3ca6aa">61,066</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41802e9d47eb481aabfdd816c5c9fa7b_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMjQtNy0xLTEtMTc0MTA_1c8ccee2-37d4-4e8e-ad64-3a0fe4ae9a45">2,621</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62a88fb8485b4d7fb2c08fb2266ed449_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMjQtOS0xLTEtMTc0MTA_44eddd1d-5591-4b6b-9c17-552966098248">138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e93d5bb9951458aa70810e8b5e84de2_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMjQtMTEtMS0xLTE3NDEw_34308b6a-dc4e-42b0-9d0c-8fc4f6064ba3">63,859</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contributions from non-controlling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19cfd321237247ab9bd9651da54e7476_D20210101-20210930" decimals="-3" name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMjUtOS0xLTEtMTc0MTA_84fa2ba3-fa05-4ecf-a683-8b10d27977d9">195</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930" decimals="-3" name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMjUtMTEtMS0xLTE3NDEw_2a331ac6-1296-4b9e-9a34-c4bda1c43f6b">195</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issued on stock options exercises for cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5f055e88f44443e39bd36692989fa841_D20210101-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMjYtMS0xLTEtMTc0MTA_f744a0a9-5961-4e84-8b97-79bdac4190c8">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6310af3213b546f996d5b2f97fb70bfd_D20210101-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMjYtNS0xLTEtMTc0MTA_53a7f25a-3b75-4aa0-97ae-ccb680e9fabf">49</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMjYtMTEtMS0xLTE3NDEw_124ccae7-4d25-4a05-b535-15373bc4a742">49</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6310af3213b546f996d5b2f97fb70bfd_D20210101-20210930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMjctNS0xLTEtMTc0MTA_159c5799-de97-4d29-9985-cad2d99c3bcf">3,747</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMjctMTEtMS0xLTE3NDEw_d76976f7-8f96-4714-bc09-ed30bf44775b">3,747</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issued on net settlement of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5f055e88f44443e39bd36692989fa841_D20210101-20210930" decimals="-3" name="apyx:StockSwapToAcquireOptionsShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMjgtMS0xLTEtMTc0MTA_c4effc9c-545d-4b29-8736-031f133e1335">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i66bc1f8757d7488a99f1a6c5eb9a7e4c_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMzAtNy0xLTEtMTc0MTA_e611937e-aa38-4e68-8863-ecd616edc87f">13,169</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i19cfd321237247ab9bd9651da54e7476_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMzAtOS0xLTEtMTc0MTA_1008ca97-4622-4344-a8bd-20dfd4fb2ca9">21</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMzAtMTEtMS0xLTE3NDEw_18747303-88ec-48eb-a6dc-79b605681bf1">13,190</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib6078f16f5134a2e9e175491969aa315_I20210930" decimals="-3" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMzEtMS0xLTEtMTc0MTA_c225d535-201c-4155-8cae-a658910660fd">34,340</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6078f16f5134a2e9e175491969aa315_I20210930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMzEtMy0xLTEtMTc0MTA_5accb27d-be2c-4245-a308-f5c481b19c72">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d63a53f125c4acd96a77b7410be5951_I20210930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMzEtNS0xLTEtMTc0MTA_dc0c34ff-bb42-418e-a91b-0e66aae368d7">64,862</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6459bdf630814b27874dad87632c646a_I20210930" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMzEtNy0xLTEtMTc0MTA_5cf3d631-2fee-46c5-a31e-6fa92b0feb64">10,548</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia98a748ab05948eda52b8c8873f240ed_I20210930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMzEtOS0xLTEtMTc0MTA_91e520f1-940d-4c85-9b82-2a8745ed22fe">312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i524cd9c9acd4440f8d2e862dbb84f261_I20210930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMzEtMTEtMS0xLTE3NDEw_5c4908e8-a8c9-4cf3-af1d-a989a6d9b50f">54,660</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i10702330b75541919ad22c7f751db016_I20211231" decimals="-3" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMzMtMS0xLTEtMTc0MTA_00a1dfa9-799f-4f1d-a8a8-224ec222386b">34,410</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10702330b75541919ad22c7f751db016_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMzMtMy0xLTEtMTc0MTA_cdf81dde-c548-4779-8387-4ec05fa99662">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f0faf73be0941df9ec5505291b94bde_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMzMtNS0xLTEtMTc0MTA_518376bc-20d7-4c8d-af4c-b4919f936bd0">66,221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iec03140df24341ec90f156ca4aeabce3_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMzMtNy0xLTEtMTc0MTA_5774dce6-9b99-46e7-8ac4-46c7d2cc357d">12,551</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d002bf5ac274c73b635110b5036d873_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMzMtOS0xLTEtMTc0MTA_52945cc0-6c7a-4b91-af0d-28f2d23ca6b4">305</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMzMtMTEtMS0xLTE3NDEw_b2cfb2b1-7fe8-48dc-a0cd-b9104aa683b1">54,009</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issued on stock options exercises for cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia7123184de4141839ab376b29683134c_D20220101-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMzUtMS0xLTEtMTc0MTA_650e4837-b17a-4a4b-b6fd-987f68828046">106</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7123184de4141839ab376b29683134c_D20220101-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMzUtMy0xLTEtMTc0MTA_e2fb6a16-bcf8-4da5-9699-985e94b0ce47">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic739a97c17164277aa8cc3fa9ffb8bf3_D20220101-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMzUtNS0xLTEtMTc0MTA_b6033273-54b3-4f41-8877-e48e920d51ed">364</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMzUtMTEtMS0xLTE3NDEw_cd58fc20-96d6-4558-aed5-701c8c314b1a">365</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic739a97c17164277aa8cc3fa9ffb8bf3_D20220101-20220930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMzYtNS0xLTEtMTc0MTA_403ee1b4-65fe-41ab-accd-94860193b633">5,056</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMzYtMTEtMS0xLTE3NDEw_512be9a1-eb5d-4cbf-9d1b-f9816ad1b4ca">5,056</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issued on net settlement of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia7123184de4141839ab376b29683134c_D20220101-20220930" decimals="-3" name="apyx:StockSwapToAcquireOptionsShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMzctMS0xLTEtMTc0MTA_c5378ace-2686-4391-a4b6-9d00fac8ae31">72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2fc708898034815a0206b71148a8cb0_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMzktNy0xLTEtMTc0MTA_cdd9cf5a-d346-4764-8a96-e2b9dddb6995">17,135</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i95ac060f75d24601ad4fd05a8f4e64e7_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMzktOS0xLTEtMTc0MTA_f2efbbdd-6010-453e-bec6-f497f1b68395">78</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMzktMTEtMS0xLTE3NDEw_0ea4c58f-2b14-4903-bf6f-76833e1fe659">17,213</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie3a4f0fb7c0d44a8a286050fe422e630_I20220930" decimals="-3" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfNDAtMS0xLTEtMTc0MTA_118cd184-ec5b-4ef8-a1ac-5f5d2723edbd">34,588</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3a4f0fb7c0d44a8a286050fe422e630_I20220930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfNDAtMy0xLTEtMTc0MTA_e7e076fe-1348-4a8e-8c48-6365b883a96a">35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96687d732f8d4567ad6f8406cd1293e3_I20220930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfNDAtNS0xLTEtMTc0MTA_c23754e8-bdd5-4c00-89dc-e4790cda9344">71,641</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id08f3d38045d4418a182b5f9988d3e34_I20220930" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfNDAtNy0xLTEtMTc0MTA_243c9426-5071-4054-b96f-268cd58cf053">29,686</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i229d9ac95648412aa95ce5178946ae89_I20220930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfNDAtOS0xLTEtMTc0MTA_8da6fecc-2200-4660-8249-b93feaa8f8bd">227</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfNDAtMTEtMS0xLTE3NDEw_d1f1b446-5db0-4b63-b19e-4e512531c3e5">42,217</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of the condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="ie9788c72f4874edca78c1c4f307fec05_25"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie9788c72f4874edca78c1c4f307fec05_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(In thousands)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from operating activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfMy0xLTEtMS0xNzQxMA_791b86f0-27e0-47d1-a863-200dd4a1cbca">17,213</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfMy0zLTEtMS0xNzQxMA_b73b3e61-f50c-44eb-ab46-36e134861afc">13,190</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfNS0xLTEtMS0xNzQxMA_91d0ef13-8340-475f-a31c-fb8a3b02c42c">688</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfNS0zLTEtMS0xNzQxMA_423fbf4d-6d69-48eb-b423-ac4b8e6ddaea">674</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for inventory obsolescence</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" decimals="-3" name="apyx:ProvisionForInventoryObsolescence" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfNi0xLTEtMS0xNzQxMA_e8d535b2-0a1d-451f-adbe-9e06d4154655">158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930" decimals="-3" name="apyx:ProvisionForInventoryObsolescence" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfNi0zLTEtMS0xNzQxMA_ee330124-5e7f-4bda-92fd-173b87b3a4b2">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on disposal of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfOC0xLTEtMS0xNzQxMA_3249652e-a5f5-4310-8655-f4609c821ab1">76</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfOC0zLTEtMS0xNzQxMA_cb44df0e-64d9-40b1-8886-944e6789bf2b">47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfOS0xLTEtMS0xNzQxMA_1c559a8e-650d-4b90-a610-0b165ca7b1aa">5,056</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfOS0zLTEtMS0xNzQxMA_ceaa20fb-b238-4dd5-827e-185821715bdf">3,747</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for allowance for doubtful accounts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" decimals="-3" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfMTAtMS0xLTEtMTc0MTA_fb8d584a-c844-4eb1-a463-cb6def7b4c12">283</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930" decimals="-3" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfMTAtMy0xLTEtMTc0MTA_6d8d9360-24df-4bad-b616-af30e184ef6b">57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfMTMtMS0xLTEtMTc0MTA_f9ba80e5-295f-4683-843f-0aa8784144a4">3,273</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfMTMtMy0xLTEtMTc0MTA_e3653ead-2750-42bc-a059-6f17e865d2e0">3,168</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfMTQtMS0xLTEtMTc0MTA_7c2583af-e4a0-4416-bc91-8ee851f3044a">521</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfMTQtMy0xLTEtMTc0MTA_e2a6f55d-ef55-473b-8d6e-83e5b50433d6">23</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInIncomeTaxesReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfMTUtMS0xLTEtMTc0MTA_46411c80-6d4b-4579-acef-18f00e9e5e80">97</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930" decimals="-3" name="us-gaap:IncreaseDecreaseInIncomeTaxesReceivable" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfMTUtMy0xLTEtMTc0MTA_07c70b5a-cc9b-4360-8189-506b422cde04">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfMTYtMS0xLTEtMTc0MTA_325099a0-fd3a-44d9-a25a-07514532e8d1">5,672</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfMTYtMy0xLTEtMTc0MTA_979cb6a4-69ef-47f8-96c7-d266503213aa">1,982</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfMTctMS0xLTEtMTc0MTA_57b987a5-7411-4887-8414-5f775fe5f748">439</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfMTctMy0xLTEtMTc0MTA_979545a5-8adb-48a2-883c-d2dfa20a3c71">1,555</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfMTgtMS0xLTEtMTc0MTA_be5d9fe2-ca1d-4247-93ea-a8e8e173f7bb">1,536</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfMTgtMy0xLTEtMTc0MTA_196b579c-6d02-4407-97b6-d36403bda3fe">1,605</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfMTktMS0xLTEtMTc0MTA_0b8ea599-5d76-4dce-9b70-50f4c878e74c">15,750</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfMTktMy0xLTEtMTc0MTA_93bccd90-da12-487f-9768-15324e016231">10,663</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfMjEtMS0xLTEtMTc0MTA_748da9a8-61a2-44d3-bfad-125c51098dfd">868</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfMjEtMy0xLTEtMTc0MTA_859ebd84-04f6-4c81-b7f2-7474bb3d715f">391</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfMjQtMS0xLTEtMTc0MTA_dbf5c264-2bda-4920-a7f1-25c055f22585">868</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfMjQtMy0xLTEtMTc0MTA_c4b841ff-9792-42c8-84e1-c2041d25790b">391</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from financing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from stock option exercises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" decimals="-3" name="apyx:ProceedsFromStockOptionsExercisedAndWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfMjYtMS0xLTEtMTc0MTA_b4de9ecc-fbeb-4427-bdf0-f13fa23040a3">365</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930" decimals="-3" name="apyx:ProceedsFromStockOptionsExercisedAndWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfMjYtMy0xLTEtMTc0MTA_28824005-93a4-4643-a2dc-58e54a71d102">49</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayment of finance lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" decimals="-3" name="apyx:RepaymentOfFinanceLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfMjgtMS0xLTEtMTc0MTA_62114e6a-2356-4c85-95b5-acb8f5e404ee">138</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930" decimals="-3" name="apyx:RepaymentOfFinanceLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfMjgtMy0xLTEtMTc0MTA_f2ec88c6-3d59-4ec1-97a0-8078af792be2">181</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contributions from non-controlling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" decimals="-3" name="us-gaap:ProceedsFromMinorityShareholders" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfMjktMS0xLTEtMTc0MTA_3767911e-3f37-43fe-9907-8e089a6378b8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930" decimals="-3" name="us-gaap:ProceedsFromMinorityShareholders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfMjktMy0xLTEtMTc0MTA_85179d76-cfbd-4710-bad3-1ac642ef8ecc">195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfMzAtMS0xLTEtMTc0MTA_1544162d-20ac-4076-84e4-8bb9640491fb">227</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfMzAtMy0xLTEtMTc0MTA_3403f698-ffa6-468f-854b-bca3ed161636">63</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Effect of exchange rates on cash</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfMzEtMS0xLTEtMTc0MTA_c6db5bce-3490-47e1-a66d-c496e1bb2243">354</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfMzEtMy0xLTEtMTc0MTA_b51566ce-5c82-400e-8e8a-d94e4008a961">26</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfMzItMS0xLTEtMTc0MTA_06c9a60d-21e8-4f15-aca6-8a199b6dc2c9">16,037</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfMzItMy0xLTEtMTc0MTA_74bf7a08-03eb-4f16-be54-932475443de2">11,017</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash and cash equivalents, beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfMzMtMS0xLTEtMTc0MTA_d60deabc-1278-4ac2-af78-0f96de53f9e9">30,870</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e93d5bb9951458aa70810e8b5e84de2_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfMzMtMy0xLTEtMTc0MTA_5d3bf484-8ada-4b8e-a5f5-2e759212adf3">41,915</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash and cash equivalents, end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfMzQtMS0xLTEtMTc0MTA_d8ba2aa3-ebf7-4126-984e-1328e1060f9f">14,833</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i524cd9c9acd4440f8d2e862dbb84f261_I20210930" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfMzQtMy0xLTEtMTc0MTA_42c5c6ce-cd9f-4a04-a12b-6d94087345c2">30,898</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash paid for:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfMzctMS0xLTEtMTc0MTA_ba7b07bc-017d-413c-870f-6f6603647648">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfMzctMy0xLTEtMTc0MTA_50242ca2-16ca-4679-a7dd-c8ad8c9bff3f">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" decimals="-3" name="us-gaap:IncomeTaxesPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfMzgtMS0xLTEtMTc0MTA_e7010c6e-84a7-40ae-bf8c-d8aae29a8821">128</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930" decimals="-3" name="us-gaap:IncomeTaxesPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfMzgtMy0xLTEtMTc0MTA_2cebbbb0-de91-4872-b070-20fcd06add0e">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non cash activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets capitalized and operating lease liabilities recognized upon lease modification</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" decimals="-3" name="apyx:CapitalizationOfLeaseNonCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfNDEtMS0xLTEtMTc0MTA_0fa464c5-aa9b-4452-97d7-93f8c693ca59">769</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930" decimals="-3" name="apyx:CapitalizationOfLeaseNonCash" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfNDEtMy0xLTEtMTc0MTA_e34ed663-37dc-4096-9d03-da4f4e3d44d8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets capitalized and finance lease liabilities recognized upon execution of lease</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" decimals="-3" name="apyx:CapitalizationOfLeaseExecution" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfNDItMS0xLTEtMTc0MTA_2df656aa-96f1-4074-a518-f9142a481cb0">103</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930" decimals="-3" name="apyx:CapitalizationOfLeaseExecution" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfNDItMy0xLTEtMTc0MTA_b7c03853-ebbe-4ca3-b486-0bb7e55f86cc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets and finance lease liabilities derecognized upon execution of lease modification</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfNDMtMS0xLTEtMTgyMDM_5c857a41-9611-453c-a8a2-867a56621e11">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfNDMtMy0xLTEtMTgyMDc_3d22a767-eeb3-4def-adf4-7c4779c62242">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of the condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="ie9788c72f4874edca78c1c4f307fec05_28"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie9788c72f4874edca78c1c4f307fec05_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><div><span><br/></span></div><div id="ie9788c72f4874edca78c1c4f307fec05_31"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 1. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8zMS9mcmFnOmNhYzU3NzI0YTVlNzQwNWY5YmE5ZDVlNTQ3MWRiZjVmL3RleHRyZWdpb246Y2FjNTc3MjRhNWU3NDA1ZjliYTlkNWU1NDcxZGJmNWZfMzQ4NA_199c4df4-e98f-4c60-88fd-e63bf5e1b271" continuedAt="i189f48bd1f924c61b73a43775cdacf9a" escape="true">BASIS OF PRESENTATION</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i189f48bd1f924c61b73a43775cdacf9a" continuedAt="i06fc890615184f3e9d8c6f8a89bf9edf"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Apyx Medical Corporation (&#8220;Company&#8221;, &#8220;Apyx&#8221;, &#8220;it&#8221; and similar terms) was incorporated in 1982, under the laws of the State of Delaware and has its principal executive office at 5115 Ulmerton Road, Clearwater, FL 33760.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company is an advanced energy technology company with a passion for elevating people&#8217;s lives through innovative products, including its Helium Plasma Technology products marketed and sold as Renuvion&#174; in the cosmetic surgery market and J-Plasma&#174; in the hospital surgical market. Renuvion&#174; and J-Plasma&#174; offer surgeons a unique ability to provide controlled heat to tissue to achieve their desired results. The Company also leverages its deep expertise and decades of experience in unique waveforms through OEM agreements with other medical device manufacturers. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As part of its plan to accelerate and fully fund the development of its advanced energy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">business, with a focus in the cosmetic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">surgery market, the Company sold its Core business in 2018 for gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="i9a26c2238772410b9c632db89dc2f95f_D20180101-20181231" decimals="-6" name="us-gaap:ProceedsFromDivestitureOfBusinesses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8zMS9mcmFnOmNhYzU3NzI0YTVlNzQwNWY5YmE5ZDVlNTQ3MWRiZjVmL3RleHRyZWdpb246Y2FjNTc3MjRhNWU3NDA1ZjliYTlkNWU1NDcxZGJmNWZfMTY0OTI2NzQ2NDMyOQ_aeecc9bb-8fe9-4e62-818b-90d35e6f75da">97</ix:nonFraction>&#160;million.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">These proceeds were used to launch broad marketing and sales initiatives which resulted in rapid sales growth through December 31, 2021 and into the first quarter of 2022.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">This planned growth in the business was accompanied by scaled operations, including procurement of components, expanded manufacturing capacity to turn those materials into saleable inventory, additional discretionary expenditures, including increased global participation at trade shows, additional employee trainings, user meetings, increased travel and entertainment expenses, more expansive research and development projects, and additional headcount to support those activities. Additionally, the Company had, and still has, some significant non-recurring discretionary expenditures associated with completing its multi-year marketing initiatives related to its dermal resurfacing and skin laxity clearances. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On March 14, 2022, the U.S. Food and Drug Administration (&#8220;FDA&#8221;) posted a Safety Communication that warns consumers and health care providers against the use of the Company&#8217;s Advanced Energy products outside of their FDA-cleared indications for general use in cutting, coagulation, and ablation of soft tissue during open and laparoscopic surgical procedures. Following the Safety Communication, the Company experienced slowed demand for the adoption of its Helium Plasma Technology.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On May 26, 2022, the Company announced that it had received 510(k) clearance from the FDA for the use of the Renuvion&#174; Dermal Handpiece for specific dermal resurfacing procedures. On July 18, 2022, the Company announced that it had received 510(k) clearance from the FDA for the use of the Renuvion&#174; APR Handpiece for certain skin contraction procedures. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 2, 2022, and July 21, 2022, FDA updated the Medical Device Safety Communication to recognize the new 510(k) clearances for the Renuvion&#174; Dermal handpiece, and the expanded indications for the Renuvion&#174; APR handpieces. The 510(k) clearance for the Renuvion&#174; Dermal handpiece allows surgeons to perform dermal resurfacing procedures for the treatment of moderate to severe wrinkles and rhytides, limited to patients with Fitzpatrick Skin Types I, II or III.  The 510(k) clearance for the Renuvion&#174; APR handpieces now addresses improving the appearance of lax (loose) skin in the neck and submental region.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">While management expected that receiving these clearances would materially mitigate the financial effects of the Safety Communication in future periods, the Company continues to experience reduced demand for the adoption and utilization of its technology and management believes that this may have an adverse effect in future periods.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern. The going concern basis of presentation assumes that the Company will continue in operation one year after the date these financial statements are issued and will be able to realize its assets and discharge its liabilities and commitments in the normal course of business. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Financial Accounting Standards Board&#8217;s Accounting Standards Codification (&#8220;ASC&#8221;) Topic 205-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, management must evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company&#8217;s ability to continue as a going concern for one year from the date these condensed consolidated financial statements are issued. This evaluation does not take into consideration the potential mitigating effect of management&#8217;s plans that have not been fully implemented or are not within control of the Company as of the date the condensed consolidated financial statements are issued. When substantial doubt exists under this methodology, management evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about the Company&#8217;s ability to continue as a going concern. The mitigating effect of management&#8217;s plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity&#8217;s ability to continue as a going concern </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie9788c72f4874edca78c1c4f307fec05_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="i06fc890615184f3e9d8c6f8a89bf9edf"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">within one year after the date that the financial statements are issued.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">While sales were continuing to grow into the first quarter of 2022 prior to the FDA Safety Communication, over the last few years, exclusive of the Company&#8217;s sale of the Core business segment to Symmetry Surgical during 2018, it has incurred recurring net losses and cash outflows from operations and the Company anticipates that losses will continue in the near term. During the nine months ended September 30, 2022, the Company incurred an operating loss of $<ix:nonFraction unitRef="usd" contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8zMS9mcmFnOmNhYzU3NzI0YTVlNzQwNWY5YmE5ZDVlNTQ3MWRiZjVmL3RleHRyZWdpb246Y2FjNTc3MjRhNWU3NDA1ZjliYTlkNWU1NDcxZGJmNWZfMTY0OTI2NzQ2NDI4NA_409c30af-ff33-4117-8af9-5aa065360581">17.6</ix:nonFraction>&#160;million and used $<ix:nonFraction unitRef="usd" contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8zMS9mcmFnOmNhYzU3NzI0YTVlNzQwNWY5YmE5ZDVlNTQ3MWRiZjVmL3RleHRyZWdpb246Y2FjNTc3MjRhNWU3NDA1ZjliYTlkNWU1NDcxZGJmNWZfMTY0OTI2NzQ2NDI5OQ_003ffe8f-4615-4c80-ba1d-fbd75435e3e3">15.8</ix:nonFraction>&#160;million of cash in operations. As of September 30, 2022, the Company had cash and cash equivalents of $<ix:nonFraction unitRef="usd" contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8zMS9mcmFnOmNhYzU3NzI0YTVlNzQwNWY5YmE5ZDVlNTQ3MWRiZjVmL3RleHRyZWdpb246Y2FjNTc3MjRhNWU3NDA1ZjliYTlkNWU1NDcxZGJmNWZfMTY0OTI2NzQ2NDMxNA_14c7bf5e-e7ab-410f-8e72-7c49d75bac75">14.8</ix:nonFraction>&#160;million. These conditions raise substantial doubt about the Company&#8217;s ability to continue as a going concern for a period of at least one year from the date of issuance of these unaudited condensed consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In an effort to alleviate these conditions, management is currently evaluating various funding alternatives to improve liquidity and may seek to raise additional capital through debt financing, the sale of equity securities, leveraging its unencumbered real estate, or any combination thereof. In addition, management is actively pursuing collection of the Company&#8217;s income tax receivable. Management also continues to re-assess its operating expenditures and cost structure to be commensurate with its expected levels of revenue and has the ability to reduce or delay expenditures to enhance and preserve liquidity. As the Company seeks additional sources of financing, there can be no assurance that such financing would be available to the Company on favorable terms or at all. The Company&#8217;s ability to obtain additional financing in the debt and equity capital markets is subject to several factors, including market and economic conditions, the Company&#8217;s performance and investor sentiment with respect to the Company and its industry.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Management believes that the actions and efforts it can and will take to manage operating expenditures and, while not assured, arrange alternative financing sources as described above will enable the Company to meet its obligations for a period of at least one year from the date of issuance of these unaudited condensed consolidated financial statements. As a result, management believes its plans alleviate substantial doubt about its ability to continue as a going concern. These unaudited condensed financial statements do not include any adjustments relating to the carrying amounts and classification of assets and liabilities that may be necessary should the Company be unable to continue as a going concern.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared based upon SEC rules that permit reduced disclosure for interim periods. For a more complete discussion of significant accounting policies and certain other information, please refer to the consolidated financial statements included in our Annual Report on Form 10-K for the year ended December&#160;31, 2021. In the opinion of management these condensed consolidated financial statements reflect all adjustments that are necessary for a fair presentation of results of consolidated operations and financial condition for the interim periods shown, including normal recurring accruals and other items. The results for the interim periods are not necessarily indicative of results for the full year.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8zMS9mcmFnOmNhYzU3NzI0YTVlNzQwNWY5YmE5ZDVlNTQ3MWRiZjVmL3RleHRyZWdpb246Y2FjNTc3MjRhNWU3NDA1ZjliYTlkNWU1NDcxZGJmNWZfMzQ4Mg_1570d37a-2bfd-4a94-b54e-fda48b370725" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassifications</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have reclassified certain amounts presented in the prior period to conform to the current period presentation. These reclassifications had no impact on previously reported net loss, accumulated deficit or net cash used in operating activities for the periods presented.</span></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div id="ie9788c72f4874edca78c1c4f307fec05_34"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 2. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" name="us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8zNC9mcmFnOmUzZTIwNjYzMjlmNzQwMDVhNGU2ZmRmNDc0NmM1ZjY3L3RleHRyZWdpb246ZTNlMjA2NjMyOWY3NDAwNWE0ZTZmZGY0NzQ2YzVmNjdfMTU3Mg_b7bb7500-b5db-4aaa-99b5-71109bb58901" continuedAt="iee10d478149846de9269898b6a9202dd" escape="true">RECENT ACCOUNTING PRONOUNCEMENTS </ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><ix:continuation id="iee10d478149846de9269898b6a9202dd" continuedAt="ica31307cb9874487a4224f845d4a0de0"><ix:nonNumeric contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8zNC9mcmFnOmUzZTIwNjYzMjlmNzQwMDVhNGU2ZmRmNDc0NmM1ZjY3L3RleHRyZWdpb246ZTNlMjA2NjMyOWY3NDAwNWE0ZTZmZGY0NzQ2YzVmNjdfMTU3Ng_9bd67cad-b671-4c92-80d9-eaca77f8b5b3" continuedAt="i524e9d7ecfd448999853464ddc398d93" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments&#8212;Credit Losses (Topic 326).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The update changes the impairment model for most financial assets and certain other instruments, including trade and other receivables, contract assets, held-to-maturity debt securities and loans, and requires entities to use a new forward-looking expected loss model that will result in the earlier recognition of allowance for losses. This update, as originally issued, was effective for annual and interim periods beginning after December 15, 2019, with early adoption permitted. In November 2019, the FASB issued ASU 2019-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842) Effective Dates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which deferred the effective dates of these standards for Smaller Reporting Companies until fiscal years beginning after December 15, 2022. The Company currently continues to qualify as a Smaller Reporting Company, based upon the current SEC definition, and as a result, will be utilizing the deferred elective date. While we are in the process of determining the effects of the adoption of the standard on the condensed consolidated financial statements, we do not expect the impact to be material.</span></ix:nonNumeric></ix:continuation></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie9788c72f4874edca78c1c4f307fec05_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ica31307cb9874487a4224f845d4a0de0"><ix:continuation id="i524e9d7ecfd448999853464ddc398d93">No other new accounting pronouncement issued or effective during the fiscal year had or is expected to have a material impact on our consolidated financial statements or disclosures.</ix:continuation></ix:continuation></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="ie9788c72f4874edca78c1c4f307fec05_37"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie9788c72f4874edca78c1c4f307fec05_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 3. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" name="us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8zNy9mcmFnOmU4NDcyMWI2N2NiNjRiYjViNjkyYWRkZWI4MTdkYzg5L3RleHRyZWdpb246ZTg0NzIxYjY3Y2I2NGJiNWI2OTJhZGRlYjgxN2RjODlfMTU5MA_816350dc-a51b-45e4-a7be-347d9691deaf" continuedAt="i9852797c8f724e5488404323978650f4" escape="true">DISPOSAL OF BUSINESS</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i9852797c8f724e5488404323978650f4"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 30, 2018, the Company closed on a definitive asset purchase agreement (the &#8220;Asset Purchase Agreement&#8221;) with Specialty Surgical Instrumentation Inc., a Tennessee Corporation and wholly owned subsidiary of Symmetry Surgical Inc. (&#8220;Symmetry&#8221;), pursuant to which the Company divested and sold the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> electrosurgical &#8220;Core&#8221; business segment and related intellectual property, including the Bovie&#174; brand and trademarks, to Symmetry for gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="i10095f0cb8c949fbb4f3d9e2b6c90b20_D20180830-20180830" decimals="-6" name="us-gaap:ProceedsFromDivestitureOfBusinesses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8zNy9mcmFnOmU4NDcyMWI2N2NiNjRiYjViNjkyYWRkZWI4MTdkYzg5L3RleHRyZWdpb246ZTg0NzIxYjY3Y2I2NGJiNWI2OTJhZGRlYjgxN2RjODlfNTAy_c880b1f1-36c1-4073-9950-2deee883edbf">97</ix:nonFraction>&#160;million in cash.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Asset Purchase Agreement, the Company entered into an Electro Surgical Disposables and Accessories, Cauteries and Other Products Supply Agreement with Symmetry for a <ix:nonNumeric contextRef="i8c47d3c9d755423bac06c8de9bc6733a_D20180830-20180830" name="apyx:AssetPurchaseAgreementTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8zNy9mcmFnOmU4NDcyMWI2N2NiNjRiYjViNjkyYWRkZWI4MTdkYzg5L3RleHRyZWdpb246ZTg0NzIxYjY3Y2I2NGJiNWI2OTJhZGRlYjgxN2RjODlfMTU5MQ_96fb248e-859f-4d7a-a1a2-fb58cffbfb3d">four-year</ix:nonNumeric> term, which expired August 30, 2022, whereby it manufactured certain Core pro</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ducts and sold them to Symmetry at agreed upon prices. Any activity resulting from this agreement was netted and reported in the Condensed Consolidated Statements of Operations as other income (loss). There was no significant Core activity for the three months ended September&#160;30, 2022. Core activity for the three months ended September&#160;30, 2021, amounted to $<ix:nonFraction unitRef="usd" contextRef="i4df01ef2deb2470eab833fab1b386632_D20210701-20210930" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8zNy9mcmFnOmU4NDcyMWI2N2NiNjRiYjViNjkyYWRkZWI4MTdkYzg5L3RleHRyZWdpb246ZTg0NzIxYjY3Y2I2NGJiNWI2OTJhZGRlYjgxN2RjODlfMTE5Mw_8b44fbd8-7941-49ca-a58c-bda6206f8fbe">1.6</ix:nonFraction>&#160;million with cost of sales equivalents of $<ix:nonFraction unitRef="usd" contextRef="i4df01ef2deb2470eab833fab1b386632_D20210701-20210930" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8zNy9mcmFnOmU4NDcyMWI2N2NiNjRiYjViNjkyYWRkZWI4MTdkYzg5L3RleHRyZWdpb246ZTg0NzIxYjY3Y2I2NGJiNWI2OTJhZGRlYjgxN2RjODlfMTIzMA_857c195e-e39b-40bc-99f2-96c4bfe08109">1.3</ix:nonFraction>&#160;million and related other expenses of $<ix:nonFraction unitRef="usd" contextRef="i4df01ef2deb2470eab833fab1b386632_D20210701-20210930" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8zNy9mcmFnOmU4NDcyMWI2N2NiNjRiYjViNjkyYWRkZWI4MTdkYzg5L3RleHRyZWdpb246ZTg0NzIxYjY3Y2I2NGJiNWI2OTJhZGRlYjgxN2RjODlfMTI2Mw_ee05bdd1-ae4f-47d8-bb14-739c9918899b">0.5</ix:nonFraction>&#160;million for net other loss of $<ix:nonFraction unitRef="usd" contextRef="i4df01ef2deb2470eab833fab1b386632_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8zNy9mcmFnOmU4NDcyMWI2N2NiNjRiYjViNjkyYWRkZWI4MTdkYzg5L3RleHRyZWdpb246ZTg0NzIxYjY3Y2I2NGJiNWI2OTJhZGRlYjgxN2RjODlfMTI4Ng_498f40cf-467e-41c7-b8ee-24dbb1f360da">0.3</ix:nonFraction>&#160;million. Core activity for the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine months ended September 30, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, amounted to $<ix:nonFraction unitRef="usd" contextRef="i715d6d3cb64a4d328a61c8e29b09eeb1_D20220101-20220930" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8zNy9mcmFnOmU4NDcyMWI2N2NiNjRiYjViNjkyYWRkZWI4MTdkYzg5L3RleHRyZWdpb246ZTg0NzIxYjY3Y2I2NGJiNWI2OTJhZGRlYjgxN2RjODlfMTMyOA_e93d3ba2-5ce1-48a0-bdfb-5d901405e5dc">0.6</ix:nonFraction>&#160;million with cost of sales equivalents of $<ix:nonFraction unitRef="usd" contextRef="i715d6d3cb64a4d328a61c8e29b09eeb1_D20220101-20220930" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8zNy9mcmFnOmU4NDcyMWI2N2NiNjRiYjViNjkyYWRkZWI4MTdkYzg5L3RleHRyZWdpb246ZTg0NzIxYjY3Y2I2NGJiNWI2OTJhZGRlYjgxN2RjODlfMTM2NQ_fbc5f61a-30e8-4395-b816-496e6658db36">0.5</ix:nonFraction>&#160;million and other related expenses of $<ix:nonFraction unitRef="usd" contextRef="i715d6d3cb64a4d328a61c8e29b09eeb1_D20220101-20220930" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8zNy9mcmFnOmU4NDcyMWI2N2NiNjRiYjViNjkyYWRkZWI4MTdkYzg5L3RleHRyZWdpb246ZTg0NzIxYjY3Y2I2NGJiNWI2OTJhZGRlYjgxN2RjODlfMTM5OA_946b0419-cd04-453f-9f1c-4fa2e10832db">0.1</ix:nonFraction>&#160;million&#160;for net other loss of $<ix:nonFraction unitRef="usd" contextRef="i715d6d3cb64a4d328a61c8e29b09eeb1_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8zNy9mcmFnOmU4NDcyMWI2N2NiNjRiYjViNjkyYWRkZWI4MTdkYzg5L3RleHRyZWdpb246ZTg0NzIxYjY3Y2I2NGJiNWI2OTJhZGRlYjgxN2RjODlfMTQyMQ_c8aa63b9-67b9-481c-8229-7f742319f096">0.1</ix:nonFraction>&#160;million. Core activity for the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine months ended September 30, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, amounted to $<ix:nonFraction unitRef="usd" contextRef="i10540b8b8766421e91ac2cc3944b3109_D20210101-20210930" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8zNy9mcmFnOmU4NDcyMWI2N2NiNjRiYjViNjkyYWRkZWI4MTdkYzg5L3RleHRyZWdpb246ZTg0NzIxYjY3Y2I2NGJiNWI2OTJhZGRlYjgxN2RjODlfMTQ2Mw_6831cac6-8bc6-44b7-9ab7-d17ebbe5b2d6">5.2</ix:nonFraction>&#160;million with cost of sales equivalents of $<ix:nonFraction unitRef="usd" contextRef="i10540b8b8766421e91ac2cc3944b3109_D20210101-20210930" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8zNy9mcmFnOmU4NDcyMWI2N2NiNjRiYjViNjkyYWRkZWI4MTdkYzg5L3RleHRyZWdpb246ZTg0NzIxYjY3Y2I2NGJiNWI2OTJhZGRlYjgxN2RjODlfMTUwMA_3cf4d450-1ffd-42e8-a0c1-18c77dd5e515">4.4</ix:nonFraction>&#160;million and net other related operating expenses of $<ix:nonFraction unitRef="usd" contextRef="i10540b8b8766421e91ac2cc3944b3109_D20210101-20210930" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8zNy9mcmFnOmU4NDcyMWI2N2NiNjRiYjViNjkyYWRkZWI4MTdkYzg5L3RleHRyZWdpb246ZTg0NzIxYjY3Y2I2NGJiNWI2OTJhZGRlYjgxN2RjODlfMTU0Nw_c2a819ad-9838-470e-a1fe-60144b649249">1.1</ix:nonFraction>&#160;million for net other loss of $<ix:nonFraction unitRef="usd" contextRef="i10540b8b8766421e91ac2cc3944b3109_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8zNy9mcmFnOmU4NDcyMWI2N2NiNjRiYjViNjkyYWRkZWI4MTdkYzg5L3RleHRyZWdpb246ZTg0NzIxYjY3Y2I2NGJiNWI2OTJhZGRlYjgxN2RjODlfNTQ5NzU1ODE1NzI0_cc3d0505-06b8-43ca-96f0-ed2b01630552">0.3</ix:nonFraction>&#160;million.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><div id="ie9788c72f4874edca78c1c4f307fec05_40"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie9788c72f4874edca78c1c4f307fec05_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 4. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80MC9mcmFnOmFmOTc1NGRlNDkwOTQwZTBiNGIwYmZiYjE1YWU3MjJkL3RleHRyZWdpb246YWY5NzU0ZGU0OTA5NDBlMGI0YjBiZmJiMTVhZTcyMmRfMzk0_a530cab1-a2f6-42d0-8860-b5ff22e364f8" continuedAt="ib52bbf8df15f4881a67b66a7a549a671" escape="true">INVENTORIES</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="ib52bbf8df15f4881a67b66a7a549a671"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" name="us-gaap:InventoryPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80MC9mcmFnOmFmOTc1NGRlNDkwOTQwZTBiNGIwYmZiYjE1YWU3MjJkL3RleHRyZWdpb246YWY5NzU0ZGU0OTA5NDBlMGI0YjBiZmJiMTVhZTcyMmRfMzk2_c47f3fbb-d87d-4b07-8566-ef6247abca6c" escape="true">Inventories are stated at the lower of cost or net realizable value. Cost is determined on a first in, first out basis. Finished goods and work-in-process inventories include material, labor and overhead costs. Factory overhead costs are primarily allocated to inventory manufactured in-house based upon direct labor hours.</ix:nonNumeric> </span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80MC9mcmFnOmFmOTc1NGRlNDkwOTQwZTBiNGIwYmZiYjE1YWU3MjJkL3RleHRyZWdpb246YWY5NzU0ZGU0OTA5NDBlMGI0YjBiZmJiMTVhZTcyMmRfNDA2_2ab32668-18f6-42dd-8f98-6b9964a06488" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930" decimals="-3" name="us-gaap:InventoryRawMaterials" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80MC9mcmFnOmFmOTc1NGRlNDkwOTQwZTBiNGIwYmZiYjE1YWU3MjJkL3RhYmxlOmUwZmExMjFiZWRhOTRkYmFhYjg0NWQ1MTFjMzgzNjQxL3RhYmxlcmFuZ2U6ZTBmYTEyMWJlZGE5NGRiYWFiODQ1ZDUxMWMzODM2NDFfMS0xLTEtMS0xNzQxMA_6b61d08c-f081-40ca-baf4-afc8170dd5f0">5,078</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231" decimals="-3" name="us-gaap:InventoryRawMaterials" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80MC9mcmFnOmFmOTc1NGRlNDkwOTQwZTBiNGIwYmZiYjE1YWU3MjJkL3RhYmxlOmUwZmExMjFiZWRhOTRkYmFhYjg0NWQ1MTFjMzgzNjQxL3RhYmxlcmFuZ2U6ZTBmYTEyMWJlZGE5NGRiYWFiODQ1ZDUxMWMzODM2NDFfMS0zLTEtMS0xNzQxMA_58301aa7-6fb9-47e0-8101-d7ab9db80df0">3,603</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930" decimals="-3" name="us-gaap:InventoryWorkInProcess" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80MC9mcmFnOmFmOTc1NGRlNDkwOTQwZTBiNGIwYmZiYjE1YWU3MjJkL3RhYmxlOmUwZmExMjFiZWRhOTRkYmFhYjg0NWQ1MTFjMzgzNjQxL3RhYmxlcmFuZ2U6ZTBmYTEyMWJlZGE5NGRiYWFiODQ1ZDUxMWMzODM2NDFfMi0xLTEtMS0xNzQxMA_4e63899c-ac9a-4035-ac4d-07884f33e5b4">2,414</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231" decimals="-3" name="us-gaap:InventoryWorkInProcess" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80MC9mcmFnOmFmOTc1NGRlNDkwOTQwZTBiNGIwYmZiYjE1YWU3MjJkL3RhYmxlOmUwZmExMjFiZWRhOTRkYmFhYjg0NWQ1MTFjMzgzNjQxL3RhYmxlcmFuZ2U6ZTBmYTEyMWJlZGE5NGRiYWFiODQ1ZDUxMWMzODM2NDFfMi0zLTEtMS0xNzQxMA_3ed16e89-ac10-4040-92f1-3a1d808fdf12">1,441</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930" decimals="-3" name="us-gaap:InventoryFinishedGoods" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80MC9mcmFnOmFmOTc1NGRlNDkwOTQwZTBiNGIwYmZiYjE1YWU3MjJkL3RhYmxlOmUwZmExMjFiZWRhOTRkYmFhYjg0NWQ1MTFjMzgzNjQxL3RhYmxlcmFuZ2U6ZTBmYTEyMWJlZGE5NGRiYWFiODQ1ZDUxMWMzODM2NDFfMy0xLTEtMS0xNzQxMA_70fa8382-b161-4d47-b82b-6e055c48c6bd">4,929</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231" decimals="-3" name="us-gaap:InventoryFinishedGoods" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80MC9mcmFnOmFmOTc1NGRlNDkwOTQwZTBiNGIwYmZiYjE1YWU3MjJkL3RhYmxlOmUwZmExMjFiZWRhOTRkYmFhYjg0NWQ1MTFjMzgzNjQxL3RhYmxlcmFuZ2U6ZTBmYTEyMWJlZGE5NGRiYWFiODQ1ZDUxMWMzODM2NDFfMy0zLTEtMS0xNzQxMA_ebb5261b-1c71-4c53-a52d-3f85b7e9cffa">1,997</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross inventories</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930" decimals="-3" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80MC9mcmFnOmFmOTc1NGRlNDkwOTQwZTBiNGIwYmZiYjE1YWU3MjJkL3RhYmxlOmUwZmExMjFiZWRhOTRkYmFhYjg0NWQ1MTFjMzgzNjQxL3RhYmxlcmFuZ2U6ZTBmYTEyMWJlZGE5NGRiYWFiODQ1ZDUxMWMzODM2NDFfNC0xLTEtMS0xNzQxMA_2f4c0c39-a1fd-4cf1-a992-571f76f6d909">12,421</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231" decimals="-3" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80MC9mcmFnOmFmOTc1NGRlNDkwOTQwZTBiNGIwYmZiYjE1YWU3MjJkL3RhYmxlOmUwZmExMjFiZWRhOTRkYmFhYjg0NWQ1MTFjMzgzNjQxL3RhYmxlcmFuZ2U6ZTBmYTEyMWJlZGE5NGRiYWFiODQ1ZDUxMWMzODM2NDFfNC0zLTEtMS0xNzQxMA_4490dddc-1aaa-438b-80e5-6db6cf44b6d8">7,041</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: provision for obsolescence</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930" decimals="-3" name="us-gaap:InventoryValuationReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80MC9mcmFnOmFmOTc1NGRlNDkwOTQwZTBiNGIwYmZiYjE1YWU3MjJkL3RhYmxlOmUwZmExMjFiZWRhOTRkYmFhYjg0NWQ1MTFjMzgzNjQxL3RhYmxlcmFuZ2U6ZTBmYTEyMWJlZGE5NGRiYWFiODQ1ZDUxMWMzODM2NDFfNS0xLTEtMS0xNzQxMA_dec3f809-bbbf-42bd-9792-743cad1e1de5">379</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231" decimals="-3" name="us-gaap:InventoryValuationReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80MC9mcmFnOmFmOTc1NGRlNDkwOTQwZTBiNGIwYmZiYjE1YWU3MjJkL3RhYmxlOmUwZmExMjFiZWRhOTRkYmFhYjg0NWQ1MTFjMzgzNjQxL3RhYmxlcmFuZ2U6ZTBmYTEyMWJlZGE5NGRiYWFiODQ1ZDUxMWMzODM2NDFfNS0zLTEtMS0xNzQxMA_b1cc48ec-3d85-478f-be56-e6f6a7e8d6d9">263</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80MC9mcmFnOmFmOTc1NGRlNDkwOTQwZTBiNGIwYmZiYjE1YWU3MjJkL3RhYmxlOmUwZmExMjFiZWRhOTRkYmFhYjg0NWQ1MTFjMzgzNjQxL3RhYmxlcmFuZ2U6ZTBmYTEyMWJlZGE5NGRiYWFiODQ1ZDUxMWMzODM2NDFfNi0xLTEtMS0xNzQxMA_52e0bad1-d5e1-440a-b146-71de454473fd">12,042</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80MC9mcmFnOmFmOTc1NGRlNDkwOTQwZTBiNGIwYmZiYjE1YWU3MjJkL3RhYmxlOmUwZmExMjFiZWRhOTRkYmFhYjg0NWQ1MTFjMzgzNjQxL3RhYmxlcmFuZ2U6ZTBmYTEyMWJlZGE5NGRiYWFiODQ1ZDUxMWMzODM2NDFfNi0zLTEtMS0xNzQxMA_420b1cc8-af7c-4185-ae5c-140e04e6e149">6,778</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><div id="ie9788c72f4874edca78c1c4f307fec05_43"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie9788c72f4874edca78c1c4f307fec05_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 5. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" name="us-gaap:LesseeFinanceLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80My9mcmFnOjdkYWVhMmQxMDk4MzQ2ZjFhZGEzYTkyZGRmY2E2ZThlL3RleHRyZWdpb246N2RhZWEyZDEwOTgzNDZmMWFkYTNhOTJkZGZjYTZlOGVfODc2_ea54fd16-05ce-4cda-a27d-a566798a880e" continuedAt="i9acd27b54c1140cf969f879ff83e7b84" escape="true"><ix:nonNumeric contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80My9mcmFnOjdkYWVhMmQxMDk4MzQ2ZjFhZGEzYTkyZGRmY2E2ZThlL3RleHRyZWdpb246N2RhZWEyZDEwOTgzNDZmMWFkYTNhOTJkZGZjYTZlOGVfODc2_eda45fc8-f539-461a-981d-7ad15ad0a69d" continuedAt="i21128cb481aa40809e8abafdfef5c62f" escape="true">LEASES</ix:nonNumeric></ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i9acd27b54c1140cf969f879ff83e7b84"><ix:continuation id="i21128cb481aa40809e8abafdfef5c62f"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Operating Leases</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company leases its facility in Sofia, Bulgaria and computers under non-cancelable operating lease agreements. During the three months ended September 30, 2022, the Company&#8217;s leases on the vehicles in Clearwater, Florida expired and the Company purchased the vehicles at fair value. During the three months ended September 30, 2022, the Company entered into a <ix:nonNumeric contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80My9mcmFnOjdkYWVhMmQxMDk4MzQ2ZjFhZGEzYTkyZGRmY2E2ZThlL3RleHRyZWdpb246N2RhZWEyZDEwOTgzNDZmMWFkYTNhOTJkZGZjYTZlOGVfMTY0OTI2NzQ0MzU2OA_8af013e9-8b73-4b93-89c8-8db274ca8de3">one year</ix:nonNumeric> extension on one of its leases on computer equipment. This extension resulted in reclassification of the lease from finance to operating. During the nine months ended September 30, 2022, the Company entered into a <ix:nonNumeric contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80My9mcmFnOjdkYWVhMmQxMDk4MzQ2ZjFhZGEzYTkyZGRmY2E2ZThlL3RleHRyZWdpb246N2RhZWEyZDEwOTgzNDZmMWFkYTNhOTJkZGZjYTZlOGVfODc3_1cdb8262-a8d0-4a1f-9333-06150ebebc20">five year</ix:nonNumeric> extension of its Sofia, Bulgaria facility. These operating leases have terms expiring through December 2027. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Finance Leases</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into non-cancelable finance leases for certain computer equipment and a vehicle in Clearwater, Florida. During the nine months ended September 30, 2022, the Company entered into a <ix:nonNumeric contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930" name="us-gaap:LesseeFinanceLeaseTermOfContract1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80My9mcmFnOjdkYWVhMmQxMDk4MzQ2ZjFhZGEzYTkyZGRmY2E2ZThlL3RleHRyZWdpb246N2RhZWEyZDEwOTgzNDZmMWFkYTNhOTJkZGZjYTZlOGVfODc4_6bd4e56a-629d-4c64-bdac-9d9d94736df5">63</ix:nonNumeric> month lease for computer equipment. These finance leases have terms expiring through July 2027. </span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80My9mcmFnOjdkYWVhMmQxMDk4MzQ2ZjFhZGEzYTkyZGRmY2E2ZThlL3RleHRyZWdpb246N2RhZWEyZDEwOTgzNDZmMWFkYTNhOTJkZGZjYTZlOGVfODc5_490fb205-23b2-4e44-b886-16ce58c68a50" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information about the Company&#8217;s weighted average remaining lease terms and discount rate assumptions are as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.160%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term (in years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80My9mcmFnOjdkYWVhMmQxMDk4MzQ2ZjFhZGEzYTkyZGRmY2E2ZThlL3RhYmxlOmFjYmEwMmIyMzI3NzQzNDg5ODQyNTY2YjQ1MTZlMTM4L3RhYmxlcmFuZ2U6YWNiYTAyYjIzMjc3NDM0ODk4NDI1NjZiNDUxNmUxMzhfMi0xLTEtMS0xNzQxMA_f91474cf-67e4-4d27-a534-458130a3d603">4.4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80My9mcmFnOjdkYWVhMmQxMDk4MzQ2ZjFhZGEzYTkyZGRmY2E2ZThlL3RhYmxlOmFjYmEwMmIyMzI3NzQzNDg5ODQyNTY2YjQ1MTZlMTM4L3RhYmxlcmFuZ2U6YWNiYTAyYjIzMjc3NDM0ODk4NDI1NjZiNDUxNmUxMzhfMi0yLTEtMS0xNzQxMA_99a0ce8f-ad1a-4c65-9365-0c332825e855">4.1</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80My9mcmFnOjdkYWVhMmQxMDk4MzQ2ZjFhZGEzYTkyZGRmY2E2ZThlL3RhYmxlOmFjYmEwMmIyMzI3NzQzNDg5ODQyNTY2YjQ1MTZlMTM4L3RhYmxlcmFuZ2U6YWNiYTAyYjIzMjc3NDM0ODk4NDI1NjZiNDUxNmUxMzhfMi00LTEtMS0xNzQxMA_a3b5da59-db2a-4a02-88a7-24a483a7075e">1.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80My9mcmFnOjdkYWVhMmQxMDk4MzQ2ZjFhZGEzYTkyZGRmY2E2ZThlL3RhYmxlOmFjYmEwMmIyMzI3NzQzNDg5ODQyNTY2YjQ1MTZlMTM4L3RhYmxlcmFuZ2U6YWNiYTAyYjIzMjc3NDM0ODk4NDI1NjZiNDUxNmUxMzhfMi01LTEtMS0xNzQxMA_506a8ddc-9f90-4dc2-875d-ab52cbc69fe0">0.8</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930" decimals="INF" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80My9mcmFnOjdkYWVhMmQxMDk4MzQ2ZjFhZGEzYTkyZGRmY2E2ZThlL3RhYmxlOmFjYmEwMmIyMzI3NzQzNDg5ODQyNTY2YjQ1MTZlMTM4L3RhYmxlcmFuZ2U6YWNiYTAyYjIzMjc3NDM0ODk4NDI1NjZiNDUxNmUxMzhfMy0xLTEtMS0xNzQxMA_191b537d-a655-4ed4-9e3c-68655573377d">2.75</ix:nonFraction>%</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930" decimals="INF" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80My9mcmFnOjdkYWVhMmQxMDk4MzQ2ZjFhZGEzYTkyZGRmY2E2ZThlL3RhYmxlOmFjYmEwMmIyMzI3NzQzNDg5ODQyNTY2YjQ1MTZlMTM4L3RhYmxlcmFuZ2U6YWNiYTAyYjIzMjc3NDM0ODk4NDI1NjZiNDUxNmUxMzhfMy0yLTEtMS0xNzQxMA_31399ca0-850b-41c4-bb68-0f6dcbc30910">2.64</ix:nonFraction>%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231" decimals="INF" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80My9mcmFnOjdkYWVhMmQxMDk4MzQ2ZjFhZGEzYTkyZGRmY2E2ZThlL3RhYmxlOmFjYmEwMmIyMzI3NzQzNDg5ODQyNTY2YjQ1MTZlMTM4L3RhYmxlcmFuZ2U6YWNiYTAyYjIzMjc3NDM0ODk4NDI1NjZiNDUxNmUxMzhfMy00LTEtMS0xNzQxMA_434aa496-28f7-4290-9616-b655392cf6ba">3.98</ix:nonFraction>%</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231" decimals="INF" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80My9mcmFnOjdkYWVhMmQxMDk4MzQ2ZjFhZGEzYTkyZGRmY2E2ZThlL3RhYmxlOmFjYmEwMmIyMzI3NzQzNDg5ODQyNTY2YjQ1MTZlMTM4L3RhYmxlcmFuZ2U6YWNiYTAyYjIzMjc3NDM0ODk4NDI1NjZiNDUxNmUxMzhfMy01LTEtMS0xNzQxMA_9ad54eb0-5491-4117-baeb-a20d1a9b5788">4.00</ix:nonFraction>%</span></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" name="us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80My9mcmFnOjdkYWVhMmQxMDk4MzQ2ZjFhZGEzYTkyZGRmY2E2ZThlL3RleHRyZWdpb246N2RhZWEyZDEwOTgzNDZmMWFkYTNhOTJkZGZjYTZlOGVfODgw_60206e2f-8849-47a1-980e-4a1b4f78ea97" escape="true"><ix:nonNumeric contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80My9mcmFnOjdkYWVhMmQxMDk4MzQ2ZjFhZGEzYTkyZGRmY2E2ZThlL3RleHRyZWdpb246N2RhZWEyZDEwOTgzNDZmMWFkYTNhOTJkZGZjYTZlOGVfODgw_db7c765c-d70e-4de0-873a-fe3f8e1906d9" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of lease liabilities as of September 30, 2022 are as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:76.319%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.190%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.191%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80My9mcmFnOjdkYWVhMmQxMDk4MzQ2ZjFhZGEzYTkyZGRmY2E2ZThlL3RhYmxlOmMxMDE2Y2UwMjhkYjQ3MWY5NWJkZDYzMGNkYzI2ZWQ4L3RhYmxlcmFuZ2U6YzEwMTZjZTAyOGRiNDcxZjk1YmRkNjMwY2RjMjZlZDhfMi0xLTEtMS0xNzQxMA_b1be9771-c554-4a8c-bdbe-0428111e6011">75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80My9mcmFnOjdkYWVhMmQxMDk4MzQ2ZjFhZGEzYTkyZGRmY2E2ZThlL3RhYmxlOmMxMDE2Y2UwMjhkYjQ3MWY5NWJkZDYzMGNkYzI2ZWQ4L3RhYmxlcmFuZ2U6YzEwMTZjZTAyOGRiNDcxZjk1YmRkNjMwY2RjMjZlZDhfMi0yLTEtMS0xNzQxMA_6c4b09ba-f11b-4c8b-99aa-651177ce0921">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80My9mcmFnOjdkYWVhMmQxMDk4MzQ2ZjFhZGEzYTkyZGRmY2E2ZThlL3RhYmxlOmMxMDE2Y2UwMjhkYjQ3MWY5NWJkZDYzMGNkYzI2ZWQ4L3RhYmxlcmFuZ2U6YzEwMTZjZTAyOGRiNDcxZjk1YmRkNjMwY2RjMjZlZDhfMy0xLTEtMS0xNzQxMA_c959953d-7137-41d7-a97e-2d4131123347">218</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80My9mcmFnOjdkYWVhMmQxMDk4MzQ2ZjFhZGEzYTkyZGRmY2E2ZThlL3RhYmxlOmMxMDE2Y2UwMjhkYjQ3MWY5NWJkZDYzMGNkYzI2ZWQ4L3RhYmxlcmFuZ2U6YzEwMTZjZTAyOGRiNDcxZjk1YmRkNjMwY2RjMjZlZDhfMy0yLTEtMS0xNzQxMA_80ee3039-c154-4bbe-8126-0b5a8d923f68">40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80My9mcmFnOjdkYWVhMmQxMDk4MzQ2ZjFhZGEzYTkyZGRmY2E2ZThlL3RhYmxlOmMxMDE2Y2UwMjhkYjQ3MWY5NWJkZDYzMGNkYzI2ZWQ4L3RhYmxlcmFuZ2U6YzEwMTZjZTAyOGRiNDcxZjk1YmRkNjMwY2RjMjZlZDhfNC0xLTEtMS0xNzQxMA_8fe38355-99f0-49f2-bf82-b991890f5b5a">111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80My9mcmFnOjdkYWVhMmQxMDk4MzQ2ZjFhZGEzYTkyZGRmY2E2ZThlL3RhYmxlOmMxMDE2Y2UwMjhkYjQ3MWY5NWJkZDYzMGNkYzI2ZWQ4L3RhYmxlcmFuZ2U6YzEwMTZjZTAyOGRiNDcxZjk1YmRkNjMwY2RjMjZlZDhfNC0yLTEtMS0xNzQxMA_a6ad4a7e-44f5-46a2-95e3-90ab656963cb">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80My9mcmFnOjdkYWVhMmQxMDk4MzQ2ZjFhZGEzYTkyZGRmY2E2ZThlL3RhYmxlOmMxMDE2Y2UwMjhkYjQ3MWY5NWJkZDYzMGNkYzI2ZWQ4L3RhYmxlcmFuZ2U6YzEwMTZjZTAyOGRiNDcxZjk1YmRkNjMwY2RjMjZlZDhfNS0xLTEtMS0xNzQxMA_2a39d335-94f2-4f8f-ad3f-32c7f03634da">111</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80My9mcmFnOjdkYWVhMmQxMDk4MzQ2ZjFhZGEzYTkyZGRmY2E2ZThlL3RhYmxlOmMxMDE2Y2UwMjhkYjQ3MWY5NWJkZDYzMGNkYzI2ZWQ4L3RhYmxlcmFuZ2U6YzEwMTZjZTAyOGRiNDcxZjk1YmRkNjMwY2RjMjZlZDhfNS0yLTEtMS0xNzQxMA_14d79910-03e1-41d2-86f9-65d6fcdd0c0d">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80My9mcmFnOjdkYWVhMmQxMDk4MzQ2ZjFhZGEzYTkyZGRmY2E2ZThlL3RhYmxlOmMxMDE2Y2UwMjhkYjQ3MWY5NWJkZDYzMGNkYzI2ZWQ4L3RhYmxlcmFuZ2U6YzEwMTZjZTAyOGRiNDcxZjk1YmRkNjMwY2RjMjZlZDhfNi0xLTEtMS0xNzQxMA_9f58d664-7c54-40b2-afbd-fca8ff7d57d0">111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80My9mcmFnOjdkYWVhMmQxMDk4MzQ2ZjFhZGEzYTkyZGRmY2E2ZThlL3RhYmxlOmMxMDE2Y2UwMjhkYjQ3MWY5NWJkZDYzMGNkYzI2ZWQ4L3RhYmxlcmFuZ2U6YzEwMTZjZTAyOGRiNDcxZjk1YmRkNjMwY2RjMjZlZDhfNi0yLTEtMS0xNzQxMA_36301b75-a645-4419-a37e-97ea4afe46fe">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930" decimals="-3" name="apyx:LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80My9mcmFnOjdkYWVhMmQxMDk4MzQ2ZjFhZGEzYTkyZGRmY2E2ZThlL3RhYmxlOmMxMDE2Y2UwMjhkYjQ3MWY5NWJkZDYzMGNkYzI2ZWQ4L3RhYmxlcmFuZ2U6YzEwMTZjZTAyOGRiNDcxZjk1YmRkNjMwY2RjMjZlZDhfNy0xLTEtMS0xNzQxMA_1abfbbb8-f5db-4373-9aa5-4686ca954360">111</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930" decimals="-3" name="apyx:FinanceLeaseLiabilityToBePaidDueAfterYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80My9mcmFnOjdkYWVhMmQxMDk4MzQ2ZjFhZGEzYTkyZGRmY2E2ZThlL3RhYmxlOmMxMDE2Y2UwMjhkYjQ3MWY5NWJkZDYzMGNkYzI2ZWQ4L3RhYmxlcmFuZ2U6YzEwMTZjZTAyOGRiNDcxZjk1YmRkNjMwY2RjMjZlZDhfNy0yLTEtMS0xNzQxMA_48f4c9a1-b8ef-4c92-868c-922719396759">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80My9mcmFnOjdkYWVhMmQxMDk4MzQ2ZjFhZGEzYTkyZGRmY2E2ZThlL3RhYmxlOmMxMDE2Y2UwMjhkYjQ3MWY5NWJkZDYzMGNkYzI2ZWQ4L3RhYmxlcmFuZ2U6YzEwMTZjZTAyOGRiNDcxZjk1YmRkNjMwY2RjMjZlZDhfOC0xLTEtMS0xNzQxMA_0dc85e06-3397-490a-9d18-89476073ac10">737</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80My9mcmFnOjdkYWVhMmQxMDk4MzQ2ZjFhZGEzYTkyZGRmY2E2ZThlL3RhYmxlOmMxMDE2Y2UwMjhkYjQ3MWY5NWJkZDYzMGNkYzI2ZWQ4L3RhYmxlcmFuZ2U6YzEwMTZjZTAyOGRiNDcxZjk1YmRkNjMwY2RjMjZlZDhfOC0yLTEtMS0xNzQxMA_51d20c1a-6ef3-4488-ad08-a62cc163e6de">125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80My9mcmFnOjdkYWVhMmQxMDk4MzQ2ZjFhZGEzYTkyZGRmY2E2ZThlL3RhYmxlOmMxMDE2Y2UwMjhkYjQ3MWY5NWJkZDYzMGNkYzI2ZWQ4L3RhYmxlcmFuZ2U6YzEwMTZjZTAyOGRiNDcxZjk1YmRkNjMwY2RjMjZlZDhfOS0xLTEtMS0xNzQxMA_c3ab77df-bd5f-4024-a30d-4e9c7700d6cf">43</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930" decimals="-3" name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80My9mcmFnOjdkYWVhMmQxMDk4MzQ2ZjFhZGEzYTkyZGRmY2E2ZThlL3RhYmxlOmMxMDE2Y2UwMjhkYjQ3MWY5NWJkZDYzMGNkYzI2ZWQ4L3RhYmxlcmFuZ2U6YzEwMTZjZTAyOGRiNDcxZjk1YmRkNjMwY2RjMjZlZDhfOS0yLTEtMS0xNzQxMA_b4e520f1-7476-43bc-887f-613805aba924">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930" decimals="-3" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80My9mcmFnOjdkYWVhMmQxMDk4MzQ2ZjFhZGEzYTkyZGRmY2E2ZThlL3RhYmxlOmMxMDE2Y2UwMjhkYjQ3MWY5NWJkZDYzMGNkYzI2ZWQ4L3RhYmxlcmFuZ2U6YzEwMTZjZTAyOGRiNDcxZjk1YmRkNjMwY2RjMjZlZDhfMTAtMS0xLTEtMTc0MTA_8d2849c9-d0e1-4798-8673-c44cb7e60392">694</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930" decimals="-3" name="us-gaap:FinanceLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80My9mcmFnOjdkYWVhMmQxMDk4MzQ2ZjFhZGEzYTkyZGRmY2E2ZThlL3RhYmxlOmMxMDE2Y2UwMjhkYjQ3MWY5NWJkZDYzMGNkYzI2ZWQ4L3RhYmxlcmFuZ2U6YzEwMTZjZTAyOGRiNDcxZjk1YmRkNjMwY2RjMjZlZDhfMTAtMi0xLTEtMTc0MTA_e80847ad-9cc0-4e28-bb3d-16afaac17644">120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less current portion of lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80My9mcmFnOjdkYWVhMmQxMDk4MzQ2ZjFhZGEzYTkyZGRmY2E2ZThlL3RhYmxlOmMxMDE2Y2UwMjhkYjQ3MWY5NWJkZDYzMGNkYzI2ZWQ4L3RhYmxlcmFuZ2U6YzEwMTZjZTAyOGRiNDcxZjk1YmRkNjMwY2RjMjZlZDhfMTEtMS0xLTEtMTc0MTA_c2f46474-dc02-4125-8206-dd51438ff714">240</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80My9mcmFnOjdkYWVhMmQxMDk4MzQ2ZjFhZGEzYTkyZGRmY2E2ZThlL3RhYmxlOmMxMDE2Y2UwMjhkYjQ3MWY5NWJkZDYzMGNkYzI2ZWQ4L3RhYmxlcmFuZ2U6YzEwMTZjZTAyOGRiNDcxZjk1YmRkNjMwY2RjMjZlZDhfMTEtMi0xLTEtMTc0MTA_87f8231f-5bc5-4a1f-82b5-d19bf08ab98e">42</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion of lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80My9mcmFnOjdkYWVhMmQxMDk4MzQ2ZjFhZGEzYTkyZGRmY2E2ZThlL3RhYmxlOmMxMDE2Y2UwMjhkYjQ3MWY5NWJkZDYzMGNkYzI2ZWQ4L3RhYmxlcmFuZ2U6YzEwMTZjZTAyOGRiNDcxZjk1YmRkNjMwY2RjMjZlZDhfMTItMS0xLTEtMTc0MTA_a5015eb8-fa4a-4b13-82fa-25c69c15bd31">454</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80My9mcmFnOjdkYWVhMmQxMDk4MzQ2ZjFhZGEzYTkyZGRmY2E2ZThlL3RhYmxlOmMxMDE2Y2UwMjhkYjQ3MWY5NWJkZDYzMGNkYzI2ZWQ4L3RhYmxlcmFuZ2U6YzEwMTZjZTAyOGRiNDcxZjk1YmRkNjMwY2RjMjZlZDhfMTItMi0xLTEtMTc0MTA_7166a453-3c9b-4222-991f-436eee0b4d34">78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric></ix:continuation></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><div id="ie9788c72f4874edca78c1c4f307fec05_46"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie9788c72f4874edca78c1c4f307fec05_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 6. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80Ni9mcmFnOjQ3NGYxZThlODdhMDRjODA4ZGEzYTI3YzU4MWE2MmE5L3RleHRyZWdpb246NDc0ZjFlOGU4N2EwNGM4MDhkYTNhMjdjNTgxYTYyYTlfNDE3_18ca86fe-f88e-4204-a5ab-a8fdfa99ef38" continuedAt="i0503b2c3ff084613a51b1542882a1338" escape="true">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i0503b2c3ff084613a51b1542882a1338"><ix:nonNumeric contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80Ni9mcmFnOjQ3NGYxZThlODdhMDRjODA4ZGEzYTI3YzU4MWE2MmE5L3RleHRyZWdpb246NDc0ZjFlOGU4N2EwNGM4MDhkYTNhMjdjNTgxYTYyYTlfNDE4_174e9b2f-f7ba-4c00-9924-f28ed4244586" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consisted of the following:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930" decimals="-3" name="us-gaap:AccruedSalariesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80Ni9mcmFnOjQ3NGYxZThlODdhMDRjODA4ZGEzYTI3YzU4MWE2MmE5L3RhYmxlOjY0NGYwMTE2ODliZTRkMDA5MDNkMDI3NDhmN2I0YTgyL3RhYmxlcmFuZ2U6NjQ0ZjAxMTY4OWJlNGQwMDkwM2QwMjc0OGY3YjRhODJfMS0xLTEtMS0xNzQxMA_cd13bed1-6ac2-40d3-aaf6-17211d1be9d6">879</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231" decimals="-3" name="us-gaap:AccruedSalariesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80Ni9mcmFnOjQ3NGYxZThlODdhMDRjODA4ZGEzYTI3YzU4MWE2MmE5L3RhYmxlOjY0NGYwMTE2ODliZTRkMDA5MDNkMDI3NDhmN2I0YTgyL3RhYmxlcmFuZ2U6NjQ0ZjAxMTY4OWJlNGQwMDkwM2QwMjc0OGY3YjRhODJfMS0zLTEtMS0xNzQxMA_1c253752-c172-430b-90d9-4bb68417bd3e">546</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued bonuses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930" decimals="-3" name="us-gaap:AccruedBonusesCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80Ni9mcmFnOjQ3NGYxZThlODdhMDRjODA4ZGEzYTI3YzU4MWE2MmE5L3RhYmxlOjY0NGYwMTE2ODliZTRkMDA5MDNkMDI3NDhmN2I0YTgyL3RhYmxlcmFuZ2U6NjQ0ZjAxMTY4OWJlNGQwMDkwM2QwMjc0OGY3YjRhODJfMi0xLTEtMS0xNzQxMA_23864f31-b0f1-4667-ba15-68532a4d7533">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231" decimals="-3" name="us-gaap:AccruedBonusesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80Ni9mcmFnOjQ3NGYxZThlODdhMDRjODA4ZGEzYTI3YzU4MWE2MmE5L3RhYmxlOjY0NGYwMTE2ODliZTRkMDA5MDNkMDI3NDhmN2I0YTgyL3RhYmxlcmFuZ2U6NjQ0ZjAxMTY4OWJlNGQwMDkwM2QwMjc0OGY3YjRhODJfMi0zLTEtMS0xNzQxMA_f6827d99-1dcf-4d60-b0da-2b7ecff6f31e">2,117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued commissions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930" decimals="-3" name="us-gaap:AccruedSalesCommissionCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80Ni9mcmFnOjQ3NGYxZThlODdhMDRjODA4ZGEzYTI3YzU4MWE2MmE5L3RhYmxlOjY0NGYwMTE2ODliZTRkMDA5MDNkMDI3NDhmN2I0YTgyL3RhYmxlcmFuZ2U6NjQ0ZjAxMTY4OWJlNGQwMDkwM2QwMjc0OGY3YjRhODJfMy0xLTEtMS0xNzQxMA_ac851c10-2ee4-49f5-9913-01ee75f51a7d">877</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231" decimals="-3" name="us-gaap:AccruedSalesCommissionCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80Ni9mcmFnOjQ3NGYxZThlODdhMDRjODA4ZGEzYTI3YzU4MWE2MmE5L3RhYmxlOjY0NGYwMTE2ODliZTRkMDA5MDNkMDI3NDhmN2I0YTgyL3RhYmxlcmFuZ2U6NjQ0ZjAxMTY4OWJlNGQwMDkwM2QwMjc0OGY3YjRhODJfMy0zLTEtMS0xNzQxMA_e087d8cc-f1ab-4d5c-9833-54b17c7cacfb">1,656</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued product warranties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930" decimals="-3" name="us-gaap:ProductWarrantyAccrualClassifiedCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80Ni9mcmFnOjQ3NGYxZThlODdhMDRjODA4ZGEzYTI3YzU4MWE2MmE5L3RhYmxlOjY0NGYwMTE2ODliZTRkMDA5MDNkMDI3NDhmN2I0YTgyL3RhYmxlcmFuZ2U6NjQ0ZjAxMTY4OWJlNGQwMDkwM2QwMjc0OGY3YjRhODJfNC0xLTEtMS0xNzQxMA_639378c6-92c3-40dc-9c56-699d07be3205">616</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231" decimals="-3" name="us-gaap:ProductWarrantyAccrualClassifiedCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80Ni9mcmFnOjQ3NGYxZThlODdhMDRjODA4ZGEzYTI3YzU4MWE2MmE5L3RhYmxlOjY0NGYwMTE2ODliZTRkMDA5MDNkMDI3NDhmN2I0YTgyL3RhYmxlcmFuZ2U6NjQ0ZjAxMTY4OWJlNGQwMDkwM2QwMjc0OGY3YjRhODJfNC0zLTEtMS0xNzQxMA_d9997eb2-3039-4915-ae81-fdc2cc19ef12">593</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued product liability claim insurance deductibles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930" decimals="-3" name="us-gaap:AccruedInsuranceCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80Ni9mcmFnOjQ3NGYxZThlODdhMDRjODA4ZGEzYTI3YzU4MWE2MmE5L3RhYmxlOjY0NGYwMTE2ODliZTRkMDA5MDNkMDI3NDhmN2I0YTgyL3RhYmxlcmFuZ2U6NjQ0ZjAxMTY4OWJlNGQwMDkwM2QwMjc0OGY3YjRhODJfNS0xLTEtMS0xNzQxMA_39ffa0ca-8528-4aa5-b043-72b616ec3a63">1,016</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231" decimals="-3" name="us-gaap:AccruedInsuranceCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80Ni9mcmFnOjQ3NGYxZThlODdhMDRjODA4ZGEzYTI3YzU4MWE2MmE5L3RhYmxlOjY0NGYwMTE2ODliZTRkMDA5MDNkMDI3NDhmN2I0YTgyL3RhYmxlcmFuZ2U6NjQ0ZjAxMTY4OWJlNGQwMDkwM2QwMjc0OGY3YjRhODJfNS0zLTEtMS0xNzQxMA_0d989d13-ae17-46ff-95d3-27f173f481b9">610</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees and legal related contingent liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80Ni9mcmFnOjQ3NGYxZThlODdhMDRjODA4ZGEzYTI3YzU4MWE2MmE5L3RhYmxlOjY0NGYwMTE2ODliZTRkMDA5MDNkMDI3NDhmN2I0YTgyL3RhYmxlcmFuZ2U6NjQ0ZjAxMTY4OWJlNGQwMDkwM2QwMjc0OGY3YjRhODJfNi0xLTEtMS0xNzQxMA_972617dc-595d-4300-93bf-aaeeef32bc0f">1,134</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80Ni9mcmFnOjQ3NGYxZThlODdhMDRjODA4ZGEzYTI3YzU4MWE2MmE5L3RhYmxlOjY0NGYwMTE2ODliZTRkMDA5MDNkMDI3NDhmN2I0YTgyL3RhYmxlcmFuZ2U6NjQ0ZjAxMTY4OWJlNGQwMDkwM2QwMjc0OGY3YjRhODJfNi0zLTEtMS0xNzQxMA_9ea7a24b-6e9b-4711-817a-2efce91a02d0">421</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Joint and several payroll liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930" decimals="-3" name="apyx:JointAndSeveralPayrollLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80Ni9mcmFnOjQ3NGYxZThlODdhMDRjODA4ZGEzYTI3YzU4MWE2MmE5L3RhYmxlOjY0NGYwMTE2ODliZTRkMDA5MDNkMDI3NDhmN2I0YTgyL3RhYmxlcmFuZ2U6NjQ0ZjAxMTY4OWJlNGQwMDkwM2QwMjc0OGY3YjRhODJfNy0xLTEtMS0xNzQxMA_f60cfba0-cca0-4aca-b249-4d6c048adac2">399</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231" decimals="-3" name="apyx:JointAndSeveralPayrollLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80Ni9mcmFnOjQ3NGYxZThlODdhMDRjODA4ZGEzYTI3YzU4MWE2MmE5L3RhYmxlOjY0NGYwMTE2ODliZTRkMDA5MDNkMDI3NDhmN2I0YTgyL3RhYmxlcmFuZ2U6NjQ0ZjAxMTY4OWJlNGQwMDkwM2QwMjc0OGY3YjRhODJfNy0zLTEtMS0xNzQxMA_c3b349ea-bc97-4b53-99c7-9b23a0447a2b">1,027</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term contract liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930" decimals="-3" name="apyx:ShortTermContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80Ni9mcmFnOjQ3NGYxZThlODdhMDRjODA4ZGEzYTI3YzU4MWE2MmE5L3RhYmxlOjY0NGYwMTE2ODliZTRkMDA5MDNkMDI3NDhmN2I0YTgyL3RhYmxlcmFuZ2U6NjQ0ZjAxMTY4OWJlNGQwMDkwM2QwMjc0OGY3YjRhODJfOC0xLTEtMS0xNzQxMA_e62f6de8-783c-45eb-b520-f3f744f5a6cd">1,145</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231" decimals="-3" name="apyx:ShortTermContractLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80Ni9mcmFnOjQ3NGYxZThlODdhMDRjODA4ZGEzYTI3YzU4MWE2MmE5L3RhYmxlOjY0NGYwMTE2ODliZTRkMDA5MDNkMDI3NDhmN2I0YTgyL3RhYmxlcmFuZ2U6NjQ0ZjAxMTY4OWJlNGQwMDkwM2QwMjc0OGY3YjRhODJfOC0zLTEtMS0xNzQxMA_60ee91b1-9ef9-41f7-8e24-b4e026977ce0">533</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uncertain tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930" decimals="-3" name="apyx:UncertainTaxPositionsLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80Ni9mcmFnOjQ3NGYxZThlODdhMDRjODA4ZGEzYTI3YzU4MWE2MmE5L3RhYmxlOjY0NGYwMTE2ODliZTRkMDA5MDNkMDI3NDhmN2I0YTgyL3RhYmxlcmFuZ2U6NjQ0ZjAxMTY4OWJlNGQwMDkwM2QwMjc0OGY3YjRhODJfOS0xLTEtMS0xNzQxMA_15ed4cb9-6f11-4af5-8173-150339968d53">2,024</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231" decimals="-3" name="apyx:UncertainTaxPositionsLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80Ni9mcmFnOjQ3NGYxZThlODdhMDRjODA4ZGEzYTI3YzU4MWE2MmE5L3RhYmxlOjY0NGYwMTE2ODliZTRkMDA5MDNkMDI3NDhmN2I0YTgyL3RhYmxlcmFuZ2U6NjQ0ZjAxMTY4OWJlNGQwMDkwM2QwMjc0OGY3YjRhODJfOS0zLTEtMS0xNzQxMA_9da40e20-5f2f-4428-9b46-70f5947ad371">1,863</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales tax payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930" decimals="-3" name="us-gaap:SalesAndExciseTaxPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80Ni9mcmFnOjQ3NGYxZThlODdhMDRjODA4ZGEzYTI3YzU4MWE2MmE5L3RhYmxlOjY0NGYwMTE2ODliZTRkMDA5MDNkMDI3NDhmN2I0YTgyL3RhYmxlcmFuZ2U6NjQ0ZjAxMTY4OWJlNGQwMDkwM2QwMjc0OGY3YjRhODJfMTAtMS0xLTEtMTc0MTA_01bc3dc6-bcf5-409f-a19e-eb108571a53e">135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231" decimals="-3" name="us-gaap:SalesAndExciseTaxPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80Ni9mcmFnOjQ3NGYxZThlODdhMDRjODA4ZGEzYTI3YzU4MWE2MmE5L3RhYmxlOjY0NGYwMTE2ODliZTRkMDA5MDNkMDI3NDhmN2I0YTgyL3RhYmxlcmFuZ2U6NjQ0ZjAxMTY4OWJlNGQwMDkwM2QwMjc0OGY3YjRhODJfMTAtMy0xLTEtMTc0MTA_f60b0e5c-70dc-4ab0-ab7b-80f156f458a1">428</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses and current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930" decimals="-3" name="apyx:OtherAccruedExpensesAndLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80Ni9mcmFnOjQ3NGYxZThlODdhMDRjODA4ZGEzYTI3YzU4MWE2MmE5L3RhYmxlOjY0NGYwMTE2ODliZTRkMDA5MDNkMDI3NDhmN2I0YTgyL3RhYmxlcmFuZ2U6NjQ0ZjAxMTY4OWJlNGQwMDkwM2QwMjc0OGY3YjRhODJfMTEtMS0xLTEtMTc0MTA_6e2924e7-a372-48bd-920c-b3a48411da7f">617</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231" decimals="-3" name="apyx:OtherAccruedExpensesAndLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80Ni9mcmFnOjQ3NGYxZThlODdhMDRjODA4ZGEzYTI3YzU4MWE2MmE5L3RhYmxlOjY0NGYwMTE2ODliZTRkMDA5MDNkMDI3NDhmN2I0YTgyL3RhYmxlcmFuZ2U6NjQ0ZjAxMTY4OWJlNGQwMDkwM2QwMjc0OGY3YjRhODJfMTEtMy0xLTEtMTc0MTA_cfa66e03-9d53-4f6b-b6c5-6fc5ba9e276e">493</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses and other current liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930" decimals="-3" name="apyx:AccruedLiabilitiesAndOtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80Ni9mcmFnOjQ3NGYxZThlODdhMDRjODA4ZGEzYTI3YzU4MWE2MmE5L3RhYmxlOjY0NGYwMTE2ODliZTRkMDA5MDNkMDI3NDhmN2I0YTgyL3RhYmxlcmFuZ2U6NjQ0ZjAxMTY4OWJlNGQwMDkwM2QwMjc0OGY3YjRhODJfMTItMS0xLTEtMTc0MTA_754368be-40af-4832-93a4-bd9aeaeab247">8,842</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231" decimals="-3" name="apyx:AccruedLiabilitiesAndOtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80Ni9mcmFnOjQ3NGYxZThlODdhMDRjODA4ZGEzYTI3YzU4MWE2MmE5L3RhYmxlOjY0NGYwMTE2ODliZTRkMDA5MDNkMDI3NDhmN2I0YTgyL3RhYmxlcmFuZ2U6NjQ0ZjAxMTY4OWJlNGQwMDkwM2QwMjc0OGY3YjRhODJfMTItMy0xLTEtMTc0MTA_ceb8ea06-0c03-4654-983e-bc6719d228f0">10,287</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During April 2022, the Company was relieved of approximately $<ix:nonFraction unitRef="usd" contextRef="iee62c576cfc14937a01701621d37dc74_I20220430" decimals="-4" sign="-" name="apyx:JointAndSeveralPayrollLiability" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80Ni9mcmFnOjQ3NGYxZThlODdhMDRjODA4ZGEzYTI3YzU4MWE2MmE5L3RleHRyZWdpb246NDc0ZjFlOGU4N2EwNGM4MDhkYTNhMjdjNTgxYTYyYTlfMjAz_7884c5b9-a931-4ac4-b549-20409a153a8b">650,000</ix:nonFraction> of its joint and several payroll liability due to the lapse of the statute of limitations on the liability. This adjustment is included in other income, net for the nine months ended September 30, 2022.</span></div></ix:continuation><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div><div id="ie9788c72f4874edca78c1c4f307fec05_49"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 7. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" name="us-gaap:MinorityInterestDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80OS9mcmFnOmQ3YzEyZjA2NzU4YTRkZDA5OGM1MmEyZTRjOTgxYzYyL3RleHRyZWdpb246ZDdjMTJmMDY3NThhNGRkMDk4YzUyYTJlNGM5ODFjNjJfNjI1_8518f7b7-938a-447c-b722-51e975e46a35" continuedAt="i78872b3a331d4c6c810b6e5873871edc" escape="true">CHINA JOINT VENTURE</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i78872b3a331d4c6c810b6e5873871edc"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, the Company executed a joint venture agreement with its Chinese supplier (the &#8220;China JV&#8221;) whereby the Company has a <ix:nonFraction unitRef="number" contextRef="i9be5f375baba4295ace9fc48f09fe8dc_I20191231" decimals="INF" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80OS9mcmFnOmQ3YzEyZjA2NzU4YTRkZDA5OGM1MmEyZTRjOTgxYzYyL3RleHRyZWdpb246ZDdjMTJmMDY3NThhNGRkMDk4YzUyYTJlNGM5ODFjNjJfMTYw_e34a450b-5f39-4f81-8567-1a28862045c0">51</ix:nonFraction>% interest. The China JV has been consolidated in these condensed consolidated financial statements. The agreement required the Company to make capital contributions into the newly formed entity of approximately&#160;$<ix:nonFraction unitRef="usd" contextRef="i84408c5278f544ccb03b5314b28177f5_I20211231" decimals="-3" name="apyx:NoncontrollingInterestRequiredCapitalContribution" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80OS9mcmFnOmQ3YzEyZjA2NzU4YTRkZDA5OGM1MmEyZTRjOTgxYzYyL3RleHRyZWdpb246ZDdjMTJmMDY3NThhNGRkMDk4YzUyYTJlNGM5ODFjNjJfMzcz_e2f05b80-5bda-424c-ba35-85ede6cc0c26">357,000</ix:nonFraction>, which had been fully funded as of December 31, 2021. As of the date of these condensed consolidated financial statements, the China JV has not commenced principal operations. </span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" name="apyx:NoncontrollingInterestTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80OS9mcmFnOmQ3YzEyZjA2NzU4YTRkZDA5OGM1MmEyZTRjOTgxYzYyL3RleHRyZWdpb246ZDdjMTJmMDY3NThhNGRkMDk4YzUyYTJlNGM5ODFjNjJfNjI0_7cbfbc21-8bdc-463c-ad30-6b0f62adfdc4" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> investment in the China JV were as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"></td><td style="width:47.988%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.407%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.994%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.775%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.994%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.775%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.994%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.775%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.998%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning interest in China JV</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d492a2b0cb940b3a3efba0a8c74f3b2_I20220630" decimals="-3" name="us-gaap:MinorityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80OS9mcmFnOmQ3YzEyZjA2NzU4YTRkZDA5OGM1MmEyZTRjOTgxYzYyL3RhYmxlOmRiZTkzZDc1MTA1ZjRiNjhiZjk2Yjc1Yjg2MjM5ZmQ5L3RhYmxlcmFuZ2U6ZGJlOTNkNzUxMDVmNGI2OGJmOTZiNzViODYyMzlmZDlfMi0yLTEtMS0xNzQxMA_9927c57a-b090-4d13-9a81-a4760a32e000">269</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifefbd2b1828e478481b4e147440bb47b_I20210630" decimals="-3" name="us-gaap:MinorityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80OS9mcmFnOmQ3YzEyZjA2NzU4YTRkZDA5OGM1MmEyZTRjOTgxYzYyL3RhYmxlOmRiZTkzZDc1MTA1ZjRiNjhiZjk2Yjc1Yjg2MjM5ZmQ5L3RhYmxlcmFuZ2U6ZGJlOTNkNzUxMDVmNGI2OGJmOTZiNzViODYyMzlmZDlfMi00LTEtMS0xNzQxMA_4fff2083-0232-40e1-ae7f-edd6087e6203">338</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84408c5278f544ccb03b5314b28177f5_I20211231" decimals="-3" name="us-gaap:MinorityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80OS9mcmFnOmQ3YzEyZjA2NzU4YTRkZDA5OGM1MmEyZTRjOTgxYzYyL3RhYmxlOmRiZTkzZDc1MTA1ZjRiNjhiZjk2Yjc1Yjg2MjM5ZmQ5L3RhYmxlcmFuZ2U6ZGJlOTNkNzUxMDVmNGI2OGJmOTZiNzViODYyMzlmZDlfMi02LTEtMS0xNzQxMA_84e45cec-d788-428c-ab7c-ef04d63276ab">317</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i614389ddffc7468ba138bf2516c6c05f_I20201231" decimals="-3" name="us-gaap:MinorityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80OS9mcmFnOmQ3YzEyZjA2NzU4YTRkZDA5OGM1MmEyZTRjOTgxYzYyL3RhYmxlOmRiZTkzZDc1MTA1ZjRiNjhiZjk2Yjc1Yjg2MjM5ZmQ5L3RhYmxlcmFuZ2U6ZGJlOTNkNzUxMDVmNGI2OGJmOTZiNzViODYyMzlmZDlfMi04LTEtMS0xNzQxMA_ba8af2f6-173c-4860-b30e-2589896f11a3">144</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contributions </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i971483142d77406c8234c4a4370fd3f7_D20220701-20220930" decimals="-3" name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80OS9mcmFnOmQ3YzEyZjA2NzU4YTRkZDA5OGM1MmEyZTRjOTgxYzYyL3RhYmxlOmRiZTkzZDc1MTA1ZjRiNjhiZjk2Yjc1Yjg2MjM5ZmQ5L3RhYmxlcmFuZ2U6ZGJlOTNkNzUxMDVmNGI2OGJmOTZiNzViODYyMzlmZDlfMy0yLTEtMS0xNzQxMA_2ef38abf-61a2-4e08-b248-fb357c4e7512">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ca81802bedf4dd7b618a8b1cd8ffd83_D20210701-20210930" decimals="-3" name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80OS9mcmFnOmQ3YzEyZjA2NzU4YTRkZDA5OGM1MmEyZTRjOTgxYzYyL3RhYmxlOmRiZTkzZDc1MTA1ZjRiNjhiZjk2Yjc1Yjg2MjM5ZmQ5L3RhYmxlcmFuZ2U6ZGJlOTNkNzUxMDVmNGI2OGJmOTZiNzViODYyMzlmZDlfMy00LTEtMS0xNzQxMA_47c9774e-5a77-40e5-bafc-008414a4d6f1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacbe89d9dab74e6990b6f064b9754ea4_D20220101-20220930" decimals="-3" name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80OS9mcmFnOmQ3YzEyZjA2NzU4YTRkZDA5OGM1MmEyZTRjOTgxYzYyL3RhYmxlOmRiZTkzZDc1MTA1ZjRiNjhiZjk2Yjc1Yjg2MjM5ZmQ5L3RhYmxlcmFuZ2U6ZGJlOTNkNzUxMDVmNGI2OGJmOTZiNzViODYyMzlmZDlfMy02LTEtMS0xNzQxMA_629ca95a-33ee-4c88-927b-75d4d9ce6c4a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61baec36978a4160b66435f0f2416149_D20210101-20210930" decimals="-3" name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80OS9mcmFnOmQ3YzEyZjA2NzU4YTRkZDA5OGM1MmEyZTRjOTgxYzYyL3RhYmxlOmRiZTkzZDc1MTA1ZjRiNjhiZjk2Yjc1Yjg2MjM5ZmQ5L3RhYmxlcmFuZ2U6ZGJlOTNkNzUxMDVmNGI2OGJmOTZiNzViODYyMzlmZDlfMy04LTEtMS0xNzQxMA_ae2e2f8d-6499-450b-bd74-e989e4c669b1">203</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Apyx</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i971483142d77406c8234c4a4370fd3f7_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80OS9mcmFnOmQ3YzEyZjA2NzU4YTRkZDA5OGM1MmEyZTRjOTgxYzYyL3RhYmxlOmRiZTkzZDc1MTA1ZjRiNjhiZjk2Yjc1Yjg2MjM5ZmQ5L3RhYmxlcmFuZ2U6ZGJlOTNkNzUxMDVmNGI2OGJmOTZiNzViODYyMzlmZDlfNC0yLTEtMS0xNzQxMA_969597a6-d8fb-417b-ae7b-7972751111ab">33</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7ca81802bedf4dd7b618a8b1cd8ffd83_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80OS9mcmFnOmQ3YzEyZjA2NzU4YTRkZDA5OGM1MmEyZTRjOTgxYzYyL3RhYmxlOmRiZTkzZDc1MTA1ZjRiNjhiZjk2Yjc1Yjg2MjM5ZmQ5L3RhYmxlcmFuZ2U6ZGJlOTNkNzUxMDVmNGI2OGJmOTZiNzViODYyMzlmZDlfNC00LTEtMS0xNzQxMA_7c6f8232-49ca-4f9d-b1e0-d85602cbe932">13</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iacbe89d9dab74e6990b6f064b9754ea4_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80OS9mcmFnOmQ3YzEyZjA2NzU4YTRkZDA5OGM1MmEyZTRjOTgxYzYyL3RhYmxlOmRiZTkzZDc1MTA1ZjRiNjhiZjk2Yjc1Yjg2MjM5ZmQ5L3RhYmxlcmFuZ2U6ZGJlOTNkNzUxMDVmNGI2OGJmOTZiNzViODYyMzlmZDlfNC02LTEtMS0xNzQxMA_e74fd64f-5c68-486c-9781-c16e1aeb4046">81</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61baec36978a4160b66435f0f2416149_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80OS9mcmFnOmQ3YzEyZjA2NzU4YTRkZDA5OGM1MmEyZTRjOTgxYzYyL3RhYmxlOmRiZTkzZDc1MTA1ZjRiNjhiZjk2Yjc1Yjg2MjM5ZmQ5L3RhYmxlcmFuZ2U6ZGJlOTNkNzUxMDVmNGI2OGJmOTZiNzViODYyMzlmZDlfNC04LTEtMS0xNzQxMA_a682ab1a-522f-4781-a74e-40e7f95d71ab">22</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending interest in China JV</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic03ac90c24194c2181a21dd8933c788e_I20220930" decimals="-3" name="us-gaap:MinorityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80OS9mcmFnOmQ3YzEyZjA2NzU4YTRkZDA5OGM1MmEyZTRjOTgxYzYyL3RhYmxlOmRiZTkzZDc1MTA1ZjRiNjhiZjk2Yjc1Yjg2MjM5ZmQ5L3RhYmxlcmFuZ2U6ZGJlOTNkNzUxMDVmNGI2OGJmOTZiNzViODYyMzlmZDlfNS0yLTEtMS0xNzQxMA_17f61159-39b6-460a-ae71-67528da4a818">236</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7bdc42847614ed88ba35dd3d0f7643c_I20210930" decimals="-3" name="us-gaap:MinorityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80OS9mcmFnOmQ3YzEyZjA2NzU4YTRkZDA5OGM1MmEyZTRjOTgxYzYyL3RhYmxlOmRiZTkzZDc1MTA1ZjRiNjhiZjk2Yjc1Yjg2MjM5ZmQ5L3RhYmxlcmFuZ2U6ZGJlOTNkNzUxMDVmNGI2OGJmOTZiNzViODYyMzlmZDlfNS00LTEtMS0xNzQxMA_a0ad31bf-ef3a-447e-a857-cb16c547fd16">325</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic03ac90c24194c2181a21dd8933c788e_I20220930" decimals="-3" name="us-gaap:MinorityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80OS9mcmFnOmQ3YzEyZjA2NzU4YTRkZDA5OGM1MmEyZTRjOTgxYzYyL3RhYmxlOmRiZTkzZDc1MTA1ZjRiNjhiZjk2Yjc1Yjg2MjM5ZmQ5L3RhYmxlcmFuZ2U6ZGJlOTNkNzUxMDVmNGI2OGJmOTZiNzViODYyMzlmZDlfNS02LTEtMS0xNzQxMA_875d3d87-12d7-4c87-8c33-b72a1251eb49">236</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7bdc42847614ed88ba35dd3d0f7643c_I20210930" decimals="-3" name="us-gaap:MinorityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80OS9mcmFnOmQ3YzEyZjA2NzU4YTRkZDA5OGM1MmEyZTRjOTgxYzYyL3RhYmxlOmRiZTkzZDc1MTA1ZjRiNjhiZjk2Yjc1Yjg2MjM5ZmQ5L3RhYmxlcmFuZ2U6ZGJlOTNkNzUxMDVmNGI2OGJmOTZiNzViODYyMzlmZDlfNS04LTEtMS0xNzQxMA_84b0e190-acf2-4aec-879f-5791fbcc4c91">325</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><div id="ie9788c72f4874edca78c1c4f307fec05_52"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie9788c72f4874edca78c1c4f307fec05_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 8. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81Mi9mcmFnOjg0NDU1NTJiNGIyMzRjNGU4MDVjOWY5OWYyM2Y4NTEzL3RleHRyZWdpb246ODQ0NTU1MmI0YjIzNGM0ZTgwNWM5Zjk5ZjIzZjg1MTNfNTQy_dfaacde2-ee27-4d92-a29b-141c82f8fd60" continuedAt="i8b81dd6d0c6d4020816442b5e5487f6a" escape="true">EARNINGS (LOSS) PER SHARE </ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i8b81dd6d0c6d4020816442b5e5487f6a"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings (loss) per share (&#8220;basic EPS&#8221;) is computed by dividing the net income or loss by the weighted average number of common shares outstanding for the reporting period. Diluted earnings (loss) per share (&#8220;diluted EPS&#8221;) gives effect to all dilutive potential shares outstanding. As the Company is in a net loss position for all periods presented, all potential shares outstanding are anti-dilutive. <ix:nonNumeric contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81Mi9mcmFnOjg0NDU1NTJiNGIyMzRjNGU4MDVjOWY5OWYyM2Y4NTEzL3RleHRyZWdpb246ODQ0NTU1MmI0YjIzNGM0ZTgwNWM5Zjk5ZjIzZjg1MTNfNTM0_0e071998-e6c8-4333-8ca2-7b2517f07249" continuedAt="iee63725fdb364b78aafdb6626e1f3b1f" escape="true">The following table provides the computation of basic and diluted loss per share.</ix:nonNumeric></span></div><div style="margin-top:5pt"><ix:continuation id="iee63725fdb364b78aafdb6626e1f3b1f"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"></td><td style="width:46.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.393%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.324%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.324%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.324%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.329%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands, except per share data)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to stockholders</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6ada2596cf84b118b49af7a6561fb79_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81Mi9mcmFnOjg0NDU1NTJiNGIyMzRjNGU4MDVjOWY5OWYyM2Y4NTEzL3RhYmxlOjViMGM3ZDc0Njk5OTRiMDViMjA5NDQzMWEzM2QyMzA5L3RhYmxlcmFuZ2U6NWIwYzdkNzQ2OTk5NGIwNWIyMDk0NDMxYTMzZDIzMDlfMy0yLTEtMS0xNzQxMA_0dfec637-0710-44b4-acb9-5b67fee6e05a"><ix:nonFraction unitRef="usd" contextRef="id6ada2596cf84b118b49af7a6561fb79_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81Mi9mcmFnOjg0NDU1NTJiNGIyMzRjNGU4MDVjOWY5OWYyM2Y4NTEzL3RhYmxlOjViMGM3ZDc0Njk5OTRiMDViMjA5NDQzMWEzM2QyMzA5L3RhYmxlcmFuZ2U6NWIwYzdkNzQ2OTk5NGIwNWIyMDk0NDMxYTMzZDIzMDlfMy0yLTEtMS0xNzQxMA_2a3b03ba-dae8-4dfc-9a13-22bccff9f8da">5,764</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic9b0b6a3c69447bf8f151dfd98c14ac9_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81Mi9mcmFnOjg0NDU1NTJiNGIyMzRjNGU4MDVjOWY5OWYyM2Y4NTEzL3RhYmxlOjViMGM3ZDc0Njk5OTRiMDViMjA5NDQzMWEzM2QyMzA5L3RhYmxlcmFuZ2U6NWIwYzdkNzQ2OTk5NGIwNWIyMDk0NDMxYTMzZDIzMDlfMy00LTEtMS0xNzQxMA_a3a3ce3c-c934-4db6-896e-fcc656bbb04d"><ix:nonFraction unitRef="usd" contextRef="ic9b0b6a3c69447bf8f151dfd98c14ac9_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81Mi9mcmFnOjg0NDU1NTJiNGIyMzRjNGU4MDVjOWY5OWYyM2Y4NTEzL3RhYmxlOjViMGM3ZDc0Njk5OTRiMDViMjA5NDQzMWEzM2QyMzA5L3RhYmxlcmFuZ2U6NWIwYzdkNzQ2OTk5NGIwNWIyMDk0NDMxYTMzZDIzMDlfMy00LTEtMS0xNzQxMA_b8fbdae5-aed6-4747-aa29-15cd864d1e65">4,222</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81Mi9mcmFnOjg0NDU1NTJiNGIyMzRjNGU4MDVjOWY5OWYyM2Y4NTEzL3RhYmxlOjViMGM3ZDc0Njk5OTRiMDViMjA5NDQzMWEzM2QyMzA5L3RhYmxlcmFuZ2U6NWIwYzdkNzQ2OTk5NGIwNWIyMDk0NDMxYTMzZDIzMDlfMy02LTEtMS0xNzQxMA_06b3fa3f-fef9-4542-9822-4baafacb70b3"><ix:nonFraction unitRef="usd" contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81Mi9mcmFnOjg0NDU1NTJiNGIyMzRjNGU4MDVjOWY5OWYyM2Y4NTEzL3RhYmxlOjViMGM3ZDc0Njk5OTRiMDViMjA5NDQzMWEzM2QyMzA5L3RhYmxlcmFuZ2U6NWIwYzdkNzQ2OTk5NGIwNWIyMDk0NDMxYTMzZDIzMDlfMy02LTEtMS0xNzQxMA_f15d3676-4950-4b6c-99bc-54e230596b40">17,135</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81Mi9mcmFnOjg0NDU1NTJiNGIyMzRjNGU4MDVjOWY5OWYyM2Y4NTEzL3RhYmxlOjViMGM3ZDc0Njk5OTRiMDViMjA5NDQzMWEzM2QyMzA5L3RhYmxlcmFuZ2U6NWIwYzdkNzQ2OTk5NGIwNWIyMDk0NDMxYTMzZDIzMDlfMy04LTEtMS0xNzQxMA_6ecda25d-f619-408a-9200-9ff0360fd022"><ix:nonFraction unitRef="usd" contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81Mi9mcmFnOjg0NDU1NTJiNGIyMzRjNGU4MDVjOWY5OWYyM2Y4NTEzL3RhYmxlOjViMGM3ZDc0Njk5OTRiMDViMjA5NDQzMWEzM2QyMzA5L3RhYmxlcmFuZ2U6NWIwYzdkNzQ2OTk5NGIwNWIyMDk0NDMxYTMzZDIzMDlfMy04LTEtMS0xNzQxMA_d87e46ca-d592-456b-8669-a099aa4a18f1">13,169</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding - basic and diluted<br/></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id6ada2596cf84b118b49af7a6561fb79_D20220701-20220930" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81Mi9mcmFnOjg0NDU1NTJiNGIyMzRjNGU4MDVjOWY5OWYyM2Y4NTEzL3RhYmxlOjViMGM3ZDc0Njk5OTRiMDViMjA5NDQzMWEzM2QyMzA5L3RhYmxlcmFuZ2U6NWIwYzdkNzQ2OTk5NGIwNWIyMDk0NDMxYTMzZDIzMDlfNi0yLTEtMS0xNzQxMA_e6ff927e-a540-40bd-9e99-298e98d30def"><ix:nonFraction unitRef="shares" contextRef="id6ada2596cf84b118b49af7a6561fb79_D20220701-20220930" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81Mi9mcmFnOjg0NDU1NTJiNGIyMzRjNGU4MDVjOWY5OWYyM2Y4NTEzL3RhYmxlOjViMGM3ZDc0Njk5OTRiMDViMjA5NDQzMWEzM2QyMzA5L3RhYmxlcmFuZ2U6NWIwYzdkNzQ2OTk5NGIwNWIyMDk0NDMxYTMzZDIzMDlfNi0yLTEtMS0xNzQxMA_fcb07b78-c8e7-4dee-a35f-92c57f5c6d73">34,569</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic9b0b6a3c69447bf8f151dfd98c14ac9_D20210701-20210930" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81Mi9mcmFnOjg0NDU1NTJiNGIyMzRjNGU4MDVjOWY5OWYyM2Y4NTEzL3RhYmxlOjViMGM3ZDc0Njk5OTRiMDViMjA5NDQzMWEzM2QyMzA5L3RhYmxlcmFuZ2U6NWIwYzdkNzQ2OTk5NGIwNWIyMDk0NDMxYTMzZDIzMDlfNi00LTEtMS0xNzQxMA_10122581-f14a-4142-954c-e581c04f3220"><ix:nonFraction unitRef="shares" contextRef="ic9b0b6a3c69447bf8f151dfd98c14ac9_D20210701-20210930" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81Mi9mcmFnOjg0NDU1NTJiNGIyMzRjNGU4MDVjOWY5OWYyM2Y4NTEzL3RhYmxlOjViMGM3ZDc0Njk5OTRiMDViMjA5NDQzMWEzM2QyMzA5L3RhYmxlcmFuZ2U6NWIwYzdkNzQ2OTk5NGIwNWIyMDk0NDMxYTMzZDIzMDlfNi00LTEtMS0xNzQxMA_e1310c63-cc37-4475-ac13-f89641521918">34,330</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81Mi9mcmFnOjg0NDU1NTJiNGIyMzRjNGU4MDVjOWY5OWYyM2Y4NTEzL3RhYmxlOjViMGM3ZDc0Njk5OTRiMDViMjA5NDQzMWEzM2QyMzA5L3RhYmxlcmFuZ2U6NWIwYzdkNzQ2OTk5NGIwNWIyMDk0NDMxYTMzZDIzMDlfNi02LTEtMS0xNzQxMA_42a5bd45-5cf3-4d4b-8201-5d2689b77c79"><ix:nonFraction unitRef="shares" contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81Mi9mcmFnOjg0NDU1NTJiNGIyMzRjNGU4MDVjOWY5OWYyM2Y4NTEzL3RhYmxlOjViMGM3ZDc0Njk5OTRiMDViMjA5NDQzMWEzM2QyMzA5L3RhYmxlcmFuZ2U6NWIwYzdkNzQ2OTk5NGIwNWIyMDk0NDMxYTMzZDIzMDlfNi02LTEtMS0xNzQxMA_5e3cc976-5197-4772-afac-436749f0113f">34,488</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81Mi9mcmFnOjg0NDU1NTJiNGIyMzRjNGU4MDVjOWY5OWYyM2Y4NTEzL3RhYmxlOjViMGM3ZDc0Njk5OTRiMDViMjA5NDQzMWEzM2QyMzA5L3RhYmxlcmFuZ2U6NWIwYzdkNzQ2OTk5NGIwNWIyMDk0NDMxYTMzZDIzMDlfNi04LTEtMS0xNzQxMA_3c57e244-591d-4848-99a7-60f9b49bc3bc"><ix:nonFraction unitRef="shares" contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81Mi9mcmFnOjg0NDU1NTJiNGIyMzRjNGU4MDVjOWY5OWYyM2Y4NTEzL3RhYmxlOjViMGM3ZDc0Njk5OTRiMDViMjA5NDQzMWEzM2QyMzA5L3RhYmxlcmFuZ2U6NWIwYzdkNzQ2OTk5NGIwNWIyMDk0NDMxYTMzZDIzMDlfNi04LTEtMS0xNzQxMA_c19a25d9-a94b-40c5-a805-beefd493682a">34,318</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss per share:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="id6ada2596cf84b118b49af7a6561fb79_D20220701-20220930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81Mi9mcmFnOjg0NDU1NTJiNGIyMzRjNGU4MDVjOWY5OWYyM2Y4NTEzL3RhYmxlOjViMGM3ZDc0Njk5OTRiMDViMjA5NDQzMWEzM2QyMzA5L3RhYmxlcmFuZ2U6NWIwYzdkNzQ2OTk5NGIwNWIyMDk0NDMxYTMzZDIzMDlfOS0yLTEtMS0xNzQxMA_430cea00-78a9-40ab-9d13-3cb0a30214df"><ix:nonFraction unitRef="usdPerShare" contextRef="id6ada2596cf84b118b49af7a6561fb79_D20220701-20220930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81Mi9mcmFnOjg0NDU1NTJiNGIyMzRjNGU4MDVjOWY5OWYyM2Y4NTEzL3RhYmxlOjViMGM3ZDc0Njk5OTRiMDViMjA5NDQzMWEzM2QyMzA5L3RhYmxlcmFuZ2U6NWIwYzdkNzQ2OTk5NGIwNWIyMDk0NDMxYTMzZDIzMDlfOS0yLTEtMS0xNzQxMA_6983b76a-0aa6-4b3e-89d0-df62ced41be3">0.17</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ic9b0b6a3c69447bf8f151dfd98c14ac9_D20210701-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81Mi9mcmFnOjg0NDU1NTJiNGIyMzRjNGU4MDVjOWY5OWYyM2Y4NTEzL3RhYmxlOjViMGM3ZDc0Njk5OTRiMDViMjA5NDQzMWEzM2QyMzA5L3RhYmxlcmFuZ2U6NWIwYzdkNzQ2OTk5NGIwNWIyMDk0NDMxYTMzZDIzMDlfOS00LTEtMS0xNzQxMA_207b2936-6a05-422a-8b53-a3bfad0e7e2c"><ix:nonFraction unitRef="usdPerShare" contextRef="ic9b0b6a3c69447bf8f151dfd98c14ac9_D20210701-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81Mi9mcmFnOjg0NDU1NTJiNGIyMzRjNGU4MDVjOWY5OWYyM2Y4NTEzL3RhYmxlOjViMGM3ZDc0Njk5OTRiMDViMjA5NDQzMWEzM2QyMzA5L3RhYmxlcmFuZ2U6NWIwYzdkNzQ2OTk5NGIwNWIyMDk0NDMxYTMzZDIzMDlfOS00LTEtMS0xNzQxMA_50e1a700-1446-4171-85e0-3f209c9cbac1">0.12</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81Mi9mcmFnOjg0NDU1NTJiNGIyMzRjNGU4MDVjOWY5OWYyM2Y4NTEzL3RhYmxlOjViMGM3ZDc0Njk5OTRiMDViMjA5NDQzMWEzM2QyMzA5L3RhYmxlcmFuZ2U6NWIwYzdkNzQ2OTk5NGIwNWIyMDk0NDMxYTMzZDIzMDlfOS02LTEtMS0xNzQxMA_0cdfae6c-c765-4b59-be65-df91281219ec"><ix:nonFraction unitRef="usdPerShare" contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81Mi9mcmFnOjg0NDU1NTJiNGIyMzRjNGU4MDVjOWY5OWYyM2Y4NTEzL3RhYmxlOjViMGM3ZDc0Njk5OTRiMDViMjA5NDQzMWEzM2QyMzA5L3RhYmxlcmFuZ2U6NWIwYzdkNzQ2OTk5NGIwNWIyMDk0NDMxYTMzZDIzMDlfOS02LTEtMS0xNzQxMA_10523e10-af4b-4c4a-afcf-38d26c1b5144">0.50</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81Mi9mcmFnOjg0NDU1NTJiNGIyMzRjNGU4MDVjOWY5OWYyM2Y4NTEzL3RhYmxlOjViMGM3ZDc0Njk5OTRiMDViMjA5NDQzMWEzM2QyMzA5L3RhYmxlcmFuZ2U6NWIwYzdkNzQ2OTk5NGIwNWIyMDk0NDMxYTMzZDIzMDlfOS04LTEtMS0xNzQxMA_129f8030-4ae2-4ea2-9dca-837a0ff1a867"><ix:nonFraction unitRef="usdPerShare" contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81Mi9mcmFnOjg0NDU1NTJiNGIyMzRjNGU4MDVjOWY5OWYyM2Y4NTEzL3RhYmxlOjViMGM3ZDc0Njk5OTRiMDViMjA5NDQzMWEzM2QyMzA5L3RhYmxlcmFuZ2U6NWIwYzdkNzQ2OTk5NGIwNWIyMDk0NDMxYTMzZDIzMDlfOS04LTEtMS0xNzQxMA_4f320c74-1566-453f-916d-4ba561d349b3">0.38</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive instruments excluded from diluted loss per common share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia08951cf06e540858ba8bf177ab2b743_D20220701-20220930" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81Mi9mcmFnOjg0NDU1NTJiNGIyMzRjNGU4MDVjOWY5OWYyM2Y4NTEzL3RhYmxlOjViMGM3ZDc0Njk5OTRiMDViMjA5NDQzMWEzM2QyMzA5L3RhYmxlcmFuZ2U6NWIwYzdkNzQ2OTk5NGIwNWIyMDk0NDMxYTMzZDIzMDlfMTMtMi0xLTEtMTc0MTA_7bf47bc5-5696-497c-88fa-da4d0d61e15f">6,635</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i42b97828049d4ebdaf08135fff616832_D20210701-20210930" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81Mi9mcmFnOjg0NDU1NTJiNGIyMzRjNGU4MDVjOWY5OWYyM2Y4NTEzL3RhYmxlOjViMGM3ZDc0Njk5OTRiMDViMjA5NDQzMWEzM2QyMzA5L3RhYmxlcmFuZ2U6NWIwYzdkNzQ2OTk5NGIwNWIyMDk0NDMxYTMzZDIzMDlfMTMtNC0xLTEtMTc0MTA_80a147fb-56db-4d3b-a4d8-710d2d98f04d">5,534</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib5e3c2254a1e4a9db8e760889439789b_D20220101-20220930" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81Mi9mcmFnOjg0NDU1NTJiNGIyMzRjNGU4MDVjOWY5OWYyM2Y4NTEzL3RhYmxlOjViMGM3ZDc0Njk5OTRiMDViMjA5NDQzMWEzM2QyMzA5L3RhYmxlcmFuZ2U6NWIwYzdkNzQ2OTk5NGIwNWIyMDk0NDMxYTMzZDIzMDlfMTMtNi0xLTEtMTc0MTA_2c207726-99a1-44be-a7c0-e03678946036">6,635</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i87a2f188443846f38dac55f8e2d32c45_D20210101-20210930" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81Mi9mcmFnOjg0NDU1NTJiNGIyMzRjNGU4MDVjOWY5OWYyM2Y4NTEzL3RhYmxlOjViMGM3ZDc0Njk5OTRiMDViMjA5NDQzMWEzM2QyMzA5L3RhYmxlcmFuZ2U6NWIwYzdkNzQ2OTk5NGIwNWIyMDk0NDMxYTMzZDIzMDlfMTMtOC0xLTEtMTc0MTA_3ab9685b-923b-4a58-8013-c5ea80c652b2">5,534</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><div id="ie9788c72f4874edca78c1c4f307fec05_55"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie9788c72f4874edca78c1c4f307fec05_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 9. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81NS9mcmFnOjhiZmNkOGRlMWFlODQwNzc4YzM3NTNjNDllMjc2NWMxL3RleHRyZWdpb246OGJmY2Q4ZGUxYWU4NDA3NzhjMzc1M2M0OWUyNzY1YzFfMTY5MA_0962a108-3f04-45e9-a88d-7c73dbb5753c" continuedAt="if2e73ed70dfe4b189f9aae04e37c5b92" escape="true">STOCK-BASED COMPENSATION </ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="if2e73ed70dfe4b189f9aae04e37c5b92"><div style="text-align:justify"><ix:nonNumeric contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81NS9mcmFnOjhiZmNkOGRlMWFlODQwNzc4YzM3NTNjNDllMjc2NWMxL3RleHRyZWdpb246OGJmY2Q4ZGUxYWU4NDA3NzhjMzc1M2M0OWUyNzY1YzFfMTY5OA_fed5cfcd-6565-4d7b-b8d5-c2afd1905ad9" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Company&#8217;s stock option plans, the Board of Directors may grant restricted stock and options to purchase common shares to the Company's employees, officers, directors and consultants. The Company accounts for stock options in accordance with FASB ASC Topic 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation - Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, with stock-based compensation expense recognized over the vesting period based on the fair value on the grant date utilizing the Black-Scholes model, which includes a number of estimates that affect the grant date fair value and the amount of expense to recognize.</span></ix:nonNumeric></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized approximately $<ix:nonFraction unitRef="usd" contextRef="id6ada2596cf84b118b49af7a6561fb79_D20220701-20220930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81NS9mcmFnOjhiZmNkOGRlMWFlODQwNzc4YzM3NTNjNDllMjc2NWMxL3RleHRyZWdpb246OGJmY2Q4ZGUxYWU4NDA3NzhjMzc1M2M0OWUyNzY1YzFfNjUw_dbb803ce-ea65-4e2d-a960-0c421e3a3605">1,692,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81NS9mcmFnOjhiZmNkOGRlMWFlODQwNzc4YzM3NTNjNDllMjc2NWMxL3RleHRyZWdpb246OGJmY2Q4ZGUxYWU4NDA3NzhjMzc1M2M0OWUyNzY1YzFfNjU3_941d98ce-8065-424b-88db-185b418bd0a1">5,056,000</ix:nonFraction>, respectively, in stock-based compensation expense during the three and nine months ended September 30, 2022, as compared with $<ix:nonFraction unitRef="usd" contextRef="ic9b0b6a3c69447bf8f151dfd98c14ac9_D20210701-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81NS9mcmFnOjhiZmNkOGRlMWFlODQwNzc4YzM3NTNjNDllMjc2NWMxL3RleHRyZWdpb246OGJmY2Q4ZGUxYWU4NDA3NzhjMzc1M2M0OWUyNzY1YzFfNzUz_e2712c6b-9e70-4b4b-8b41-d4c299706133">1,184,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81NS9mcmFnOjhiZmNkOGRlMWFlODQwNzc4YzM3NTNjNDllMjc2NWMxL3RleHRyZWdpb246OGJmY2Q4ZGUxYWU4NDA3NzhjMzc1M2M0OWUyNzY1YzFfNzYw_652bda87-ed9e-4c7f-9732-0ad3908eee53">3,747,000</ix:nonFraction>, respectively, for the three and nine months ended September 30, 2021.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81NS9mcmFnOjhiZmNkOGRlMWFlODQwNzc4YzM3NTNjNDllMjc2NWMxL3RleHRyZWdpb246OGJmY2Q4ZGUxYWU4NDA3NzhjMzc1M2M0OWUyNzY1YzFfMTY5Mg_546ddaa2-b426-42ec-91c9-351d12edfe1c" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option activity is summarized as follows:</span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average exercise price</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81NS9mcmFnOjhiZmNkOGRlMWFlODQwNzc4YzM3NTNjNDllMjc2NWMxL3RhYmxlOjNmNmVlZDZmMTQ4NDQ1YjU5NDVhYzNhNzg3MDMwZjliL3RhYmxlcmFuZ2U6M2Y2ZWVkNmYxNDg0NDViNTk0NWFjM2E3ODcwMzBmOWJfNS0xLTEtMS0xNzQxMA_bee7d836-2725-46b3-b343-28e0ed8df902">5,397,691</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81NS9mcmFnOjhiZmNkOGRlMWFlODQwNzc4YzM3NTNjNDllMjc2NWMxL3RhYmxlOjNmNmVlZDZmMTQ4NDQ1YjU5NDVhYzNhNzg3MDMwZjliL3RhYmxlcmFuZ2U6M2Y2ZWVkNmYxNDg0NDViNTk0NWFjM2E3ODcwMzBmOWJfNS0zLTEtMS0xNzQxMA_6d564b70-6a3f-425a-8d04-0eb5a972cd11">5.95</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81NS9mcmFnOjhiZmNkOGRlMWFlODQwNzc4YzM3NTNjNDllMjc2NWMxL3RhYmxlOjNmNmVlZDZmMTQ4NDQ1YjU5NDVhYzNhNzg3MDMwZjliL3RhYmxlcmFuZ2U6M2Y2ZWVkNmYxNDg0NDViNTk0NWFjM2E3ODcwMzBmOWJfNi0xLTEtMS0xNzQxMA_e2fe6c5d-1afb-45aa-9a8b-b5f07e7788d6">1,692,419</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81NS9mcmFnOjhiZmNkOGRlMWFlODQwNzc4YzM3NTNjNDllMjc2NWMxL3RhYmxlOjNmNmVlZDZmMTQ4NDQ1YjU5NDVhYzNhNzg3MDMwZjliL3RhYmxlcmFuZ2U6M2Y2ZWVkNmYxNDg0NDViNTk0NWFjM2E3ODcwMzBmOWJfNi0zLTEtMS0xNzQxMA_cc0d11d0-8670-46cd-a8af-f83499fc4bf9">10.64</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81NS9mcmFnOjhiZmNkOGRlMWFlODQwNzc4YzM3NTNjNDllMjc2NWMxL3RhYmxlOjNmNmVlZDZmMTQ4NDQ1YjU5NDVhYzNhNzg3MDMwZjliL3RhYmxlcmFuZ2U6M2Y2ZWVkNmYxNDg0NDViNTk0NWFjM2E3ODcwMzBmOWJfNy0xLTEtMS0xNzQxMA_54986b89-6345-4b21-a357-253761704a0d">299,006</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81NS9mcmFnOjhiZmNkOGRlMWFlODQwNzc4YzM3NTNjNDllMjc2NWMxL3RhYmxlOjNmNmVlZDZmMTQ4NDQ1YjU5NDVhYzNhNzg3MDMwZjliL3RhYmxlcmFuZ2U6M2Y2ZWVkNmYxNDg0NDViNTk0NWFjM2E3ODcwMzBmOWJfNy0zLTEtMS0xNzQxMA_5ae75b1d-2fe9-492d-823e-f23fca17456e">4.57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81NS9mcmFnOjhiZmNkOGRlMWFlODQwNzc4YzM3NTNjNDllMjc2NWMxL3RhYmxlOjNmNmVlZDZmMTQ4NDQ1YjU5NDVhYzNhNzg3MDMwZjliL3RhYmxlcmFuZ2U6M2Y2ZWVkNmYxNDg0NDViNTk0NWFjM2E3ODcwMzBmOWJfOC0xLTEtMS0xNzQxMA_d2173c40-b45b-44c7-9af3-c274ce5ff46c">155,697</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81NS9mcmFnOjhiZmNkOGRlMWFlODQwNzc4YzM3NTNjNDllMjc2NWMxL3RhYmxlOjNmNmVlZDZmMTQ4NDQ1YjU5NDVhYzNhNzg3MDMwZjliL3RhYmxlcmFuZ2U6M2Y2ZWVkNmYxNDg0NDViNTk0NWFjM2E3ODcwMzBmOWJfOC0zLTEtMS0xNzQxMA_7dd5da29-4483-4837-b061-d36ab229522a">9.20</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at September&#160;30, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81NS9mcmFnOjhiZmNkOGRlMWFlODQwNzc4YzM3NTNjNDllMjc2NWMxL3RhYmxlOjNmNmVlZDZmMTQ4NDQ1YjU5NDVhYzNhNzg3MDMwZjliL3RhYmxlcmFuZ2U6M2Y2ZWVkNmYxNDg0NDViNTk0NWFjM2E3ODcwMzBmOWJfOS0xLTEtMS0xNzQxMA_571213d1-8164-4555-939d-290fdb8654ad">6,635,409</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81NS9mcmFnOjhiZmNkOGRlMWFlODQwNzc4YzM3NTNjNDllMjc2NWMxL3RhYmxlOjNmNmVlZDZmMTQ4NDQ1YjU5NDVhYzNhNzg3MDMwZjliL3RhYmxlcmFuZ2U6M2Y2ZWVkNmYxNDg0NDViNTk0NWFjM2E3ODcwMzBmOWJfOS0zLTEtMS0xNzQxMA_ae4ea06c-a2e2-42e2-9a0a-7baa3fadc9b8">7.13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company allows stock option holders to exercise stock-based awards by surrendering stock-based awards with an intrinsic value equal to the cumulative exercise price of the stock-based awards being exercised, referred to as net settlements. These surrenders are included in stock options exercised in the options rollforward above. For the three months ended September&#160;30, 2022 and 2021, respectively, we received <ix:nonFraction unitRef="shares" contextRef="id6ada2596cf84b118b49af7a6561fb79_D20220701-20220930" decimals="0" name="apyx:StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81NS9mcmFnOjhiZmNkOGRlMWFlODQwNzc4YzM3NTNjNDllMjc2NWMxL3RleHRyZWdpb246OGJmY2Q4ZGUxYWU4NDA3NzhjMzc1M2M0OWUyNzY1YzFfMTI1MQ_077e1d69-cb60-4b0e-a988-66a9a64e1558">55,853</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ic9b0b6a3c69447bf8f151dfd98c14ac9_D20210701-20210930" decimals="0" name="apyx:StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81NS9mcmFnOjhiZmNkOGRlMWFlODQwNzc4YzM3NTNjNDllMjc2NWMxL3RleHRyZWdpb246OGJmY2Q4ZGUxYWU4NDA3NzhjMzc1M2M0OWUyNzY1YzFfMTI1OA_346a2cc5-d48c-4994-92f6-8c49ad016efb">37,049</ix:nonFraction> options as payment in the exercise of <ix:nonFraction unitRef="shares" contextRef="id6ada2596cf84b118b49af7a6561fb79_D20220701-20220930" decimals="0" name="apyx:StockIssuedDuringPeriodSharesStockSwaps" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81NS9mcmFnOjhiZmNkOGRlMWFlODQwNzc4YzM3NTNjNDllMjc2NWMxL3RleHRyZWdpb246OGJmY2Q4ZGUxYWU4NDA3NzhjMzc1M2M0OWUyNzY1YzFfMTI5OQ_5342ceb9-46ce-4da5-8b74-96b7c6b5e396">33,313</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ic9b0b6a3c69447bf8f151dfd98c14ac9_D20210701-20210930" decimals="0" name="apyx:StockIssuedDuringPeriodSharesStockSwaps" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81NS9mcmFnOjhiZmNkOGRlMWFlODQwNzc4YzM3NTNjNDllMjc2NWMxL3RleHRyZWdpb246OGJmY2Q4ZGUxYWU4NDA3NzhjMzc1M2M0OWUyNzY1YzFfMTMwNg_3ae273e7-ad08-44a9-9981-3a9d8557c78a">13,285</ix:nonFraction> options. For the nine months ended September 30, 2022 and 2021, respectively, we received <ix:nonFraction unitRef="shares" contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" decimals="0" name="apyx:StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81NS9mcmFnOjhiZmNkOGRlMWFlODQwNzc4YzM3NTNjNDllMjc2NWMxL3RleHRyZWdpb246OGJmY2Q4ZGUxYWU4NDA3NzhjMzc1M2M0OWUyNzY1YzFfMTM2Mw_5a006506-c145-4642-908b-edd512d77ba0">92,520</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930" decimals="0" name="apyx:StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81NS9mcmFnOjhiZmNkOGRlMWFlODQwNzc4YzM3NTNjNDllMjc2NWMxL3RleHRyZWdpb246OGJmY2Q4ZGUxYWU4NDA3NzhjMzc1M2M0OWUyNzY1YzFfMTM3MA_fa139795-7019-4c5d-a4b2-0460e307c932">59,104</ix:nonFraction> options as payment in the exercise of <ix:nonFraction unitRef="shares" contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" decimals="0" name="apyx:StockIssuedDuringPeriodSharesStockSwaps" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81NS9mcmFnOjhiZmNkOGRlMWFlODQwNzc4YzM3NTNjNDllMjc2NWMxL3RleHRyZWdpb246OGJmY2Q4ZGUxYWU4NDA3NzhjMzc1M2M0OWUyNzY1YzFfMTQxMQ_d991c690-140c-437e-89b1-08d1fe28378f">72,313</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930" decimals="0" name="apyx:StockIssuedDuringPeriodSharesStockSwaps" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81NS9mcmFnOjhiZmNkOGRlMWFlODQwNzc4YzM3NTNjNDllMjc2NWMxL3RleHRyZWdpb246OGJmY2Q4ZGUxYWU4NDA3NzhjMzc1M2M0OWUyNzY1YzFfMTQxOA_c9f86f26-5092-4037-bf10-7d90b29afc5d">39,312</ix:nonFraction> options.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common shares required to be issued upon the exercise of stock options would be issued from authorized and unissued shares. <ix:nonNumeric contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81NS9mcmFnOjhiZmNkOGRlMWFlODQwNzc4YzM3NTNjNDllMjc2NWMxL3RleHRyZWdpb246OGJmY2Q4ZGUxYWU4NDA3NzhjMzc1M2M0OWUyNzY1YzFfMTcwMQ_4dbef092-ad80-42c4-911a-757b3113e5db" continuedAt="i43433527f0164edea687a952c9185811" escape="true">The Company calculated the grant date fair value of options granted in 2022 (&#8220;2022 Grants&#8221;) utilizing a Black-Scholes model.</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><ix:continuation id="i43433527f0164edea687a952c9185811"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:58.771%"><tr><td style="width:1.0%"></td><td style="width:65.815%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.825%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.133%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.827%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022 Grants</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Strike price</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="iee9cabca77f2439a98f1d745e8aa8fbf_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81NS9mcmFnOjhiZmNkOGRlMWFlODQwNzc4YzM3NTNjNDllMjc2NWMxL3RhYmxlOjYyMTUzMTA2YjM3MTQ2MjNhOWY0Yjc3N2M0MzUwOTQ0L3RhYmxlcmFuZ2U6NjIxNTMxMDZiMzcxNDYyM2E5ZjRiNzc3YzQzNTA5NDRfMS0xLTEtMS0xNzQxMA_b7f77e1b-a333-42ae-bd30-2891df66cc5f">5.10</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i569c520a81a0408e8dcae24590fd7f45_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81NS9mcmFnOjhiZmNkOGRlMWFlODQwNzc4YzM3NTNjNDllMjc2NWMxL3RhYmxlOjYyMTUzMTA2YjM3MTQ2MjNhOWY0Yjc3N2M0MzUwOTQ0L3RhYmxlcmFuZ2U6NjIxNTMxMDZiMzcxNDYyM2E5ZjRiNzc3YzQzNTA5NDRfMS0zLTEtMS0xNzQxMA_3724c2f2-31a5-463e-8155-c06aa2b7c362">10.56</ix:nonFraction></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iee9cabca77f2439a98f1d745e8aa8fbf_D20220101-20220930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81NS9mcmFnOjhiZmNkOGRlMWFlODQwNzc4YzM3NTNjNDllMjc2NWMxL3RhYmxlOjYyMTUzMTA2YjM3MTQ2MjNhOWY0Yjc3N2M0MzUwOTQ0L3RhYmxlcmFuZ2U6NjIxNTMxMDZiMzcxNDYyM2E5ZjRiNzc3YzQzNTA5NDRfMi0xLTEtMS0xNzQxMA_d53fef75-492e-4949-8812-726efecaddec">1.6</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i569c520a81a0408e8dcae24590fd7f45_D20220101-20220930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81NS9mcmFnOjhiZmNkOGRlMWFlODQwNzc4YzM3NTNjNDllMjc2NWMxL3RhYmxlOjYyMTUzMTA2YjM3MTQ2MjNhOWY0Yjc3N2M0MzUwOTQ0L3RhYmxlcmFuZ2U6NjIxNTMxMDZiMzcxNDYyM2E5ZjRiNzc3YzQzNTA5NDRfMi0zLTEtMS0xNzQxMA_02205b0a-3c93-4e47-b906-119b5fe0cb63">3.9</ix:nonFraction>%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81NS9mcmFnOjhiZmNkOGRlMWFlODQwNzc4YzM3NTNjNDllMjc2NWMxL3RhYmxlOjYyMTUzMTA2YjM3MTQ2MjNhOWY0Yjc3N2M0MzUwOTQ0L3RhYmxlcmFuZ2U6NjIxNTMxMDZiMzcxNDYyM2E5ZjRiNzc3YzQzNTA5NDRfMy0xLTEtMS0xNzQxMA_024d421a-2599-41e7-b3e7-fc0626055095">&#8212;</ix:nonFraction></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iee9cabca77f2439a98f1d745e8aa8fbf_D20220101-20220930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81NS9mcmFnOjhiZmNkOGRlMWFlODQwNzc4YzM3NTNjNDllMjc2NWMxL3RhYmxlOjYyMTUzMTA2YjM3MTQ2MjNhOWY0Yjc3N2M0MzUwOTQ0L3RhYmxlcmFuZ2U6NjIxNTMxMDZiMzcxNDYyM2E5ZjRiNzc3YzQzNTA5NDRfNC0xLTEtMS0xNzQxMA_62d3043c-d72a-4d26-a390-d2e12cf21933">69.6</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i569c520a81a0408e8dcae24590fd7f45_D20220101-20220930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81NS9mcmFnOjhiZmNkOGRlMWFlODQwNzc4YzM3NTNjNDllMjc2NWMxL3RhYmxlOjYyMTUzMTA2YjM3MTQ2MjNhOWY0Yjc3N2M0MzUwOTQ0L3RhYmxlcmFuZ2U6NjIxNTMxMDZiMzcxNDYyM2E5ZjRiNzc3YzQzNTA5NDRfNC0zLTEtMS0xNzQxMA_cf16d789-f69b-4b8c-98bf-4be7c66c5e44">78.5</ix:nonFraction>%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81NS9mcmFnOjhiZmNkOGRlMWFlODQwNzc4YzM3NTNjNDllMjc2NWMxL3RhYmxlOjYyMTUzMTA2YjM3MTQ2MjNhOWY0Yjc3N2M0MzUwOTQ0L3RhYmxlcmFuZ2U6NjIxNTMxMDZiMzcxNDYyM2E5ZjRiNzc3YzQzNTA5NDRfNS0xLTEtMS0xNzQxMA_c8eca355-11fd-487f-9393-956494b2817e">5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i569c520a81a0408e8dcae24590fd7f45_D20220101-20220930" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81NS9mcmFnOjhiZmNkOGRlMWFlODQwNzc4YzM3NTNjNDllMjc2NWMxL3RhYmxlOjYyMTUzMTA2YjM3MTQ2MjNhOWY0Yjc3N2M0MzUwOTQ0L3RhYmxlcmFuZ2U6NjIxNTMxMDZiMzcxNDYyM2E5ZjRiNzc3YzQzNTA5NDRfNS0zLTEtMS0xNzQxMA_65d7fde4-8716-4ca6-b1c1-bfcf3547b82f">6</ix:nonNumeric></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div></ix:continuation><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div id="ie9788c72f4874edca78c1c4f307fec05_58"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 10. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81OC9mcmFnOjhlNGI2OTRhOTAzYTQ5ZDY5ZGYxNzk5MjA2ODI0ZDk0L3RleHRyZWdpb246OGU0YjY5NGE5MDNhNDlkNjlkZjE3OTkyMDY4MjRkOTRfMTgzNw_35081693-6efc-4d66-ab6a-ff3c69b230f3" continuedAt="ia928c94357ee4d5295addd326ac3f9ad" escape="true">INCOME TAXES </ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia928c94357ee4d5295addd326ac3f9ad" continuedAt="i38c9f8ed1dbf4f5088ab34f22d013c72">Income tax expense was approximately $<ix:nonFraction unitRef="usd" contextRef="id6ada2596cf84b118b49af7a6561fb79_D20220701-20220930" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81OC9mcmFnOjhlNGI2OTRhOTAzYTQ5ZDY5ZGYxNzk5MjA2ODI0ZDk0L3RleHRyZWdpb246OGU0YjY5NGE5MDNhNDlkNjlkZjE3OTkyMDY4MjRkOTRfNjc_3af1d98a-1a69-4972-afc1-937034c7d66c">50,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ic9b0b6a3c69447bf8f151dfd98c14ac9_D20210701-20210930" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81OC9mcmFnOjhlNGI2OTRhOTAzYTQ5ZDY5ZGYxNzk5MjA2ODI0ZDk0L3RleHRyZWdpb246OGU0YjY5NGE5MDNhNDlkNjlkZjE3OTkyMDY4MjRkOTRfNzQ_465642b7-fd7e-46de-bb20-d672486577fa">73,000</ix:nonFraction> with effective tax rates of (<ix:nonFraction unitRef="number" contextRef="id6ada2596cf84b118b49af7a6561fb79_D20220701-20220930" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81OC9mcmFnOjhlNGI2OTRhOTAzYTQ5ZDY5ZGYxNzk5MjA2ODI0ZDk0L3RleHRyZWdpb246OGU0YjY5NGE5MDNhNDlkNjlkZjE3OTkyMDY4MjRkOTRfMTA1_82389a41-a4a2-4891-ab24-5f396fdcb3ed">0.9</ix:nonFraction>)% and (<ix:nonFraction unitRef="number" contextRef="ic9b0b6a3c69447bf8f151dfd98c14ac9_D20210701-20210930" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81OC9mcmFnOjhlNGI2OTRhOTAzYTQ5ZDY5ZGYxNzk5MjA2ODI0ZDk0L3RleHRyZWdpb246OGU0YjY5NGE5MDNhNDlkNjlkZjE3OTkyMDY4MjRkOTRfMTEy_90420106-3203-438f-ac46-0b5b90a032fd">1.8</ix:nonFraction>)% for the three months ended September&#160;30, 2022 and 2021, respectively. Income tax expense was approximately $<ix:nonFraction unitRef="usd" contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81OC9mcmFnOjhlNGI2OTRhOTAzYTQ5ZDY5ZGYxNzk5MjA2ODI0ZDk0L3RleHRyZWdpb246OGU0YjY5NGE5MDNhNDlkNjlkZjE3OTkyMDY4MjRkOTRfMjA0_e79a2880-7410-4b9f-84f2-e6d5abcb4e58">216,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81OC9mcmFnOjhlNGI2OTRhOTAzYTQ5ZDY5ZGYxNzk5MjA2ODI0ZDk0L3RleHRyZWdpb246OGU0YjY5NGE5MDNhNDlkNjlkZjE3OTkyMDY4MjRkOTRfMjEx_d87dfbe7-bf9d-481d-a66f-0a4bdbff16f5">246,000</ix:nonFraction> with effective tax rates of (<ix:nonFraction unitRef="number" contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81OC9mcmFnOjhlNGI2OTRhOTAzYTQ5ZDY5ZGYxNzk5MjA2ODI0ZDk0L3RleHRyZWdpb246OGU0YjY5NGE5MDNhNDlkNjlkZjE3OTkyMDY4MjRkOTRfMjQy_6097ccbc-5848-42fd-afd1-7c6e7df9b434">1.3</ix:nonFraction>)% and (<ix:nonFraction unitRef="number" contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81OC9mcmFnOjhlNGI2OTRhOTAzYTQ5ZDY5ZGYxNzk5MjA2ODI0ZDk0L3RleHRyZWdpb246OGU0YjY5NGE5MDNhNDlkNjlkZjE3OTkyMDY4MjRkOTRfMjQ5_9cc69296-d5a5-45ec-b423-805d48a4f748">1.9</ix:nonFraction>)% for the nine months ended September 30, 2022 and 2021, respectively. For the three and nine months ended September&#160;30, 2022 and 2021, the effective rates differ from the statutory rate primarily due to the full valuation allowance recorded on the net operating loss (&#8220;NOL&#8221;) generated during the period, combined with interest and penalties on uncertain tax positions. </ix:continuation></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie9788c72f4874edca78c1c4f307fec05_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i38c9f8ed1dbf4f5088ab34f22d013c72">The Company has gross unrecognized tax benefits of approximately $<ix:nonFraction unitRef="usd" contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81OC9mcmFnOjhlNGI2OTRhOTAzYTQ5ZDY5ZGYxNzk5MjA2ODI0ZDk0L3RleHRyZWdpb246OGU0YjY5NGE5MDNhNDlkNjlkZjE3OTkyMDY4MjRkOTRfNjIz_90ccdd0d-11aa-478f-bd69-984e5d8d5f88">1,313,000</ix:nonFraction> at September&#160;30, 2022. It recognized accrued interest and penalties related to unrecognized tax benefits in the provision for income taxes in the condensed consolidated financial statements. As of September&#160;30, 2022, the Company had approximately $<ix:nonFraction unitRef="usd" contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81OC9mcmFnOjhlNGI2OTRhOTAzYTQ5ZDY5ZGYxNzk5MjA2ODI0ZDk0L3RleHRyZWdpb246OGU0YjY5NGE5MDNhNDlkNjlkZjE3OTkyMDY4MjRkOTRfODQx_d16685a2-71c8-4128-98b1-a8d04bb51109">711,000</ix:nonFraction> in accrued interest and penalties related to unrecognized tax benefits. Included in the income tax expense for the three months ended September&#160;30, 2022 and 2021, respectively, are approximately $<ix:nonFraction unitRef="usd" contextRef="id6ada2596cf84b118b49af7a6561fb79_D20220701-20220930" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81OC9mcmFnOjhlNGI2OTRhOTAzYTQ5ZDY5ZGYxNzk5MjA2ODI0ZDk0L3RleHRyZWdpb246OGU0YjY5NGE5MDNhNDlkNjlkZjE3OTkyMDY4MjRkOTRfMTAyMQ_a1b4c59b-162e-4320-8efe-53d803a99138">54,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ic9b0b6a3c69447bf8f151dfd98c14ac9_D20210701-20210930" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81OC9mcmFnOjhlNGI2OTRhOTAzYTQ5ZDY5ZGYxNzk5MjA2ODI0ZDk0L3RleHRyZWdpb246OGU0YjY5NGE5MDNhNDlkNjlkZjE3OTkyMDY4MjRkOTRfMTAyOA_e27c656d-c98c-4223-aa49-9a8d3889d90f">52,000</ix:nonFraction> of interest and penalties on the Company's uncertain tax positions. Included in the income tax expense for the nine months ended September 30, 2022 and 2021, respectively, are approximately $<ix:nonFraction unitRef="usd" contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81OC9mcmFnOjhlNGI2OTRhOTAzYTQ5ZDY5ZGYxNzk5MjA2ODI0ZDk0L3RleHRyZWdpb246OGU0YjY5NGE5MDNhNDlkNjlkZjE3OTkyMDY4MjRkOTRfMTE4NQ_5c26a4c7-2148-415e-b65b-9466eb506e8c">160,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81OC9mcmFnOjhlNGI2OTRhOTAzYTQ5ZDY5ZGYxNzk5MjA2ODI0ZDk0L3RleHRyZWdpb246OGU0YjY5NGE5MDNhNDlkNjlkZjE3OTkyMDY4MjRkOTRfMTE5Mg_5daf5587-2b12-48a6-ad51-e4bee2a3606e">152,000</ix:nonFraction> of interest and penalties on the Company's uncertain tax positions. If the Company were to prevail on all uncertain tax positions, the resulting impact will be material as the Company will recognize approximately $<ix:nonFraction unitRef="usd" contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81OC9mcmFnOjhlNGI2OTRhOTAzYTQ5ZDY5ZGYxNzk5MjA2ODI0ZDk0L3RleHRyZWdpb246OGU0YjY5NGE5MDNhNDlkNjlkZjE3OTkyMDY4MjRkOTRfMTQwOA_c66ac85a-51b2-4c0a-89c6-640bdff72f1e">2,024,000</ix:nonFraction> of income tax benefits in the consolidated statement of operations. During June 2022, the Company was notified by the Internal Revenue Service (&#8220;IRS&#8221;) that it is examining the Company&#8217;s 2018, 2019 and 2020 federal income tax returns. The examination is expected to be completed no later than May 2023. It is expected that all of the uncertain tax positions should be resolved with the completion of the IRS examination.</ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div id="ie9788c72f4874edca78c1c4f307fec05_61"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 11. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82MS9mcmFnOmQ5MzUyMGI2YmIyYjQxYjdiYzQ0MDAwN2Y1NmM2OGZkL3RleHRyZWdpb246ZDkzNTIwYjZiYjJiNDFiN2JjNDQwMDA3ZjU2YzY4ZmRfNTQxNA_c2a0731d-116f-4b54-a7de-a4c8e526eaf7" continuedAt="i74d51a90bc6f4ac2960bf0463c99ef06" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i74d51a90bc6f4ac2960bf0463c99ef06" continuedAt="ie85aa1bf8c9949ada06e6ac197d1e9ce"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Litigation </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The medical device industry is characterized by frequent claims and litigation, and the Company may become subject to various claims, lawsuits and proceedings in the ordinary course of our business. Such claims may include claims by current or former employees, distributors and competitors, claims concerning the marketing and promotion of our products and product liability claims.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is involved in a number of legal actions relating to the use of our Helium Plasma technology. The outcomes of these legal actions are not within the Company&#8217;s control and may not be known for prolonged periods of time. It believes that such claims are adequately covered by insurance; however, in the case of one of the Company&#8217;s carriers, the Company is in a dispute regarding the total level of coverage available. Notwithstanding the foregoing, in the opinion of management, the Company has meritorious defenses, and such claims are not expected, individually or in the aggregate, to result in a material, adverse effect on its financial condition, results of operations and cash flows. However, in the event that damages exceed the aggregate coverage limits of the Company&#8217;s policies or if its insurance carriers disclaim coverage, management believes it is possible that costs associated with these claims could have a material adverse impact on the consolidated financial condition, results of operations and cash flows.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During December 2021, the Company provided notice of contract termination to an international distributor of the Company. In March 2022, the Company received a letter from the former distributor citing improper contract termination and alleging damages. While the matter is still in the early stages, management has determined that a loss is probable and that a range of estimated losses is approximately $<ix:nonFraction unitRef="usd" contextRef="ifb875bc28ba541afbdc97bd369d0b276_I20220930" decimals="-4" name="us-gaap:LossContingencyEstimateOfPossibleLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82MS9mcmFnOmQ5MzUyMGI2YmIyYjQxYjdiYzQ0MDAwN2Y1NmM2OGZkL3RleHRyZWdpb246ZDkzNTIwYjZiYjJiNDFiN2JjNDQwMDA3ZjU2YzY4ZmRfMTg4OQ_e5fa8f7d-5038-4e65-bad1-4af6ae87ba4b">250,000</ix:nonFraction> to $<ix:nonFraction unitRef="usd" contextRef="i0e86764ca7f24ce6a39afdcc54d3ea31_I20220930" decimals="-6" name="us-gaap:LossContingencyEstimateOfPossibleLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82MS9mcmFnOmQ5MzUyMGI2YmIyYjQxYjdiYzQ0MDAwN2Y1NmM2OGZkL3RleHRyZWdpb246ZDkzNTIwYjZiYjJiNDFiN2JjNDQwMDA3ZjU2YzY4ZmRfMTg5NQ_2f0c7ff9-60c2-4fe8-9731-be04b4264ecf">1,000,000</ix:nonFraction>. The Company has recorded an estimated loss of $<ix:nonFraction unitRef="usd" contextRef="i1887856679e9469f916771312e57a2e9_I20220930" decimals="-4" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82MS9mcmFnOmQ5MzUyMGI2YmIyYjQxYjdiYzQ0MDAwN2Y1NmM2OGZkL3RleHRyZWdpb246ZDkzNTIwYjZiYjJiNDFiN2JjNDQwMDA3ZjU2YzY4ZmRfMTY0OTI2NzQ1NzUzMQ_9d990f02-091a-4f15-b01c-2af7a9184c29">250,000</ix:nonFraction> in professional services in the accompanying Condensed Consolidated Statement of Operations for the nine months ended September 30, 2022. It is at least possible that a change in the actual amount of loss will occur in the near term, though management expects the actual amount of loss will be within the estimated range of losses.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as previously disclosed with the U.S. Securities and Exchange Commission on the Company&#8217;s Current Report on Form 8-K filed June 7, 2022, on June 6, 2022, a complaint (the &#8220;Complaint&#8221;) was filed in the United States District Court for the Middle District of Florida by plaintiff William E. Hattaway, individually and on behalf of all others similarly situated against the Company, Charles D. Goodwin (&#8220;Goodwin&#8221;), the Company&#8217;s President and Chief Executive Officer and a member of the Company&#8217;s Board of Directors, and Tara Semb (&#8220;Semb&#8221;), the Company&#8217;s Chief Financial Officer, Treasurer and Secretary, alleging violations by the Company, Goodwin and Semb of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder, primarily related to certain public statements and disclosures concerning the off-label usage of certain of the Company&#8217;s Advanced Energy products and the impact such usage would have on the Company&#8217;s business, operations and prospects. The Complaint seeks an unspecified amount of damages. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the ultimate outcome of this matter cannot be determined with certainty, the Company believes that the allegations stated in the Complaint are without merit. The Company, Goodwin and Semb intend to defend themselves vigorously in the suit. In the opinion of management, such claims are adequately covered by insurance, however, in the event that damages exceed the aggregate coverage limits of our policy or if our insurance carriers disclaim coverage, we believe it is possible that costs associated with this claim could have a material adverse impact on our consolidated results of operations, financial </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie9788c72f4874edca78c1c4f307fec05_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="ie85aa1bf8c9949ada06e6ac197d1e9ce"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">position or cash flows. While the matter is still in the early stages, management has determined that a loss is probable and that a range of estimated losses is approximately $<ix:nonFraction unitRef="usd" contextRef="icc81989264bf4729990e5332a7d926ff_I20220930" decimals="-3" name="us-gaap:LossContingencyEstimateOfPossibleLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82MS9mcmFnOmQ5MzUyMGI2YmIyYjQxYjdiYzQ0MDAwN2Y1NmM2OGZkL3RleHRyZWdpb246ZDkzNTIwYjZiYjJiNDFiN2JjNDQwMDA3ZjU2YzY4ZmRfNDEyMQ_134b34d4-2540-4ddb-a3ad-1b44d37b27f3">475,000</ix:nonFraction> to $<ix:nonFraction unitRef="usd" contextRef="i47884c866bfd4b0bb5978e741a32ff7a_I20220930" decimals="-5" name="us-gaap:LossContingencyEstimateOfPossibleLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82MS9mcmFnOmQ5MzUyMGI2YmIyYjQxYjdiYzQ0MDAwN2Y1NmM2OGZkL3RleHRyZWdpb246ZDkzNTIwYjZiYjJiNDFiN2JjNDQwMDA3ZjU2YzY4ZmRfNDEyNw_a65a3dfb-3277-4f8e-90cf-a04d24ac51aa">2,500,000</ix:nonFraction>. The Company has recorded an estimated loss of $<ix:nonFraction unitRef="usd" contextRef="i5d8aee9372fb4f169e0a8eb66390bb67_I20220930" decimals="-3" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82MS9mcmFnOmQ5MzUyMGI2YmIyYjQxYjdiYzQ0MDAwN2Y1NmM2OGZkL3RleHRyZWdpb246ZDkzNTIwYjZiYjJiNDFiN2JjNDQwMDA3ZjU2YzY4ZmRfNDE3Nw_ae64c9a8-cda0-42e5-9e1f-6f64b0619986">475,000</ix:nonFraction> in professional services in the accompanying Condensed Consolidated Statement of Operations for the nine months ended September 30, 2022. It is at least possible that a change in the actual amount of loss will occur in the near term, though management expects the actual amount of loss will be within the estimated range of losses.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accrues a liability in its consolidated financial statements for these actions when a loss is known or considered probable and the amount can be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is recorded. If a loss is reasonably possible, but not known or probable, and can be reasonably estimated, the estimated loss or range of loss is disclosed in the notes to the condensed consolidated financial statements. In most cases, significant judgment is required to estimate the amount and timing of a loss to be recorded, actual results may differ from these estimates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Purchase Commitments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September&#160;30, 2022, the Company had purchase commitments totaling approximately $<ix:nonFraction unitRef="usd" contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930" decimals="-5" name="us-gaap:PurchaseObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82MS9mcmFnOmQ5MzUyMGI2YmIyYjQxYjdiYzQ0MDAwN2Y1NmM2OGZkL3RleHRyZWdpb246ZDkzNTIwYjZiYjJiNDFiN2JjNDQwMDA3ZjU2YzY4ZmRfNTMyMA_573a30d2-e7c9-4aa2-9d97-d62e3177bb09">3.1</ix:nonFraction>&#160;million, substantially all of which is expected to be purchased within the next fifteen months.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><div id="ie9788c72f4874edca78c1c4f307fec05_64"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie9788c72f4874edca78c1c4f307fec05_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 12. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82NC9mcmFnOjcwYzZhYjdjMTM3NjRiMDNiZTg2ZDVhNzY5M2MwNzhiL3RleHRyZWdpb246NzBjNmFiN2MxMzc2NGIwM2JlODZkNWE3NjkzYzA3OGJfODQ0_4423d130-97e4-40ee-a60a-e4b74adfa235" continuedAt="ifcb35d8f7d55424ea569306626cff99b" escape="true">RELATED PARTY TRANSACTIONS</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="ifcb35d8f7d55424ea569306626cff99b"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Several relatives of Nikolay Shilev, Apyx Bulgaria&#8217;s Managing Director, are considered related parties. Teodora Shileva, Mr. Shilev&#8217;s spouse, is an employee of the Company working in the accounting department. Antoaneta Dimitrova Shileva-Toromanova, Mr. Shilev&#8217;s sister, is the manager of human resources. Svetoslav Shilev, Mr. Shilev&#8217;s son, is a quality manager in the quality assurance department.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The partner in the Company's China joint venture is also a supplier to the Company. For the three months ended September&#160;30, 2022 and 2021, the Company made purchases from this supplier of approximately $<ix:nonFraction unitRef="usd" contextRef="if06767f062cc44ada17fa9800b45b707_D20220701-20220930" decimals="-3" name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82NC9mcmFnOjcwYzZhYjdjMTM3NjRiMDNiZTg2ZDVhNzY5M2MwNzhiL3RleHRyZWdpb246NzBjNmFiN2MxMzc2NGIwM2JlODZkNWE3NjkzYzA3OGJfNjI5_173d27a8-398f-4916-91e6-58494a4e3eaf">85,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="if24822e015bf406fa7a58fe352a3de87_D20210701-20210930" decimals="-3" name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82NC9mcmFnOjcwYzZhYjdjMTM3NjRiMDNiZTg2ZDVhNzY5M2MwNzhiL3RleHRyZWdpb246NzBjNmFiN2MxMzc2NGIwM2JlODZkNWE3NjkzYzA3OGJfNjM2_bd1e5f34-e57a-45ea-96e4-0549f7a5b3da">456,000</ix:nonFraction>, respectively. For the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine months ended September 30, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and 2021, the Company made purchases from this supplier of approximately $<ix:nonFraction unitRef="usd" contextRef="i1cce60115e9e4b31be367f868dcccb14_D20220101-20220930" decimals="-3" name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82NC9mcmFnOjcwYzZhYjdjMTM3NjRiMDNiZTg2ZDVhNzY5M2MwNzhiL3RleHRyZWdpb246NzBjNmFiN2MxMzc2NGIwM2JlODZkNWE3NjkzYzA3OGJfNzM2_6adbc7d8-1faf-47e4-b30e-19019d935795">455,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i10d9cc88ef7f4a2cb54fd0ce01238148_D20210101-20210930" decimals="-3" name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82NC9mcmFnOjcwYzZhYjdjMTM3NjRiMDNiZTg2ZDVhNzY5M2MwNzhiL3RleHRyZWdpb246NzBjNmFiN2MxMzc2NGIwM2JlODZkNWE3NjkzYzA3OGJfNzQz_a076e5a2-eb50-4bfe-9a72-52e27bdef60d">1,102,000</ix:nonFraction>, respectively. At September&#160;30, 2022 and December&#160;31, 2021, respectively, the Company owed this supplier approximately $<ix:nonFraction unitRef="usd" contextRef="if76fe4dedddf40aca527d7e4b7a2654c_I20220930" decimals="-3" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82NC9mcmFnOjcwYzZhYjdjMTM3NjRiMDNiZTg2ZDVhNzY5M2MwNzhiL3RleHRyZWdpb246NzBjNmFiN2MxMzc2NGIwM2JlODZkNWE3NjkzYzA3OGJfODM0_579539c7-850a-409f-a4a7-7fab29aef7d7">41,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ib8f8d460633b499797d344045f093397_I20211231" decimals="-3" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82NC9mcmFnOjcwYzZhYjdjMTM3NjRiMDNiZTg2ZDVhNzY5M2MwNzhiL3RleHRyZWdpb246NzBjNmFiN2MxMzc2NGIwM2JlODZkNWE3NjkzYzA3OGJfODQx_46b10c6e-e2cf-4196-a3e3-f5649c10424a">1,000</ix:nonFraction>.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="ie9788c72f4874edca78c1c4f307fec05_67"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 13. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RleHRyZWdpb246YTQzN2Q5YmQxMWFiNGVlYjg3ODFhYzFmZWUyODdiYTNfMTY3OA_d85a1981-6888-4e11-a02d-4583dc653c4c" continuedAt="i3257732634b141db91542e23b7299a44" escape="true">GEOGRAPHIC AND SEGMENT INFORMATION </ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i3257732634b141db91542e23b7299a44" continuedAt="i99bdffbc0c7f4e88b3775c920dad4e75"><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are aggregated into reportable segments only if they exhibit similar economic characteristics. In addition to similar economic characteristics, the Company also considers the following factors in determining the reportable segments: the nature of business activities, the management structure directly accountable to its chief operating decision maker for operating and administrative activities, availability of discrete financial information and information presented to the Board of Directors and investors. Asset information is not reviewed by the chief operating decision maker by segment and is not available by segment, accordingly, the Company has not presented a measure of assets by segment.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s reportable segments are disclosed as principally organized and managed as <ix:nonFraction unitRef="segment" contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RleHRyZWdpb246YTQzN2Q5YmQxMWFiNGVlYjg3ODFhYzFmZWUyODdiYTNfODYy_3dab7a3e-a86e-4244-bd9a-aa458c87103f"><ix:nonFraction unitRef="segment" contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RleHRyZWdpb246YTQzN2Q5YmQxMWFiNGVlYjg3ODFhYzFmZWUyODdiYTNfODYy_86893244-2d05-4a2c-90c6-976590558044">two</ix:nonFraction></ix:nonFraction> operating segments: Advanced Energy and OEM. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate &amp; Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> includes certain unallocated corporate and administrative costs which were not specifically attributed to any reportable segment. The OEM segment is primarily development and manufacturing contract and product driven, all related expenses are recorded as cost of sales, therefore no segment specific operating expenses are incurred.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RleHRyZWdpb246YTQzN2Q5YmQxMWFiNGVlYjg3ODFhYzFmZWUyODdiYTNfMTY4Mw_7a26e60e-45ea-4ce0-8c7d-88ae423cc6c9" continuedAt="i424aaf43415c478189a2c5731114030b" escape="true">Summarized financial information with respect to reportable segments is as follows:</ix:nonNumeric></span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie9788c72f4874edca78c1c4f307fec05_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="i99bdffbc0c7f4e88b3775c920dad4e75" continuedAt="if7cf65fa926c4004bcde29587f041a1d"><ix:continuation id="i424aaf43415c478189a2c5731114030b" continuedAt="i93952b95dbea474491ffc0e26ff4e486"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:45.811%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.696%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Advanced Energy</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OEM</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate &amp; Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib86c17a29ad64fff8b4f5645ccc11575_D20220701-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmE5OWEwMGU5ODkwNTQ5N2VhZGFiYTU4ZjQ4YzU1YmVjL3RhYmxlcmFuZ2U6YTk5YTAwZTk4OTA1NDk3ZWFkYWJhNThmNDhjNTViZWNfMi0zLTEtMS0xNzQxMA_59d46f9d-1580-4129-beee-902148e43a57">7,080</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaaa11755febd4f87a4971e2cdb19bccd_D20220701-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmE5OWEwMGU5ODkwNTQ5N2VhZGFiYTU4ZjQ4YzU1YmVjL3RhYmxlcmFuZ2U6YTk5YTAwZTk4OTA1NDk3ZWFkYWJhNThmNDhjNTViZWNfMi01LTEtMS0xNzQxMA_728ea0ea-892a-4dc0-b172-d7840ef35027">2,034</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12ee9d61be8f4dc6a652027fc6bd93b9_D20220701-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmE5OWEwMGU5ODkwNTQ5N2VhZGFiYTU4ZjQ4YzU1YmVjL3RhYmxlcmFuZ2U6YTk5YTAwZTk4OTA1NDk3ZWFkYWJhNThmNDhjNTViZWNfMi03LTEtMS0xNzQxMA_d37acec1-5939-4018-80bd-a3a4936a6b1e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6ada2596cf84b118b49af7a6561fb79_D20220701-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmE5OWEwMGU5ODkwNTQ5N2VhZGFiYTU4ZjQ4YzU1YmVjL3RhYmxlcmFuZ2U6YTk5YTAwZTk4OTA1NDk3ZWFkYWJhNThmNDhjNTViZWNfMi05LTEtMS0xNzQxMA_e0264de1-92cf-40a8-9d47-323e63bf2c8a">9,114</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib86c17a29ad64fff8b4f5645ccc11575_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmE5OWEwMGU5ODkwNTQ5N2VhZGFiYTU4ZjQ4YzU1YmVjL3RhYmxlcmFuZ2U6YTk5YTAwZTk4OTA1NDk3ZWFkYWJhNThmNDhjNTViZWNfMTQtMy0xLTEtMTc0MTA_485695f7-11d6-44a4-8d8b-59014f1b4735">1,174</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaaa11755febd4f87a4971e2cdb19bccd_D20220701-20220930" decimals="-3" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmE5OWEwMGU5ODkwNTQ5N2VhZGFiYTU4ZjQ4YzU1YmVjL3RhYmxlcmFuZ2U6YTk5YTAwZTk4OTA1NDk3ZWFkYWJhNThmNDhjNTViZWNfMTQtNS0xLTEtMTc0MTA_a4dbbc5c-026f-45f8-85d7-d7e1aa75dfd9">356</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12ee9d61be8f4dc6a652027fc6bd93b9_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmE5OWEwMGU5ODkwNTQ5N2VhZGFiYTU4ZjQ4YzU1YmVjL3RhYmxlcmFuZ2U6YTk5YTAwZTk4OTA1NDk3ZWFkYWJhNThmNDhjNTViZWNfMTQtNy0xLTEtMTc0MTA_48f67360-adb1-4c3a-9c1f-2d144a3da957">4,964</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6ada2596cf84b118b49af7a6561fb79_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmE5OWEwMGU5ODkwNTQ5N2VhZGFiYTU4ZjQ4YzU1YmVjL3RhYmxlcmFuZ2U6YTk5YTAwZTk4OTA1NDk3ZWFkYWJhNThmNDhjNTViZWNfMTQtOS0xLTEtMTc0MTA_ae51e453-77ad-405c-be3c-cf7e0fd70e95">5,782</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib86c17a29ad64fff8b4f5645ccc11575_D20220701-20220930" decimals="-3" name="us-gaap:InterestIncomeOperating" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmE5OWEwMGU5ODkwNTQ5N2VhZGFiYTU4ZjQ4YzU1YmVjL3RhYmxlcmFuZ2U6YTk5YTAwZTk4OTA1NDk3ZWFkYWJhNThmNDhjNTViZWNfMTYtMy0xLTEtMTc0MTA_489deba4-d90b-4b1d-ab97-6e748d3d6cfb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaaa11755febd4f87a4971e2cdb19bccd_D20220701-20220930" decimals="-3" name="us-gaap:InterestIncomeOperating" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmE5OWEwMGU5ODkwNTQ5N2VhZGFiYTU4ZjQ4YzU1YmVjL3RhYmxlcmFuZ2U6YTk5YTAwZTk4OTA1NDk3ZWFkYWJhNThmNDhjNTViZWNfMTYtNS0xLTEtMTc0MTA_3072867d-fbf2-4185-b494-f1acf3668b14">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12ee9d61be8f4dc6a652027fc6bd93b9_D20220701-20220930" decimals="-3" name="us-gaap:InterestIncomeOperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmE5OWEwMGU5ODkwNTQ5N2VhZGFiYTU4ZjQ4YzU1YmVjL3RhYmxlcmFuZ2U6YTk5YTAwZTk4OTA1NDk3ZWFkYWJhNThmNDhjNTViZWNfMTYtNy0xLTEtMTc0MTA_d3f66ded-3c2c-451d-958d-e27c2c855540">73</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6ada2596cf84b118b49af7a6561fb79_D20220701-20220930" decimals="-3" name="us-gaap:InterestIncomeOperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmE5OWEwMGU5ODkwNTQ5N2VhZGFiYTU4ZjQ4YzU1YmVjL3RhYmxlcmFuZ2U6YTk5YTAwZTk4OTA1NDk3ZWFkYWJhNThmNDhjNTViZWNfMTYtOS0xLTEtMTc0MTA_9f40a70b-01da-4a17-bf4b-2f330efbfca8">73</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib86c17a29ad64fff8b4f5645ccc11575_D20220701-20220930" decimals="-3" name="us-gaap:InterestExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmE5OWEwMGU5ODkwNTQ5N2VhZGFiYTU4ZjQ4YzU1YmVjL3RhYmxlcmFuZ2U6YTk5YTAwZTk4OTA1NDk3ZWFkYWJhNThmNDhjNTViZWNfMTctMy0xLTEtMTc0MTA_d4264f3d-951a-45b7-bc2a-4234db7ef9f6">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaaa11755febd4f87a4971e2cdb19bccd_D20220701-20220930" decimals="-3" name="us-gaap:InterestExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmE5OWEwMGU5ODkwNTQ5N2VhZGFiYTU4ZjQ4YzU1YmVjL3RhYmxlcmFuZ2U6YTk5YTAwZTk4OTA1NDk3ZWFkYWJhNThmNDhjNTViZWNfMTctNS0xLTEtMTc0MTA_2383f9d1-f075-4da1-b04e-01b1a6dd40e8">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12ee9d61be8f4dc6a652027fc6bd93b9_D20220701-20220930" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmE5OWEwMGU5ODkwNTQ5N2VhZGFiYTU4ZjQ4YzU1YmVjL3RhYmxlcmFuZ2U6YTk5YTAwZTk4OTA1NDk3ZWFkYWJhNThmNDhjNTViZWNfMTctNy0xLTEtMTc0MTA_1a1640e7-a400-4b1c-838a-d6a3af25d919">1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6ada2596cf84b118b49af7a6561fb79_D20220701-20220930" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmE5OWEwMGU5ODkwNTQ5N2VhZGFiYTU4ZjQ4YzU1YmVjL3RhYmxlcmFuZ2U6YTk5YTAwZTk4OTA1NDk3ZWFkYWJhNThmNDhjNTViZWNfMTctOS0xLTEtMTc0MTA_ea18db85-8fc9-400b-b516-61d14b3b2f90">1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other loss, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib86c17a29ad64fff8b4f5645ccc11575_D20220701-20220930" decimals="-3" name="us-gaap:OtherOperatingIncomeExpenseNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmE5OWEwMGU5ODkwNTQ5N2VhZGFiYTU4ZjQ4YzU1YmVjL3RhYmxlcmFuZ2U6YTk5YTAwZTk4OTA1NDk3ZWFkYWJhNThmNDhjNTViZWNfMTgtMy0xLTEtMTc0MTA_720d50b1-961b-48d5-9ed8-d0ec08d21c3e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaaa11755febd4f87a4971e2cdb19bccd_D20220701-20220930" decimals="-3" name="us-gaap:OtherOperatingIncomeExpenseNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmE5OWEwMGU5ODkwNTQ5N2VhZGFiYTU4ZjQ4YzU1YmVjL3RhYmxlcmFuZ2U6YTk5YTAwZTk4OTA1NDk3ZWFkYWJhNThmNDhjNTViZWNfMTgtNS0xLTEtMTc0MTA_471374ce-a0e1-4c45-89bb-32a0f399a304">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12ee9d61be8f4dc6a652027fc6bd93b9_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmE5OWEwMGU5ODkwNTQ5N2VhZGFiYTU4ZjQ4YzU1YmVjL3RhYmxlcmFuZ2U6YTk5YTAwZTk4OTA1NDk3ZWFkYWJhNThmNDhjNTViZWNfMTgtNy0xLTEtMTc0MTA_3e08346a-488b-4b61-a7a0-af5831e78f2e">35</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6ada2596cf84b118b49af7a6561fb79_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmE5OWEwMGU5ODkwNTQ5N2VhZGFiYTU4ZjQ4YzU1YmVjL3RhYmxlcmFuZ2U6YTk5YTAwZTk4OTA1NDk3ZWFkYWJhNThmNDhjNTViZWNfMTgtOS0xLTEtMTc0MTA_9aed8336-23d6-402d-940e-982428978ea9">35</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib86c17a29ad64fff8b4f5645ccc11575_D20220701-20220930" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmE5OWEwMGU5ODkwNTQ5N2VhZGFiYTU4ZjQ4YzU1YmVjL3RhYmxlcmFuZ2U6YTk5YTAwZTk4OTA1NDk3ZWFkYWJhNThmNDhjNTViZWNfMjItMy0xLTEtMTc0MTA_672daaa4-7d59-493a-b2a7-0512a763d898">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaaa11755febd4f87a4971e2cdb19bccd_D20220701-20220930" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmE5OWEwMGU5ODkwNTQ5N2VhZGFiYTU4ZjQ4YzU1YmVjL3RhYmxlcmFuZ2U6YTk5YTAwZTk4OTA1NDk3ZWFkYWJhNThmNDhjNTViZWNfMjItNS0xLTEtMTc0MTA_32493819-7b00-4682-8f8d-bf10ea95789b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12ee9d61be8f4dc6a652027fc6bd93b9_D20220701-20220930" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmE5OWEwMGU5ODkwNTQ5N2VhZGFiYTU4ZjQ4YzU1YmVjL3RhYmxlcmFuZ2U6YTk5YTAwZTk4OTA1NDk3ZWFkYWJhNThmNDhjNTViZWNfMjItNy0xLTEtMTc0MTA_73d82e61-b5d2-45b0-9bcc-040a22097d78">50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6ada2596cf84b118b49af7a6561fb79_D20220701-20220930" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmE5OWEwMGU5ODkwNTQ5N2VhZGFiYTU4ZjQ4YzU1YmVjL3RhYmxlcmFuZ2U6YTk5YTAwZTk4OTA1NDk3ZWFkYWJhNThmNDhjNTViZWNfMjItOS0xLTEtMTc0MTA_6b1036de-5489-4a7c-8efb-cb172765b51a">50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:45.811%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.696%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Advanced Energy</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OEM</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate &amp; Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14808dab5a9a44dda4de75eaaebf7f2c_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOjMyZDQ5NDQyNWZiZDQwMjBhMzRlNjg2ZTlhZGFiMzdlL3RhYmxlcmFuZ2U6MzJkNDk0NDI1ZmJkNDAyMGEzNGU2ODZlOWFkYWIzN2VfMi0zLTEtMS0xNzQxMA_087dde11-485a-4ed2-92ec-665b1350c931">10,313</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35bc95fa11524622b8a7f5abe7f7a8d0_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOjMyZDQ5NDQyNWZiZDQwMjBhMzRlNjg2ZTlhZGFiMzdlL3RhYmxlcmFuZ2U6MzJkNDk0NDI1ZmJkNDAyMGEzNGU2ODZlOWFkYWIzN2VfMi01LTEtMS0xNzQxMA_92844b93-c1ec-4131-a72e-e75ecc1c20f1">1,518</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id24ea483328641d39abd6bbf5097a73b_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOjMyZDQ5NDQyNWZiZDQwMjBhMzRlNjg2ZTlhZGFiMzdlL3RhYmxlcmFuZ2U6MzJkNDk0NDI1ZmJkNDAyMGEzNGU2ODZlOWFkYWIzN2VfMi03LTEtMS0xNzQxMA_d521b0af-53ce-4940-af99-e9053417408e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9b0b6a3c69447bf8f151dfd98c14ac9_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOjMyZDQ5NDQyNWZiZDQwMjBhMzRlNjg2ZTlhZGFiMzdlL3RhYmxlcmFuZ2U6MzJkNDk0NDI1ZmJkNDAyMGEzNGU2ODZlOWFkYWIzN2VfMi05LTEtMS0xNzQxMA_c89aa9f3-9926-4f98-9ce1-3f9e18b5261f">11,831</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14808dab5a9a44dda4de75eaaebf7f2c_D20210701-20210930" decimals="-3" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOjMyZDQ5NDQyNWZiZDQwMjBhMzRlNjg2ZTlhZGFiMzdlL3RhYmxlcmFuZ2U6MzJkNDk0NDI1ZmJkNDAyMGEzNGU2ODZlOWFkYWIzN2VfMTQtMy0xLTEtMTc0MTA_6ee975af-dc0b-4729-b225-2897a0a945c4">52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35bc95fa11524622b8a7f5abe7f7a8d0_D20210701-20210930" decimals="-3" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOjMyZDQ5NDQyNWZiZDQwMjBhMzRlNjg2ZTlhZGFiMzdlL3RhYmxlcmFuZ2U6MzJkNDk0NDI1ZmJkNDAyMGEzNGU2ODZlOWFkYWIzN2VfMTQtNS0xLTEtMTc0MTA_5bfb1653-1824-4650-8e8b-d2772b81db20">328</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id24ea483328641d39abd6bbf5097a73b_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOjMyZDQ5NDQyNWZiZDQwMjBhMzRlNjg2ZTlhZGFiMzdlL3RhYmxlcmFuZ2U6MzJkNDk0NDI1ZmJkNDAyMGEzNGU2ODZlOWFkYWIzN2VfMTQtNy0xLTEtMTc0MTA_1595f1a1-225d-43da-bb7e-9c21311c206b">4,348</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic9b0b6a3c69447bf8f151dfd98c14ac9_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOjMyZDQ5NDQyNWZiZDQwMjBhMzRlNjg2ZTlhZGFiMzdlL3RhYmxlcmFuZ2U6MzJkNDk0NDI1ZmJkNDAyMGEzNGU2ODZlOWFkYWIzN2VfMTQtOS0xLTEtMTc0MTA_43444b64-641e-4fc0-97bf-bda77e64f5f2">3,968</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14808dab5a9a44dda4de75eaaebf7f2c_D20210701-20210930" decimals="-3" name="us-gaap:InterestIncomeOperating" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOjMyZDQ5NDQyNWZiZDQwMjBhMzRlNjg2ZTlhZGFiMzdlL3RhYmxlcmFuZ2U6MzJkNDk0NDI1ZmJkNDAyMGEzNGU2ODZlOWFkYWIzN2VfMTYtMy0xLTEtMTc0MTA_8ba539f1-717b-4573-a2a4-f4dcb1a8d260">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35bc95fa11524622b8a7f5abe7f7a8d0_D20210701-20210930" decimals="-3" name="us-gaap:InterestIncomeOperating" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOjMyZDQ5NDQyNWZiZDQwMjBhMzRlNjg2ZTlhZGFiMzdlL3RhYmxlcmFuZ2U6MzJkNDk0NDI1ZmJkNDAyMGEzNGU2ODZlOWFkYWIzN2VfMTYtNS0xLTEtMTc0MTA_9669ee3d-eafe-46cd-96f5-af0640459408">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id24ea483328641d39abd6bbf5097a73b_D20210701-20210930" decimals="-3" name="us-gaap:InterestIncomeOperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOjMyZDQ5NDQyNWZiZDQwMjBhMzRlNjg2ZTlhZGFiMzdlL3RhYmxlcmFuZ2U6MzJkNDk0NDI1ZmJkNDAyMGEzNGU2ODZlOWFkYWIzN2VfMTYtNy0xLTEtMTc0MTA_9baefdd2-f269-4e93-8255-70dabfe8407e">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9b0b6a3c69447bf8f151dfd98c14ac9_D20210701-20210930" decimals="-3" name="us-gaap:InterestIncomeOperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOjMyZDQ5NDQyNWZiZDQwMjBhMzRlNjg2ZTlhZGFiMzdlL3RhYmxlcmFuZ2U6MzJkNDk0NDI1ZmJkNDAyMGEzNGU2ODZlOWFkYWIzN2VfMTYtOS0xLTEtMTc0MTA_8d9e7a48-3e27-4905-bf82-c0327853a534">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14808dab5a9a44dda4de75eaaebf7f2c_D20210701-20210930" decimals="-3" name="us-gaap:InterestExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOjMyZDQ5NDQyNWZiZDQwMjBhMzRlNjg2ZTlhZGFiMzdlL3RhYmxlcmFuZ2U6MzJkNDk0NDI1ZmJkNDAyMGEzNGU2ODZlOWFkYWIzN2VfMTgtMy0xLTEtMTc0MTA_efd786f1-218c-4c5d-ac01-992af17495a1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35bc95fa11524622b8a7f5abe7f7a8d0_D20210701-20210930" decimals="-3" name="us-gaap:InterestExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOjMyZDQ5NDQyNWZiZDQwMjBhMzRlNjg2ZTlhZGFiMzdlL3RhYmxlcmFuZ2U6MzJkNDk0NDI1ZmJkNDAyMGEzNGU2ODZlOWFkYWIzN2VfMTgtNS0xLTEtMTc0MTA_dbb43a7b-4762-4f8f-aeaa-e2998ddc3779">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id24ea483328641d39abd6bbf5097a73b_D20210701-20210930" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOjMyZDQ5NDQyNWZiZDQwMjBhMzRlNjg2ZTlhZGFiMzdlL3RhYmxlcmFuZ2U6MzJkNDk0NDI1ZmJkNDAyMGEzNGU2ODZlOWFkYWIzN2VfMTgtNy0xLTEtMTc0MTA_6e373303-e209-4f27-9a76-02a047965ee1">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic9b0b6a3c69447bf8f151dfd98c14ac9_D20210701-20210930" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOjMyZDQ5NDQyNWZiZDQwMjBhMzRlNjg2ZTlhZGFiMzdlL3RhYmxlcmFuZ2U6MzJkNDk0NDI1ZmJkNDAyMGEzNGU2ODZlOWFkYWIzN2VfMTgtOS0xLTEtMTc0MTA_3f3107bf-9225-44a7-8164-3dafbe585835">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other loss, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14808dab5a9a44dda4de75eaaebf7f2c_D20210701-20210930" decimals="-3" name="us-gaap:OtherOperatingIncomeExpenseNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOjMyZDQ5NDQyNWZiZDQwMjBhMzRlNjg2ZTlhZGFiMzdlL3RhYmxlcmFuZ2U6MzJkNDk0NDI1ZmJkNDAyMGEzNGU2ODZlOWFkYWIzN2VfMTktMy0xLTEtMTc0MTA_3eb52121-0681-4b1d-a779-7de1c4cf881d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35bc95fa11524622b8a7f5abe7f7a8d0_D20210701-20210930" decimals="-3" name="us-gaap:OtherOperatingIncomeExpenseNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOjMyZDQ5NDQyNWZiZDQwMjBhMzRlNjg2ZTlhZGFiMzdlL3RhYmxlcmFuZ2U6MzJkNDk0NDI1ZmJkNDAyMGEzNGU2ODZlOWFkYWIzN2VfMTktNS0xLTEtMTc0MTA_db6d5e61-dee0-4426-a075-baee1e6dd2f4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id24ea483328641d39abd6bbf5097a73b_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOjMyZDQ5NDQyNWZiZDQwMjBhMzRlNjg2ZTlhZGFiMzdlL3RhYmxlcmFuZ2U6MzJkNDk0NDI1ZmJkNDAyMGEzNGU2ODZlOWFkYWIzN2VfMTktNy0xLTEtMTc0MTA_b6954d4d-b371-4b45-b254-ef107576a36f">192</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic9b0b6a3c69447bf8f151dfd98c14ac9_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOjMyZDQ5NDQyNWZiZDQwMjBhMzRlNjg2ZTlhZGFiMzdlL3RhYmxlcmFuZ2U6MzJkNDk0NDI1ZmJkNDAyMGEzNGU2ODZlOWFkYWIzN2VfMTktOS0xLTEtMTc0MTA_21143455-6c98-43e2-9593-071fd721def4">192</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14808dab5a9a44dda4de75eaaebf7f2c_D20210701-20210930" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOjMyZDQ5NDQyNWZiZDQwMjBhMzRlNjg2ZTlhZGFiMzdlL3RhYmxlcmFuZ2U6MzJkNDk0NDI1ZmJkNDAyMGEzNGU2ODZlOWFkYWIzN2VfMjMtMy0xLTEtMTc0MTA_18395edf-cbe5-4887-97ea-06cc1e439428">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35bc95fa11524622b8a7f5abe7f7a8d0_D20210701-20210930" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOjMyZDQ5NDQyNWZiZDQwMjBhMzRlNjg2ZTlhZGFiMzdlL3RhYmxlcmFuZ2U6MzJkNDk0NDI1ZmJkNDAyMGEzNGU2ODZlOWFkYWIzN2VfMjMtNS0xLTEtMTc0MTA_2379d217-2950-4fee-8300-90e0a97bed54">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id24ea483328641d39abd6bbf5097a73b_D20210701-20210930" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOjMyZDQ5NDQyNWZiZDQwMjBhMzRlNjg2ZTlhZGFiMzdlL3RhYmxlcmFuZ2U6MzJkNDk0NDI1ZmJkNDAyMGEzNGU2ODZlOWFkYWIzN2VfMjMtNy0xLTEtMTc0MTA_b2436174-ba99-4776-940e-f9e0e1966b50">73</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9b0b6a3c69447bf8f151dfd98c14ac9_D20210701-20210930" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOjMyZDQ5NDQyNWZiZDQwMjBhMzRlNjg2ZTlhZGFiMzdlL3RhYmxlcmFuZ2U6MzJkNDk0NDI1ZmJkNDAyMGEzNGU2ODZlOWFkYWIzN2VfMjMtOS0xLTEtMTc0MTA_e027fd43-032e-447c-8ac9-2eaed117b138">73</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:45.811%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.696%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Advanced Energy</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OEM</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate &amp; Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic79a2007f9024641a9822f1b84d5f8cd_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmNiYTNlYmM0NzNkOTRlZGZhMjBjMjA0NzA3M2MxYjM2L3RhYmxlcmFuZ2U6Y2JhM2ViYzQ3M2Q5NGVkZmEyMGMyMDQ3MDczYzFiMzZfMi0zLTEtMS0xNzQxMA_034c4cfd-2867-4cca-9320-3ba74e3be0c3">26,258</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i859943e8321b4443a613d8938534494e_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmNiYTNlYmM0NzNkOTRlZGZhMjBjMjA0NzA3M2MxYjM2L3RhYmxlcmFuZ2U6Y2JhM2ViYzQ3M2Q5NGVkZmEyMGMyMDQ3MDczYzFiMzZfMi01LTEtMS0xNzQxMA_667cde3a-4266-4ce9-a0d3-597993fa70c3">5,641</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i042c28c1eeda4c15bb204324175550d5_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmNiYTNlYmM0NzNkOTRlZGZhMjBjMjA0NzA3M2MxYjM2L3RhYmxlcmFuZ2U6Y2JhM2ViYzQ3M2Q5NGVkZmEyMGMyMDQ3MDczYzFiMzZfMi03LTEtMS0xNzQxMA_f286a121-f663-48bc-b1fc-da52bf089ec7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmNiYTNlYmM0NzNkOTRlZGZhMjBjMjA0NzA3M2MxYjM2L3RhYmxlcmFuZ2U6Y2JhM2ViYzQ3M2Q5NGVkZmEyMGMyMDQ3MDczYzFiMzZfMi05LTEtMS0xNzQxMA_7cc2b930-3051-409e-9744-df728ccf05de">31,899</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic79a2007f9024641a9822f1b84d5f8cd_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmNiYTNlYmM0NzNkOTRlZGZhMjBjMjA0NzA3M2MxYjM2L3RhYmxlcmFuZ2U6Y2JhM2ViYzQ3M2Q5NGVkZmEyMGMyMDQ3MDczYzFiMzZfMTQtMy0xLTEtMTc0MTA_f2f0bc28-c87a-4e7c-8fea-db66ebe86b07">3,765</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i859943e8321b4443a613d8938534494e_D20220101-20220930" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmNiYTNlYmM0NzNkOTRlZGZhMjBjMjA0NzA3M2MxYjM2L3RhYmxlcmFuZ2U6Y2JhM2ViYzQ3M2Q5NGVkZmEyMGMyMDQ3MDczYzFiMzZfMTQtNS0xLTEtMTc0MTA_cb00662f-430f-4988-b98b-b253c5c0f08a">1,142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i042c28c1eeda4c15bb204324175550d5_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmNiYTNlYmM0NzNkOTRlZGZhMjBjMjA0NzA3M2MxYjM2L3RhYmxlcmFuZ2U6Y2JhM2ViYzQ3M2Q5NGVkZmEyMGMyMDQ3MDczYzFiMzZfMTQtNy0xLTEtMTc0MTA_e3013a23-df9e-4419-9476-6b9ae2219626">15,006</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmNiYTNlYmM0NzNkOTRlZGZhMjBjMjA0NzA3M2MxYjM2L3RhYmxlcmFuZ2U6Y2JhM2ViYzQ3M2Q5NGVkZmEyMGMyMDQ3MDczYzFiMzZfMTQtOS0xLTEtMTc0MTA_df579936-3377-42f0-b816-8df8a66613b8">17,629</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic79a2007f9024641a9822f1b84d5f8cd_D20220101-20220930" decimals="-3" name="us-gaap:InterestIncomeOperating" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmNiYTNlYmM0NzNkOTRlZGZhMjBjMjA0NzA3M2MxYjM2L3RhYmxlcmFuZ2U6Y2JhM2ViYzQ3M2Q5NGVkZmEyMGMyMDQ3MDczYzFiMzZfMTYtMy0xLTEtMTc0MTA_799a664c-91c0-45d0-ba6d-62b4313c2d0d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i859943e8321b4443a613d8938534494e_D20220101-20220930" decimals="-3" name="us-gaap:InterestIncomeOperating" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmNiYTNlYmM0NzNkOTRlZGZhMjBjMjA0NzA3M2MxYjM2L3RhYmxlcmFuZ2U6Y2JhM2ViYzQ3M2Q5NGVkZmEyMGMyMDQ3MDczYzFiMzZfMTYtNS0xLTEtMTc0MTA_acdbf349-ccbf-4aa6-be56-59cacdc97594">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i042c28c1eeda4c15bb204324175550d5_D20220101-20220930" decimals="-3" name="us-gaap:InterestIncomeOperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmNiYTNlYmM0NzNkOTRlZGZhMjBjMjA0NzA3M2MxYjM2L3RhYmxlcmFuZ2U6Y2JhM2ViYzQ3M2Q5NGVkZmEyMGMyMDQ3MDczYzFiMzZfMTYtNy0xLTEtMTc0MTA_dd46e0d1-a48e-4850-9dea-6a68a9a6f1ee">93</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" decimals="-3" name="us-gaap:InterestIncomeOperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmNiYTNlYmM0NzNkOTRlZGZhMjBjMjA0NzA3M2MxYjM2L3RhYmxlcmFuZ2U6Y2JhM2ViYzQ3M2Q5NGVkZmEyMGMyMDQ3MDczYzFiMzZfMTYtOS0xLTEtMTc0MTA_ebea55c7-2172-4d1c-8782-6a9c202e0325">93</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic79a2007f9024641a9822f1b84d5f8cd_D20220101-20220930" decimals="-3" name="us-gaap:InterestExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmNiYTNlYmM0NzNkOTRlZGZhMjBjMjA0NzA3M2MxYjM2L3RhYmxlcmFuZ2U6Y2JhM2ViYzQ3M2Q5NGVkZmEyMGMyMDQ3MDczYzFiMzZfMTctMy0xLTEtMTc0MTA_dddaed07-4881-4406-9227-ab5edb3be858">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i859943e8321b4443a613d8938534494e_D20220101-20220930" decimals="-3" name="us-gaap:InterestExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmNiYTNlYmM0NzNkOTRlZGZhMjBjMjA0NzA3M2MxYjM2L3RhYmxlcmFuZ2U6Y2JhM2ViYzQ3M2Q5NGVkZmEyMGMyMDQ3MDczYzFiMzZfMTctNS0xLTEtMTc0MTA_94695743-983f-4305-8a5b-8523a6d28e89">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i042c28c1eeda4c15bb204324175550d5_D20220101-20220930" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmNiYTNlYmM0NzNkOTRlZGZhMjBjMjA0NzA3M2MxYjM2L3RhYmxlcmFuZ2U6Y2JhM2ViYzQ3M2Q5NGVkZmEyMGMyMDQ3MDczYzFiMzZfMTctNy0xLTEtMTc0MTA_e3d770c7-47c8-4150-925f-fff957327bd9">12</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmNiYTNlYmM0NzNkOTRlZGZhMjBjMjA0NzA3M2MxYjM2L3RhYmxlcmFuZ2U6Y2JhM2ViYzQ3M2Q5NGVkZmEyMGMyMDQ3MDczYzFiMzZfMTctOS0xLTEtMTc0MTA_ee4abb5c-eb48-45d9-bace-7f83e5da2137">12</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic79a2007f9024641a9822f1b84d5f8cd_D20220101-20220930" decimals="-3" name="us-gaap:OtherOperatingIncomeExpenseNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmNiYTNlYmM0NzNkOTRlZGZhMjBjMjA0NzA3M2MxYjM2L3RhYmxlcmFuZ2U6Y2JhM2ViYzQ3M2Q5NGVkZmEyMGMyMDQ3MDczYzFiMzZfMTgtMy0xLTEtMTc0MTA_df59871f-fbaa-4058-893f-fd72854b9bd9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i859943e8321b4443a613d8938534494e_D20220101-20220930" decimals="-3" name="us-gaap:OtherOperatingIncomeExpenseNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmNiYTNlYmM0NzNkOTRlZGZhMjBjMjA0NzA3M2MxYjM2L3RhYmxlcmFuZ2U6Y2JhM2ViYzQ3M2Q5NGVkZmEyMGMyMDQ3MDczYzFiMzZfMTgtNS0xLTEtMTc0MTA_2e130893-a5e7-4f4f-b455-e43f005fc301">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i042c28c1eeda4c15bb204324175550d5_D20220101-20220930" decimals="-3" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmNiYTNlYmM0NzNkOTRlZGZhMjBjMjA0NzA3M2MxYjM2L3RhYmxlcmFuZ2U6Y2JhM2ViYzQ3M2Q5NGVkZmEyMGMyMDQ3MDczYzFiMzZfMTgtNy0xLTEtMTc0MTA_b23374d2-f5a6-4261-98ca-f7cf242643ab">551</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" decimals="-3" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmNiYTNlYmM0NzNkOTRlZGZhMjBjMjA0NzA3M2MxYjM2L3RhYmxlcmFuZ2U6Y2JhM2ViYzQ3M2Q5NGVkZmEyMGMyMDQ3MDczYzFiMzZfMTgtOS0xLTEtMTc0MTA_fbb0f409-cd5d-4b24-a721-6cc3cb6bec79">551</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic79a2007f9024641a9822f1b84d5f8cd_D20220101-20220930" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmNiYTNlYmM0NzNkOTRlZGZhMjBjMjA0NzA3M2MxYjM2L3RhYmxlcmFuZ2U6Y2JhM2ViYzQ3M2Q5NGVkZmEyMGMyMDQ3MDczYzFiMzZfMjItMy0xLTEtMTc0MTA_62e21d26-3c5f-428a-b5b6-fb62a3d18e48">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i859943e8321b4443a613d8938534494e_D20220101-20220930" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmNiYTNlYmM0NzNkOTRlZGZhMjBjMjA0NzA3M2MxYjM2L3RhYmxlcmFuZ2U6Y2JhM2ViYzQ3M2Q5NGVkZmEyMGMyMDQ3MDczYzFiMzZfMjItNS0xLTEtMTc0MTA_e438430f-56df-4e8f-aefa-12b4150509ec">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i042c28c1eeda4c15bb204324175550d5_D20220101-20220930" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmNiYTNlYmM0NzNkOTRlZGZhMjBjMjA0NzA3M2MxYjM2L3RhYmxlcmFuZ2U6Y2JhM2ViYzQ3M2Q5NGVkZmEyMGMyMDQ3MDczYzFiMzZfMjItNy0xLTEtMTc0MTA_ddafa99d-f21e-4b6b-a969-205351de6508">216</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmNiYTNlYmM0NzNkOTRlZGZhMjBjMjA0NzA3M2MxYjM2L3RhYmxlcmFuZ2U6Y2JhM2ViYzQ3M2Q5NGVkZmEyMGMyMDQ3MDczYzFiMzZfMjItOS0xLTEtMTc0MTA_c8011edf-2c25-4ed4-8007-b3c2759ca86f">216</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie9788c72f4874edca78c1c4f307fec05_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="if7cf65fa926c4004bcde29587f041a1d"><div style="text-align:justify"><ix:continuation id="i93952b95dbea474491ffc0e26ff4e486"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:45.811%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.696%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Advanced Energy</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OEM</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate &amp; Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab38511a317c44aa9f0dc79521e2a6d5_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOjk5NTliMzg5MzQwYTRjNTA4ZjBmMTYyZTBmOGMyOTFjL3RhYmxlcmFuZ2U6OTk1OWIzODkzNDBhNGM1MDhmMGYxNjJlMGY4YzI5MWNfMi0zLTEtMS0xNzQxMA_3d72f8aa-2a24-48c4-8cdb-6187c265873d">27,951</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7bfacb65a9e6459ea08bf4947d3b9c2b_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOjk5NTliMzg5MzQwYTRjNTA4ZjBmMTYyZTBmOGMyOTFjL3RhYmxlcmFuZ2U6OTk1OWIzODkzNDBhNGM1MDhmMGYxNjJlMGY4YzI5MWNfMi01LTEtMS0xNzQxMA_487f7040-d345-4466-a8fa-245c7c8d62f6">3,742</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6944c3767530469d9f26618cb4e807e6_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOjk5NTliMzg5MzQwYTRjNTA4ZjBmMTYyZTBmOGMyOTFjL3RhYmxlcmFuZ2U6OTk1OWIzODkzNDBhNGM1MDhmMGYxNjJlMGY4YzI5MWNfMi03LTEtMS0xNzQxMA_f12ba92f-3223-4aee-95ab-ffec04fe585e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOjk5NTliMzg5MzQwYTRjNTA4ZjBmMTYyZTBmOGMyOTFjL3RhYmxlcmFuZ2U6OTk1OWIzODkzNDBhNGM1MDhmMGYxNjJlMGY4YzI5MWNfMi05LTEtMS0xNzQxMA_cdc25023-a7fc-4eae-89a9-21d9b272b410">31,693</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab38511a317c44aa9f0dc79521e2a6d5_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOjk5NTliMzg5MzQwYTRjNTA4ZjBmMTYyZTBmOGMyOTFjL3RhYmxlcmFuZ2U6OTk1OWIzODkzNDBhNGM1MDhmMGYxNjJlMGY4YzI5MWNfMTQtMy0xLTEtMTc0MTA_cfac1446-dd45-4419-a5aa-978cffcf7939">224</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7bfacb65a9e6459ea08bf4947d3b9c2b_D20210101-20210930" decimals="-3" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOjk5NTliMzg5MzQwYTRjNTA4ZjBmMTYyZTBmOGMyOTFjL3RhYmxlcmFuZ2U6OTk1OWIzODkzNDBhNGM1MDhmMGYxNjJlMGY4YzI5MWNfMTQtNS0xLTEtMTc0MTA_702fbbd6-4e6e-4b58-9c20-dc733cbdb90d">588</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6944c3767530469d9f26618cb4e807e6_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOjk5NTliMzg5MzQwYTRjNTA4ZjBmMTYyZTBmOGMyOTFjL3RhYmxlcmFuZ2U6OTk1OWIzODkzNDBhNGM1MDhmMGYxNjJlMGY4YzI5MWNfMTQtNy0xLTEtMTc0MTA_a585e005-cc63-4e6a-a34d-67eda98bccc7">13,120</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOjk5NTliMzg5MzQwYTRjNTA4ZjBmMTYyZTBmOGMyOTFjL3RhYmxlcmFuZ2U6OTk1OWIzODkzNDBhNGM1MDhmMGYxNjJlMGY4YzI5MWNfMTQtOS0xLTEtMTc0MTA_b5703f9f-22f4-4a3a-a661-1a88373df3f3">12,756</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab38511a317c44aa9f0dc79521e2a6d5_D20210101-20210930" decimals="-3" name="us-gaap:InterestIncomeOperating" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOjk5NTliMzg5MzQwYTRjNTA4ZjBmMTYyZTBmOGMyOTFjL3RhYmxlcmFuZ2U6OTk1OWIzODkzNDBhNGM1MDhmMGYxNjJlMGY4YzI5MWNfMTYtMy0xLTEtMTc0MTA_4b0a1c83-6aa0-4140-9f43-c7cf40b05355">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7bfacb65a9e6459ea08bf4947d3b9c2b_D20210101-20210930" decimals="-3" name="us-gaap:InterestIncomeOperating" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOjk5NTliMzg5MzQwYTRjNTA4ZjBmMTYyZTBmOGMyOTFjL3RhYmxlcmFuZ2U6OTk1OWIzODkzNDBhNGM1MDhmMGYxNjJlMGY4YzI5MWNfMTYtNS0xLTEtMTc0MTA_9310dc32-5db0-43ab-97df-53511fbc6e64">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6944c3767530469d9f26618cb4e807e6_D20210101-20210930" decimals="-3" name="us-gaap:InterestIncomeOperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOjk5NTliMzg5MzQwYTRjNTA4ZjBmMTYyZTBmOGMyOTFjL3RhYmxlcmFuZ2U6OTk1OWIzODkzNDBhNGM1MDhmMGYxNjJlMGY4YzI5MWNfMTYtNy0xLTEtMTc0MTA_35042933-a1d4-407a-ab3a-0df53fd7dbbd">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930" decimals="-3" name="us-gaap:InterestIncomeOperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOjk5NTliMzg5MzQwYTRjNTA4ZjBmMTYyZTBmOGMyOTFjL3RhYmxlcmFuZ2U6OTk1OWIzODkzNDBhNGM1MDhmMGYxNjJlMGY4YzI5MWNfMTYtOS0xLTEtMTc0MTA_7d2a609b-5a10-4a79-8c0f-a72b81310d51">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab38511a317c44aa9f0dc79521e2a6d5_D20210101-20210930" decimals="-3" name="us-gaap:InterestExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOjk5NTliMzg5MzQwYTRjNTA4ZjBmMTYyZTBmOGMyOTFjL3RhYmxlcmFuZ2U6OTk1OWIzODkzNDBhNGM1MDhmMGYxNjJlMGY4YzI5MWNfMTctMy0xLTEtMTc0MTA_c550b2bb-8ec0-4588-96e2-c9a2a2c2fa3b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7bfacb65a9e6459ea08bf4947d3b9c2b_D20210101-20210930" decimals="-3" name="us-gaap:InterestExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOjk5NTliMzg5MzQwYTRjNTA4ZjBmMTYyZTBmOGMyOTFjL3RhYmxlcmFuZ2U6OTk1OWIzODkzNDBhNGM1MDhmMGYxNjJlMGY4YzI5MWNfMTctNS0xLTEtMTc0MTA_6c3fa659-7f32-4eba-babb-adfb29dffd03">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6944c3767530469d9f26618cb4e807e6_D20210101-20210930" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOjk5NTliMzg5MzQwYTRjNTA4ZjBmMTYyZTBmOGMyOTFjL3RhYmxlcmFuZ2U6OTk1OWIzODkzNDBhNGM1MDhmMGYxNjJlMGY4YzI5MWNfMTctNy0xLTEtMTc0MTA_5ac558d3-7a68-49ca-b2f4-29bffbb9c5dc">9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOjk5NTliMzg5MzQwYTRjNTA4ZjBmMTYyZTBmOGMyOTFjL3RhYmxlcmFuZ2U6OTk1OWIzODkzNDBhNGM1MDhmMGYxNjJlMGY4YzI5MWNfMTctOS0xLTEtMTc0MTA_529b0988-e155-4f87-ad4a-e386ec90811b">9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other loss, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab38511a317c44aa9f0dc79521e2a6d5_D20210101-20210930" decimals="-3" name="us-gaap:OtherOperatingIncomeExpenseNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOjk5NTliMzg5MzQwYTRjNTA4ZjBmMTYyZTBmOGMyOTFjL3RhYmxlcmFuZ2U6OTk1OWIzODkzNDBhNGM1MDhmMGYxNjJlMGY4YzI5MWNfMTgtMy0xLTEtMTc0MTA_bb06a8cb-50a5-43a6-b9bb-70bce28dc2fd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7bfacb65a9e6459ea08bf4947d3b9c2b_D20210101-20210930" decimals="-3" name="us-gaap:OtherOperatingIncomeExpenseNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOjk5NTliMzg5MzQwYTRjNTA4ZjBmMTYyZTBmOGMyOTFjL3RhYmxlcmFuZ2U6OTk1OWIzODkzNDBhNGM1MDhmMGYxNjJlMGY4YzI5MWNfMTgtNS0xLTEtMTc0MTA_5cceb087-55df-4e14-a368-de24b498d44d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6944c3767530469d9f26618cb4e807e6_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOjk5NTliMzg5MzQwYTRjNTA4ZjBmMTYyZTBmOGMyOTFjL3RhYmxlcmFuZ2U6OTk1OWIzODkzNDBhNGM1MDhmMGYxNjJlMGY4YzI5MWNfMTgtNy0xLTEtMTc0MTA_d0d2db93-a252-4df5-86c3-881bcd7dfb86">188</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOjk5NTliMzg5MzQwYTRjNTA4ZjBmMTYyZTBmOGMyOTFjL3RhYmxlcmFuZ2U6OTk1OWIzODkzNDBhNGM1MDhmMGYxNjJlMGY4YzI5MWNfMTgtOS0xLTEtMTc0MTA_2e02826d-c59b-4dd4-be30-a1ab47fcb12f">188</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab38511a317c44aa9f0dc79521e2a6d5_D20210101-20210930" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOjk5NTliMzg5MzQwYTRjNTA4ZjBmMTYyZTBmOGMyOTFjL3RhYmxlcmFuZ2U6OTk1OWIzODkzNDBhNGM1MDhmMGYxNjJlMGY4YzI5MWNfMjItMy0xLTEtMTc0MTA_b5bcc937-3aaa-43c3-aa69-657cc71face9">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7bfacb65a9e6459ea08bf4947d3b9c2b_D20210101-20210930" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOjk5NTliMzg5MzQwYTRjNTA4ZjBmMTYyZTBmOGMyOTFjL3RhYmxlcmFuZ2U6OTk1OWIzODkzNDBhNGM1MDhmMGYxNjJlMGY4YzI5MWNfMjItNS0xLTEtMTc0MTA_3601496a-59b1-4131-b6d3-e30cf59d9c1d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6944c3767530469d9f26618cb4e807e6_D20210101-20210930" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOjk5NTliMzg5MzQwYTRjNTA4ZjBmMTYyZTBmOGMyOTFjL3RhYmxlcmFuZ2U6OTk1OWIzODkzNDBhNGM1MDhmMGYxNjJlMGY4YzI5MWNfMjItNy0xLTEtMTc0MTA_99061aab-9491-4fb8-91e2-6352bef2e5f8">246</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOjk5NTliMzg5MzQwYTRjNTA4ZjBmMTYyZTBmOGMyOTFjL3RhYmxlcmFuZ2U6OTk1OWIzODkzNDBhNGM1MDhmMGYxNjJlMGY4YzI5MWNfMjItOS0xLTEtMTc0MTA_473fb86d-620f-4517-a7f3-8ccd9bb76cae">246</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">International sales represented approximately <ix:nonFraction unitRef="number" contextRef="id6ada2596cf84b118b49af7a6561fb79_D20220701-20220930" decimals="3" name="apyx:TotalRevenuePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RleHRyZWdpb246YTQzN2Q5YmQxMWFiNGVlYjg3ODFhYzFmZWUyODdiYTNfMTQwNg_473664c5-b908-4e7b-8628-77a39c92d973">23.2</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" decimals="3" name="apyx:TotalRevenuePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RleHRyZWdpb246YTQzN2Q5YmQxMWFiNGVlYjg3ODFhYzFmZWUyODdiYTNfMTQxMw_86c11696-5df3-4939-beea-9bcfead0b46d">29.5</ix:nonFraction>% of total revenues for the three and nine months ended September 30, 2022, respectively, as compared with approximately <ix:nonFraction unitRef="number" contextRef="ic9b0b6a3c69447bf8f151dfd98c14ac9_D20210701-20210930" decimals="3" name="apyx:TotalRevenuePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RleHRyZWdpb246YTQzN2Q5YmQxMWFiNGVlYjg3ODFhYzFmZWUyODdiYTNfMTUwMQ_8c01f0a5-3314-44d2-9832-eed5a9f426a7">33.1</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930" decimals="3" name="apyx:TotalRevenuePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RleHRyZWdpb246YTQzN2Q5YmQxMWFiNGVlYjg3ODFhYzFmZWUyODdiYTNfMTUwOA_1d830657-4f62-48dc-a100-68a706a680dd">34.2</ix:nonFraction>% of total revenues for the three and nine months ended September 30, 2021, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" name="us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RleHRyZWdpb246YTQzN2Q5YmQxMWFiNGVlYjg3ODFhYzFmZWUyODdiYTNfMTY4MQ_3d13faaa-ee63-44e0-bb5f-760b93f3a378" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue by geographic region, based on the customer's &#8220;ship to&#8221; location on the invoice, are as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Sales by Domestic and International</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c92311eeeba414cba8eeea9eae36a73_D20220701-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmI5YzQ3Yjk4OTEwZTQwYTZhZDE2YTQzOWRkMjEyMjZiL3RhYmxlcmFuZ2U6YjljNDdiOTg5MTBlNDBhNmFkMTZhNDM5ZGQyMTIyNmJfMy0xLTEtMS0xNzQxMA_748dd521-2d1c-4584-9ef5-920fadf5a8ac">6,997</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cbcf0bb6950436780b8711457cab3c0_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmI5YzQ3Yjk4OTEwZTQwYTZhZDE2YTQzOWRkMjEyMjZiL3RhYmxlcmFuZ2U6YjljNDdiOTg5MTBlNDBhNmFkMTZhNDM5ZGQyMTIyNmJfMy0zLTEtMS0xNzQxMA_42ee38f7-526f-4e10-a4d1-01671b4f3c62">7,911</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36f2a37affac45d0a14e5ea2173cf5e1_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmI5YzQ3Yjk4OTEwZTQwYTZhZDE2YTQzOWRkMjEyMjZiL3RhYmxlcmFuZ2U6YjljNDdiOTg5MTBlNDBhNmFkMTZhNDM5ZGQyMTIyNmJfMy01LTEtMS0xNzQxMA_3883a4e0-cb4c-4556-8942-65f18ab5b954">22,492</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cf11e8a8ad24223ab309b02dcedcecb_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmI5YzQ3Yjk4OTEwZTQwYTZhZDE2YTQzOWRkMjEyMjZiL3RhYmxlcmFuZ2U6YjljNDdiOTg5MTBlNDBhNmFkMTZhNDM5ZGQyMTIyNmJfMy03LTEtMS0xNzQxMA_c066a7ba-e50c-42f2-a04f-e969313dbe86">20,860</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd22960d67cd4d7fadc9314e44177757_D20220701-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmI5YzQ3Yjk4OTEwZTQwYTZhZDE2YTQzOWRkMjEyMjZiL3RhYmxlcmFuZ2U6YjljNDdiOTg5MTBlNDBhNmFkMTZhNDM5ZGQyMTIyNmJfNC0xLTEtMS0xNzQxMA_a41819e2-3c10-43a9-b699-d0ad4b998edb">2,117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6227c7fe3e8c479d92f2f099128bd674_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmI5YzQ3Yjk4OTEwZTQwYTZhZDE2YTQzOWRkMjEyMjZiL3RhYmxlcmFuZ2U6YjljNDdiOTg5MTBlNDBhNmFkMTZhNDM5ZGQyMTIyNmJfNC0zLTEtMS0xNzQxMA_779d4511-617f-4cec-80dc-20e336003a34">3,920</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d94b2111aef41dfb83851bf1579dc6e_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmI5YzQ3Yjk4OTEwZTQwYTZhZDE2YTQzOWRkMjEyMjZiL3RhYmxlcmFuZ2U6YjljNDdiOTg5MTBlNDBhNmFkMTZhNDM5ZGQyMTIyNmJfNC01LTEtMS0xNzQxMA_696f4e5d-ba1e-44b8-af35-75f72276713c">9,407</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbb33a02347e4099b5d0a31dcb304fdb_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmI5YzQ3Yjk4OTEwZTQwYTZhZDE2YTQzOWRkMjEyMjZiL3RhYmxlcmFuZ2U6YjljNDdiOTg5MTBlNDBhNmFkMTZhNDM5ZGQyMTIyNmJfNC03LTEtMS0xNzQxMA_3293f5d7-e420-4f6e-ae37-747e98da0b53">10,833</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6ada2596cf84b118b49af7a6561fb79_D20220701-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmI5YzQ3Yjk4OTEwZTQwYTZhZDE2YTQzOWRkMjEyMjZiL3RhYmxlcmFuZ2U6YjljNDdiOTg5MTBlNDBhNmFkMTZhNDM5ZGQyMTIyNmJfNS0xLTEtMS0xNzQxMA_21c46bb0-6eaa-4a28-aed4-0290e21eff54">9,114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9b0b6a3c69447bf8f151dfd98c14ac9_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmI5YzQ3Yjk4OTEwZTQwYTZhZDE2YTQzOWRkMjEyMjZiL3RhYmxlcmFuZ2U6YjljNDdiOTg5MTBlNDBhNmFkMTZhNDM5ZGQyMTIyNmJfNS0zLTEtMS0xNzQxMA_638db13e-99fc-4d31-a4fb-6074615db920">11,831</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmI5YzQ3Yjk4OTEwZTQwYTZhZDE2YTQzOWRkMjEyMjZiL3RhYmxlcmFuZ2U6YjljNDdiOTg5MTBlNDBhNmFkMTZhNDM5ZGQyMTIyNmJfNS01LTEtMS0xNzQxMA_536a1ec6-176f-4f33-893d-79f47f22761e">31,899</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmI5YzQ3Yjk4OTEwZTQwYTZhZDE2YTQzOWRkMjEyMjZiL3RhYmxlcmFuZ2U6YjljNDdiOTg5MTBlNDBhNmFkMTZhNDM5ZGQyMTIyNmJfNS03LTEtMS0xNzQxMA_97c6d48a-438e-4e84-9786-e4373e129559">31,693</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><div id="ie9788c72f4874edca78c1c4f307fec05_70"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie9788c72f4874edca78c1c4f307fec05_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT'S DISCUSSION AND ANALYSIS OF</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should read the following discussion and analysis in conjunction with our financial statements and related notes contained elsewhere in this report. This discussion contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of a variety of factors discussed in this report and those discussed in other documents we file with the SEC. In light of these risks, uncertainties and assumptions, readers are cautioned not to place undue reliance on such forward-looking statements. These forward-looking statements represent beliefs and assumptions as of the date of this report. While we may elect to update forward-looking statements and at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change. Past performance does not guarantee future results.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Executive Level Overview</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an advanced energy technology company with a passion for elevating people&#8217;s lives through innovative products, including our Helium Plasma Technology products marketed and sold as Renuvion&#174; in the cosmetic surgery market and J-Plasma&#174; in the hospital surgical market. Renuvion&#174; and J-Plasma&#174; offer surgeons a unique ability to provide controlled heat to tissue to achieve their desired results. We also leverage our deep expertise and decades of experience in unique waveforms through OEM agreements with other medical device manufacturers.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 14, 2022, the U.S. Food and Drug Administration (&#8220;FDA&#8221;) posted a Safety Communication that warns consumers and health care providers against the use of our Advanced Energy products outside of their FDA-cleared indications for general use in cutting, coagulation, and ablation of soft tissue during open and laparoscopic surgical procedures. Following the Safety Communication, we experienced slowed demand for the adoption of our Helium Plasma Technology. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As part of our plan to accelerate and fully fund the development of our advanced energy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">business, with a focus in the cosmetic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">surgery market, we sold our Core business in 2018 for gross proceeds of $97 million.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">These proceeds were used to launch broad marketing and sales initiatives which resulted in rapid sales growth through December 31, 2021 and into the first quarter of 2022.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">This planned growth in the business was accompanied by scaled operations, including procurement of components, expanded manufacturing capacity to turn those materials into saleable inventory, additional discretionary expenditures, including increased global participation at trade shows, additional employee trainings, user meetings, increased travel and entertainment expenses, more expansive research and development projects, and additional headcount to support those activities. Additionally, we had and still have, some significant non-recurring discretionary expenditures associated with completing our multi-year marketing initiatives related to our dermal resurfacing and skin laxity clearances. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 26, 2022, we announced that we received 510(k) clearance from the FDA for the use of the Renuvion Dermal Handpiece for specific dermal resurfacing procedures. On July 18, 2022, we announced that we received 510(k) clearance from the FDA for the use of the Renuvion&#174; APR Handpiece for certain skin contraction procedures. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 2, 2022, and July 21, 2022, FDA updated the Medical Device Safety Communication to recognize the new 510(k) clearances for the Renuvion&#174; Dermal handpiece, and the expanded indications for the Renuvion&#174; APR handpieces. The 510(k) clearance for the Renuvion&#174; Dermal handpiece allows surgeons to perform dermal resurfacing procedures for the treatment of moderate to severe wrinkles and rhytides, limited to patients with Fitzpatrick Skin Types I, II or III. The 510(k) clearance for the Renuvion&#174; APR handpieces now addresses improving the appearance of lax (loose) skin in the neck and submental region. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we expected that receiving these clearances would materially mitigate the financial effects of the Safety Communication in future periods, we continue to experience reduced demand for the adoption and utilization of our technology and we believe that this may have an adverse effect in future periods.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While sales were continuing to grow into the first quarter of 2022 prior to the FDA Safety Communication, over the last few years, exclusive of our sale of the Core business segment to Symmetry Surgical during 2018, we have incurred recurring net losses and cash outflows from operations and we anticipate that losses will continue in the near term. During the nine months ended September 30, 2022, we incurred an operating loss of $17.6 million and used $15.8 million of cash in operations. As of September 30, 2022, we had cash and cash equivalents of $14.8 million. These conditions raise substantial doubt about our ability to continue as a going concern for a period of at least one year from the date of issuance of these unaudited condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie9788c72f4874edca78c1c4f307fec05_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT'S DISCUSSION AND ANALYSIS OF</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL CONDITION AND RESULTS OF OPERATIONS - Continued</span></div><div><span><br/></span></div></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In an effort to alleviate these conditions, we are currently evaluating various funding alternatives to improve liquidity and may seek to raise additional capital through debt financing, the sale of equity securities, leveraging our unencumbered real estate, or any combination thereof. In addition, we are actively pursuing collection of our income tax receivable. We also continue to re-assess our operating expenditures and cost structure to be commensurate with our expected levels of revenue and we have the ability to reduce or delay expenditures to enhance and preserve liquidity. As we seek additional sources of financing, there can be no assurance that such financing would be available to us on favorable terms or at all. Our ability to obtain additional financing in the debt and equity capital markets is subject to several factors, including market and economic conditions, our performance and investor sentiment with respect to us and our industry. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the actions and efforts we can and will take to manage operating expenditures and, while not assured, arrange alternative financing sources as described above will enable us to meet our obligations for a period of at least one year from the date of issuance of these unaudited condensed consolidated financial statements. As a result, we believe our plans alleviate substantial doubt about our ability to continue as a going concern. These unaudited condensed financial statements do not include any adjustments relating to the carrying amounts and classification of assets and liabilities that may be necessary should we be unable to continue as a going concern.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to focus our efforts to increase the adoption of our Advanced Energy technology and utilization of our handpieces by surgeons in the U.S. and fulfilling demand from distributors in our international markets. Management estimates that our products have been sold in more than 60 countries. As of September&#160;30, 2022, we had a direct sales force of 35 field-based selling professionals and utilized 3 independent sales agencies. We also had 4 sales managers. This selling organization is focused on the use of Renuvion&#174; and J-Plasma&#174; in the cosmetic and hospital surgical markets, supported by our global medical affairs team. This global team of clinical support specialists focuses on supporting our users to ensure optimal outcomes for their patients. In addition, we have invested in training programs and marketing-related activities to support accelerated adoption of Renuvion&#174; into surgeons' practices.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In regards to our operating segments, our results are aggregated into reportable segments only if they exhibit similar economic characteristics. In addition to similar economic characteristics, we also consider the following factors in determining the reportable segments: the nature of business activities, the management structure directly accountable to our chief operating decision maker for operating and administrative activities, availability of discrete financial information, and information presented to the Board of Directors and investors. Asset information is not reviewed by the chief operating decision maker by segment and is not available by segment and, accordingly, we have not presented a measure of assets by reportable segment.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our reportable segments are disclosed as principally organized and managed as two operating segments: Advanced Energy and OEM. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate &amp; Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> includes certain unallocated corporate and administrative costs which are not specifically attributed to any reportable segment. The OEM segment is primarily development and manufacturing contract and product driven, and all related expenses are recorded as cost of sales, therefore no segment specific operating expenses are incurred.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In response to the global supply chain instability and inflationary cost increases, we continue to take action to minimize, as much as possible, any potential adverse impacts by working closely with our suppliers to closely monitor the availability of raw material components (i.e. semiconductors and plastics), lead times, and freight carrier availability.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect global supply chain instability will continue to have an impact on our business, but to date that has not been material to our financial performance. The consequences of the pandemic, global supply chain instability and inflationary cost increases and their adverse impact to the global economy, continue to evolve. Accordingly, the significance of the future impact to our business and financial statements remains subject to significant uncertainty.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We strongly encourage investors to visit our website: </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">www.apyxmedical.com</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to view the most current news and to review our filings with the Securities and Exchange Commission.</span></div><div><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie9788c72f4874edca78c1c4f307fec05_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT'S DISCUSSION AND ANALYSIS OF</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL CONDITION AND RESULTS OF OPERATIONS - Continued</span></div><div><span><br/></span></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:30.811%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.639%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Sales by Reportable Segment</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advanced Energy</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,080&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,313&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,258&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,951&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OEM</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,034&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,518&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,641&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,742&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,114&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,831&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,899&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,693&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#cceeff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(632,000)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Sales by Domestic and International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,997&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,911&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,492&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,860&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,117&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,920&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,407&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,833&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,114&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,831&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,899&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,693&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:3pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue decreased by </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23.0%</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, or approximately $(2.7)&#160;million, for the three months ended September&#160;30, 2022 when compared with the three months ended September&#160;30, 2021. Advanced Energy segmen</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">t sales decreased 31.3%, or approximately </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$(3.2)&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for the three</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> months ended September 30, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> when compared with the three </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended September 30, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Advanced Energy sales decrease is due to global decreases in </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">utilization based demand for our handpieces and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the adoption of our generator technology following the FDA Safety Communication on March 14, 2022. OEM segmen</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">t sales increased 34.0%, or approximately </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$0.7&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three months ended September&#160;30, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> when compared with the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three months ended September&#160;30, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The increase in OEM sales was due to increases in sales volume to existing customers, including Symmetry Surgical, under our 10-year generator manufacturing and supply agreement.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue increased by </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.6%</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, or approximately $0.2&#160;million, for the nine months ended September 30, 2022 when compared with the nine months ended September 30, 2021. Advanced Energy segmen</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">t sales decreased (6.1)%, or approximately </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$(1.7)&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine months ended September 30, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> when compared with the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine months ended September 30, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Advanced Energy sales decrease is due to global decreases in </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">utilization based demand for our handpieces and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the adoption of our generator technology following the FDA Safety Communication on March 14, 2022. The Advanced Energy sales decrease was partially offset by an increase in global utilization based demand for our handpieces and adoption of our generator technology in international markets for most of the first quarter before the FDA Safety Communication. OEM segmen</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">t sales increased 50.7%, or approximately </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1.9&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine months ended September 30, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> when compared with the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine months ended September 30, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The increase in OEM sales was due to increases in sales volume to existing customers, including Symmetry Surgical, under our 10-year generator manufacturing and supply agreement, as well as incremental new sales upon the commencement of the supply arrangement related to the completion of the development portion of some of our OEM development agreements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">International sales represented approximately 23.2% and 29.5% of total revenues for the three and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine months ended September 30, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, respectively, as compared with 33.1% and 34.2% of total revenues for the same period in the prior year. Management estimates our products have been sold in more than 60 countries through local dealers coordinated by sales and marketing personnel through our facilities in Clearwater, Florida and Sofia, Bulgaria.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gross Profit</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:30.811%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,357&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,775&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,009&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,243&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Percentage of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:30.811%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,757&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,056&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,890&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Percentage of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:3pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross profit for the three months ended September&#160;30, 2022, decreased 28.5% to $5.8 million, compared to $8.1 million for the same period in the prior year. Gross margin for the three months ended September&#160;30, 2022, was 63.2%, compared to 68.1% for </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie9788c72f4874edca78c1c4f307fec05_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT'S DISCUSSION AND ANALYSIS OF</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL CONDITION AND RESULTS OF OPERATIONS - Continued</span></div><div><span><br/></span></div></div><div style="margin-top:3pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the same period in 2021. Gross profit for the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine months ended September 30, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, decreased (2.6)% to $20.9 million, compared to $21.5 million for the same period in the prior year. Gross margin for the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine months ended September 30, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, was 65.5%, compared to 67.7% for the same period in 2021. The decrease in gross profit margins for the three and nine </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended September 30, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> from the prior year periods is primarily attributable to changes in the sales mix between our two segments, with our OEM segment comprising a higher percentage of total sales, product mix within our Advanced Energy Segment and higher material and inbound shipping costs to manufacture our inventory. These decreases were partially offset by geographic mix within our Advanced Energy segment, with domestic sales comprising a higher percentage of total sales and the mix of newer product models as we obtain registrations, allowing these products to be introduced into the markets we serve.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Costs and Expenses</span></div><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span></div><div style="margin-bottom:3pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:30.811%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,061&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,175&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,289&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,374&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Percentage of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses decreased 9.7% for the</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> three </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended September&#160;30, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, primarily due to lower spending on our two investigational device exemption (IDE) clinical studies and other product development initiatives ($0.1 million).</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses decreased 2.5% for the</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine months ended September 30, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, primarily due to lower spending on our two investigational device exemption (IDE) clinical studies and other product development initiatives ($0.3 million). This decrease was partially offset by increased labor and benefit costs from the same period in the prior year ($0.2 million). </span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Professional services</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:30.811%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional services expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,936&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,032&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,611&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,442&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Percentage of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Professional ser</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">vices expense decreased (4.7)% for the three months ended September&#160;30, 2022, primarily attributable to a decrease in physician consulting fees ($0.2 million). This decrease was partially offset by an increase in Board of Directors option expense ($0.1 million) and accounting and auditing fees ($0.1 million). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Professional ser</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">vices expense increased 21.5% for the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine months ended September 30, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, primarily attributable to increases in legal expenses ($0.7 million), primarily associated with the estimated loss recorded for the class action lawsuit, Board of Directors option expense ($0.3 million), accounting and auditing fees ($0.2 million), physician consulting fees ($0.1 million), and employee recruitment expense ($0.1 million). These increases were partially offset by a decrease in option expense for our partner physicians ($0.2 million).</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie9788c72f4874edca78c1c4f307fec05_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT'S DISCUSSION AND ANALYSIS OF</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL CONDITION AND RESULTS OF OPERATIONS - Continued</span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Salaries and related costs</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:30.811%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries and related expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,871&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,206&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,944&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,794&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Percentage of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September&#160;30, 2022, salaries and related expenses decreased (8.0)%, primarily driven by a decrease in bonus expense ($1.1 million) as we determined we would not meet our 2022 bonus plan and reversed our entire bonus accrual during the quarter. This decrease is partially offset by higher compensation and benefits ($0.4 million) and stock compensation expense ($0.4 million) as compared to the same period in the prior year. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine months ended September 30, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, salaries and related expenses increased 9.0%, primarily driven by higher compensation and benefits ($1.4 million) and stock compensation expense ($1.0 million) as compared to the same period in the prior year. These increases are partially offset by a decrease in bonus expense ($1.3 million) as we determined we would not meet our 2022 bonus plan, accordingly we have recorded no bonus expense in 2022. </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative expenses</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:30.811%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SG&amp;A expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,671&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,611&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,675&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,596&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Percentage of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September&#160;30, 2022, selling, general and administrative expense increased 1.3%, primarily driven by higher insurance expense, including product liability claims on our policies ($0.7 million), travel and entertainment expense ($0.2 million), exchange rate losses ($0.2 million) and other public company related costs ($0.1 million). These increases were partially offset by lower commissions on Advanced Energy sales ($0.8 million), advertising expense, including trade show fees and related costs ($0.3 million) and employee training and other meeting expenses ($0.1 million).</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine months ended September 30, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, selling, general and administrative expense increased 16.5%, primarily driven by higher travel and entertainment expense ($0.9 million), employee training and other meeting expenses ($0.7 million), advertising expense, including trade show fees and related costs ($0.6 million), insurance expense, including product liability claims on our policies ($0.7 million), bad debt expense ($0.2 million), exchange rate losses ($0.1 million), and other public company related costs ($0.1 million). These increases were partially offset by decreases in commissions on Advanced Energy sales ($0.9 million), OEM product recall costs ($0.2 million) as we experienced no product recalls in 2022, and lower regulatory registration expenses ($0.1 million).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other income (loss)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:30.811%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (loss) income, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(192)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(81.8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">551&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(188)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(393.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Percentage of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other (loss) income, net decreased </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81.8%</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">393.1% </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the three and nine months ended September&#160;30, 2022, as compared with the same periods in the prior year</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. For the three month period, this decrease was primarily driven by the wind down of the supply arrangement with Symmetry in the Core business segment. For the nine month period, this decrease was primarily attributable to the release of a portion of our</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> joint and several payroll liability due to the lapse of the statute of limitations on a portion of the liability ($0.6 million).</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie9788c72f4874edca78c1c4f307fec05_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT'S DISCUSSION AND ANALYSIS OF</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL CONDITION AND RESULTS OF OPERATIONS - Continued</span></div><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:30.657%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.535%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense (benefit)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our income tax expense was approximately $50,000 and $73,000 with effective tax rates of (0.9)% and (1.8)% for the three months ended September&#160;30, 2022 and 2021, respectively. Our income tax expense was approximately $216,000 and $246,000 with effective tax rates of (1.3)% and (1.9)% for the nine months ended September 30, 2022 and 2021, respectively. For the three and nine months ended September 30, 2022 and 2021, the effective rates differ from statutory rates primarily due to the full valuation allowance recorded on our NOL generated during the periods, combined with interest and penalties on our uncertain tax positions. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our working capital at September&#160;30, 2022 was approximately $35.1 million compared with $47.5 million at December&#160;31, 2021. The decrease in working capital from December&#160;31, 2021 was primarily due to the net loss incurred by the Company during the first nine months of 2022, excluding non-cash activity, comprised primarily of stock-based compensation expense.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine months ended September 30, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, net cash used in operating activities was approximately $15.8 million, which principally funded our loss from operations of $17.6 million, compared with net cash used in operating activities of approximately $10.7 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the same period for 2021. As discussed in the Executive Level Overview, our operating loss, cash used in operations and current cash and cash equivalents balance of $14.8 million raise substantial doubt about our ability to continue as a going concern for a period of at least one year from the date of issuance of these unaudited condensed consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities for the nine months ended September 30, 2022 and 2021, was </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$0.9 million and $0.4 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, respectively, related to investments in property and equipment. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September&#160;30, 2022, we had purchase commitments totaling approximately </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$3.1 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, substantially all of which is expected to be purchased within the next fifteen months.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><div id="ie9788c72f4874edca78c1c4f307fec05_76"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie9788c72f4874edca78c1c4f307fec05_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT'S DISCUSSION AND ANALYSIS OF</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL CONDITION AND RESULTS OF OPERATIONS - Continued</span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Estimates</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In preparing the consolidated financial statements in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP), we have adopted various accounting policies. Our most significant accounting policies are disclosed in Note 2 to the consolidated financial statements included in our 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Form 10-K</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, filed with the SEC on March 17, 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Our estimates and assumptions, including those related to inventories, intangible assets, property, plant and equipment, legal proceedings, research and development, warranty obligations, product liability, sales returns and discounts, stock-based compensation and income taxes are updated as appropriate, which in most cases is at least quarterly. We base our estimates on historical experience, or various assumptions that are believed to be reasonable under the circumstances and the results form the basis for making judgments about the reported values of assets, liabilities, revenues and expenses. Actual results may materially differ from these estimates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimates are considered to be critical if they meet both of the following criteria: (1) the estimate requires assumptions about material matters that are uncertain at the time the accounting estimates are made and (2) other materially different estimates could have been reasonably made or material changes in the estimates are reasonably likely to occur from period to period. Our critical accounting estimates include the following:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-based Compensation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our stock option plans, options to purchase common shares of the Company may be granted to employees, officers and directors of the Company by the Board of Directors. We account for stock options in accordance with FASB ASC Topic 718-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation-Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, with compensation expense recognized over the vesting period. Options are valued using the Black-Scholes model, which includes a number of estimates that affect the amount of our expense. We have determined that the most critical of these estimates are the estimates of expected life and volatility used in the calculations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected life</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For employee stock-based compensation awards, we estimate the expected life of awards utilizing the SEC's simplified method. We utilize this method, as we have not historically granted stock-based compensation awards to employees in sufficient volumes to determine a reasonable estimate of the life of awards. For awards granted to non-employees, we calculate expected life using a combination of past exercise behavior, the contractual term and expected remaining exercise behavior.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Volatility</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine the volatility by utilizing the historical volatility of our stock over the period of the awards expected life. The SEC allows us to include periods in excess of the useful life if we determine that they provide a more reasonable basis for the volatility of our stock. Additionally, ASC 718-10 allows us to exclude periods from the volatility if they pertain to events or circumstances that in our judgment are specific to us and if the event or transaction is not reasonably expected to occur again during the expected term of the awards. We have not included any additional periods, nor disregarded any periods, in calculating our volatility.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts Receivable Allowance</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain a reserve for uncollectible accounts receivable. When evaluating the adequacy of the allowance for doubtful accounts, we analyze specific unremitted customer balances for known collectability issues, review historical bad debt experience, customer credit worthiness and economic trends, and we make estimates in connection with establishing the allowance for doubtful accounts, including the future impacts of current trends. Changes in estimates are reflected in the period they are made. If the financial condition of our customers deteriorates, resulting in an inability to make payments, additional allowances may be required.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie9788c72f4874edca78c1c4f307fec05_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT'S DISCUSSION AND ANALYSIS OF</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL CONDITION AND RESULTS OF OPERATIONS - Continued</span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventory Obsolescence Allowance</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain a reserve for excess and obsolete inventory resulting from the potential inability to sell our products at prices in excess of current carrying costs. The markets in which we operate are highly competitive, with new products and surgical procedures introduced on an ongoing basis. Such marketplace changes may cause our products to become obsolete. We make estimates regarding the future recoverability of the costs of these products and record a provision for excess and obsolete inventories based on historical experience and expected future trends. If actual product life cycles, product demand or acceptance of new product introductions are less favorable than projected by management, additional inventory write-downs may be required, which would unfavorably affect future operating results.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Litigation Contingencies</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with authoritative guidance, we record a liability in our consolidated financial statements for these actions when a loss is known or considered probable and the amount can be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is reasonably possible, but not known or probable, and can be reasonably estimated, the estimated loss or range of loss is disclosed in the notes to the consolidated financial statements. In most cases, significant judgment is required to estimate the amount and timing of a loss to be recorded; actual results may differ from these estimates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes includes federal, foreign, state and local income taxes currently payable and those deferred because of temporary differences between the financial statement and tax bases of assets and liabilities. Deferred tax assets or liabilities are computed based on the difference between the financial statement and income tax bases of assets and liabilities using enacted marginal tax rates. Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not that a tax benefit will not be realized. Deferred income tax expenses or credits are based on the changes in the asset or liability from period to period.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of historical losses and our expectation to continue to generate losses in the near future, we recorded a valuation allowance on our net deferred tax assets. Exclusive of the carryback provisions of the CARES Act and the associated income tax benefit recognized in 2020, we do not anticipate recording an income tax benefit related to our deferred tax assets. We will reassess the realization of deferred tax assets each reporting period and will be able to reduce the valuation allowance to the extent our results of operations improve, and it becomes more likely than not that the deferred tax assets will be realized. As Management has not fully determined the timing of when it will generate taxable income in the U.S., we continued to record a valuation allowance on the net deferred tax assets balance as of  September&#160;30, 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess the financial statement impact of an uncertain tax position taken or expected to be taken on an income tax return at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized in the financial statements unless it is more likely than not of being sustained.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inflation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consequences of the pandemic, global supply chain instability and inflationary cost increases and their adverse impact to the global economy, continue to evolve. Accordingly, the significance of the future impact to our business and financial statements remains subject to significant uncertainty. Inflation has not, to date, materially impacted our operations or financial performance. However, as these trends continue for raw materials, freight, and labor costs, our future financial performance could be adversely impacted.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no off-balance sheet arrangements at this time.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie9788c72f4874edca78c1c4f307fec05_34">See Note 2 of the Notes to Condensed Consolidated Financial Statements in Part I, Item 1 of this Form 10-Q</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><div id="ie9788c72f4874edca78c1c4f307fec05_79"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie9788c72f4874edca78c1c4f307fec05_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Quantitative and Qualitative Disclosures about Market Risk</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><div id="ie9788c72f4874edca78c1c4f307fec05_82"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie9788c72f4874edca78c1c4f307fec05_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4. Controls and Procedures</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:4.55pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Disclosure Controls and Procedures </span></div><div style="margin-top:0.45pt"><span><br/></span></div><div style="margin-top:4.55pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Disclosure Controls and Procedures </span></div><div style="margin-top:0.45pt"><span><br/></span></div><div style="margin-top:4.55pt;padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management has established and maintains disclosure controls and procedures that are designed to ensure that the information required to be disclosed by us in reports that we file or submit under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission's rules and forms, and that such information is accumulated and communicated to management, including the Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Management carried out an evaluation, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this report. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that as of September&#160;30, 2022, the Company&#8217;s disclosure controls and procedures were effective.</span></div><div style="margin-top:4.55pt;padding-right:4.5pt;text-align:justify"><span><br/></span></div><div style="margin-top:4.59pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div style="margin-top:0.45pt"><span><br/></span></div><div style="margin-top:4.55pt;padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting during the quarter ended September 30, 2022, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="margin-top:4.55pt;padding-right:4.5pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><div id="ie9788c72f4874edca78c1c4f307fec05_85"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie9788c72f4874edca78c1c4f307fec05_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II. &#160;&#160;&#160;&#160;Other Information</span></div><div style="text-align:justify"><span><br/></span></div><div id="ie9788c72f4874edca78c1c4f307fec05_88"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. Legal Proceedings</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie9788c72f4874edca78c1c4f307fec05_61">See Note 11 of Notes to Condensed Consolidated Financial Statements in Part I, Item 1 of this Form 10-Q.</a></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><div id="ie9788c72f4874edca78c1c4f307fec05_91"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie9788c72f4874edca78c1c4f307fec05_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A. Risk factors</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">There have been no material changes to the risk factors described under Item 1A of our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2021, except for the following:</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We have had a history of operating losses that have impacted our overall cash flows and may impact our ability to continue as a going concern. We anticipate that we may need to adjust our operating expenditures to be commensurate with our expected levels of revenue and/or raise additional capital to finance operations.</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Due to our recurring net losses and the continued impact of the FDA Safety Communication on demand for the adoption and utilization of our technology, we may need to raise additional capital to fund our future operations. Our cash needs will depend on numerous factors, including our revenues, successful completion of our FDA product clearance activities, our continued ability to commercialize our advanced energy products, and our ability to reduce and control costs. If we are unable to secure such additional financing on terms that are acceptable to us, it will have a material adverse effect on our business and we may have to limit operations in a manner inconsistent with our growth strategy. If additional funds are raised through the issuance of equity securities, it will be dilutive to our stockholders and could result in a decrease in our stock price. If we are unable to obtain the requisite amount of financing needed to fund our planned operations, it would have a material adverse effect on our business and ability to continue as a going concern.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><div id="ie9788c72f4874edca78c1c4f307fec05_97"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie9788c72f4874edca78c1c4f307fec05_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div><span><br/></span></div><div id="ie9788c72f4874edca78c1c4f307fec05_100"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3. Defaults Upon Senior Securities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div><span><br/></span></div><div id="ie9788c72f4874edca78c1c4f307fec05_103"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4. Mine Safety Disclosures</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not Applicable.</span></div><div style="text-align:justify"><span><br/></span></div><div id="ie9788c72f4874edca78c1c4f307fec05_106"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 5. Other Information</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><div id="ie9788c72f4874edca78c1c4f307fec05_109"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie9788c72f4874edca78c1c4f307fec05_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="-sec-extract:summary;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6. Exhibits</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:9.603%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.464%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/719135/000100944811000015/exhibit31.htm">Articles of Incorporation of the Registrant (Incorporated by reference to the Registrant&#8217;s report on Form 10-K/A filed on March 31, 2011)</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/719135/000100944811000015/exhibit32.htm">By laws of the Registrant (Incorporated by reference to the Registrant&#8217;s Annual Report on Form 10-K/A filed on March 31, 2011)</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/719135/000071913517000064/a2017q3exhibit35.htm">Certificate of Amendment of the Certificate of Incorporation of the Registrant (Incorporated by reference to the Registrant&#8217;s Quarterly Report on Form 10-Q filed on November 3, 2017).</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/719135/000071913518000021/bvx_201805xex31certificate.htm">Certificate of Elimination (Incorporated by reference to the Registrant&#8217;s Current Report on Form 8-K filed on May 3, 2018)</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/719135/000071913518000086/0000719135-18-000086-index.htm">Certificate of Amendment of the Certificate of Incorporation of the Registrant (Incorporated by reference to the Registrant's Current Report of Form 8-K filed on December 28, 2018)</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="a2022q310-qexhibit311.htm">Certification pursuant to Section 302 of Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="a2022q310-qexhibit312.htm">Certification pursuant to Section 302 of Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="a2022q310-qexhibit321.htm">Certification pursuant to Section 906 of Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="a2022q310-qexhibit322.htm">Certification pursuant to Section 906 of Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS**</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH**</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema Document</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL**</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF**</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB**</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE**</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Label Presentation Document</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Filed herewith.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">** XBRL (Extensible Business Reporting Language) information is furnished and not filed or a part of registration&#160;statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended and otherwise is not subject to liability under these sections.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><div id="ie9788c72f4874edca78c1c4f307fec05_112"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie9788c72f4874edca78c1c4f307fec05_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:46.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.275%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.740%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Apyx Medical Corporation</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: November 10, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ Charles D. Goodwin II</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charles D. Goodwin II</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President, Chief Executive Officer and Director</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: November 10, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ Tara Semb</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tara Semb</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer,</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasurer and Secretary</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>a2022q310-qexhibit311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i0766cf6571b74b4b9a1e03ef901aa6ac_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:right;text-indent:42.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.1</font></div><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certificate Pursuant to Section&#160;302</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">of Sarbanes &#8211; Oxley Act of 2002</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CEO</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Charles D Goodwin II, the Registrant's Chief Executive Officer, certify that&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">I have reviewed this quarterly report on Form 10-Q of Apyx Medical Corporation&#59;</font></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, the financial statements and other financial information included in this report fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected or is reasonably likely to materially affect the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal controls over financial reporting.</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:46.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.064%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.951%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; November 10, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#47;s&#47; Charles D. Goodwin II</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charles D. Goodwin II</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>a2022q310-qexhibit312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ia5451f34f08d4882bcb50c7d80d5c84b_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:right;text-indent:42.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.2</font></div><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certificate Pursuant to Section&#160;302</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">of Sarbanes &#8211; Oxley Act of 2002</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CFO</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Tara Semb, the Registrant's Chief Financial Officer, certify that&#58;</font></div><div><font><br></font></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">I have reviewed this quarterly report on Form 10-Q of Apyx Medical Corporation&#59;</font></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, the financial statements and other financial information included in this report fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected or is reasonably likely to materially affect the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal controls over financial reporting.</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:46.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.621%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.294%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; November 10, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#47;s&#47; Tara Semb</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tara Semb</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer, Treasurer and Secretary</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:justify;text-indent:42.75pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>a2022q310-qexhibit321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ic1682582caef486494d7b95114a32400_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:right;text-indent:42.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 32.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certificate Pursuant to 18 U.S.C Section 1350, as adopted pursuant to</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section&#160;906 of Sarbanes &#8211; Oxley Act of 2002</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CEO</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the quarterly report on Form 10-Q of Apyx Medical Corporation (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#34;Company&#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) for the period ended September&#160;30, 2022, as filed with the Securities and Exchange Commission on the date hereof (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#34;Report&#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), the undersigned Chief Executive Officer certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes - Oxley Act of 2002, that&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:46.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.064%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.951%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; November 10, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#47;s&#47; Charles D. Goodwin II</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charles D. Goodwin II</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>a2022q310-qexhibit322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i79af49b84cdd4b498521051f5a1c4f9c_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 32.2</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certificate Pursuant to 18 U.S.C Section 1350, as adopted pursuant to</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section&#160;906 of Sarbanes &#8211; Oxley Act of 2002</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CFO</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the quarterly report on Form 10-Q of Apyx Medical Corporation (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#34;Company&#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) for the period ended September&#160;30, 2022, as filed with the Securities and Exchange Commission on the date hereof (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#34;Report&#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), the undersigned Chief Financial Officer certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes - Oxley Act of 2002, that&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:46.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.034%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.981%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; November 10, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#47;s&#47; Tara Semb</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tara Semb</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer, Treasurer and Secretary</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>apyx-20220930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:90964edb-9ed2-4911-9f65-50e8b3fbc396,g:6dc5a8ef-7d14-451f-bd94-08d276b52e31-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:apyx="http://apyxmedical.com/20220930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://apyxmedical.com/20220930">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="apyx-20220930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="apyx-20220930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="apyx-20220930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="apyx-20220930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://apyxmedical.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETS" roleURI="http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS">
        <link:definition>0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" roleURI="http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS">
        <link:definition>0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" roleURI="http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY">
        <link:definition>0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BASISOFPRESENTATION" roleURI="http://apyxmedical.com/role/BASISOFPRESENTATION">
        <link:definition>0000007 - Disclosure - BASIS OF PRESENTATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RECENTACCOUNTINGPRONOUNCEMENTS" roleURI="http://apyxmedical.com/role/RECENTACCOUNTINGPRONOUNCEMENTS">
        <link:definition>0000008 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DISPOSALOFBUSINESS" roleURI="http://apyxmedical.com/role/DISPOSALOFBUSINESS">
        <link:definition>0000009 - Disclosure - DISPOSAL OF BUSINESS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVENTORIES" roleURI="http://apyxmedical.com/role/INVENTORIES">
        <link:definition>0000010 - Disclosure - INVENTORIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASES" roleURI="http://apyxmedical.com/role/LEASES">
        <link:definition>0000011 - Disclosure - LEASES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES" roleURI="http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES">
        <link:definition>0000012 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CHINAJOINTVENTURE" roleURI="http://apyxmedical.com/role/CHINAJOINTVENTURE">
        <link:definition>0000013 - Disclosure - CHINA JOINT VENTURE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EARNINGSLOSSPERSHARE" roleURI="http://apyxmedical.com/role/EARNINGSLOSSPERSHARE">
        <link:definition>0000014 - Disclosure - EARNINGS (LOSS) PER SHARE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATION" roleURI="http://apyxmedical.com/role/STOCKBASEDCOMPENSATION">
        <link:definition>0000015 - Disclosure - STOCK-BASED COMPENSATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXES" roleURI="http://apyxmedical.com/role/INCOMETAXES">
        <link:definition>0000016 - Disclosure - INCOME TAXES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIES" roleURI="http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIES">
        <link:definition>0000017 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RELATEDPARTYTRANSACTIONS" roleURI="http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONS">
        <link:definition>0000018 - Disclosure - RELATED PARTY TRANSACTIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GEOGRAPHICANDSEGMENTINFORMATION" roleURI="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATION">
        <link:definition>0000019 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BASISOFPRESENTATIONPolicies" roleURI="http://apyxmedical.com/role/BASISOFPRESENTATIONPolicies">
        <link:definition>0000020 - Disclosure - BASIS OF PRESENTATION (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVENTORIESTables" roleURI="http://apyxmedical.com/role/INVENTORIESTables">
        <link:definition>0000021 - Disclosure - INVENTORIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESTables" roleURI="http://apyxmedical.com/role/LEASESTables">
        <link:definition>0000022 - Disclosure - LEASES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables" roleURI="http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables">
        <link:definition>0000023 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CHINAJOINTVENTURETables" roleURI="http://apyxmedical.com/role/CHINAJOINTVENTURETables">
        <link:definition>0000024 - Disclosure - CHINA JOINT VENTURE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EARNINGSLOSSPERSHARETables" roleURI="http://apyxmedical.com/role/EARNINGSLOSSPERSHARETables">
        <link:definition>0000025 - Disclosure - EARNINGS (LOSS) PER SHARE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONTables" roleURI="http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONTables">
        <link:definition>0000026 - Disclosure - STOCK-BASED COMPENSATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GEOGRAPHICANDSEGMENTINFORMATIONTables" roleURI="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONTables">
        <link:definition>0000027 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BASISOFPRESENTATIONNARRATIVEDetails" roleURI="http://apyxmedical.com/role/BASISOFPRESENTATIONNARRATIVEDetails">
        <link:definition>0000028 - Disclosure - BASIS OF PRESENTATION - NARRATIVE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DISPOSALOFBUSINESSDetails" roleURI="http://apyxmedical.com/role/DISPOSALOFBUSINESSDetails">
        <link:definition>0000029 - Disclosure - DISPOSAL OF BUSINESS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVENTORIESDetails" roleURI="http://apyxmedical.com/role/INVENTORIESDetails">
        <link:definition>0000030 - Disclosure - INVENTORIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESNarrativeDetails" roleURI="http://apyxmedical.com/role/LEASESNarrativeDetails">
        <link:definition>0000031 - Disclosure - LEASES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESLeaseTermsandDiscountRatesDetails" roleURI="http://apyxmedical.com/role/LEASESLeaseTermsandDiscountRatesDetails">
        <link:definition>0000032 - Disclosure - LEASES - Lease Terms and Discount Rates (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESMaturitiesofLeaseLiabilitiesDetails" roleURI="http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails">
        <link:definition>0000033 - Disclosure - LEASES - Maturities of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESMaturitiesofLeaseLiabilitiesDetails_1" roleURI="http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails_1">
        <link:definition>0000033 - Disclosure - LEASES - Maturities of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" roleURI="http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails">
        <link:definition>0000034 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESNarrativeDetails" roleURI="http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESNarrativeDetails">
        <link:definition>0000035 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CHINAJOINTVENTURENarrativeDetails" roleURI="http://apyxmedical.com/role/CHINAJOINTVENTURENarrativeDetails">
        <link:definition>0000036 - Disclosure - CHINA JOINT VENTURE - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CHINAJOINTVENTURERollforwardofJointVentureDetails" roleURI="http://apyxmedical.com/role/CHINAJOINTVENTURERollforwardofJointVentureDetails">
        <link:definition>0000037 - Disclosure - CHINA JOINT VENTURE - Rollforward of Joint Venture (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EARNINGSLOSSPERSHAREDetails" roleURI="http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails">
        <link:definition>0000038 - Disclosure - EARNINGS (LOSS) PER SHARE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONNarrativeDetails" roleURI="http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails">
        <link:definition>0000039 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONSummaryofStockOptionsDetails" roleURI="http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONSummaryofStockOptionsDetails">
        <link:definition>0000040 - Disclosure - STOCK-BASED COMPENSATION - Summary of Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONFairValueAssumptionsDetails" roleURI="http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONFairValueAssumptionsDetails">
        <link:definition>0000041 - Disclosure - STOCK-BASED COMPENSATION - Fair Value Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESDetails" roleURI="http://apyxmedical.com/role/INCOMETAXESDetails">
        <link:definition>0000042 - Disclosure - INCOME TAXES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESNarrativeDetails" roleURI="http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails">
        <link:definition>0000043 - Disclosure - COMMITMENTS AND CONTINGENCIES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RELATEDPARTYTRANSACTIONSDetails" roleURI="http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSDetails">
        <link:definition>0000044 - Disclosure - RELATED PARTY TRANSACTIONS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GEOGRAPHICANDSEGMENTINFORMATIONNarrativeDetails" roleURI="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONNarrativeDetails">
        <link:definition>0000045 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails" roleURI="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails">
        <link:definition>0000046 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION - Reportable Segment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails" roleURI="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails">
        <link:definition>0000047 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION - Geographic (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="apyx_FinanceLeaseLiabilityToBePaidDueAfterYearFour" abstract="false" name="FinanceLeaseLiabilityToBePaidDueAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember" abstract="true" name="ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="apyx_ShortTermContractLiabilities" abstract="false" name="ShortTermContractLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_SymmetrySurgicalInc.Member" abstract="true" name="SymmetrySurgicalInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="apyx_OperatingLeaseCostsAbstract" abstract="true" name="OperatingLeaseCostsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="apyx_ProvisionForInventoryObsolescence" abstract="false" name="ProvisionForInventoryObsolescence" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_ProvisionForObsolescenceInventory" abstract="false" name="ProvisionForObsolescenceInventory" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_OtherAccruedExpensesAndLiabilitiesCurrent" abstract="false" name="OtherAccruedExpensesAndLiabilitiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_StockSwapToAcquireOptionsShares" abstract="false" name="StockSwapToAcquireOptionsShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="apyx_AdvancedEnergyMember" abstract="true" name="AdvancedEnergyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="apyx_TotalRevenuePercent" abstract="false" name="TotalRevenuePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived" abstract="false" name="StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="apyx_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour" abstract="false" name="LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_SuitAgainstGoodwinAndSimbMember" abstract="true" name="SuitAgainstGoodwinAndSimbMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="apyx_OEMMember" abstract="false" name="OEMMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="apyx_StockIssuedDuringPeriodSharesStockSwaps" abstract="false" name="StockIssuedDuringPeriodSharesStockSwaps" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="apyx_ContractWithInternationalDistributorMember" abstract="true" name="ContractWithInternationalDistributorMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="apyx_NoncontrollingInterestTableTextBlock" abstract="false" name="NoncontrollingInterestTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="apyx_UncertainTaxPositionsLiability" abstract="false" name="UncertainTaxPositionsLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_FinanceLeaseCostsAbstract" abstract="true" name="FinanceLeaseCostsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="apyx_CapitalizationOfLeaseExecution" abstract="false" name="CapitalizationOfLeaseExecution" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_CapitalizationOfLeaseNonCash" abstract="false" name="CapitalizationOfLeaseNonCash" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_NoncontrollingInterestRequiredCapitalContribution" abstract="false" name="NoncontrollingInterestRequiredCapitalContribution" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_ChineseSupplierMember" abstract="true" name="ChineseSupplierMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent" abstract="false" name="AccruedLiabilitiesAndOtherLiabilitiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_AssetPurchaseAgreementTerm" abstract="false" name="AssetPurchaseAgreementTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="apyx_RepaymentOfFinanceLeaseLiabilities" abstract="false" name="RepaymentOfFinanceLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_JointAndSeveralPayrollLiability" abstract="false" name="JointAndSeveralPayrollLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised" abstract="false" name="ProceedsFromStockOptionsExercisedAndWarrantsExercised" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>apyx-20220930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:90964edb-9ed2-4911-9f65-50e8b3fbc396,g:6dc5a8ef-7d14-451f-bd94-08d276b52e31-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="apyx-20220930.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_cf33c3be-61e2-4585-8497-86ac1d8fed9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_abbd3d3f-7aa4-48f2-a3a8-11a7bfb2f918" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_cf33c3be-61e2-4585-8497-86ac1d8fed9d" xlink:to="loc_us-gaap_LiabilitiesCurrent_abbd3d3f-7aa4-48f2-a3a8-11a7bfb2f918" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_fd530986-434b-495a-8bdf-7654011c6ab6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_cf33c3be-61e2-4585-8497-86ac1d8fed9d" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_fd530986-434b-495a-8bdf-7654011c6ab6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_715da5cd-2a44-42ac-a650-188ed312e481" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_cf33c3be-61e2-4585-8497-86ac1d8fed9d" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_715da5cd-2a44-42ac-a650-188ed312e481" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_26b915e4-37bc-4ab2-b21b-2238180cc1f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_cf33c3be-61e2-4585-8497-86ac1d8fed9d" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_26b915e4-37bc-4ab2-b21b-2238180cc1f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_fb98eb2b-98cf-44d4-a463-9495a9d96640" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_cf33c3be-61e2-4585-8497-86ac1d8fed9d" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_fb98eb2b-98cf-44d4-a463-9495a9d96640" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_49ca3192-b421-47c7-b3f9-4e04395bc685" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_660330d7-59cf-421c-8667-f417d5c063b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_49ca3192-b421-47c7-b3f9-4e04395bc685" xlink:to="loc_us-gaap_CommonStockValue_660330d7-59cf-421c-8667-f417d5c063b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_ae8a7f83-0e53-4df0-bc50-a920117e839e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_49ca3192-b421-47c7-b3f9-4e04395bc685" xlink:to="loc_us-gaap_AdditionalPaidInCapital_ae8a7f83-0e53-4df0-bc50-a920117e839e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ef1ae8ff-0f1e-4a1a-a820-8f6a913d3066" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_49ca3192-b421-47c7-b3f9-4e04395bc685" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ef1ae8ff-0f1e-4a1a-a820-8f6a913d3066" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_1331d86b-6784-4cae-9c48-f58931e3103e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_d48cadd7-d432-4922-b131-7b7bbcb9069a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_1331d86b-6784-4cae-9c48-f58931e3103e" xlink:to="loc_us-gaap_Liabilities_d48cadd7-d432-4922-b131-7b7bbcb9069a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_31eaac8c-6592-4d4a-b910-900d1b720a9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_1331d86b-6784-4cae-9c48-f58931e3103e" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_31eaac8c-6592-4d4a-b910-900d1b720a9b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_feee3773-c4b2-4f53-b3eb-9f07cd44f218" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_61996ccb-4799-449a-90d2-0a64fe7a01ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_feee3773-c4b2-4f53-b3eb-9f07cd44f218" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_61996ccb-4799-449a-90d2-0a64fe7a01ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_fcce58b6-7dd6-410d-869c-6e97323edaac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_feee3773-c4b2-4f53-b3eb-9f07cd44f218" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_fcce58b6-7dd6-410d-869c-6e97323edaac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable_5439e7ec-c0ea-4136-aa7b-976bab3dec69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_feee3773-c4b2-4f53-b3eb-9f07cd44f218" xlink:to="loc_us-gaap_IncomeTaxesReceivable_5439e7ec-c0ea-4136-aa7b-976bab3dec69" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_7f3d9bbb-f4f0-499d-955a-5699954d3e0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_feee3773-c4b2-4f53-b3eb-9f07cd44f218" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_7f3d9bbb-f4f0-499d-955a-5699954d3e0a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_5d452bda-d39b-409c-9885-0de8352b44a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_feee3773-c4b2-4f53-b3eb-9f07cd44f218" xlink:to="loc_us-gaap_InventoryNet_5d452bda-d39b-409c-9885-0de8352b44a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_200a9349-fdd3-4134-8f85-0956c23023b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_feee3773-c4b2-4f53-b3eb-9f07cd44f218" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_200a9349-fdd3-4134-8f85-0956c23023b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0dfa0d4d-067c-422c-92a4-871a89c07770" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2004c7d7-ba89-4f06-82ef-dd6b37daa987" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0dfa0d4d-067c-422c-92a4-871a89c07770" xlink:to="loc_us-gaap_StockholdersEquity_2004c7d7-ba89-4f06-82ef-dd6b37daa987" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_60150185-b75b-49ed-b705-90b5da32aa36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0dfa0d4d-067c-422c-92a4-871a89c07770" xlink:to="loc_us-gaap_MinorityInterest_60150185-b75b-49ed-b705-90b5da32aa36" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_81666047-2393-4838-a67d-90ea132c260f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_9cdc1758-9097-4918-87ce-6534f3733fba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_81666047-2393-4838-a67d-90ea132c260f" xlink:to="loc_us-gaap_AssetsCurrent_9cdc1758-9097-4918-87ce-6534f3733fba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_6b609505-a231-48fc-8ec6-a7ce283e0cf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_81666047-2393-4838-a67d-90ea132c260f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_6b609505-a231-48fc-8ec6-a7ce283e0cf6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_2632772f-d49c-4e90-9d0e-90ef82efbd2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_81666047-2393-4838-a67d-90ea132c260f" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_2632772f-d49c-4e90-9d0e-90ef82efbd2e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_c72493ec-61ec-41c8-8b45-0a1894e1e99d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_81666047-2393-4838-a67d-90ea132c260f" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_c72493ec-61ec-41c8-8b45-0a1894e1e99d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_b677bea0-d11b-4a76-a017-73ea74d11217" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_81666047-2393-4838-a67d-90ea132c260f" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_b677bea0-d11b-4a76-a017-73ea74d11217" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_bec89907-4978-4043-8542-43d5d08e8a14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_7f5cd61e-25ae-4af0-9a2e-815dc06ec361" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_bec89907-4978-4043-8542-43d5d08e8a14" xlink:to="loc_us-gaap_AccountsPayableCurrent_7f5cd61e-25ae-4af0-9a2e-815dc06ec361" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent_1e7d7955-51b1-49c0-9005-4d53d2143606" xlink:href="apyx-20220930.xsd#apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_bec89907-4978-4043-8542-43d5d08e8a14" xlink:to="loc_apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent_1e7d7955-51b1-49c0-9005-4d53d2143606" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_f8549c10-731e-43f6-a8ba-7e51a3cb7599" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_bec89907-4978-4043-8542-43d5d08e8a14" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_f8549c10-731e-43f6-a8ba-7e51a3cb7599" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_8c798d21-8942-4910-af4e-a11f24f9142d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_bec89907-4978-4043-8542-43d5d08e8a14" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_8c798d21-8942-4910-af4e-a11f24f9142d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="apyx-20220930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_d27a9605-366f-4c75-8dd0-56d8ee61414f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_081ecb76-6031-4a1e-8e2a-2738982984ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_d27a9605-366f-4c75-8dd0-56d8ee61414f" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_081ecb76-6031-4a1e-8e2a-2738982984ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_86987dce-a24c-4374-b7b3-e284f33614d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_d27a9605-366f-4c75-8dd0-56d8ee61414f" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_86987dce-a24c-4374-b7b3-e284f33614d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4b6f18c4-d08d-4730-8268-d9c23116f9f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_241b9690-4aa2-49da-a2ad-31fe110f16fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4b6f18c4-d08d-4730-8268-d9c23116f9f2" xlink:to="loc_us-gaap_OperatingIncomeLoss_241b9690-4aa2-49da-a2ad-31fe110f16fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_2a600bde-b03e-46fe-ac1b-6fcaaf683cf5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4b6f18c4-d08d-4730-8268-d9c23116f9f2" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_2a600bde-b03e-46fe-ac1b-6fcaaf683cf5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_93ff134c-0bcb-48d8-bc70-96a5692a4650" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_9b381104-037c-4ea1-b49f-f288a19627c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_93ff134c-0bcb-48d8-bc70-96a5692a4650" xlink:to="loc_us-gaap_ProfitLoss_9b381104-037c-4ea1-b49f-f288a19627c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_a4a3006f-a7a4-4ede-bfac-3f56fbcb3a7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_93ff134c-0bcb-48d8-bc70-96a5692a4650" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_a4a3006f-a7a4-4ede-bfac-3f56fbcb3a7f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_a7ed71b9-13ff-472c-a2ef-bb87c5688c88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_f822235a-d5d9-46b5-bcff-70807a0d9490" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_a7ed71b9-13ff-472c-a2ef-bb87c5688c88" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_f822235a-d5d9-46b5-bcff-70807a0d9490" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfessionalFees_445bee6d-0b3d-47b9-8dc3-e137ece2e5b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfessionalFees"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_a7ed71b9-13ff-472c-a2ef-bb87c5688c88" xlink:to="loc_us-gaap_ProfessionalFees_445bee6d-0b3d-47b9-8dc3-e137ece2e5b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalariesAndWages_3b8d1684-d665-4fda-8fe8-3e971611e15e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalariesAndWages"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_a7ed71b9-13ff-472c-a2ef-bb87c5688c88" xlink:to="loc_us-gaap_SalariesAndWages_3b8d1684-d665-4fda-8fe8-3e971611e15e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_1182ebc8-662a-4204-9f98-aeaef1f46b34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_a7ed71b9-13ff-472c-a2ef-bb87c5688c88" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_1182ebc8-662a-4204-9f98-aeaef1f46b34" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_12c7ab8a-db11-4ec4-b06e-080a520c3a65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ac36f64a-d7b0-4da7-835e-8a5bec994d3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_12c7ab8a-db11-4ec4-b06e-080a520c3a65" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ac36f64a-d7b0-4da7-835e-8a5bec994d3d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_645b1b8a-5fbe-4587-b031-e5fe964866a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_12c7ab8a-db11-4ec4-b06e-080a520c3a65" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_645b1b8a-5fbe-4587-b031-e5fe964866a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_6db2a89b-08af-4199-a715-f3ecfe061dfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOperating_79d033bb-377a-4306-b96f-f5a5a0b166cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeOperating"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_6db2a89b-08af-4199-a715-f3ecfe061dfc" xlink:to="loc_us-gaap_InterestIncomeOperating_79d033bb-377a-4306-b96f-f5a5a0b166cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_ff1f8d95-368f-40cb-a0ba-a211f14c79df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_6db2a89b-08af-4199-a715-f3ecfe061dfc" xlink:to="loc_us-gaap_InterestExpense_ff1f8d95-368f-40cb-a0ba-a211f14c79df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_7427bba2-89fe-41c9-9cad-8b5104a113f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_6db2a89b-08af-4199-a715-f3ecfe061dfc" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_7427bba2-89fe-41c9-9cad-8b5104a113f2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="apyx-20220930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_02332f66-e8f6-4b4d-b104-eb61650a0494" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised_ff28e838-c4ae-490c-9252-ce4f277218d8" xlink:href="apyx-20220930.xsd#apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_02332f66-e8f6-4b4d-b104-eb61650a0494" xlink:to="loc_apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised_ff28e838-c4ae-490c-9252-ce4f277218d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_RepaymentOfFinanceLeaseLiabilities_c67badc4-89b9-4ac9-9ea8-ff4690313810" xlink:href="apyx-20220930.xsd#apyx_RepaymentOfFinanceLeaseLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_02332f66-e8f6-4b4d-b104-eb61650a0494" xlink:to="loc_apyx_RepaymentOfFinanceLeaseLiabilities_c67badc4-89b9-4ac9-9ea8-ff4690313810" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMinorityShareholders_46e3e2d8-caa1-4d9c-a544-6cd655ac725f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMinorityShareholders"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_02332f66-e8f6-4b4d-b104-eb61650a0494" xlink:to="loc_us-gaap_ProceedsFromMinorityShareholders_46e3e2d8-caa1-4d9c-a544-6cd655ac725f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9dd0f7ea-262c-4985-8008-aa48263f0aa6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_5b9de967-454b-498b-8d77-f0907b1a606c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9dd0f7ea-262c-4985-8008-aa48263f0aa6" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_5b9de967-454b-498b-8d77-f0907b1a606c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6c5364e2-6a44-4532-bc18-f9b79ce300d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_ace9bc32-7f48-4fad-b8b4-57b73d2e0552" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6c5364e2-6a44-4532-bc18-f9b79ce300d3" xlink:to="loc_us-gaap_ProfitLoss_ace9bc32-7f48-4fad-b8b4-57b73d2e0552" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_f149d50f-7623-4d11-a934-953980a0e105" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6c5364e2-6a44-4532-bc18-f9b79ce300d3" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_f149d50f-7623-4d11-a934-953980a0e105" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ProvisionForInventoryObsolescence_d4204475-b83b-4325-92c3-f025e620bb3e" xlink:href="apyx-20220930.xsd#apyx_ProvisionForInventoryObsolescence"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6c5364e2-6a44-4532-bc18-f9b79ce300d3" xlink:to="loc_apyx_ProvisionForInventoryObsolescence_d4204475-b83b-4325-92c3-f025e620bb3e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_785ab6d1-f723-4a15-8df8-f7512578dbb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6c5364e2-6a44-4532-bc18-f9b79ce300d3" xlink:to="loc_us-gaap_ShareBasedCompensation_785ab6d1-f723-4a15-8df8-f7512578dbb2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_a49b5995-ffef-4dff-9db0-ac7061cbce95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6c5364e2-6a44-4532-bc18-f9b79ce300d3" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_a49b5995-ffef-4dff-9db0-ac7061cbce95" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_b124311a-880a-4613-911b-928a4ea9b093" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6c5364e2-6a44-4532-bc18-f9b79ce300d3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_b124311a-880a-4613-911b-928a4ea9b093" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_64c0f000-beeb-4c2b-bed1-a4e23b3e17f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6c5364e2-6a44-4532-bc18-f9b79ce300d3" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_64c0f000-beeb-4c2b-bed1-a4e23b3e17f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_be3cd252-8570-4189-8497-60f298ba5f60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6c5364e2-6a44-4532-bc18-f9b79ce300d3" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_be3cd252-8570-4189-8497-60f298ba5f60" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_69ac7c09-91d3-4037-a98d-db695392ebe4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6c5364e2-6a44-4532-bc18-f9b79ce300d3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_69ac7c09-91d3-4037-a98d-db695392ebe4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_69c1b98c-f5ca-49ad-a45e-6df5cf501d4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6c5364e2-6a44-4532-bc18-f9b79ce300d3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_69c1b98c-f5ca-49ad-a45e-6df5cf501d4b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_85e80471-3e94-4ffe-a0a1-0fc05894d7e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6c5364e2-6a44-4532-bc18-f9b79ce300d3" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_85e80471-3e94-4ffe-a0a1-0fc05894d7e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_518c6853-8844-4ae7-a53b-e3b53a248c62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6c5364e2-6a44-4532-bc18-f9b79ce300d3" xlink:to="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_518c6853-8844-4ae7-a53b-e3b53a248c62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f5d0e650-bcd9-4357-ad88-ec7bc32b9a27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2df4f1b1-0fd3-43a0-b659-a6e4b7203088" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f5d0e650-bcd9-4357-ad88-ec7bc32b9a27" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2df4f1b1-0fd3-43a0-b659-a6e4b7203088" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5d08c0c1-90e5-4683-85d5-5db2023aaa85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f5d0e650-bcd9-4357-ad88-ec7bc32b9a27" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5d08c0c1-90e5-4683-85d5-5db2023aaa85" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_48de59e1-449d-46ef-bd79-3b5fdacd83d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f5d0e650-bcd9-4357-ad88-ec7bc32b9a27" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_48de59e1-449d-46ef-bd79-3b5fdacd83d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9928baa4-71da-4a40-bbf5-198aef7b4b79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f5d0e650-bcd9-4357-ad88-ec7bc32b9a27" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9928baa4-71da-4a40-bbf5-198aef7b4b79" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/INVENTORIESDetails" xlink:type="simple" xlink:href="apyx-20220930.xsd#INVENTORIESDetails"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/INVENTORIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_868cfd37-885c-482d-ab2d-fa8b47966ad9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_bd03515a-8432-4018-b925-9812cb362ee1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_868cfd37-885c-482d-ab2d-fa8b47966ad9" xlink:to="loc_us-gaap_InventoryGross_bd03515a-8432-4018-b925-9812cb362ee1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves_e8e52d53-d808-4ae2-99c1-7ae6ba98f20e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryValuationReserves"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_868cfd37-885c-482d-ab2d-fa8b47966ad9" xlink:to="loc_us-gaap_InventoryValuationReserves_e8e52d53-d808-4ae2-99c1-7ae6ba98f20e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_2ebb9c4b-0cbd-498a-a4f5-2d813091440e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_8336336e-00a0-417c-ad34-aa1193c268e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_2ebb9c4b-0cbd-498a-a4f5-2d813091440e" xlink:to="loc_us-gaap_InventoryRawMaterials_8336336e-00a0-417c-ad34-aa1193c268e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_e52b6a34-0778-4175-8cd2-11fee5b32bb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_2ebb9c4b-0cbd-498a-a4f5-2d813091440e" xlink:to="loc_us-gaap_InventoryWorkInProcess_e52b6a34-0778-4175-8cd2-11fee5b32bb2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_50b3ef99-0606-461f-af4d-2c01d7f29284" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_2ebb9c4b-0cbd-498a-a4f5-2d813091440e" xlink:to="loc_us-gaap_InventoryFinishedGoods_50b3ef99-0606-461f-af4d-2c01d7f29284" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="apyx-20220930.xsd#LEASESMaturitiesofLeaseLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_9f92acc2-e7a5-49a2-9722-516824bae024" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_ff0fb641-dc6b-45c0-bf00-4f2e699da7d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_9f92acc2-e7a5-49a2-9722-516824bae024" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_ff0fb641-dc6b-45c0-bf00-4f2e699da7d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_cfd720f7-9cc2-442d-9f51-0497598a1d8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_9f92acc2-e7a5-49a2-9722-516824bae024" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_cfd720f7-9cc2-442d-9f51-0497598a1d8c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4d39ff28-55a5-4f05-9d99-5e465acf7b59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_8269f953-273c-438d-a07b-f1a3637a92f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4d39ff28-55a5-4f05-9d99-5e465acf7b59" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_8269f953-273c-438d-a07b-f1a3637a92f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_3a8be80c-816a-41f4-93d1-873cb4536bbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4d39ff28-55a5-4f05-9d99-5e465acf7b59" xlink:to="loc_us-gaap_OperatingLeaseLiability_3a8be80c-816a-41f4-93d1-873cb4536bbe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_3ba68b79-e286-4298-8144-303354641b82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_57b9ceca-68f6-475c-b85b-ae7dc212d060" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiability_3ba68b79-e286-4298-8144-303354641b82" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_57b9ceca-68f6-475c-b85b-ae7dc212d060" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_d2f6bdfe-ec6a-4e03-9d17-4dfdee38a226" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiability_3ba68b79-e286-4298-8144-303354641b82" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_d2f6bdfe-ec6a-4e03-9d17-4dfdee38a226" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_2338b91d-e70f-4ad9-b4c3-b88849524927" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_ce28dc8a-aded-4b18-99b1-df698d81ddf4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_2338b91d-e70f-4ad9-b4c3-b88849524927" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_ce28dc8a-aded-4b18-99b1-df698d81ddf4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_caa43dce-218f-4766-b348-ca39293316ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_2338b91d-e70f-4ad9-b4c3-b88849524927" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_caa43dce-218f-4766-b348-ca39293316ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_0489d77f-d7d4-4ec2-9deb-553bb6b41a91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_2338b91d-e70f-4ad9-b4c3-b88849524927" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_0489d77f-d7d4-4ec2-9deb-553bb6b41a91" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_6c2fa06f-9191-4c2c-ba55-941fc119e54e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_2338b91d-e70f-4ad9-b4c3-b88849524927" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_6c2fa06f-9191-4c2c-ba55-941fc119e54e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_FinanceLeaseLiabilityToBePaidDueAfterYearFour_eb143de2-c57a-41ff-9047-a42d35d82610" xlink:href="apyx-20220930.xsd#apyx_FinanceLeaseLiabilityToBePaidDueAfterYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_2338b91d-e70f-4ad9-b4c3-b88849524927" xlink:to="loc_apyx_FinanceLeaseLiabilityToBePaidDueAfterYearFour_eb143de2-c57a-41ff-9047-a42d35d82610" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_d1319c5b-a84a-4501-aaab-721ef0f07bc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_2338b91d-e70f-4ad9-b4c3-b88849524927" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_d1319c5b-a84a-4501-aaab-721ef0f07bc7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="apyx-20220930.xsd#LEASESMaturitiesofLeaseLiabilitiesDetails_1"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e7aa37ab-cd86-43d6-93a8-d6f9ec12b9ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_eb936dd7-3fbe-4c29-92f0-6de5c69f45d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e7aa37ab-cd86-43d6-93a8-d6f9ec12b9ee" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_eb936dd7-3fbe-4c29-92f0-6de5c69f45d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_8234e551-02ed-4b80-8db5-b28dd52269d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e7aa37ab-cd86-43d6-93a8-d6f9ec12b9ee" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_8234e551-02ed-4b80-8db5-b28dd52269d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_c5665639-42f8-4fe3-aea1-fe1c20fbeda2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e7aa37ab-cd86-43d6-93a8-d6f9ec12b9ee" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_c5665639-42f8-4fe3-aea1-fe1c20fbeda2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_98184e0b-4840-4f4b-af12-756a55c84a14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e7aa37ab-cd86-43d6-93a8-d6f9ec12b9ee" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_98184e0b-4840-4f4b-af12-756a55c84a14" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_4601fd5a-c110-494a-85f8-b81a7184e234" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e7aa37ab-cd86-43d6-93a8-d6f9ec12b9ee" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_4601fd5a-c110-494a-85f8-b81a7184e234" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour_97b09061-70a4-434d-a659-b9b056924f12" xlink:href="apyx-20220930.xsd#apyx_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e7aa37ab-cd86-43d6-93a8-d6f9ec12b9ee" xlink:to="loc_apyx_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour_97b09061-70a4-434d-a659-b9b056924f12" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_b5403728-40fe-4f7f-af2c-ed00a602c272" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_6b76f4ad-de89-40bc-b8b9-3b294a53d934" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_b5403728-40fe-4f7f-af2c-ed00a602c272" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_6b76f4ad-de89-40bc-b8b9-3b294a53d934" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_6810bad1-6e74-4f95-8d6b-bd5c5868f022" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_b5403728-40fe-4f7f-af2c-ed00a602c272" xlink:to="loc_us-gaap_FinanceLeaseLiability_6810bad1-6e74-4f95-8d6b-bd5c5868f022" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" xlink:type="simple" xlink:href="apyx-20220930.xsd#ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent_213a4e75-2149-4011-bd11-7c0dac235fa9" xlink:href="apyx-20220930.xsd#apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent_83a9d8c3-8dad-4f69-9904-833d676965a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent_213a4e75-2149-4011-bd11-7c0dac235fa9" xlink:to="loc_us-gaap_AccruedSalariesCurrent_83a9d8c3-8dad-4f69-9904-833d676965a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedBonusesCurrent_3ea675da-1818-4480-adc1-487b60afa7ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedBonusesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent_213a4e75-2149-4011-bd11-7c0dac235fa9" xlink:to="loc_us-gaap_AccruedBonusesCurrent_3ea675da-1818-4480-adc1-487b60afa7ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalesCommissionCurrent_bc92f824-9072-442e-a6bb-c8cc603abbc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedSalesCommissionCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent_213a4e75-2149-4011-bd11-7c0dac235fa9" xlink:to="loc_us-gaap_AccruedSalesCommissionCurrent_bc92f824-9072-442e-a6bb-c8cc603abbc4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent_7600b6a3-7e1b-44b2-b271-a4d5d585720a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductWarrantyAccrualClassifiedCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent_213a4e75-2149-4011-bd11-7c0dac235fa9" xlink:to="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent_7600b6a3-7e1b-44b2-b271-a4d5d585720a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedInsuranceCurrent_4b871dae-ba15-440f-a9a8-844a0182b9d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedInsuranceCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent_213a4e75-2149-4011-bd11-7c0dac235fa9" xlink:to="loc_us-gaap_AccruedInsuranceCurrent_4b871dae-ba15-440f-a9a8-844a0182b9d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_e173a3f1-2bde-44ca-99ca-20b05b13f9de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent_213a4e75-2149-4011-bd11-7c0dac235fa9" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_e173a3f1-2bde-44ca-99ca-20b05b13f9de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_JointAndSeveralPayrollLiability_636df126-2310-4e48-b70a-1b62dfbc26e2" xlink:href="apyx-20220930.xsd#apyx_JointAndSeveralPayrollLiability"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent_213a4e75-2149-4011-bd11-7c0dac235fa9" xlink:to="loc_apyx_JointAndSeveralPayrollLiability_636df126-2310-4e48-b70a-1b62dfbc26e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_UncertainTaxPositionsLiability_ecc3b047-343d-4a05-babc-7dd4f0739303" xlink:href="apyx-20220930.xsd#apyx_UncertainTaxPositionsLiability"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent_213a4e75-2149-4011-bd11-7c0dac235fa9" xlink:to="loc_apyx_UncertainTaxPositionsLiability_ecc3b047-343d-4a05-babc-7dd4f0739303" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesAndExciseTaxPayableCurrent_4653e68f-1b75-4a1b-a0b6-387f9f5723eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesAndExciseTaxPayableCurrent"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent_213a4e75-2149-4011-bd11-7c0dac235fa9" xlink:to="loc_us-gaap_SalesAndExciseTaxPayableCurrent_4653e68f-1b75-4a1b-a0b6-387f9f5723eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_OtherAccruedExpensesAndLiabilitiesCurrent_113629ab-e519-4fe3-ad5a-9ed845627ebb" xlink:href="apyx-20220930.xsd#apyx_OtherAccruedExpensesAndLiabilitiesCurrent"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent_213a4e75-2149-4011-bd11-7c0dac235fa9" xlink:to="loc_apyx_OtherAccruedExpensesAndLiabilitiesCurrent_113629ab-e519-4fe3-ad5a-9ed845627ebb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ShortTermContractLiabilities_76a021f1-2bee-4f95-9b25-5385a72e8c02" xlink:href="apyx-20220930.xsd#apyx_ShortTermContractLiabilities"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent_213a4e75-2149-4011-bd11-7c0dac235fa9" xlink:to="loc_apyx_ShortTermContractLiabilities_76a021f1-2bee-4f95-9b25-5385a72e8c02" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>apyx-20220930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:90964edb-9ed2-4911-9f65-50e8b3fbc396,g:6dc5a8ef-7d14-451f-bd94-08d276b52e31-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" xlink:type="simple" xlink:href="apyx-20220930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" xlink:type="extended" id="ifb52fe1d9b6e4165a728f784cf056bf5_CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_9321c96e-db1a-4e3b-a58b-660f036118c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3ced745f-8456-420e-b11e-43a6810f4426" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9321c96e-db1a-4e3b-a58b-660f036118c7" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3ced745f-8456-420e-b11e-43a6810f4426" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_2ac0d1fc-f751-4324-9ce3-f8bc640b6a81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3ced745f-8456-420e-b11e-43a6810f4426" xlink:to="loc_us-gaap_SharesIssued_2ac0d1fc-f751-4324-9ce3-f8bc640b6a81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4c60123c-b246-4034-a2a7-fcbb7fba66dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3ced745f-8456-420e-b11e-43a6810f4426" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4c60123c-b246-4034-a2a7-fcbb7fba66dd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_4385824e-cdf9-429d-b093-281ecd603671" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3ced745f-8456-420e-b11e-43a6810f4426" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_4385824e-cdf9-429d-b093-281ecd603671" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_40befe33-d214-416a-b00e-51b40953a765" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3ced745f-8456-420e-b11e-43a6810f4426" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_40befe33-d214-416a-b00e-51b40953a765" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_5861a543-e780-49fe-84b3-13ecb7ff1d30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3ced745f-8456-420e-b11e-43a6810f4426" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_5861a543-e780-49fe-84b3-13ecb7ff1d30" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0f630614-a825-421f-ba59-8b6ffd2f125e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3ced745f-8456-420e-b11e-43a6810f4426" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0f630614-a825-421f-ba59-8b6ffd2f125e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_StockSwapToAcquireOptionsShares_9d5e4272-0c68-45ec-86c8-7130ae7a4d0b" xlink:href="apyx-20220930.xsd#apyx_StockSwapToAcquireOptionsShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3ced745f-8456-420e-b11e-43a6810f4426" xlink:to="loc_apyx_StockSwapToAcquireOptionsShares_9d5e4272-0c68-45ec-86c8-7130ae7a4d0b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_2005330b-2437-4714-92fb-406ee0230cc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3ced745f-8456-420e-b11e-43a6810f4426" xlink:to="loc_us-gaap_ProfitLoss_2005330b-2437-4714-92fb-406ee0230cc3" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_5088159a-1a95-4e19-9ff6-698e78266fe8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_139872b3-ce95-4e83-841e-fa6bd6343003" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_05418fc7-937a-448a-a519-242859322678" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_9321c96e-db1a-4e3b-a58b-660f036118c7" xlink:to="loc_us-gaap_StatementTable_05418fc7-937a-448a-a519-242859322678" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_a9e32be1-1ab1-411b-8da6-a78d012a141d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_05418fc7-937a-448a-a519-242859322678" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_a9e32be1-1ab1-411b-8da6-a78d012a141d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a9e32be1-1ab1-411b-8da6-a78d012a141d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a9e32be1-1ab1-411b-8da6-a78d012a141d" xlink:to="loc_us-gaap_EquityComponentDomain_a9e32be1-1ab1-411b-8da6-a78d012a141d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_30086249-996d-4c41-bcd0-8ce1e4bad554" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a9e32be1-1ab1-411b-8da6-a78d012a141d" xlink:to="loc_us-gaap_EquityComponentDomain_30086249-996d-4c41-bcd0-8ce1e4bad554" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_4f3ce62a-9e6c-4180-b23d-360d9ab5f0d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_30086249-996d-4c41-bcd0-8ce1e4bad554" xlink:to="loc_us-gaap_CommonStockMember_4f3ce62a-9e6c-4180-b23d-360d9ab5f0d8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_a0a4cf7d-3a5f-4619-9bb1-18b90ff79f0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_30086249-996d-4c41-bcd0-8ce1e4bad554" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_a0a4cf7d-3a5f-4619-9bb1-18b90ff79f0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_5687157d-d644-4e8f-b055-5e5e7faf271c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_30086249-996d-4c41-bcd0-8ce1e4bad554" xlink:to="loc_us-gaap_RetainedEarningsMember_5687157d-d644-4e8f-b055-5e5e7faf271c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_1eeaec45-03e7-4729-be66-4323802e644a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_30086249-996d-4c41-bcd0-8ce1e4bad554" xlink:to="loc_us-gaap_NoncontrollingInterestMember_1eeaec45-03e7-4729-be66-4323802e644a" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/DISPOSALOFBUSINESSDetails" xlink:type="simple" xlink:href="apyx-20220930.xsd#DISPOSALOFBUSINESSDetails"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/DISPOSALOFBUSINESSDetails" xlink:type="extended" id="i4054678de58c4b3c955abdb1f509a9e9_DISPOSALOFBUSINESSDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1208bc4b-cf6c-4f05-a894-4621941ba192" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_0df0d912-c14d-4e78-b362-04544574fa38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1208bc4b-cf6c-4f05-a894-4621941ba192" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_0df0d912-c14d-4e78-b362-04544574fa38" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_AssetPurchaseAgreementTerm_61fd1bec-c4ab-4b3f-a40d-dc4e20e3b1dc" xlink:href="apyx-20220930.xsd#apyx_AssetPurchaseAgreementTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1208bc4b-cf6c-4f05-a894-4621941ba192" xlink:to="loc_apyx_AssetPurchaseAgreementTerm_61fd1bec-c4ab-4b3f-a40d-dc4e20e3b1dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_a564b498-2c7c-49f1-a2bb-4db94e8f4040" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1208bc4b-cf6c-4f05-a894-4621941ba192" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_a564b498-2c7c-49f1-a2bb-4db94e8f4040" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_8932d9c0-e495-43d7-954a-b296be4e25d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1208bc4b-cf6c-4f05-a894-4621941ba192" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_8932d9c0-e495-43d7-954a-b296be4e25d3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_de4d601c-2992-4846-afca-32ce7e288a38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1208bc4b-cf6c-4f05-a894-4621941ba192" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_de4d601c-2992-4846-afca-32ce7e288a38" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_08e5820c-67b1-4022-a69f-94384b401d40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1208bc4b-cf6c-4f05-a894-4621941ba192" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_08e5820c-67b1-4022-a69f-94384b401d40" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_7ad8ab34-7560-4965-b41e-5cb8db30b1ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1208bc4b-cf6c-4f05-a894-4621941ba192" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_7ad8ab34-7560-4965-b41e-5cb8db30b1ed" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ae76b1df-0cd8-49d1-b0af-f2d05be1e8d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_7ad8ab34-7560-4965-b41e-5cb8db30b1ed" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ae76b1df-0cd8-49d1-b0af-f2d05be1e8d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_ae76b1df-0cd8-49d1-b0af-f2d05be1e8d0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ae76b1df-0cd8-49d1-b0af-f2d05be1e8d0" xlink:to="loc_us-gaap_RelatedPartyDomain_ae76b1df-0cd8-49d1-b0af-f2d05be1e8d0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_c91cfa5b-62b5-425d-9ad1-e5f88f7fe856" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ae76b1df-0cd8-49d1-b0af-f2d05be1e8d0" xlink:to="loc_us-gaap_RelatedPartyDomain_c91cfa5b-62b5-425d-9ad1-e5f88f7fe856" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SymmetrySurgicalInc.Member_a8345133-aa36-4c25-90e5-7edffd1b4540" xlink:href="apyx-20220930.xsd#apyx_SymmetrySurgicalInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_c91cfa5b-62b5-425d-9ad1-e5f88f7fe856" xlink:to="loc_apyx_SymmetrySurgicalInc.Member_a8345133-aa36-4c25-90e5-7edffd1b4540" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_a925d42e-dac9-4874-a383-ba3aaf31c651" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_7ad8ab34-7560-4965-b41e-5cb8db30b1ed" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_a925d42e-dac9-4874-a383-ba3aaf31c651" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_a925d42e-dac9-4874-a383-ba3aaf31c651_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_a925d42e-dac9-4874-a383-ba3aaf31c651" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_a925d42e-dac9-4874-a383-ba3aaf31c651_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_2a2f2327-6e5f-409c-aeff-f0899160ca09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_a925d42e-dac9-4874-a383-ba3aaf31c651" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_2a2f2327-6e5f-409c-aeff-f0899160ca09" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember_4759df96-5636-4c03-ac43-1ddd5c692da7" xlink:href="apyx-20220930.xsd#apyx_ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_2a2f2327-6e5f-409c-aeff-f0899160ca09" xlink:to="loc_apyx_ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember_4759df96-5636-4c03-ac43-1ddd5c692da7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/CHINAJOINTVENTURENarrativeDetails" xlink:type="simple" xlink:href="apyx-20220930.xsd#CHINAJOINTVENTURENarrativeDetails"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/CHINAJOINTVENTURENarrativeDetails" xlink:type="extended" id="if82cc4fc924948bca8582293144fbd59_CHINAJOINTVENTURENarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_f1e74e4e-9d76-4316-a0a1-d2e5593bdce0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_d036af4f-839f-4b37-8026-9d7e336b2487" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_f1e74e4e-9d76-4316-a0a1-d2e5593bdce0" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_d036af4f-839f-4b37-8026-9d7e336b2487" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_NoncontrollingInterestRequiredCapitalContribution_a442917b-51e3-4bca-9012-43bb374c3b6a" xlink:href="apyx-20220930.xsd#apyx_NoncontrollingInterestRequiredCapitalContribution"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_f1e74e4e-9d76-4316-a0a1-d2e5593bdce0" xlink:to="loc_apyx_NoncontrollingInterestRequiredCapitalContribution_a442917b-51e3-4bca-9012-43bb374c3b6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_3597912f-1a51-4eb3-9a8c-f64ecc4834db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_MinorityInterestLineItems_f1e74e4e-9d76-4316-a0a1-d2e5593bdce0" xlink:to="loc_us-gaap_MinorityInterestTable_3597912f-1a51-4eb3-9a8c-f64ecc4834db" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f341141f-6580-4497-a3a3-f6502757ec81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_3597912f-1a51-4eb3-9a8c-f64ecc4834db" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f341141f-6580-4497-a3a3-f6502757ec81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_f341141f-6580-4497-a3a3-f6502757ec81_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f341141f-6580-4497-a3a3-f6502757ec81" xlink:to="loc_us-gaap_RelatedPartyDomain_f341141f-6580-4497-a3a3-f6502757ec81_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_16136535-12ce-446d-b77a-e05906779930" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f341141f-6580-4497-a3a3-f6502757ec81" xlink:to="loc_us-gaap_RelatedPartyDomain_16136535-12ce-446d-b77a-e05906779930" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateJointVentureMember_8760fdb1-77a6-494e-a009-5b546368f874" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateJointVentureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_16136535-12ce-446d-b77a-e05906779930" xlink:to="loc_us-gaap_CorporateJointVentureMember_8760fdb1-77a6-494e-a009-5b546368f874" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_96def841-fbc7-4cb7-9e4c-5ae380b6c08e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_3597912f-1a51-4eb3-9a8c-f64ecc4834db" xlink:to="loc_srt_OwnershipAxis_96def841-fbc7-4cb7-9e4c-5ae380b6c08e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_96def841-fbc7-4cb7-9e4c-5ae380b6c08e_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_96def841-fbc7-4cb7-9e4c-5ae380b6c08e" xlink:to="loc_srt_OwnershipDomain_96def841-fbc7-4cb7-9e4c-5ae380b6c08e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_da8b01b3-8e63-44f0-ab0b-616364a13459" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_96def841-fbc7-4cb7-9e4c-5ae380b6c08e" xlink:to="loc_srt_OwnershipDomain_da8b01b3-8e63-44f0-ab0b-616364a13459" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ChineseSupplierMember_0c217796-34c6-4a1d-8953-be033c72cdfd" xlink:href="apyx-20220930.xsd#apyx_ChineseSupplierMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_da8b01b3-8e63-44f0-ab0b-616364a13459" xlink:to="loc_apyx_ChineseSupplierMember_0c217796-34c6-4a1d-8953-be033c72cdfd" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/CHINAJOINTVENTURERollforwardofJointVentureDetails" xlink:type="simple" xlink:href="apyx-20220930.xsd#CHINAJOINTVENTURERollforwardofJointVentureDetails"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/CHINAJOINTVENTURERollforwardofJointVentureDetails" xlink:type="extended" id="i0e46fd66290e46e8b5fa479b363a96ba_CHINAJOINTVENTURERollforwardofJointVentureDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_b462bc94-428e-4aee-960f-a80162e9acb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInMinorityInterestRollForward_3c6278a5-29ce-4419-9c74-85073e11d6d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MovementInMinorityInterestRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_b462bc94-428e-4aee-960f-a80162e9acb2" xlink:to="loc_us-gaap_MovementInMinorityInterestRollForward_3c6278a5-29ce-4419-9c74-85073e11d6d3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_e296333a-a3ee-4660-b612-7e44058a0137" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_3c6278a5-29ce-4419-9c74-85073e11d6d3" xlink:to="loc_us-gaap_MinorityInterest_e296333a-a3ee-4660-b612-7e44058a0137" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_1510ae2b-cd9b-4cfa-9fe1-9850dcf98df1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_3c6278a5-29ce-4419-9c74-85073e11d6d3" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_1510ae2b-cd9b-4cfa-9fe1-9850dcf98df1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_e9421250-3a9b-4348-8042-acc00f43e8b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_3c6278a5-29ce-4419-9c74-85073e11d6d3" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_e9421250-3a9b-4348-8042-acc00f43e8b3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_c4af3ae6-f068-4653-9688-056aab3fb675" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_d1599e91-3c32-4f46-8a02-c80228302a1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_MinorityInterestLineItems_b462bc94-428e-4aee-960f-a80162e9acb2" xlink:to="loc_us-gaap_MinorityInterestTable_d1599e91-3c32-4f46-8a02-c80228302a1c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3401d6ea-f90d-4a1d-a37b-e8345fad25f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_d1599e91-3c32-4f46-8a02-c80228302a1c" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3401d6ea-f90d-4a1d-a37b-e8345fad25f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_3401d6ea-f90d-4a1d-a37b-e8345fad25f5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3401d6ea-f90d-4a1d-a37b-e8345fad25f5" xlink:to="loc_us-gaap_RelatedPartyDomain_3401d6ea-f90d-4a1d-a37b-e8345fad25f5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_8f294d70-a0a8-4909-9cc3-49838c04ea67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3401d6ea-f90d-4a1d-a37b-e8345fad25f5" xlink:to="loc_us-gaap_RelatedPartyDomain_8f294d70-a0a8-4909-9cc3-49838c04ea67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateJointVentureMember_9e12d29c-b45d-4b37-8990-e4f9268e53c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateJointVentureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_8f294d70-a0a8-4909-9cc3-49838c04ea67" xlink:to="loc_us-gaap_CorporateJointVentureMember_9e12d29c-b45d-4b37-8990-e4f9268e53c9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails" xlink:type="simple" xlink:href="apyx-20220930.xsd#EARNINGSLOSSPERSHAREDetails"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails" xlink:type="extended" id="ie8afa3bd5e40421f87a9992166fdbfd4_EARNINGSLOSSPERSHAREDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ef173deb-0ebf-4b29-a3d8-6d548496b7c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract_aff9970d-5941-450e-b8af-4f8c31f346ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ef173deb-0ebf-4b29-a3d8-6d548496b7c0" xlink:to="loc_us-gaap_EarningsPerShareReconciliationAbstract_aff9970d-5941-450e-b8af-4f8c31f346ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_6d8b4078-57fa-4914-b8fe-71471d577c35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_aff9970d-5941-450e-b8af-4f8c31f346ca" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_6d8b4078-57fa-4914-b8fe-71471d577c35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_a63a4966-f5c7-4e74-bad3-a882d09f147a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_aff9970d-5941-450e-b8af-4f8c31f346ca" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_a63a4966-f5c7-4e74-bad3-a882d09f147a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_b949215f-e812-434c-a452-7220247ce90a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DilutiveSecuritiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ef173deb-0ebf-4b29-a3d8-6d548496b7c0" xlink:to="loc_us-gaap_DilutiveSecuritiesAbstract_b949215f-e812-434c-a452-7220247ce90a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d59529d8-981a-413b-8ad4-e80c6149753b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_b949215f-e812-434c-a452-7220247ce90a" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d59529d8-981a-413b-8ad4-e80c6149753b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_fb08d6e2-a6a4-4bed-ba98-06b58ae5139e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_b949215f-e812-434c-a452-7220247ce90a" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_fb08d6e2-a6a4-4bed-ba98-06b58ae5139e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_bc1681ff-cb55-4336-8b9e-68e63351ad53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ef173deb-0ebf-4b29-a3d8-6d548496b7c0" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_bc1681ff-cb55-4336-8b9e-68e63351ad53" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_99cfa746-40a4-474c-962e-c778bcefc743" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_bc1681ff-cb55-4336-8b9e-68e63351ad53" xlink:to="loc_us-gaap_EarningsPerShareBasic_99cfa746-40a4-474c-962e-c778bcefc743" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_bdc8f896-d882-4db3-afda-887a94a035fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_bc1681ff-cb55-4336-8b9e-68e63351ad53" xlink:to="loc_us-gaap_EarningsPerShareDiluted_bdc8f896-d882-4db3-afda-887a94a035fe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_08b35430-64d3-4575-9941-920bd581e85a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ef173deb-0ebf-4b29-a3d8-6d548496b7c0" xlink:to="loc_us-gaap_EarningsPerShareDilutedAbstract_08b35430-64d3-4575-9941-920bd581e85a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1ecb3a47-79c8-4cba-a29f-0f32e23d3252" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_08b35430-64d3-4575-9941-920bd581e85a" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1ecb3a47-79c8-4cba-a29f-0f32e23d3252" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_2316a182-2cd5-4af6-b5c2-82a17222e857" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ef173deb-0ebf-4b29-a3d8-6d548496b7c0" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_2316a182-2cd5-4af6-b5c2-82a17222e857" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_e967cad8-a9f0-44dd-823f-74918323e5d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_2316a182-2cd5-4af6-b5c2-82a17222e857" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_e967cad8-a9f0-44dd-823f-74918323e5d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e967cad8-a9f0-44dd-823f-74918323e5d5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_e967cad8-a9f0-44dd-823f-74918323e5d5" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e967cad8-a9f0-44dd-823f-74918323e5d5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_aea979c7-6230-4a48-b8bd-2092407cabfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_e967cad8-a9f0-44dd-823f-74918323e5d5" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_aea979c7-6230-4a48-b8bd-2092407cabfd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_8313f73d-4466-417e-b011-5a706e49bc26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_aea979c7-6230-4a48-b8bd-2092407cabfd" xlink:to="loc_us-gaap_EmployeeStockOptionMember_8313f73d-4466-417e-b011-5a706e49bc26" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONFairValueAssumptionsDetails" xlink:type="simple" xlink:href="apyx-20220930.xsd#STOCKBASEDCOMPENSATIONFairValueAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONFairValueAssumptionsDetails" xlink:type="extended" id="i5c8f1de61f80436a926702574d417982_STOCKBASEDCOMPENSATIONFairValueAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_c45f49bb-2a67-4119-b39b-479200b0fa98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c2a39dc6-7101-495f-892a-f97bdf8e7701" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_c45f49bb-2a67-4119-b39b-479200b0fa98" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c2a39dc6-7101-495f-892a-f97bdf8e7701" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_3ebdde05-a4ad-4db2-8373-921c523524f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_c45f49bb-2a67-4119-b39b-479200b0fa98" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_3ebdde05-a4ad-4db2-8373-921c523524f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c1c314b0-d576-4f71-b487-1bff57c0f809" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_c45f49bb-2a67-4119-b39b-479200b0fa98" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c1c314b0-d576-4f71-b487-1bff57c0f809" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_a251f3d0-084d-4771-b4ee-f752293b61cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_c45f49bb-2a67-4119-b39b-479200b0fa98" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_a251f3d0-084d-4771-b4ee-f752293b61cd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_88b5eb4e-2983-4c7d-aca2-bbf8c8b80dc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_c45f49bb-2a67-4119-b39b-479200b0fa98" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_88b5eb4e-2983-4c7d-aca2-bbf8c8b80dc6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_dd8709e1-fa50-433f-a918-970847d40bda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_c45f49bb-2a67-4119-b39b-479200b0fa98" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_dd8709e1-fa50-433f-a918-970847d40bda" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0c74d6aa-88b8-42eb-aa49-557376f68a4e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_dd8709e1-fa50-433f-a918-970847d40bda" xlink:to="loc_srt_RangeAxis_0c74d6aa-88b8-42eb-aa49-557376f68a4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0c74d6aa-88b8-42eb-aa49-557376f68a4e_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_0c74d6aa-88b8-42eb-aa49-557376f68a4e" xlink:to="loc_srt_RangeMember_0c74d6aa-88b8-42eb-aa49-557376f68a4e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f8947491-2d43-495a-a5d2-53ce92d0006d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_0c74d6aa-88b8-42eb-aa49-557376f68a4e" xlink:to="loc_srt_RangeMember_f8947491-2d43-495a-a5d2-53ce92d0006d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c32f2c05-e90a-438f-bc5e-4fe7f54bf260" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f8947491-2d43-495a-a5d2-53ce92d0006d" xlink:to="loc_srt_MinimumMember_c32f2c05-e90a-438f-bc5e-4fe7f54bf260" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9caa90e3-ff11-4721-b427-88fc32e1545c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f8947491-2d43-495a-a5d2-53ce92d0006d" xlink:to="loc_srt_MaximumMember_9caa90e3-ff11-4721-b427-88fc32e1545c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" xlink:type="simple" xlink:href="apyx-20220930.xsd#COMMITMENTSANDCONTINGENCIESNarrativeDetails"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" xlink:type="extended" id="ic25fc2223fbc4c3f865b6842a5b28ccc_COMMITMENTSANDCONTINGENCIESNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_a0f2ff46-7bac-4e76-9c29-1a03ccce3c44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_fcb72af9-f5bc-4b84-9d15-2b11f761dce8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_a0f2ff46-7bac-4e76-9c29-1a03ccce3c44" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_fcb72af9-f5bc-4b84-9d15-2b11f761dce8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_058ac5d3-d639-4417-b9b2-4a9dc84d2b9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_a0f2ff46-7bac-4e76-9c29-1a03ccce3c44" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_058ac5d3-d639-4417-b9b2-4a9dc84d2b9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation_31690cc7-df6a-4423-b14b-a270c7483842" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_a0f2ff46-7bac-4e76-9c29-1a03ccce3c44" xlink:to="loc_us-gaap_PurchaseObligation_31690cc7-df6a-4423-b14b-a270c7483842" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_e9706a74-bae9-4414-9301-4b90af9df70d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_a0f2ff46-7bac-4e76-9c29-1a03ccce3c44" xlink:to="loc_us-gaap_LossContingenciesTable_e9706a74-bae9-4414-9301-4b90af9df70d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d89a67ae-e570-4ee8-a223-3d481c3de197" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_e9706a74-bae9-4414-9301-4b90af9df70d" xlink:to="loc_srt_RangeAxis_d89a67ae-e570-4ee8-a223-3d481c3de197" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d89a67ae-e570-4ee8-a223-3d481c3de197_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_d89a67ae-e570-4ee8-a223-3d481c3de197" xlink:to="loc_srt_RangeMember_d89a67ae-e570-4ee8-a223-3d481c3de197_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4f9c707a-7807-47e1-99f4-648f6a0768f9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_d89a67ae-e570-4ee8-a223-3d481c3de197" xlink:to="loc_srt_RangeMember_4f9c707a-7807-47e1-99f4-648f6a0768f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_292a7999-d752-4c42-9276-d3a3106ee0fb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4f9c707a-7807-47e1-99f4-648f6a0768f9" xlink:to="loc_srt_MinimumMember_292a7999-d752-4c42-9276-d3a3106ee0fb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9c55f733-f447-40b0-8828-f020337865f5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4f9c707a-7807-47e1-99f4-648f6a0768f9" xlink:to="loc_srt_MaximumMember_9c55f733-f447-40b0-8828-f020337865f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_278126af-f6dd-4b49-a838-d744a8fffffd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_e9706a74-bae9-4414-9301-4b90af9df70d" xlink:to="loc_srt_LitigationCaseAxis_278126af-f6dd-4b49-a838-d744a8fffffd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_278126af-f6dd-4b49-a838-d744a8fffffd_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_278126af-f6dd-4b49-a838-d744a8fffffd" xlink:to="loc_srt_LitigationCaseTypeDomain_278126af-f6dd-4b49-a838-d744a8fffffd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_4b31bc23-5dd8-4bbd-ab62-49984ec113ce" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_278126af-f6dd-4b49-a838-d744a8fffffd" xlink:to="loc_srt_LitigationCaseTypeDomain_4b31bc23-5dd8-4bbd-ab62-49984ec113ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ContractWithInternationalDistributorMember_22d3e93a-f5db-4cec-b095-f497261246ba" xlink:href="apyx-20220930.xsd#apyx_ContractWithInternationalDistributorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_4b31bc23-5dd8-4bbd-ab62-49984ec113ce" xlink:to="loc_apyx_ContractWithInternationalDistributorMember_22d3e93a-f5db-4cec-b095-f497261246ba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SuitAgainstGoodwinAndSimbMember_9b011875-ba07-4f98-b638-a39118e50d8b" xlink:href="apyx-20220930.xsd#apyx_SuitAgainstGoodwinAndSimbMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_4b31bc23-5dd8-4bbd-ab62-49984ec113ce" xlink:to="loc_apyx_SuitAgainstGoodwinAndSimbMember_9b011875-ba07-4f98-b638-a39118e50d8b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSDetails" xlink:type="simple" xlink:href="apyx-20220930.xsd#RELATEDPARTYTRANSACTIONSDetails"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSDetails" xlink:type="extended" id="i6a10e1ee33594ee88708a3c58170558c_RELATEDPARTYTRANSACTIONSDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_95d2e485-1ecb-45ef-aa45-ff3fb154c7c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_4987a269-7106-438c-89e2-5b408e877324" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_95d2e485-1ecb-45ef-aa45-ff3fb154c7c5" xlink:to="loc_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_4987a269-7106-438c-89e2-5b408e877324" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_6a1ec68f-64f7-4db0-8f72-b12e0605d6c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_95d2e485-1ecb-45ef-aa45-ff3fb154c7c5" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_6a1ec68f-64f7-4db0-8f72-b12e0605d6c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_da3a2449-4c85-4b99-8be6-f847c3964df8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_95d2e485-1ecb-45ef-aa45-ff3fb154c7c5" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_da3a2449-4c85-4b99-8be6-f847c3964df8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_b88357b8-5438-470c-8b2c-910c55314cfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_da3a2449-4c85-4b99-8be6-f847c3964df8" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_b88357b8-5438-470c-8b2c-910c55314cfa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_b88357b8-5438-470c-8b2c-910c55314cfa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_b88357b8-5438-470c-8b2c-910c55314cfa" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_b88357b8-5438-470c-8b2c-910c55314cfa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_2e007523-fedd-4adf-acb3-1cdf34b63293" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_b88357b8-5438-470c-8b2c-910c55314cfa" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_2e007523-fedd-4adf-acb3-1cdf34b63293" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CoVenturerMember_c4352e4d-fe39-4e98-be91-acffdebc472d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CoVenturerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_2e007523-fedd-4adf-acb3-1cdf34b63293" xlink:to="loc_us-gaap_CoVenturerMember_c4352e4d-fe39-4e98-be91-acffdebc472d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails" xlink:type="simple" xlink:href="apyx-20220930.xsd#GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails" xlink:type="extended" id="i8f98b2c4721a4e0f811a803943b0b4ad_GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_8d18a27e-f32d-4943-a029-9b6476758aa5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_196bad2f-5f32-46d7-b05e-42b12abd29aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_8d18a27e-f32d-4943-a029-9b6476758aa5" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_196bad2f-5f32-46d7-b05e-42b12abd29aa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_c4228493-46fb-4dfa-9dfe-1d3578a4e4ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_8d18a27e-f32d-4943-a029-9b6476758aa5" xlink:to="loc_us-gaap_OperatingIncomeLoss_c4228493-46fb-4dfa-9dfe-1d3578a4e4ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOperating_ab0c9b84-6dad-4e4b-a1b1-b0e719b0a944" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeOperating"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_8d18a27e-f32d-4943-a029-9b6476758aa5" xlink:to="loc_us-gaap_InterestIncomeOperating_ab0c9b84-6dad-4e4b-a1b1-b0e719b0a944" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_1485fcad-ff71-4144-a167-e762865739b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_8d18a27e-f32d-4943-a029-9b6476758aa5" xlink:to="loc_us-gaap_InterestExpense_1485fcad-ff71-4144-a167-e762865739b7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_1d81c583-35cd-4b64-aa34-f2b42135abff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_8d18a27e-f32d-4943-a029-9b6476758aa5" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_1d81c583-35cd-4b64-aa34-f2b42135abff" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_a03a08d4-3834-4956-b1d7-1feaf32a254f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_8d18a27e-f32d-4943-a029-9b6476758aa5" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_a03a08d4-3834-4956-b1d7-1feaf32a254f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0526741e-c61e-4336-bd04-16d280a2cf13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_8d18a27e-f32d-4943-a029-9b6476758aa5" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0526741e-c61e-4336-bd04-16d280a2cf13" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_81639865-3f8e-4f7f-8b63-0445687cd960" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0526741e-c61e-4336-bd04-16d280a2cf13" xlink:to="loc_srt_ConsolidationItemsAxis_81639865-3f8e-4f7f-8b63-0445687cd960" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_81639865-3f8e-4f7f-8b63-0445687cd960_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_81639865-3f8e-4f7f-8b63-0445687cd960" xlink:to="loc_srt_ConsolidationItemsDomain_81639865-3f8e-4f7f-8b63-0445687cd960_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_67ca60d2-0e2e-46d4-9052-2dce1a1d731b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_81639865-3f8e-4f7f-8b63-0445687cd960" xlink:to="loc_srt_ConsolidationItemsDomain_67ca60d2-0e2e-46d4-9052-2dce1a1d731b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_70ae37dd-164c-4684-8bee-dd27ebb64071" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_67ca60d2-0e2e-46d4-9052-2dce1a1d731b" xlink:to="loc_us-gaap_OperatingSegmentsMember_70ae37dd-164c-4684-8bee-dd27ebb64071" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_2c19d1dc-5638-489b-98e2-e346685c9b46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_67ca60d2-0e2e-46d4-9052-2dce1a1d731b" xlink:to="loc_us-gaap_CorporateNonSegmentMember_2c19d1dc-5638-489b-98e2-e346685c9b46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_67e28c17-8e45-4ffd-9eee-fb866804a5fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0526741e-c61e-4336-bd04-16d280a2cf13" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_67e28c17-8e45-4ffd-9eee-fb866804a5fb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_67e28c17-8e45-4ffd-9eee-fb866804a5fb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_67e28c17-8e45-4ffd-9eee-fb866804a5fb" xlink:to="loc_us-gaap_SegmentDomain_67e28c17-8e45-4ffd-9eee-fb866804a5fb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_942583c2-d5a1-4bfd-84b5-9942abcd9a28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_67e28c17-8e45-4ffd-9eee-fb866804a5fb" xlink:to="loc_us-gaap_SegmentDomain_942583c2-d5a1-4bfd-84b5-9942abcd9a28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_AdvancedEnergyMember_6381a7b1-aba7-4fdb-b848-c6962c499b4e" xlink:href="apyx-20220930.xsd#apyx_AdvancedEnergyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_942583c2-d5a1-4bfd-84b5-9942abcd9a28" xlink:to="loc_apyx_AdvancedEnergyMember_6381a7b1-aba7-4fdb-b848-c6962c499b4e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_OEMMember_74e130ef-0fd4-4800-9b30-4ec339f3b98a" xlink:href="apyx-20220930.xsd#apyx_OEMMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_942583c2-d5a1-4bfd-84b5-9942abcd9a28" xlink:to="loc_apyx_OEMMember_74e130ef-0fd4-4800-9b30-4ec339f3b98a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails" xlink:type="simple" xlink:href="apyx-20220930.xsd#GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails" xlink:type="extended" id="i85b052035cc0405587eb4dba255bad16_GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_60a5df63-44c1-4f78-8685-cb5f69bed83c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b171948c-c109-47fc-9236-23594f2ecb3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_60a5df63-44c1-4f78-8685-cb5f69bed83c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b171948c-c109-47fc-9236-23594f2ecb3b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f40324b3-7102-4a34-ac2c-f4f864a127aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_60a5df63-44c1-4f78-8685-cb5f69bed83c" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f40324b3-7102-4a34-ac2c-f4f864a127aa" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_583409e7-9798-4990-97fb-77948ff75aa3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f40324b3-7102-4a34-ac2c-f4f864a127aa" xlink:to="loc_srt_StatementGeographicalAxis_583409e7-9798-4990-97fb-77948ff75aa3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_583409e7-9798-4990-97fb-77948ff75aa3_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_583409e7-9798-4990-97fb-77948ff75aa3" xlink:to="loc_srt_SegmentGeographicalDomain_583409e7-9798-4990-97fb-77948ff75aa3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_8a17dcc4-8eb1-4840-b890-7025d3cc370b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_583409e7-9798-4990-97fb-77948ff75aa3" xlink:to="loc_srt_SegmentGeographicalDomain_8a17dcc4-8eb1-4840-b890-7025d3cc370b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_e426ba7d-746d-4d98-864a-048c93da3ec2" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_8a17dcc4-8eb1-4840-b890-7025d3cc370b" xlink:to="loc_country_US_e426ba7d-746d-4d98-864a-048c93da3ec2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_448ca0de-baa7-40b5-af24-43c84dfc978e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_8a17dcc4-8eb1-4840-b890-7025d3cc370b" xlink:to="loc_us-gaap_NonUsMember_448ca0de-baa7-40b5-af24-43c84dfc978e" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>apyx-20220930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:90964edb-9ed2-4911-9f65-50e8b3fbc396,g:6dc5a8ef-7d14-451f-bd94-08d276b52e31-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_323246e0-e089-424c-a6bb-cd65c3d8ddae_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contributions from non-controlling interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_0d5d47fb-f157-446c-91c1-915eec9811d5_verboseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contributions</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Increase from Subsidiary Equity Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:to="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_34bc6815-3205-4069-8502-29c623b2db73_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9c88faea-abf2-458e-992e-16fd3d3df852_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_199c1994-1897-4d37-9be4-762edb269425_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_56cc233c-6124-4175-9786-d1a6a6377e1c_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_8ddd7158-3e51-4294-a4e4-daa354a5dcae_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_8c86d96c-2d7a-4cdc-9ce0-2ce1f12c0d31_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_d3a2b0aa-33e2-47f8-ad0f-6f5f7071686f_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_dd904769-fa52-40ad-a977-75ab9e9fb8c6_terseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for allowance for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_8cb6e89d-d727-436c-9cbe-8b24eae5c3da_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_217da958-8c45-440d-9f6e-bfd3d00c6373_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_7ddb688c-5968-4ff1-b858-7e6b2fdbfe74_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_9ca14de2-c41a-419a-924f-cc1b98227ea9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_e849e1b5-9384-4abb-9337-099091febcd6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_bf784043-1868-430d-ae61-9b818c7fb363_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_8184f68c-ee4a-4447-94a9-687020130349_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_84a8cea2-2a4f-4570-89b0-1259aa7c9557_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_8f697f6a-4c0e-42f7-9f8e-7528ec599505_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, after Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_f96c00b5-316b-49c6-ac23-5e596335f017_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss per share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeOperating_bc79518e-fd1f-41c9-bc03-5e28dddf18ab_verboseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeOperating" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InterestIncomeOperating_861cf8c0-5a71-4e98-aeb8-9be91a6d75a8_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeOperating" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InterestIncomeOperating_label_en-US" xlink:label="lab_us-gaap_InterestIncomeOperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income, Operating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOperating" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeOperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeOperating" xlink:to="lab_us-gaap_InterestIncomeOperating" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_dfb91725-1488-4faa-bd75-4f14bbea51c1_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_63a647b3-4efa-4623-842d-1ba1a18d49ec_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares outstanding - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a5388e7f-6c72-4d99-b576-63d402cae05f_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_dcde3a0a-2183-42b2-9704-312f1c948423_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_TotalRevenuePercent_fe9ddb28-eeaa-48e7-a93d-9f1c0e5d2589_terseLabel_en-US" xlink:label="lab_apyx_TotalRevenuePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International sales, percent of total revenue</link:label>
    <link:label id="lab_apyx_TotalRevenuePercent_label_en-US" xlink:label="lab_apyx_TotalRevenuePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Revenue, Percent</link:label>
    <link:label id="lab_apyx_TotalRevenuePercent_documentation_en-US" xlink:label="lab_apyx_TotalRevenuePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Revenue, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_TotalRevenuePercent" xlink:href="apyx-20220930.xsd#apyx_TotalRevenuePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_TotalRevenuePercent" xlink:to="lab_apyx_TotalRevenuePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_d0275173-ad82-47a8-871c-ae549c19cb46_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_f539d6f2-12bd-4a6c-a11f-87030e364519_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_609c37d2-4fe3-46e6-9ed3-61366feb1bd4_totalLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiability" xlink:to="lab_us-gaap_FinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_8c12ee61-18a6-47cb-b4f3-a26ae68c10d7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_StockIssuedDuringPeriodSharesStockSwaps_5b0d1bfa-802a-4c04-8e05-898ed62a24cf_terseLabel_en-US" xlink:label="lab_apyx_StockIssuedDuringPeriodSharesStockSwaps" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock swaps (in shares)</link:label>
    <link:label id="lab_apyx_StockIssuedDuringPeriodSharesStockSwaps_label_en-US" xlink:label="lab_apyx_StockIssuedDuringPeriodSharesStockSwaps" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Stock Swaps</link:label>
    <link:label id="lab_apyx_StockIssuedDuringPeriodSharesStockSwaps_documentation_en-US" xlink:label="lab_apyx_StockIssuedDuringPeriodSharesStockSwaps" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Stock Swaps</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_StockIssuedDuringPeriodSharesStockSwaps" xlink:href="apyx-20220930.xsd#apyx_StockIssuedDuringPeriodSharesStockSwaps"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_StockIssuedDuringPeriodSharesStockSwaps" xlink:to="lab_apyx_StockIssuedDuringPeriodSharesStockSwaps" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_e1146c72-e899-48a1-9af7-48317b5025dc_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value; 75,000,000 shares authorized; 34,588,398 issued and outstanding as of September&#160;30, 2022, and 34,409,912 issued and outstanding as of December 31, 2021</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_702d06cc-89da-4009-9864-c436cf91ea26_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_3ec05c03-cabd-4827-95c9-179b2da2c96f_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_CapitalizationOfLeaseExecution_f46a7d72-01b4-4d6c-9e67-c55cc4fa011f_terseLabel_en-US" xlink:label="lab_apyx_CapitalizationOfLeaseExecution" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets capitalized and finance lease liabilities recognized upon execution of lease</link:label>
    <link:label id="lab_apyx_CapitalizationOfLeaseExecution_label_en-US" xlink:label="lab_apyx_CapitalizationOfLeaseExecution" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalization Of Lease, Execution</link:label>
    <link:label id="lab_apyx_CapitalizationOfLeaseExecution_documentation_en-US" xlink:label="lab_apyx_CapitalizationOfLeaseExecution" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalization Of Lease, Execution</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_CapitalizationOfLeaseExecution" xlink:href="apyx-20220930.xsd#apyx_CapitalizationOfLeaseExecution"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_CapitalizationOfLeaseExecution" xlink:to="lab_apyx_CapitalizationOfLeaseExecution" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_0ed9cfa7-3800-41b3-baf7-b1d02bf54fb2_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_03b0d41e-26c2-4b61-b8cf-832263147180_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_8f010d08-930a-4a1f-81ce-558e263e1cbf_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (loss) income, net</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_d1e9a5f9-92fd-4db0-9882-0949a3a4293c_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (loss), net</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_label_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Income (Expense), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_62d91f10-dc6e-4355-8696-04ede402a5ef_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_95198c16-d976-4cf8-b405-a3e4d9a67819_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments</link:label>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_label_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingSegmentsMember" xlink:to="lab_us-gaap_OperatingSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_11ec9e28-a827-4aff-a247-e43e230a07a5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6d34f201-43f6-475f-8b9f-ffe914a2ebf4_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_ff240ad3-9c57-43f9-afae-fade64906338_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Costs of Goods Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_OEMMember_3692dfbe-8ace-4954-a516-472acc13ac20_terseLabel_en-US" xlink:label="lab_apyx_OEMMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OEM</link:label>
    <link:label id="lab_apyx_OEMMember_label_en-US" xlink:label="lab_apyx_OEMMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OEM [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_OEMMember" xlink:href="apyx-20220930.xsd#apyx_OEMMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_OEMMember" xlink:to="lab_apyx_OEMMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_eb243719-2dda-4444-a972-5efc4315f184_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b3347818-0fed-43e7-b78e-de6d57d163a8_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5975e535-421c-4fbc-b8d4-800ffc6f4d02_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedBonusesCurrent_5ace9919-b239-4619-88e1-5d8f8a93a66b_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedBonusesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued bonuses</link:label>
    <link:label id="lab_us-gaap_AccruedBonusesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedBonusesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Bonuses, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedBonusesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedBonusesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedBonusesCurrent" xlink:to="lab_us-gaap_AccruedBonusesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_5768138c-7686-440e-a466-c423608b6206_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to non-controlling interest</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_b3114376-5e05-4cb8-9837-3ffcb2e1eebd_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to Apyx</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_171a364c-1be1-4004-83fe-d2c6075b5d41_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_cca100ad-582f-4caa-827c-cd368b95a563_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_48e2bca2-2551-49ea-843c-70a0050e5278_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to stockholders, basic</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_2d572888-81da-4b2e-9b82-04a35c4e82d3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_e2fa3b68-2aa7-4cce-8791-3cfaf28bda51_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_716f6d35-c02e-49bc-a373-9cc05d4ba204_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_932b2f9f-e77d-411f-8093-661d145ad02b_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to stockholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised_1badecda-1c0f-43ed-b4a1-75ce9e06f031_terseLabel_en-US" xlink:label="lab_apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from stock option exercises</link:label>
    <link:label id="lab_apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised_label_en-US" xlink:label="lab_apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Stock Options Exercised And Warrants Exercised</link:label>
    <link:label id="lab_apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised_documentation_en-US" xlink:label="lab_apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Stock Options Exercised And Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised" xlink:href="apyx-20220930.xsd#apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised" xlink:to="lab_apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_046e0ef2-5c2d-4acc-aa6f-4dbb982f289c_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_5b3ff225-79f4-4b18-a0ac-19b3637cf7c5_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-dilutive instruments (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_5fde2ae4-6abb-4ae6-b1af-a8eb8e3bb8bf_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LEASES</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:to="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_OperatingLeaseCostsAbstract_63aeab9e-5397-4649-b688-d0b20599be27_terseLabel_en-US" xlink:label="lab_apyx_OperatingLeaseCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating</link:label>
    <link:label id="lab_apyx_OperatingLeaseCostsAbstract_label_en-US" xlink:label="lab_apyx_OperatingLeaseCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Costs [Abstract]</link:label>
    <link:label id="lab_apyx_OperatingLeaseCostsAbstract_documentation_en-US" xlink:label="lab_apyx_OperatingLeaseCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Costs [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_OperatingLeaseCostsAbstract" xlink:href="apyx-20220930.xsd#apyx_OperatingLeaseCostsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_OperatingLeaseCostsAbstract" xlink:to="lab_apyx_OperatingLeaseCostsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_7fbc5510-2c5c-477b-966f-4e4852517b12_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_4d2e8aeb-c0ba-4df5-ac0d-b44d75beb84d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_a928370e-fbfa-4b04-9e5f-e966df9dc736_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_3e32d36a-d8e9-44bc-8d7a-8bfa9c6e98ca_negatedLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less current portion of lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_a2f65ee1-07e0-4825-9d3b-b177c6b3c3ac_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_87f70f10-cce8-43c2-8522-8ebaa163f899_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_d5ad4732-75ad-4a16-bb81-7f571affea37_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease extension</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_AssetPurchaseAgreementTerm_3a15fc95-4862-424d-bc05-b47c82cfae6e_terseLabel_en-US" xlink:label="lab_apyx_AssetPurchaseAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset purchase agreement, term</link:label>
    <link:label id="lab_apyx_AssetPurchaseAgreementTerm_label_en-US" xlink:label="lab_apyx_AssetPurchaseAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Purchase Agreement, Term</link:label>
    <link:label id="lab_apyx_AssetPurchaseAgreementTerm_documentation_en-US" xlink:label="lab_apyx_AssetPurchaseAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Purchase Agreement, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_AssetPurchaseAgreementTerm" xlink:href="apyx-20220930.xsd#apyx_AssetPurchaseAgreementTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_AssetPurchaseAgreementTerm" xlink:to="lab_apyx_AssetPurchaseAgreementTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_a21b001c-b3ae-467a-8daa-90fb8902b6ea_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfessionalFees_2968d082-9c60-46d0-85b8-807c3d651b5b_terseLabel_en-US" xlink:label="lab_us-gaap_ProfessionalFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional services</link:label>
    <link:label id="lab_us-gaap_ProfessionalFees_label_en-US" xlink:label="lab_us-gaap_ProfessionalFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfessionalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfessionalFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfessionalFees" xlink:to="lab_us-gaap_ProfessionalFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_b3e6a8cb-f155-4e36-b41a-794f7451d88c_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share Reconciliation [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract" xlink:to="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_2db10a89-b27c-4000-87a2-965ae68de838_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_RepaymentOfFinanceLeaseLiabilities_cb52fc9a-5bda-4cb9-b082-e14f2fb4f0e8_negatedTerseLabel_en-US" xlink:label="lab_apyx_RepaymentOfFinanceLeaseLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of finance lease liabilities</link:label>
    <link:label id="lab_apyx_RepaymentOfFinanceLeaseLiabilities_label_en-US" xlink:label="lab_apyx_RepaymentOfFinanceLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment Of Finance Lease Liabilities</link:label>
    <link:label id="lab_apyx_RepaymentOfFinanceLeaseLiabilities_documentation_en-US" xlink:label="lab_apyx_RepaymentOfFinanceLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment Of Finance Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_RepaymentOfFinanceLeaseLiabilities" xlink:href="apyx-20220930.xsd#apyx_RepaymentOfFinanceLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_RepaymentOfFinanceLeaseLiabilities" xlink:to="lab_apyx_RepaymentOfFinanceLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_4b26a6dd-fa8b-43a9-9266-dfa8a2b06a6b_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_930bd177-8522-402e-8562-13297d3c015f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LEASES</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_1af1eb8e-8fb2-4b80-ab75-50f651f86da2_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Estimate of Possible Loss</link:label>
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_label_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Estimate of Possible Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:to="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_a0832bee-e09c-4324-b5fe-ac4216e39e3a_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_acfea7f0-3f5c-4460-a0d9-85f75bfe1551_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of reporting information by segment</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_66aefce4-d82d-478c-b7f8-1bd6a88b7bc7_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_57004c6f-91ed-4394-8265-e03a876246e7_terseLabel_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DilutiveSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract" xlink:to="lab_us-gaap_DilutiveSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_1adc7dd0-b11f-4ad8-85f9-9a6bd2d3637b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_b9e8406e-79ad-47ee-a7b9-b7c61acd8b76_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases from related party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Purchases from Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:to="lab_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_9b77d4cf-63ab-4b78-8010-c3090bb5f501_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_7c908213-a67d-41e7-82f9-5a5031a0de82_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_0fc45420-ed8a-440a-b0dc-3bcc2786d0a2_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_ef6dda47-66b8-4676-8acb-1b9b1aa01c9c_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract" xlink:to="lab_us-gaap_NoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_9ab942f1-a53e-41b0-a74d-38b5a784bc26_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_3aad03b1-ba9c-4235-8372-77735aa1b13d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_895585aa-0835-4b60-8007-aa9e22fc3a75_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5d3f57dd-5278-4560-8dbd-7e52565a6dad_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_dc5beadf-c6b6-4542-9ef2-48dadee3777e_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_caca7e57-a6ca-46ce-9a26-0dc5c95bd2bd_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_7eb17907-b39c-4820-8e39-73ec1caba690_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash used in operations</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_00450429-2a0a-4014-ad4b-2c36170caddb_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_1dc2c2ca-7552-4764-aedb-c4b4056ca777_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_c59783fe-e471-4f03-8e25-575f3923ff86_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_2e68203f-2562-4a24-8426-c8a64ed185bf_negatedLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less current portion of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2fa5a5d3-b625-4d28-8d31-784d10acda18_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rates on cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_79efdf9e-5d04-4c7a-8512-c35ddd73e0c4_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net of accumulated depreciation and amortization of $5,335 and $5,316</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_34af22a6-baf1-4761-afa5-33478689a3c6_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinesses_d682521d-bec3-4bff-9243-a8bbcd8aea3f_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the disposition of Core business</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinesses_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Divestiture of Businesses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:to="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_ProvisionForObsolescenceInventory_b04ba91c-38ce-4dcc-8247-e5a6714ca621_terseLabel_en-US" xlink:label="lab_apyx_ProvisionForObsolescenceInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories, provision for obsolescence</link:label>
    <link:label id="lab_apyx_ProvisionForObsolescenceInventory_label_en-US" xlink:label="lab_apyx_ProvisionForObsolescenceInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision For Obsolescence, Inventory</link:label>
    <link:label id="lab_apyx_ProvisionForObsolescenceInventory_documentation_en-US" xlink:label="lab_apyx_ProvisionForObsolescenceInventory" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision For Obsolescence, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ProvisionForObsolescenceInventory" xlink:href="apyx-20220930.xsd#apyx_ProvisionForObsolescenceInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_ProvisionForObsolescenceInventory" xlink:to="lab_apyx_ProvisionForObsolescenceInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_d0c9325d-eaf4-4748-8fe2-a56520ed2ed6_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_69fdb515-edc8-4338-8855-cb9e824e888b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour_5ca13bd8-36e2-4dd1-a829-13778962854d_terseLabel_en-US" xlink:label="lab_apyx_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_apyx_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour_label_en-US" xlink:label="lab_apyx_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Due after Year Four</link:label>
    <link:label id="lab_apyx_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour_documentation_en-US" xlink:label="lab_apyx_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Due after Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour" xlink:href="apyx-20220930.xsd#apyx_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour" xlink:to="lab_apyx_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_f21bcf43-b06e-4096-98eb-68908d2a0607_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other costs and expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_f88ad4b7-cc4c-466d-994f-848a8785977f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_8e57ee24-2dbe-4c6b-8ca7-2ffb1b239938_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Operating Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_a05e94e6-6653-421d-9f6f-cccc1c51d5e2_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued on stock options exercises for cash</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_def441cd-5d59-4efd-8653-08d63a6f6e8e_totalLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other income (loss), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_c43a2351-3da7-438e-9cb2-22053c9f9f9e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_84826746-7058-42a0-9270-98c61f397731_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateJointVentureMember_aa9b1884-ff17-4bf6-aa56-f3d108b1c167_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateJointVentureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Joint Venture</link:label>
    <link:label id="lab_us-gaap_CorporateJointVentureMember_label_en-US" xlink:label="lab_us-gaap_CorporateJointVentureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Joint Venture [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateJointVentureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateJointVentureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateJointVentureMember" xlink:to="lab_us-gaap_CorporateJointVentureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_e069b3b8-5eac-430a-8b44-d4a650a17d49_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_82a49ccf-5973-4dea-94d3-fb6202540dc4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_3d98ef18-d974-4c67-b363-28531cc0fb77_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_31c8d6ad-b7c9-418c-93f8-a8195253daab_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other costs and expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_7136812e-6ed7-4ca9-aad1-011fc6cdf65f_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3125ba83-506c-4a1f-ad76-95218ec01297_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_fd9777a7-90cb-459b-95ec-8a6dac1ba67b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of revenue by geographic area</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:to="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_bf037920-f14e-4bca-b961-12584fa4db1b_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_3166b00a-7608-4b0f-a3b6-f25eb1c51e62_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_96a445c1-998e-41ec-9a42-15fcc8f10d42_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcess" xlink:to="lab_us-gaap_InventoryWorkInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_bac3cb37-855c-45a1-a0f3-ba7a2559104a_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_308b9fb6-632b-46b0-aea9-4327eb8ad933_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Abstract]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:to="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_eb0f3d24-c117-451f-be76-f05fbba3e39d_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e0bdb5ee-e0da-4060-a849-b8b905909427_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_8df28a8c-c8cd-46a3-93ca-694985352eed_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_a5e667c7-c2a2-4a47-b52e-cfc56b514dce_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non cash activities:</link:label>
    <link:label id="lab_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Cash Flow Elements and Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_af5c11c5-72fb-4a03-9569-4bb47666015c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled and forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_e84b253e-480c-400a-ac3c-5643c09f276b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_7cd6f5cd-59d7-45c1-96ed-921318a27108_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax receivables</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Income Taxes Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_f6356b54-51a8-4ebd-8a43-b2ed7631cd84_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_ab6c326f-ec17-4dc6-9980-2327c1da451e_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_cbf60fef-2f6a-4801-98f8-8af89dc48b26_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_5e2395d6-0e6f-4d1a-99eb-a7a103e7abac_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_24e50ebc-080b-4590-9dd1-7576833cfc91_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_e7eb05a2-6e7b-4f51-bcf1-194197ce21da_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade receivables</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_ec33a3fd-1f9c-4d69-93ed-805502f7bc27_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_3fa15685-97ae-4ef9-ba9c-50a2b2c2d938_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BASIS OF PRESENTATION</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_bed9b910-db02-4198-99fd-4c82a54406a5_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsDomain_2d48fdc6-bee8-4b7b-8457-c8e078e0d21a_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:label id="lab_srt_ConsolidationItemsDomain_label_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_858e443c-6ea1-42ca-94a3-1d8ecc2062c2_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedSalariesCurrent_99fdb2d9-381d-4431-8978-b4e8a69b1c79_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedSalariesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued payroll</link:label>
    <link:label id="lab_us-gaap_AccruedSalariesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedSalariesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Salaries, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedSalariesCurrent" xlink:to="lab_us-gaap_AccruedSalariesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_44be5ce9-e524-4474-99b3-a970b781b44b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_a59faff2-9306-498f-ab2e-e5c03ed1e73a_terseLabel_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductWarrantyAccrualClassifiedCurrent_a7387880-f94e-4c38-a0dc-29fe109489be_terseLabel_en-US" xlink:label="lab_us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued product warranties</link:label>
    <link:label id="lab_us-gaap_ProductWarrantyAccrualClassifiedCurrent_label_en-US" xlink:label="lab_us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Warranty Accrual, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductWarrantyAccrualClassifiedCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:to="lab_us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_f6d28933-bb84-43db-91de-ce53b672af79_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued on stock options exercises for cash (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_b3013644-5ce9-48b8-a754-bea6980cd47d_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_7c4a5f85-a472-4118-a953-f3d8209823c2_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_66838f6f-ecad-4062-afd5-d91618f85a3f_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GEOGRAPHIC AND SEGMENT INFORMATION</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_9bc53058-57fa-43c9-bbbf-866ba7875cc9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_06972de6-dacc-4fd5-88ad-7641aa8d9267_totalLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_e969a565-3344-4ff6-bf0e-b8c60e305a0f_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss per share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember_62806850-d496-44fb-b2ff-3c1594d0ad1c_terseLabel_en-US" xlink:label="lab_apyx_ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Electro Surgical Disposables and Accessories, Cauteries and Other Products Supply Agreement</link:label>
    <link:label id="lab_apyx_ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember_label_en-US" xlink:label="lab_apyx_ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Electro Surgical Disposables And Accessories, Cauteries And Other Products Supply Agreement [Member]</link:label>
    <link:label id="lab_apyx_ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember_documentation_en-US" xlink:label="lab_apyx_ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Electro Surgical Disposables And Accessories, Cauteries And Other Products Supply Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember" xlink:href="apyx-20220930.xsd#apyx_ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember" xlink:to="lab_apyx_ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_296ee098-9634-40b2-8d80-44b0ce4cbf7f_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities of Finance Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Fiscal Year Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesAndExciseTaxPayableCurrent_30dfa41e-d4be-46e1-83ad-96d17672a1ec_terseLabel_en-US" xlink:label="lab_us-gaap_SalesAndExciseTaxPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales tax payable</link:label>
    <link:label id="lab_us-gaap_SalesAndExciseTaxPayableCurrent_label_en-US" xlink:label="lab_us-gaap_SalesAndExciseTaxPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales and Excise Tax Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesAndExciseTaxPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesAndExciseTaxPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesAndExciseTaxPayableCurrent" xlink:to="lab_us-gaap_SalesAndExciseTaxPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestTable_43f7775e-2d86-4be1-bbb3-a894c4be6ad1_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Table]</link:label>
    <link:label id="lab_us-gaap_MinorityInterestTable_label_en-US" xlink:label="lab_us-gaap_MinorityInterestTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestTable" xlink:to="lab_us-gaap_MinorityInterestTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_52939ed9-a0d2-4f62-afca-b2e16e309027_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeaseTermOfContract1_ad4d94ac-ae20-49c3-a0e0-589309854951_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease, term of contract</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeaseTermOfContract1_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:to="lab_us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4940b6a3-98a8-46e2-8bf8-9089167b79d5_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_103931db-055a-46cd-8c63-49e6ee91aba3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssued_ea0d1228-0d16-493e-b708-21dbf6ef6274_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_c0965555-604e-4898-905e-3ad4d533ffc0_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_label_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_38a0b084-c65c-45ce-b7dc-4929539228e5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_6c0196b4-ae66-4d65-a794-75682254407a_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strike price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_0a1318d8-3786-43c4-a865-23af6b5e7f4c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled and forfeited (in dollars per shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_47c41dce-115c-41bd-8d57-6c00e5b20507_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_a7bbc530-67f2-405d-8e7d-d4dd2c305d60_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_f5775a60-87c0-475e-9078-ea4c8dcbd9ab_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories, net of provision for obsolescence of $379 and $263</link:label>
    <link:label id="lab_us-gaap_InventoryNet_052437ac-4157-4c98-8e65-1b7193869ea6_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_a1a7bcfe-edb0-473b-bce3-c96aa2eda3b5_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_fc4e37b7-33a8-49f6-97b1-46e3966ce95a_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_cdeebf5a-126e-4850-b339-8b325a68150f_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EQUITY</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_dd6bca84-1d0d-4e39-93e6-dfec1966dc30_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_3fe83946-04ab-4545-9407-346314c51a2d_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_daa1d020-0a00-4f38-8c67-eb084a4ad178_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EARNINGS (LOSS) PER SHARE</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestDisclosureTextBlock_2b36a4f3-c185-4ec8-afa2-b7765c46ca37_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CHINA JOINT VENTURE</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDisclosureTextBlock" xlink:to="lab_us-gaap_MinorityInterestDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_2c29a582-6755-4a69-8c37-9f78aa900a2a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of option fair value assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_e29d4a1f-1df1-4259-93f6-38f58680396c_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_aa9f71db-f190-486a-b8c7-5739134d0731_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term portion of lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedSalesCommissionCurrent_63fcf613-c64d-4b2e-934f-420e45cf6a9f_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedSalesCommissionCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued commissions</link:label>
    <link:label id="lab_us-gaap_AccruedSalesCommissionCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedSalesCommissionCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Sales Commission, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalesCommissionCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedSalesCommissionCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedSalesCommissionCurrent" xlink:to="lab_us-gaap_AccruedSalesCommissionCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_ea4a0262-4545-44df-a9df-1fa6f94b90d3_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_df8ebcc3-9e4d-4f93-9d9d-02addbc46623_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_79c878b0-beda-41e7-8743-483ca42f7f0b_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares outstanding - basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_f8b6e3a0-8201-4a7a-9c29-712dd963c5a0_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_UncertainTaxPositionsLiability_a0083208-6460-4a62-bb2b-fd682a8c8336_terseLabel_en-US" xlink:label="lab_apyx_UncertainTaxPositionsLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Uncertain tax positions</link:label>
    <link:label id="lab_apyx_UncertainTaxPositionsLiability_label_en-US" xlink:label="lab_apyx_UncertainTaxPositionsLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Uncertain Tax Positions Liability</link:label>
    <link:label id="lab_apyx_UncertainTaxPositionsLiability_documentation_en-US" xlink:label="lab_apyx_UncertainTaxPositionsLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Uncertain Tax Positions Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_UncertainTaxPositionsLiability" xlink:href="apyx-20220930.xsd#apyx_UncertainTaxPositionsLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_UncertainTaxPositionsLiability" xlink:to="lab_apyx_UncertainTaxPositionsLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_8e4bb8e4-5bd7-4d43-86e7-371767f0f168_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_f155858b-d94b-458b-9582-00c705a467d3_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs accrued</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesReceivable_5b333da7-9598-4cd8-b184-5591a2ebc1d5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax receivables</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesReceivable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesReceivable" xlink:to="lab_us-gaap_IncomeTaxesReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_2a2fbf99-ab12-40d1-b3e9-6a3d9413902b_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods" xlink:to="lab_us-gaap_InventoryFinishedGoods" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_423e051e-a4ad-4181-873a-5364bb42c1e6_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock based compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrossProfit_cb155952-7ee0-4a7b-9f7b-72a106f1f630_totalLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross profit</link:label>
    <link:label id="lab_us-gaap_GrossProfit_label_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_0199b582-1315-4271-90f1-520bb7f404d7_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_792da3aa-001e-4963-97d9-71f8a121191e_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_450af519-2626-4552-8b61-c8b3bef32d04_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_cad97e7e-119f-4cd6-a34e-2d2dde84dc80_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, end of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_StockSwapToAcquireOptionsShares_cd0304f1-bb40-416f-aed6-000ba2288176_terseLabel_en-US" xlink:label="lab_apyx_StockSwapToAcquireOptionsShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued on net settlement of stock options (in shares)</link:label>
    <link:label id="lab_apyx_StockSwapToAcquireOptionsShares_label_en-US" xlink:label="lab_apyx_StockSwapToAcquireOptionsShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock swap to acquire options, Shares</link:label>
    <link:label id="lab_apyx_StockSwapToAcquireOptionsShares_documentation_en-US" xlink:label="lab_apyx_StockSwapToAcquireOptionsShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock swap to acquire options shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_StockSwapToAcquireOptionsShares" xlink:href="apyx-20220930.xsd#apyx_StockSwapToAcquireOptionsShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_StockSwapToAcquireOptionsShares" xlink:to="lab_apyx_StockSwapToAcquireOptionsShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_cee13423-9e4e-4dbd-9980-46dd9a624f22_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_491d41c5-85a8-4557-bcab-dc7cdfec382e_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_OtherAccruedExpensesAndLiabilitiesCurrent_47179b45-bc6f-42b4-94ba-0ba740887730_terseLabel_en-US" xlink:label="lab_apyx_OtherAccruedExpensesAndLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued expenses and current liabilities</link:label>
    <link:label id="lab_apyx_OtherAccruedExpensesAndLiabilitiesCurrent_label_en-US" xlink:label="lab_apyx_OtherAccruedExpensesAndLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Expenses And Liabilities, Current</link:label>
    <link:label id="lab_apyx_OtherAccruedExpensesAndLiabilitiesCurrent_documentation_en-US" xlink:label="lab_apyx_OtherAccruedExpensesAndLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Expenses And Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_OtherAccruedExpensesAndLiabilitiesCurrent" xlink:href="apyx-20220930.xsd#apyx_OtherAccruedExpensesAndLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_OtherAccruedExpensesAndLiabilitiesCurrent" xlink:to="lab_apyx_OtherAccruedExpensesAndLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_4b0e96df-91c6-4258-9c2f-0ad782a5ed0d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_9e492fe1-f758-43cd-a0d2-99676379274a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net other loss</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_6deaed1e-7b32-4031-84ff-bc8d2d6a1d14_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_6d249979-7f27-4737-b59d-8ef92e1770c3_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7bb4a041-3b49-49d0-b438-05246e555a71_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_fc1266b4-980d-4229-ab54-b332f9779d09_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5c773e50-32e1-4ad9-8112-782bde9a52e9_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_083e3e9a-493f-44d4-9c00-7a9a04e2177b_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">STOCK-BASED COMPENSATION</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_dc5a7a4b-d1a3-4502-978a-f5ea57b2205b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_7bb0e788-acfa-4244-87eb-99e9db3d6158_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for doubtful accounts receivable</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_6443ec27-5005-410b-b2b5-451c5777b280_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_f8443e17-d548-49e1-b862-e8252eee3b88_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average discount rate</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_86b0e3a1-5be7-44a4-9088-19bed5b8dade_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_1199fa53-59f5-4f6d-b63c-4f242b23212e_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-controlling interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_79b4ae13-8a63-4331-8d94-9bf8c8eb70a9_periodStartLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning interest in China JV</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_908ab3e1-c4fd-45d3-8406-55f6de43e135_periodEndLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending interest in China JV</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_c3d084ed-5c27-41d2-9b7b-fba6923c023e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_fb05426f-dd0f-4a1d-8e68-0d2d55055cef_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_CapitalizationOfLeaseNonCash_76853f72-5892-45a0-9c35-b19b1ee795d5_terseLabel_en-US" xlink:label="lab_apyx_CapitalizationOfLeaseNonCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets capitalized and operating lease liabilities recognized upon lease modification</link:label>
    <link:label id="lab_apyx_CapitalizationOfLeaseNonCash_label_en-US" xlink:label="lab_apyx_CapitalizationOfLeaseNonCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalization Of Lease, Non Cash</link:label>
    <link:label id="lab_apyx_CapitalizationOfLeaseNonCash_documentation_en-US" xlink:label="lab_apyx_CapitalizationOfLeaseNonCash" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalization Of Lease, Non Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_CapitalizationOfLeaseNonCash" xlink:href="apyx-20220930.xsd#apyx_CapitalizationOfLeaseNonCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_CapitalizationOfLeaseNonCash" xlink:to="lab_apyx_CapitalizationOfLeaseNonCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_e26d710a-72ed-4425-8e0c-25e789c18204_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_2f1c26ea-a983-400b-864f-fc515d650110_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-controlling Interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_ContractWithInternationalDistributorMember_daae83d0-22a0-4f29-ae14-564281a6d3c6_terseLabel_en-US" xlink:label="lab_apyx_ContractWithInternationalDistributorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with International Distributor</link:label>
    <link:label id="lab_apyx_ContractWithInternationalDistributorMember_label_en-US" xlink:label="lab_apyx_ContractWithInternationalDistributorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with International Distributor [Member]</link:label>
    <link:label id="lab_apyx_ContractWithInternationalDistributorMember_documentation_en-US" xlink:label="lab_apyx_ContractWithInternationalDistributorMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with International Distributor</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ContractWithInternationalDistributorMember" xlink:href="apyx-20220930.xsd#apyx_ContractWithInternationalDistributorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_ContractWithInternationalDistributorMember" xlink:to="lab_apyx_ContractWithInternationalDistributorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_543d1732-42e3-4183-87b4-4c4cdc4c45b2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_JointAndSeveralPayrollLiability_3601ee32-acc3-4538-b193-9b4df11d004f_terseLabel_en-US" xlink:label="lab_apyx_JointAndSeveralPayrollLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint and several payroll liability</link:label>
    <link:label id="lab_apyx_JointAndSeveralPayrollLiability_61eb33e4-8d28-44fb-8731-77495cc51b51_negatedLabel_en-US" xlink:label="lab_apyx_JointAndSeveralPayrollLiability" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint and several payroll liability</link:label>
    <link:label id="lab_apyx_JointAndSeveralPayrollLiability_label_en-US" xlink:label="lab_apyx_JointAndSeveralPayrollLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint And Several Payroll Liability</link:label>
    <link:label id="lab_apyx_JointAndSeveralPayrollLiability_documentation_en-US" xlink:label="lab_apyx_JointAndSeveralPayrollLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint And Several Payroll Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_JointAndSeveralPayrollLiability" xlink:href="apyx-20220930.xsd#apyx_JointAndSeveralPayrollLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_JointAndSeveralPayrollLiability" xlink:to="lab_apyx_JointAndSeveralPayrollLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_fa857241-4e3f-4c06-aa87-ecccfc94932b_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_ff08b237-8101-449b-967a-bc5d14a4d77a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_2bc0e1ae-0fa5-4443-9048-cf40270ac8b1_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_729f7582-0eb3-4331-ac84-fbe6160eb3c9_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_93de6e4a-eaf6-4c44-924c-d61b81f67190_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_33e79600-6e36-4dbb-bad7-14441cf46635_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_972c0ce3-fe46-42d3-b16c-2ed83053a911_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term contract liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_d7d38d96-2f69-4fc0-abd7-973b79067ab4_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-dilutive instruments excluded from diluted loss per common share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_aa5a52f4-6127-4aac-a8eb-14ae7e3c630b_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_5b705bcd-efc3-45b6-a449-26e750237d98_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_719aa900-5b43-43de-86a1-09f732804bac_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f8bd9a1a-50fc-440a-bb82-ac7763a1e65c_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective income tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_67321b2b-9c84-4172-83a3-df2586b2f5e8_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_10fdb624-46a7-4470-9f51-4c8f546a77df_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest and penalties</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_b9525e16-e5b3-4579-8a04-347c66c66d1f_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_f1db1290-2406-45bc-a2bf-81d332503693_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_5e38ba8d-9421-40af-86a7-9e76e336d4ba_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to stockholders, diluted</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_11b4bba8-abac-44c4-b3eb-798c5ef0db7e_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedInsuranceCurrent_81e2718f-29cd-47a8-aa83-661b1c5ca5c7_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedInsuranceCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued product liability claim insurance deductibles</link:label>
    <link:label id="lab_us-gaap_AccruedInsuranceCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedInsuranceCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Insurance, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedInsuranceCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedInsuranceCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedInsuranceCurrent" xlink:to="lab_us-gaap_AccruedInsuranceCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterials_4290ffc8-7ea3-4292-afc5-430ba1072d92_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterials_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterials" xlink:to="lab_us-gaap_InventoryRawMaterials" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_cb64f948-e8c0-47ab-a110-b129a3ec4b6d_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_bd5da0ec-71cd-470c-a8ec-fce53f20fa87_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on disposal of property and equipment</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CoVenturerMember_894cc6e3-ee7f-46c5-8de7-ca57aef728a1_terseLabel_en-US" xlink:label="lab_us-gaap_CoVenturerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Co-venturer</link:label>
    <link:label id="lab_us-gaap_CoVenturerMember_label_en-US" xlink:label="lab_us-gaap_CoVenturerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Co-venturer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CoVenturerMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CoVenturerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CoVenturerMember" xlink:to="lab_us-gaap_CoVenturerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_f91fc75e-4595-4979-83de-5f0e40477bab_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsAxis_329c5439-f4de-4ddb-b875-14524fab88c0_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:label id="lab_srt_ConsolidationItemsAxis_label_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_7dd537ce-68e7-4fdd-9885-83d253e8f039_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_bc240099-3a1c-40cc-85b4-aeed09e17313_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_NoncontrollingInterestTableTextBlock_209c1fd7-5eec-4c44-8370-461c37d72ee0_terseLabel_en-US" xlink:label="lab_apyx_NoncontrollingInterestTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of China Joint Venture</link:label>
    <link:label id="lab_apyx_NoncontrollingInterestTableTextBlock_label_en-US" xlink:label="lab_apyx_NoncontrollingInterestTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Table Text Block]</link:label>
    <link:label id="lab_apyx_NoncontrollingInterestTableTextBlock_documentation_en-US" xlink:label="lab_apyx_NoncontrollingInterestTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_NoncontrollingInterestTableTextBlock" xlink:href="apyx-20220930.xsd#apyx_NoncontrollingInterestTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_NoncontrollingInterestTableTextBlock" xlink:to="lab_apyx_NoncontrollingInterestTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_7e841b8f-24ca-4488-bf91-d686771967a8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INCOME TAXES</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_6503165b-2c4c-47ff-a196-ce7f9d711038_terseLabel_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to related parties</link:label>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_126e29f6-0f2e-454d-a574-62f5500e3ed4_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_AdvancedEnergyMember_9fc0fd12-87d4-40f0-b938-0caa89a8f86b_terseLabel_en-US" xlink:label="lab_apyx_AdvancedEnergyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advanced Energy</link:label>
    <link:label id="lab_apyx_AdvancedEnergyMember_label_en-US" xlink:label="lab_apyx_AdvancedEnergyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advanced Energy [Member]</link:label>
    <link:label id="lab_apyx_AdvancedEnergyMember_documentation_en-US" xlink:label="lab_apyx_AdvancedEnergyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advanced Energy [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_AdvancedEnergyMember" xlink:href="apyx-20220930.xsd#apyx_AdvancedEnergyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_AdvancedEnergyMember" xlink:to="lab_apyx_AdvancedEnergyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_d611b197-c337-425b-9d3a-481a395903fe_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_9c8321c6-f964-4960-ac88-52cfd785e961_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_154d3f4e-a2df-42c0-b933-3bbf4f985a92_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DISPOSAL OF BUSINESS</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_a9b61cef-053a-423b-99ae-192277eb1f12_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Uncertain tax positions that would impact effective tax rate</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_5ef8f986-c5a9-4fd3-9844-5b5cf00dd913_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_SuitAgainstGoodwinAndSimbMember_9a23cc81-4f6c-41c2-91c8-1a4dff17daeb_terseLabel_en-US" xlink:label="lab_apyx_SuitAgainstGoodwinAndSimbMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Suit Against Goodwin and Simb</link:label>
    <link:label id="lab_apyx_SuitAgainstGoodwinAndSimbMember_label_en-US" xlink:label="lab_apyx_SuitAgainstGoodwinAndSimbMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Suit against Goodwin and Simb [Member]</link:label>
    <link:label id="lab_apyx_SuitAgainstGoodwinAndSimbMember_documentation_en-US" xlink:label="lab_apyx_SuitAgainstGoodwinAndSimbMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Suit against Goodwin and Simb</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SuitAgainstGoodwinAndSimbMember" xlink:href="apyx-20220930.xsd#apyx_SuitAgainstGoodwinAndSimbMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_SuitAgainstGoodwinAndSimbMember" xlink:to="lab_apyx_SuitAgainstGoodwinAndSimbMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_f416fd3f-e884-4254-8b8d-2b935e8d95fb_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate &amp; Other</link:label>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_label_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate, Non-Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateNonSegmentMember" xlink:to="lab_us-gaap_CorporateNonSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_77239dd3-cfe9-441c-9779-6f5c047bc350_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities of Operating Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_NoncontrollingInterestRequiredCapitalContribution_c1788a41-d33f-43a2-a148-9b0a49bdc5f0_terseLabel_en-US" xlink:label="lab_apyx_NoncontrollingInterestRequiredCapitalContribution" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Required capital contribution</link:label>
    <link:label id="lab_apyx_NoncontrollingInterestRequiredCapitalContribution_label_en-US" xlink:label="lab_apyx_NoncontrollingInterestRequiredCapitalContribution" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Required Capital Contribution</link:label>
    <link:label id="lab_apyx_NoncontrollingInterestRequiredCapitalContribution_documentation_en-US" xlink:label="lab_apyx_NoncontrollingInterestRequiredCapitalContribution" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Required Capital Contribution</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_NoncontrollingInterestRequiredCapitalContribution" xlink:href="apyx-20220930.xsd#apyx_NoncontrollingInterestRequiredCapitalContribution"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_NoncontrollingInterestRequiredCapitalContribution" xlink:to="lab_apyx_NoncontrollingInterestRequiredCapitalContribution" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_a660d201-1ff0-43e5-acfb-5f28dfc3cf93_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_ee3d902e-1a36-4017-a12f-edbe738d0602_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_3a08220e-89b4-4ebd-a766-8225ea826663_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_8e43fba9-f3a5-4dd6-bea3-fdd7dd2b73c7_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_5e3b7624-ac8d-416e-8671-048b47a8ed92_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets and finance lease liabilities derecognized upon execution of lease modification</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Finance Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_05214587-dc38-46df-9405-8b149f5504f0_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_9a252ffe-91c8-4488-ba58-3e1c2941de25_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_FinanceLeaseCostsAbstract_86d25ef1-9f9b-4ac6-b7fd-4f0e26d9bc6d_terseLabel_en-US" xlink:label="lab_apyx_FinanceLeaseCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance</link:label>
    <link:label id="lab_apyx_FinanceLeaseCostsAbstract_label_en-US" xlink:label="lab_apyx_FinanceLeaseCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Costs [Abstract]</link:label>
    <link:label id="lab_apyx_FinanceLeaseCostsAbstract_documentation_en-US" xlink:label="lab_apyx_FinanceLeaseCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Costs [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_FinanceLeaseCostsAbstract" xlink:href="apyx-20220930.xsd#apyx_FinanceLeaseCostsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_FinanceLeaseCostsAbstract" xlink:to="lab_apyx_FinanceLeaseCostsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_008e788a-a699-4ab6-8368-859d8504d0fa_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_1f90945e-ce89-41cc-87a9-d0b8137bb210_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestLineItems_edca071a-6d50-4419-9254-4d548d125bd2_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Line Items]</link:label>
    <link:label id="lab_us-gaap_MinorityInterestLineItems_label_en-US" xlink:label="lab_us-gaap_MinorityInterestLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestLineItems" xlink:to="lab_us-gaap_MinorityInterestLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_455103ee-9a71-4097-a5b1-84f155438344_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryValuationReserves_03079f6e-0b47-4d2e-9417-e978453a695e_negatedLabel_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: provision for obsolescence</link:label>
    <link:label id="lab_us-gaap_InventoryValuationReserves_label_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Valuation Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryValuationReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryValuationReserves" xlink:to="lab_us-gaap_InventoryValuationReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_1cb54c59-8e41-4c64-8c47-b9dc5d7d847d_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVENTORIES</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_83a1926a-b6bb-41fe-9648-10c9d874ef07_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_0ad4c104-8f31-4773-938d-b04b662f9343_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_7946a595-97d5-4c20-9aa1-c53f41d9f8cc_terseLabel_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherReceivablesNetCurrent" xlink:to="lab_us-gaap_OtherReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_29ebff0a-5fdf-4e78-939b-0481d70e14da_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_fa4b07c2-db09-4199-8d8f-9975b8349ce6_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_0730da4b-bbb7-4b60-beea-91220ada586f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived_6f9e36d9-20d8-4bbf-b1cb-94aa4049d5d6_terseLabel_en-US" xlink:label="lab_apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock swaps equity instruments received (in shares)</link:label>
    <link:label id="lab_apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived_label_en-US" xlink:label="lab_apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Stock Swaps Equity Instruments Received</link:label>
    <link:label id="lab_apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived_documentation_en-US" xlink:label="lab_apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Stock Swaps Equity Instruments Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived" xlink:href="apyx-20220930.xsd#apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived" xlink:to="lab_apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_8693b8c5-aad8-4c93-b185-c2d9fda3fe5e_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_583cf12d-6b20-4da7-b3d8-aa0d1bb7bdb9_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Costs</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_bae08bb7-d53f-44af-b6b9-f1bd4ed6f53a_terseLabel_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassifications</link:label>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_label_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification, Comparability Adjustment [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_083ebfb3-a832-45b9-bc57-f06ffa27864f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent_b2381a0e-1fea-48bd-b85e-646b61f7dc17_terseLabel_en-US" xlink:label="lab_apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent_c09c8351-3592-4d17-ae7f-23e087c58880_totalLabel_en-US" xlink:label="lab_apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued expenses and other current liabilities</link:label>
    <link:label id="lab_apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent_label_en-US" xlink:label="lab_apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities and Other Liabilities, Current</link:label>
    <link:label id="lab_apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent_documentation_en-US" xlink:label="lab_apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities and Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:href="apyx-20220930.xsd#apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:to="lab_apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_db2a09c7-8ade-4640-96ff-8cc1f3fba872_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, extension</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_f2d99d2f-83a4-4ea1-8e2f-7231150e0ce3_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_ShortTermContractLiabilities_b7c768c7-2a66-41e3-9ade-3d82147d776e_terseLabel_en-US" xlink:label="lab_apyx_ShortTermContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term contract liabilities</link:label>
    <link:label id="lab_apyx_ShortTermContractLiabilities_label_en-US" xlink:label="lab_apyx_ShortTermContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Contract Liabilities</link:label>
    <link:label id="lab_apyx_ShortTermContractLiabilities_documentation_en-US" xlink:label="lab_apyx_ShortTermContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Contract Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ShortTermContractLiabilities" xlink:href="apyx-20220930.xsd#apyx_ShortTermContractLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_ShortTermContractLiabilities" xlink:to="lab_apyx_ShortTermContractLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_b9e811f2-83ad-41f3-a585-b7d27cc48da5_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_302ed8d1-d5c8-412c-80f5-62eb18e3321e_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_6c4a5862-9b16-4965-bd68-b4f49d6d4a4d_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and penalties included in income tax expense</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_cef60da8-9177-4b50-aef7-ee379382226b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_d4a3e91c-1257-426c-b1e0-7b3b11fe4d32_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term portion of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_0d553d97-4622-4813-83d2-38038fa05801_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_ChineseSupplierMember_865fbfd2-2dff-4fe0-a576-f7861c241486_terseLabel_en-US" xlink:label="lab_apyx_ChineseSupplierMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chinese Supplier</link:label>
    <link:label id="lab_apyx_ChineseSupplierMember_label_en-US" xlink:label="lab_apyx_ChineseSupplierMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chinese Supplier [Member]</link:label>
    <link:label id="lab_apyx_ChineseSupplierMember_documentation_en-US" xlink:label="lab_apyx_ChineseSupplierMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chinese Supplier</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ChineseSupplierMember" xlink:href="apyx-20220930.xsd#apyx_ChineseSupplierMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_ChineseSupplierMember" xlink:to="lab_apyx_ChineseSupplierMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_dc4c0ab8-7e70-4deb-9ab7-3eb957b22de7_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_a49a598b-129e-42aa-bed3-ba4a59990a81_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_4214f30c-685d-4250-8594-ce8d99766f36_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_2d819814-bd7a-4efa-922d-9a8e50e923fa_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade accounts receivable, net of allowance of $634 and $430</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_f12b9676-c135-4aee-a17d-409155b95835_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_3667bd29-1181-40c0-aedc-88b2e662a990_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_b399c87f-0e38-4628-9529-6895c0fe4c76_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMinorityShareholders_eaa1a757-c25e-446d-8189-b394ebc9f9c2_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMinorityShareholders" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contributions from non-controlling interests</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMinorityShareholders_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMinorityShareholders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Noncontrolling Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMinorityShareholders" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMinorityShareholders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMinorityShareholders" xlink:to="lab_us-gaap_ProceedsFromMinorityShareholders" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_20ae8978-dfb7-4f4d-859d-2f71cae63568_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_4d850f70-d0e0-48cc-9272-c8509019e7d1_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RELATED PARTY TRANSACTIONS</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_FinanceLeaseLiabilityToBePaidDueAfterYearFour_489ebdf1-542f-4fe7-ab50-ed900122307a_terseLabel_en-US" xlink:label="lab_apyx_FinanceLeaseLiabilityToBePaidDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_apyx_FinanceLeaseLiabilityToBePaidDueAfterYearFour_label_en-US" xlink:label="lab_apyx_FinanceLeaseLiabilityToBePaidDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, liability, To Be Paid, Due After Year Four</link:label>
    <link:label id="lab_apyx_FinanceLeaseLiabilityToBePaidDueAfterYearFour_documentation_en-US" xlink:label="lab_apyx_FinanceLeaseLiabilityToBePaidDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, liability, To Be Paid, Due After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_FinanceLeaseLiabilityToBePaidDueAfterYearFour" xlink:href="apyx-20220930.xsd#apyx_FinanceLeaseLiabilityToBePaidDueAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_FinanceLeaseLiabilityToBePaidDueAfterYearFour" xlink:to="lab_apyx_FinanceLeaseLiabilityToBePaidDueAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_fd27a1ec-e68e-4c3c-8224-ee2639097f66_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5db99bf6-9d74-444a-8dc1-121e7c09cdd3_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_974824c2-a0ed-4aa8-9d40-046d1bd95409_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_620132a9-b397-47fd-9048-aaee8e155dce_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued professional fees and legal related contingent liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_85d51297-0a74-4dfc-9b20-4fac85383289_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_bf3c0087-d06b-4976-b06e-2824c18fde9c_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MovementInMinorityInterestRollForward_5173f8b6-1987-45fd-a8e8-2e078f10b0db_terseLabel_en-US" xlink:label="lab_us-gaap_MovementInMinorityInterestRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_MovementInMinorityInterestRollForward_label_en-US" xlink:label="lab_us-gaap_MovementInMinorityInterestRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInMinorityInterestRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MovementInMinorityInterestRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward" xlink:to="lab_us-gaap_MovementInMinorityInterestRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligation_e59f784d-7080-4db2-8e55-3d1c8020aa81_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase obligation</link:label>
    <link:label id="lab_us-gaap_PurchaseObligation_label_en-US" xlink:label="lab_us-gaap_PurchaseObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligation" xlink:to="lab_us-gaap_PurchaseObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_07fdb29a-037e-4331-b1fa-6db4e7385e7b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_631e61d3-5e2f-4794-91cf-0a3565711fa5_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_SymmetrySurgicalInc.Member_2723b09b-7a59-449c-8382-9235dfeb0ca9_terseLabel_en-US" xlink:label="lab_apyx_SymmetrySurgicalInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Symmetry Surgical Inc.</link:label>
    <link:label id="lab_apyx_SymmetrySurgicalInc.Member_label_en-US" xlink:label="lab_apyx_SymmetrySurgicalInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Symmetry Surgical Inc. [Member]</link:label>
    <link:label id="lab_apyx_SymmetrySurgicalInc.Member_documentation_en-US" xlink:label="lab_apyx_SymmetrySurgicalInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Symmetry Surgical Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SymmetrySurgicalInc.Member" xlink:href="apyx-20220930.xsd#apyx_SymmetrySurgicalInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_SymmetrySurgicalInc.Member" xlink:to="lab_apyx_SymmetrySurgicalInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_82295601-44d0-43d7-bafa-d9f0393c62ab_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RECENT ACCOUNTING PRONOUNCEMENTS</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_244eaab5-3f42-4f8b-8380-3470f0cd032e_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1de0a955-c07c-4693-a220-4ea2e79534f1_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_94974cff-c600-427b-b90b-d09a3a2434df_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_4c194d9f-60c0-4fdb-9635-342f8b28c28a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_4576395b-441d-4b75-bccd-09cc57c6d362_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less imputed interest</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalariesAndWages_d6ab42c6-1e95-47fd-a76a-26d7625c892a_terseLabel_en-US" xlink:label="lab_us-gaap_SalariesAndWages" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salaries and related costs</link:label>
    <link:label id="lab_us-gaap_SalariesAndWages_label_en-US" xlink:label="lab_us-gaap_SalariesAndWages" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salary and Wage, NonOfficer, Excluding Cost of Good and Service Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalariesAndWages" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalariesAndWages"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalariesAndWages" xlink:to="lab_us-gaap_SalariesAndWages" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_c664250e-66f4-4298-9f81-d8f3753fb0e0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_ProvisionForInventoryObsolescence_027dcfc6-bcc6-4549-ac12-0aad84c3e036_terseLabel_en-US" xlink:label="lab_apyx_ProvisionForInventoryObsolescence" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for inventory obsolescence</link:label>
    <link:label id="lab_apyx_ProvisionForInventoryObsolescence_label_en-US" xlink:label="lab_apyx_ProvisionForInventoryObsolescence" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision For Inventory Obsolescence</link:label>
    <link:label id="lab_apyx_ProvisionForInventoryObsolescence_documentation_en-US" xlink:label="lab_apyx_ProvisionForInventoryObsolescence" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision For Inventory Obsolescence</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ProvisionForInventoryObsolescence" xlink:href="apyx-20220930.xsd#apyx_ProvisionForInventoryObsolescence"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_ProvisionForInventoryObsolescence" xlink:to="lab_apyx_ProvisionForInventoryObsolescence" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_8756a26a-be61-4338-9113-afa488940b5f_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_ac4ca50b-a9a8-4f40-8c38-5c590a8f34a0_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_9ed6584f-8173-49d9-beac-70e64e7ed33e_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_00157860-e399-49df-936c-0b51482b8666_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of stock options and stock awards</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_c6bb69fa-776f-4869-8746-2bdecd654611_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_d0395f29-9402-4473-94e9-33ba50a92150_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_d1260a3c-c0d0-4e7c-af53-1c1d84e80e01_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_13197b30-c2ac-4ee2-b2c9-ca0069b31c26_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_0ca0d68e-f4a3-4016-a015-bc70249d577b_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_0c2bea4d-e197-4303-a7b8-6ac64fd6c8ce_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and diluted earnings (loss) per share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_050b80e0-3c64-48f0-b498-efde4d2d5833_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_2af12b3b-93ad-43cb-9d13-d6f1168dd3c9_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryGross_1949e6ad-4689-43e9-8aa9-dfdbf76a58b7_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross inventories</link:label>
    <link:label id="lab_us-gaap_InventoryGross_label_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryGross" xlink:to="lab_us-gaap_InventoryGross" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>apyx-20220930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:90964edb-9ed2-4911-9f65-50e8b3fbc396,g:6dc5a8ef-7d14-451f-bd94-08d276b52e31-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://apyxmedical.com/role/Cover" xlink:type="simple" xlink:href="apyx-20220930.xsd#Cover"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_6ecd937f-8c24-4b76-ba18-4fbfcfab80aa" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_8a4e710e-9b37-42d6-9524-5674ccfb7958" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6ecd937f-8c24-4b76-ba18-4fbfcfab80aa" xlink:to="loc_dei_DocumentType_8a4e710e-9b37-42d6-9524-5674ccfb7958" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_ba5ac0f9-dfa1-4def-9403-8f01471eab4b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6ecd937f-8c24-4b76-ba18-4fbfcfab80aa" xlink:to="loc_dei_DocumentQuarterlyReport_ba5ac0f9-dfa1-4def-9403-8f01471eab4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_d2d77c1f-a0e8-4c35-acc2-53d1e64ba6ae" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6ecd937f-8c24-4b76-ba18-4fbfcfab80aa" xlink:to="loc_dei_DocumentPeriodEndDate_d2d77c1f-a0e8-4c35-acc2-53d1e64ba6ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_9d82d0bf-bf85-413f-a4d6-e5fc017e7ef8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6ecd937f-8c24-4b76-ba18-4fbfcfab80aa" xlink:to="loc_dei_DocumentTransitionReport_9d82d0bf-bf85-413f-a4d6-e5fc017e7ef8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_7df21e05-f6a3-4b39-9172-ee9afe3838e8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6ecd937f-8c24-4b76-ba18-4fbfcfab80aa" xlink:to="loc_dei_EntityFileNumber_7df21e05-f6a3-4b39-9172-ee9afe3838e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_20ecf56f-3f8f-410f-ab70-cec1a51d0128" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6ecd937f-8c24-4b76-ba18-4fbfcfab80aa" xlink:to="loc_dei_EntityRegistrantName_20ecf56f-3f8f-410f-ab70-cec1a51d0128" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_552830fa-1c44-454d-afb3-9dacac9daee3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6ecd937f-8c24-4b76-ba18-4fbfcfab80aa" xlink:to="loc_dei_EntityIncorporationStateCountryCode_552830fa-1c44-454d-afb3-9dacac9daee3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_31e6d448-e2a5-456b-bc7e-56358d3ce623" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6ecd937f-8c24-4b76-ba18-4fbfcfab80aa" xlink:to="loc_dei_EntityTaxIdentificationNumber_31e6d448-e2a5-456b-bc7e-56358d3ce623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_21f5ec50-b59f-4288-8da2-aab9fd6643f9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6ecd937f-8c24-4b76-ba18-4fbfcfab80aa" xlink:to="loc_dei_EntityAddressAddressLine1_21f5ec50-b59f-4288-8da2-aab9fd6643f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_95d4eb1d-c01b-4d81-8c41-8dfb7d8569ec" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6ecd937f-8c24-4b76-ba18-4fbfcfab80aa" xlink:to="loc_dei_EntityAddressCityOrTown_95d4eb1d-c01b-4d81-8c41-8dfb7d8569ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_5039c9cf-de71-4482-993a-31c07ffdee3b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6ecd937f-8c24-4b76-ba18-4fbfcfab80aa" xlink:to="loc_dei_EntityAddressStateOrProvince_5039c9cf-de71-4482-993a-31c07ffdee3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_f6abc928-a2ad-47aa-8149-4b1508926453" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6ecd937f-8c24-4b76-ba18-4fbfcfab80aa" xlink:to="loc_dei_EntityAddressPostalZipCode_f6abc928-a2ad-47aa-8149-4b1508926453" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_545197d8-1928-4c0d-8a10-c94543fcb74b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6ecd937f-8c24-4b76-ba18-4fbfcfab80aa" xlink:to="loc_dei_CityAreaCode_545197d8-1928-4c0d-8a10-c94543fcb74b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_4acf838b-0c1d-47c5-af60-adf599c749a9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6ecd937f-8c24-4b76-ba18-4fbfcfab80aa" xlink:to="loc_dei_LocalPhoneNumber_4acf838b-0c1d-47c5-af60-adf599c749a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_84e2e211-eb4e-454c-a5ff-487dfe8b4b9c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6ecd937f-8c24-4b76-ba18-4fbfcfab80aa" xlink:to="loc_dei_Security12bTitle_84e2e211-eb4e-454c-a5ff-487dfe8b4b9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_1dee7370-aa46-4b62-8bfa-86be0953e61f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6ecd937f-8c24-4b76-ba18-4fbfcfab80aa" xlink:to="loc_dei_TradingSymbol_1dee7370-aa46-4b62-8bfa-86be0953e61f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_a599083d-b793-4bb4-abd3-939817d94d27" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6ecd937f-8c24-4b76-ba18-4fbfcfab80aa" xlink:to="loc_dei_SecurityExchangeName_a599083d-b793-4bb4-abd3-939817d94d27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_104544ec-24c4-4869-b379-f43c31051d65" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6ecd937f-8c24-4b76-ba18-4fbfcfab80aa" xlink:to="loc_dei_EntityCurrentReportingStatus_104544ec-24c4-4869-b379-f43c31051d65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_60d1ecb6-5e06-4881-9f90-698f22dc392f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6ecd937f-8c24-4b76-ba18-4fbfcfab80aa" xlink:to="loc_dei_EntityInteractiveDataCurrent_60d1ecb6-5e06-4881-9f90-698f22dc392f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_4629284e-65b3-4741-a44f-3cfcba3b770d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6ecd937f-8c24-4b76-ba18-4fbfcfab80aa" xlink:to="loc_dei_EntityFilerCategory_4629284e-65b3-4741-a44f-3cfcba3b770d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_9e847774-b4fb-4af4-883f-b4c2400cb859" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6ecd937f-8c24-4b76-ba18-4fbfcfab80aa" xlink:to="loc_dei_EntitySmallBusiness_9e847774-b4fb-4af4-883f-b4c2400cb859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_db9ca612-5f5b-4c24-86e3-1770f3be63ae" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6ecd937f-8c24-4b76-ba18-4fbfcfab80aa" xlink:to="loc_dei_EntityEmergingGrowthCompany_db9ca612-5f5b-4c24-86e3-1770f3be63ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_f77fc600-7813-4e6d-b708-fbdc05c4ee3e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6ecd937f-8c24-4b76-ba18-4fbfcfab80aa" xlink:to="loc_dei_EntityShellCompany_f77fc600-7813-4e6d-b708-fbdc05c4ee3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_78a35027-2c9b-454a-8e18-5c8bdbdbe3e2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6ecd937f-8c24-4b76-ba18-4fbfcfab80aa" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_78a35027-2c9b-454a-8e18-5c8bdbdbe3e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_adcd42c8-861c-4cd4-bb6b-33159cbf1117" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6ecd937f-8c24-4b76-ba18-4fbfcfab80aa" xlink:to="loc_dei_EntityCentralIndexKey_adcd42c8-861c-4cd4-bb6b-33159cbf1117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_ca965618-b347-45ea-8ec5-d768138775d6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6ecd937f-8c24-4b76-ba18-4fbfcfab80aa" xlink:to="loc_dei_AmendmentFlag_ca965618-b347-45ea-8ec5-d768138775d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_62c8649a-e2aa-42a4-bf00-2575da37de18" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6ecd937f-8c24-4b76-ba18-4fbfcfab80aa" xlink:to="loc_dei_CurrentFiscalYearEndDate_62c8649a-e2aa-42a4-bf00-2575da37de18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_5bb6f9a0-9294-4328-b346-28b9bbbb8d5a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6ecd937f-8c24-4b76-ba18-4fbfcfab80aa" xlink:to="loc_dei_DocumentFiscalPeriodFocus_5bb6f9a0-9294-4328-b346-28b9bbbb8d5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_8a9aa18f-7314-4c9e-b296-38cc7fcdff9e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6ecd937f-8c24-4b76-ba18-4fbfcfab80aa" xlink:to="loc_dei_DocumentFiscalYearFocus_8a9aa18f-7314-4c9e-b296-38cc7fcdff9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="apyx-20220930.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_041208c0-7da5-4874-adbf-60ba4ef93097" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_f3892183-d4ce-4c9f-b34b-c115ccd917eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_041208c0-7da5-4874-adbf-60ba4ef93097" xlink:to="loc_us-gaap_AssetsAbstract_f3892183-d4ce-4c9f-b34b-c115ccd917eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_15d5d08e-70bb-4f0e-9812-280e5f7b9afe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f3892183-d4ce-4c9f-b34b-c115ccd917eb" xlink:to="loc_us-gaap_AssetsCurrentAbstract_15d5d08e-70bb-4f0e-9812-280e5f7b9afe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_617c7f13-1a2e-411b-8a74-78f5bb4802b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_15d5d08e-70bb-4f0e-9812-280e5f7b9afe" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_617c7f13-1a2e-411b-8a74-78f5bb4802b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_deb6062c-9ce8-4a7c-9f14-c79a044edbf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_15d5d08e-70bb-4f0e-9812-280e5f7b9afe" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_deb6062c-9ce8-4a7c-9f14-c79a044edbf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable_b64bee64-57e3-458a-96f1-f14aa2eb46b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_15d5d08e-70bb-4f0e-9812-280e5f7b9afe" xlink:to="loc_us-gaap_IncomeTaxesReceivable_b64bee64-57e3-458a-96f1-f14aa2eb46b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_0a1ac01a-7a89-4c6f-8d39-2f3c526fc0d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_15d5d08e-70bb-4f0e-9812-280e5f7b9afe" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_0a1ac01a-7a89-4c6f-8d39-2f3c526fc0d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_e8ff5794-8623-43ef-bc24-c7ab730b8ff0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_15d5d08e-70bb-4f0e-9812-280e5f7b9afe" xlink:to="loc_us-gaap_InventoryNet_e8ff5794-8623-43ef-bc24-c7ab730b8ff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_b80d5de7-450a-48e4-ba01-2d7176f7b235" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_15d5d08e-70bb-4f0e-9812-280e5f7b9afe" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_b80d5de7-450a-48e4-ba01-2d7176f7b235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_36220fa1-12b8-4f84-9384-a4f238a5de8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_15d5d08e-70bb-4f0e-9812-280e5f7b9afe" xlink:to="loc_us-gaap_AssetsCurrent_36220fa1-12b8-4f84-9384-a4f238a5de8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_d8c171de-267c-4817-a929-e52b27837822" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f3892183-d4ce-4c9f-b34b-c115ccd917eb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_d8c171de-267c-4817-a929-e52b27837822" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_7b97c7ed-8a5f-4c09-8835-11634921e2b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f3892183-d4ce-4c9f-b34b-c115ccd917eb" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_7b97c7ed-8a5f-4c09-8835-11634921e2b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_af316e80-f0a6-4363-9ce8-408349522310" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f3892183-d4ce-4c9f-b34b-c115ccd917eb" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_af316e80-f0a6-4363-9ce8-408349522310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_eb9b4fef-6211-4c5a-9757-8d6169f64ce0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f3892183-d4ce-4c9f-b34b-c115ccd917eb" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_eb9b4fef-6211-4c5a-9757-8d6169f64ce0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_2086f75f-698e-4408-a144-74bc93a0d96e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f3892183-d4ce-4c9f-b34b-c115ccd917eb" xlink:to="loc_us-gaap_Assets_2086f75f-698e-4408-a144-74bc93a0d96e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_fa5df4fc-eeef-40e4-b8e0-93c454fbb3a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_041208c0-7da5-4874-adbf-60ba4ef93097" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_fa5df4fc-eeef-40e4-b8e0-93c454fbb3a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_c0dcb2e1-afa6-4706-9300-e1c68a94cb87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_fa5df4fc-eeef-40e4-b8e0-93c454fbb3a3" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_c0dcb2e1-afa6-4706-9300-e1c68a94cb87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_0b6a9719-fa05-46d5-8e48-5dd74ee0ff4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c0dcb2e1-afa6-4706-9300-e1c68a94cb87" xlink:to="loc_us-gaap_AccountsPayableCurrent_0b6a9719-fa05-46d5-8e48-5dd74ee0ff4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent_45ef62ba-445c-4073-a480-ea6e01a0789a" xlink:href="apyx-20220930.xsd#apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c0dcb2e1-afa6-4706-9300-e1c68a94cb87" xlink:to="loc_apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent_45ef62ba-445c-4073-a480-ea6e01a0789a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_b897b9c3-e779-4a9f-abdc-fdf91f6a3f67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c0dcb2e1-afa6-4706-9300-e1c68a94cb87" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_b897b9c3-e779-4a9f-abdc-fdf91f6a3f67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_fb6cdf42-1ef1-4f71-8002-e31989a1e77c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c0dcb2e1-afa6-4706-9300-e1c68a94cb87" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_fb6cdf42-1ef1-4f71-8002-e31989a1e77c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_96b182ee-1b40-4fd4-8250-3d2fb8e6c6c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c0dcb2e1-afa6-4706-9300-e1c68a94cb87" xlink:to="loc_us-gaap_LiabilitiesCurrent_96b182ee-1b40-4fd4-8250-3d2fb8e6c6c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b47f4d0d-c9e1-49d9-aeb0-ba13a7c35fc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_fa5df4fc-eeef-40e4-b8e0-93c454fbb3a3" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b47f4d0d-c9e1-49d9-aeb0-ba13a7c35fc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_bce8a751-0906-4ba6-b659-218fb1f9226f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_fa5df4fc-eeef-40e4-b8e0-93c454fbb3a3" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_bce8a751-0906-4ba6-b659-218fb1f9226f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_06189e33-a501-478e-9622-30032069aa3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_fa5df4fc-eeef-40e4-b8e0-93c454fbb3a3" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_06189e33-a501-478e-9622-30032069aa3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_a11290ff-b758-4135-9ce0-f0a87ca2d514" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_fa5df4fc-eeef-40e4-b8e0-93c454fbb3a3" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_a11290ff-b758-4135-9ce0-f0a87ca2d514" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_b271b083-2fcc-4153-b6b4-b84b00302889" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_fa5df4fc-eeef-40e4-b8e0-93c454fbb3a3" xlink:to="loc_us-gaap_Liabilities_b271b083-2fcc-4153-b6b4-b84b00302889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_36168582-d01f-498f-b62d-75bb6dabf451" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_fa5df4fc-eeef-40e4-b8e0-93c454fbb3a3" xlink:to="loc_us-gaap_StockholdersEquityAbstract_36168582-d01f-498f-b62d-75bb6dabf451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_35769529-5cd9-4401-a373-e45f35f62cc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_36168582-d01f-498f-b62d-75bb6dabf451" xlink:to="loc_us-gaap_CommonStockValue_35769529-5cd9-4401-a373-e45f35f62cc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_31b2684e-ff7c-44a2-a419-58109df36e58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_36168582-d01f-498f-b62d-75bb6dabf451" xlink:to="loc_us-gaap_AdditionalPaidInCapital_31b2684e-ff7c-44a2-a419-58109df36e58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e7664034-c294-44da-b0a1-9d1c73c5a3a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_36168582-d01f-498f-b62d-75bb6dabf451" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e7664034-c294-44da-b0a1-9d1c73c5a3a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b39408c4-9995-4a9d-b672-075f18a0d3a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_36168582-d01f-498f-b62d-75bb6dabf451" xlink:to="loc_us-gaap_StockholdersEquity_b39408c4-9995-4a9d-b672-075f18a0d3a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_1debcbee-d116-4b7e-9c10-3cb1e644f6d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_36168582-d01f-498f-b62d-75bb6dabf451" xlink:to="loc_us-gaap_MinorityInterest_1debcbee-d116-4b7e-9c10-3cb1e644f6d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_de8e1fde-b2f7-472c-a82a-fbdb632c9060" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_36168582-d01f-498f-b62d-75bb6dabf451" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_de8e1fde-b2f7-472c-a82a-fbdb632c9060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_ed03593f-9d88-47ae-9384-75178cef860c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_fa5df4fc-eeef-40e4-b8e0-93c454fbb3a3" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_ed03593f-9d88-47ae-9384-75178cef860c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="apyx-20220930.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_2d5eee1e-9500-4a9e-aebf-091f568181f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_beb61059-a968-41c9-8019-0bfd11cf92f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2d5eee1e-9500-4a9e-aebf-091f568181f7" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_beb61059-a968-41c9-8019-0bfd11cf92f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ProvisionForObsolescenceInventory_b9c6ddb0-57f0-4ff6-9311-f20ae924df6c" xlink:href="apyx-20220930.xsd#apyx_ProvisionForObsolescenceInventory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2d5eee1e-9500-4a9e-aebf-091f568181f7" xlink:to="loc_apyx_ProvisionForObsolescenceInventory_b9c6ddb0-57f0-4ff6-9311-f20ae924df6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1650998e-4497-4bb7-abc9-550de2e7e171" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2d5eee1e-9500-4a9e-aebf-091f568181f7" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1650998e-4497-4bb7-abc9-550de2e7e171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_e1acd988-32c6-4e2e-a13f-3f9669f592ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2d5eee1e-9500-4a9e-aebf-091f568181f7" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_e1acd988-32c6-4e2e-a13f-3f9669f592ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_6f5c02d0-f731-40e4-86e4-b1371d0c7b65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2d5eee1e-9500-4a9e-aebf-091f568181f7" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_6f5c02d0-f731-40e4-86e4-b1371d0c7b65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_e966bd9e-227a-4213-85d0-5506669178c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2d5eee1e-9500-4a9e-aebf-091f568181f7" xlink:to="loc_us-gaap_CommonStockSharesIssued_e966bd9e-227a-4213-85d0-5506669178c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_ec024c04-a633-4eb9-8677-818c44acf7b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2d5eee1e-9500-4a9e-aebf-091f568181f7" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_ec024c04-a633-4eb9-8677-818c44acf7b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="apyx-20220930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_d7327d69-519a-4dda-b42d-5e32d6c301b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f539297c-a9de-46bb-ac82-47b9295616b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d7327d69-519a-4dda-b42d-5e32d6c301b1" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f539297c-a9de-46bb-ac82-47b9295616b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_39a3b604-ee9b-414b-99c4-0fd9816e729c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d7327d69-519a-4dda-b42d-5e32d6c301b1" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_39a3b604-ee9b-414b-99c4-0fd9816e729c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_1379a7a2-dc5b-4d25-86af-fce0263d3cea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d7327d69-519a-4dda-b42d-5e32d6c301b1" xlink:to="loc_us-gaap_GrossProfit_1379a7a2-dc5b-4d25-86af-fce0263d3cea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_5529f494-379b-430c-8a8f-bda77885d002" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d7327d69-519a-4dda-b42d-5e32d6c301b1" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_5529f494-379b-430c-8a8f-bda77885d002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_5937af1b-636d-4036-ad24-e937bbeadf28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_5529f494-379b-430c-8a8f-bda77885d002" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_5937af1b-636d-4036-ad24-e937bbeadf28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfessionalFees_82e56ff0-9e9e-4c4b-ae47-8f104a62f448" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfessionalFees"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_5529f494-379b-430c-8a8f-bda77885d002" xlink:to="loc_us-gaap_ProfessionalFees_82e56ff0-9e9e-4c4b-ae47-8f104a62f448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalariesAndWages_4a4edc06-a8f6-4db5-984f-8030514c3f25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalariesAndWages"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_5529f494-379b-430c-8a8f-bda77885d002" xlink:to="loc_us-gaap_SalariesAndWages_4a4edc06-a8f6-4db5-984f-8030514c3f25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_75a42be2-6289-4a59-889e-1da6ed9b713f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_5529f494-379b-430c-8a8f-bda77885d002" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_75a42be2-6289-4a59-889e-1da6ed9b713f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_63f7fae4-8cc3-4c7f-9e13-88b14a5d959e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_5529f494-379b-430c-8a8f-bda77885d002" xlink:to="loc_us-gaap_OperatingExpenses_63f7fae4-8cc3-4c7f-9e13-88b14a5d959e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_e2024029-0a32-42bd-b8cb-2a66433e010a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d7327d69-519a-4dda-b42d-5e32d6c301b1" xlink:to="loc_us-gaap_OperatingIncomeLoss_e2024029-0a32-42bd-b8cb-2a66433e010a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOperating_808d63c6-153e-49ae-a634-74e9a8246f91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeOperating"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d7327d69-519a-4dda-b42d-5e32d6c301b1" xlink:to="loc_us-gaap_InterestIncomeOperating_808d63c6-153e-49ae-a634-74e9a8246f91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_b4df5d6d-1f57-4ad2-a9b5-142a185a8969" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d7327d69-519a-4dda-b42d-5e32d6c301b1" xlink:to="loc_us-gaap_InterestExpense_b4df5d6d-1f57-4ad2-a9b5-142a185a8969" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_8c6a7bc0-13ce-4738-aa68-d2b79e358ec7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d7327d69-519a-4dda-b42d-5e32d6c301b1" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_8c6a7bc0-13ce-4738-aa68-d2b79e358ec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_a34d0904-4002-461e-be21-2fb47834694b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d7327d69-519a-4dda-b42d-5e32d6c301b1" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_a34d0904-4002-461e-be21-2fb47834694b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f0badecf-e658-459c-b0d8-e888256a8d2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d7327d69-519a-4dda-b42d-5e32d6c301b1" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f0badecf-e658-459c-b0d8-e888256a8d2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_0f23db74-4322-4b97-b524-a07475cbf9a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d7327d69-519a-4dda-b42d-5e32d6c301b1" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_0f23db74-4322-4b97-b524-a07475cbf9a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_8cc23941-c881-476c-b5b4-9dd7a7d9c83c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d7327d69-519a-4dda-b42d-5e32d6c301b1" xlink:to="loc_us-gaap_ProfitLoss_8cc23941-c881-476c-b5b4-9dd7a7d9c83c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_2843de04-eeca-4d21-a821-a9946dbdfc9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d7327d69-519a-4dda-b42d-5e32d6c301b1" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_2843de04-eeca-4d21-a821-a9946dbdfc9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_00c0b166-22fb-41f9-aeb7-ca36b3c7a889" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d7327d69-519a-4dda-b42d-5e32d6c301b1" xlink:to="loc_us-gaap_NetIncomeLoss_00c0b166-22fb-41f9-aeb7-ca36b3c7a889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_f7f4d056-17d2-4bd3-99c2-795ec29daf99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d7327d69-519a-4dda-b42d-5e32d6c301b1" xlink:to="loc_us-gaap_EarningsPerShareAbstract_f7f4d056-17d2-4bd3-99c2-795ec29daf99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_60f4ecd2-6066-45b1-9865-341ce3a3e363" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f7f4d056-17d2-4bd3-99c2-795ec29daf99" xlink:to="loc_us-gaap_EarningsPerShareBasic_60f4ecd2-6066-45b1-9865-341ce3a3e363" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_895a2766-a3a1-48b0-9527-49ab342cc6b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f7f4d056-17d2-4bd3-99c2-795ec29daf99" xlink:to="loc_us-gaap_EarningsPerShareDiluted_895a2766-a3a1-48b0-9527-49ab342cc6b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" xlink:type="simple" xlink:href="apyx-20220930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_3db31a3d-8486-46df-9cb9-4410ff8b3fd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_05418fc7-937a-448a-a519-242859322678" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_3db31a3d-8486-46df-9cb9-4410ff8b3fd0" xlink:to="loc_us-gaap_StatementTable_05418fc7-937a-448a-a519-242859322678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_a9e32be1-1ab1-411b-8da6-a78d012a141d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_05418fc7-937a-448a-a519-242859322678" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_a9e32be1-1ab1-411b-8da6-a78d012a141d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_30086249-996d-4c41-bcd0-8ce1e4bad554" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a9e32be1-1ab1-411b-8da6-a78d012a141d" xlink:to="loc_us-gaap_EquityComponentDomain_30086249-996d-4c41-bcd0-8ce1e4bad554" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_4f3ce62a-9e6c-4180-b23d-360d9ab5f0d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_30086249-996d-4c41-bcd0-8ce1e4bad554" xlink:to="loc_us-gaap_CommonStockMember_4f3ce62a-9e6c-4180-b23d-360d9ab5f0d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_a0a4cf7d-3a5f-4619-9bb1-18b90ff79f0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_30086249-996d-4c41-bcd0-8ce1e4bad554" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_a0a4cf7d-3a5f-4619-9bb1-18b90ff79f0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_5687157d-d644-4e8f-b055-5e5e7faf271c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_30086249-996d-4c41-bcd0-8ce1e4bad554" xlink:to="loc_us-gaap_RetainedEarningsMember_5687157d-d644-4e8f-b055-5e5e7faf271c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_1eeaec45-03e7-4729-be66-4323802e644a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_30086249-996d-4c41-bcd0-8ce1e4bad554" xlink:to="loc_us-gaap_NoncontrollingInterestMember_1eeaec45-03e7-4729-be66-4323802e644a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_9321c96e-db1a-4e3b-a58b-660f036118c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_05418fc7-937a-448a-a519-242859322678" xlink:to="loc_us-gaap_StatementLineItems_9321c96e-db1a-4e3b-a58b-660f036118c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3ced745f-8456-420e-b11e-43a6810f4426" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9321c96e-db1a-4e3b-a58b-660f036118c7" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3ced745f-8456-420e-b11e-43a6810f4426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_2ac0d1fc-f751-4324-9ce3-f8bc640b6a81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3ced745f-8456-420e-b11e-43a6810f4426" xlink:to="loc_us-gaap_SharesIssued_2ac0d1fc-f751-4324-9ce3-f8bc640b6a81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4c60123c-b246-4034-a2a7-fcbb7fba66dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3ced745f-8456-420e-b11e-43a6810f4426" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4c60123c-b246-4034-a2a7-fcbb7fba66dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_4385824e-cdf9-429d-b093-281ecd603671" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3ced745f-8456-420e-b11e-43a6810f4426" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_4385824e-cdf9-429d-b093-281ecd603671" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_40befe33-d214-416a-b00e-51b40953a765" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3ced745f-8456-420e-b11e-43a6810f4426" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_40befe33-d214-416a-b00e-51b40953a765" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_5861a543-e780-49fe-84b3-13ecb7ff1d30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3ced745f-8456-420e-b11e-43a6810f4426" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_5861a543-e780-49fe-84b3-13ecb7ff1d30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0f630614-a825-421f-ba59-8b6ffd2f125e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3ced745f-8456-420e-b11e-43a6810f4426" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0f630614-a825-421f-ba59-8b6ffd2f125e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_StockSwapToAcquireOptionsShares_9d5e4272-0c68-45ec-86c8-7130ae7a4d0b" xlink:href="apyx-20220930.xsd#apyx_StockSwapToAcquireOptionsShares"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3ced745f-8456-420e-b11e-43a6810f4426" xlink:to="loc_apyx_StockSwapToAcquireOptionsShares_9d5e4272-0c68-45ec-86c8-7130ae7a4d0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_2005330b-2437-4714-92fb-406ee0230cc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3ced745f-8456-420e-b11e-43a6810f4426" xlink:to="loc_us-gaap_ProfitLoss_2005330b-2437-4714-92fb-406ee0230cc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_5088159a-1a95-4e19-9ff6-698e78266fe8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3ced745f-8456-420e-b11e-43a6810f4426" xlink:to="loc_us-gaap_SharesIssued_5088159a-1a95-4e19-9ff6-698e78266fe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_139872b3-ce95-4e83-841e-fa6bd6343003" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3ced745f-8456-420e-b11e-43a6810f4426" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_139872b3-ce95-4e83-841e-fa6bd6343003" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="apyx-20220930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_e83566db-d84e-4601-87ef-d94d2501a53b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b437c1d5-8006-4abd-a8db-7c3fb9c3a4fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e83566db-d84e-4601-87ef-d94d2501a53b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b437c1d5-8006-4abd-a8db-7c3fb9c3a4fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_983280b9-468c-4eb0-be0a-5061dc96b715" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b437c1d5-8006-4abd-a8db-7c3fb9c3a4fe" xlink:to="loc_us-gaap_ProfitLoss_983280b9-468c-4eb0-be0a-5061dc96b715" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_74fe2d7a-521c-48cf-a010-382d322b0841" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b437c1d5-8006-4abd-a8db-7c3fb9c3a4fe" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_74fe2d7a-521c-48cf-a010-382d322b0841" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_b72039c8-4d8f-4900-bd84-febabb9935e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_74fe2d7a-521c-48cf-a010-382d322b0841" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_b72039c8-4d8f-4900-bd84-febabb9935e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ProvisionForInventoryObsolescence_498b4f88-9ce5-4e85-996f-069022cd8134" xlink:href="apyx-20220930.xsd#apyx_ProvisionForInventoryObsolescence"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_74fe2d7a-521c-48cf-a010-382d322b0841" xlink:to="loc_apyx_ProvisionForInventoryObsolescence_498b4f88-9ce5-4e85-996f-069022cd8134" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_1d85617c-fe79-4125-840f-3b53ecc1fc3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_74fe2d7a-521c-48cf-a010-382d322b0841" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_1d85617c-fe79-4125-840f-3b53ecc1fc3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_d2ef58a2-9e6d-4ebf-9b16-efaa8fd41162" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_74fe2d7a-521c-48cf-a010-382d322b0841" xlink:to="loc_us-gaap_ShareBasedCompensation_d2ef58a2-9e6d-4ebf-9b16-efaa8fd41162" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_5f893742-7161-47b5-b346-190c467ea81e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_74fe2d7a-521c-48cf-a010-382d322b0841" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_5f893742-7161-47b5-b346-190c467ea81e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8e370e3a-315a-426c-acac-05a1ce6ce20f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_74fe2d7a-521c-48cf-a010-382d322b0841" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8e370e3a-315a-426c-acac-05a1ce6ce20f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_fcd5d8bb-436b-45e1-a36e-cdc0bcfcec5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8e370e3a-315a-426c-acac-05a1ce6ce20f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_fcd5d8bb-436b-45e1-a36e-cdc0bcfcec5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_13f41ff5-eb5b-49c9-bc5d-5dc32327d29e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8e370e3a-315a-426c-acac-05a1ce6ce20f" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_13f41ff5-eb5b-49c9-bc5d-5dc32327d29e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_4c73de42-39e4-4711-9cd6-29149dfb335d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8e370e3a-315a-426c-acac-05a1ce6ce20f" xlink:to="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_4c73de42-39e4-4711-9cd6-29149dfb335d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_91437219-1af4-48e6-bc01-428746b56cd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8e370e3a-315a-426c-acac-05a1ce6ce20f" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_91437219-1af4-48e6-bc01-428746b56cd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_fc7c37b9-4819-4bde-b68e-4091e4e8728d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8e370e3a-315a-426c-acac-05a1ce6ce20f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_fc7c37b9-4819-4bde-b68e-4091e4e8728d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_f792ecc0-f674-4814-ae08-7f5adf6d205f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8e370e3a-315a-426c-acac-05a1ce6ce20f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_f792ecc0-f674-4814-ae08-7f5adf6d205f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0e7ea67e-1a8a-4209-805c-4d82072e3fe1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b437c1d5-8006-4abd-a8db-7c3fb9c3a4fe" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0e7ea67e-1a8a-4209-805c-4d82072e3fe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f69d7ea7-90a1-4e97-a1d6-0b7bcdfc5600" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e83566db-d84e-4601-87ef-d94d2501a53b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f69d7ea7-90a1-4e97-a1d6-0b7bcdfc5600" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_a91b8e6c-ef91-4641-8b96-c5ca827e761e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f69d7ea7-90a1-4e97-a1d6-0b7bcdfc5600" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_a91b8e6c-ef91-4641-8b96-c5ca827e761e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_40b550d9-70ab-46d1-852a-1ca1141303bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f69d7ea7-90a1-4e97-a1d6-0b7bcdfc5600" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_40b550d9-70ab-46d1-852a-1ca1141303bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ed609d96-212b-462e-94e2-b4f50462996a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e83566db-d84e-4601-87ef-d94d2501a53b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ed609d96-212b-462e-94e2-b4f50462996a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised_26df60c4-26d5-40f7-a3e1-233eb2b895b2" xlink:href="apyx-20220930.xsd#apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ed609d96-212b-462e-94e2-b4f50462996a" xlink:to="loc_apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised_26df60c4-26d5-40f7-a3e1-233eb2b895b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_RepaymentOfFinanceLeaseLiabilities_b5547745-e523-4566-bab3-a29d0f31f528" xlink:href="apyx-20220930.xsd#apyx_RepaymentOfFinanceLeaseLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ed609d96-212b-462e-94e2-b4f50462996a" xlink:to="loc_apyx_RepaymentOfFinanceLeaseLiabilities_b5547745-e523-4566-bab3-a29d0f31f528" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMinorityShareholders_5d55c870-6846-4835-9797-2ab513fb6cc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMinorityShareholders"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ed609d96-212b-462e-94e2-b4f50462996a" xlink:to="loc_us-gaap_ProceedsFromMinorityShareholders_5d55c870-6846-4835-9797-2ab513fb6cc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e239dadb-fc0c-4ce4-a48f-1454cdeba721" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ed609d96-212b-462e-94e2-b4f50462996a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e239dadb-fc0c-4ce4-a48f-1454cdeba721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_bc18ece9-9065-44a2-b2a1-d38c00ea296b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e83566db-d84e-4601-87ef-d94d2501a53b" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_bc18ece9-9065-44a2-b2a1-d38c00ea296b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_859d1eb9-cae7-4ad6-88b2-26b1a4313d96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e83566db-d84e-4601-87ef-d94d2501a53b" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_859d1eb9-cae7-4ad6-88b2-26b1a4313d96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_39e59787-adf6-415d-ad20-029a1a2396d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e83566db-d84e-4601-87ef-d94d2501a53b" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_39e59787-adf6-415d-ad20-029a1a2396d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5da8805d-39df-496e-b889-85bf5e2a3961" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e83566db-d84e-4601-87ef-d94d2501a53b" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5da8805d-39df-496e-b889-85bf5e2a3961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_aa3a4f8b-85fc-4a1b-b1c5-6ac76177eeb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e83566db-d84e-4601-87ef-d94d2501a53b" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_aa3a4f8b-85fc-4a1b-b1c5-6ac76177eeb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_f50c9b90-2743-4cf3-af82-02b70cf24c37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_aa3a4f8b-85fc-4a1b-b1c5-6ac76177eeb4" xlink:to="loc_us-gaap_InterestPaidNet_f50c9b90-2743-4cf3-af82-02b70cf24c37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_0785fe01-3fee-41a4-ab1e-365ddf438193" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_aa3a4f8b-85fc-4a1b-b1c5-6ac76177eeb4" xlink:to="loc_us-gaap_IncomeTaxesPaid_0785fe01-3fee-41a4-ab1e-365ddf438193" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_b2e9653e-9b37-475d-a75d-258ba516f7d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e83566db-d84e-4601-87ef-d94d2501a53b" xlink:to="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_b2e9653e-9b37-475d-a75d-258ba516f7d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_CapitalizationOfLeaseNonCash_df0fce4d-1ee0-4012-a308-f06165caf82d" xlink:href="apyx-20220930.xsd#apyx_CapitalizationOfLeaseNonCash"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_b2e9653e-9b37-475d-a75d-258ba516f7d0" xlink:to="loc_apyx_CapitalizationOfLeaseNonCash_df0fce4d-1ee0-4012-a308-f06165caf82d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_CapitalizationOfLeaseExecution_5e73214b-8bad-43db-9108-2b59824d9e26" xlink:href="apyx-20220930.xsd#apyx_CapitalizationOfLeaseExecution"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_b2e9653e-9b37-475d-a75d-258ba516f7d0" xlink:to="loc_apyx_CapitalizationOfLeaseExecution_5e73214b-8bad-43db-9108-2b59824d9e26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_dd944f80-becc-4181-a9fb-879e61ba1cc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_b2e9653e-9b37-475d-a75d-258ba516f7d0" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_dd944f80-becc-4181-a9fb-879e61ba1cc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/BASISOFPRESENTATION" xlink:type="simple" xlink:href="apyx-20220930.xsd#BASISOFPRESENTATION"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/BASISOFPRESENTATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_61ef4298-97a7-4cdf-91af-ed6616c9823a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_1b1cc56f-6025-4edf-8236-ddce18664082" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_61ef4298-97a7-4cdf-91af-ed6616c9823a" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_1b1cc56f-6025-4edf-8236-ddce18664082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/RECENTACCOUNTINGPRONOUNCEMENTS" xlink:type="simple" xlink:href="apyx-20220930.xsd#RECENTACCOUNTINGPRONOUNCEMENTS"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/RECENTACCOUNTINGPRONOUNCEMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_6ab32e17-dc92-4fd6-82ef-f325f307a040" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_612b0261-d657-4ad1-ad2b-6e22af20264e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_6ab32e17-dc92-4fd6-82ef-f325f307a040" xlink:to="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_612b0261-d657-4ad1-ad2b-6e22af20264e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/DISPOSALOFBUSINESS" xlink:type="simple" xlink:href="apyx-20220930.xsd#DISPOSALOFBUSINESS"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/DISPOSALOFBUSINESS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_0aa3b1ba-7331-4374-a271-80bbc3729bff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_22519181-9426-46b8-8f2c-44b95da68b85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_0aa3b1ba-7331-4374-a271-80bbc3729bff" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_22519181-9426-46b8-8f2c-44b95da68b85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/INVENTORIES" xlink:type="simple" xlink:href="apyx-20220930.xsd#INVENTORIES"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/INVENTORIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_2f3f7714-5e6e-4642-a16d-fd444bcb3b3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_1aea11ba-6b36-4e93-aefb-13392689eedd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_2f3f7714-5e6e-4642-a16d-fd444bcb3b3b" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_1aea11ba-6b36-4e93-aefb-13392689eedd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/LEASES" xlink:type="simple" xlink:href="apyx-20220930.xsd#LEASES"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/LEASES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_8bc46a9d-2459-4920-afe8-3938a1723b27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_48e9df8f-0716-462a-a8cc-ba744cdf7ac1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8bc46a9d-2459-4920-afe8-3938a1723b27" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_48e9df8f-0716-462a-a8cc-ba744cdf7ac1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock_9e802406-f733-4025-95f5-f5318f1f6dc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8bc46a9d-2459-4920-afe8-3938a1723b27" xlink:to="loc_us-gaap_LesseeFinanceLeasesTextBlock_9e802406-f733-4025-95f5-f5318f1f6dc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES" xlink:type="simple" xlink:href="apyx-20220930.xsd#ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_c3b7ba3c-9594-4d80-ae15-d2f0243abd47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_3e51aa3c-1daf-42f4-ada5-59f40509d990" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_c3b7ba3c-9594-4d80-ae15-d2f0243abd47" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_3e51aa3c-1daf-42f4-ada5-59f40509d990" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/CHINAJOINTVENTURE" xlink:type="simple" xlink:href="apyx-20220930.xsd#CHINAJOINTVENTURE"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/CHINAJOINTVENTURE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_fb70458c-d51b-4ebe-9f4f-d70e56ebe774" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDisclosureTextBlock_2af5398c-d0e7-42a7-8079-7a864038e4ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_fb70458c-d51b-4ebe-9f4f-d70e56ebe774" xlink:to="loc_us-gaap_MinorityInterestDisclosureTextBlock_2af5398c-d0e7-42a7-8079-7a864038e4ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/EARNINGSLOSSPERSHARE" xlink:type="simple" xlink:href="apyx-20220930.xsd#EARNINGSLOSSPERSHARE"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/EARNINGSLOSSPERSHARE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_cb80277c-a630-4719-8ccd-c705f1b58f8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_caeb84d3-7e5f-4586-912a-c335f9481048" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_cb80277c-a630-4719-8ccd-c705f1b58f8b" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_caeb84d3-7e5f-4586-912a-c335f9481048" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/STOCKBASEDCOMPENSATION" xlink:type="simple" xlink:href="apyx-20220930.xsd#STOCKBASEDCOMPENSATION"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/STOCKBASEDCOMPENSATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fa1c7a54-7fac-4d96-9fac-2e6b64cba6d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_05b14e18-fe89-4ac2-85a0-ca7209da6ccb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fa1c7a54-7fac-4d96-9fac-2e6b64cba6d7" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_05b14e18-fe89-4ac2-85a0-ca7209da6ccb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/INCOMETAXES" xlink:type="simple" xlink:href="apyx-20220930.xsd#INCOMETAXES"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/INCOMETAXES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_e4e30c55-2d1d-4404-b3c7-7a3ccbac42b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_a5020268-1fc5-4de0-b551-31130b9366ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e4e30c55-2d1d-4404-b3c7-7a3ccbac42b6" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_a5020268-1fc5-4de0-b551-31130b9366ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="apyx-20220930.xsd#COMMITMENTSANDCONTINGENCIES"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_97abe6c2-d8db-4731-969b-8d5394d04425" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_fbeb3548-20fe-40db-beee-1a9ba4afa704" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_97abe6c2-d8db-4731-969b-8d5394d04425" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_fbeb3548-20fe-40db-beee-1a9ba4afa704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONS" xlink:type="simple" xlink:href="apyx-20220930.xsd#RELATEDPARTYTRANSACTIONS"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_691c3620-a0f5-4263-a85c-62ea0654a08a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_ea61c43d-6c52-410b-ac3f-57b0e988b8d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_691c3620-a0f5-4263-a85c-62ea0654a08a" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_ea61c43d-6c52-410b-ac3f-57b0e988b8d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATION" xlink:type="simple" xlink:href="apyx-20220930.xsd#GEOGRAPHICANDSEGMENTINFORMATION"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_6c1ec31f-c24f-4b54-8ea5-5d09ea6d3b39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_2053c74d-80db-4a25-b475-3e5cc698a070" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_6c1ec31f-c24f-4b54-8ea5-5d09ea6d3b39" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_2053c74d-80db-4a25-b475-3e5cc698a070" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/BASISOFPRESENTATIONPolicies" xlink:type="simple" xlink:href="apyx-20220930.xsd#BASISOFPRESENTATIONPolicies"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/BASISOFPRESENTATIONPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_132707c8-a040-4ac2-9ea3-f6381f99d451" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_d563554a-e214-4a32-92a7-90e55d149d02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_132707c8-a040-4ac2-9ea3-f6381f99d451" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_d563554a-e214-4a32-92a7-90e55d149d02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_b10dbc61-eba1-4824-83c8-e68327e220c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_132707c8-a040-4ac2-9ea3-f6381f99d451" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_b10dbc61-eba1-4824-83c8-e68327e220c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_5c61eb5f-b3b1-4e29-bfae-8118be679515" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_132707c8-a040-4ac2-9ea3-f6381f99d451" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_5c61eb5f-b3b1-4e29-bfae-8118be679515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_218d7b57-4f73-49d1-b372-a53b3e19bef9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_132707c8-a040-4ac2-9ea3-f6381f99d451" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_218d7b57-4f73-49d1-b372-a53b3e19bef9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/INVENTORIESTables" xlink:type="simple" xlink:href="apyx-20220930.xsd#INVENTORIESTables"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/INVENTORIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_b79cd3b8-489e-4009-884d-b02372b362cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_8f1017d6-af70-42e0-ae15-596a17791315" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_b79cd3b8-489e-4009-884d-b02372b362cb" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_8f1017d6-af70-42e0-ae15-596a17791315" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/LEASESTables" xlink:type="simple" xlink:href="apyx-20220930.xsd#LEASESTables"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/LEASESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_3622fcd7-8874-49ea-acff-064944d4b8d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_133d0ee2-b553-41f2-a237-61d2f47fa1ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3622fcd7-8874-49ea-acff-064944d4b8d2" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_133d0ee2-b553-41f2-a237-61d2f47fa1ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_f1b99929-caf9-4b32-94a5-749bef65bf04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3622fcd7-8874-49ea-acff-064944d4b8d2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_f1b99929-caf9-4b32-94a5-749bef65bf04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_53f39706-b915-43f3-90aa-4df614d24a9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3622fcd7-8874-49ea-acff-064944d4b8d2" xlink:to="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_53f39706-b915-43f3-90aa-4df614d24a9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables" xlink:type="simple" xlink:href="apyx-20220930.xsd#ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_8e71b918-040a-4b20-9c6a-fdf6920dcd9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_9e85fe8a-8720-4d25-9b13-51a7c1828e91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_8e71b918-040a-4b20-9c6a-fdf6920dcd9e" xlink:to="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_9e85fe8a-8720-4d25-9b13-51a7c1828e91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/CHINAJOINTVENTURETables" xlink:type="simple" xlink:href="apyx-20220930.xsd#CHINAJOINTVENTURETables"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/CHINAJOINTVENTURETables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_2d00fafb-e913-471a-bc15-4792274ab02d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_NoncontrollingInterestTableTextBlock_1b433146-9acd-4ec2-b963-17ac6a4b68e2" xlink:href="apyx-20220930.xsd#apyx_NoncontrollingInterestTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_2d00fafb-e913-471a-bc15-4792274ab02d" xlink:to="loc_apyx_NoncontrollingInterestTableTextBlock_1b433146-9acd-4ec2-b963-17ac6a4b68e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/EARNINGSLOSSPERSHARETables" xlink:type="simple" xlink:href="apyx-20220930.xsd#EARNINGSLOSSPERSHARETables"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/EARNINGSLOSSPERSHARETables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_e7291ab7-0906-4822-a260-79fe7bcf10e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_014a6201-cb1b-4796-90e9-df5703b2d607" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_e7291ab7-0906-4822-a260-79fe7bcf10e4" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_014a6201-cb1b-4796-90e9-df5703b2d607" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONTables" xlink:type="simple" xlink:href="apyx-20220930.xsd#STOCKBASEDCOMPENSATIONTables"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_265b0088-23a2-4f77-832f-014d51578033" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_cb10aa14-d470-4d1c-a24d-2436634165ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_265b0088-23a2-4f77-832f-014d51578033" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_cb10aa14-d470-4d1c-a24d-2436634165ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_224d1c18-3d43-4870-a964-d9500c9f665d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_265b0088-23a2-4f77-832f-014d51578033" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_224d1c18-3d43-4870-a964-d9500c9f665d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONTables" xlink:type="simple" xlink:href="apyx-20220930.xsd#GEOGRAPHICANDSEGMENTINFORMATIONTables"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_a78429af-af2f-4e92-a707-ea702e9188c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_d6ec2842-4562-4965-b8f9-e735043d7130" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_a78429af-af2f-4e92-a707-ea702e9188c4" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_d6ec2842-4562-4965-b8f9-e735043d7130" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_c24f932c-24e6-4943-ac84-a7dcaa4e67c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_a78429af-af2f-4e92-a707-ea702e9188c4" xlink:to="loc_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_c24f932c-24e6-4943-ac84-a7dcaa4e67c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/BASISOFPRESENTATIONNARRATIVEDetails" xlink:type="simple" xlink:href="apyx-20220930.xsd#BASISOFPRESENTATIONNARRATIVEDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/BASISOFPRESENTATIONNARRATIVEDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_28b6c88f-c171-4409-92fb-c6bf8aea7164" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_c0b4f165-7244-41b2-82a7-51555c87f316" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_28b6c88f-c171-4409-92fb-c6bf8aea7164" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_c0b4f165-7244-41b2-82a7-51555c87f316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_bcb2264d-a5ad-41d5-8f9c-5059576c92d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_28b6c88f-c171-4409-92fb-c6bf8aea7164" xlink:to="loc_us-gaap_OperatingIncomeLoss_bcb2264d-a5ad-41d5-8f9c-5059576c92d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_32c951ff-3dfc-48f6-9349-70a257d19f32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_28b6c88f-c171-4409-92fb-c6bf8aea7164" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_32c951ff-3dfc-48f6-9349-70a257d19f32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7c6d0798-7523-4055-a0c1-999cad2677a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_28b6c88f-c171-4409-92fb-c6bf8aea7164" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7c6d0798-7523-4055-a0c1-999cad2677a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/DISPOSALOFBUSINESSDetails" xlink:type="simple" xlink:href="apyx-20220930.xsd#DISPOSALOFBUSINESSDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/DISPOSALOFBUSINESSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_25eb3889-88c6-4ab1-ae8b-8843721c771d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_7ad8ab34-7560-4965-b41e-5cb8db30b1ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_25eb3889-88c6-4ab1-ae8b-8843721c771d" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_7ad8ab34-7560-4965-b41e-5cb8db30b1ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ae76b1df-0cd8-49d1-b0af-f2d05be1e8d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_7ad8ab34-7560-4965-b41e-5cb8db30b1ed" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ae76b1df-0cd8-49d1-b0af-f2d05be1e8d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_c91cfa5b-62b5-425d-9ad1-e5f88f7fe856" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ae76b1df-0cd8-49d1-b0af-f2d05be1e8d0" xlink:to="loc_us-gaap_RelatedPartyDomain_c91cfa5b-62b5-425d-9ad1-e5f88f7fe856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SymmetrySurgicalInc.Member_a8345133-aa36-4c25-90e5-7edffd1b4540" xlink:href="apyx-20220930.xsd#apyx_SymmetrySurgicalInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_c91cfa5b-62b5-425d-9ad1-e5f88f7fe856" xlink:to="loc_apyx_SymmetrySurgicalInc.Member_a8345133-aa36-4c25-90e5-7edffd1b4540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_a925d42e-dac9-4874-a383-ba3aaf31c651" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_7ad8ab34-7560-4965-b41e-5cb8db30b1ed" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_a925d42e-dac9-4874-a383-ba3aaf31c651" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_2a2f2327-6e5f-409c-aeff-f0899160ca09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_a925d42e-dac9-4874-a383-ba3aaf31c651" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_2a2f2327-6e5f-409c-aeff-f0899160ca09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember_4759df96-5636-4c03-ac43-1ddd5c692da7" xlink:href="apyx-20220930.xsd#apyx_ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_2a2f2327-6e5f-409c-aeff-f0899160ca09" xlink:to="loc_apyx_ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember_4759df96-5636-4c03-ac43-1ddd5c692da7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1208bc4b-cf6c-4f05-a894-4621941ba192" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_7ad8ab34-7560-4965-b41e-5cb8db30b1ed" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1208bc4b-cf6c-4f05-a894-4621941ba192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_0df0d912-c14d-4e78-b362-04544574fa38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1208bc4b-cf6c-4f05-a894-4621941ba192" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_0df0d912-c14d-4e78-b362-04544574fa38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_AssetPurchaseAgreementTerm_61fd1bec-c4ab-4b3f-a40d-dc4e20e3b1dc" xlink:href="apyx-20220930.xsd#apyx_AssetPurchaseAgreementTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1208bc4b-cf6c-4f05-a894-4621941ba192" xlink:to="loc_apyx_AssetPurchaseAgreementTerm_61fd1bec-c4ab-4b3f-a40d-dc4e20e3b1dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_a564b498-2c7c-49f1-a2bb-4db94e8f4040" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1208bc4b-cf6c-4f05-a894-4621941ba192" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_a564b498-2c7c-49f1-a2bb-4db94e8f4040" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_8932d9c0-e495-43d7-954a-b296be4e25d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1208bc4b-cf6c-4f05-a894-4621941ba192" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_8932d9c0-e495-43d7-954a-b296be4e25d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_de4d601c-2992-4846-afca-32ce7e288a38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1208bc4b-cf6c-4f05-a894-4621941ba192" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_de4d601c-2992-4846-afca-32ce7e288a38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_08e5820c-67b1-4022-a69f-94384b401d40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1208bc4b-cf6c-4f05-a894-4621941ba192" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_08e5820c-67b1-4022-a69f-94384b401d40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/INVENTORIESDetails" xlink:type="simple" xlink:href="apyx-20220930.xsd#INVENTORIESDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/INVENTORIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_3bf3fb63-ee2e-48f6-ad3a-d0bb8fe8bd2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_ed1fea97-7a15-492c-b581-c72d245dc91f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_3bf3fb63-ee2e-48f6-ad3a-d0bb8fe8bd2e" xlink:to="loc_us-gaap_InventoryRawMaterials_ed1fea97-7a15-492c-b581-c72d245dc91f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_c74a0369-6a9c-43e7-920b-ac2e473469da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_3bf3fb63-ee2e-48f6-ad3a-d0bb8fe8bd2e" xlink:to="loc_us-gaap_InventoryWorkInProcess_c74a0369-6a9c-43e7-920b-ac2e473469da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_551806d7-cad8-40fe-ae1d-c823a8710918" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_3bf3fb63-ee2e-48f6-ad3a-d0bb8fe8bd2e" xlink:to="loc_us-gaap_InventoryFinishedGoods_551806d7-cad8-40fe-ae1d-c823a8710918" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_88cdaeaf-7289-48d7-9e34-be89fd839b24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_3bf3fb63-ee2e-48f6-ad3a-d0bb8fe8bd2e" xlink:to="loc_us-gaap_InventoryGross_88cdaeaf-7289-48d7-9e34-be89fd839b24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves_c07e3416-7490-420a-9853-257c236daf49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryValuationReserves"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_3bf3fb63-ee2e-48f6-ad3a-d0bb8fe8bd2e" xlink:to="loc_us-gaap_InventoryValuationReserves_c07e3416-7490-420a-9853-257c236daf49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_4d081dda-0b63-4695-8ffe-c2b9deb977e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_3bf3fb63-ee2e-48f6-ad3a-d0bb8fe8bd2e" xlink:to="loc_us-gaap_InventoryNet_4d081dda-0b63-4695-8ffe-c2b9deb977e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/LEASESNarrativeDetails" xlink:type="simple" xlink:href="apyx-20220930.xsd#LEASESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/LEASESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_183141a7-d5d5-48a4-a484-d92e080ec011" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_c6c35d63-dce2-450a-a979-ea110e6fa221" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_183141a7-d5d5-48a4-a484-d92e080ec011" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_c6c35d63-dce2-450a-a979-ea110e6fa221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_b29150b6-b963-4881-93d6-3dd9f912c029" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_183141a7-d5d5-48a4-a484-d92e080ec011" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_b29150b6-b963-4881-93d6-3dd9f912c029" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseTermOfContract1_314196fb-fead-4f80-9764-c42f9a34adbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_183141a7-d5d5-48a4-a484-d92e080ec011" xlink:to="loc_us-gaap_LesseeFinanceLeaseTermOfContract1_314196fb-fead-4f80-9764-c42f9a34adbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/LEASESLeaseTermsandDiscountRatesDetails" xlink:type="simple" xlink:href="apyx-20220930.xsd#LEASESLeaseTermsandDiscountRatesDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/LEASESLeaseTermsandDiscountRatesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_e990f43c-c0c1-4a7b-9523-9d2d123c53d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_OperatingLeaseCostsAbstract_e05b189c-362e-4f7b-85bc-1c48a204a4ea" xlink:href="apyx-20220930.xsd#apyx_OperatingLeaseCostsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e990f43c-c0c1-4a7b-9523-9d2d123c53d8" xlink:to="loc_apyx_OperatingLeaseCostsAbstract_e05b189c-362e-4f7b-85bc-1c48a204a4ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_3c9a6df2-a315-40c7-9ec8-7bfca8365eba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_apyx_OperatingLeaseCostsAbstract_e05b189c-362e-4f7b-85bc-1c48a204a4ea" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_3c9a6df2-a315-40c7-9ec8-7bfca8365eba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_02831f50-48ec-4163-9e11-b0860f831ea9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_apyx_OperatingLeaseCostsAbstract_e05b189c-362e-4f7b-85bc-1c48a204a4ea" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_02831f50-48ec-4163-9e11-b0860f831ea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_FinanceLeaseCostsAbstract_332b9bbd-24a6-4b95-a686-bdb9ddc5609a" xlink:href="apyx-20220930.xsd#apyx_FinanceLeaseCostsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e990f43c-c0c1-4a7b-9523-9d2d123c53d8" xlink:to="loc_apyx_FinanceLeaseCostsAbstract_332b9bbd-24a6-4b95-a686-bdb9ddc5609a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_06a094c1-4d54-4616-a316-c329099ddc81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_apyx_FinanceLeaseCostsAbstract_332b9bbd-24a6-4b95-a686-bdb9ddc5609a" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_06a094c1-4d54-4616-a316-c329099ddc81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_2fd1bdde-5b36-46cd-9603-e80dd2eb7d84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_apyx_FinanceLeaseCostsAbstract_332b9bbd-24a6-4b95-a686-bdb9ddc5609a" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_2fd1bdde-5b36-46cd-9603-e80dd2eb7d84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="apyx-20220930.xsd#LEASESMaturitiesofLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_cd6da208-df4d-49c7-adc7-250aeadcf4f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_236cd631-d92e-477b-bbe3-96df9f34e1ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_cd6da208-df4d-49c7-adc7-250aeadcf4f2" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_236cd631-d92e-477b-bbe3-96df9f34e1ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_a2bebcf4-2320-453a-b115-4fd73541dd89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_236cd631-d92e-477b-bbe3-96df9f34e1ec" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_a2bebcf4-2320-453a-b115-4fd73541dd89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_510395aa-39c9-4c45-87e2-8fa88af8fdd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_236cd631-d92e-477b-bbe3-96df9f34e1ec" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_510395aa-39c9-4c45-87e2-8fa88af8fdd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_5cedf08d-6c2f-42c7-8d11-03cacee95380" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_236cd631-d92e-477b-bbe3-96df9f34e1ec" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_5cedf08d-6c2f-42c7-8d11-03cacee95380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_13883430-b4fe-452b-bc4f-c204855b0094" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_236cd631-d92e-477b-bbe3-96df9f34e1ec" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_13883430-b4fe-452b-bc4f-c204855b0094" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_26ef754b-97e1-4cde-9a37-c297722bb1d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_236cd631-d92e-477b-bbe3-96df9f34e1ec" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_26ef754b-97e1-4cde-9a37-c297722bb1d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour_a6ab6b30-26f8-487a-85d2-95866826a873" xlink:href="apyx-20220930.xsd#apyx_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_236cd631-d92e-477b-bbe3-96df9f34e1ec" xlink:to="loc_apyx_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour_a6ab6b30-26f8-487a-85d2-95866826a873" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a885d86b-9070-4ce0-a2f7-644b5534e5a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_236cd631-d92e-477b-bbe3-96df9f34e1ec" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a885d86b-9070-4ce0-a2f7-644b5534e5a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_c7ab363a-658d-4136-adee-bab23abd4705" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_236cd631-d92e-477b-bbe3-96df9f34e1ec" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_c7ab363a-658d-4136-adee-bab23abd4705" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_6870024b-f89e-4984-8b13-c66cf6018982" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_236cd631-d92e-477b-bbe3-96df9f34e1ec" xlink:to="loc_us-gaap_OperatingLeaseLiability_6870024b-f89e-4984-8b13-c66cf6018982" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_cdde5b30-0825-4cb1-a41a-793cb3b26e6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_236cd631-d92e-477b-bbe3-96df9f34e1ec" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_cdde5b30-0825-4cb1-a41a-793cb3b26e6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_10532905-e2a9-49c4-a693-907b066b2933" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_236cd631-d92e-477b-bbe3-96df9f34e1ec" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_10532905-e2a9-49c4-a693-907b066b2933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_99df6321-c91a-4c8f-ba2a-c3bc9915dcd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_cd6da208-df4d-49c7-adc7-250aeadcf4f2" xlink:to="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_99df6321-c91a-4c8f-ba2a-c3bc9915dcd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_22c02fc4-6e64-4443-a600-6a094d2fece9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_99df6321-c91a-4c8f-ba2a-c3bc9915dcd8" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_22c02fc4-6e64-4443-a600-6a094d2fece9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_86f32e74-622c-41ff-8227-04430b899887" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_99df6321-c91a-4c8f-ba2a-c3bc9915dcd8" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_86f32e74-622c-41ff-8227-04430b899887" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_8e660600-1191-45ae-8320-21d76852320a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_99df6321-c91a-4c8f-ba2a-c3bc9915dcd8" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_8e660600-1191-45ae-8320-21d76852320a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_a0195771-3803-4c7e-85aa-3bffcac0453a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_99df6321-c91a-4c8f-ba2a-c3bc9915dcd8" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_a0195771-3803-4c7e-85aa-3bffcac0453a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_f9fc629c-8d70-4dd1-bd34-40082bbcc95d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_99df6321-c91a-4c8f-ba2a-c3bc9915dcd8" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_f9fc629c-8d70-4dd1-bd34-40082bbcc95d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_FinanceLeaseLiabilityToBePaidDueAfterYearFour_bb6d4a4d-7559-435d-8933-c9f201c0d73e" xlink:href="apyx-20220930.xsd#apyx_FinanceLeaseLiabilityToBePaidDueAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_99df6321-c91a-4c8f-ba2a-c3bc9915dcd8" xlink:to="loc_apyx_FinanceLeaseLiabilityToBePaidDueAfterYearFour_bb6d4a4d-7559-435d-8933-c9f201c0d73e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_8c14174e-80ca-44da-ae22-3c9ea09630fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_99df6321-c91a-4c8f-ba2a-c3bc9915dcd8" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_8c14174e-80ca-44da-ae22-3c9ea09630fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_65db7e1c-b019-4a54-b632-9f0bf702536d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_99df6321-c91a-4c8f-ba2a-c3bc9915dcd8" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_65db7e1c-b019-4a54-b632-9f0bf702536d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_76798c3a-feae-41bd-a54f-77f330feb2f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_99df6321-c91a-4c8f-ba2a-c3bc9915dcd8" xlink:to="loc_us-gaap_FinanceLeaseLiability_76798c3a-feae-41bd-a54f-77f330feb2f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_c9386d47-b814-4653-b47d-127478763096" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_99df6321-c91a-4c8f-ba2a-c3bc9915dcd8" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_c9386d47-b814-4653-b47d-127478763096" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_1536a74a-0b28-4b92-a685-618f585838bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_99df6321-c91a-4c8f-ba2a-c3bc9915dcd8" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_1536a74a-0b28-4b92-a685-618f585838bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="apyx-20220930.xsd#LEASESMaturitiesofLeaseLiabilitiesDetails_1"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" xlink:type="simple" xlink:href="apyx-20220930.xsd#ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_4f0c7ce5-ba73-4213-a9a1-8953f225ecea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent_e47e981d-aa71-456c-ac49-92a2e2dbfa88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_4f0c7ce5-ba73-4213-a9a1-8953f225ecea" xlink:to="loc_us-gaap_AccruedSalariesCurrent_e47e981d-aa71-456c-ac49-92a2e2dbfa88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedBonusesCurrent_4028f912-5161-4e32-a878-9a57ed8ab0c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedBonusesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_4f0c7ce5-ba73-4213-a9a1-8953f225ecea" xlink:to="loc_us-gaap_AccruedBonusesCurrent_4028f912-5161-4e32-a878-9a57ed8ab0c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalesCommissionCurrent_bcafd8ba-55d0-4e63-8d5a-441dfc2b8226" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedSalesCommissionCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_4f0c7ce5-ba73-4213-a9a1-8953f225ecea" xlink:to="loc_us-gaap_AccruedSalesCommissionCurrent_bcafd8ba-55d0-4e63-8d5a-441dfc2b8226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent_2fa863a1-1d47-4ff7-bc8a-8e038cfa4bfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductWarrantyAccrualClassifiedCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_4f0c7ce5-ba73-4213-a9a1-8953f225ecea" xlink:to="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent_2fa863a1-1d47-4ff7-bc8a-8e038cfa4bfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedInsuranceCurrent_0625aa8c-f33d-4f9f-8336-bca192b9472a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedInsuranceCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_4f0c7ce5-ba73-4213-a9a1-8953f225ecea" xlink:to="loc_us-gaap_AccruedInsuranceCurrent_0625aa8c-f33d-4f9f-8336-bca192b9472a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_abcca1f8-fbed-41a3-afcd-a18e1468ca1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_4f0c7ce5-ba73-4213-a9a1-8953f225ecea" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_abcca1f8-fbed-41a3-afcd-a18e1468ca1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_JointAndSeveralPayrollLiability_60e76ec8-33f7-4990-9001-a5689961cd31" xlink:href="apyx-20220930.xsd#apyx_JointAndSeveralPayrollLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_4f0c7ce5-ba73-4213-a9a1-8953f225ecea" xlink:to="loc_apyx_JointAndSeveralPayrollLiability_60e76ec8-33f7-4990-9001-a5689961cd31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ShortTermContractLiabilities_b8a322a8-e267-48bd-80b1-7b2a0b88391d" xlink:href="apyx-20220930.xsd#apyx_ShortTermContractLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_4f0c7ce5-ba73-4213-a9a1-8953f225ecea" xlink:to="loc_apyx_ShortTermContractLiabilities_b8a322a8-e267-48bd-80b1-7b2a0b88391d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_UncertainTaxPositionsLiability_4ef4ef96-b960-4b7a-a6b6-a281e5585a2d" xlink:href="apyx-20220930.xsd#apyx_UncertainTaxPositionsLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_4f0c7ce5-ba73-4213-a9a1-8953f225ecea" xlink:to="loc_apyx_UncertainTaxPositionsLiability_4ef4ef96-b960-4b7a-a6b6-a281e5585a2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesAndExciseTaxPayableCurrent_98277e9e-2913-438a-aba8-f1477a02f5aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesAndExciseTaxPayableCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_4f0c7ce5-ba73-4213-a9a1-8953f225ecea" xlink:to="loc_us-gaap_SalesAndExciseTaxPayableCurrent_98277e9e-2913-438a-aba8-f1477a02f5aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_OtherAccruedExpensesAndLiabilitiesCurrent_94f0a35a-214f-4478-9783-f24398182ca0" xlink:href="apyx-20220930.xsd#apyx_OtherAccruedExpensesAndLiabilitiesCurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_4f0c7ce5-ba73-4213-a9a1-8953f225ecea" xlink:to="loc_apyx_OtherAccruedExpensesAndLiabilitiesCurrent_94f0a35a-214f-4478-9783-f24398182ca0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent_b516e875-227e-493f-97ca-bfedda69bb8c" xlink:href="apyx-20220930.xsd#apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_4f0c7ce5-ba73-4213-a9a1-8953f225ecea" xlink:to="loc_apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent_b516e875-227e-493f-97ca-bfedda69bb8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESNarrativeDetails" xlink:type="simple" xlink:href="apyx-20220930.xsd#ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_6f5b08c3-1ee2-4ce1-bec7-a863f5f79a5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_JointAndSeveralPayrollLiability_abe81662-63b9-4cb6-a33d-96f544782081" xlink:href="apyx-20220930.xsd#apyx_JointAndSeveralPayrollLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_6f5b08c3-1ee2-4ce1-bec7-a863f5f79a5c" xlink:to="loc_apyx_JointAndSeveralPayrollLiability_abe81662-63b9-4cb6-a33d-96f544782081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/CHINAJOINTVENTURENarrativeDetails" xlink:type="simple" xlink:href="apyx-20220930.xsd#CHINAJOINTVENTURENarrativeDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/CHINAJOINTVENTURENarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_7bef65c2-2883-41a5-87be-40d21f9dd643" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_3597912f-1a51-4eb3-9a8c-f64ecc4834db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_7bef65c2-2883-41a5-87be-40d21f9dd643" xlink:to="loc_us-gaap_MinorityInterestTable_3597912f-1a51-4eb3-9a8c-f64ecc4834db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f341141f-6580-4497-a3a3-f6502757ec81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_3597912f-1a51-4eb3-9a8c-f64ecc4834db" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f341141f-6580-4497-a3a3-f6502757ec81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_16136535-12ce-446d-b77a-e05906779930" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f341141f-6580-4497-a3a3-f6502757ec81" xlink:to="loc_us-gaap_RelatedPartyDomain_16136535-12ce-446d-b77a-e05906779930" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateJointVentureMember_8760fdb1-77a6-494e-a009-5b546368f874" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateJointVentureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_16136535-12ce-446d-b77a-e05906779930" xlink:to="loc_us-gaap_CorporateJointVentureMember_8760fdb1-77a6-494e-a009-5b546368f874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_96def841-fbc7-4cb7-9e4c-5ae380b6c08e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_3597912f-1a51-4eb3-9a8c-f64ecc4834db" xlink:to="loc_srt_OwnershipAxis_96def841-fbc7-4cb7-9e4c-5ae380b6c08e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_da8b01b3-8e63-44f0-ab0b-616364a13459" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_96def841-fbc7-4cb7-9e4c-5ae380b6c08e" xlink:to="loc_srt_OwnershipDomain_da8b01b3-8e63-44f0-ab0b-616364a13459" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ChineseSupplierMember_0c217796-34c6-4a1d-8953-be033c72cdfd" xlink:href="apyx-20220930.xsd#apyx_ChineseSupplierMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_da8b01b3-8e63-44f0-ab0b-616364a13459" xlink:to="loc_apyx_ChineseSupplierMember_0c217796-34c6-4a1d-8953-be033c72cdfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_f1e74e4e-9d76-4316-a0a1-d2e5593bdce0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_3597912f-1a51-4eb3-9a8c-f64ecc4834db" xlink:to="loc_us-gaap_MinorityInterestLineItems_f1e74e4e-9d76-4316-a0a1-d2e5593bdce0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_d036af4f-839f-4b37-8026-9d7e336b2487" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_f1e74e4e-9d76-4316-a0a1-d2e5593bdce0" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_d036af4f-839f-4b37-8026-9d7e336b2487" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_NoncontrollingInterestRequiredCapitalContribution_a442917b-51e3-4bca-9012-43bb374c3b6a" xlink:href="apyx-20220930.xsd#apyx_NoncontrollingInterestRequiredCapitalContribution"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_f1e74e4e-9d76-4316-a0a1-d2e5593bdce0" xlink:to="loc_apyx_NoncontrollingInterestRequiredCapitalContribution_a442917b-51e3-4bca-9012-43bb374c3b6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/CHINAJOINTVENTURERollforwardofJointVentureDetails" xlink:type="simple" xlink:href="apyx-20220930.xsd#CHINAJOINTVENTURERollforwardofJointVentureDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/CHINAJOINTVENTURERollforwardofJointVentureDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_0fbff764-eb1b-40b0-9335-83988ca722c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_d1599e91-3c32-4f46-8a02-c80228302a1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_0fbff764-eb1b-40b0-9335-83988ca722c6" xlink:to="loc_us-gaap_MinorityInterestTable_d1599e91-3c32-4f46-8a02-c80228302a1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3401d6ea-f90d-4a1d-a37b-e8345fad25f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_d1599e91-3c32-4f46-8a02-c80228302a1c" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3401d6ea-f90d-4a1d-a37b-e8345fad25f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_8f294d70-a0a8-4909-9cc3-49838c04ea67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3401d6ea-f90d-4a1d-a37b-e8345fad25f5" xlink:to="loc_us-gaap_RelatedPartyDomain_8f294d70-a0a8-4909-9cc3-49838c04ea67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateJointVentureMember_9e12d29c-b45d-4b37-8990-e4f9268e53c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateJointVentureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_8f294d70-a0a8-4909-9cc3-49838c04ea67" xlink:to="loc_us-gaap_CorporateJointVentureMember_9e12d29c-b45d-4b37-8990-e4f9268e53c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_b462bc94-428e-4aee-960f-a80162e9acb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_d1599e91-3c32-4f46-8a02-c80228302a1c" xlink:to="loc_us-gaap_MinorityInterestLineItems_b462bc94-428e-4aee-960f-a80162e9acb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInMinorityInterestRollForward_3c6278a5-29ce-4419-9c74-85073e11d6d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MovementInMinorityInterestRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_b462bc94-428e-4aee-960f-a80162e9acb2" xlink:to="loc_us-gaap_MovementInMinorityInterestRollForward_3c6278a5-29ce-4419-9c74-85073e11d6d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_e296333a-a3ee-4660-b612-7e44058a0137" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_3c6278a5-29ce-4419-9c74-85073e11d6d3" xlink:to="loc_us-gaap_MinorityInterest_e296333a-a3ee-4660-b612-7e44058a0137" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_1510ae2b-cd9b-4cfa-9fe1-9850dcf98df1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_3c6278a5-29ce-4419-9c74-85073e11d6d3" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_1510ae2b-cd9b-4cfa-9fe1-9850dcf98df1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_e9421250-3a9b-4348-8042-acc00f43e8b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_3c6278a5-29ce-4419-9c74-85073e11d6d3" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_e9421250-3a9b-4348-8042-acc00f43e8b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_c4af3ae6-f068-4653-9688-056aab3fb675" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_3c6278a5-29ce-4419-9c74-85073e11d6d3" xlink:to="loc_us-gaap_MinorityInterest_c4af3ae6-f068-4653-9688-056aab3fb675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails" xlink:type="simple" xlink:href="apyx-20220930.xsd#EARNINGSLOSSPERSHAREDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_da8c98f4-2ab2-4a07-8188-b7e97f400c45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_2316a182-2cd5-4af6-b5c2-82a17222e857" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_da8c98f4-2ab2-4a07-8188-b7e97f400c45" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_2316a182-2cd5-4af6-b5c2-82a17222e857" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_e967cad8-a9f0-44dd-823f-74918323e5d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_2316a182-2cd5-4af6-b5c2-82a17222e857" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_e967cad8-a9f0-44dd-823f-74918323e5d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_aea979c7-6230-4a48-b8bd-2092407cabfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_e967cad8-a9f0-44dd-823f-74918323e5d5" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_aea979c7-6230-4a48-b8bd-2092407cabfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_8313f73d-4466-417e-b011-5a706e49bc26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_aea979c7-6230-4a48-b8bd-2092407cabfd" xlink:to="loc_us-gaap_EmployeeStockOptionMember_8313f73d-4466-417e-b011-5a706e49bc26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ef173deb-0ebf-4b29-a3d8-6d548496b7c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_2316a182-2cd5-4af6-b5c2-82a17222e857" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ef173deb-0ebf-4b29-a3d8-6d548496b7c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract_aff9970d-5941-450e-b8af-4f8c31f346ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ef173deb-0ebf-4b29-a3d8-6d548496b7c0" xlink:to="loc_us-gaap_EarningsPerShareReconciliationAbstract_aff9970d-5941-450e-b8af-4f8c31f346ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_6d8b4078-57fa-4914-b8fe-71471d577c35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_aff9970d-5941-450e-b8af-4f8c31f346ca" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_6d8b4078-57fa-4914-b8fe-71471d577c35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_a63a4966-f5c7-4e74-bad3-a882d09f147a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_aff9970d-5941-450e-b8af-4f8c31f346ca" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_a63a4966-f5c7-4e74-bad3-a882d09f147a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_b949215f-e812-434c-a452-7220247ce90a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DilutiveSecuritiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ef173deb-0ebf-4b29-a3d8-6d548496b7c0" xlink:to="loc_us-gaap_DilutiveSecuritiesAbstract_b949215f-e812-434c-a452-7220247ce90a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d59529d8-981a-413b-8ad4-e80c6149753b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_b949215f-e812-434c-a452-7220247ce90a" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d59529d8-981a-413b-8ad4-e80c6149753b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_fb08d6e2-a6a4-4bed-ba98-06b58ae5139e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_b949215f-e812-434c-a452-7220247ce90a" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_fb08d6e2-a6a4-4bed-ba98-06b58ae5139e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_bc1681ff-cb55-4336-8b9e-68e63351ad53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ef173deb-0ebf-4b29-a3d8-6d548496b7c0" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_bc1681ff-cb55-4336-8b9e-68e63351ad53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_99cfa746-40a4-474c-962e-c778bcefc743" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_bc1681ff-cb55-4336-8b9e-68e63351ad53" xlink:to="loc_us-gaap_EarningsPerShareBasic_99cfa746-40a4-474c-962e-c778bcefc743" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_bdc8f896-d882-4db3-afda-887a94a035fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_bc1681ff-cb55-4336-8b9e-68e63351ad53" xlink:to="loc_us-gaap_EarningsPerShareDiluted_bdc8f896-d882-4db3-afda-887a94a035fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_08b35430-64d3-4575-9941-920bd581e85a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ef173deb-0ebf-4b29-a3d8-6d548496b7c0" xlink:to="loc_us-gaap_EarningsPerShareDilutedAbstract_08b35430-64d3-4575-9941-920bd581e85a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1ecb3a47-79c8-4cba-a29f-0f32e23d3252" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_08b35430-64d3-4575-9941-920bd581e85a" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1ecb3a47-79c8-4cba-a29f-0f32e23d3252" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" xlink:type="simple" xlink:href="apyx-20220930.xsd#STOCKBASEDCOMPENSATIONNarrativeDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_603d66d3-0fee-4166-9682-d3545bcc82d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_fd765e1b-9495-4d56-8eba-de85431241b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_603d66d3-0fee-4166-9682-d3545bcc82d0" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_fd765e1b-9495-4d56-8eba-de85431241b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived_dafdbf93-0897-494c-bdb6-6338821ac6d9" xlink:href="apyx-20220930.xsd#apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_603d66d3-0fee-4166-9682-d3545bcc82d0" xlink:to="loc_apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived_dafdbf93-0897-494c-bdb6-6338821ac6d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_StockIssuedDuringPeriodSharesStockSwaps_ab097306-cbff-40e3-8901-50e517b0318a" xlink:href="apyx-20220930.xsd#apyx_StockIssuedDuringPeriodSharesStockSwaps"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_603d66d3-0fee-4166-9682-d3545bcc82d0" xlink:to="loc_apyx_StockIssuedDuringPeriodSharesStockSwaps_ab097306-cbff-40e3-8901-50e517b0318a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONSummaryofStockOptionsDetails" xlink:type="simple" xlink:href="apyx-20220930.xsd#STOCKBASEDCOMPENSATIONSummaryofStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONSummaryofStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1f53f372-588d-44f8-87a8-f02e950b32a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a2e66997-59b5-40ce-baef-c4a247be18cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1f53f372-588d-44f8-87a8-f02e950b32a8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a2e66997-59b5-40ce-baef-c4a247be18cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e3704336-8b31-42f7-b19c-4ef38b8bc17f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a2e66997-59b5-40ce-baef-c4a247be18cf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e3704336-8b31-42f7-b19c-4ef38b8bc17f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0a011663-e665-4d9b-b5ac-91391598ba81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a2e66997-59b5-40ce-baef-c4a247be18cf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0a011663-e665-4d9b-b5ac-91391598ba81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_5f38034d-7420-4846-8c30-cfc03ba94660" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a2e66997-59b5-40ce-baef-c4a247be18cf" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_5f38034d-7420-4846-8c30-cfc03ba94660" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_fecdf43c-5a61-4e5a-aa55-945ea7c6c150" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a2e66997-59b5-40ce-baef-c4a247be18cf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_fecdf43c-5a61-4e5a-aa55-945ea7c6c150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_56e23039-6909-4a85-af74-16ebd40194f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a2e66997-59b5-40ce-baef-c4a247be18cf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_56e23039-6909-4a85-af74-16ebd40194f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7a2a0ddb-8ad9-497f-bd8e-c03fb1a2dfc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1f53f372-588d-44f8-87a8-f02e950b32a8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7a2a0ddb-8ad9-497f-bd8e-c03fb1a2dfc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e8f7aa30-ca46-4ddd-9b56-5fd7f9dc61b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7a2a0ddb-8ad9-497f-bd8e-c03fb1a2dfc4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e8f7aa30-ca46-4ddd-9b56-5fd7f9dc61b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_e749f71d-bccc-4b95-b580-45b9b785562f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7a2a0ddb-8ad9-497f-bd8e-c03fb1a2dfc4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_e749f71d-bccc-4b95-b580-45b9b785562f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_8f415761-f25a-46ee-8f60-0027ee2569f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7a2a0ddb-8ad9-497f-bd8e-c03fb1a2dfc4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_8f415761-f25a-46ee-8f60-0027ee2569f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_20736990-9f2d-499c-ad26-6d5dce852524" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7a2a0ddb-8ad9-497f-bd8e-c03fb1a2dfc4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_20736990-9f2d-499c-ad26-6d5dce852524" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e319c5a5-00ec-402a-8c2f-3c4f1c9a1942" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7a2a0ddb-8ad9-497f-bd8e-c03fb1a2dfc4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e319c5a5-00ec-402a-8c2f-3c4f1c9a1942" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONFairValueAssumptionsDetails" xlink:type="simple" xlink:href="apyx-20220930.xsd#STOCKBASEDCOMPENSATIONFairValueAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONFairValueAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a3335963-568b-4c87-b452-dd58ccad1759" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_dd8709e1-fa50-433f-a918-970847d40bda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a3335963-568b-4c87-b452-dd58ccad1759" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_dd8709e1-fa50-433f-a918-970847d40bda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0c74d6aa-88b8-42eb-aa49-557376f68a4e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_dd8709e1-fa50-433f-a918-970847d40bda" xlink:to="loc_srt_RangeAxis_0c74d6aa-88b8-42eb-aa49-557376f68a4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f8947491-2d43-495a-a5d2-53ce92d0006d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_0c74d6aa-88b8-42eb-aa49-557376f68a4e" xlink:to="loc_srt_RangeMember_f8947491-2d43-495a-a5d2-53ce92d0006d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c32f2c05-e90a-438f-bc5e-4fe7f54bf260" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f8947491-2d43-495a-a5d2-53ce92d0006d" xlink:to="loc_srt_MinimumMember_c32f2c05-e90a-438f-bc5e-4fe7f54bf260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9caa90e3-ff11-4721-b427-88fc32e1545c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f8947491-2d43-495a-a5d2-53ce92d0006d" xlink:to="loc_srt_MaximumMember_9caa90e3-ff11-4721-b427-88fc32e1545c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_c45f49bb-2a67-4119-b39b-479200b0fa98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_dd8709e1-fa50-433f-a918-970847d40bda" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_c45f49bb-2a67-4119-b39b-479200b0fa98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c2a39dc6-7101-495f-892a-f97bdf8e7701" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_c45f49bb-2a67-4119-b39b-479200b0fa98" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c2a39dc6-7101-495f-892a-f97bdf8e7701" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_3ebdde05-a4ad-4db2-8373-921c523524f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_c45f49bb-2a67-4119-b39b-479200b0fa98" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_3ebdde05-a4ad-4db2-8373-921c523524f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c1c314b0-d576-4f71-b487-1bff57c0f809" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_c45f49bb-2a67-4119-b39b-479200b0fa98" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c1c314b0-d576-4f71-b487-1bff57c0f809" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_a251f3d0-084d-4771-b4ee-f752293b61cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_c45f49bb-2a67-4119-b39b-479200b0fa98" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_a251f3d0-084d-4771-b4ee-f752293b61cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_88b5eb4e-2983-4c7d-aca2-bbf8c8b80dc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_c45f49bb-2a67-4119-b39b-479200b0fa98" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_88b5eb4e-2983-4c7d-aca2-bbf8c8b80dc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/INCOMETAXESDetails" xlink:type="simple" xlink:href="apyx-20220930.xsd#INCOMETAXESDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/INCOMETAXESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_f2807f89-eaad-4a2b-b584-ae7349001032" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_2b934d31-d941-4b54-99cf-39a9884c75a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f2807f89-eaad-4a2b-b584-ae7349001032" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_2b934d31-d941-4b54-99cf-39a9884c75a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f6d1908a-259a-4591-9eac-eb21186a0569" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f2807f89-eaad-4a2b-b584-ae7349001032" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f6d1908a-259a-4591-9eac-eb21186a0569" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_db771441-24ad-45c0-b331-c3b512a6bf91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f2807f89-eaad-4a2b-b584-ae7349001032" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_db771441-24ad-45c0-b331-c3b512a6bf91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_0a330f49-6b3a-4c44-adf2-e529da499689" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f2807f89-eaad-4a2b-b584-ae7349001032" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_0a330f49-6b3a-4c44-adf2-e529da499689" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_e54494f0-e815-4920-afb8-4db2f6152c70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f2807f89-eaad-4a2b-b584-ae7349001032" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_e54494f0-e815-4920-afb8-4db2f6152c70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_5992d83f-a29c-4907-9bfc-2bdce122e599" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f2807f89-eaad-4a2b-b584-ae7349001032" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_5992d83f-a29c-4907-9bfc-2bdce122e599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" xlink:type="simple" xlink:href="apyx-20220930.xsd#COMMITMENTSANDCONTINGENCIESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2f91b06f-797d-4f7f-a730-cfd1fc61c129" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_e9706a74-bae9-4414-9301-4b90af9df70d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2f91b06f-797d-4f7f-a730-cfd1fc61c129" xlink:to="loc_us-gaap_LossContingenciesTable_e9706a74-bae9-4414-9301-4b90af9df70d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d89a67ae-e570-4ee8-a223-3d481c3de197" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_e9706a74-bae9-4414-9301-4b90af9df70d" xlink:to="loc_srt_RangeAxis_d89a67ae-e570-4ee8-a223-3d481c3de197" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4f9c707a-7807-47e1-99f4-648f6a0768f9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_d89a67ae-e570-4ee8-a223-3d481c3de197" xlink:to="loc_srt_RangeMember_4f9c707a-7807-47e1-99f4-648f6a0768f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_292a7999-d752-4c42-9276-d3a3106ee0fb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4f9c707a-7807-47e1-99f4-648f6a0768f9" xlink:to="loc_srt_MinimumMember_292a7999-d752-4c42-9276-d3a3106ee0fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9c55f733-f447-40b0-8828-f020337865f5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4f9c707a-7807-47e1-99f4-648f6a0768f9" xlink:to="loc_srt_MaximumMember_9c55f733-f447-40b0-8828-f020337865f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_278126af-f6dd-4b49-a838-d744a8fffffd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_e9706a74-bae9-4414-9301-4b90af9df70d" xlink:to="loc_srt_LitigationCaseAxis_278126af-f6dd-4b49-a838-d744a8fffffd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_4b31bc23-5dd8-4bbd-ab62-49984ec113ce" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_278126af-f6dd-4b49-a838-d744a8fffffd" xlink:to="loc_srt_LitigationCaseTypeDomain_4b31bc23-5dd8-4bbd-ab62-49984ec113ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ContractWithInternationalDistributorMember_22d3e93a-f5db-4cec-b095-f497261246ba" xlink:href="apyx-20220930.xsd#apyx_ContractWithInternationalDistributorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_4b31bc23-5dd8-4bbd-ab62-49984ec113ce" xlink:to="loc_apyx_ContractWithInternationalDistributorMember_22d3e93a-f5db-4cec-b095-f497261246ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SuitAgainstGoodwinAndSimbMember_9b011875-ba07-4f98-b638-a39118e50d8b" xlink:href="apyx-20220930.xsd#apyx_SuitAgainstGoodwinAndSimbMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_4b31bc23-5dd8-4bbd-ab62-49984ec113ce" xlink:to="loc_apyx_SuitAgainstGoodwinAndSimbMember_9b011875-ba07-4f98-b638-a39118e50d8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_a0f2ff46-7bac-4e76-9c29-1a03ccce3c44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_e9706a74-bae9-4414-9301-4b90af9df70d" xlink:to="loc_us-gaap_LossContingenciesLineItems_a0f2ff46-7bac-4e76-9c29-1a03ccce3c44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_fcb72af9-f5bc-4b84-9d15-2b11f761dce8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_a0f2ff46-7bac-4e76-9c29-1a03ccce3c44" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_fcb72af9-f5bc-4b84-9d15-2b11f761dce8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_058ac5d3-d639-4417-b9b2-4a9dc84d2b9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_a0f2ff46-7bac-4e76-9c29-1a03ccce3c44" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_058ac5d3-d639-4417-b9b2-4a9dc84d2b9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation_31690cc7-df6a-4423-b14b-a270c7483842" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_a0f2ff46-7bac-4e76-9c29-1a03ccce3c44" xlink:to="loc_us-gaap_PurchaseObligation_31690cc7-df6a-4423-b14b-a270c7483842" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSDetails" xlink:type="simple" xlink:href="apyx-20220930.xsd#RELATEDPARTYTRANSACTIONSDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_0386284f-fa58-4481-ad1e-023992aa9fe3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_da3a2449-4c85-4b99-8be6-f847c3964df8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0386284f-fa58-4481-ad1e-023992aa9fe3" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_da3a2449-4c85-4b99-8be6-f847c3964df8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_b88357b8-5438-470c-8b2c-910c55314cfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_da3a2449-4c85-4b99-8be6-f847c3964df8" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_b88357b8-5438-470c-8b2c-910c55314cfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_2e007523-fedd-4adf-acb3-1cdf34b63293" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_b88357b8-5438-470c-8b2c-910c55314cfa" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_2e007523-fedd-4adf-acb3-1cdf34b63293" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CoVenturerMember_c4352e4d-fe39-4e98-be91-acffdebc472d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CoVenturerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_2e007523-fedd-4adf-acb3-1cdf34b63293" xlink:to="loc_us-gaap_CoVenturerMember_c4352e4d-fe39-4e98-be91-acffdebc472d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_95d2e485-1ecb-45ef-aa45-ff3fb154c7c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_da3a2449-4c85-4b99-8be6-f847c3964df8" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_95d2e485-1ecb-45ef-aa45-ff3fb154c7c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_4987a269-7106-438c-89e2-5b408e877324" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_95d2e485-1ecb-45ef-aa45-ff3fb154c7c5" xlink:to="loc_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_4987a269-7106-438c-89e2-5b408e877324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_6a1ec68f-64f7-4db0-8f72-b12e0605d6c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_95d2e485-1ecb-45ef-aa45-ff3fb154c7c5" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_6a1ec68f-64f7-4db0-8f72-b12e0605d6c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONNarrativeDetails" xlink:type="simple" xlink:href="apyx-20220930.xsd#GEOGRAPHICANDSEGMENTINFORMATIONNarrativeDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_6ebd7ec7-402c-48c0-b4be-bfe401b0d353" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_eef67ee2-244d-4363-a00e-65787e26b113" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_6ebd7ec7-402c-48c0-b4be-bfe401b0d353" xlink:to="loc_us-gaap_NumberOfReportableSegments_eef67ee2-244d-4363-a00e-65787e26b113" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_827ab173-244d-44eb-811f-f0c7d88ebb31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_6ebd7ec7-402c-48c0-b4be-bfe401b0d353" xlink:to="loc_us-gaap_NumberOfOperatingSegments_827ab173-244d-44eb-811f-f0c7d88ebb31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_TotalRevenuePercent_fb2f4957-5a68-4376-9b1d-738a310a9b56" xlink:href="apyx-20220930.xsd#apyx_TotalRevenuePercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_6ebd7ec7-402c-48c0-b4be-bfe401b0d353" xlink:to="loc_apyx_TotalRevenuePercent_fb2f4957-5a68-4376-9b1d-738a310a9b56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails" xlink:type="simple" xlink:href="apyx-20220930.xsd#GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_c433f95c-6e7e-472c-8ccd-84b5fde8f920" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0526741e-c61e-4336-bd04-16d280a2cf13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_c433f95c-6e7e-472c-8ccd-84b5fde8f920" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0526741e-c61e-4336-bd04-16d280a2cf13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_81639865-3f8e-4f7f-8b63-0445687cd960" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0526741e-c61e-4336-bd04-16d280a2cf13" xlink:to="loc_srt_ConsolidationItemsAxis_81639865-3f8e-4f7f-8b63-0445687cd960" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_67ca60d2-0e2e-46d4-9052-2dce1a1d731b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_81639865-3f8e-4f7f-8b63-0445687cd960" xlink:to="loc_srt_ConsolidationItemsDomain_67ca60d2-0e2e-46d4-9052-2dce1a1d731b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_70ae37dd-164c-4684-8bee-dd27ebb64071" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_67ca60d2-0e2e-46d4-9052-2dce1a1d731b" xlink:to="loc_us-gaap_OperatingSegmentsMember_70ae37dd-164c-4684-8bee-dd27ebb64071" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_2c19d1dc-5638-489b-98e2-e346685c9b46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_67ca60d2-0e2e-46d4-9052-2dce1a1d731b" xlink:to="loc_us-gaap_CorporateNonSegmentMember_2c19d1dc-5638-489b-98e2-e346685c9b46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_67e28c17-8e45-4ffd-9eee-fb866804a5fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0526741e-c61e-4336-bd04-16d280a2cf13" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_67e28c17-8e45-4ffd-9eee-fb866804a5fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_942583c2-d5a1-4bfd-84b5-9942abcd9a28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_67e28c17-8e45-4ffd-9eee-fb866804a5fb" xlink:to="loc_us-gaap_SegmentDomain_942583c2-d5a1-4bfd-84b5-9942abcd9a28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_AdvancedEnergyMember_6381a7b1-aba7-4fdb-b848-c6962c499b4e" xlink:href="apyx-20220930.xsd#apyx_AdvancedEnergyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_942583c2-d5a1-4bfd-84b5-9942abcd9a28" xlink:to="loc_apyx_AdvancedEnergyMember_6381a7b1-aba7-4fdb-b848-c6962c499b4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_OEMMember_74e130ef-0fd4-4800-9b30-4ec339f3b98a" xlink:href="apyx-20220930.xsd#apyx_OEMMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_942583c2-d5a1-4bfd-84b5-9942abcd9a28" xlink:to="loc_apyx_OEMMember_74e130ef-0fd4-4800-9b30-4ec339f3b98a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_8d18a27e-f32d-4943-a029-9b6476758aa5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0526741e-c61e-4336-bd04-16d280a2cf13" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_8d18a27e-f32d-4943-a029-9b6476758aa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_196bad2f-5f32-46d7-b05e-42b12abd29aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_8d18a27e-f32d-4943-a029-9b6476758aa5" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_196bad2f-5f32-46d7-b05e-42b12abd29aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_c4228493-46fb-4dfa-9dfe-1d3578a4e4ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_8d18a27e-f32d-4943-a029-9b6476758aa5" xlink:to="loc_us-gaap_OperatingIncomeLoss_c4228493-46fb-4dfa-9dfe-1d3578a4e4ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOperating_ab0c9b84-6dad-4e4b-a1b1-b0e719b0a944" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeOperating"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_8d18a27e-f32d-4943-a029-9b6476758aa5" xlink:to="loc_us-gaap_InterestIncomeOperating_ab0c9b84-6dad-4e4b-a1b1-b0e719b0a944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_1485fcad-ff71-4144-a167-e762865739b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_8d18a27e-f32d-4943-a029-9b6476758aa5" xlink:to="loc_us-gaap_InterestExpense_1485fcad-ff71-4144-a167-e762865739b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_1d81c583-35cd-4b64-aa34-f2b42135abff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_8d18a27e-f32d-4943-a029-9b6476758aa5" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_1d81c583-35cd-4b64-aa34-f2b42135abff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_a03a08d4-3834-4956-b1d7-1feaf32a254f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_8d18a27e-f32d-4943-a029-9b6476758aa5" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_a03a08d4-3834-4956-b1d7-1feaf32a254f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails" xlink:type="simple" xlink:href="apyx-20220930.xsd#GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_930bfe6a-34a5-482d-ad92-14a2c4c8066b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f40324b3-7102-4a34-ac2c-f4f864a127aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_930bfe6a-34a5-482d-ad92-14a2c4c8066b" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f40324b3-7102-4a34-ac2c-f4f864a127aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_583409e7-9798-4990-97fb-77948ff75aa3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f40324b3-7102-4a34-ac2c-f4f864a127aa" xlink:to="loc_srt_StatementGeographicalAxis_583409e7-9798-4990-97fb-77948ff75aa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_8a17dcc4-8eb1-4840-b890-7025d3cc370b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_583409e7-9798-4990-97fb-77948ff75aa3" xlink:to="loc_srt_SegmentGeographicalDomain_8a17dcc4-8eb1-4840-b890-7025d3cc370b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_e426ba7d-746d-4d98-864a-048c93da3ec2" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_8a17dcc4-8eb1-4840-b890-7025d3cc370b" xlink:to="loc_country_US_e426ba7d-746d-4d98-864a-048c93da3ec2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_448ca0de-baa7-40b5-af24-43c84dfc978e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_8a17dcc4-8eb1-4840-b890-7025d3cc370b" xlink:to="loc_us-gaap_NonUsMember_448ca0de-baa7-40b5-af24-43c84dfc978e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_60a5df63-44c1-4f78-8685-cb5f69bed83c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f40324b3-7102-4a34-ac2c-f4f864a127aa" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_60a5df63-44c1-4f78-8685-cb5f69bed83c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b171948c-c109-47fc-9236-23594f2ecb3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_60a5df63-44c1-4f78-8685-cb5f69bed83c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b171948c-c109-47fc-9236-23594f2ecb3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>apyx-20220930_g1.jpg
<TEXT>
begin 644 apyx-20220930_g1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" *0 _(# 2(  A$! Q$!_\0
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MG[CPEF'UO ^PD_>IZ?+I_E\AE%%%?&'VX5]*?LA^.-LFI^%+F3 ;_3;3<>_
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MVX9RCZ]6^LUE^[A^+[?+=_<?#<49S]0H?5J+_>3_  7?U>R^;->BBBOV<_$
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MK\\/$WA^Y\*^(-1TB['^D64[0L<8#8/##V(P1[&OR+B_ ^RQ$<7%:3T?JO\
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MR/R+C3'^TK0P47I'5^KV^Y?F%%%%?HI^:!1110 4444 %%%% !1110 4444
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M^G*+BY Z&9Q\H/\ NH?_ !\^E?3GB;Q!;>%?#^H:O>'%M9PM,PZ%L#A1[DX
M^M?GCKNL7/B+6K[4[Q]]U>3//(W^TQS^5? <78[V.&CA(/6>_HO\W^3/T/@W
M+_;8F6,FM(:+U?\ DOS11HHHK\A/V4***LZ;I]QJ^HVMC:1F6ZNI5ABC'5G8
M@ ?F132<G9";44V]CZ/_ &0_ ORZEXKN8^?^/*TR/H9&'_CJ@_[PKZ8K#\%^
M%[?P7X5TS1;;!CLX5C+@8WOU9OQ8D_C6Y7]"Y3@5E^#A0ZK5^KW_ ,C^<<XQ
M[S+&U,1T;LO1;?Y^H4445ZYXP4444 %%8?A/QIHWCBSO+O1+^._M[2]GT^9X
M^B3PN4D7\".#T(((X-;E-IQ=F)--704444AA6'XT\+V_C3PKJ>BW.!'>0M&'
M(SL?JK?@P!_"MRBHJ0C4@X35T]&:4ZDJ4U4@[-.Z]4?FQJ6GW&D:C=6-W&8K
MJUE:&6,]5=201^8-5J]S_:N\"_V'XQ@\06\>+35DQ*5'"SH #]-R[3[D,:\,
MK^=<PPDL#BIX>7V7^'1_<?TGE^,CF&$IXF/VE^/5?>%%%%>>>B7M"UBY\.ZU
M8ZG9OLNK.9)XV_VE.?RK]#O#/B"V\5>']/U>S.;:\A691U*Y'*GW!R#]*_..
MOJ7]D7QQ]KTO4?"MP^9+4F[M<G_EFQ =1]&(/_ S7WG"6/\ 88IX63TGMZK_
M #7Z'Y_QAE_UC"+%P7O4]_\ "_\ )V_$^BZ***_83\7"BBB@ HHHH **** /
MSU^)_P#R4KQ;_P!A>[_]'/7,UTWQ/_Y*5XM_["]W_P"CGKF:_FO%?[Q4]7^9
M_3V%_P!WI_X5^2"BBBN8ZCT+]G[_ )+%X:_Z[2?^BGK[NKX1_9^_Y+%X:_Z[
M2?\ HIZ^[J_8.#?]QJ?XW^2/QGC;_?Z?^!?FPHHHK[T_/0HHHH **** "BBB
M@ HHHH **** "BBB@ K"\>?\B/XA_P"P=<_^BFK=K"\>?\B/XA_[!US_ .BF
MK#$?P9^C_(Z,/_&AZK\S\[****_FD_J **** /H[]C7_ )"7BG_KC;_^A25]
M15\N_L:_\A+Q3_UQM_\ T*2OJ*OW/AC_ )%5+_M[_P!*9^"<5?\ (WJ_]N_^
MDH****^J/D@KY2_:Z\%_8=>T[Q/ F(KY/LUR0/\ EJ@^4GW*<?\ ;.OJVN/^
M+/@P>// .K:2J[KEH_-MO:9/F3\R-I]F->'G6!_M# U*27O+5>J_SV^9[^1X
M_P#L['TZS?NO1^C_ ,M_D?G_ $4K*T;%6!5E."",$&DK^?C^B0HHHH ^IOV0
M_&OVS2=2\+W$F9;1OM=JK'_EFQPX'L&P?^VE?15?GW\*_&3> _'FDZQN(MXY
M?+N .\+?*_UP#D>X%?H"CK(BNC!E89#*<@CUK]IX5QWUK!>QD_>IZ?+I_E\C
M\.XMP'U7'^WBO=J:_/K^C^8^BBBOM#X@**** "OC+]J/QK_PDGQ".EPONL]&
M3[.,'(,S8,A_]!7_ (!7U;X\\50^"?!^JZW-M(M("R*W >0\(OXL0/QK\]+N
MZFOKJ:YN)#+<3.TDDC=68G))^I-?G7&&.]G1A@XO66K]%M][_(_2N"\![2M/
M&S6D=%ZO?[E^9%1117Y.?KP445U7PM\&MX\\=Z3H^"8)9=]PP[0K\S\]N 0/
M<BM:-*5>I&E!:R:2^9C6JPH4Y5:CM&*;?HCZR_9P\%?\(A\-K2::/9?:H?ML
MN>H5@/+7_OG!QZL:]4ID<:QQJB*$11A548 'H*?7]&X3#QP="&'AM%6_KU/Y
MIQF)GC,1/$3WD[_UZ!11176<84444 %%%% !1110 4444 %%%% !1110!X=^
MTO\ "7_A+=$/B/3(,ZQI\9\Z.,?-<0#D_5EY(]1D<\5\@5^F%?$7[1G@?3?!
M'C]ETR6,6]_']K-FG!MF+$%<= I()'IR,8 S^6\695&#_M"EI?22\^C_ ,_O
M[GZQP?F\JB_LZKK;6+\NJ_R^[L>64445^:'Z@%%%% !6AX?T.]\3:U9Z5IT)
MGO;J01QH/4]SZ #))[ $UGU]5?LE^!]-AT&Y\4M+%=:G-(UJBKR;5 1D'T9N
M#_NX]2*]C*<O>9XN.'3LMWZ+?YGC9OF*RO!RQ#5WLO5[7\CUSX;> K/X<>$[
M31[3#NH\RXGQS-,0-S_3C '8 "NJHHK^@*5*%"G&E35HK1'\[5JTZ]256H[R
MD[MA1116IB%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%17%Q%9V\L\SB*&)"[NW 50,D_E2O;5CWT1\\_M=>./LFEZ=X5MWQ)=$7=U@
M_P#+-20BGZL"?^ "OEJNE^(_C"7QYXUU76WW!+B4^2C?P1+\J+_WR!^.:YJO
MY]SC'?VAC9UE\.R]%M]^_P S^B\EP']FX&G0:][=^KW^[;Y!1117BGN!7N?[
M*/@?^W/&-QK]Q'FUTE,19'#3N"!]=J[C[$J:\- +$ #)/ Q7WM\&? X\ ?#W
M3=.>/9?2+]IN\]?-< D'_=&%_P" U]?PQ@/KF.522]VGK\^GXZ_(^-XJS#ZE
M@'2B_>J:?+K^&GS.YHHHK]N/PD**** "O)?VIOC OP/^"/B+Q)'*L>J&+['I
MBMC+74N5C('?;\TA'HAKUJOR[_X*;?&3_A+/B=I_@.QFW:=X;B\V["GA[R50
M<'UV1[0/0NXKT,#A_K%>,7LM7Z''BJWL:3DM^A=_X)C_ !I;0/B)K'@'4[IC
M:>(E-Y9F1B<7L:Y<<GJ\8.3U)B4=Z_3>OP \)^*-0\$^*-)\0:5,;?4M,NH[
MNWD'9T8,,^HR.1W'%?NO\,_'NG_%'X?Z!XLTM@;+5K1+E5SDQL1AXR?56#*?
M=37HYQA^2HJRVE^9QY;6YH.F]T=11117SQ[ 4444 <-\9O X\?\ P]U+3DCW
MWT:_:;3'7S4!( _WAE?^!5\$D%201@C@YK]+Z^'/VAO O_"%_$:]:"(II^I?
MZ;;X' +'YU'T;/'8%:_,^,,!>,,;!;>Z_P!'^GW'ZCP7F%I3P,WO[T?U7Y/[
MSS*BBBORX_5PKI?AQXPE\!^-=*UM-Q2WE'G(O\<3?*Z_]\D_CBN:HK6E4E1J
M1JP=FG=?(RJTX5J<J5174E9^C/TKM[B*\MXIX7$L,J!T=>0RD9!_*I:\9_9=
M\<_\)-X!_LJ>3=>Z,P@Y/)A.3&?PPR_\!%>S5_16!Q4<;AH8B&TE_P .ODS^
M:\=A)X'$U,-/>+M\NC^:U"BBBNXX HHHH **** /SU^)_P#R4KQ;_P!A>[_]
M'/7,UTWQ/_Y*5XM_["]W_P"CGKF:_FO%?[Q4]7^9_3V%_P!WI_X5^2"BBBN8
MZCT+]G[_ )+%X:_Z[2?^BGK[NKX1_9^_Y+%X:_Z[2?\ HIZ^[J_8.#?]QJ?X
MW^2/QGC;_?Z?^!?FPHHHK[T_/0HHHH **** "BBB@ HHHH **** "BBB@ K"
M\>?\B/XA_P"P=<_^BFK=K"\>?\B/XA_[!US_ .BFK#$?P9^C_(Z,/_&AZK\S
M\[****_FD_J **** /H[]C7_ )"7BG_KC;_^A25]15\N_L:_\A+Q3_UQM_\
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M6C7I.THO^OO.7%86GC*$\/65XR5OZ]#]+E99%5E(96&00<@BG5X+^R[\5/\
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MYJZ:L_F:4ZDJ,XU(.S3NO5'YJ7=K-8W4UM<1F*XA=HY(VZJP."#]"*BKV/\
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M<![#"O%36L]O1?YO]#\8XQS#ZQBHX2#]VGO_ (G_ )*WXA1117WI^?!1110
MUF"*68@*!DD]!7XE?M6_&)OCC\<?$/B**4R:3')]@TL9.!:Q$A&&>F\[I,=C
M(:_27]OCXR_\*F^ FI6EI/Y6N>)2=)M-K89(V7]_(._$>5R.C2(:_'ZOJ\EP
M]E*O+T7ZG@9E6NU27JPHHHKZ@\,**** "OV(_80^,O\ PMWX":7'>3^;KGAX
MC2;W<V6=44>3(<\G='M!)ZLCU^.]?3?_  3Y^,P^%GQVM=*O9_*T3Q0JZ9<;
MCA4GSFW<_P# R4]A*3VKR<SP_M\.[;QU._!5O95E?9Z'Z\4445\$?6!1110
M5\K_ +7/@;['J^G^*K>/$5X!:71 Z2J/D8^Y4$?\ %?5%<Q\2?!T?CSP3JNB
MN%\V>(F!V_@E7YD/_?0&?8FO$SG _P!H8*=%+WMUZK;[]OF>[DF/_LW'4Z[^
M'9^CW^[?Y'Y[45)<6\EI<2P3(T4T;%'1A@JP."#^-1U_/K5M&?T7YH**** /
MI#]D/QSY5UJ/A2YD^64&\M Q_B&!(H^HVMC_ &6-?4%?G-X1\27/@_Q-INLV
MA_?V<RRA<XW#^)3[$9!^M?H;H^JVVN:7::A9OYMK=1+-$_JK $?SK]CX3Q_U
MC"/#3?O4_P GM]SO^!^+<89?]7Q:Q4%[M3?_ !+?[U9_>7****^Z/@ HHHH
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M/X/HG_H6?05X'7XYQ1FWUNO]4I/W(;^<O^!M]Y^U<*91]3H?6ZR]^:T\H_\
M!W^X****^%/O@HHKJOAGX!NOB1XNL]'M]T<+'S+F=1GR80?F;Z] /<BM:-*=
M>I&E35Y-V1C6K0P].56J[1BKL]B_95^%OVRZ;QEJ47[B!FCT]&'WI.C2_0?=
M'OGT%?4E4](TFUT+2[73[&%;>TM8UBBC7H% P*N5_0.5Y?#+<+&A'?=ON^O_
M  /(_G7-LRGFF*EB)[;)=ET_X/F%07=I!J%K-:W,2SV\R&.2)QE64C!!'H14
M]%>LTFK,\A-IW1\#?&#X<S?#/QE<Z< SZ?-^^LIF_BB)Z$^JGY3],]ZXBON_
MXV?#./XF>#9K6-5&JVN9[&0X'SXY0GT8<?7![5\)S0R6\TD,R-%+&Q1T<896
M!P01V.:_"L_RIY;BGR+]W+5?JOE^5C]^X=S99IA%SO\ >0TEY]G\_P [C***
M*^8/J0KW#]F/XJ?\(KX@_P"$<U&;;I.IR#R6<\0W!P ?8-PI]]OO7A]'2N_
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M,_9.#<O]CAI8R:UGHO1?YO\ )!1117Y^?H@5);V\EW<100HTLTC!$11DLQ.
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MK[B/[/H=F?EG_P .LOBO_P!#!X-_\#;O_P"1:/\ AUE\5_\ H8/!O_@;=_\
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M:<8'EN2=H]E;<O\ P&OO.O$?VJO W_"0>"8M;MTW7FCN6; Y:!\!_P CM;V
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MWK#[DW#!6!"0GYG<WN"M>WU7L;&#3;*WL[:,16]O&L44:]%50 !^ %6*_HK
M82.!PT,/'[*_'J_FS^:\PQDL?BJF)G]I_AT7R04445WGGA1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !5>^L8-2LKBSN8Q+;W$;12QMT96
M!!'X@U8HI-)JS&FXNZ/SM\>>%)_!'B_5=$GR3:3%$<_QQGE&_%2#^-8-?3G[
M7G@?S(--\5VZ?-'_ *%=D?W228V/T.X?BM?,=?SWF^!>7XV=#INO1[?Y']'9
M/CUF6!IXCKL_5;_Y_,****\<]D<CM&ZNC%74Y#*<$&OOWX2^-E^('@/2]6+
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M/#1J_"M?=EOUZ=SY>HKZA_X8UL_^AIG_ / )?_BZ/^&-;/\ Z&F?_P  E_\
MBZ\[_5C-?^?7_DT?\ST_]:LH_P"?O_DLO\CY>KZI_93^&,^CV=QXLU& Q37D
M?DV*.,,(<Y:3'^T0,>P)Z$5T_@O]F'PCX5NH[N[$VNW2'*_;<>2I]?+ P?\
M@1(KU_IP.!7UV1<-5,'66*Q;5ULEKKW?Z?>?&Y_Q/3QE!X3!IV>[>FG9?K?T
ML+1117Z*?FH4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% &/XN\-6WC#PSJ6BW?\ J+R%HBV,E#U5A[A@"/I7Y^^*O"^H>#=>
MN](U2 P7=NVUA_"P[,I[J1R#7Z-5R_CCX;>'_B)9I;ZW8K.T8(BN$.R:+/\
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MX'Z]CX1DO=C[S^7^;LCYKB+'_P!GY?.47[TO=7J_\E=GME%%%?O1_/@4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?GK\3_P#DI7BW_L+W
M?_HYZYFNF^)__)2O%O\ V%[O_P!'/7,U_->*_P!XJ>K_ #/Z>PO^[T_\*_)!
M1117,=1Z%^S]_P EB\-?]=I/_13U]W5\(_L_?\EB\-?]=I/_ $4]?=U?L'!O
M^XU/\;_)'XSQM_O]/_ OS84445]Z?GH4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %<O\2/'%M\/?!]_K5R59
MXUV6\)/^MF/"+^?)]@3VJYXL\::-X'TQK_6K^*R@ ^56.7D/]U%'+'Z5\6_&
M/XNWOQ4UQ7VM:Z/:DBTM">>>KOZL?R X'<GYC/,YIY;1<8N]5[+MYO\ K4^J
MR')*N:5XRFK4EN^_DO-_@<)?7T^IWUQ>74AFN;B1I99&ZL[$DD_4DU!117X4
MVY.[/WU))604444AFSX-\-S^,?%6EZ+;9$M[.L6X#.Q>K-] H)_"OT-TW3[?
M2=/M;&UC$5M;1+#$@Z*J@ #\A7S+^R'X*^TZEJGBBXCREL/L=J3_ 'V&9&'N
M%VC_ (&:^I*_8^$L#[#"/$R6M1_@MOQO^!^+<8X_ZQC%A8OW::_%[_A;\0HH
MHK[H^ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 ?GK\3_^2E>+?^PO=_\ HYZY
MFNF^)_\ R4KQ;_V%[O\ ]'/7,U_->*_WBIZO\S^GL+_N]/\ PK\D%%%%<QU'
MH7[/W_)8O#7_ %VD_P#13U]W5\(_L_?\EB\-?]=I/_13U]W5^P<&_P"XU/\
M&_R1^,\;?[_3_P "_-A1117WI^>A1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 5\-_M)?\EJ\1?\ ;M_Z315]R5\-_M)?\EJ\1?\
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MBBOK#Y **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[QJ7(N "Q"C)  SV%<O_ ,/3?BO_ -"_X-_\ KO_ .2:^>?VBO\ DX+XG?\
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MO':^]HX'#2I1;@KV1\I4Q593DE+J?8__  ]-^*__ $+_ (-_\ KO_P"2:/\
MAZ;\5_\ H7_!O_@%=_\ R37QQ16WU#"_\^T9?6Z_\[/L?_AZ;\5_^A?\&_\
M@%=__)-3V?\ P50^)L<V;OPSX3GC_NPV]U&?S,[?RKXQHH_L_"_\^T'UNO\
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MB5%,L3'WRC(/^NAKLS/#JM0<K:QU_P SGP-9TJJ71Z'ZVT445\&?5A7YZ_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 ?A;^T5_R<%\3O\ L9]4_P#2N6O/J]!_:*_Y."^)
MW_8SZI_Z5RUY]7Z;1_AQ]$?$5/CEZA0K%&#*2K Y!'45[S\1/@BMK^RK\*OB
MAID&%NC>Z7J^Q?XQ?7)@F/U4&,D_W8QWKP:G3J1JIN/1M?<*<'!I/R?WG[4_
MLA_&@?'+X':)K5S/Y^N6:_V=JN?O&XC !<_[ZE'^KD=J]JK\G?\ @G+\;/\
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MN<8RQ4$U=K.\._\ (OZ7_P!>L7_H K1K\Y>Y]DM@HHHI#/Q._;&_Y.<^(O\
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M_>:GJSZS"_P8>@4445Q'2?B=^V-_R<Y\1?\ L*-_Z"M>.U[%^V-_R<Y\1?\
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M97/B?(_?BQM%L;&WMD8LD,:QJS=2 ,<_E5BBBORT^Z"OSU_X*T_\TJ_[BO\
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M_!AZ+\CXJM_$EZL_6S_@FQ_R;#8_]A2[_P#0A7U/7RQ_P38_Y-AL?^PI=_\
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M*7D89X!VJ0,]R.O2OT>4HTH-O1(^,BG.5ENSSNBOTZ_X=4_#[_H;O$WYV_\
M\:H_X=4_#[_H;O$WYV__ ,:KRO[6PO=_<>A_9]?M^)^8M%?IU_PZI^'W_0W>
M)OSM_P#XU1_PZI^'W_0W>)OSM_\ XU1_:V%[O[@_L^OV_$_,6BOTZ_X=4_#[
M_H;O$WYV_P#\:KX]_;"_9M@_9K^(&G:5IM[=:GHFI6(NK:ZO OF;PQ62,[0
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MJ]!_:*_Y."^)W_8SZI_Z5RUY]7Z;1_AQ]$?$5/CEZG[&_P#!/_\ Y-&\!_\
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M,E9:16W^9]/A,*L/&[^)A1117E'>%?GK_P %:?\ FE7_ '%?_;.OT*K\]?\
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MOP-:I.LHRDVC[9HHHKXT^D"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M6*W\[^]A[&G_ "K[CQO_ (8[^"W_ $3K1O\ OVW_ ,51_P ,=_!;_HG6C?\
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M?C-XLC\-^%=9N+[5I(7G6*2PFA&Q!ECN90.]>T5^2/\ P39_Y.>L?^P7=_\
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MUYHHHKQ3TPHHHH XWXT?\D=\=_\ 8!O_ /TG>OP>K]X?C1_R1WQW_P!@&_\
M_2=Z_!ZOK<D^"?JCY_-/BB?L;_P3_P#^31O ?_;_ /\ I?<U]#5\\_\ !/\
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MPG5]E9IGVS1117DGH!17Y'_&#]N[XHWWQ0\42>$_&5QIOAI;^6/3K>&W@91
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MW8[_ '>7]=3Y(_8Y_P"3G/AU_P!A1?\ T%J_;&OQ._8Y_P"3G/AU_P!A1?\
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MY;:?BSBI<F)Q#G5>G]61[5I_["OP.L=)-A_P@MO<(R@--<7=PTS>^_S,J?\
M=P*^-?VT/V%[7X-Z$_C?P-+<S^&(Y%2_TVY?S)+'<0JR*_5HRQ"D'YE)!R03
MM^T/^&XO@;_T4"S_ / 6Y_\ C5<O\4/VN/@5XY^&_BGP])XZL;@:IIEQ:",V
MMP,L\;*N#Y?!R00>Q&:\+#U<=2J*4E)KK=,]2M3PM2#2<4^FQ^:7[.OQFO\
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M*G_DL7BW_L G_P!*(J^8_CK\3I/C)\7/%'C)HF@35+LO!"_WD@11'"K>XC1
M<=P:^G/^"5/_ "6+Q;_V 3_Z415]MB(.GE[@]U%?H?+T9*IC.9;-L_3VO*/V
MI/A;_P +A^!/BSPY%%YNH-:F[L /O?:8CYD8'IN*[#[.:]7HKXFG-TY*<=T?
M42BIQ<7LS^>^&:6SN(Y8G:&:)@Z.IPRL#D$>A!K]6?CG^TE%>_L)Q^,[6X5-
M4\5Z=%I2>6P&VZE!CNE7'0H$N,8_NCI7P=^V5\+?^%2_M#>*-,AB$.F7TO\
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M&T"-;A&UO0;>/2M2M=PWHT:[8Y"/1T56SC&=X_A-?0%<-7-,52J2IR2T\O\
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MGZ5^.=FL+7<"W+,EN742,G4+GDCWQFNG)J,.259K6]C#,JLN94UMN>P_"?\
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MJ<.(_P!]^:_0_9^BBBOBCZ8_&_\ ;^_Y.Y\>?]N'_I!;5[M_P2=_Y&#XC_\
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M^\T_5?F<V)_@S]&?D%7]"=?SV5_0G7NYY_R[^?Z'EY7]OY?J%?C1^W)\*_\
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ML1/$=TO^#^AX$J[J48T>W](_2_\ X)?_  L/AOX6ZUXVNX=EUXBNO(MF8?\
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M:XN/ %K'(3G;:7MU;)_WS%*J_I7:_#O]GOX;_"BX%UX4\'Z9I-X 5%X(S+<
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M/4_$;G6+C<,$(X A7Z>4J-]7-?2=06=G#I]G!:VT206\"+%%%&,*B@8"@=@
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MO4KGQ#K=S=ZE>:A.YEU&Z+.9I %+#<>I 9.!T!7H,5[=^P#_ ,G<^ _^W_\
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M=P=_D>-_9M5.RDK'Y$7?PC\3Z=\+8?B#>Z=)9>&KG48],M)[@%&NI'CED+1
MCYD41$%NF2 ,X;"?!?\ Y+%X$_[#UC_Z4)7Z&_\ !4[4;6S^"'A/25VQS3>(
M(YX8U  \N*VG5L#T!E3\Z_/WX!Z?)JWQS^'EG'G=-XAT]<@9VC[0F3CV&3^%
M>CA\0\3AY59*VYQUJ*HUE33OL?NQ1117Y^?7!1110!QOQH_Y([X[_P"P#?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M<91P]#ZMAW=[>B_S'AL/4K5?;5EYG6T445\D?0A1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139878286204144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Nov. 09, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-12183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">APYX MEDICAL CORPORATION<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">11-2644611<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">5115 Ulmerton Road,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Clearwater<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">FL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">33760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">384-2323<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">APYX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,597,822<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000719135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139878286666848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 14,833<span></span>
</td>
<td class="nump">$ 30,870<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Trade accounts receivable, net of allowance of $634 and $430</a></td>
<td class="nump">9,094<span></span>
</td>
<td class="nump">13,038<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesReceivable', window );">Income tax receivables</a></td>
<td class="nump">7,545<span></span>
</td>
<td class="nump">7,642<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">483<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories, net of provision for obsolescence of $379 and $263</a></td>
<td class="nump">12,042<span></span>
</td>
<td class="nump">6,778<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">2,774<span></span>
</td>
<td class="nump">1,926<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">46,307<span></span>
</td>
<td class="nump">60,737<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net of accumulated depreciation and amortization of $5,335 and $5,316</a></td>
<td class="nump">6,810<span></span>
</td>
<td class="nump">6,575<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">774<span></span>
</td>
<td class="nump">121<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance lease right-of-use assets</a></td>
<td class="nump">124<span></span>
</td>
<td class="nump">178<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">1,253<span></span>
</td>
<td class="nump">1,110<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">55,268<span></span>
</td>
<td class="nump">68,721<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">2,070<span></span>
</td>
<td class="nump">2,631<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">8,842<span></span>
</td>
<td class="nump">10,287<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liabilities</a></td>
<td class="nump">240<span></span>
</td>
<td class="nump">122<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Current portion of finance lease liabilities</a></td>
<td class="nump">42<span></span>
</td>
<td class="nump">165<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">11,194<span></span>
</td>
<td class="nump">13,205<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="nump">454<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Long-term finance lease liabilities</a></td>
<td class="nump">78<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Long-term contract liabilities</a></td>
<td class="nump">1,192<span></span>
</td>
<td class="nump">1,323<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">133<span></span>
</td>
<td class="nump">166<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">13,051<span></span>
</td>
<td class="nump">14,712<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 75,000,000 shares authorized; 34,588,398 issued and outstanding as of September&#160;30, 2022, and 34,409,912 issued and outstanding as of December 31, 2021</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">71,641<span></span>
</td>
<td class="nump">66,221<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(29,686)<span></span>
</td>
<td class="num">(12,551)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">41,990<span></span>
</td>
<td class="nump">53,704<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Non-controlling interest</a></td>
<td class="nump">227<span></span>
</td>
<td class="nump">305<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="nump">42,217<span></span>
</td>
<td class="nump">54,009<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="nump">$ 55,268<span></span>
</td>
<td class="nump">$ 68,721<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Liabilities and Other Liabilities, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.5(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139878287002816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowance for doubtful accounts receivable</a></td>
<td class="nump">$ 634<span></span>
</td>
<td class="nump">$ 430<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_ProvisionForObsolescenceInventory', window );">Inventories, provision for obsolescence</a></td>
<td class="nump">379<span></span>
</td>
<td class="nump">263<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation and amortization</a></td>
<td class="nump">$ 5,335<span></span>
</td>
<td class="nump">$ 5,316<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">75,000,000<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">34,588,398<span></span>
</td>
<td class="nump">34,409,912<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">34,588,398<span></span>
</td>
<td class="nump">34,409,912<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_ProvisionForObsolescenceInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Provision For Obsolescence, Inventory</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_ProvisionForObsolescenceInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139878286320064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales</a></td>
<td class="nump">$ 9,114<span></span>
</td>
<td class="nump">$ 11,831<span></span>
</td>
<td class="nump">$ 31,899<span></span>
</td>
<td class="nump">$ 31,693<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="nump">3,357<span></span>
</td>
<td class="nump">3,775<span></span>
</td>
<td class="nump">11,009<span></span>
</td>
<td class="nump">10,243<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">5,757<span></span>
</td>
<td class="nump">8,056<span></span>
</td>
<td class="nump">20,890<span></span>
</td>
<td class="nump">21,450<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Other costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">1,061<span></span>
</td>
<td class="nump">1,175<span></span>
</td>
<td class="nump">3,289<span></span>
</td>
<td class="nump">3,374<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Professional services</a></td>
<td class="nump">1,936<span></span>
</td>
<td class="nump">2,032<span></span>
</td>
<td class="nump">6,611<span></span>
</td>
<td class="nump">5,442<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalariesAndWages', window );">Salaries and related costs</a></td>
<td class="nump">3,871<span></span>
</td>
<td class="nump">4,206<span></span>
</td>
<td class="nump">13,944<span></span>
</td>
<td class="nump">12,794<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">4,671<span></span>
</td>
<td class="nump">4,611<span></span>
</td>
<td class="nump">14,675<span></span>
</td>
<td class="nump">12,596<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total other costs and expenses</a></td>
<td class="nump">11,539<span></span>
</td>
<td class="nump">12,024<span></span>
</td>
<td class="nump">38,519<span></span>
</td>
<td class="nump">34,206<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(5,782)<span></span>
</td>
<td class="num">(3,968)<span></span>
</td>
<td class="num">(17,629)<span></span>
</td>
<td class="num">(12,756)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeOperating', window );">Interest income</a></td>
<td class="nump">73<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">93<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other (loss) income, net</a></td>
<td class="num">(35)<span></span>
</td>
<td class="num">(192)<span></span>
</td>
<td class="nump">551<span></span>
</td>
<td class="num">(188)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Total other income (loss), net</a></td>
<td class="nump">37<span></span>
</td>
<td class="num">(193)<span></span>
</td>
<td class="nump">632<span></span>
</td>
<td class="num">(188)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(5,745)<span></span>
</td>
<td class="num">(4,161)<span></span>
</td>
<td class="num">(16,997)<span></span>
</td>
<td class="num">(12,944)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">73<span></span>
</td>
<td class="nump">216<span></span>
</td>
<td class="nump">246<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(5,795)<span></span>
</td>
<td class="num">(4,234)<span></span>
</td>
<td class="num">(17,213)<span></span>
</td>
<td class="num">(13,190)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to non-controlling interest</a></td>
<td class="num">(31)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="num">(78)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to stockholders</a></td>
<td class="num">$ (5,764)<span></span>
</td>
<td class="num">$ (4,222)<span></span>
</td>
<td class="num">$ (17,135)<span></span>
</td>
<td class="num">$ (13,169)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="num">$ (0.17)<span></span>
</td>
<td class="num">$ (0.12)<span></span>
</td>
<td class="num">$ (0.50)<span></span>
</td>
<td class="num">$ (0.38)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="num">$ (0.17)<span></span>
</td>
<td class="num">$ (0.12)<span></span>
</td>
<td class="num">$ (0.50)<span></span>
</td>
<td class="num">$ (0.38)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.2(a),(b),(c),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401555&amp;loc=SL114874292-224272<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433917&amp;loc=SL114874205-224268<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalariesAndWages">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalariesAndWages</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139878287293264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Non-controlling Interest</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,289<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 63,859<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
<td class="nump">$ 61,066<span></span>
</td>
<td class="nump">$ 2,621<span></span>
</td>
<td class="nump">$ 138<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance', window );">Contributions from non-controlling interest</a></td>
<td class="nump">195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">195<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares issued on stock options exercises for cash (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Shares issued on stock options exercises for cash</a></td>
<td class="nump">49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock based compensation</a></td>
<td class="nump">3,747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_StockSwapToAcquireOptionsShares', window );">Shares issued on net settlement of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(13,190)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,169)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2021</a></td>
<td class="nump">54,660<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
<td class="nump">64,862<span></span>
</td>
<td class="num">(10,548)<span></span>
</td>
<td class="nump">312<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,323<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Jun. 30, 2021</a></td>
<td class="nump">57,682<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
<td class="nump">63,650<span></span>
</td>
<td class="num">(6,326)<span></span>
</td>
<td class="nump">324<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares issued on stock options exercises for cash (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Shares issued on stock options exercises for cash</a></td>
<td class="nump">28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock based compensation</a></td>
<td class="nump">1,184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_StockSwapToAcquireOptionsShares', window );">Shares issued on net settlement of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(4,234)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,222)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2021</a></td>
<td class="nump">54,660<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
<td class="nump">64,862<span></span>
</td>
<td class="num">(10,548)<span></span>
</td>
<td class="nump">312<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">54,009<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
<td class="nump">66,221<span></span>
</td>
<td class="num">(12,551)<span></span>
</td>
<td class="nump">305<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares issued on stock options exercises for cash (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Shares issued on stock options exercises for cash</a></td>
<td class="nump">365<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock based compensation</a></td>
<td class="nump">5,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_StockSwapToAcquireOptionsShares', window );">Shares issued on net settlement of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(17,213)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17,135)<span></span>
</td>
<td class="num">(78)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2022</a></td>
<td class="nump">42,217<span></span>
</td>
<td class="nump">$ 35<span></span>
</td>
<td class="nump">71,641<span></span>
</td>
<td class="num">(29,686)<span></span>
</td>
<td class="nump">227<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,493<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Jun. 30, 2022</a></td>
<td class="nump">46,163<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
<td class="nump">69,793<span></span>
</td>
<td class="num">(23,922)<span></span>
</td>
<td class="nump">258<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares issued on stock options exercises for cash (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Shares issued on stock options exercises for cash</a></td>
<td class="nump">157<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock based compensation</a></td>
<td class="nump">1,692<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,692<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_StockSwapToAcquireOptionsShares', window );">Shares issued on net settlement of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(5,795)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,764)<span></span>
</td>
<td class="num">(31)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2022</a></td>
<td class="nump">$ 42,217<span></span>
</td>
<td class="nump">$ 35<span></span>
</td>
<td class="nump">$ 71,641<span></span>
</td>
<td class="num">$ (29,686)<span></span>
</td>
<td class="nump">$ 227<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_StockSwapToAcquireOptionsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock swap to acquire options shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_StockSwapToAcquireOptionsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569655-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139878286623856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (17,213)<span></span>
</td>
<td class="num">$ (13,190)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">688<span></span>
</td>
<td class="nump">674<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_ProvisionForInventoryObsolescence', window );">Provision for inventory obsolescence</a></td>
<td class="nump">158<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of property and equipment</a></td>
<td class="nump">76<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="nump">5,056<span></span>
</td>
<td class="nump">3,747<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for allowance for doubtful accounts</a></td>
<td class="nump">283<span></span>
</td>
<td class="nump">57<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Trade receivables</a></td>
<td class="nump">3,273<span></span>
</td>
<td class="num">(3,168)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(521)<span></span>
</td>
<td class="num">(23)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable', window );">Income tax receivables</a></td>
<td class="nump">97<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(5,672)<span></span>
</td>
<td class="num">(1,982)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(439)<span></span>
</td>
<td class="nump">1,555<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued and other liabilities</a></td>
<td class="num">(1,536)<span></span>
</td>
<td class="nump">1,605<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(15,750)<span></span>
</td>
<td class="num">(10,663)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(868)<span></span>
</td>
<td class="num">(391)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(868)<span></span>
</td>
<td class="num">(391)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised', window );">Proceeds from stock option exercises</a></td>
<td class="nump">365<span></span>
</td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_RepaymentOfFinanceLeaseLiabilities', window );">Repayment of finance lease liabilities</a></td>
<td class="num">(138)<span></span>
</td>
<td class="num">(181)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromMinorityShareholders', window );">Contributions from non-controlling interests</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">195<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">227<span></span>
</td>
<td class="nump">63<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rates on cash</a></td>
<td class="nump">354<span></span>
</td>
<td class="num">(26)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash and cash equivalents</a></td>
<td class="num">(16,037)<span></span>
</td>
<td class="num">(11,017)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of period</a></td>
<td class="nump">30,870<span></span>
</td>
<td class="nump">41,915<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of period</a></td>
<td class="nump">14,833<span></span>
</td>
<td class="nump">30,898<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Cash paid for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Income taxes</a></td>
<td class="nump">128<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract', window );"><strong>Non cash activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_CapitalizationOfLeaseNonCash', window );">Right-of-use assets capitalized and operating lease liabilities recognized upon lease modification</a></td>
<td class="nump">769<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_CapitalizationOfLeaseExecution', window );">Right-of-use assets capitalized and finance lease liabilities recognized upon execution of lease</a></td>
<td class="nump">103<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability', window );">Right-of-use assets and finance lease liabilities derecognized upon execution of lease modification</a></td>
<td class="nump">$ 28<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_CapitalizationOfLeaseExecution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Capitalization Of Lease, Execution</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_CapitalizationOfLeaseExecution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_CapitalizationOfLeaseNonCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Capitalization Of Lease, Non Cash</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_CapitalizationOfLeaseNonCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Stock Options Exercised And Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_ProvisionForInventoryObsolescence">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Provision For Inventory Obsolescence</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_ProvisionForInventoryObsolescence</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_RepaymentOfFinanceLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Repayment Of Finance Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_RepaymentOfFinanceLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInIncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from a noncontrolling interest. Includes, but is not limited to, purchase of additional shares or other increase in noncontrolling interest ownership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139878288539408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">BASIS OF PRESENTATION</a></td>
<td class="text">BASIS OF PRESENTATION<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Apyx Medical Corporation (&#8220;Company&#8221;, &#8220;Apyx&#8221;, &#8220;it&#8221; and similar terms) was incorporated in 1982, under the laws of the State of Delaware and has its principal executive office at 5115 Ulmerton Road, Clearwater, FL 33760.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company is an advanced energy technology company with a passion for elevating people&#8217;s lives through innovative products, including its Helium Plasma Technology products marketed and sold as Renuvion&#174; in the cosmetic surgery market and J-Plasma&#174; in the hospital surgical market. Renuvion&#174; and J-Plasma&#174; offer surgeons a unique ability to provide controlled heat to tissue to achieve their desired results. The Company also leverages its deep expertise and decades of experience in unique waveforms through OEM agreements with other medical device manufacturers. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As part of its plan to accelerate and fully fund the development of its advanced energy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">business, with a focus in the cosmetic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">surgery market, the Company sold its Core business in 2018 for gross proceeds of $97&#160;million.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">These proceeds were used to launch broad marketing and sales initiatives which resulted in rapid sales growth through December 31, 2021 and into the first quarter of 2022.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">This planned growth in the business was accompanied by scaled operations, including procurement of components, expanded manufacturing capacity to turn those materials into saleable inventory, additional discretionary expenditures, including increased global participation at trade shows, additional employee trainings, user meetings, increased travel and entertainment expenses, more expansive research and development projects, and additional headcount to support those activities. Additionally, the Company had, and still has, some significant non-recurring discretionary expenditures associated with completing its multi-year marketing initiatives related to its dermal resurfacing and skin laxity clearances. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On March 14, 2022, the U.S. Food and Drug Administration (&#8220;FDA&#8221;) posted a Safety Communication that warns consumers and health care providers against the use of the Company&#8217;s Advanced Energy products outside of their FDA-cleared indications for general use in cutting, coagulation, and ablation of soft tissue during open and laparoscopic surgical procedures. Following the Safety Communication, the Company experienced slowed demand for the adoption of its Helium Plasma Technology.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On May 26, 2022, the Company announced that it had received 510(k) clearance from the FDA for the use of the Renuvion&#174; Dermal Handpiece for specific dermal resurfacing procedures. On July 18, 2022, the Company announced that it had received 510(k) clearance from the FDA for the use of the Renuvion&#174; APR Handpiece for certain skin contraction procedures. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 2, 2022, and July 21, 2022, FDA updated the Medical Device Safety Communication to recognize the new 510(k) clearances for the Renuvion&#174; Dermal handpiece, and the expanded indications for the Renuvion&#174; APR handpieces. The 510(k) clearance for the Renuvion&#174; Dermal handpiece allows surgeons to perform dermal resurfacing procedures for the treatment of moderate to severe wrinkles and rhytides, limited to patients with Fitzpatrick Skin Types I, II or III.  The 510(k) clearance for the Renuvion&#174; APR handpieces now addresses improving the appearance of lax (loose) skin in the neck and submental region.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">While management expected that receiving these clearances would materially mitigate the financial effects of the Safety Communication in future periods, the Company continues to experience reduced demand for the adoption and utilization of its technology and management believes that this may have an adverse effect in future periods.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern. The going concern basis of presentation assumes that the Company will continue in operation one year after the date these financial statements are issued and will be able to realize its assets and discharge its liabilities and commitments in the normal course of business. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Financial Accounting Standards Board&#8217;s Accounting Standards Codification (&#8220;ASC&#8221;) Topic 205-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, management must evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company&#8217;s ability to continue as a going concern for one year from the date these condensed consolidated financial statements are issued. This evaluation does not take into consideration the potential mitigating effect of management&#8217;s plans that have not been fully implemented or are not within control of the Company as of the date the condensed consolidated financial statements are issued. When substantial doubt exists under this methodology, management evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about the Company&#8217;s ability to continue as a going concern. The mitigating effect of management&#8217;s plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity&#8217;s ability to continue as a going concern </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">within one year after the date that the financial statements are issued.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">While sales were continuing to grow into the first quarter of 2022 prior to the FDA Safety Communication, over the last few years, exclusive of the Company&#8217;s sale of the Core business segment to Symmetry Surgical during 2018, it has incurred recurring net losses and cash outflows from operations and the Company anticipates that losses will continue in the near term. During the nine months ended September 30, 2022, the Company incurred an operating loss of $17.6&#160;million and used $15.8&#160;million of cash in operations. As of September 30, 2022, the Company had cash and cash equivalents of $14.8&#160;million. These conditions raise substantial doubt about the Company&#8217;s ability to continue as a going concern for a period of at least one year from the date of issuance of these unaudited condensed consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In an effort to alleviate these conditions, management is currently evaluating various funding alternatives to improve liquidity and may seek to raise additional capital through debt financing, the sale of equity securities, leveraging its unencumbered real estate, or any combination thereof. In addition, management is actively pursuing collection of the Company&#8217;s income tax receivable. Management also continues to re-assess its operating expenditures and cost structure to be commensurate with its expected levels of revenue and has the ability to reduce or delay expenditures to enhance and preserve liquidity. As the Company seeks additional sources of financing, there can be no assurance that such financing would be available to the Company on favorable terms or at all. The Company&#8217;s ability to obtain additional financing in the debt and equity capital markets is subject to several factors, including market and economic conditions, the Company&#8217;s performance and investor sentiment with respect to the Company and its industry.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Management believes that the actions and efforts it can and will take to manage operating expenditures and, while not assured, arrange alternative financing sources as described above will enable the Company to meet its obligations for a period of at least one year from the date of issuance of these unaudited condensed consolidated financial statements. As a result, management believes its plans alleviate substantial doubt about its ability to continue as a going concern. These unaudited condensed financial statements do not include any adjustments relating to the carrying amounts and classification of assets and liabilities that may be necessary should the Company be unable to continue as a going concern.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared based upon SEC rules that permit reduced disclosure for interim periods. For a more complete discussion of significant accounting policies and certain other information, please refer to the consolidated financial statements included in our Annual Report on Form 10-K for the year ended December&#160;31, 2021. In the opinion of management these condensed consolidated financial statements reflect all adjustments that are necessary for a fair presentation of results of consolidated operations and financial condition for the interim periods shown, including normal recurring accruals and other items. The results for the interim periods are not necessarily indicative of results for the full year.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassifications</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have reclassified certain amounts presented in the prior period to conform to the current period presentation. These reclassifications had no impact on previously reported net loss, accumulated deficit or net cash used in operating activities for the periods presented.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139878289013088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RECENT ACCOUNTING PRONOUNCEMENTS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract', window );"><strong>Accounting Standards Update and Change in Accounting Principle [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">RECENT ACCOUNTING PRONOUNCEMENTS</a></td>
<td class="text">RECENT ACCOUNTING PRONOUNCEMENTS <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments&#8212;Credit Losses (Topic 326).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The update changes the impairment model for most financial assets and certain other instruments, including trade and other receivables, contract assets, held-to-maturity debt securities and loans, and requires entities to use a new forward-looking expected loss model that will result in the earlier recognition of allowance for losses. This update, as originally issued, was effective for annual and interim periods beginning after December 15, 2019, with early adoption permitted. In November 2019, the FASB issued ASU 2019-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842) Effective Dates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which deferred the effective dates of these standards for Smaller Reporting Companies until fiscal years beginning after December 15, 2022. The Company currently continues to qualify as a Smaller Reporting Company, based upon the current SEC definition, and as a result, will be utilizing the deferred elective date. While we are in the process of determining the effects of the adoption of the standard on the condensed consolidated financial statements, we do not expect the impact to be material.</span>No other new accounting pronouncement issued or effective during the fiscal year had or is expected to have a material impact on our consolidated financial statements or disclosures.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI https://asc.fasb.org/topic&amp;trid=2122394<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=d3e31137-122693<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL122150809-237846<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=SL108384541-122693<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (f)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139878289909088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DISPOSAL OF BUSINESS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">DISPOSAL OF BUSINESS</a></td>
<td class="text">DISPOSAL OF BUSINESS<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 30, 2018, the Company closed on a definitive asset purchase agreement (the &#8220;Asset Purchase Agreement&#8221;) with Specialty Surgical Instrumentation Inc., a Tennessee Corporation and wholly owned subsidiary of Symmetry Surgical Inc. (&#8220;Symmetry&#8221;), pursuant to which the Company divested and sold the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> electrosurgical &#8220;Core&#8221; business segment and related intellectual property, including the Bovie&#174; brand and trademarks, to Symmetry for gross proceeds of $97&#160;million in cash.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Asset Purchase Agreement, the Company entered into an Electro Surgical Disposables and Accessories, Cauteries and Other Products Supply Agreement with Symmetry for a four-year term, which expired August 30, 2022, whereby it manufactured certain Core pro</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ducts and sold them to Symmetry at agreed upon prices. Any activity resulting from this agreement was netted and reported in the Condensed Consolidated Statements of Operations as other income (loss). There was no significant Core activity for the three months ended September&#160;30, 2022. Core activity for the three months ended September&#160;30, 2021, amounted to $1.6&#160;million with cost of sales equivalents of $1.3&#160;million and related other expenses of $0.5&#160;million for net other loss of $0.3&#160;million. Core activity for the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine months ended September 30, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, amounted to $0.6&#160;million with cost of sales equivalents of $0.5&#160;million and other related expenses of $0.1&#160;million&#160;for net other loss of $0.1&#160;million. Core activity for the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine months ended September 30, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, amounted to $5.2&#160;million with cost of sales equivalents of $4.4&#160;million and net other related operating expenses of $1.1&#160;million for net other loss of $0.3&#160;million.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=2122178<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139878294404464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORIES</a></td>
<td class="text">INVENTORIES<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost or net realizable value. Cost is determined on a first in, first out basis. Finished goods and work-in-process inventories include material, labor and overhead costs. Factory overhead costs are primarily allocated to inventory manufactured in-house based upon direct labor hours. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.543%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,078&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,603&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,414&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,441&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,929&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,997&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross inventories</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,421&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,041&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: provision for obsolescence</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(379)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(263)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,042&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,778&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139878294186512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">LEASES</a></td>
<td class="text">LEASES<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Operating Leases</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company leases its facility in Sofia, Bulgaria and computers under non-cancelable operating lease agreements. During the three months ended September 30, 2022, the Company&#8217;s leases on the vehicles in Clearwater, Florida expired and the Company purchased the vehicles at fair value. During the three months ended September 30, 2022, the Company entered into a one year extension on one of its leases on computer equipment. This extension resulted in reclassification of the lease from finance to operating. During the nine months ended September 30, 2022, the Company entered into a five year extension of its Sofia, Bulgaria facility. These operating leases have terms expiring through December 2027. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Finance Leases</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into non-cancelable finance leases for certain computer equipment and a vehicle in Clearwater, Florida. During the nine months ended September 30, 2022, the Company entered into a 63 month lease for computer equipment. These finance leases have terms expiring through July 2027. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information about the Company&#8217;s weighted average remaining lease terms and discount rate assumptions are as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.160%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term (in years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.75%</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.64%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.98%</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.00%</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of lease liabilities as of September 30, 2022 are as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:76.319%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.190%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.191%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">737&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">694&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less current portion of lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(240)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion of lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeasesTextBlock', window );">LEASES</a></td>
<td class="text">LEASES<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Operating Leases</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company leases its facility in Sofia, Bulgaria and computers under non-cancelable operating lease agreements. During the three months ended September 30, 2022, the Company&#8217;s leases on the vehicles in Clearwater, Florida expired and the Company purchased the vehicles at fair value. During the three months ended September 30, 2022, the Company entered into a one year extension on one of its leases on computer equipment. This extension resulted in reclassification of the lease from finance to operating. During the nine months ended September 30, 2022, the Company entered into a five year extension of its Sofia, Bulgaria facility. These operating leases have terms expiring through December 2027. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Finance Leases</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into non-cancelable finance leases for certain computer equipment and a vehicle in Clearwater, Florida. During the nine months ended September 30, 2022, the Company entered into a 63 month lease for computer equipment. These finance leases have terms expiring through July 2027. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information about the Company&#8217;s weighted average remaining lease terms and discount rate assumptions are as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.160%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term (in years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.75%</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.64%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.98%</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.00%</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of lease liabilities as of September 30, 2022 are as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:76.319%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.190%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.191%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">737&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">694&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less current portion of lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(240)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion of lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139878289905712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</a></td>
<td class="text">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consisted of the following:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.543%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">879&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">546&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued bonuses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued commissions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,656&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued product warranties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">616&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">593&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued product liability claim insurance deductibles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,016&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">610&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees and legal related contingent liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,134&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">421&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Joint and several payroll liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">399&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,027&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term contract liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">533&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uncertain tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,024&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,863&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales tax payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">428&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses and current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">617&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses and other current liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,842&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,287&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During April 2022, the Company was relieved of approximately $650,000 of its joint and several payroll liability due to the lapse of the statute of limitations on the liability. This adjustment is included in other income, net for the nine months ended September 30, 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139878288536608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CHINA JOINT VENTURE<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestAbstract', window );"><strong>Noncontrolling Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDisclosureTextBlock', window );">CHINA JOINT VENTURE</a></td>
<td class="text">CHINA JOINT VENTURE<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, the Company executed a joint venture agreement with its Chinese supplier (the &#8220;China JV&#8221;) whereby the Company has a 51% interest. The China JV has been consolidated in these condensed consolidated financial statements. The agreement required the Company to make capital contributions into the newly formed entity of approximately&#160;$357,000, which had been fully funded as of December 31, 2021. As of the date of these condensed consolidated financial statements, the China JV has not commenced principal operations. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> investment in the China JV were as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"/><td style="width:47.988%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.407%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.994%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.775%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.994%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.775%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.994%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.775%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.998%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning interest in China JV</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contributions </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Apyx</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(81)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending interest in China JV</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for noncontrolling interest in consolidated subsidiaries, which could include the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139878288647808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS (LOSS) PER SHARE<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">EARNINGS (LOSS) PER SHARE</a></td>
<td class="text">EARNINGS (LOSS) PER SHARE <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings (loss) per share (&#8220;basic EPS&#8221;) is computed by dividing the net income or loss by the weighted average number of common shares outstanding for the reporting period. Diluted earnings (loss) per share (&#8220;diluted EPS&#8221;) gives effect to all dilutive potential shares outstanding. As the Company is in a net loss position for all periods presented, all potential shares outstanding are anti-dilutive. The following table provides the computation of basic and diluted loss per share.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"/><td style="width:46.822%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.393%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.324%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.728%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.324%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.728%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.324%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.728%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.329%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands, except per share data)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to stockholders</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,764)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,222)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,135)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,169)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding - basic and diluted<br/></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,569&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,330&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,488&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,318&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss per share:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.50)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.38)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive instruments excluded from diluted loss per common share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,635&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,534&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,635&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,534&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139878289970960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK-BASED COMPENSATION</a></td>
<td class="text">STOCK-BASED COMPENSATION <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Company&#8217;s stock option plans, the Board of Directors may grant restricted stock and options to purchase common shares to the Company's employees, officers, directors and consultants. The Company accounts for stock options in accordance with FASB ASC Topic 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation - Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, with stock-based compensation expense recognized over the vesting period based on the fair value on the grant date utilizing the Black-Scholes model, which includes a number of estimates that affect the grant date fair value and the amount of expense to recognize.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized approximately $1,692,000 and $5,056,000, respectively, in stock-based compensation expense during the three and nine months ended September 30, 2022, as compared with $1,184,000 and $3,747,000, respectively, for the three and nine months ended September 30, 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option activity is summarized as follows:</span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average exercise price</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,397,691&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.95&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,692,419&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.64&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(299,006)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(155,697)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.20&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at September&#160;30, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,635,409&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company allows stock option holders to exercise stock-based awards by surrendering stock-based awards with an intrinsic value equal to the cumulative exercise price of the stock-based awards being exercised, referred to as net settlements. These surrenders are included in stock options exercised in the options rollforward above. For the three months ended September&#160;30, 2022 and 2021, respectively, we received 55,853 and 37,049 options as payment in the exercise of 33,313 and 13,285 options. For the nine months ended September 30, 2022 and 2021, respectively, we received 92,520 and 59,104 options as payment in the exercise of 72,313 and 39,312 options.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common shares required to be issued upon the exercise of stock options would be issued from authorized and unissued shares. The Company calculated the grant date fair value of options granted in 2022 (&#8220;2022 Grants&#8221;) utilizing a Black-Scholes model.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:58.771%"><tr><td style="width:1.0%"/><td style="width:65.815%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.825%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.133%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.827%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022 Grants</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Strike price</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$5.10</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$10.56</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69.6%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.5%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139878288368784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text">INCOME TAXES Income tax expense was approximately $50,000 and $73,000 with effective tax rates of (0.9)% and (1.8)% for the three months ended September&#160;30, 2022 and 2021, respectively. Income tax expense was approximately $216,000 and $246,000 with effective tax rates of (1.3)% and (1.9)% for the nine months ended September 30, 2022 and 2021, respectively. For the three and nine months ended September&#160;30, 2022 and 2021, the effective rates differ from the statutory rate primarily due to the full valuation allowance recorded on the net operating loss (&#8220;NOL&#8221;) generated during the period, combined with interest and penalties on uncertain tax positions. The Company has gross unrecognized tax benefits of approximately $1,313,000 at September&#160;30, 2022. It recognized accrued interest and penalties related to unrecognized tax benefits in the provision for income taxes in the condensed consolidated financial statements. As of September&#160;30, 2022, the Company had approximately $711,000 in accrued interest and penalties related to unrecognized tax benefits. Included in the income tax expense for the three months ended September&#160;30, 2022 and 2021, respectively, are approximately $54,000 and $52,000 of interest and penalties on the Company's uncertain tax positions. Included in the income tax expense for the nine months ended September 30, 2022 and 2021, respectively, are approximately $160,000 and $152,000 of interest and penalties on the Company's uncertain tax positions. If the Company were to prevail on all uncertain tax positions, the resulting impact will be material as the Company will recognize approximately $2,024,000 of income tax benefits in the consolidated statement of operations. During June 2022, the Company was notified by the Internal Revenue Service (&#8220;IRS&#8221;) that it is examining the Company&#8217;s 2018, 2019 and 2020 federal income tax returns. The examination is expected to be completed no later than May 2023. It is expected that all of the uncertain tax positions should be resolved with the completion of the IRS examination.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139878289935120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Litigation </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The medical device industry is characterized by frequent claims and litigation, and the Company may become subject to various claims, lawsuits and proceedings in the ordinary course of our business. Such claims may include claims by current or former employees, distributors and competitors, claims concerning the marketing and promotion of our products and product liability claims.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is involved in a number of legal actions relating to the use of our Helium Plasma technology. The outcomes of these legal actions are not within the Company&#8217;s control and may not be known for prolonged periods of time. It believes that such claims are adequately covered by insurance; however, in the case of one of the Company&#8217;s carriers, the Company is in a dispute regarding the total level of coverage available. Notwithstanding the foregoing, in the opinion of management, the Company has meritorious defenses, and such claims are not expected, individually or in the aggregate, to result in a material, adverse effect on its financial condition, results of operations and cash flows. However, in the event that damages exceed the aggregate coverage limits of the Company&#8217;s policies or if its insurance carriers disclaim coverage, management believes it is possible that costs associated with these claims could have a material adverse impact on the consolidated financial condition, results of operations and cash flows.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During December 2021, the Company provided notice of contract termination to an international distributor of the Company. In March 2022, the Company received a letter from the former distributor citing improper contract termination and alleging damages. While the matter is still in the early stages, management has determined that a loss is probable and that a range of estimated losses is approximately $250,000 to $1,000,000. The Company has recorded an estimated loss of $250,000 in professional services in the accompanying Condensed Consolidated Statement of Operations for the nine months ended September 30, 2022. It is at least possible that a change in the actual amount of loss will occur in the near term, though management expects the actual amount of loss will be within the estimated range of losses.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as previously disclosed with the U.S. Securities and Exchange Commission on the Company&#8217;s Current Report on Form 8-K filed June 7, 2022, on June 6, 2022, a complaint (the &#8220;Complaint&#8221;) was filed in the United States District Court for the Middle District of Florida by plaintiff William E. Hattaway, individually and on behalf of all others similarly situated against the Company, Charles D. Goodwin (&#8220;Goodwin&#8221;), the Company&#8217;s President and Chief Executive Officer and a member of the Company&#8217;s Board of Directors, and Tara Semb (&#8220;Semb&#8221;), the Company&#8217;s Chief Financial Officer, Treasurer and Secretary, alleging violations by the Company, Goodwin and Semb of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder, primarily related to certain public statements and disclosures concerning the off-label usage of certain of the Company&#8217;s Advanced Energy products and the impact such usage would have on the Company&#8217;s business, operations and prospects. The Complaint seeks an unspecified amount of damages. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the ultimate outcome of this matter cannot be determined with certainty, the Company believes that the allegations stated in the Complaint are without merit. The Company, Goodwin and Semb intend to defend themselves vigorously in the suit. In the opinion of management, such claims are adequately covered by insurance, however, in the event that damages exceed the aggregate coverage limits of our policy or if our insurance carriers disclaim coverage, we believe it is possible that costs associated with this claim could have a material adverse impact on our consolidated results of operations, financial </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">position or cash flows. While the matter is still in the early stages, management has determined that a loss is probable and that a range of estimated losses is approximately $475,000 to $2,500,000. The Company has recorded an estimated loss of $475,000 in professional services in the accompanying Condensed Consolidated Statement of Operations for the nine months ended September 30, 2022. It is at least possible that a change in the actual amount of loss will occur in the near term, though management expects the actual amount of loss will be within the estimated range of losses.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accrues a liability in its consolidated financial statements for these actions when a loss is known or considered probable and the amount can be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is recorded. If a loss is reasonably possible, but not known or probable, and can be reasonably estimated, the estimated loss or range of loss is disclosed in the notes to the condensed consolidated financial statements. In most cases, significant judgment is required to estimate the amount and timing of a loss to be recorded, actual results may differ from these estimates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Purchase Commitments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September&#160;30, 2022, the Company had purchase commitments totaling approximately $3.1&#160;million, substantially all of which is expected to be purchased within the next fifteen months.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139878288062144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text">RELATED PARTY TRANSACTIONS<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Several relatives of Nikolay Shilev, Apyx Bulgaria&#8217;s Managing Director, are considered related parties. Teodora Shileva, Mr. Shilev&#8217;s spouse, is an employee of the Company working in the accounting department. Antoaneta Dimitrova Shileva-Toromanova, Mr. Shilev&#8217;s sister, is the manager of human resources. Svetoslav Shilev, Mr. Shilev&#8217;s son, is a quality manager in the quality assurance department.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The partner in the Company's China joint venture is also a supplier to the Company. For the three months ended September&#160;30, 2022 and 2021, the Company made purchases from this supplier of approximately $85,000 and $456,000, respectively. For the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine months ended September 30, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and 2021, the Company made purchases from this supplier of approximately $455,000 and $1,102,000, respectively. At September&#160;30, 2022 and December&#160;31, 2021, respectively, the Company owed this supplier approximately $41,000 and $1,000.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI https://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139878294404464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GEOGRAPHIC AND SEGMENT INFORMATION<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">GEOGRAPHIC AND SEGMENT INFORMATION</a></td>
<td class="text">GEOGRAPHIC AND SEGMENT INFORMATION <div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are aggregated into reportable segments only if they exhibit similar economic characteristics. In addition to similar economic characteristics, the Company also considers the following factors in determining the reportable segments: the nature of business activities, the management structure directly accountable to its chief operating decision maker for operating and administrative activities, availability of discrete financial information and information presented to the Board of Directors and investors. Asset information is not reviewed by the chief operating decision maker by segment and is not available by segment, accordingly, the Company has not presented a measure of assets by segment.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s reportable segments are disclosed as principally organized and managed as two operating segments: Advanced Energy and OEM. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate &amp; Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> includes certain unallocated corporate and administrative costs which were not specifically attributed to any reportable segment. The OEM segment is primarily development and manufacturing contract and product driven, all related expenses are recorded as cost of sales, therefore no segment specific operating expenses are incurred.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized financial information with respect to reportable segments is as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:45.811%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.696%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Advanced Energy</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OEM</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate &amp; Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,080&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,034&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,114&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,174)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,964)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,782)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other loss, net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:45.811%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.696%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Advanced Energy</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OEM</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate &amp; Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,313&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,518&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,831&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,348)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,968)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other loss, net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(192)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(192)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:45.811%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.696%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Advanced Energy</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OEM</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate &amp; Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,258&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,641&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,899&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,765)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,006)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,629)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">551&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">551&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:45.811%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.696%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Advanced Energy</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OEM</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate &amp; Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,951&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,742&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,693&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(224)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">588&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,120)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,756)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other loss, net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(188)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(188)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">International sales represented approximately 23.2% and 29.5% of total revenues for the three and nine months ended September 30, 2022, respectively, as compared with approximately 33.1% and 34.2% of total revenues for the three and nine months ended September 30, 2021, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue by geographic region, based on the customer's &#8220;ship to&#8221; location on the invoice, are as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Sales by Domestic and International</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,997&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,911&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,492&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,860&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,920&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,407&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,833&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,114&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,831&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,899&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,693&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI https://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139878288107856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassifications</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassifications</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have reclassified certain amounts presented in the prior period to conform to the current period presentation. These reclassifications had no impact on previously reported net loss, accumulated deficit or net cash used in operating activities for the periods presented.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments&#8212;Credit Losses (Topic 326).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The update changes the impairment model for most financial assets and certain other instruments, including trade and other receivables, contract assets, held-to-maturity debt securities and loans, and requires entities to use a new forward-looking expected loss model that will result in the earlier recognition of allowance for losses. This update, as originally issued, was effective for annual and interim periods beginning after December 15, 2019, with early adoption permitted. In November 2019, the FASB issued ASU 2019-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842) Effective Dates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which deferred the effective dates of these standards for Smaller Reporting Companies until fiscal years beginning after December 15, 2022. The Company currently continues to qualify as a Smaller Reporting Company, based upon the current SEC definition, and as a result, will be utilizing the deferred elective date. While we are in the process of determining the effects of the adoption of the standard on the condensed consolidated financial statements, we do not expect the impact to be material.</span>No other new accounting pronouncement issued or effective during the fiscal year had or is expected to have a material impact on our consolidated financial statements or disclosures.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text">Inventories are stated at the lower of cost or net realizable value. Cost is determined on a first in, first out basis. Finished goods and work-in-process inventories include material, labor and overhead costs. Factory overhead costs are primarily allocated to inventory manufactured in-house based upon direct labor hours.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share based compensation</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Company&#8217;s stock option plans, the Board of Directors may grant restricted stock and options to purchase common shares to the Company's employees, officers, directors and consultants. The Company accounts for stock options in accordance with FASB ASC Topic 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation - Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, with stock-based compensation expense recognized over the vesting period based on the fair value on the grant date utilizing the Black-Scholes model, which includes a number of estimates that affect the grant date fair value and the amount of expense to recognize.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126900757&amp;loc=d3e543-108305<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429488&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139878294404464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of inventory</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.543%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,078&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,603&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,414&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,441&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,929&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,997&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross inventories</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,421&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,041&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: provision for obsolescence</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(379)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(263)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,042&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,778&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139878288910736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Lease Costs</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information about the Company&#8217;s weighted average remaining lease terms and discount rate assumptions are as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.160%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term (in years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.75%</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.64%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.98%</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.00%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Maturities of Operating Lease Liabilities</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of lease liabilities as of September 30, 2022 are as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:76.319%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.190%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.191%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">737&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">694&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less current portion of lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(240)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion of lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock', window );">Maturities of Finance Lease Liabilities</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of lease liabilities as of September 30, 2022 are as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:76.319%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.190%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.191%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">737&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">694&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less current portion of lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(240)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion of lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139878288510912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accounts Payable and Accrued Liabilities</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consisted of the following:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.543%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">879&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">546&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued bonuses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued commissions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,656&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued product warranties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">616&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">593&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued product liability claim insurance deductibles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,016&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">610&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees and legal related contingent liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,134&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">421&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Joint and several payroll liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">399&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,027&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term contract liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">533&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uncertain tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,024&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,863&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales tax payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">428&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses and current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">617&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses and other current liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,842&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,287&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139878288566112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CHINA JOINT VENTURE (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestAbstract', window );"><strong>Noncontrolling Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_NoncontrollingInterestTableTextBlock', window );">Schedule of China Joint Venture</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> investment in the China JV were as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"/><td style="width:47.988%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.407%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.994%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.775%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.994%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.775%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.994%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.775%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.998%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning interest in China JV</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contributions </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Apyx</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(81)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending interest in China JV</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_NoncontrollingInterestTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling Interest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_NoncontrollingInterestTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139878288374304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS (LOSS) PER SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Basic and diluted earnings (loss) per share</a></td>
<td class="text">The following table provides the computation of basic and diluted loss per share.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"/><td style="width:46.822%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.393%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.324%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.728%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.324%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.728%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.324%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.728%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.329%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands, except per share data)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to stockholders</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,764)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,222)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,135)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,169)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding - basic and diluted<br/></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,569&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,330&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,488&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,318&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss per share:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.50)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.38)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive instruments excluded from diluted loss per common share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,635&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,534&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,635&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,534&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139878288598016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of stock options and stock awards</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option activity is summarized as follows:</span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average exercise price</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,397,691&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.95&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,692,419&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.64&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(299,006)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(155,697)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.20&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at September&#160;30, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,635,409&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of option fair value assumptions</a></td>
<td class="text">The Company calculated the grant date fair value of options granted in 2022 (&#8220;2022 Grants&#8221;) utilizing a Black-Scholes model.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:58.771%"><tr><td style="width:1.0%"/><td style="width:65.815%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.825%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.133%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.827%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022 Grants</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Strike price</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$5.10</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$10.56</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69.6%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.5%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139878288111696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GEOGRAPHIC AND SEGMENT INFORMATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of reporting information by segment</a></td>
<td class="text">Summarized financial information with respect to reportable segments is as follows:<div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:45.811%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.696%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Advanced Energy</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OEM</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate &amp; Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,080&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,034&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,114&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,174)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,964)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,782)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other loss, net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:45.811%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.696%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Advanced Energy</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OEM</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate &amp; Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,313&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,518&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,831&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,348)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,968)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other loss, net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(192)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(192)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:45.811%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.696%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Advanced Energy</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OEM</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate &amp; Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,258&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,641&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,899&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,765)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,006)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,629)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">551&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">551&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:45.811%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.696%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Advanced Energy</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OEM</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate &amp; Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,951&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,742&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,693&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(224)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">588&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,120)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,756)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other loss, net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(188)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(188)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock', window );">Schedule of revenue by geographic area</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue by geographic region, based on the customer's &#8220;ship to&#8221; location on the invoice, are as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Sales by Domestic and International</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,997&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,911&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,492&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,860&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,920&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,407&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,833&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,114&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,831&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,899&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,693&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the names of foreign countries from which revenue is material and the amount of revenue from external customers attributed to those countries. An entity may also provide subtotals of geographic information about groups of countries.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139878282106720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION - NARRATIVE (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinesses', window );">Proceeds from the disposition of Core business</a></td>
<td class="nump">$ 97,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 97,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,782<span></span>
</td>
<td class="nump">$ 3,968<span></span>
</td>
<td class="nump">$ 17,629<span></span>
</td>
<td class="nump">$ 12,756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,833<span></span>
</td>
<td class="nump">$ 30,898<span></span>
</td>
<td class="nump">14,833<span></span>
</td>
<td class="nump">30,898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,870<span></span>
</td>
<td class="nump">$ 41,915<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Cash used in operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,750<span></span>
</td>
<td class="nump">$ 10,663<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139878286550000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DISPOSAL OF BUSINESS (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinesses', window );">Proceeds from the disposition of Core business</a></td>
<td class="nump">$ 97.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 97.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=apyx_SymmetrySurgicalInc.Member', window );">Symmetry Surgical Inc. | Electro Surgical Disposables and Accessories, Cauteries and Other Products Supply Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_AssetPurchaseAgreementTerm', window );">Asset purchase agreement, term</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue', window );">Sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.6<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="nump">$ 5.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold', window );">Cost of sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.3<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">4.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense', window );">Operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss', window );">Net other loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_AssetPurchaseAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset Purchase Agreement, Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_AssetPurchaseAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating income (loss) attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=apyx_SymmetrySurgicalInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=apyx_SymmetrySurgicalInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=apyx_ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=apyx_ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139878286692544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INVENTORIES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 5,078<span></span>
</td>
<td class="nump">$ 3,603<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work in process</a></td>
<td class="nump">2,414<span></span>
</td>
<td class="nump">1,441<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">4,929<span></span>
</td>
<td class="nump">1,997<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Gross inventories</a></td>
<td class="nump">12,421<span></span>
</td>
<td class="nump">7,041<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Less: provision for obsolescence</a></td>
<td class="num">(379)<span></span>
</td>
<td class="num">(263)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories, net</a></td>
<td class="nump">$ 12,042<span></span>
</td>
<td class="nump">$ 6,778<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139878294374368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASES - Narrative (Details)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease, extension</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Operating lease extension</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseTermOfContract1', window );">Finance lease, term of contract</a></td>
<td class="text">63 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseTermOfContract1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseTermOfContract1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139878286585200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASES - Lease Terms and Discount Rates (Details)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_OperatingLeaseCostsAbstract', window );"><strong>Operating</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term</a></td>
<td class="text">4 years 4 months 24 days<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">2.75%<span></span>
</td>
<td class="nump">3.98%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_FinanceLeaseCostsAbstract', window );"><strong>Finance</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term</a></td>
<td class="text">4 years 1 month 6 days<span></span>
</td>
<td class="text">9 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">2.64%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_FinanceLeaseCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance Lease, Costs [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_FinanceLeaseCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_OperatingLeaseCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Costs [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_OperatingLeaseCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139878285899168">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASES - Maturities of Lease Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2022</a></td>
<td class="nump">$ 75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">218<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour', window );">Thereafter</a></td>
<td class="nump">111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(43)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">694<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less current portion of lease liabilities</a></td>
<td class="num">(240)<span></span>
</td>
<td class="num">$ (122)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term portion of lease liabilities</a></td>
<td class="nump">454<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Finance Lease, Liability, Payment, Due [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2022</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_FinanceLeaseLiabilityToBePaidDueAfterYearFour', window );">Thereafter</a></td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Less current portion of lease liabilities</a></td>
<td class="num">(42)<span></span>
</td>
<td class="num">(165)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Long-term portion of lease liabilities</a></td>
<td class="nump">$ 78<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_FinanceLeaseLiabilityToBePaidDueAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance Lease, liability, To Be Paid, Due After Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_FinanceLeaseLiabilityToBePaidDueAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, to be Paid, Due after Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139878286217376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Apr. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Accrued payroll</a></td>
<td class="nump">$ 879<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 546<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedBonusesCurrent', window );">Accrued bonuses</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,117<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedSalesCommissionCurrent', window );">Accrued commissions</a></td>
<td class="nump">877<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,656<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductWarrantyAccrualClassifiedCurrent', window );">Accrued product warranties</a></td>
<td class="nump">616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">593<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedInsuranceCurrent', window );">Accrued product liability claim insurance deductibles</a></td>
<td class="nump">1,016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">610<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees and legal related contingent liabilities</a></td>
<td class="nump">1,134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">421<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_JointAndSeveralPayrollLiability', window );">Joint and several payroll liability</a></td>
<td class="nump">399<span></span>
</td>
<td class="num">$ (650)<span></span>
</td>
<td class="nump">1,027<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_ShortTermContractLiabilities', window );">Short-term contract liabilities</a></td>
<td class="nump">1,145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">533<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_UncertainTaxPositionsLiability', window );">Uncertain tax positions</a></td>
<td class="nump">2,024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,863<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalesAndExciseTaxPayableCurrent', window );">Sales tax payable</a></td>
<td class="nump">135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">428<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_OtherAccruedExpensesAndLiabilitiesCurrent', window );">Other accrued expenses and current liabilities</a></td>
<td class="nump">617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">493<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent', window );">Total accrued expenses and other current liabilities</a></td>
<td class="nump">$ 8,842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,287<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Liabilities and Other Liabilities, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_JointAndSeveralPayrollLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Joint And Several Payroll Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_JointAndSeveralPayrollLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_OtherAccruedExpensesAndLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Accrued Expenses And Liabilities, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_OtherAccruedExpensesAndLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_ShortTermContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Short-Term Contract Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_ShortTermContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_UncertainTaxPositionsLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Uncertain Tax Positions Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_UncertainTaxPositionsLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedBonusesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedBonusesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedInsuranceCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable to insurance entities to mitigate potential loss from various risks or to satisfy a promise to provide certain coverage's to employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedInsuranceCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalesCommissionCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for sales commissions. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalesCommissionCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductWarrantyAccrualClassifiedCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers. For classified balance sheets, represents the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126907703&amp;loc=d3e12524-110249<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 25<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126907644&amp;loc=d3e11281-110244<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductWarrantyAccrualClassifiedCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesAndExciseTaxPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred through that date and payable for statutory sales and use taxes, including value added tax. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesAndExciseTaxPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139878294394896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Apr. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_JointAndSeveralPayrollLiability', window );">Joint and several payroll liability</a></td>
<td class="num">$ (399)<span></span>
</td>
<td class="nump">$ 650<span></span>
</td>
<td class="num">$ (1,027)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_JointAndSeveralPayrollLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Joint And Several Payroll Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_JointAndSeveralPayrollLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139878286538720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CHINA JOINT VENTURE - Narrative (Details) - Corporate Joint Venture - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_NoncontrollingInterestRequiredCapitalContribution', window );">Required capital contribution</a></td>
<td class="nump">$ 357<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember', window );">Chinese Supplier</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_NoncontrollingInterestRequiredCapitalContribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling Interest, Required Capital Contribution</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_NoncontrollingInterestRequiredCapitalContribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=apyx_ChineseSupplierMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=apyx_ChineseSupplierMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139878286917200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CHINA JOINT VENTURE - Rollforward of Joint Venture (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInMinorityInterestRollForward', window );"><strong>Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Beginning interest in China JV</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 305<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance', window );">Contributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 195<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to Apyx</a></td>
<td class="num">$ (31)<span></span>
</td>
<td class="num">$ (12)<span></span>
</td>
<td class="num">(78)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Ending interest in China JV</a></td>
<td class="nump">227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember', window );">Corporate Joint Venture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInMinorityInterestRollForward', window );"><strong>Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Beginning interest in China JV</a></td>
<td class="nump">269<span></span>
</td>
<td class="nump">338<span></span>
</td>
<td class="nump">317<span></span>
</td>
<td class="nump">144<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance', window );">Contributions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">203<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to Apyx</a></td>
<td class="num">(33)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
<td class="num">(81)<span></span>
</td>
<td class="num">(22)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Ending interest in China JV</a></td>
<td class="nump">$ 236<span></span>
</td>
<td class="nump">$ 325<span></span>
</td>
<td class="nump">$ 236<span></span>
</td>
<td class="nump">$ 325<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInMinorityInterestRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInMinorityInterestRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569655-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139878286766784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS (LOSS) PER SHARE (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareReconciliationAbstract', window );"><strong>Earnings Per Share Reconciliation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to stockholders, basic</a></td>
<td class="num">$ (5,764)<span></span>
</td>
<td class="num">$ (4,222)<span></span>
</td>
<td class="num">$ (17,135)<span></span>
</td>
<td class="num">$ (13,169)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net loss attributable to stockholders, diluted</a></td>
<td class="num">$ (5,764)<span></span>
</td>
<td class="num">$ (4,222)<span></span>
</td>
<td class="num">$ (17,135)<span></span>
</td>
<td class="num">$ (13,169)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding - basic (in shares)</a></td>
<td class="nump">34,569<span></span>
</td>
<td class="nump">34,330<span></span>
</td>
<td class="nump">34,488<span></span>
</td>
<td class="nump">34,318<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding - diluted (in shares)</a></td>
<td class="nump">34,569<span></span>
</td>
<td class="nump">34,330<span></span>
</td>
<td class="nump">34,488<span></span>
</td>
<td class="nump">34,318<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="num">$ (0.17)<span></span>
</td>
<td class="num">$ (0.12)<span></span>
</td>
<td class="num">$ (0.50)<span></span>
</td>
<td class="num">$ (0.38)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="num">$ (0.17)<span></span>
</td>
<td class="num">$ (0.12)<span></span>
</td>
<td class="num">$ (0.50)<span></span>
</td>
<td class="num">$ (0.38)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Anti-dilutive instruments excluded from diluted loss per common share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive instruments (in shares)</a></td>
<td class="nump">6,635<span></span>
</td>
<td class="nump">5,534<span></span>
</td>
<td class="nump">6,635<span></span>
</td>
<td class="nump">5,534<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DilutiveSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DilutiveSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139878288258688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock based compensation</a></td>
<td class="nump">$ 1,692<span></span>
</td>
<td class="nump">$ 1,184<span></span>
</td>
<td class="nump">$ 5,056<span></span>
</td>
<td class="nump">$ 3,747<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived', window );">Stock swaps equity instruments received (in shares)</a></td>
<td class="nump">55,853<span></span>
</td>
<td class="nump">37,049<span></span>
</td>
<td class="nump">92,520<span></span>
</td>
<td class="nump">59,104<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_StockIssuedDuringPeriodSharesStockSwaps', window );">Stock swaps (in shares)</a></td>
<td class="nump">33,313<span></span>
</td>
<td class="nump">13,285<span></span>
</td>
<td class="nump">72,313<span></span>
</td>
<td class="nump">39,312<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_StockIssuedDuringPeriodSharesStockSwaps">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Stock Swaps</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_StockIssuedDuringPeriodSharesStockSwaps</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Stock Swaps Equity Instruments Received</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139878286562576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Summary of Stock Options (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, beginning of period (in shares) | shares</a></td>
<td class="nump">5,397,691<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="nump">1,692,419<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares) | shares</a></td>
<td class="num">(299,006)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Canceled and forfeited (in shares) | shares</a></td>
<td class="num">(155,697)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, end of period (in shares) | shares</a></td>
<td class="nump">6,635,409<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted average exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, beginning of period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 5.95<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">10.64<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share) | $ / shares</a></td>
<td class="nump">4.57<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Canceled and forfeited (in dollars per shares) | $ / shares</a></td>
<td class="nump">9.20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, end of period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 7.13<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139878285954896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Fair Value Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2022 </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Strike price (in dollars per share)</a></td>
<td class="nump">$ 10.64<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Strike price (in dollars per share)</a></td>
<td class="nump">$ 5.10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate</a></td>
<td class="nump">1.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">69.60%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Strike price (in dollars per share)</a></td>
<td class="nump">$ 10.56<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate</a></td>
<td class="nump">3.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">78.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139878288147008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">$ 50<span></span>
</td>
<td class="nump">$ 73<span></span>
</td>
<td class="nump">$ 216<span></span>
</td>
<td class="nump">$ 246<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="num">(0.90%)<span></span>
</td>
<td class="num">(1.80%)<span></span>
</td>
<td class="num">(1.30%)<span></span>
</td>
<td class="num">(1.90%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">$ 1,313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Accrued interest and penalties</a></td>
<td class="nump">711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Interest and penalties included in income tax expense</a></td>
<td class="nump">54<span></span>
</td>
<td class="nump">$ 52<span></span>
</td>
<td class="nump">160<span></span>
</td>
<td class="nump">$ 152<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Uncertain tax positions that would impact effective tax rate</a></td>
<td class="nump">$ 2,024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139878285939088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligation', window );">Purchase obligation</a></td>
<td class="nump">$ 3,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=apyx_ContractWithInternationalDistributorMember', window );">Contract with International Distributor</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Costs accrued</a></td>
<td class="nump">250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=apyx_SuitAgainstGoodwinAndSimbMember', window );">Suit Against Goodwin and Simb</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Costs accrued</a></td>
<td class="nump">475<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Contract with International Distributor</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Loss Contingency, Estimate of Possible Loss</a></td>
<td class="nump">250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Suit Against Goodwin and Simb</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Loss Contingency, Estimate of Possible Loss</a></td>
<td class="nump">475<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Contract with International Distributor</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Loss Contingency, Estimate of Possible Loss</a></td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Suit Against Goodwin and Simb</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Loss Contingency, Estimate of Possible Loss</a></td>
<td class="nump">$ 2,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14615-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyEstimateOfPossibleLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124440162&amp;loc=d3e12021-110248<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyEstimateOfPossibleLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=apyx_ContractWithInternationalDistributorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=apyx_ContractWithInternationalDistributorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=apyx_SuitAgainstGoodwinAndSimbMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=apyx_SuitAgainstGoodwinAndSimbMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139878286281056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS (Details) - Co-venturer - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty', window );">Purchases from related party</a></td>
<td class="nump">$ 85<span></span>
</td>
<td class="nump">$ 456<span></span>
</td>
<td class="nump">$ 455<span></span>
</td>
<td class="nump">$ 1,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Due to related parties</a></td>
<td class="nump">$ 41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(3),(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=us-gaap_CoVenturerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=us-gaap_CoVenturerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139878287228368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GEOGRAPHIC AND SEGMENT INFORMATION - Narrative (Details) - segment<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_TotalRevenuePercent', window );">International sales, percent of total revenue</a></td>
<td class="nump">23.20%<span></span>
</td>
<td class="nump">33.10%<span></span>
</td>
<td class="nump">29.50%<span></span>
</td>
<td class="nump">34.20%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_TotalRevenuePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total Revenue, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_TotalRevenuePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139878282009344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GEOGRAPHIC AND SEGMENT INFORMATION - Reportable Segment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales</a></td>
<td class="nump">$ 9,114<span></span>
</td>
<td class="nump">$ 11,831<span></span>
</td>
<td class="nump">$ 31,899<span></span>
</td>
<td class="nump">$ 31,693<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="num">(5,782)<span></span>
</td>
<td class="num">(3,968)<span></span>
</td>
<td class="num">(17,629)<span></span>
</td>
<td class="num">(12,756)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeOperating', window );">Interest income</a></td>
<td class="nump">73<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">93<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other income (loss), net</a></td>
<td class="num">(35)<span></span>
</td>
<td class="num">(192)<span></span>
</td>
<td class="nump">551<span></span>
</td>
<td class="num">(188)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">73<span></span>
</td>
<td class="nump">216<span></span>
</td>
<td class="nump">246<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Advanced Energy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales</a></td>
<td class="nump">7,080<span></span>
</td>
<td class="nump">10,313<span></span>
</td>
<td class="nump">26,258<span></span>
</td>
<td class="nump">27,951<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="num">(1,174)<span></span>
</td>
<td class="nump">52<span></span>
</td>
<td class="num">(3,765)<span></span>
</td>
<td class="num">(224)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeOperating', window );">Interest income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other income (loss), net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | OEM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales</a></td>
<td class="nump">2,034<span></span>
</td>
<td class="nump">1,518<span></span>
</td>
<td class="nump">5,641<span></span>
</td>
<td class="nump">3,742<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="nump">356<span></span>
</td>
<td class="nump">328<span></span>
</td>
<td class="nump">1,142<span></span>
</td>
<td class="nump">588<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeOperating', window );">Interest income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other income (loss), net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate &amp; Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="num">(4,964)<span></span>
</td>
<td class="num">(4,348)<span></span>
</td>
<td class="num">(15,006)<span></span>
</td>
<td class="num">(13,120)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeOperating', window );">Interest income</a></td>
<td class="nump">73<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">93<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other income (loss), net</a></td>
<td class="num">(35)<span></span>
</td>
<td class="num">(192)<span></span>
</td>
<td class="nump">551<span></span>
</td>
<td class="num">(188)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">$ 50<span></span>
</td>
<td class="nump">$ 73<span></span>
</td>
<td class="nump">$ 216<span></span>
</td>
<td class="nump">$ 246<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=apyx_AdvancedEnergyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=apyx_AdvancedEnergyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=apyx_OEMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=apyx_OEMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139878288026528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GEOGRAPHIC AND SEGMENT INFORMATION - Geographic (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales</a></td>
<td class="nump">$ 9,114<span></span>
</td>
<td class="nump">$ 11,831<span></span>
</td>
<td class="nump">$ 31,899<span></span>
</td>
<td class="nump">$ 31,693<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">Domestic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales</a></td>
<td class="nump">6,997<span></span>
</td>
<td class="nump">7,911<span></span>
</td>
<td class="nump">22,492<span></span>
</td>
<td class="nump">20,860<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales</a></td>
<td class="nump">$ 2,117<span></span>
</td>
<td class="nump">$ 3,920<span></span>
</td>
<td class="nump">$ 9,407<span></span>
</td>
<td class="nump">$ 10,833<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>apyx-20220930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:apyx="http://apyxmedical.com/20220930"
  xmlns:country="http://xbrl.sec.gov/country/2022"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="apyx-20220930.xsd" xlink:type="simple"/>
    <context id="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="id27600d5964346308b9afb6a5de31f45_I20221109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
        </entity>
        <period>
            <instant>2022-11-09</instant>
        </period>
    </context>
    <context id="ic42af16cc8974cebbc452370076f22e5_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i6366ccfc5be94d939469c44eee70e010_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id6ada2596cf84b118b49af7a6561fb79_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ic9b0b6a3c69447bf8f151dfd98c14ac9_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0915370fdc66433087f61be1a6429895_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ia6bd5470a522440896a96cb114d94bc9_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i1602e279f8a54d59a4619d5751091e77_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i70c60e5ef978483d94930f1744a9d3af_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i138bdba832374d1f808c394db84be422_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="iecb0fed55763430baf6093ea22f40d87_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ica2773a2e5304f8480d1f69944277492_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i102d87338ba6454f85cc738690cc4358_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2ad330e6cdd442be8bf971667788ba23_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib6078f16f5134a2e9e175491969aa315_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i3d63a53f125c4acd96a77b7410be5951_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i6459bdf630814b27874dad87632c646a_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ia98a748ab05948eda52b8c8873f240ed_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i524cd9c9acd4440f8d2e862dbb84f261_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i6b3b8a89480b4a8680824601cb0552b9_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i02b00de331904fcebd2e5c7c0add0881_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i3d3946eaa70742e3a1d7332eacba51a6_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ie9d5039cab3a4fa5a3b9b29f5d4f1ce0_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ic1a290f8b3eb4985ac22e7ccb81b66e5_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i2682ba64e91149fb8218158d95782bd3_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i1211ee2c038f40b8b5feff5fd9d6fe4c_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i87921e2d34bd4d828c5d4930daeb8fc8_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i2b2ac4e7bb8a4fab90de0f2a2f18a839_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ie3a4f0fb7c0d44a8a286050fe422e630_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i96687d732f8d4567ad6f8406cd1293e3_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="id08f3d38045d4418a182b5f9988d3e34_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i229d9ac95648412aa95ce5178946ae89_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="iac6178b585a24bdd9c611d8f43b21488_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4281c98f6d154bc0bbdaa5ef88536da4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i41802e9d47eb481aabfdd816c5c9fa7b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i62a88fb8485b4d7fb2c08fb2266ed449_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1e93d5bb9951458aa70810e8b5e84de2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i19cfd321237247ab9bd9651da54e7476_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5f055e88f44443e39bd36692989fa841_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6310af3213b546f996d5b2f97fb70bfd_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i66bc1f8757d7488a99f1a6c5eb9a7e4c_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i10702330b75541919ad22c7f751db016_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5f0faf73be0941df9ec5505291b94bde_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iec03140df24341ec90f156ca4aeabce3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9d002bf5ac274c73b635110b5036d873_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia7123184de4141839ab376b29683134c_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ic739a97c17164277aa8cc3fa9ffb8bf3_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="if2fc708898034815a0206b71148a8cb0_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i95ac060f75d24601ad4fd05a8f4e64e7_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i9a26c2238772410b9c632db89dc2f95f_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i10095f0cb8c949fbb4f3d9e2b6c90b20_D20180830-20180830">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
        </entity>
        <period>
            <startDate>2018-08-30</startDate>
            <endDate>2018-08-30</endDate>
        </period>
    </context>
    <context id="i8c47d3c9d755423bac06c8de9bc6733a_D20180830-20180830">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">apyx:ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apyx:SymmetrySurgicalInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-08-30</startDate>
            <endDate>2018-08-30</endDate>
        </period>
    </context>
    <context id="i4df01ef2deb2470eab833fab1b386632_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">apyx:ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apyx:SymmetrySurgicalInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i715d6d3cb64a4d328a61c8e29b09eeb1_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">apyx:ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apyx:SymmetrySurgicalInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i10540b8b8766421e91ac2cc3944b3109_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">apyx:ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apyx:SymmetrySurgicalInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iee62c576cfc14937a01701621d37dc74_I20220430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
        </entity>
        <period>
            <instant>2022-04-30</instant>
        </period>
    </context>
    <context id="i9be5f375baba4295ace9fc48f09fe8dc_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">apyx:ChineseSupplierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i84408c5278f544ccb03b5314b28177f5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8d492a2b0cb940b3a3efba0a8c74f3b2_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ifefbd2b1828e478481b4e147440bb47b_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i614389ddffc7468ba138bf2516c6c05f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i971483142d77406c8234c4a4370fd3f7_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i7ca81802bedf4dd7b618a8b1cd8ffd83_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iacbe89d9dab74e6990b6f064b9754ea4_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i61baec36978a4160b66435f0f2416149_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic03ac90c24194c2181a21dd8933c788e_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ia7bdc42847614ed88ba35dd3d0f7643c_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ia08951cf06e540858ba8bf177ab2b743_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i42b97828049d4ebdaf08135fff616832_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib5e3c2254a1e4a9db8e760889439789b_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i87a2f188443846f38dac55f8e2d32c45_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iee9cabca77f2439a98f1d745e8aa8fbf_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i569c520a81a0408e8dcae24590fd7f45_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ifb875bc28ba541afbdc97bd369d0b276_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">apyx:ContractWithInternationalDistributorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i0e86764ca7f24ce6a39afdcc54d3ea31_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">apyx:ContractWithInternationalDistributorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i1887856679e9469f916771312e57a2e9_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">apyx:ContractWithInternationalDistributorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="icc81989264bf4729990e5332a7d926ff_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">apyx:SuitAgainstGoodwinAndSimbMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i47884c866bfd4b0bb5978e741a32ff7a_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">apyx:SuitAgainstGoodwinAndSimbMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i5d8aee9372fb4f169e0a8eb66390bb67_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">apyx:SuitAgainstGoodwinAndSimbMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="if06767f062cc44ada17fa9800b45b707_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:CoVenturerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="if24822e015bf406fa7a58fe352a3de87_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:CoVenturerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1cce60115e9e4b31be367f868dcccb14_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:CoVenturerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i10d9cc88ef7f4a2cb54fd0ce01238148_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:CoVenturerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if76fe4dedddf40aca527d7e4b7a2654c_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:CoVenturerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ib8f8d460633b499797d344045f093397_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:CoVenturerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib86c17a29ad64fff8b4f5645ccc11575_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">apyx:AdvancedEnergyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iaaa11755febd4f87a4971e2cdb19bccd_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">apyx:OEMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i12ee9d61be8f4dc6a652027fc6bd93b9_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i14808dab5a9a44dda4de75eaaebf7f2c_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">apyx:AdvancedEnergyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i35bc95fa11524622b8a7f5abe7f7a8d0_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">apyx:OEMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id24ea483328641d39abd6bbf5097a73b_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic79a2007f9024641a9822f1b84d5f8cd_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">apyx:AdvancedEnergyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i859943e8321b4443a613d8938534494e_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">apyx:OEMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i042c28c1eeda4c15bb204324175550d5_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iab38511a317c44aa9f0dc79521e2a6d5_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">apyx:AdvancedEnergyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7bfacb65a9e6459ea08bf4947d3b9c2b_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">apyx:OEMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6944c3767530469d9f26618cb4e807e6_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8c92311eeeba414cba8eeea9eae36a73_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i1cbcf0bb6950436780b8711457cab3c0_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i36f2a37affac45d0a14e5ea2173cf5e1_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i4cf11e8a8ad24223ab309b02dcedcecb_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ifd22960d67cd4d7fadc9314e44177757_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i6227c7fe3e8c479d92f2f099128bd674_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1d94b2111aef41dfb83851bf1579dc6e_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="idbb33a02347e4099b5d0a31dcb304fdb_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="segment">
        <measure>apyx:segment</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80L2ZyYWc6NmIzMjRlNjZkZjZmNGNjMjk2N2ZkYmViZDM5ZjhlYTYvdGFibGU6ZjNjNzgwMjhiMzJkNGFlYWI3NmI2ZGY5YjMzYTVmMTMvdGFibGVyYW5nZTpmM2M3ODAyOGIzMmQ0YWVhYjc2YjZkZjliMzNhNWYxM18xLTEtMS0xLTE3NDEw_40339711-f057-4def-856e-ee826e87bcec">0000719135</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80L2ZyYWc6NmIzMjRlNjZkZjZmNGNjMjk2N2ZkYmViZDM5ZjhlYTYvdGFibGU6ZjNjNzgwMjhiMzJkNGFlYWI3NmI2ZGY5YjMzYTVmMTMvdGFibGVyYW5nZTpmM2M3ODAyOGIzMmQ0YWVhYjc2YjZkZjliMzNhNWYxM18yLTEtMS0xLTE3NDEw_78649979-5c95-4d59-8723-7aebc0d8d4a4">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80L2ZyYWc6NmIzMjRlNjZkZjZmNGNjMjk2N2ZkYmViZDM5ZjhlYTYvdGFibGU6ZjNjNzgwMjhiMzJkNGFlYWI3NmI2ZGY5YjMzYTVmMTMvdGFibGVyYW5nZTpmM2M3ODAyOGIzMmQ0YWVhYjc2YjZkZjliMzNhNWYxM18zLTEtMS0xLTE3NDEw_8a4ff273-3aa3-49c6-b9f0-372cec333a40">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80L2ZyYWc6NmIzMjRlNjZkZjZmNGNjMjk2N2ZkYmViZDM5ZjhlYTYvdGFibGU6ZjNjNzgwMjhiMzJkNGFlYWI3NmI2ZGY5YjMzYTVmMTMvdGFibGVyYW5nZTpmM2M3ODAyOGIzMmQ0YWVhYjc2YjZkZjliMzNhNWYxM180LTEtMS0xLTE3NDEw_b6b0fee9-cba9-4f45-a437-6bb604496eaf">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80L2ZyYWc6NmIzMjRlNjZkZjZmNGNjMjk2N2ZkYmViZDM5ZjhlYTYvdGFibGU6ZjNjNzgwMjhiMzJkNGFlYWI3NmI2ZGY5YjMzYTVmMTMvdGFibGVyYW5nZTpmM2M3ODAyOGIzMmQ0YWVhYjc2YjZkZjliMzNhNWYxM181LTEtMS0xLTE3NDEw_d59df853-57ad-4d50-b8c2-13519d12ece3">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentType
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xL2ZyYWc6MzZiOWVmNTdlMzc0NDI0NDhlZTU0ODZhZTEwYzdkMDAvdGV4dHJlZ2lvbjozNmI5ZWY1N2UzNzQ0MjQ0OGVlNTQ4NmFlMTBjN2QwMF8xNTM1_6153605e-f607-4cd3-85c2-894558f2ed1e">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xL2ZyYWc6MzZiOWVmNTdlMzc0NDI0NDhlZTU0ODZhZTEwYzdkMDAvdGFibGU6Y2I2YjY3ZmVmYmE4NGJkMzg5ZWJlNjZmZmYxM2Q5YzcvdGFibGVyYW5nZTpjYjZiNjdmZWZiYTg0YmQzODllYmU2NmZmZjEzZDljN18wLTItMS0xLTE3NDEw_cead7bb7-bcf9-476c-adea-12382c74b36c">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xL2ZyYWc6MzZiOWVmNTdlMzc0NDI0NDhlZTU0ODZhZTEwYzdkMDAvdGFibGU6Y2I2YjY3ZmVmYmE4NGJkMzg5ZWJlNjZmZmYxM2Q5YzcvdGFibGVyYW5nZTpjYjZiNjdmZWZiYTg0YmQzODllYmU2NmZmZjEzZDljN18xLTQtMS0xLTE3NDEw_0266a46a-2d9a-483b-9dac-1bae6773ba1d">2022-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xL2ZyYWc6MzZiOWVmNTdlMzc0NDI0NDhlZTU0ODZhZTEwYzdkMDAvdGFibGU6Y2I2YjY3ZmVmYmE4NGJkMzg5ZWJlNjZmZmYxM2Q5YzcvdGFibGVyYW5nZTpjYjZiNjdmZWZiYTg0YmQzODllYmU2NmZmZjEzZDljN181LTItMS0xLTE3NDEw_de1f9b69-215e-4b31-9cc6-c408a9229574">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xL2ZyYWc6MzZiOWVmNTdlMzc0NDI0NDhlZTU0ODZhZTEwYzdkMDAvdGFibGU6Y2I2YjY3ZmVmYmE4NGJkMzg5ZWJlNjZmZmYxM2Q5YzcvdGFibGVyYW5nZTpjYjZiNjdmZWZiYTg0YmQzODllYmU2NmZmZjEzZDljN183LTQtMS0xLTE3NDEw_3624ad49-34a6-473e-a5d5-237fc912bd96">0-12183</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xL2ZyYWc6MzZiOWVmNTdlMzc0NDI0NDhlZTU0ODZhZTEwYzdkMDAvdGFibGU6MjU5NTFiMWVhMGRhNGMwMTlhNjBiYmEzZjJjNGU1YjAvdGFibGVyYW5nZToyNTk1MWIxZWEwZGE0YzAxOWE2MGJiYTNmMmM0ZTViMF8xLTAtMS0xLTE3NDEw_e2bf45ee-3e8e-46a4-b454-df5f8d64ba96">APYX MEDICAL CORPORATION</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xL2ZyYWc6MzZiOWVmNTdlMzc0NDI0NDhlZTU0ODZhZTEwYzdkMDAvdGFibGU6NGQ2ODBjMzk5ZTg1NGUyOGJhNWMxMGI5OTY5NTBjYjIvdGFibGVyYW5nZTo0ZDY4MGMzOTllODU0ZTI4YmE1YzEwYjk5Njk1MGNiMl8wLTAtMS0xLTE3NDEw_455d69a4-cb55-46d3-ae12-62280262b4eb">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xL2ZyYWc6MzZiOWVmNTdlMzc0NDI0NDhlZTU0ODZhZTEwYzdkMDAvdGFibGU6NGQ2ODBjMzk5ZTg1NGUyOGJhNWMxMGI5OTY5NTBjYjIvdGFibGVyYW5nZTo0ZDY4MGMzOTllODU0ZTI4YmE1YzEwYjk5Njk1MGNiMl8wLTItMS0xLTE3NDEw_c437b952-aaa1-40e0-b6e7-0bb54c008719">11-2644611</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xL2ZyYWc6MzZiOWVmNTdlMzc0NDI0NDhlZTU0ODZhZTEwYzdkMDAvdGV4dHJlZ2lvbjozNmI5ZWY1N2UzNzQ0MjQ0OGVlNTQ4NmFlMTBjN2QwMF8xNTM4_f9ecd1da-35ef-42b8-9be9-eee7075eb1de">5115 Ulmerton Road,</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xL2ZyYWc6MzZiOWVmNTdlMzc0NDI0NDhlZTU0ODZhZTEwYzdkMDAvdGV4dHJlZ2lvbjozNmI5ZWY1N2UzNzQ0MjQ0OGVlNTQ4NmFlMTBjN2QwMF8xNTM5_400378f4-ccdb-4400-be35-ae67ff86d69b">Clearwater</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xL2ZyYWc6MzZiOWVmNTdlMzc0NDI0NDhlZTU0ODZhZTEwYzdkMDAvdGV4dHJlZ2lvbjozNmI5ZWY1N2UzNzQ0MjQ0OGVlNTQ4NmFlMTBjN2QwMF8xNTQw_b74882fe-819b-48b4-8038-27182358df3a">FL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xL2ZyYWc6MzZiOWVmNTdlMzc0NDI0NDhlZTU0ODZhZTEwYzdkMDAvdGV4dHJlZ2lvbjozNmI5ZWY1N2UzNzQ0MjQ0OGVlNTQ4NmFlMTBjN2QwMF8xNTQx_a9c2a3da-19e6-4259-b3c0-68c956f422db">33760</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xL2ZyYWc6MzZiOWVmNTdlMzc0NDI0NDhlZTU0ODZhZTEwYzdkMDAvdGV4dHJlZ2lvbjozNmI5ZWY1N2UzNzQ0MjQ0OGVlNTQ4NmFlMTBjN2QwMF8xNTM2_7de06702-8366-4927-adb5-7f7c86c44c3e">727</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xL2ZyYWc6MzZiOWVmNTdlMzc0NDI0NDhlZTU0ODZhZTEwYzdkMDAvdGV4dHJlZ2lvbjozNmI5ZWY1N2UzNzQ0MjQ0OGVlNTQ4NmFlMTBjN2QwMF8xNTM3_403a339c-8293-4c46-86bb-5f1f87c2f568">384-2323</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xL2ZyYWc6MzZiOWVmNTdlMzc0NDI0NDhlZTU0ODZhZTEwYzdkMDAvdGFibGU6N2MwZGIxOTIxN2JiNDE2MGIwYjcyNjlkYThiOTkyOTgvdGFibGVyYW5nZTo3YzBkYjE5MjE3YmI0MTYwYjBiNzI2OWRhOGI5OTI5OF8xLTAtMS0xLTE3NDEw_26308608-e3e8-490f-8daf-70ebb85e7019">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xL2ZyYWc6MzZiOWVmNTdlMzc0NDI0NDhlZTU0ODZhZTEwYzdkMDAvdGFibGU6N2MwZGIxOTIxN2JiNDE2MGIwYjcyNjlkYThiOTkyOTgvdGFibGVyYW5nZTo3YzBkYjE5MjE3YmI0MTYwYjBiNzI2OWRhOGI5OTI5OF8xLTEtMS0xLTE3NDEw_f7c5d4e6-0e5e-4116-a8d1-5608be04ca76">APYX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xL2ZyYWc6MzZiOWVmNTdlMzc0NDI0NDhlZTU0ODZhZTEwYzdkMDAvdGFibGU6N2MwZGIxOTIxN2JiNDE2MGIwYjcyNjlkYThiOTkyOTgvdGFibGVyYW5nZTo3YzBkYjE5MjE3YmI0MTYwYjBiNzI2OWRhOGI5OTI5OF8xLTItMS0xLTE3NDEw_8563be23-aaa9-47bc-a8ac-d94d2740aceb">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xL2ZyYWc6MzZiOWVmNTdlMzc0NDI0NDhlZTU0ODZhZTEwYzdkMDAvdGV4dHJlZ2lvbjozNmI5ZWY1N2UzNzQ0MjQ0OGVlNTQ4NmFlMTBjN2QwMF8xNTQy_bbeaeeed-647f-486f-a41d-cbabf6337f94">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xL2ZyYWc6MzZiOWVmNTdlMzc0NDI0NDhlZTU0ODZhZTEwYzdkMDAvdGV4dHJlZ2lvbjozNmI5ZWY1N2UzNzQ0MjQ0OGVlNTQ4NmFlMTBjN2QwMF8xNTQz_b9d168f5-48d1-430d-84bd-8c1dbf59ec48">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xL2ZyYWc6MzZiOWVmNTdlMzc0NDI0NDhlZTU0ODZhZTEwYzdkMDAvdGFibGU6ZGJiMTZjMTgzZmVjNDBkZGI4NWI5YTI5ZGZkNmI4ODcvdGFibGVyYW5nZTpkYmIxNmMxODNmZWM0MGRkYjg1YjlhMjlkZmQ2Yjg4N18xLTAtMS0xLTE3NDEw_7d363f0c-46e0-4080-ad3c-8898edaae595">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xL2ZyYWc6MzZiOWVmNTdlMzc0NDI0NDhlZTU0ODZhZTEwYzdkMDAvdGFibGU6ZGJiMTZjMTgzZmVjNDBkZGI4NWI5YTI5ZGZkNmI4ODcvdGFibGVyYW5nZTpkYmIxNmMxODNmZWM0MGRkYjg1YjlhMjlkZmQ2Yjg4N18xLTQtMS0xLTE3NDEw_d8f29d2d-70f0-4d8b-8787-ce05436677ee">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xL2ZyYWc6MzZiOWVmNTdlMzc0NDI0NDhlZTU0ODZhZTEwYzdkMDAvdGFibGU6ZGJiMTZjMTgzZmVjNDBkZGI4NWI5YTI5ZGZkNmI4ODcvdGFibGVyYW5nZTpkYmIxNmMxODNmZWM0MGRkYjg1YjlhMjlkZmQ2Yjg4N18yLTQtMS0xLTE3NDEw_a2f3d99f-9aee-400c-aef1-d735c039a940">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xL2ZyYWc6MzZiOWVmNTdlMzc0NDI0NDhlZTU0ODZhZTEwYzdkMDAvdGV4dHJlZ2lvbjozNmI5ZWY1N2UzNzQ0MjQ0OGVlNTQ4NmFlMTBjN2QwMF8xNTQ0_98a8e928-b06c-4a80-865d-dc375112588d">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="id27600d5964346308b9afb6a5de31f45_I20221109"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xL2ZyYWc6MzZiOWVmNTdlMzc0NDI0NDhlZTU0ODZhZTEwYzdkMDAvdGV4dHJlZ2lvbjozNmI5ZWY1N2UzNzQ0MjQ0OGVlNTQ4NmFlMTBjN2QwMF8xNDU3_b680c738-5ed3-4ab3-9b5d-706aeab5f52a"
      unitRef="shares">34597822</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMy0xLTEtMS0xNzQxMA_1c85159b-ac31-4a76-bfe4-b8c05b87f3f9"
      unitRef="usd">14833000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMy0zLTEtMS0xNzQxMA_166564e4-3c5a-4d2e-8f1b-e9f8c75ca101"
      unitRef="usd">30870000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfNC0wLTEtMS0xNzQxMC90ZXh0cmVnaW9uOjIyNzdiYTA2MmQ4MjRhZTRiNTgwODQxNGMyZGNlZjI1XzU0_2ef072d4-cddc-43d5-9977-a4a64a8d2267"
      unitRef="usd">634000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfNC0wLTEtMS0xNzQxMC90ZXh0cmVnaW9uOjIyNzdiYTA2MmQ4MjRhZTRiNTgwODQxNGMyZGNlZjI1XzYx_b7848692-02e2-49e6-bde2-fc0fee519cdf"
      unitRef="usd">430000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfNC0xLTEtMS0xNzQxMA_f79cfd6e-9786-4261-86e8-6bd51e6e068f"
      unitRef="usd">9094000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfNC0zLTEtMS0xNzQxMA_53ddd200-c236-459c-bdb2-304e1637024e"
      unitRef="usd">13038000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:IncomeTaxesReceivable
      contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfNS0xLTEtMS0xNzQxMA_86f39a34-b3c2-44b2-97a3-6e4364345d3f"
      unitRef="usd">7545000</us-gaap:IncomeTaxesReceivable>
    <us-gaap:IncomeTaxesReceivable
      contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfNS0zLTEtMS0xNzQxMA_850cb3ba-e01b-4ec4-b616-56e24493a376"
      unitRef="usd">7642000</us-gaap:IncomeTaxesReceivable>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfNi0xLTEtMS0xNzQxMA_a93ea1c1-1f8f-4d4a-9501-3a36625be742"
      unitRef="usd">19000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfNi0zLTEtMS0xNzQxMA_e6887cc7-0c31-42d5-aaf6-e9ecb42f4ec4"
      unitRef="usd">483000</us-gaap:OtherReceivablesNetCurrent>
    <apyx:ProvisionForObsolescenceInventory
      contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfNy0wLTEtMS0xNzQxMC90ZXh0cmVnaW9uOjYxNDNmZjdiZjhhZjQ4NmY5NjFiYWQ0YTE5Zjk5MjYzXzU0_ba570541-9fc1-4c6d-84c4-a390e3efe064"
      unitRef="usd">379000</apyx:ProvisionForObsolescenceInventory>
    <apyx:ProvisionForObsolescenceInventory
      contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfNy0wLTEtMS0xNzQxMC90ZXh0cmVnaW9uOjYxNDNmZjdiZjhhZjQ4NmY5NjFiYWQ0YTE5Zjk5MjYzXzYx_d3383b79-fffc-42f9-9d54-2a0b006249c0"
      unitRef="usd">263000</apyx:ProvisionForObsolescenceInventory>
    <us-gaap:InventoryNet
      contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfNy0xLTEtMS0xNzQxMA_2fc8ad41-9fc4-4db8-a37a-4b0db8f7990b"
      unitRef="usd">12042000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfNy0zLTEtMS0xNzQxMA_9ead2ffe-802d-4699-944d-35e9879390fd"
      unitRef="usd">6778000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfOC0xLTEtMS0xNzQxMA_edd7a1fc-032e-4e51-8e7f-5c0a259bd7ac"
      unitRef="usd">2774000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfOC0zLTEtMS0xNzQxMA_1428d36b-07d2-408a-94aa-5de5548dbe84"
      unitRef="usd">1926000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfOS0xLTEtMS0xNzQxMA_20a09c21-155f-40b0-aef2-2f7d8d9a7d94"
      unitRef="usd">46307000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfOS0zLTEtMS0xNzQxMA_5fc0a08e-aa07-4086-8591-a2ce67929dbb"
      unitRef="usd">60737000</us-gaap:AssetsCurrent>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMTAtMC0xLTEtMTc0MTAvdGV4dHJlZ2lvbjo5ZTgxMzI0ZDA5OWY0ZWZiYWMxYWQ5ZDlmNjZhZjlmYV84MA_48474e5d-9c22-4ae2-b4c1-60209cf4c6e2"
      unitRef="usd">5335000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMTAtMC0xLTEtMTc0MTAvdGV4dHJlZ2lvbjo5ZTgxMzI0ZDA5OWY0ZWZiYWMxYWQ5ZDlmNjZhZjlmYV85MQ_b12b75de-b67c-4305-acf5-fbfc1eb9727a"
      unitRef="usd">5316000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMTAtMS0xLTEtMTc0MTA_f6f4e0f3-598c-445e-9f0e-66c2ac5d7843"
      unitRef="usd">6810000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMTAtMy0xLTEtMTc0MTA_74984c0b-6bb5-43e8-8a9f-44f134c63846"
      unitRef="usd">6575000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMTEtMS0xLTEtMTc0MTA_786cfcb5-2029-4009-af3a-df49f12e60dc"
      unitRef="usd">774000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMTEtMy0xLTEtMTc0MTA_bc91ae96-9062-4c76-8404-bda707fa452e"
      unitRef="usd">121000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMTItMS0xLTEtMTc0MTA_9348d839-47b9-4fc9-aac0-6b76384b78f6"
      unitRef="usd">124000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMTItMy0xLTEtMTc0MTA_32e71505-932b-4d1f-8648-d251c08749e3"
      unitRef="usd">178000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMTQtMS0xLTEtMTc0MTA_896a9aca-28a9-4f5f-ae2a-a837aa294b2e"
      unitRef="usd">1253000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMTQtMy0xLTEtMTc0MTA_431060ff-6e63-4106-9717-0e9b9cd4b33d"
      unitRef="usd">1110000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMTUtMS0xLTEtMTc0MTA_50376d42-1235-4ea6-b546-339711a79ea6"
      unitRef="usd">55268000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMTUtMy0xLTEtMTc0MTA_cc2d6262-09d9-43e6-ba95-1c0dbc49f9ff"
      unitRef="usd">68721000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMjEtMS0xLTEtMTc0MTA_0e47683c-bc8f-48b9-bb32-30a499b91655"
      unitRef="usd">2070000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMjEtMy0xLTEtMTc0MTA_0961e7a7-ced1-482e-bd89-fa99f95ee6d0"
      unitRef="usd">2631000</us-gaap:AccountsPayableCurrent>
    <apyx:AccruedLiabilitiesAndOtherLiabilitiesCurrent
      contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMjItMS0xLTEtMTc0MTA_754368be-40af-4832-93a4-bd9aeaeab247"
      unitRef="usd">8842000</apyx:AccruedLiabilitiesAndOtherLiabilitiesCurrent>
    <apyx:AccruedLiabilitiesAndOtherLiabilitiesCurrent
      contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMjItMy0xLTEtMTc0MTA_a39f1773-2ef7-4a08-a6b1-e5ae852348d3"
      unitRef="usd">10287000</apyx:AccruedLiabilitiesAndOtherLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMjMtMS0xLTEtMTc0MTA_7208b769-9ba1-40b8-9598-c2614c6d9f6b"
      unitRef="usd">240000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMjMtMy0xLTEtMTc0MTA_65e81184-ba07-476e-a50e-bf375c0d03d1"
      unitRef="usd">122000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMjQtMS0xLTEtMTc0MTA_40cd20b2-95ff-4f2d-8326-0cd4d9772bf3"
      unitRef="usd">42000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMjQtMy0xLTEtMTc0MTA_34ed69f8-e872-43c3-87e3-d0980a43833d"
      unitRef="usd">165000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMjYtMS0xLTEtMTc0MTA_dc9286e4-985d-4177-85a3-f645dd90e35c"
      unitRef="usd">11194000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMjYtMy0xLTEtMTc0MTA_f4b194e5-ade3-45f8-8d96-4523431d8ec1"
      unitRef="usd">13205000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMjctMS0xLTEtMTc0MTA_260d366f-79ab-43da-9a20-bcd6c866d7fb"
      unitRef="usd">454000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMjctMy0xLTEtMTc0MTA_2ac5fe04-88f1-4e67-84b5-4a72adfb3383"
      unitRef="usd">0</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMjgtMS0xLTEtMTc0MTA_a3ae713c-75cd-4118-ba30-4ebb202af6e7"
      unitRef="usd">78000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMjgtMy0xLTEtMTc0MTA_3fcfa8ec-bf18-42b8-8023-5f2ad8896e82"
      unitRef="usd">18000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMjktMS0xLTEtMTc0MTA_9e45a79c-18ae-4264-946a-661d2ca26aad"
      unitRef="usd">1192000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMjktMy0xLTEtMTc0MTA_77fef9f1-6f5f-4364-8fdd-75550846ef3d"
      unitRef="usd">1323000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMzAtMS0xLTEtMTc0MTA_ce26a9f3-1c44-4f76-8dd2-b746e81d827f"
      unitRef="usd">133000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMzAtMy0xLTEtMTc0MTA_fe9f18fe-56c8-43d7-86a4-ab02dfe26430"
      unitRef="usd">166000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMzEtMS0xLTEtMTc0MTA_095ae7bd-2e18-48af-9410-5d313e9d1f4f"
      unitRef="usd">13051000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMzEtMy0xLTEtMTc0MTA_27a1e819-5196-4675-8fd2-bafacc458f95"
      unitRef="usd">14712000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMzMtMC0xLTEtMTc0MTAvdGV4dHJlZ2lvbjo3NjcxZjE3MzU1YzI0ZDgxOTVhZTAwOTFlNWMzNDZjYl8xOA_b7973ed2-83e9-40f1-ad38-667bfeab5bad"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMzMtMC0xLTEtMTc0MTAvdGV4dHJlZ2lvbjo3NjcxZjE3MzU1YzI0ZDgxOTVhZTAwOTFlNWMzNDZjYl8xOA_e71dafa9-90b6-4bd1-937d-c94465a35805"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMzMtMC0xLTEtMTc0MTAvdGV4dHJlZ2lvbjo3NjcxZjE3MzU1YzI0ZDgxOTVhZTAwOTFlNWMzNDZjYl8zMg_53da56ad-5c73-4669-80fa-d008fcb941a4"
      unitRef="shares">75000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMzMtMC0xLTEtMTc0MTAvdGV4dHJlZ2lvbjo3NjcxZjE3MzU1YzI0ZDgxOTVhZTAwOTFlNWMzNDZjYl8zMg_dea71242-fca9-49e3-9b7e-e57ef96ab681"
      unitRef="shares">75000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMzMtMC0xLTEtMTc0MTAvdGV4dHJlZ2lvbjo3NjcxZjE3MzU1YzI0ZDgxOTVhZTAwOTFlNWMzNDZjYl81NA_7e5c9750-9351-4635-815c-bbfe1a2b7dba"
      unitRef="shares">34588398</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMzMtMC0xLTEtMTc0MTAvdGV4dHJlZ2lvbjo3NjcxZjE3MzU1YzI0ZDgxOTVhZTAwOTFlNWMzNDZjYl81NA_906d36bb-fb47-47c7-abd3-c6e08e278e6b"
      unitRef="shares">34588398</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMzMtMC0xLTEtMTc0MTAvdGV4dHJlZ2lvbjo3NjcxZjE3MzU1YzI0ZDgxOTVhZTAwOTFlNWMzNDZjYl85NA_a2d0efc5-6717-4505-9008-5278a0f94e5a"
      unitRef="shares">34409912</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMzMtMC0xLTEtMTc0MTAvdGV4dHJlZ2lvbjo3NjcxZjE3MzU1YzI0ZDgxOTVhZTAwOTFlNWMzNDZjYl85NA_c2b910f4-aa2b-4bab-b8c0-662a362d9148"
      unitRef="shares">34409912</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMzMtMS0xLTEtMTc0MTA_812efc43-4864-4b7c-a0e8-7a2559c527e0"
      unitRef="usd">35000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMzMtMy0xLTEtMTc0MTA_f59484b2-ecee-48fe-a15b-7f91ecda4de8"
      unitRef="usd">34000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMzQtMS0xLTEtMTc0MTA_1a703c19-82cb-4934-9757-d35b182caced"
      unitRef="usd">71641000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMzQtMy0xLTEtMTc0MTA_4297a77a-8966-47a0-a098-3f704ee72059"
      unitRef="usd">66221000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMzUtMS0xLTEtMTc0MTA_204af99e-45aa-4b78-bcb2-508d34469fb9"
      unitRef="usd">-29686000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMzUtMy0xLTEtMTc0MTA_780313d0-0f10-4f92-a06f-4449945f0ba0"
      unitRef="usd">-12551000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMzYtMS0xLTEtMTc0MTA_5fb361ad-8dbb-4545-b86a-eaba3858f868"
      unitRef="usd">41990000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMzYtMy0xLTEtMTc0MTA_26d7d5f8-b99c-4f48-805a-39aa2374befb"
      unitRef="usd">53704000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMzctMS0xLTEtMTc0MTA_1cd3072b-1184-4ffd-a6c7-41a3dda547bf"
      unitRef="usd">227000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMzctMy0xLTEtMTc0MTA_795f08cb-9297-484f-a851-fcf39d0e75c8"
      unitRef="usd">305000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMzgtMS0xLTEtMTc0MTA_aec5e40f-9fa3-46a4-aa3d-9031f9318dc1"
      unitRef="usd">42217000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMzgtMy0xLTEtMTc0MTA_e673aacf-b639-4f2d-94f3-8b02c388cdb9"
      unitRef="usd">54009000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMzktMS0xLTEtMTc0MTA_c221fd73-1c2c-4e69-ad26-4c0e6b95775e"
      unitRef="usd">55268000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xNi9mcmFnOjg3NTA2NjI2YmU4MTQ4Nzc5ODc2NWYxN2ZjMmQwMWFmL3RhYmxlOjdmZGE3NjlmZjU2MTQ1OTZiNWE1ZDQ3ZjdkZjc5NDBlL3RhYmxlcmFuZ2U6N2ZkYTc2OWZmNTYxNDU5NmI1YTVkNDdmN2RmNzk0MGVfMzktMy0xLTEtMTc0MTA_c36fb7c7-4088-4aaa-85cf-7f9f2f16866a"
      unitRef="usd">68721000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id6ada2596cf84b118b49af7a6561fb79_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMi0xLTEtMS0xNzQxMA_db506cbc-1dfc-4ec7-b0a7-1600356e1b8e"
      unitRef="usd">9114000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic9b0b6a3c69447bf8f151dfd98c14ac9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMi0zLTEtMS0xNzQxMA_6f4318cb-5999-4436-ad6c-a641f2a36ce5"
      unitRef="usd">11831000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMi01LTEtMS0xNzQxMA_47b9c36c-bcb8-4b98-8de7-8c8abc4b2765"
      unitRef="usd">31899000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMi03LTEtMS0xNzQxMA_43ab1d24-6e35-4ff7-8919-b0d3f2ceacbb"
      unitRef="usd">31693000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="id6ada2596cf84b118b49af7a6561fb79_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMy0xLTEtMS0xNzQxMA_fd184a9a-a48c-496c-a779-0cb97fbb4ca6"
      unitRef="usd">3357000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ic9b0b6a3c69447bf8f151dfd98c14ac9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMy0zLTEtMS0xNzQxMA_1c72bb0f-9c5a-4db2-8f14-6cbb3182ab72"
      unitRef="usd">3775000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMy01LTEtMS0xNzQxMA_75f197e7-3881-4d98-88bd-d1b9819ba180"
      unitRef="usd">11009000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMy03LTEtMS0xNzQxMA_a2b81290-33d4-4fa5-97ee-eebfe71f192f"
      unitRef="usd">10243000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="id6ada2596cf84b118b49af7a6561fb79_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfNC0xLTEtMS0xNzQxMA_8dd7ce71-7b8a-4685-b6b7-5f9ed214b7ca"
      unitRef="usd">5757000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="ic9b0b6a3c69447bf8f151dfd98c14ac9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfNC0zLTEtMS0xNzQxMA_a49f9497-dfe1-43cc-93f9-449bddfc8e59"
      unitRef="usd">8056000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfNC01LTEtMS0xNzQxMA_bfb4327f-b1ad-4c3b-9f2b-b49dd87dc383"
      unitRef="usd">20890000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfNC03LTEtMS0xNzQxMA_473a4422-a682-41f9-a237-27100c4e4f76"
      unitRef="usd">21450000</us-gaap:GrossProfit>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="id6ada2596cf84b118b49af7a6561fb79_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfNi0xLTEtMS0xNzQxMA_9420f3f2-72b2-408a-904d-29aa9652ee81"
      unitRef="usd">1061000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ic9b0b6a3c69447bf8f151dfd98c14ac9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfNi0zLTEtMS0xNzQxMA_4b0a4faf-2c34-4b10-a613-561a3a265817"
      unitRef="usd">1175000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfNi01LTEtMS0xNzQxMA_3d8883dd-8dde-4475-a2ae-73e833b5d5d0"
      unitRef="usd">3289000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfNi03LTEtMS0xNzQxMA_fce27f91-a19f-41f6-a084-6f4516840894"
      unitRef="usd">3374000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ProfessionalFees
      contextRef="id6ada2596cf84b118b49af7a6561fb79_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfNy0xLTEtMS0xNzQxMA_ac387865-f122-4f14-916f-0e595ff5f2d1"
      unitRef="usd">1936000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="ic9b0b6a3c69447bf8f151dfd98c14ac9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfNy0zLTEtMS0xNzQxMA_ce339846-e802-49b7-99c9-a7b905a52e63"
      unitRef="usd">2032000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfNy01LTEtMS0xNzQxMA_c5c99628-b9a3-4231-97af-9e8fa56716ab"
      unitRef="usd">6611000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfNy03LTEtMS0xNzQxMA_72214844-88a5-40e3-b0e6-54c3c84f4a5f"
      unitRef="usd">5442000</us-gaap:ProfessionalFees>
    <us-gaap:SalariesAndWages
      contextRef="id6ada2596cf84b118b49af7a6561fb79_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfOC0xLTEtMS0xNzQxMA_a231f3ff-20c4-4ea7-aab7-097d54069dfa"
      unitRef="usd">3871000</us-gaap:SalariesAndWages>
    <us-gaap:SalariesAndWages
      contextRef="ic9b0b6a3c69447bf8f151dfd98c14ac9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfOC0zLTEtMS0xNzQxMA_67bbfd7b-e645-49e1-9a25-2ddb90064764"
      unitRef="usd">4206000</us-gaap:SalariesAndWages>
    <us-gaap:SalariesAndWages
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfOC01LTEtMS0xNzQxMA_774899a9-a5f7-470d-bd00-e42b7969eafb"
      unitRef="usd">13944000</us-gaap:SalariesAndWages>
    <us-gaap:SalariesAndWages
      contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfOC03LTEtMS0xNzQxMA_2c3b8d11-8750-464c-9104-8bae708778a3"
      unitRef="usd">12794000</us-gaap:SalariesAndWages>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="id6ada2596cf84b118b49af7a6561fb79_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfOS0xLTEtMS0xNzQxMA_a950c113-d5da-43cb-b12c-cc8fbe7d1630"
      unitRef="usd">4671000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ic9b0b6a3c69447bf8f151dfd98c14ac9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfOS0zLTEtMS0xNzQxMA_15c4dc28-2270-44c5-b1a3-e932da592e42"
      unitRef="usd">4611000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfOS01LTEtMS0xNzQxMA_1116405d-95d9-472c-a601-c393b2e6c359"
      unitRef="usd">14675000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfOS03LTEtMS0xNzQxMA_1cf28576-29e9-48a5-8849-d24fa629635d"
      unitRef="usd">12596000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="id6ada2596cf84b118b49af7a6561fb79_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMTAtMS0xLTEtMTc0MTA_bd0dab55-1895-4356-bb6c-829803a4a95d"
      unitRef="usd">11539000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="ic9b0b6a3c69447bf8f151dfd98c14ac9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMTAtMy0xLTEtMTc0MTA_4ecbd706-ef97-4509-ad0e-31a502a5e54d"
      unitRef="usd">12024000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMTAtNS0xLTEtMTc0MTA_e214b0db-d469-4361-b4d8-56910a6b4e01"
      unitRef="usd">38519000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMTAtNy0xLTEtMTc0MTA_c877225d-dbff-491b-b6fb-8182e0622a1f"
      unitRef="usd">34206000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="id6ada2596cf84b118b49af7a6561fb79_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMTEtMS0xLTEtMTc0MTA_4da79582-222f-4106-971a-a914fa811f74"
      unitRef="usd">-5782000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ic9b0b6a3c69447bf8f151dfd98c14ac9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMTEtMy0xLTEtMTc0MTA_5cc8b389-fa5a-4900-8e47-731ca8d7dd94"
      unitRef="usd">-3968000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMTEtNS0xLTEtMTc0MTA_0f24df18-f17e-41b5-9f94-763d37f5f9ed"
      unitRef="usd">-17629000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMTEtNy0xLTEtMTc0MTA_858526e6-b410-476d-b2f0-79138d5d4c6b"
      unitRef="usd">-12756000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeOperating
      contextRef="id6ada2596cf84b118b49af7a6561fb79_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMTItMS0xLTEtMTc0MTA_69aeda59-2237-4db2-a8bd-73f8682db494"
      unitRef="usd">73000</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="ic9b0b6a3c69447bf8f151dfd98c14ac9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMTItMy0xLTEtMTc0MTA_181d1dd5-722d-40a1-b637-709134295dd0"
      unitRef="usd">2000</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMTItNS0xLTEtMTc0MTA_990202e6-2838-4422-8511-176a9f720203"
      unitRef="usd">93000</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMTItNy0xLTEtMTc0MTA_5a8ac1ad-f147-4f04-ae1d-56dc48ba70ed"
      unitRef="usd">9000</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestExpense
      contextRef="id6ada2596cf84b118b49af7a6561fb79_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMTMtMS0xLTEtMTc0MTA_9461e78b-5dc1-476f-be37-308d4f143fd4"
      unitRef="usd">1000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ic9b0b6a3c69447bf8f151dfd98c14ac9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMTMtMy0xLTEtMTc0MTA_6188d003-7fd9-4558-99b0-1d109a9a56ce"
      unitRef="usd">3000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMTMtNS0xLTEtMTc0MTA_a61d4ba5-385e-4064-98bf-f6772dd86fc7"
      unitRef="usd">12000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMTMtNy0xLTEtMTc0MTA_15f2d749-c611-4165-956a-7e0e62d6afd0"
      unitRef="usd">9000</us-gaap:InterestExpense>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="id6ada2596cf84b118b49af7a6561fb79_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMTQtMS0xLTEtMTc0MTA_b8d75bc4-67f2-4f7c-96ec-dcc2f08cbcea"
      unitRef="usd">-35000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="ic9b0b6a3c69447bf8f151dfd98c14ac9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMTQtMy0xLTEtMTc0MTA_991a5b02-c569-4618-aa02-507482907e96"
      unitRef="usd">-192000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMTQtNS0xLTEtMTc0MTA_a28ead73-4acb-4c98-8865-9ac55f753090"
      unitRef="usd">551000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMTQtNy0xLTEtMTc0MTA_11eb9701-1fa1-4a1f-8abc-07f94f008507"
      unitRef="usd">-188000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="id6ada2596cf84b118b49af7a6561fb79_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMTUtMS0xLTEtMTc0MTA_95af418f-66bb-4cfb-b6f0-362a36d78f70"
      unitRef="usd">37000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ic9b0b6a3c69447bf8f151dfd98c14ac9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMTUtMy0xLTEtMTc0MTA_ef6d7f63-2820-42a8-ae86-035559af5424"
      unitRef="usd">-193000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMTUtNS0xLTEtMTc0MTA_f5d69c57-7bd4-49d1-9f85-fcecef232e18"
      unitRef="usd">632000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMTUtNy0xLTEtMTc0MTA_375c0e0f-b461-4c1f-89f2-e945b1cc1a15"
      unitRef="usd">-188000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="id6ada2596cf84b118b49af7a6561fb79_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMTYtMS0xLTEtMTc0MTA_5a3f7805-9607-46e9-b1e3-0133c4c0698f"
      unitRef="usd">-5745000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ic9b0b6a3c69447bf8f151dfd98c14ac9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMTYtMy0xLTEtMTc0MTA_2ea1e02b-46f2-44a7-ad8b-054135f33f6c"
      unitRef="usd">-4161000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMTYtNS0xLTEtMTc0MTA_6ab036e4-e017-4659-a0ab-03d8c5d456b9"
      unitRef="usd">-16997000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMTYtNy0xLTEtMTc0MTA_494b41d5-86a8-4bdf-8cae-f8310dff26d4"
      unitRef="usd">-12944000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="id6ada2596cf84b118b49af7a6561fb79_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMTctMS0xLTEtMTc0MTA_f69729c5-db75-4e35-b874-1ccee52c4149"
      unitRef="usd">50000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ic9b0b6a3c69447bf8f151dfd98c14ac9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMTctMy0xLTEtMTc0MTA_6dc3b75f-5027-419d-b3b9-ebe87b7ab17c"
      unitRef="usd">73000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMTctNS0xLTEtMTc0MTA_a4726fad-f30f-44c5-ad4b-081107690181"
      unitRef="usd">216000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMTctNy0xLTEtMTc0MTA_e1f853e0-fabb-42bb-8c74-394eb06e854e"
      unitRef="usd">246000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="id6ada2596cf84b118b49af7a6561fb79_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMTgtMS0xLTEtMTc0MTA_7da3fdd7-5c53-47bf-ab42-70fac6662fda"
      unitRef="usd">-5795000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ic9b0b6a3c69447bf8f151dfd98c14ac9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMTgtMy0xLTEtMTc0MTA_6db9c690-188c-4a31-814e-1f38e7298307"
      unitRef="usd">-4234000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMTgtNS0xLTEtMTc0MTA_290617b7-babf-40dd-9961-e89c619cd75a"
      unitRef="usd">-17213000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMTgtNy0xLTEtMTc0MTA_3b06e07b-2561-4f36-8df0-a798d51a5f9b"
      unitRef="usd">-13190000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="id6ada2596cf84b118b49af7a6561fb79_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMTktMS0xLTEtMTc0MTA_65dcc184-756e-4dda-aa5f-29a695a0087e"
      unitRef="usd">-31000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ic9b0b6a3c69447bf8f151dfd98c14ac9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMTktMy0xLTEtMTc0MTA_0d0bf830-62fa-4a49-925f-3c43d50edb41"
      unitRef="usd">-12000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMTktNS0xLTEtMTc0MTA_15f049a6-e1e9-424f-82f5-eb30b87b1a5e"
      unitRef="usd">-78000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMTktNy0xLTEtMTc0MTA_3b9dcdbe-fcbf-47d4-80b8-9941ed6ec988"
      unitRef="usd">-21000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="id6ada2596cf84b118b49af7a6561fb79_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMjAtMS0xLTEtMTc0MTA_bf353b51-01c2-435e-90e6-bf5a9b76374f"
      unitRef="usd">-5764000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic9b0b6a3c69447bf8f151dfd98c14ac9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMjAtMy0xLTEtMTc0MTA_0267997a-c009-45da-a994-f6e63ad3a616"
      unitRef="usd">-4222000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMjAtNS0xLTEtMTc0MTA_8fae707b-42cf-4fb6-a7be-8913daf102d1"
      unitRef="usd">-17135000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMjAtNy0xLTEtMTc0MTA_215875f0-d710-455b-b8f2-85b92b71bb67"
      unitRef="usd">-13169000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="id6ada2596cf84b118b49af7a6561fb79_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMjQtMS0xLTEtMTc0MTA_06487251-ea0a-407e-a1b7-12b83c717f0b"
      unitRef="usdPerShare">-0.17</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="id6ada2596cf84b118b49af7a6561fb79_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMjQtMS0xLTEtMTc0MTA_ca7abe26-b0d2-4991-9b50-a2e00e1d6840"
      unitRef="usdPerShare">-0.17</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="ic9b0b6a3c69447bf8f151dfd98c14ac9_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMjQtMy0xLTEtMTc0MTA_77f20804-9876-47a8-bc2e-bf8f0f23c71c"
      unitRef="usdPerShare">-0.12</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ic9b0b6a3c69447bf8f151dfd98c14ac9_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMjQtMy0xLTEtMTc0MTA_d8e9c6c8-2c66-4d1e-b334-ba05318f6f43"
      unitRef="usdPerShare">-0.12</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMjQtNS0xLTEtMTc0MTA_810b2514-2695-4f61-aa66-76180ed3aeb7"
      unitRef="usdPerShare">-0.50</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMjQtNS0xLTEtMTc0MTA_cc781c32-042a-4dbe-bf1b-f519d2f53c47"
      unitRef="usdPerShare">-0.50</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMjQtNy0xLTEtMTc0MTA_e225f3ec-92c2-4761-bac7-9dcc2af13f03"
      unitRef="usdPerShare">-0.38</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8xOS9mcmFnOmJlNzc1Y2QyMTllZTQ1OWVhZmVmM2ZiNjgwZTEzNTBiL3RhYmxlOjJjNmI1ZTdhYzljMzQ5YzFhMDc4ODc2ODgyYTA5NjdkL3RhYmxlcmFuZ2U6MmM2YjVlN2FjOWMzNDljMWEwNzg4NzY4ODJhMDk2N2RfMjQtNy0xLTEtMTc0MTA_eaa74bb1-be3a-4800-9c90-a29ef24b53fb"
      unitRef="usdPerShare">-0.38</us-gaap:EarningsPerShareBasic>
    <us-gaap:SharesIssued
      contextRef="i0915370fdc66433087f61be1a6429895_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMy0xLTEtMS0xNzQxMA_f593a5a6-4ce8-40b6-bea0-c20ae0f4c038"
      unitRef="shares">34323000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0915370fdc66433087f61be1a6429895_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMy0zLTEtMS0xNzQxMA_234438b1-af5f-43be-baae-a3bbea26181c"
      unitRef="usd">34000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia6bd5470a522440896a96cb114d94bc9_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMy01LTEtMS0xNzQxMA_bec9dd10-94df-40a8-a050-2b3e0494f9d6"
      unitRef="usd">63650000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1602e279f8a54d59a4619d5751091e77_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMy03LTEtMS0xNzQxMA_1b4ce6b5-f8e9-4c44-be6b-1e0f6ae75a10"
      unitRef="usd">-6326000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i70c60e5ef978483d94930f1744a9d3af_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMy05LTEtMS0xNzQxMA_7f834d7a-60cb-4aa8-9378-caefca870a16"
      unitRef="usd">324000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i138bdba832374d1f808c394db84be422_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMy0xMS0xLTEtMTc0MTA_ea37ecb9-1fe7-46ea-bc4b-1b0eba460c5a"
      unitRef="usd">57682000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="iecb0fed55763430baf6093ea22f40d87_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfNS0xLTEtMS0xNzQxMA_5b25e102-df4a-4ccb-a054-6d9c4dbfc6b1"
      unitRef="shares">3000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ica2773a2e5304f8480d1f69944277492_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfNS01LTEtMS0xNzQxMA_6a68d1b1-3499-419b-aac6-dc05a648241b"
      unitRef="usd">28000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ic9b0b6a3c69447bf8f151dfd98c14ac9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfNS0xMS0xLTEtMTc0MTA_fea6daed-9b67-4633-826a-5c689d694738"
      unitRef="usd">28000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ica2773a2e5304f8480d1f69944277492_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfNi01LTEtMS0xNzQxMA_b417c403-e363-4729-96ac-a2a815bd87a0"
      unitRef="usd">1184000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ic9b0b6a3c69447bf8f151dfd98c14ac9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfNi0xMS0xLTEtMTc0MTA_de01cf3e-9527-4bfb-84a7-ead3be6148bd"
      unitRef="usd">1184000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <apyx:StockSwapToAcquireOptionsShares
      contextRef="iecb0fed55763430baf6093ea22f40d87_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfNy0xLTEtMS0xNzQxMA_24202e88-b7d5-4aca-b5ac-aee3ec9eaa00"
      unitRef="shares">14000</apyx:StockSwapToAcquireOptionsShares>
    <us-gaap:ProfitLoss
      contextRef="i102d87338ba6454f85cc738690cc4358_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfOS03LTEtMS0xNzQxMA_816fc5b0-32f5-439a-b756-daaf21921e58"
      unitRef="usd">-4222000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i2ad330e6cdd442be8bf971667788ba23_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfOS05LTEtMS0xNzQxMA_8a65cadd-d27a-43bc-a714-40cc8f64426e"
      unitRef="usd">-12000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ic9b0b6a3c69447bf8f151dfd98c14ac9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfOS0xMS0xLTEtMTc0MTA_97287cee-3eea-4303-95c7-d5dd4e7cd0a1"
      unitRef="usd">-4234000</us-gaap:ProfitLoss>
    <us-gaap:SharesIssued
      contextRef="ib6078f16f5134a2e9e175491969aa315_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMTAtMS0xLTEtMTc0MTA_e5d571c1-185e-47d7-923d-5acd9447384d"
      unitRef="shares">34340000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib6078f16f5134a2e9e175491969aa315_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMTAtMy0xLTEtMTc0MTA_68348507-69b7-4c1c-945c-0a19e2bec6f9"
      unitRef="usd">34000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3d63a53f125c4acd96a77b7410be5951_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMTAtNS0xLTEtMTc0MTA_c3e23b1b-b73a-4048-8bcd-9d18b03111e1"
      unitRef="usd">64862000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6459bdf630814b27874dad87632c646a_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMTAtNy0xLTEtMTc0MTA_6f8a3344-8366-4226-8b38-8f610f32eeb0"
      unitRef="usd">-10548000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia98a748ab05948eda52b8c8873f240ed_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMTAtOS0xLTEtMTc0MTA_f713234d-11c3-4cb0-b770-9398181e8e55"
      unitRef="usd">312000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i524cd9c9acd4440f8d2e862dbb84f261_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMTAtMTEtMS0xLTE3NDEw_6aa9e41f-bd7c-457e-86b3-afefd3e8fee7"
      unitRef="usd">54660000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="i6b3b8a89480b4a8680824601cb0552b9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMTItMS0xLTEtMTc0MTA_b0ebc734-b37f-4151-b939-d53e6a24e199"
      unitRef="shares">34493000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6b3b8a89480b4a8680824601cb0552b9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMTItMy0xLTEtMTc0MTA_24d116a1-0579-4e3a-b08c-9faf748d4385"
      unitRef="usd">34000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i02b00de331904fcebd2e5c7c0add0881_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMTItNS0xLTEtMTc0MTA_abdcf884-cab0-4193-bf6d-7eff63ee8622"
      unitRef="usd">69793000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3d3946eaa70742e3a1d7332eacba51a6_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMTItNy0xLTEtMTc0MTA_b4fe53c2-ecb3-4676-a68b-6bbd7a11db1e"
      unitRef="usd">-23922000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie9d5039cab3a4fa5a3b9b29f5d4f1ce0_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMTItOS0xLTEtMTc0MTA_6088373d-8d8a-4ec9-912a-2eeaaee83e76"
      unitRef="usd">258000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic1a290f8b3eb4985ac22e7ccb81b66e5_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMTItMTEtMS0xLTE3NDEw_90f19f1e-932b-4554-99d4-2cad217f1e77"
      unitRef="usd">46163000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i2682ba64e91149fb8218158d95782bd3_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMTQtMS0xLTEtMTc0MTA_7cf06426-3d37-492e-8799-0b42098cb088"
      unitRef="shares">62000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i2682ba64e91149fb8218158d95782bd3_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMTQtMy0xLTEtMTc0MTA_3b61db59-b50c-4af4-a157-69b9d3ffc1fa"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i1211ee2c038f40b8b5feff5fd9d6fe4c_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMTQtNS0xLTEtMTc0MTA_9b460541-8074-4871-bd5b-b104bb1eda9b"
      unitRef="usd">156000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="id6ada2596cf84b118b49af7a6561fb79_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMTQtMTEtMS0xLTE3NDEw_e6f3ea82-78a1-4ce7-bd33-764c21da0d7f"
      unitRef="usd">157000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i1211ee2c038f40b8b5feff5fd9d6fe4c_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMTUtNS0xLTEtMTc0MTA_8ab1eca8-d2da-4646-bbdf-d215ac525dd5"
      unitRef="usd">1692000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="id6ada2596cf84b118b49af7a6561fb79_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMTUtMTEtMS0xLTE3NDEw_5ed7155c-6f9c-46e4-a901-75d3a372161d"
      unitRef="usd">1692000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <apyx:StockSwapToAcquireOptionsShares
      contextRef="i2682ba64e91149fb8218158d95782bd3_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMTYtMS0xLTEtMTc0MTA_186f2992-a538-40a8-a7bc-564d28d685f8"
      unitRef="shares">33000</apyx:StockSwapToAcquireOptionsShares>
    <us-gaap:ProfitLoss
      contextRef="i87921e2d34bd4d828c5d4930daeb8fc8_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMTgtNy0xLTEtMTc0MTA_685304b7-9195-4714-a503-7d5681d17555"
      unitRef="usd">-5764000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i2b2ac4e7bb8a4fab90de0f2a2f18a839_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMTgtOS0xLTEtMTc0MTA_50a95a2a-1ae6-40da-9bf9-8ef6f9c501fa"
      unitRef="usd">-31000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="id6ada2596cf84b118b49af7a6561fb79_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMTgtMTEtMS0xLTE3NDEw_b0854b16-98df-4264-951b-e4efbff5ec28"
      unitRef="usd">-5795000</us-gaap:ProfitLoss>
    <us-gaap:SharesIssued
      contextRef="ie3a4f0fb7c0d44a8a286050fe422e630_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMTktMS0xLTEtMTc0MTA_50d37219-35db-4fbc-92d9-99742411b115"
      unitRef="shares">34588000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie3a4f0fb7c0d44a8a286050fe422e630_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMTktMy0xLTEtMTc0MTA_a0846286-9e9d-4986-b62b-60ee80488f24"
      unitRef="usd">35000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i96687d732f8d4567ad6f8406cd1293e3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMTktNS0xLTEtMTc0MTA_9ffffeef-85de-434e-8d89-58673d827b36"
      unitRef="usd">71641000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id08f3d38045d4418a182b5f9988d3e34_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMTktNy0xLTEtMTc0MTA_4c08c3df-97d5-4d4e-8b7a-22f264788a00"
      unitRef="usd">-29686000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i229d9ac95648412aa95ce5178946ae89_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMTktOS0xLTEtMTc0MTA_df88a3cb-dc1e-45df-b12c-f1ad26af626d"
      unitRef="usd">227000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMTktMTEtMS0xLTE3NDEw_7efb9f6a-be09-4b5a-b93e-fc4a2505b679"
      unitRef="usd">42217000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="iac6178b585a24bdd9c611d8f43b21488_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMjQtMS0xLTEtMTc0MTA_24a8ee41-6ad2-47c6-8057-6bc0a636f80d"
      unitRef="shares">34289000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iac6178b585a24bdd9c611d8f43b21488_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMjQtMy0xLTEtMTc0MTA_b9eb4365-b91b-4bdb-ab5e-9fd971ae6c2d"
      unitRef="usd">34000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4281c98f6d154bc0bbdaa5ef88536da4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMjQtNS0xLTEtMTc0MTA_ee6f806f-1224-41bd-ab07-c305ee3ca6aa"
      unitRef="usd">61066000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i41802e9d47eb481aabfdd816c5c9fa7b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMjQtNy0xLTEtMTc0MTA_1c8ccee2-37d4-4e8e-ad64-3a0fe4ae9a45"
      unitRef="usd">2621000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i62a88fb8485b4d7fb2c08fb2266ed449_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMjQtOS0xLTEtMTc0MTA_44eddd1d-5591-4b6b-9c17-552966098248"
      unitRef="usd">138000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1e93d5bb9951458aa70810e8b5e84de2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMjQtMTEtMS0xLTE3NDEw_34308b6a-dc4e-42b0-9d0c-8fc4f6064ba3"
      unitRef="usd">63859000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="i19cfd321237247ab9bd9651da54e7476_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMjUtOS0xLTEtMTc0MTA_84fa2ba3-fa05-4ecf-a683-8b10d27977d9"
      unitRef="usd">195000</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMjUtMTEtMS0xLTE3NDEw_2a331ac6-1296-4b9e-9a34-c4bda1c43f6b"
      unitRef="usd">195000</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i5f055e88f44443e39bd36692989fa841_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMjYtMS0xLTEtMTc0MTA_f744a0a9-5961-4e84-8b97-79bdac4190c8"
      unitRef="shares">11000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i6310af3213b546f996d5b2f97fb70bfd_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMjYtNS0xLTEtMTc0MTA_53a7f25a-3b75-4aa0-97ae-ccb680e9fabf"
      unitRef="usd">49000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMjYtMTEtMS0xLTE3NDEw_124ccae7-4d25-4a05-b535-15373bc4a742"
      unitRef="usd">49000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i6310af3213b546f996d5b2f97fb70bfd_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMjctNS0xLTEtMTc0MTA_159c5799-de97-4d29-9985-cad2d99c3bcf"
      unitRef="usd">3747000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMjctMTEtMS0xLTE3NDEw_d76976f7-8f96-4714-bc09-ed30bf44775b"
      unitRef="usd">3747000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <apyx:StockSwapToAcquireOptionsShares
      contextRef="i5f055e88f44443e39bd36692989fa841_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMjgtMS0xLTEtMTc0MTA_c4effc9c-545d-4b29-8736-031f133e1335"
      unitRef="shares">40000</apyx:StockSwapToAcquireOptionsShares>
    <us-gaap:ProfitLoss
      contextRef="i66bc1f8757d7488a99f1a6c5eb9a7e4c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMzAtNy0xLTEtMTc0MTA_e611937e-aa38-4e68-8863-ecd616edc87f"
      unitRef="usd">-13169000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i19cfd321237247ab9bd9651da54e7476_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMzAtOS0xLTEtMTc0MTA_1008ca97-4622-4344-a8bd-20dfd4fb2ca9"
      unitRef="usd">-21000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMzAtMTEtMS0xLTE3NDEw_18747303-88ec-48eb-a6dc-79b605681bf1"
      unitRef="usd">-13190000</us-gaap:ProfitLoss>
    <us-gaap:SharesIssued
      contextRef="ib6078f16f5134a2e9e175491969aa315_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMzEtMS0xLTEtMTc0MTA_c225d535-201c-4155-8cae-a658910660fd"
      unitRef="shares">34340000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib6078f16f5134a2e9e175491969aa315_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMzEtMy0xLTEtMTc0MTA_5accb27d-be2c-4245-a308-f5c481b19c72"
      unitRef="usd">34000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3d63a53f125c4acd96a77b7410be5951_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMzEtNS0xLTEtMTc0MTA_dc0c34ff-bb42-418e-a91b-0e66aae368d7"
      unitRef="usd">64862000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6459bdf630814b27874dad87632c646a_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMzEtNy0xLTEtMTc0MTA_5cf3d631-2fee-46c5-a31e-6fa92b0feb64"
      unitRef="usd">-10548000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia98a748ab05948eda52b8c8873f240ed_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMzEtOS0xLTEtMTc0MTA_91e520f1-940d-4c85-9b82-2a8745ed22fe"
      unitRef="usd">312000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i524cd9c9acd4440f8d2e862dbb84f261_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMzEtMTEtMS0xLTE3NDEw_5c4908e8-a8c9-4cf3-af1d-a989a6d9b50f"
      unitRef="usd">54660000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="i10702330b75541919ad22c7f751db016_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMzMtMS0xLTEtMTc0MTA_00a1dfa9-799f-4f1d-a8a8-224ec222386b"
      unitRef="shares">34410000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i10702330b75541919ad22c7f751db016_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMzMtMy0xLTEtMTc0MTA_cdf81dde-c548-4779-8387-4ec05fa99662"
      unitRef="usd">34000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5f0faf73be0941df9ec5505291b94bde_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMzMtNS0xLTEtMTc0MTA_518376bc-20d7-4c8d-af4c-b4919f936bd0"
      unitRef="usd">66221000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iec03140df24341ec90f156ca4aeabce3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMzMtNy0xLTEtMTc0MTA_5774dce6-9b99-46e7-8ac4-46c7d2cc357d"
      unitRef="usd">-12551000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9d002bf5ac274c73b635110b5036d873_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMzMtOS0xLTEtMTc0MTA_52945cc0-6c7a-4b91-af0d-28f2d23ca6b4"
      unitRef="usd">305000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMzMtMTEtMS0xLTE3NDEw_b2cfb2b1-7fe8-48dc-a0cd-b9104aa683b1"
      unitRef="usd">54009000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ia7123184de4141839ab376b29683134c_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMzUtMS0xLTEtMTc0MTA_650e4837-b17a-4a4b-b6fd-987f68828046"
      unitRef="shares">106000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ia7123184de4141839ab376b29683134c_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMzUtMy0xLTEtMTc0MTA_e2fb6a16-bcf8-4da5-9699-985e94b0ce47"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ic739a97c17164277aa8cc3fa9ffb8bf3_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMzUtNS0xLTEtMTc0MTA_b6033273-54b3-4f41-8877-e48e920d51ed"
      unitRef="usd">364000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMzUtMTEtMS0xLTE3NDEw_cd58fc20-96d6-4558-aed5-701c8c314b1a"
      unitRef="usd">365000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ic739a97c17164277aa8cc3fa9ffb8bf3_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMzYtNS0xLTEtMTc0MTA_403ee1b4-65fe-41ab-accd-94860193b633"
      unitRef="usd">5056000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMzYtMTEtMS0xLTE3NDEw_512be9a1-eb5d-4cbf-9d1b-f9816ad1b4ca"
      unitRef="usd">5056000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <apyx:StockSwapToAcquireOptionsShares
      contextRef="ia7123184de4141839ab376b29683134c_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMzctMS0xLTEtMTc0MTA_c5378ace-2686-4391-a4b6-9d00fac8ae31"
      unitRef="shares">72000</apyx:StockSwapToAcquireOptionsShares>
    <us-gaap:ProfitLoss
      contextRef="if2fc708898034815a0206b71148a8cb0_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMzktNy0xLTEtMTc0MTA_cdd9cf5a-d346-4764-8a96-e2b9dddb6995"
      unitRef="usd">-17135000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i95ac060f75d24601ad4fd05a8f4e64e7_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMzktOS0xLTEtMTc0MTA_f2efbbdd-6010-453e-bec6-f497f1b68395"
      unitRef="usd">-78000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfMzktMTEtMS0xLTE3NDEw_0ea4c58f-2b14-4903-bf6f-76833e1fe659"
      unitRef="usd">-17213000</us-gaap:ProfitLoss>
    <us-gaap:SharesIssued
      contextRef="ie3a4f0fb7c0d44a8a286050fe422e630_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfNDAtMS0xLTEtMTc0MTA_118cd184-ec5b-4ef8-a1ac-5f5d2723edbd"
      unitRef="shares">34588000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie3a4f0fb7c0d44a8a286050fe422e630_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfNDAtMy0xLTEtMTc0MTA_e7e076fe-1348-4a8e-8c48-6365b883a96a"
      unitRef="usd">35000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i96687d732f8d4567ad6f8406cd1293e3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfNDAtNS0xLTEtMTc0MTA_c23754e8-bdd5-4c00-89dc-e4790cda9344"
      unitRef="usd">71641000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id08f3d38045d4418a182b5f9988d3e34_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfNDAtNy0xLTEtMTc0MTA_243c9426-5071-4054-b96f-268cd58cf053"
      unitRef="usd">-29686000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i229d9ac95648412aa95ce5178946ae89_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfNDAtOS0xLTEtMTc0MTA_8da6fecc-2200-4660-8249-b93feaa8f8bd"
      unitRef="usd">227000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yMi9mcmFnOjM5MmEwODE3MmEwODRmZmViZTRkZGQ5Yzg0ODhjY2RmL3RhYmxlOmI5ZDFhYjUzZjgzMTQwNGM4NzEzMjFkMThhMzJmYWU0L3RhYmxlcmFuZ2U6YjlkMWFiNTNmODMxNDA0Yzg3MTMyMWQxOGEzMmZhZTRfNDAtMTEtMS0xLTE3NDEw_d1f1b446-5db0-4b63-b19e-4e512531c3e5"
      unitRef="usd">42217000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfMy0xLTEtMS0xNzQxMA_791b86f0-27e0-47d1-a863-200dd4a1cbca"
      unitRef="usd">-17213000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfMy0zLTEtMS0xNzQxMA_b73b3e61-f50c-44eb-ab46-36e134861afc"
      unitRef="usd">-13190000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfNS0xLTEtMS0xNzQxMA_91d0ef13-8340-475f-a31c-fb8a3b02c42c"
      unitRef="usd">688000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfNS0zLTEtMS0xNzQxMA_423fbf4d-6d69-48eb-b423-ac4b8e6ddaea"
      unitRef="usd">674000</us-gaap:DepreciationDepletionAndAmortization>
    <apyx:ProvisionForInventoryObsolescence
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfNi0xLTEtMS0xNzQxMA_e8d535b2-0a1d-451f-adbe-9e06d4154655"
      unitRef="usd">158000</apyx:ProvisionForInventoryObsolescence>
    <apyx:ProvisionForInventoryObsolescence
      contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfNi0zLTEtMS0xNzQxMA_ee330124-5e7f-4bda-92fd-173b87b3a4b2"
      unitRef="usd">15000</apyx:ProvisionForInventoryObsolescence>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfOC0xLTEtMS0xNzQxMA_3249652e-a5f5-4310-8655-f4609c821ab1"
      unitRef="usd">-76000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfOC0zLTEtMS0xNzQxMA_cb44df0e-64d9-40b1-8886-944e6789bf2b"
      unitRef="usd">-47000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:ShareBasedCompensation
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfOS0xLTEtMS0xNzQxMA_1c559a8e-650d-4b90-a610-0b165ca7b1aa"
      unitRef="usd">5056000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfOS0zLTEtMS0xNzQxMA_ceaa20fb-b238-4dd5-827e-185821715bdf"
      unitRef="usd">3747000</us-gaap:ShareBasedCompensation>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfMTAtMS0xLTEtMTc0MTA_fb8d584a-c844-4eb1-a463-cb6def7b4c12"
      unitRef="usd">283000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfMTAtMy0xLTEtMTc0MTA_6d8d9360-24df-4bad-b616-af30e184ef6b"
      unitRef="usd">57000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfMTMtMS0xLTEtMTc0MTA_f9ba80e5-295f-4683-843f-0aa8784144a4"
      unitRef="usd">-3273000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfMTMtMy0xLTEtMTc0MTA_e3653ead-2750-42bc-a059-6f17e865d2e0"
      unitRef="usd">3168000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfMTQtMS0xLTEtMTc0MTA_7c2583af-e4a0-4416-bc91-8ee851f3044a"
      unitRef="usd">521000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfMTQtMy0xLTEtMTc0MTA_e2a6f55d-ef55-473b-8d6e-83e5b50433d6"
      unitRef="usd">23000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfMTUtMS0xLTEtMTc0MTA_46411c80-6d4b-4579-acef-18f00e9e5e80"
      unitRef="usd">-97000</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable
      contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfMTUtMy0xLTEtMTc0MTA_07c70b5a-cc9b-4360-8189-506b422cde04"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfMTYtMS0xLTEtMTc0MTA_325099a0-fd3a-44d9-a25a-07514532e8d1"
      unitRef="usd">5672000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfMTYtMy0xLTEtMTc0MTA_979cb6a4-69ef-47f8-96c7-d266503213aa"
      unitRef="usd">1982000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfMTctMS0xLTEtMTc0MTA_57b987a5-7411-4887-8414-5f775fe5f748"
      unitRef="usd">-439000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfMTctMy0xLTEtMTc0MTA_979545a5-8adb-48a2-883c-d2dfa20a3c71"
      unitRef="usd">1555000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfMTgtMS0xLTEtMTc0MTA_be5d9fe2-ca1d-4247-93ea-a8e8e173f7bb"
      unitRef="usd">-1536000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfMTgtMy0xLTEtMTc0MTA_196b579c-6d02-4407-97b6-d36403bda3fe"
      unitRef="usd">1605000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfMTktMS0xLTEtMTc0MTA_0b8ea599-5d76-4dce-9b70-50f4c878e74c"
      unitRef="usd">-15750000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfMTktMy0xLTEtMTc0MTA_93bccd90-da12-487f-9768-15324e016231"
      unitRef="usd">-10663000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfMjEtMS0xLTEtMTc0MTA_748da9a8-61a2-44d3-bfad-125c51098dfd"
      unitRef="usd">868000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfMjEtMy0xLTEtMTc0MTA_859ebd84-04f6-4c81-b7f2-7474bb3d715f"
      unitRef="usd">391000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfMjQtMS0xLTEtMTc0MTA_dbf5c264-2bda-4920-a7f1-25c055f22585"
      unitRef="usd">-868000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfMjQtMy0xLTEtMTc0MTA_c4b841ff-9792-42c8-84e1-c2041d25790b"
      unitRef="usd">-391000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <apyx:ProceedsFromStockOptionsExercisedAndWarrantsExercised
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfMjYtMS0xLTEtMTc0MTA_b4de9ecc-fbeb-4427-bdf0-f13fa23040a3"
      unitRef="usd">365000</apyx:ProceedsFromStockOptionsExercisedAndWarrantsExercised>
    <apyx:ProceedsFromStockOptionsExercisedAndWarrantsExercised
      contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfMjYtMy0xLTEtMTc0MTA_28824005-93a4-4643-a2dc-58e54a71d102"
      unitRef="usd">49000</apyx:ProceedsFromStockOptionsExercisedAndWarrantsExercised>
    <apyx:RepaymentOfFinanceLeaseLiabilities
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfMjgtMS0xLTEtMTc0MTA_62114e6a-2356-4c85-95b5-acb8f5e404ee"
      unitRef="usd">138000</apyx:RepaymentOfFinanceLeaseLiabilities>
    <apyx:RepaymentOfFinanceLeaseLiabilities
      contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfMjgtMy0xLTEtMTc0MTA_f2ec88c6-3d59-4ec1-97a0-8078af792be2"
      unitRef="usd">181000</apyx:RepaymentOfFinanceLeaseLiabilities>
    <us-gaap:ProceedsFromMinorityShareholders
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfMjktMS0xLTEtMTc0MTA_3767911e-3f37-43fe-9907-8e089a6378b8"
      unitRef="usd">0</us-gaap:ProceedsFromMinorityShareholders>
    <us-gaap:ProceedsFromMinorityShareholders
      contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfMjktMy0xLTEtMTc0MTA_85179d76-cfbd-4710-bad3-1ac642ef8ecc"
      unitRef="usd">195000</us-gaap:ProceedsFromMinorityShareholders>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfMzAtMS0xLTEtMTc0MTA_1544162d-20ac-4076-84e4-8bb9640491fb"
      unitRef="usd">227000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfMzAtMy0xLTEtMTc0MTA_3403f698-ffa6-468f-854b-bca3ed161636"
      unitRef="usd">63000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfMzEtMS0xLTEtMTc0MTA_c6db5bce-3490-47e1-a66d-c496e1bb2243"
      unitRef="usd">354000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfMzEtMy0xLTEtMTc0MTA_b51566ce-5c82-400e-8e8a-d94e4008a961"
      unitRef="usd">-26000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfMzItMS0xLTEtMTc0MTA_06c9a60d-21e8-4f15-aca6-8a199b6dc2c9"
      unitRef="usd">-16037000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfMzItMy0xLTEtMTc0MTA_74bf7a08-03eb-4f16-be54-932475443de2"
      unitRef="usd">-11017000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfMzMtMS0xLTEtMTc0MTA_d60deabc-1278-4ac2-af78-0f96de53f9e9"
      unitRef="usd">30870000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i1e93d5bb9951458aa70810e8b5e84de2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfMzMtMy0xLTEtMTc0MTA_5d3bf484-8ada-4b8e-a5f5-2e759212adf3"
      unitRef="usd">41915000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfMzQtMS0xLTEtMTc0MTA_d8ba2aa3-ebf7-4126-984e-1328e1060f9f"
      unitRef="usd">14833000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i524cd9c9acd4440f8d2e862dbb84f261_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfMzQtMy0xLTEtMTc0MTA_42c5c6ce-cd9f-4a04-a12b-6d94087345c2"
      unitRef="usd">30898000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfMzctMS0xLTEtMTc0MTA_ba7b07bc-017d-413c-870f-6f6603647648"
      unitRef="usd">12000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfMzctMy0xLTEtMTc0MTA_50242ca2-16ca-4679-a7dd-c8ad8c9bff3f"
      unitRef="usd">8000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaid
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfMzgtMS0xLTEtMTc0MTA_e7010c6e-84a7-40ae-bf8c-d8aae29a8821"
      unitRef="usd">128000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfMzgtMy0xLTEtMTc0MTA_2cebbbb0-de91-4872-b070-20fcd06add0e"
      unitRef="usd">13000</us-gaap:IncomeTaxesPaid>
    <apyx:CapitalizationOfLeaseNonCash
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfNDEtMS0xLTEtMTc0MTA_0fa464c5-aa9b-4452-97d7-93f8c693ca59"
      unitRef="usd">769000</apyx:CapitalizationOfLeaseNonCash>
    <apyx:CapitalizationOfLeaseNonCash
      contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfNDEtMy0xLTEtMTc0MTA_e34ed663-37dc-4096-9d03-da4f4e3d44d8"
      unitRef="usd">0</apyx:CapitalizationOfLeaseNonCash>
    <apyx:CapitalizationOfLeaseExecution
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfNDItMS0xLTEtMTc0MTA_2df656aa-96f1-4074-a518-f9142a481cb0"
      unitRef="usd">103000</apyx:CapitalizationOfLeaseExecution>
    <apyx:CapitalizationOfLeaseExecution
      contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfNDItMy0xLTEtMTc0MTA_b7c03853-ebbe-4ca3-b486-0bb7e55f86cc"
      unitRef="usd">0</apyx:CapitalizationOfLeaseExecution>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfNDMtMS0xLTEtMTgyMDM_5c857a41-9611-453c-a8a2-867a56621e11"
      unitRef="usd">28000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8yNS9mcmFnOjhjN2RkYzYzZjFjZDRlNmVhMTE1YjUwOTIzNDdmMjhlL3RhYmxlOmU1NzZmZDEwZjQyODQ2ZmJiOWZkZDc3YzBkMWU1NjkyL3RhYmxlcmFuZ2U6ZTU3NmZkMTBmNDI4NDZmYmI5ZmRkNzdjMGQxZTU2OTJfNDMtMy0xLTEtMTgyMDc_3d22a767-eeb3-4def-adf4-7c4779c62242"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8zMS9mcmFnOmNhYzU3NzI0YTVlNzQwNWY5YmE5ZDVlNTQ3MWRiZjVmL3RleHRyZWdpb246Y2FjNTc3MjRhNWU3NDA1ZjliYTlkNWU1NDcxZGJmNWZfMzQ4NA_199c4df4-e98f-4c60-88fd-e63bf5e1b271">BASIS OF PRESENTATION&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Apyx Medical Corporation (&#x201c;Company&#x201d;, &#x201c;Apyx&#x201d;, &#x201c;it&#x201d; and similar terms) was incorporated in 1982, under the laws of the State of Delaware and has its principal executive office at 5115 Ulmerton Road, Clearwater, FL 33760.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company is an advanced energy technology company with a passion for elevating people&#x2019;s lives through innovative products, including its Helium Plasma Technology products marketed and sold as Renuvion&#xae; in the cosmetic surgery market and J-Plasma&#xae; in the hospital surgical market. Renuvion&#xae; and J-Plasma&#xae; offer surgeons a unique ability to provide controlled heat to tissue to achieve their desired results. The Company also leverages its deep expertise and decades of experience in unique waveforms through OEM agreements with other medical device manufacturers. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;As part of its plan to accelerate and fully fund the development of its advanced energy&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;business, with a focus in the cosmetic&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;surgery market, the Company sold its Core business in 2018 for gross proceeds of $97&#160;million.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;These proceeds were used to launch broad marketing and sales initiatives which resulted in rapid sales growth through December 31, 2021 and into the first quarter of 2022.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;This planned growth in the business was accompanied by scaled operations, including procurement of components, expanded manufacturing capacity to turn those materials into saleable inventory, additional discretionary expenditures, including increased global participation at trade shows, additional employee trainings, user meetings, increased travel and entertainment expenses, more expansive research and development projects, and additional headcount to support those activities. Additionally, the Company had, and still has, some significant non-recurring discretionary expenditures associated with completing its multi-year marketing initiatives related to its dermal resurfacing and skin laxity clearances. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On March 14, 2022, the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) posted a Safety Communication that warns consumers and health care providers against the use of the Company&#x2019;s Advanced Energy products outside of their FDA-cleared indications for general use in cutting, coagulation, and ablation of soft tissue during open and laparoscopic surgical procedures. Following the Safety Communication, the Company experienced slowed demand for the adoption of its Helium Plasma Technology.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On May 26, 2022, the Company announced that it had received 510(k) clearance from the FDA for the use of the Renuvion&#xae; Dermal Handpiece for specific dermal resurfacing procedures. On July 18, 2022, the Company announced that it had received 510(k) clearance from the FDA for the use of the Renuvion&#xae; APR Handpiece for certain skin contraction procedures. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 2, 2022, and July 21, 2022, FDA updated the Medical Device Safety Communication to recognize the new 510(k) clearances for the Renuvion&#xae; Dermal handpiece, and the expanded indications for the Renuvion&#xae; APR handpieces. The 510(k) clearance for the Renuvion&#xae; Dermal handpiece allows surgeons to perform dermal resurfacing procedures for the treatment of moderate to severe wrinkles and rhytides, limited to patients with Fitzpatrick Skin Types I, II or III.  The 510(k) clearance for the Renuvion&#xae; APR handpieces now addresses improving the appearance of lax (loose) skin in the neck and submental region.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;While management expected that receiving these clearances would materially mitigate the financial effects of the Safety Communication in future periods, the Company continues to experience reduced demand for the adoption and utilization of its technology and management believes that this may have an adverse effect in future periods.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern. The going concern basis of presentation assumes that the Company will continue in operation one year after the date these financial statements are issued and will be able to realize its assets and discharge its liabilities and commitments in the normal course of business. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the requirements of the Financial Accounting Standards Board&#x2019;s Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 205-40, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Disclosure of Uncertainties about an Entity&#x2019;s Ability to Continue as a Going Concern&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, management must evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company&#x2019;s ability to continue as a going concern for one year from the date these condensed consolidated financial statements are issued. This evaluation does not take into consideration the potential mitigating effect of management&#x2019;s plans that have not been fully implemented or are not within control of the Company as of the date the condensed consolidated financial statements are issued. When substantial doubt exists under this methodology, management evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about the Company&#x2019;s ability to continue as a going concern. The mitigating effect of management&#x2019;s plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity&#x2019;s ability to continue as a going concern &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;within one year after the date that the financial statements are issued.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;While sales were continuing to grow into the first quarter of 2022 prior to the FDA Safety Communication, over the last few years, exclusive of the Company&#x2019;s sale of the Core business segment to Symmetry Surgical during 2018, it has incurred recurring net losses and cash outflows from operations and the Company anticipates that losses will continue in the near term. During the nine months ended September 30, 2022, the Company incurred an operating loss of $17.6&#160;million and used $15.8&#160;million of cash in operations. As of September 30, 2022, the Company had cash and cash equivalents of $14.8&#160;million. These conditions raise substantial doubt about the Company&#x2019;s ability to continue as a going concern for a period of at least one year from the date of issuance of these unaudited condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In an effort to alleviate these conditions, management is currently evaluating various funding alternatives to improve liquidity and may seek to raise additional capital through debt financing, the sale of equity securities, leveraging its unencumbered real estate, or any combination thereof. In addition, management is actively pursuing collection of the Company&#x2019;s income tax receivable. Management also continues to re-assess its operating expenditures and cost structure to be commensurate with its expected levels of revenue and has the ability to reduce or delay expenditures to enhance and preserve liquidity. As the Company seeks additional sources of financing, there can be no assurance that such financing would be available to the Company on favorable terms or at all. The Company&#x2019;s ability to obtain additional financing in the debt and equity capital markets is subject to several factors, including market and economic conditions, the Company&#x2019;s performance and investor sentiment with respect to the Company and its industry.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Management believes that the actions and efforts it can and will take to manage operating expenditures and, while not assured, arrange alternative financing sources as described above will enable the Company to meet its obligations for a period of at least one year from the date of issuance of these unaudited condensed consolidated financial statements. As a result, management believes its plans alleviate substantial doubt about its ability to continue as a going concern. These unaudited condensed financial statements do not include any adjustments relating to the carrying amounts and classification of assets and liabilities that may be necessary should the Company be unable to continue as a going concern.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements have been prepared based upon SEC rules that permit reduced disclosure for interim periods. For a more complete discussion of significant accounting policies and certain other information, please refer to the consolidated financial statements included in our Annual Report on Form 10-K for the year ended December&#160;31, 2021. In the opinion of management these condensed consolidated financial statements reflect all adjustments that are necessary for a fair presentation of results of consolidated operations and financial condition for the interim periods shown, including normal recurring accruals and other items. The results for the interim periods are not necessarily indicative of results for the full year.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Reclassifications&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have reclassified certain amounts presented in the prior period to conform to the current period presentation. These reclassifications had no impact on previously reported net loss, accumulated deficit or net cash used in operating activities for the periods presented.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:ProceedsFromDivestitureOfBusinesses
      contextRef="i9a26c2238772410b9c632db89dc2f95f_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8zMS9mcmFnOmNhYzU3NzI0YTVlNzQwNWY5YmE5ZDVlNTQ3MWRiZjVmL3RleHRyZWdpb246Y2FjNTc3MjRhNWU3NDA1ZjliYTlkNWU1NDcxZGJmNWZfMTY0OTI2NzQ2NDMyOQ_aeecc9bb-8fe9-4e62-818b-90d35e6f75da"
      unitRef="usd">97000000</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8zMS9mcmFnOmNhYzU3NzI0YTVlNzQwNWY5YmE5ZDVlNTQ3MWRiZjVmL3RleHRyZWdpb246Y2FjNTc3MjRhNWU3NDA1ZjliYTlkNWU1NDcxZGJmNWZfMTY0OTI2NzQ2NDI4NA_409c30af-ff33-4117-8af9-5aa065360581"
      unitRef="usd">-17600000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8zMS9mcmFnOmNhYzU3NzI0YTVlNzQwNWY5YmE5ZDVlNTQ3MWRiZjVmL3RleHRyZWdpb246Y2FjNTc3MjRhNWU3NDA1ZjliYTlkNWU1NDcxZGJmNWZfMTY0OTI2NzQ2NDI5OQ_003ffe8f-4615-4c80-ba1d-fbd75435e3e3"
      unitRef="usd">-15800000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8zMS9mcmFnOmNhYzU3NzI0YTVlNzQwNWY5YmE5ZDVlNTQ3MWRiZjVmL3RleHRyZWdpb246Y2FjNTc3MjRhNWU3NDA1ZjliYTlkNWU1NDcxZGJmNWZfMTY0OTI2NzQ2NDMxNA_14c7bf5e-e7ab-410f-8e72-7c49d75bac75"
      unitRef="usd">14800000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8zMS9mcmFnOmNhYzU3NzI0YTVlNzQwNWY5YmE5ZDVlNTQ3MWRiZjVmL3RleHRyZWdpb246Y2FjNTc3MjRhNWU3NDA1ZjliYTlkNWU1NDcxZGJmNWZfMzQ4Mg_1570d37a-2bfd-4a94-b54e-fda48b370725">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Reclassifications&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have reclassified certain amounts presented in the prior period to conform to the current period presentation. These reclassifications had no impact on previously reported net loss, accumulated deficit or net cash used in operating activities for the periods presented.&lt;/span&gt;&lt;/div&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8zNC9mcmFnOmUzZTIwNjYzMjlmNzQwMDVhNGU2ZmRmNDc0NmM1ZjY3L3RleHRyZWdpb246ZTNlMjA2NjMyOWY3NDAwNWE0ZTZmZGY0NzQ2YzVmNjdfMTU3Mg_b7bb7500-b5db-4aaa-99b5-71109bb58901">RECENT ACCOUNTING PRONOUNCEMENTS &lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2016-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments&#x2014;Credit Losses (Topic 326).&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The update changes the impairment model for most financial assets and certain other instruments, including trade and other receivables, contract assets, held-to-maturity debt securities and loans, and requires entities to use a new forward-looking expected loss model that will result in the earlier recognition of allowance for losses. This update, as originally issued, was effective for annual and interim periods beginning after December 15, 2019, with early adoption permitted. In November 2019, the FASB issued ASU 2019-10, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842) Effective Dates&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which deferred the effective dates of these standards for Smaller Reporting Companies until fiscal years beginning after December 15, 2022. The Company currently continues to qualify as a Smaller Reporting Company, based upon the current SEC definition, and as a result, will be utilizing the deferred elective date. While we are in the process of determining the effects of the adoption of the standard on the condensed consolidated financial statements, we do not expect the impact to be material.&lt;/span&gt;No other new accounting pronouncement issued or effective during the fiscal year had or is expected to have a material impact on our consolidated financial statements or disclosures.</us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8zNC9mcmFnOmUzZTIwNjYzMjlmNzQwMDVhNGU2ZmRmNDc0NmM1ZjY3L3RleHRyZWdpb246ZTNlMjA2NjMyOWY3NDAwNWE0ZTZmZGY0NzQ2YzVmNjdfMTU3Ng_9bd67cad-b671-4c92-80d9-eaca77f8b5b3">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2016-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments&#x2014;Credit Losses (Topic 326).&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The update changes the impairment model for most financial assets and certain other instruments, including trade and other receivables, contract assets, held-to-maturity debt securities and loans, and requires entities to use a new forward-looking expected loss model that will result in the earlier recognition of allowance for losses. This update, as originally issued, was effective for annual and interim periods beginning after December 15, 2019, with early adoption permitted. In November 2019, the FASB issued ASU 2019-10, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842) Effective Dates&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which deferred the effective dates of these standards for Smaller Reporting Companies until fiscal years beginning after December 15, 2022. The Company currently continues to qualify as a Smaller Reporting Company, based upon the current SEC definition, and as a result, will be utilizing the deferred elective date. While we are in the process of determining the effects of the adoption of the standard on the condensed consolidated financial statements, we do not expect the impact to be material.&lt;/span&gt;No other new accounting pronouncement issued or effective during the fiscal year had or is expected to have a material impact on our consolidated financial statements or disclosures.</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8zNy9mcmFnOmU4NDcyMWI2N2NiNjRiYjViNjkyYWRkZWI4MTdkYzg5L3RleHRyZWdpb246ZTg0NzIxYjY3Y2I2NGJiNWI2OTJhZGRlYjgxN2RjODlfMTU5MA_816350dc-a51b-45e4-a7be-347d9691deaf">DISPOSAL OF BUSINESS&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 30, 2018, the Company closed on a definitive asset purchase agreement (the &#x201c;Asset Purchase Agreement&#x201d;) with Specialty Surgical Instrumentation Inc., a Tennessee Corporation and wholly owned subsidiary of Symmetry Surgical Inc. (&#x201c;Symmetry&#x201d;), pursuant to which the Company divested and sold the &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Company&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2019;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; electrosurgical &#x201c;Core&#x201d; business segment and related intellectual property, including the Bovie&#xae; brand and trademarks, to Symmetry for gross proceeds of $97&#160;million in cash.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Asset Purchase Agreement, the Company entered into an Electro Surgical Disposables and Accessories, Cauteries and Other Products Supply Agreement with Symmetry for a four-year term, which expired August 30, 2022, whereby it manufactured certain Core pro&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ducts and sold them to Symmetry at agreed upon prices. Any activity resulting from this agreement was netted and reported in the Condensed Consolidated Statements of Operations as other income (loss). There was no significant Core activity for the three months ended September&#160;30, 2022. Core activity for the three months ended September&#160;30, 2021, amounted to $1.6&#160;million with cost of sales equivalents of $1.3&#160;million and related other expenses of $0.5&#160;million for net other loss of $0.3&#160;million. Core activity for the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;nine months ended September 30, 2022&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, amounted to $0.6&#160;million with cost of sales equivalents of $0.5&#160;million and other related expenses of $0.1&#160;million&#160;for net other loss of $0.1&#160;million. Core activity for the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;nine months ended September 30, 2021&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, amounted to $5.2&#160;million with cost of sales equivalents of $4.4&#160;million and net other related operating expenses of $1.1&#160;million for net other loss of $0.3&#160;million.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
    <us-gaap:ProceedsFromDivestitureOfBusinesses
      contextRef="i10095f0cb8c949fbb4f3d9e2b6c90b20_D20180830-20180830"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8zNy9mcmFnOmU4NDcyMWI2N2NiNjRiYjViNjkyYWRkZWI4MTdkYzg5L3RleHRyZWdpb246ZTg0NzIxYjY3Y2I2NGJiNWI2OTJhZGRlYjgxN2RjODlfNTAy_c880b1f1-36c1-4073-9950-2deee883edbf"
      unitRef="usd">97000000</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <apyx:AssetPurchaseAgreementTerm
      contextRef="i8c47d3c9d755423bac06c8de9bc6733a_D20180830-20180830"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8zNy9mcmFnOmU4NDcyMWI2N2NiNjRiYjViNjkyYWRkZWI4MTdkYzg5L3RleHRyZWdpb246ZTg0NzIxYjY3Y2I2NGJiNWI2OTJhZGRlYjgxN2RjODlfMTU5MQ_96fb248e-859f-4d7a-a1a2-fb58cffbfb3d">P4Y</apyx:AssetPurchaseAgreementTerm>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="i4df01ef2deb2470eab833fab1b386632_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8zNy9mcmFnOmU4NDcyMWI2N2NiNjRiYjViNjkyYWRkZWI4MTdkYzg5L3RleHRyZWdpb246ZTg0NzIxYjY3Y2I2NGJiNWI2OTJhZGRlYjgxN2RjODlfMTE5Mw_8b44fbd8-7941-49ca-a58c-bda6206f8fbe"
      unitRef="usd">1600000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold
      contextRef="i4df01ef2deb2470eab833fab1b386632_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8zNy9mcmFnOmU4NDcyMWI2N2NiNjRiYjViNjkyYWRkZWI4MTdkYzg5L3RleHRyZWdpb246ZTg0NzIxYjY3Y2I2NGJiNWI2OTJhZGRlYjgxN2RjODlfMTIzMA_857c195e-e39b-40bc-99f2-96c4bfe08109"
      unitRef="usd">1300000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense
      contextRef="i4df01ef2deb2470eab833fab1b386632_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8zNy9mcmFnOmU4NDcyMWI2N2NiNjRiYjViNjkyYWRkZWI4MTdkYzg5L3RleHRyZWdpb246ZTg0NzIxYjY3Y2I2NGJiNWI2OTJhZGRlYjgxN2RjODlfMTI2Mw_ee05bdd1-ae4f-47d8-bb14-739c9918899b"
      unitRef="usd">500000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss
      contextRef="i4df01ef2deb2470eab833fab1b386632_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8zNy9mcmFnOmU4NDcyMWI2N2NiNjRiYjViNjkyYWRkZWI4MTdkYzg5L3RleHRyZWdpb246ZTg0NzIxYjY3Y2I2NGJiNWI2OTJhZGRlYjgxN2RjODlfMTI4Ng_498f40cf-467e-41c7-b8ee-24dbb1f360da"
      unitRef="usd">-300000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="i715d6d3cb64a4d328a61c8e29b09eeb1_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8zNy9mcmFnOmU4NDcyMWI2N2NiNjRiYjViNjkyYWRkZWI4MTdkYzg5L3RleHRyZWdpb246ZTg0NzIxYjY3Y2I2NGJiNWI2OTJhZGRlYjgxN2RjODlfMTMyOA_e93d3ba2-5ce1-48a0-bdfb-5d901405e5dc"
      unitRef="usd">600000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold
      contextRef="i715d6d3cb64a4d328a61c8e29b09eeb1_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8zNy9mcmFnOmU4NDcyMWI2N2NiNjRiYjViNjkyYWRkZWI4MTdkYzg5L3RleHRyZWdpb246ZTg0NzIxYjY3Y2I2NGJiNWI2OTJhZGRlYjgxN2RjODlfMTM2NQ_fbc5f61a-30e8-4395-b816-496e6658db36"
      unitRef="usd">500000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense
      contextRef="i715d6d3cb64a4d328a61c8e29b09eeb1_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8zNy9mcmFnOmU4NDcyMWI2N2NiNjRiYjViNjkyYWRkZWI4MTdkYzg5L3RleHRyZWdpb246ZTg0NzIxYjY3Y2I2NGJiNWI2OTJhZGRlYjgxN2RjODlfMTM5OA_946b0419-cd04-453f-9f1c-4fa2e10832db"
      unitRef="usd">100000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss
      contextRef="i715d6d3cb64a4d328a61c8e29b09eeb1_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8zNy9mcmFnOmU4NDcyMWI2N2NiNjRiYjViNjkyYWRkZWI4MTdkYzg5L3RleHRyZWdpb246ZTg0NzIxYjY3Y2I2NGJiNWI2OTJhZGRlYjgxN2RjODlfMTQyMQ_c8aa63b9-67b9-481c-8229-7f742319f096"
      unitRef="usd">-100000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="i10540b8b8766421e91ac2cc3944b3109_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8zNy9mcmFnOmU4NDcyMWI2N2NiNjRiYjViNjkyYWRkZWI4MTdkYzg5L3RleHRyZWdpb246ZTg0NzIxYjY3Y2I2NGJiNWI2OTJhZGRlYjgxN2RjODlfMTQ2Mw_6831cac6-8bc6-44b7-9ab7-d17ebbe5b2d6"
      unitRef="usd">5200000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold
      contextRef="i10540b8b8766421e91ac2cc3944b3109_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8zNy9mcmFnOmU4NDcyMWI2N2NiNjRiYjViNjkyYWRkZWI4MTdkYzg5L3RleHRyZWdpb246ZTg0NzIxYjY3Y2I2NGJiNWI2OTJhZGRlYjgxN2RjODlfMTUwMA_3cf4d450-1ffd-42e8-a0c1-18c77dd5e515"
      unitRef="usd">4400000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense
      contextRef="i10540b8b8766421e91ac2cc3944b3109_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8zNy9mcmFnOmU4NDcyMWI2N2NiNjRiYjViNjkyYWRkZWI4MTdkYzg5L3RleHRyZWdpb246ZTg0NzIxYjY3Y2I2NGJiNWI2OTJhZGRlYjgxN2RjODlfMTU0Nw_c2a819ad-9838-470e-a1fe-60144b649249"
      unitRef="usd">1100000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss
      contextRef="i10540b8b8766421e91ac2cc3944b3109_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV8zNy9mcmFnOmU4NDcyMWI2N2NiNjRiYjViNjkyYWRkZWI4MTdkYzg5L3RleHRyZWdpb246ZTg0NzIxYjY3Y2I2NGJiNWI2OTJhZGRlYjgxN2RjODlfNTQ5NzU1ODE1NzI0_cc3d0505-06b8-43ca-96f0-ed2b01630552"
      unitRef="usd">-300000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80MC9mcmFnOmFmOTc1NGRlNDkwOTQwZTBiNGIwYmZiYjE1YWU3MjJkL3RleHRyZWdpb246YWY5NzU0ZGU0OTA5NDBlMGI0YjBiZmJiMTVhZTcyMmRfMzk0_a530cab1-a2f6-42d0-8860-b5ff22e364f8">INVENTORIES&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories are stated at the lower of cost or net realizable value. Cost is determined on a first in, first out basis. Finished goods and work-in-process inventories include material, labor and overhead costs. Factory overhead costs are primarily allocated to inventory manufactured in-house based upon direct labor hours. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: provision for obsolescence&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(379)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(263)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventories, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80MC9mcmFnOmFmOTc1NGRlNDkwOTQwZTBiNGIwYmZiYjE1YWU3MjJkL3RleHRyZWdpb246YWY5NzU0ZGU0OTA5NDBlMGI0YjBiZmJiMTVhZTcyMmRfMzk2_c47f3fbb-d87d-4b07-8566-ef6247abca6c">Inventories are stated at the lower of cost or net realizable value. Cost is determined on a first in, first out basis. Finished goods and work-in-process inventories include material, labor and overhead costs. Factory overhead costs are primarily allocated to inventory manufactured in-house based upon direct labor hours.</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80MC9mcmFnOmFmOTc1NGRlNDkwOTQwZTBiNGIwYmZiYjE1YWU3MjJkL3RleHRyZWdpb246YWY5NzU0ZGU0OTA5NDBlMGI0YjBiZmJiMTVhZTcyMmRfNDA2_2ab32668-18f6-42dd-8f98-6b9964a06488">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: provision for obsolescence&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(379)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(263)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventories, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterials
      contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80MC9mcmFnOmFmOTc1NGRlNDkwOTQwZTBiNGIwYmZiYjE1YWU3MjJkL3RhYmxlOmUwZmExMjFiZWRhOTRkYmFhYjg0NWQ1MTFjMzgzNjQxL3RhYmxlcmFuZ2U6ZTBmYTEyMWJlZGE5NGRiYWFiODQ1ZDUxMWMzODM2NDFfMS0xLTEtMS0xNzQxMA_6b61d08c-f081-40ca-baf4-afc8170dd5f0"
      unitRef="usd">5078000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials
      contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80MC9mcmFnOmFmOTc1NGRlNDkwOTQwZTBiNGIwYmZiYjE1YWU3MjJkL3RhYmxlOmUwZmExMjFiZWRhOTRkYmFhYjg0NWQ1MTFjMzgzNjQxL3RhYmxlcmFuZ2U6ZTBmYTEyMWJlZGE5NGRiYWFiODQ1ZDUxMWMzODM2NDFfMS0zLTEtMS0xNzQxMA_58301aa7-6fb9-47e0-8101-d7ab9db80df0"
      unitRef="usd">3603000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryWorkInProcess
      contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80MC9mcmFnOmFmOTc1NGRlNDkwOTQwZTBiNGIwYmZiYjE1YWU3MjJkL3RhYmxlOmUwZmExMjFiZWRhOTRkYmFhYjg0NWQ1MTFjMzgzNjQxL3RhYmxlcmFuZ2U6ZTBmYTEyMWJlZGE5NGRiYWFiODQ1ZDUxMWMzODM2NDFfMi0xLTEtMS0xNzQxMA_4e63899c-ac9a-4035-ac4d-07884f33e5b4"
      unitRef="usd">2414000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess
      contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80MC9mcmFnOmFmOTc1NGRlNDkwOTQwZTBiNGIwYmZiYjE1YWU3MjJkL3RhYmxlOmUwZmExMjFiZWRhOTRkYmFhYjg0NWQ1MTFjMzgzNjQxL3RhYmxlcmFuZ2U6ZTBmYTEyMWJlZGE5NGRiYWFiODQ1ZDUxMWMzODM2NDFfMi0zLTEtMS0xNzQxMA_3ed16e89-ac10-4040-92f1-3a1d808fdf12"
      unitRef="usd">1441000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods
      contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80MC9mcmFnOmFmOTc1NGRlNDkwOTQwZTBiNGIwYmZiYjE1YWU3MjJkL3RhYmxlOmUwZmExMjFiZWRhOTRkYmFhYjg0NWQ1MTFjMzgzNjQxL3RhYmxlcmFuZ2U6ZTBmYTEyMWJlZGE5NGRiYWFiODQ1ZDUxMWMzODM2NDFfMy0xLTEtMS0xNzQxMA_70fa8382-b161-4d47-b82b-6e055c48c6bd"
      unitRef="usd">4929000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80MC9mcmFnOmFmOTc1NGRlNDkwOTQwZTBiNGIwYmZiYjE1YWU3MjJkL3RhYmxlOmUwZmExMjFiZWRhOTRkYmFhYjg0NWQ1MTFjMzgzNjQxL3RhYmxlcmFuZ2U6ZTBmYTEyMWJlZGE5NGRiYWFiODQ1ZDUxMWMzODM2NDFfMy0zLTEtMS0xNzQxMA_ebb5261b-1c71-4c53-a52d-3f85b7e9cffa"
      unitRef="usd">1997000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryGross
      contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80MC9mcmFnOmFmOTc1NGRlNDkwOTQwZTBiNGIwYmZiYjE1YWU3MjJkL3RhYmxlOmUwZmExMjFiZWRhOTRkYmFhYjg0NWQ1MTFjMzgzNjQxL3RhYmxlcmFuZ2U6ZTBmYTEyMWJlZGE5NGRiYWFiODQ1ZDUxMWMzODM2NDFfNC0xLTEtMS0xNzQxMA_2f4c0c39-a1fd-4cf1-a992-571f76f6d909"
      unitRef="usd">12421000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80MC9mcmFnOmFmOTc1NGRlNDkwOTQwZTBiNGIwYmZiYjE1YWU3MjJkL3RhYmxlOmUwZmExMjFiZWRhOTRkYmFhYjg0NWQ1MTFjMzgzNjQxL3RhYmxlcmFuZ2U6ZTBmYTEyMWJlZGE5NGRiYWFiODQ1ZDUxMWMzODM2NDFfNC0zLTEtMS0xNzQxMA_4490dddc-1aaa-438b-80e5-6db6cf44b6d8"
      unitRef="usd">7041000</us-gaap:InventoryGross>
    <us-gaap:InventoryValuationReserves
      contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80MC9mcmFnOmFmOTc1NGRlNDkwOTQwZTBiNGIwYmZiYjE1YWU3MjJkL3RhYmxlOmUwZmExMjFiZWRhOTRkYmFhYjg0NWQ1MTFjMzgzNjQxL3RhYmxlcmFuZ2U6ZTBmYTEyMWJlZGE5NGRiYWFiODQ1ZDUxMWMzODM2NDFfNS0xLTEtMS0xNzQxMA_dec3f809-bbbf-42bd-9792-743cad1e1de5"
      unitRef="usd">379000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryValuationReserves
      contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80MC9mcmFnOmFmOTc1NGRlNDkwOTQwZTBiNGIwYmZiYjE1YWU3MjJkL3RhYmxlOmUwZmExMjFiZWRhOTRkYmFhYjg0NWQ1MTFjMzgzNjQxL3RhYmxlcmFuZ2U6ZTBmYTEyMWJlZGE5NGRiYWFiODQ1ZDUxMWMzODM2NDFfNS0zLTEtMS0xNzQxMA_b1cc48ec-3d85-478f-be56-e6f6a7e8d6d9"
      unitRef="usd">263000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryNet
      contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80MC9mcmFnOmFmOTc1NGRlNDkwOTQwZTBiNGIwYmZiYjE1YWU3MjJkL3RhYmxlOmUwZmExMjFiZWRhOTRkYmFhYjg0NWQ1MTFjMzgzNjQxL3RhYmxlcmFuZ2U6ZTBmYTEyMWJlZGE5NGRiYWFiODQ1ZDUxMWMzODM2NDFfNi0xLTEtMS0xNzQxMA_52e0bad1-d5e1-440a-b146-71de454473fd"
      unitRef="usd">12042000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80MC9mcmFnOmFmOTc1NGRlNDkwOTQwZTBiNGIwYmZiYjE1YWU3MjJkL3RhYmxlOmUwZmExMjFiZWRhOTRkYmFhYjg0NWQ1MTFjMzgzNjQxL3RhYmxlcmFuZ2U6ZTBmYTEyMWJlZGE5NGRiYWFiODQ1ZDUxMWMzODM2NDFfNi0zLTEtMS0xNzQxMA_420b1cc8-af7c-4185-ae5c-140e04e6e149"
      unitRef="usd">6778000</us-gaap:InventoryNet>
    <us-gaap:LesseeFinanceLeasesTextBlock
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80My9mcmFnOjdkYWVhMmQxMDk4MzQ2ZjFhZGEzYTkyZGRmY2E2ZThlL3RleHRyZWdpb246N2RhZWEyZDEwOTgzNDZmMWFkYTNhOTJkZGZjYTZlOGVfODc2_ea54fd16-05ce-4cda-a27d-a566798a880e">LEASES&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;Operating Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company leases its facility in Sofia, Bulgaria and computers under non-cancelable operating lease agreements. During the three months ended September 30, 2022, the Company&#x2019;s leases on the vehicles in Clearwater, Florida expired and the Company purchased the vehicles at fair value. During the three months ended September 30, 2022, the Company entered into a one year extension on one of its leases on computer equipment. This extension resulted in reclassification of the lease from finance to operating. During the nine months ended September 30, 2022, the Company entered into a five year extension of its Sofia, Bulgaria facility. These operating leases have terms expiring through December 2027. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Finance Leases&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has entered into non-cancelable finance leases for certain computer equipment and a vehicle in Clearwater, Florida. During the nine months ended September 30, 2022, the Company entered into a 63 month lease for computer equipment. These finance leases have terms expiring through July 2027. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Information about the Company&#x2019;s weighted average remaining lease terms and discount rate assumptions are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.160%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Finance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Finance&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.75%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.64%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.98%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.00%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of lease liabilities as of September 30, 2022 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.319%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.190%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Finance&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less current portion of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(240)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term portion of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeFinanceLeasesTextBlock>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80My9mcmFnOjdkYWVhMmQxMDk4MzQ2ZjFhZGEzYTkyZGRmY2E2ZThlL3RleHRyZWdpb246N2RhZWEyZDEwOTgzNDZmMWFkYTNhOTJkZGZjYTZlOGVfODc2_eda45fc8-f539-461a-981d-7ad15ad0a69d">LEASES&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;Operating Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company leases its facility in Sofia, Bulgaria and computers under non-cancelable operating lease agreements. During the three months ended September 30, 2022, the Company&#x2019;s leases on the vehicles in Clearwater, Florida expired and the Company purchased the vehicles at fair value. During the three months ended September 30, 2022, the Company entered into a one year extension on one of its leases on computer equipment. This extension resulted in reclassification of the lease from finance to operating. During the nine months ended September 30, 2022, the Company entered into a five year extension of its Sofia, Bulgaria facility. These operating leases have terms expiring through December 2027. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Finance Leases&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has entered into non-cancelable finance leases for certain computer equipment and a vehicle in Clearwater, Florida. During the nine months ended September 30, 2022, the Company entered into a 63 month lease for computer equipment. These finance leases have terms expiring through July 2027. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Information about the Company&#x2019;s weighted average remaining lease terms and discount rate assumptions are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.160%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Finance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Finance&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.75%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.64%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.98%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.00%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of lease liabilities as of September 30, 2022 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.319%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.190%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Finance&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less current portion of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(240)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term portion of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80My9mcmFnOjdkYWVhMmQxMDk4MzQ2ZjFhZGEzYTkyZGRmY2E2ZThlL3RleHRyZWdpb246N2RhZWEyZDEwOTgzNDZmMWFkYTNhOTJkZGZjYTZlOGVfMTY0OTI2NzQ0MzU2OA_8af013e9-8b73-4b93-89c8-8db274ca8de3">P1Y</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80My9mcmFnOjdkYWVhMmQxMDk4MzQ2ZjFhZGEzYTkyZGRmY2E2ZThlL3RleHRyZWdpb246N2RhZWEyZDEwOTgzNDZmMWFkYTNhOTJkZGZjYTZlOGVfODc3_1cdb8262-a8d0-4a1f-9333-06150ebebc20">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeFinanceLeaseTermOfContract1
      contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80My9mcmFnOjdkYWVhMmQxMDk4MzQ2ZjFhZGEzYTkyZGRmY2E2ZThlL3RleHRyZWdpb246N2RhZWEyZDEwOTgzNDZmMWFkYTNhOTJkZGZjYTZlOGVfODc4_6bd4e56a-629d-4c64-bdac-9d9d94736df5">P63M</us-gaap:LesseeFinanceLeaseTermOfContract1>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80My9mcmFnOjdkYWVhMmQxMDk4MzQ2ZjFhZGEzYTkyZGRmY2E2ZThlL3RleHRyZWdpb246N2RhZWEyZDEwOTgzNDZmMWFkYTNhOTJkZGZjYTZlOGVfODc5_490fb205-23b2-4e44-b886-16ce58c68a50">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Information about the Company&#x2019;s weighted average remaining lease terms and discount rate assumptions are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.160%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Finance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Finance&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.75%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.64%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.98%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.00%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80My9mcmFnOjdkYWVhMmQxMDk4MzQ2ZjFhZGEzYTkyZGRmY2E2ZThlL3RhYmxlOmFjYmEwMmIyMzI3NzQzNDg5ODQyNTY2YjQ1MTZlMTM4L3RhYmxlcmFuZ2U6YWNiYTAyYjIzMjc3NDM0ODk4NDI1NjZiNDUxNmUxMzhfMi0xLTEtMS0xNzQxMA_f91474cf-67e4-4d27-a534-458130a3d603">P4Y4M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80My9mcmFnOjdkYWVhMmQxMDk4MzQ2ZjFhZGEzYTkyZGRmY2E2ZThlL3RhYmxlOmFjYmEwMmIyMzI3NzQzNDg5ODQyNTY2YjQ1MTZlMTM4L3RhYmxlcmFuZ2U6YWNiYTAyYjIzMjc3NDM0ODk4NDI1NjZiNDUxNmUxMzhfMi0yLTEtMS0xNzQxMA_99a0ce8f-ad1a-4c65-9365-0c332825e855">P4Y1M6D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80My9mcmFnOjdkYWVhMmQxMDk4MzQ2ZjFhZGEzYTkyZGRmY2E2ZThlL3RhYmxlOmFjYmEwMmIyMzI3NzQzNDg5ODQyNTY2YjQ1MTZlMTM4L3RhYmxlcmFuZ2U6YWNiYTAyYjIzMjc3NDM0ODk4NDI1NjZiNDUxNmUxMzhfMi00LTEtMS0xNzQxMA_a3b5da59-db2a-4a02-88a7-24a483a7075e">P1Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80My9mcmFnOjdkYWVhMmQxMDk4MzQ2ZjFhZGEzYTkyZGRmY2E2ZThlL3RhYmxlOmFjYmEwMmIyMzI3NzQzNDg5ODQyNTY2YjQ1MTZlMTM4L3RhYmxlcmFuZ2U6YWNiYTAyYjIzMjc3NDM0ODk4NDI1NjZiNDUxNmUxMzhfMi01LTEtMS0xNzQxMA_506a8ddc-9f90-4dc2-875d-ab52cbc69fe0">P0Y9M18D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80My9mcmFnOjdkYWVhMmQxMDk4MzQ2ZjFhZGEzYTkyZGRmY2E2ZThlL3RhYmxlOmFjYmEwMmIyMzI3NzQzNDg5ODQyNTY2YjQ1MTZlMTM4L3RhYmxlcmFuZ2U6YWNiYTAyYjIzMjc3NDM0ODk4NDI1NjZiNDUxNmUxMzhfMy0xLTEtMS0xNzQxMA_191b537d-a655-4ed4-9e3c-68655573377d"
      unitRef="number">0.0275</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80My9mcmFnOjdkYWVhMmQxMDk4MzQ2ZjFhZGEzYTkyZGRmY2E2ZThlL3RhYmxlOmFjYmEwMmIyMzI3NzQzNDg5ODQyNTY2YjQ1MTZlMTM4L3RhYmxlcmFuZ2U6YWNiYTAyYjIzMjc3NDM0ODk4NDI1NjZiNDUxNmUxMzhfMy0yLTEtMS0xNzQxMA_31399ca0-850b-41c4-bb68-0f6dcbc30910"
      unitRef="number">0.0264</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80My9mcmFnOjdkYWVhMmQxMDk4MzQ2ZjFhZGEzYTkyZGRmY2E2ZThlL3RhYmxlOmFjYmEwMmIyMzI3NzQzNDg5ODQyNTY2YjQ1MTZlMTM4L3RhYmxlcmFuZ2U6YWNiYTAyYjIzMjc3NDM0ODk4NDI1NjZiNDUxNmUxMzhfMy00LTEtMS0xNzQxMA_434aa496-28f7-4290-9616-b655392cf6ba"
      unitRef="number">0.0398</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80My9mcmFnOjdkYWVhMmQxMDk4MzQ2ZjFhZGEzYTkyZGRmY2E2ZThlL3RhYmxlOmFjYmEwMmIyMzI3NzQzNDg5ODQyNTY2YjQ1MTZlMTM4L3RhYmxlcmFuZ2U6YWNiYTAyYjIzMjc3NDM0ODk4NDI1NjZiNDUxNmUxMzhfMy01LTEtMS0xNzQxMA_9ad54eb0-5491-4117-baeb-a20d1a9b5788"
      unitRef="number">0.0400</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80My9mcmFnOjdkYWVhMmQxMDk4MzQ2ZjFhZGEzYTkyZGRmY2E2ZThlL3RleHRyZWdpb246N2RhZWEyZDEwOTgzNDZmMWFkYTNhOTJkZGZjYTZlOGVfODgw_60206e2f-8849-47a1-980e-4a1b4f78ea97">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of lease liabilities as of September 30, 2022 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.319%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.190%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Finance&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less current portion of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(240)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term portion of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80My9mcmFnOjdkYWVhMmQxMDk4MzQ2ZjFhZGEzYTkyZGRmY2E2ZThlL3RleHRyZWdpb246N2RhZWEyZDEwOTgzNDZmMWFkYTNhOTJkZGZjYTZlOGVfODgw_db7c765c-d70e-4de0-873a-fe3f8e1906d9">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of lease liabilities as of September 30, 2022 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.319%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.190%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Finance&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less current portion of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(240)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term portion of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80My9mcmFnOjdkYWVhMmQxMDk4MzQ2ZjFhZGEzYTkyZGRmY2E2ZThlL3RhYmxlOmMxMDE2Y2UwMjhkYjQ3MWY5NWJkZDYzMGNkYzI2ZWQ4L3RhYmxlcmFuZ2U6YzEwMTZjZTAyOGRiNDcxZjk1YmRkNjMwY2RjMjZlZDhfMi0xLTEtMS0xNzQxMA_b1be9771-c554-4a8c-bdbe-0428111e6011"
      unitRef="usd">75000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80My9mcmFnOjdkYWVhMmQxMDk4MzQ2ZjFhZGEzYTkyZGRmY2E2ZThlL3RhYmxlOmMxMDE2Y2UwMjhkYjQ3MWY5NWJkZDYzMGNkYzI2ZWQ4L3RhYmxlcmFuZ2U6YzEwMTZjZTAyOGRiNDcxZjk1YmRkNjMwY2RjMjZlZDhfMi0yLTEtMS0xNzQxMA_6c4b09ba-f11b-4c8b-99aa-651177ce0921"
      unitRef="usd">10000</us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80My9mcmFnOjdkYWVhMmQxMDk4MzQ2ZjFhZGEzYTkyZGRmY2E2ZThlL3RhYmxlOmMxMDE2Y2UwMjhkYjQ3MWY5NWJkZDYzMGNkYzI2ZWQ4L3RhYmxlcmFuZ2U6YzEwMTZjZTAyOGRiNDcxZjk1YmRkNjMwY2RjMjZlZDhfMy0xLTEtMS0xNzQxMA_c959953d-7137-41d7-a97e-2d4131123347"
      unitRef="usd">218000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80My9mcmFnOjdkYWVhMmQxMDk4MzQ2ZjFhZGEzYTkyZGRmY2E2ZThlL3RhYmxlOmMxMDE2Y2UwMjhkYjQ3MWY5NWJkZDYzMGNkYzI2ZWQ4L3RhYmxlcmFuZ2U6YzEwMTZjZTAyOGRiNDcxZjk1YmRkNjMwY2RjMjZlZDhfMy0yLTEtMS0xNzQxMA_80ee3039-c154-4bbe-8126-0b5a8d923f68"
      unitRef="usd">40000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80My9mcmFnOjdkYWVhMmQxMDk4MzQ2ZjFhZGEzYTkyZGRmY2E2ZThlL3RhYmxlOmMxMDE2Y2UwMjhkYjQ3MWY5NWJkZDYzMGNkYzI2ZWQ4L3RhYmxlcmFuZ2U6YzEwMTZjZTAyOGRiNDcxZjk1YmRkNjMwY2RjMjZlZDhfNC0xLTEtMS0xNzQxMA_8fe38355-99f0-49f2-bf82-b991890f5b5a"
      unitRef="usd">111000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80My9mcmFnOjdkYWVhMmQxMDk4MzQ2ZjFhZGEzYTkyZGRmY2E2ZThlL3RhYmxlOmMxMDE2Y2UwMjhkYjQ3MWY5NWJkZDYzMGNkYzI2ZWQ4L3RhYmxlcmFuZ2U6YzEwMTZjZTAyOGRiNDcxZjk1YmRkNjMwY2RjMjZlZDhfNC0yLTEtMS0xNzQxMA_a6ad4a7e-44f5-46a2-95e3-90ab656963cb"
      unitRef="usd">21000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80My9mcmFnOjdkYWVhMmQxMDk4MzQ2ZjFhZGEzYTkyZGRmY2E2ZThlL3RhYmxlOmMxMDE2Y2UwMjhkYjQ3MWY5NWJkZDYzMGNkYzI2ZWQ4L3RhYmxlcmFuZ2U6YzEwMTZjZTAyOGRiNDcxZjk1YmRkNjMwY2RjMjZlZDhfNS0xLTEtMS0xNzQxMA_2a39d335-94f2-4f8f-ad3f-32c7f03634da"
      unitRef="usd">111000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree
      contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80My9mcmFnOjdkYWVhMmQxMDk4MzQ2ZjFhZGEzYTkyZGRmY2E2ZThlL3RhYmxlOmMxMDE2Y2UwMjhkYjQ3MWY5NWJkZDYzMGNkYzI2ZWQ4L3RhYmxlcmFuZ2U6YzEwMTZjZTAyOGRiNDcxZjk1YmRkNjMwY2RjMjZlZDhfNS0yLTEtMS0xNzQxMA_14d79910-03e1-41d2-86f9-65d6fcdd0c0d"
      unitRef="usd">21000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80My9mcmFnOjdkYWVhMmQxMDk4MzQ2ZjFhZGEzYTkyZGRmY2E2ZThlL3RhYmxlOmMxMDE2Y2UwMjhkYjQ3MWY5NWJkZDYzMGNkYzI2ZWQ4L3RhYmxlcmFuZ2U6YzEwMTZjZTAyOGRiNDcxZjk1YmRkNjMwY2RjMjZlZDhfNi0xLTEtMS0xNzQxMA_9f58d664-7c54-40b2-afbd-fca8ff7d57d0"
      unitRef="usd">111000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour
      contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80My9mcmFnOjdkYWVhMmQxMDk4MzQ2ZjFhZGEzYTkyZGRmY2E2ZThlL3RhYmxlOmMxMDE2Y2UwMjhkYjQ3MWY5NWJkZDYzMGNkYzI2ZWQ4L3RhYmxlcmFuZ2U6YzEwMTZjZTAyOGRiNDcxZjk1YmRkNjMwY2RjMjZlZDhfNi0yLTEtMS0xNzQxMA_36301b75-a645-4419-a37e-97ea4afe46fe"
      unitRef="usd">21000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour>
    <apyx:LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour
      contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80My9mcmFnOjdkYWVhMmQxMDk4MzQ2ZjFhZGEzYTkyZGRmY2E2ZThlL3RhYmxlOmMxMDE2Y2UwMjhkYjQ3MWY5NWJkZDYzMGNkYzI2ZWQ4L3RhYmxlcmFuZ2U6YzEwMTZjZTAyOGRiNDcxZjk1YmRkNjMwY2RjMjZlZDhfNy0xLTEtMS0xNzQxMA_1abfbbb8-f5db-4373-9aa5-4686ca954360"
      unitRef="usd">111000</apyx:LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour>
    <apyx:FinanceLeaseLiabilityToBePaidDueAfterYearFour
      contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80My9mcmFnOjdkYWVhMmQxMDk4MzQ2ZjFhZGEzYTkyZGRmY2E2ZThlL3RhYmxlOmMxMDE2Y2UwMjhkYjQ3MWY5NWJkZDYzMGNkYzI2ZWQ4L3RhYmxlcmFuZ2U6YzEwMTZjZTAyOGRiNDcxZjk1YmRkNjMwY2RjMjZlZDhfNy0yLTEtMS0xNzQxMA_48f4c9a1-b8ef-4c92-868c-922719396759"
      unitRef="usd">12000</apyx:FinanceLeaseLiabilityToBePaidDueAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80My9mcmFnOjdkYWVhMmQxMDk4MzQ2ZjFhZGEzYTkyZGRmY2E2ZThlL3RhYmxlOmMxMDE2Y2UwMjhkYjQ3MWY5NWJkZDYzMGNkYzI2ZWQ4L3RhYmxlcmFuZ2U6YzEwMTZjZTAyOGRiNDcxZjk1YmRkNjMwY2RjMjZlZDhfOC0xLTEtMS0xNzQxMA_0dc85e06-3397-490a-9d18-89476073ac10"
      unitRef="usd">737000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80My9mcmFnOjdkYWVhMmQxMDk4MzQ2ZjFhZGEzYTkyZGRmY2E2ZThlL3RhYmxlOmMxMDE2Y2UwMjhkYjQ3MWY5NWJkZDYzMGNkYzI2ZWQ4L3RhYmxlcmFuZ2U6YzEwMTZjZTAyOGRiNDcxZjk1YmRkNjMwY2RjMjZlZDhfOC0yLTEtMS0xNzQxMA_51d20c1a-6ef3-4488-ad08-a62cc163e6de"
      unitRef="usd">125000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80My9mcmFnOjdkYWVhMmQxMDk4MzQ2ZjFhZGEzYTkyZGRmY2E2ZThlL3RhYmxlOmMxMDE2Y2UwMjhkYjQ3MWY5NWJkZDYzMGNkYzI2ZWQ4L3RhYmxlcmFuZ2U6YzEwMTZjZTAyOGRiNDcxZjk1YmRkNjMwY2RjMjZlZDhfOS0xLTEtMS0xNzQxMA_c3ab77df-bd5f-4024-a30d-4e9c7700d6cf"
      unitRef="usd">43000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount
      contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80My9mcmFnOjdkYWVhMmQxMDk4MzQ2ZjFhZGEzYTkyZGRmY2E2ZThlL3RhYmxlOmMxMDE2Y2UwMjhkYjQ3MWY5NWJkZDYzMGNkYzI2ZWQ4L3RhYmxlcmFuZ2U6YzEwMTZjZTAyOGRiNDcxZjk1YmRkNjMwY2RjMjZlZDhfOS0yLTEtMS0xNzQxMA_b4e520f1-7476-43bc-887f-613805aba924"
      unitRef="usd">5000</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80My9mcmFnOjdkYWVhMmQxMDk4MzQ2ZjFhZGEzYTkyZGRmY2E2ZThlL3RhYmxlOmMxMDE2Y2UwMjhkYjQ3MWY5NWJkZDYzMGNkYzI2ZWQ4L3RhYmxlcmFuZ2U6YzEwMTZjZTAyOGRiNDcxZjk1YmRkNjMwY2RjMjZlZDhfMTAtMS0xLTEtMTc0MTA_8d2849c9-d0e1-4798-8673-c44cb7e60392"
      unitRef="usd">694000</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80My9mcmFnOjdkYWVhMmQxMDk4MzQ2ZjFhZGEzYTkyZGRmY2E2ZThlL3RhYmxlOmMxMDE2Y2UwMjhkYjQ3MWY5NWJkZDYzMGNkYzI2ZWQ4L3RhYmxlcmFuZ2U6YzEwMTZjZTAyOGRiNDcxZjk1YmRkNjMwY2RjMjZlZDhfMTAtMi0xLTEtMTc0MTA_e80847ad-9cc0-4e28-bb3d-16afaac17644"
      unitRef="usd">120000</us-gaap:FinanceLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80My9mcmFnOjdkYWVhMmQxMDk4MzQ2ZjFhZGEzYTkyZGRmY2E2ZThlL3RhYmxlOmMxMDE2Y2UwMjhkYjQ3MWY5NWJkZDYzMGNkYzI2ZWQ4L3RhYmxlcmFuZ2U6YzEwMTZjZTAyOGRiNDcxZjk1YmRkNjMwY2RjMjZlZDhfMTEtMS0xLTEtMTc0MTA_c2f46474-dc02-4125-8206-dd51438ff714"
      unitRef="usd">240000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80My9mcmFnOjdkYWVhMmQxMDk4MzQ2ZjFhZGEzYTkyZGRmY2E2ZThlL3RhYmxlOmMxMDE2Y2UwMjhkYjQ3MWY5NWJkZDYzMGNkYzI2ZWQ4L3RhYmxlcmFuZ2U6YzEwMTZjZTAyOGRiNDcxZjk1YmRkNjMwY2RjMjZlZDhfMTEtMi0xLTEtMTc0MTA_87f8231f-5bc5-4a1f-82b5-d19bf08ab98e"
      unitRef="usd">42000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80My9mcmFnOjdkYWVhMmQxMDk4MzQ2ZjFhZGEzYTkyZGRmY2E2ZThlL3RhYmxlOmMxMDE2Y2UwMjhkYjQ3MWY5NWJkZDYzMGNkYzI2ZWQ4L3RhYmxlcmFuZ2U6YzEwMTZjZTAyOGRiNDcxZjk1YmRkNjMwY2RjMjZlZDhfMTItMS0xLTEtMTc0MTA_a5015eb8-fa4a-4b13-82fa-25c69c15bd31"
      unitRef="usd">454000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80My9mcmFnOjdkYWVhMmQxMDk4MzQ2ZjFhZGEzYTkyZGRmY2E2ZThlL3RhYmxlOmMxMDE2Y2UwMjhkYjQ3MWY5NWJkZDYzMGNkYzI2ZWQ4L3RhYmxlcmFuZ2U6YzEwMTZjZTAyOGRiNDcxZjk1YmRkNjMwY2RjMjZlZDhfMTItMi0xLTEtMTc0MTA_7166a453-3c9b-4222-991f-436eee0b4d34"
      unitRef="usd">78000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80Ni9mcmFnOjQ3NGYxZThlODdhMDRjODA4ZGEzYTI3YzU4MWE2MmE5L3RleHRyZWdpb246NDc0ZjFlOGU4N2EwNGM4MDhkYTNhMjdjNTgxYTYyYTlfNDE3_18ca86fe-f88e-4204-a5ab-a8fdfa99ef38">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses and other current liabilities consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued payroll&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued bonuses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued commissions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued product warranties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued product liability claim insurance deductibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued professional fees and legal related contingent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Joint and several payroll liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Uncertain tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales tax payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued expenses and current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During April 2022, the Company was relieved of approximately $650,000 of its joint and several payroll liability due to the lapse of the statute of limitations on the liability. This adjustment is included in other income, net for the nine months ended September 30, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80Ni9mcmFnOjQ3NGYxZThlODdhMDRjODA4ZGEzYTI3YzU4MWE2MmE5L3RleHRyZWdpb246NDc0ZjFlOGU4N2EwNGM4MDhkYTNhMjdjNTgxYTYyYTlfNDE4_174e9b2f-f7ba-4c00-9924-f28ed4244586">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses and other current liabilities consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued payroll&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued bonuses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued commissions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued product warranties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued product liability claim insurance deductibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued professional fees and legal related contingent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Joint and several payroll liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Uncertain tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales tax payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued expenses and current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedSalariesCurrent
      contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80Ni9mcmFnOjQ3NGYxZThlODdhMDRjODA4ZGEzYTI3YzU4MWE2MmE5L3RhYmxlOjY0NGYwMTE2ODliZTRkMDA5MDNkMDI3NDhmN2I0YTgyL3RhYmxlcmFuZ2U6NjQ0ZjAxMTY4OWJlNGQwMDkwM2QwMjc0OGY3YjRhODJfMS0xLTEtMS0xNzQxMA_cd13bed1-6ac2-40d3-aaf6-17211d1be9d6"
      unitRef="usd">879000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedSalariesCurrent
      contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80Ni9mcmFnOjQ3NGYxZThlODdhMDRjODA4ZGEzYTI3YzU4MWE2MmE5L3RhYmxlOjY0NGYwMTE2ODliZTRkMDA5MDNkMDI3NDhmN2I0YTgyL3RhYmxlcmFuZ2U6NjQ0ZjAxMTY4OWJlNGQwMDkwM2QwMjc0OGY3YjRhODJfMS0zLTEtMS0xNzQxMA_1c253752-c172-430b-90d9-4bb68417bd3e"
      unitRef="usd">546000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedBonusesCurrent
      contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80Ni9mcmFnOjQ3NGYxZThlODdhMDRjODA4ZGEzYTI3YzU4MWE2MmE5L3RhYmxlOjY0NGYwMTE2ODliZTRkMDA5MDNkMDI3NDhmN2I0YTgyL3RhYmxlcmFuZ2U6NjQ0ZjAxMTY4OWJlNGQwMDkwM2QwMjc0OGY3YjRhODJfMi0xLTEtMS0xNzQxMA_23864f31-b0f1-4667-ba15-68532a4d7533"
      unitRef="usd">0</us-gaap:AccruedBonusesCurrent>
    <us-gaap:AccruedBonusesCurrent
      contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80Ni9mcmFnOjQ3NGYxZThlODdhMDRjODA4ZGEzYTI3YzU4MWE2MmE5L3RhYmxlOjY0NGYwMTE2ODliZTRkMDA5MDNkMDI3NDhmN2I0YTgyL3RhYmxlcmFuZ2U6NjQ0ZjAxMTY4OWJlNGQwMDkwM2QwMjc0OGY3YjRhODJfMi0zLTEtMS0xNzQxMA_f6827d99-1dcf-4d60-b0da-2b7ecff6f31e"
      unitRef="usd">2117000</us-gaap:AccruedBonusesCurrent>
    <us-gaap:AccruedSalesCommissionCurrent
      contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80Ni9mcmFnOjQ3NGYxZThlODdhMDRjODA4ZGEzYTI3YzU4MWE2MmE5L3RhYmxlOjY0NGYwMTE2ODliZTRkMDA5MDNkMDI3NDhmN2I0YTgyL3RhYmxlcmFuZ2U6NjQ0ZjAxMTY4OWJlNGQwMDkwM2QwMjc0OGY3YjRhODJfMy0xLTEtMS0xNzQxMA_ac851c10-2ee4-49f5-9913-01ee75f51a7d"
      unitRef="usd">877000</us-gaap:AccruedSalesCommissionCurrent>
    <us-gaap:AccruedSalesCommissionCurrent
      contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80Ni9mcmFnOjQ3NGYxZThlODdhMDRjODA4ZGEzYTI3YzU4MWE2MmE5L3RhYmxlOjY0NGYwMTE2ODliZTRkMDA5MDNkMDI3NDhmN2I0YTgyL3RhYmxlcmFuZ2U6NjQ0ZjAxMTY4OWJlNGQwMDkwM2QwMjc0OGY3YjRhODJfMy0zLTEtMS0xNzQxMA_e087d8cc-f1ab-4d5c-9833-54b17c7cacfb"
      unitRef="usd">1656000</us-gaap:AccruedSalesCommissionCurrent>
    <us-gaap:ProductWarrantyAccrualClassifiedCurrent
      contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80Ni9mcmFnOjQ3NGYxZThlODdhMDRjODA4ZGEzYTI3YzU4MWE2MmE5L3RhYmxlOjY0NGYwMTE2ODliZTRkMDA5MDNkMDI3NDhmN2I0YTgyL3RhYmxlcmFuZ2U6NjQ0ZjAxMTY4OWJlNGQwMDkwM2QwMjc0OGY3YjRhODJfNC0xLTEtMS0xNzQxMA_639378c6-92c3-40dc-9c56-699d07be3205"
      unitRef="usd">616000</us-gaap:ProductWarrantyAccrualClassifiedCurrent>
    <us-gaap:ProductWarrantyAccrualClassifiedCurrent
      contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80Ni9mcmFnOjQ3NGYxZThlODdhMDRjODA4ZGEzYTI3YzU4MWE2MmE5L3RhYmxlOjY0NGYwMTE2ODliZTRkMDA5MDNkMDI3NDhmN2I0YTgyL3RhYmxlcmFuZ2U6NjQ0ZjAxMTY4OWJlNGQwMDkwM2QwMjc0OGY3YjRhODJfNC0zLTEtMS0xNzQxMA_d9997eb2-3039-4915-ae81-fdc2cc19ef12"
      unitRef="usd">593000</us-gaap:ProductWarrantyAccrualClassifiedCurrent>
    <us-gaap:AccruedInsuranceCurrent
      contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80Ni9mcmFnOjQ3NGYxZThlODdhMDRjODA4ZGEzYTI3YzU4MWE2MmE5L3RhYmxlOjY0NGYwMTE2ODliZTRkMDA5MDNkMDI3NDhmN2I0YTgyL3RhYmxlcmFuZ2U6NjQ0ZjAxMTY4OWJlNGQwMDkwM2QwMjc0OGY3YjRhODJfNS0xLTEtMS0xNzQxMA_39ffa0ca-8528-4aa5-b043-72b616ec3a63"
      unitRef="usd">1016000</us-gaap:AccruedInsuranceCurrent>
    <us-gaap:AccruedInsuranceCurrent
      contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80Ni9mcmFnOjQ3NGYxZThlODdhMDRjODA4ZGEzYTI3YzU4MWE2MmE5L3RhYmxlOjY0NGYwMTE2ODliZTRkMDA5MDNkMDI3NDhmN2I0YTgyL3RhYmxlcmFuZ2U6NjQ0ZjAxMTY4OWJlNGQwMDkwM2QwMjc0OGY3YjRhODJfNS0zLTEtMS0xNzQxMA_0d989d13-ae17-46ff-95d3-27f173f481b9"
      unitRef="usd">610000</us-gaap:AccruedInsuranceCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80Ni9mcmFnOjQ3NGYxZThlODdhMDRjODA4ZGEzYTI3YzU4MWE2MmE5L3RhYmxlOjY0NGYwMTE2ODliZTRkMDA5MDNkMDI3NDhmN2I0YTgyL3RhYmxlcmFuZ2U6NjQ0ZjAxMTY4OWJlNGQwMDkwM2QwMjc0OGY3YjRhODJfNi0xLTEtMS0xNzQxMA_972617dc-595d-4300-93bf-aaeeef32bc0f"
      unitRef="usd">1134000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80Ni9mcmFnOjQ3NGYxZThlODdhMDRjODA4ZGEzYTI3YzU4MWE2MmE5L3RhYmxlOjY0NGYwMTE2ODliZTRkMDA5MDNkMDI3NDhmN2I0YTgyL3RhYmxlcmFuZ2U6NjQ0ZjAxMTY4OWJlNGQwMDkwM2QwMjc0OGY3YjRhODJfNi0zLTEtMS0xNzQxMA_9ea7a24b-6e9b-4711-817a-2efce91a02d0"
      unitRef="usd">421000</us-gaap:AccruedProfessionalFeesCurrent>
    <apyx:JointAndSeveralPayrollLiability
      contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80Ni9mcmFnOjQ3NGYxZThlODdhMDRjODA4ZGEzYTI3YzU4MWE2MmE5L3RhYmxlOjY0NGYwMTE2ODliZTRkMDA5MDNkMDI3NDhmN2I0YTgyL3RhYmxlcmFuZ2U6NjQ0ZjAxMTY4OWJlNGQwMDkwM2QwMjc0OGY3YjRhODJfNy0xLTEtMS0xNzQxMA_f60cfba0-cca0-4aca-b249-4d6c048adac2"
      unitRef="usd">399000</apyx:JointAndSeveralPayrollLiability>
    <apyx:JointAndSeveralPayrollLiability
      contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80Ni9mcmFnOjQ3NGYxZThlODdhMDRjODA4ZGEzYTI3YzU4MWE2MmE5L3RhYmxlOjY0NGYwMTE2ODliZTRkMDA5MDNkMDI3NDhmN2I0YTgyL3RhYmxlcmFuZ2U6NjQ0ZjAxMTY4OWJlNGQwMDkwM2QwMjc0OGY3YjRhODJfNy0zLTEtMS0xNzQxMA_c3b349ea-bc97-4b53-99c7-9b23a0447a2b"
      unitRef="usd">1027000</apyx:JointAndSeveralPayrollLiability>
    <apyx:ShortTermContractLiabilities
      contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80Ni9mcmFnOjQ3NGYxZThlODdhMDRjODA4ZGEzYTI3YzU4MWE2MmE5L3RhYmxlOjY0NGYwMTE2ODliZTRkMDA5MDNkMDI3NDhmN2I0YTgyL3RhYmxlcmFuZ2U6NjQ0ZjAxMTY4OWJlNGQwMDkwM2QwMjc0OGY3YjRhODJfOC0xLTEtMS0xNzQxMA_e62f6de8-783c-45eb-b520-f3f744f5a6cd"
      unitRef="usd">1145000</apyx:ShortTermContractLiabilities>
    <apyx:ShortTermContractLiabilities
      contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80Ni9mcmFnOjQ3NGYxZThlODdhMDRjODA4ZGEzYTI3YzU4MWE2MmE5L3RhYmxlOjY0NGYwMTE2ODliZTRkMDA5MDNkMDI3NDhmN2I0YTgyL3RhYmxlcmFuZ2U6NjQ0ZjAxMTY4OWJlNGQwMDkwM2QwMjc0OGY3YjRhODJfOC0zLTEtMS0xNzQxMA_60ee91b1-9ef9-41f7-8e24-b4e026977ce0"
      unitRef="usd">533000</apyx:ShortTermContractLiabilities>
    <apyx:UncertainTaxPositionsLiability
      contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80Ni9mcmFnOjQ3NGYxZThlODdhMDRjODA4ZGEzYTI3YzU4MWE2MmE5L3RhYmxlOjY0NGYwMTE2ODliZTRkMDA5MDNkMDI3NDhmN2I0YTgyL3RhYmxlcmFuZ2U6NjQ0ZjAxMTY4OWJlNGQwMDkwM2QwMjc0OGY3YjRhODJfOS0xLTEtMS0xNzQxMA_15ed4cb9-6f11-4af5-8173-150339968d53"
      unitRef="usd">2024000</apyx:UncertainTaxPositionsLiability>
    <apyx:UncertainTaxPositionsLiability
      contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80Ni9mcmFnOjQ3NGYxZThlODdhMDRjODA4ZGEzYTI3YzU4MWE2MmE5L3RhYmxlOjY0NGYwMTE2ODliZTRkMDA5MDNkMDI3NDhmN2I0YTgyL3RhYmxlcmFuZ2U6NjQ0ZjAxMTY4OWJlNGQwMDkwM2QwMjc0OGY3YjRhODJfOS0zLTEtMS0xNzQxMA_9da40e20-5f2f-4428-9b46-70f5947ad371"
      unitRef="usd">1863000</apyx:UncertainTaxPositionsLiability>
    <us-gaap:SalesAndExciseTaxPayableCurrent
      contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80Ni9mcmFnOjQ3NGYxZThlODdhMDRjODA4ZGEzYTI3YzU4MWE2MmE5L3RhYmxlOjY0NGYwMTE2ODliZTRkMDA5MDNkMDI3NDhmN2I0YTgyL3RhYmxlcmFuZ2U6NjQ0ZjAxMTY4OWJlNGQwMDkwM2QwMjc0OGY3YjRhODJfMTAtMS0xLTEtMTc0MTA_01bc3dc6-bcf5-409f-a19e-eb108571a53e"
      unitRef="usd">135000</us-gaap:SalesAndExciseTaxPayableCurrent>
    <us-gaap:SalesAndExciseTaxPayableCurrent
      contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80Ni9mcmFnOjQ3NGYxZThlODdhMDRjODA4ZGEzYTI3YzU4MWE2MmE5L3RhYmxlOjY0NGYwMTE2ODliZTRkMDA5MDNkMDI3NDhmN2I0YTgyL3RhYmxlcmFuZ2U6NjQ0ZjAxMTY4OWJlNGQwMDkwM2QwMjc0OGY3YjRhODJfMTAtMy0xLTEtMTc0MTA_f60b0e5c-70dc-4ab0-ab7b-80f156f458a1"
      unitRef="usd">428000</us-gaap:SalesAndExciseTaxPayableCurrent>
    <apyx:OtherAccruedExpensesAndLiabilitiesCurrent
      contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80Ni9mcmFnOjQ3NGYxZThlODdhMDRjODA4ZGEzYTI3YzU4MWE2MmE5L3RhYmxlOjY0NGYwMTE2ODliZTRkMDA5MDNkMDI3NDhmN2I0YTgyL3RhYmxlcmFuZ2U6NjQ0ZjAxMTY4OWJlNGQwMDkwM2QwMjc0OGY3YjRhODJfMTEtMS0xLTEtMTc0MTA_6e2924e7-a372-48bd-920c-b3a48411da7f"
      unitRef="usd">617000</apyx:OtherAccruedExpensesAndLiabilitiesCurrent>
    <apyx:OtherAccruedExpensesAndLiabilitiesCurrent
      contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80Ni9mcmFnOjQ3NGYxZThlODdhMDRjODA4ZGEzYTI3YzU4MWE2MmE5L3RhYmxlOjY0NGYwMTE2ODliZTRkMDA5MDNkMDI3NDhmN2I0YTgyL3RhYmxlcmFuZ2U6NjQ0ZjAxMTY4OWJlNGQwMDkwM2QwMjc0OGY3YjRhODJfMTEtMy0xLTEtMTc0MTA_cfa66e03-9d53-4f6b-b6c5-6fc5ba9e276e"
      unitRef="usd">493000</apyx:OtherAccruedExpensesAndLiabilitiesCurrent>
    <apyx:AccruedLiabilitiesAndOtherLiabilitiesCurrent
      contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80Ni9mcmFnOjQ3NGYxZThlODdhMDRjODA4ZGEzYTI3YzU4MWE2MmE5L3RhYmxlOjY0NGYwMTE2ODliZTRkMDA5MDNkMDI3NDhmN2I0YTgyL3RhYmxlcmFuZ2U6NjQ0ZjAxMTY4OWJlNGQwMDkwM2QwMjc0OGY3YjRhODJfMTItMS0xLTEtMTc0MTA_754368be-40af-4832-93a4-bd9aeaeab247"
      unitRef="usd">8842000</apyx:AccruedLiabilitiesAndOtherLiabilitiesCurrent>
    <apyx:AccruedLiabilitiesAndOtherLiabilitiesCurrent
      contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80Ni9mcmFnOjQ3NGYxZThlODdhMDRjODA4ZGEzYTI3YzU4MWE2MmE5L3RhYmxlOjY0NGYwMTE2ODliZTRkMDA5MDNkMDI3NDhmN2I0YTgyL3RhYmxlcmFuZ2U6NjQ0ZjAxMTY4OWJlNGQwMDkwM2QwMjc0OGY3YjRhODJfMTItMy0xLTEtMTc0MTA_ceb8ea06-0c03-4654-983e-bc6719d228f0"
      unitRef="usd">10287000</apyx:AccruedLiabilitiesAndOtherLiabilitiesCurrent>
    <apyx:JointAndSeveralPayrollLiability
      contextRef="iee62c576cfc14937a01701621d37dc74_I20220430"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80Ni9mcmFnOjQ3NGYxZThlODdhMDRjODA4ZGEzYTI3YzU4MWE2MmE5L3RleHRyZWdpb246NDc0ZjFlOGU4N2EwNGM4MDhkYTNhMjdjNTgxYTYyYTlfMjAz_7884c5b9-a931-4ac4-b549-20409a153a8b"
      unitRef="usd">-650000</apyx:JointAndSeveralPayrollLiability>
    <us-gaap:MinorityInterestDisclosureTextBlock
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80OS9mcmFnOmQ3YzEyZjA2NzU4YTRkZDA5OGM1MmEyZTRjOTgxYzYyL3RleHRyZWdpb246ZDdjMTJmMDY3NThhNGRkMDk4YzUyYTJlNGM5ODFjNjJfNjI1_8518f7b7-938a-447c-b722-51e975e46a35">CHINA JOINT VENTURE&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2019, the Company executed a joint venture agreement with its Chinese supplier (the &#x201c;China JV&#x201d;) whereby the Company has a 51% interest. The China JV has been consolidated in these condensed consolidated financial statements. The agreement required the Company to make capital contributions into the newly formed entity of approximately&#160;$357,000, which had been fully funded as of December 31, 2021. As of the date of these condensed consolidated financial statements, the China JV has not commenced principal operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in the &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Company&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2019;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; investment in the China JV were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.988%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.407%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.994%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.775%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.994%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.775%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.994%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.775%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.998%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning interest in China JV&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contributions &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to Apyx&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(81)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending interest in China JV&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:MinorityInterestDisclosureTextBlock>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="i9be5f375baba4295ace9fc48f09fe8dc_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80OS9mcmFnOmQ3YzEyZjA2NzU4YTRkZDA5OGM1MmEyZTRjOTgxYzYyL3RleHRyZWdpb246ZDdjMTJmMDY3NThhNGRkMDk4YzUyYTJlNGM5ODFjNjJfMTYw_e34a450b-5f39-4f81-8567-1a28862045c0"
      unitRef="number">0.51</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <apyx:NoncontrollingInterestRequiredCapitalContribution
      contextRef="i84408c5278f544ccb03b5314b28177f5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80OS9mcmFnOmQ3YzEyZjA2NzU4YTRkZDA5OGM1MmEyZTRjOTgxYzYyL3RleHRyZWdpb246ZDdjMTJmMDY3NThhNGRkMDk4YzUyYTJlNGM5ODFjNjJfMzcz_e2f05b80-5bda-424c-ba35-85ede6cc0c26"
      unitRef="usd">357000</apyx:NoncontrollingInterestRequiredCapitalContribution>
    <apyx:NoncontrollingInterestTableTextBlock
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80OS9mcmFnOmQ3YzEyZjA2NzU4YTRkZDA5OGM1MmEyZTRjOTgxYzYyL3RleHRyZWdpb246ZDdjMTJmMDY3NThhNGRkMDk4YzUyYTJlNGM5ODFjNjJfNjI0_7cbfbc21-8bdc-463c-ad30-6b0f62adfdc4">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in the &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Company&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2019;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; investment in the China JV were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.988%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.407%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.994%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.775%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.994%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.775%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.994%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.775%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.998%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning interest in China JV&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contributions &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to Apyx&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(81)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending interest in China JV&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</apyx:NoncontrollingInterestTableTextBlock>
    <us-gaap:MinorityInterest
      contextRef="i8d492a2b0cb940b3a3efba0a8c74f3b2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80OS9mcmFnOmQ3YzEyZjA2NzU4YTRkZDA5OGM1MmEyZTRjOTgxYzYyL3RhYmxlOmRiZTkzZDc1MTA1ZjRiNjhiZjk2Yjc1Yjg2MjM5ZmQ5L3RhYmxlcmFuZ2U6ZGJlOTNkNzUxMDVmNGI2OGJmOTZiNzViODYyMzlmZDlfMi0yLTEtMS0xNzQxMA_9927c57a-b090-4d13-9a81-a4760a32e000"
      unitRef="usd">269000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="ifefbd2b1828e478481b4e147440bb47b_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80OS9mcmFnOmQ3YzEyZjA2NzU4YTRkZDA5OGM1MmEyZTRjOTgxYzYyL3RhYmxlOmRiZTkzZDc1MTA1ZjRiNjhiZjk2Yjc1Yjg2MjM5ZmQ5L3RhYmxlcmFuZ2U6ZGJlOTNkNzUxMDVmNGI2OGJmOTZiNzViODYyMzlmZDlfMi00LTEtMS0xNzQxMA_4fff2083-0232-40e1-ae7f-edd6087e6203"
      unitRef="usd">338000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="i84408c5278f544ccb03b5314b28177f5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80OS9mcmFnOmQ3YzEyZjA2NzU4YTRkZDA5OGM1MmEyZTRjOTgxYzYyL3RhYmxlOmRiZTkzZDc1MTA1ZjRiNjhiZjk2Yjc1Yjg2MjM5ZmQ5L3RhYmxlcmFuZ2U6ZGJlOTNkNzUxMDVmNGI2OGJmOTZiNzViODYyMzlmZDlfMi02LTEtMS0xNzQxMA_84e45cec-d788-428c-ab7c-ef04d63276ab"
      unitRef="usd">317000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="i614389ddffc7468ba138bf2516c6c05f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80OS9mcmFnOmQ3YzEyZjA2NzU4YTRkZDA5OGM1MmEyZTRjOTgxYzYyL3RhYmxlOmRiZTkzZDc1MTA1ZjRiNjhiZjk2Yjc1Yjg2MjM5ZmQ5L3RhYmxlcmFuZ2U6ZGJlOTNkNzUxMDVmNGI2OGJmOTZiNzViODYyMzlmZDlfMi04LTEtMS0xNzQxMA_ba8af2f6-173c-4860-b30e-2589896f11a3"
      unitRef="usd">144000</us-gaap:MinorityInterest>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="i971483142d77406c8234c4a4370fd3f7_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80OS9mcmFnOmQ3YzEyZjA2NzU4YTRkZDA5OGM1MmEyZTRjOTgxYzYyL3RhYmxlOmRiZTkzZDc1MTA1ZjRiNjhiZjk2Yjc1Yjg2MjM5ZmQ5L3RhYmxlcmFuZ2U6ZGJlOTNkNzUxMDVmNGI2OGJmOTZiNzViODYyMzlmZDlfMy0yLTEtMS0xNzQxMA_2ef38abf-61a2-4e08-b248-fb357c4e7512"
      unitRef="usd">0</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="i7ca81802bedf4dd7b618a8b1cd8ffd83_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80OS9mcmFnOmQ3YzEyZjA2NzU4YTRkZDA5OGM1MmEyZTRjOTgxYzYyL3RhYmxlOmRiZTkzZDc1MTA1ZjRiNjhiZjk2Yjc1Yjg2MjM5ZmQ5L3RhYmxlcmFuZ2U6ZGJlOTNkNzUxMDVmNGI2OGJmOTZiNzViODYyMzlmZDlfMy00LTEtMS0xNzQxMA_47c9774e-5a77-40e5-bafc-008414a4d6f1"
      unitRef="usd">0</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="iacbe89d9dab74e6990b6f064b9754ea4_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80OS9mcmFnOmQ3YzEyZjA2NzU4YTRkZDA5OGM1MmEyZTRjOTgxYzYyL3RhYmxlOmRiZTkzZDc1MTA1ZjRiNjhiZjk2Yjc1Yjg2MjM5ZmQ5L3RhYmxlcmFuZ2U6ZGJlOTNkNzUxMDVmNGI2OGJmOTZiNzViODYyMzlmZDlfMy02LTEtMS0xNzQxMA_629ca95a-33ee-4c88-927b-75d4d9ce6c4a"
      unitRef="usd">0</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="i61baec36978a4160b66435f0f2416149_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80OS9mcmFnOmQ3YzEyZjA2NzU4YTRkZDA5OGM1MmEyZTRjOTgxYzYyL3RhYmxlOmRiZTkzZDc1MTA1ZjRiNjhiZjk2Yjc1Yjg2MjM5ZmQ5L3RhYmxlcmFuZ2U6ZGJlOTNkNzUxMDVmNGI2OGJmOTZiNzViODYyMzlmZDlfMy04LTEtMS0xNzQxMA_ae2e2f8d-6499-450b-bd74-e989e4c669b1"
      unitRef="usd">203000</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i971483142d77406c8234c4a4370fd3f7_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80OS9mcmFnOmQ3YzEyZjA2NzU4YTRkZDA5OGM1MmEyZTRjOTgxYzYyL3RhYmxlOmRiZTkzZDc1MTA1ZjRiNjhiZjk2Yjc1Yjg2MjM5ZmQ5L3RhYmxlcmFuZ2U6ZGJlOTNkNzUxMDVmNGI2OGJmOTZiNzViODYyMzlmZDlfNC0yLTEtMS0xNzQxMA_969597a6-d8fb-417b-ae7b-7972751111ab"
      unitRef="usd">-33000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i7ca81802bedf4dd7b618a8b1cd8ffd83_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80OS9mcmFnOmQ3YzEyZjA2NzU4YTRkZDA5OGM1MmEyZTRjOTgxYzYyL3RhYmxlOmRiZTkzZDc1MTA1ZjRiNjhiZjk2Yjc1Yjg2MjM5ZmQ5L3RhYmxlcmFuZ2U6ZGJlOTNkNzUxMDVmNGI2OGJmOTZiNzViODYyMzlmZDlfNC00LTEtMS0xNzQxMA_7c6f8232-49ca-4f9d-b1e0-d85602cbe932"
      unitRef="usd">-13000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="iacbe89d9dab74e6990b6f064b9754ea4_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80OS9mcmFnOmQ3YzEyZjA2NzU4YTRkZDA5OGM1MmEyZTRjOTgxYzYyL3RhYmxlOmRiZTkzZDc1MTA1ZjRiNjhiZjk2Yjc1Yjg2MjM5ZmQ5L3RhYmxlcmFuZ2U6ZGJlOTNkNzUxMDVmNGI2OGJmOTZiNzViODYyMzlmZDlfNC02LTEtMS0xNzQxMA_e74fd64f-5c68-486c-9781-c16e1aeb4046"
      unitRef="usd">-81000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i61baec36978a4160b66435f0f2416149_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80OS9mcmFnOmQ3YzEyZjA2NzU4YTRkZDA5OGM1MmEyZTRjOTgxYzYyL3RhYmxlOmRiZTkzZDc1MTA1ZjRiNjhiZjk2Yjc1Yjg2MjM5ZmQ5L3RhYmxlcmFuZ2U6ZGJlOTNkNzUxMDVmNGI2OGJmOTZiNzViODYyMzlmZDlfNC04LTEtMS0xNzQxMA_a682ab1a-522f-4781-a74e-40e7f95d71ab"
      unitRef="usd">-22000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:MinorityInterest
      contextRef="ic03ac90c24194c2181a21dd8933c788e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80OS9mcmFnOmQ3YzEyZjA2NzU4YTRkZDA5OGM1MmEyZTRjOTgxYzYyL3RhYmxlOmRiZTkzZDc1MTA1ZjRiNjhiZjk2Yjc1Yjg2MjM5ZmQ5L3RhYmxlcmFuZ2U6ZGJlOTNkNzUxMDVmNGI2OGJmOTZiNzViODYyMzlmZDlfNS0yLTEtMS0xNzQxMA_17f61159-39b6-460a-ae71-67528da4a818"
      unitRef="usd">236000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="ia7bdc42847614ed88ba35dd3d0f7643c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80OS9mcmFnOmQ3YzEyZjA2NzU4YTRkZDA5OGM1MmEyZTRjOTgxYzYyL3RhYmxlOmRiZTkzZDc1MTA1ZjRiNjhiZjk2Yjc1Yjg2MjM5ZmQ5L3RhYmxlcmFuZ2U6ZGJlOTNkNzUxMDVmNGI2OGJmOTZiNzViODYyMzlmZDlfNS00LTEtMS0xNzQxMA_a0ad31bf-ef3a-447e-a857-cb16c547fd16"
      unitRef="usd">325000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="ic03ac90c24194c2181a21dd8933c788e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80OS9mcmFnOmQ3YzEyZjA2NzU4YTRkZDA5OGM1MmEyZTRjOTgxYzYyL3RhYmxlOmRiZTkzZDc1MTA1ZjRiNjhiZjk2Yjc1Yjg2MjM5ZmQ5L3RhYmxlcmFuZ2U6ZGJlOTNkNzUxMDVmNGI2OGJmOTZiNzViODYyMzlmZDlfNS02LTEtMS0xNzQxMA_875d3d87-12d7-4c87-8c33-b72a1251eb49"
      unitRef="usd">236000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="ia7bdc42847614ed88ba35dd3d0f7643c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV80OS9mcmFnOmQ3YzEyZjA2NzU4YTRkZDA5OGM1MmEyZTRjOTgxYzYyL3RhYmxlOmRiZTkzZDc1MTA1ZjRiNjhiZjk2Yjc1Yjg2MjM5ZmQ5L3RhYmxlcmFuZ2U6ZGJlOTNkNzUxMDVmNGI2OGJmOTZiNzViODYyMzlmZDlfNS04LTEtMS0xNzQxMA_84b0e190-acf2-4aec-879f-5791fbcc4c91"
      unitRef="usd">325000</us-gaap:MinorityInterest>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81Mi9mcmFnOjg0NDU1NTJiNGIyMzRjNGU4MDVjOWY5OWYyM2Y4NTEzL3RleHRyZWdpb246ODQ0NTU1MmI0YjIzNGM0ZTgwNWM5Zjk5ZjIzZjg1MTNfNTQy_dfaacde2-ee27-4d92-a29b-141c82f8fd60">EARNINGS (LOSS) PER SHARE &lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic earnings (loss) per share (&#x201c;basic EPS&#x201d;) is computed by dividing the net income or loss by the weighted average number of common shares outstanding for the reporting period. Diluted earnings (loss) per share (&#x201c;diluted EPS&#x201d;) gives effect to all dilutive potential shares outstanding. As the Company is in a net loss position for all periods presented, all potential shares outstanding are anti-dilutive. The following table provides the computation of basic and diluted loss per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.822%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.393%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.324%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.728%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.324%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.728%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.324%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.728%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands, except per share data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to stockholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,764)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,222)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,135)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,169)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares outstanding - basic and diluted&lt;br/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss per share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Anti-dilutive instruments excluded from diluted loss per common share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81Mi9mcmFnOjg0NDU1NTJiNGIyMzRjNGU4MDVjOWY5OWYyM2Y4NTEzL3RleHRyZWdpb246ODQ0NTU1MmI0YjIzNGM0ZTgwNWM5Zjk5ZjIzZjg1MTNfNTM0_0e071998-e6c8-4333-8ca2-7b2517f07249">The following table provides the computation of basic and diluted loss per share.&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.822%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.393%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.324%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.728%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.324%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.728%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.324%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.728%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands, except per share data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to stockholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,764)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,222)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,135)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,169)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares outstanding - basic and diluted&lt;br/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss per share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Anti-dilutive instruments excluded from diluted loss per common share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="id6ada2596cf84b118b49af7a6561fb79_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81Mi9mcmFnOjg0NDU1NTJiNGIyMzRjNGU4MDVjOWY5OWYyM2Y4NTEzL3RhYmxlOjViMGM3ZDc0Njk5OTRiMDViMjA5NDQzMWEzM2QyMzA5L3RhYmxlcmFuZ2U6NWIwYzdkNzQ2OTk5NGIwNWIyMDk0NDMxYTMzZDIzMDlfMy0yLTEtMS0xNzQxMA_0dfec637-0710-44b4-acb9-5b67fee6e05a"
      unitRef="usd">-5764000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="id6ada2596cf84b118b49af7a6561fb79_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81Mi9mcmFnOjg0NDU1NTJiNGIyMzRjNGU4MDVjOWY5OWYyM2Y4NTEzL3RhYmxlOjViMGM3ZDc0Njk5OTRiMDViMjA5NDQzMWEzM2QyMzA5L3RhYmxlcmFuZ2U6NWIwYzdkNzQ2OTk5NGIwNWIyMDk0NDMxYTMzZDIzMDlfMy0yLTEtMS0xNzQxMA_2a3b03ba-dae8-4dfc-9a13-22bccff9f8da"
      unitRef="usd">-5764000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="ic9b0b6a3c69447bf8f151dfd98c14ac9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81Mi9mcmFnOjg0NDU1NTJiNGIyMzRjNGU4MDVjOWY5OWYyM2Y4NTEzL3RhYmxlOjViMGM3ZDc0Njk5OTRiMDViMjA5NDQzMWEzM2QyMzA5L3RhYmxlcmFuZ2U6NWIwYzdkNzQ2OTk5NGIwNWIyMDk0NDMxYTMzZDIzMDlfMy00LTEtMS0xNzQxMA_a3a3ce3c-c934-4db6-896e-fcc656bbb04d"
      unitRef="usd">-4222000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="ic9b0b6a3c69447bf8f151dfd98c14ac9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81Mi9mcmFnOjg0NDU1NTJiNGIyMzRjNGU4MDVjOWY5OWYyM2Y4NTEzL3RhYmxlOjViMGM3ZDc0Njk5OTRiMDViMjA5NDQzMWEzM2QyMzA5L3RhYmxlcmFuZ2U6NWIwYzdkNzQ2OTk5NGIwNWIyMDk0NDMxYTMzZDIzMDlfMy00LTEtMS0xNzQxMA_b8fbdae5-aed6-4747-aa29-15cd864d1e65"
      unitRef="usd">-4222000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81Mi9mcmFnOjg0NDU1NTJiNGIyMzRjNGU4MDVjOWY5OWYyM2Y4NTEzL3RhYmxlOjViMGM3ZDc0Njk5OTRiMDViMjA5NDQzMWEzM2QyMzA5L3RhYmxlcmFuZ2U6NWIwYzdkNzQ2OTk5NGIwNWIyMDk0NDMxYTMzZDIzMDlfMy02LTEtMS0xNzQxMA_06b3fa3f-fef9-4542-9822-4baafacb70b3"
      unitRef="usd">-17135000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81Mi9mcmFnOjg0NDU1NTJiNGIyMzRjNGU4MDVjOWY5OWYyM2Y4NTEzL3RhYmxlOjViMGM3ZDc0Njk5OTRiMDViMjA5NDQzMWEzM2QyMzA5L3RhYmxlcmFuZ2U6NWIwYzdkNzQ2OTk5NGIwNWIyMDk0NDMxYTMzZDIzMDlfMy02LTEtMS0xNzQxMA_f15d3676-4950-4b6c-99bc-54e230596b40"
      unitRef="usd">-17135000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81Mi9mcmFnOjg0NDU1NTJiNGIyMzRjNGU4MDVjOWY5OWYyM2Y4NTEzL3RhYmxlOjViMGM3ZDc0Njk5OTRiMDViMjA5NDQzMWEzM2QyMzA5L3RhYmxlcmFuZ2U6NWIwYzdkNzQ2OTk5NGIwNWIyMDk0NDMxYTMzZDIzMDlfMy04LTEtMS0xNzQxMA_6ecda25d-f619-408a-9200-9ff0360fd022"
      unitRef="usd">-13169000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81Mi9mcmFnOjg0NDU1NTJiNGIyMzRjNGU4MDVjOWY5OWYyM2Y4NTEzL3RhYmxlOjViMGM3ZDc0Njk5OTRiMDViMjA5NDQzMWEzM2QyMzA5L3RhYmxlcmFuZ2U6NWIwYzdkNzQ2OTk5NGIwNWIyMDk0NDMxYTMzZDIzMDlfMy04LTEtMS0xNzQxMA_d87e46ca-d592-456b-8669-a099aa4a18f1"
      unitRef="usd">-13169000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="id6ada2596cf84b118b49af7a6561fb79_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81Mi9mcmFnOjg0NDU1NTJiNGIyMzRjNGU4MDVjOWY5OWYyM2Y4NTEzL3RhYmxlOjViMGM3ZDc0Njk5OTRiMDViMjA5NDQzMWEzM2QyMzA5L3RhYmxlcmFuZ2U6NWIwYzdkNzQ2OTk5NGIwNWIyMDk0NDMxYTMzZDIzMDlfNi0yLTEtMS0xNzQxMA_e6ff927e-a540-40bd-9e99-298e98d30def"
      unitRef="shares">34569000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="id6ada2596cf84b118b49af7a6561fb79_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81Mi9mcmFnOjg0NDU1NTJiNGIyMzRjNGU4MDVjOWY5OWYyM2Y4NTEzL3RhYmxlOjViMGM3ZDc0Njk5OTRiMDViMjA5NDQzMWEzM2QyMzA5L3RhYmxlcmFuZ2U6NWIwYzdkNzQ2OTk5NGIwNWIyMDk0NDMxYTMzZDIzMDlfNi0yLTEtMS0xNzQxMA_fcb07b78-c8e7-4dee-a35f-92c57f5c6d73"
      unitRef="shares">34569000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ic9b0b6a3c69447bf8f151dfd98c14ac9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81Mi9mcmFnOjg0NDU1NTJiNGIyMzRjNGU4MDVjOWY5OWYyM2Y4NTEzL3RhYmxlOjViMGM3ZDc0Njk5OTRiMDViMjA5NDQzMWEzM2QyMzA5L3RhYmxlcmFuZ2U6NWIwYzdkNzQ2OTk5NGIwNWIyMDk0NDMxYTMzZDIzMDlfNi00LTEtMS0xNzQxMA_10122581-f14a-4142-954c-e581c04f3220"
      unitRef="shares">34330000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ic9b0b6a3c69447bf8f151dfd98c14ac9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81Mi9mcmFnOjg0NDU1NTJiNGIyMzRjNGU4MDVjOWY5OWYyM2Y4NTEzL3RhYmxlOjViMGM3ZDc0Njk5OTRiMDViMjA5NDQzMWEzM2QyMzA5L3RhYmxlcmFuZ2U6NWIwYzdkNzQ2OTk5NGIwNWIyMDk0NDMxYTMzZDIzMDlfNi00LTEtMS0xNzQxMA_e1310c63-cc37-4475-ac13-f89641521918"
      unitRef="shares">34330000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81Mi9mcmFnOjg0NDU1NTJiNGIyMzRjNGU4MDVjOWY5OWYyM2Y4NTEzL3RhYmxlOjViMGM3ZDc0Njk5OTRiMDViMjA5NDQzMWEzM2QyMzA5L3RhYmxlcmFuZ2U6NWIwYzdkNzQ2OTk5NGIwNWIyMDk0NDMxYTMzZDIzMDlfNi02LTEtMS0xNzQxMA_42a5bd45-5cf3-4d4b-8201-5d2689b77c79"
      unitRef="shares">34488000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81Mi9mcmFnOjg0NDU1NTJiNGIyMzRjNGU4MDVjOWY5OWYyM2Y4NTEzL3RhYmxlOjViMGM3ZDc0Njk5OTRiMDViMjA5NDQzMWEzM2QyMzA5L3RhYmxlcmFuZ2U6NWIwYzdkNzQ2OTk5NGIwNWIyMDk0NDMxYTMzZDIzMDlfNi02LTEtMS0xNzQxMA_5e3cc976-5197-4772-afac-436749f0113f"
      unitRef="shares">34488000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81Mi9mcmFnOjg0NDU1NTJiNGIyMzRjNGU4MDVjOWY5OWYyM2Y4NTEzL3RhYmxlOjViMGM3ZDc0Njk5OTRiMDViMjA5NDQzMWEzM2QyMzA5L3RhYmxlcmFuZ2U6NWIwYzdkNzQ2OTk5NGIwNWIyMDk0NDMxYTMzZDIzMDlfNi04LTEtMS0xNzQxMA_3c57e244-591d-4848-99a7-60f9b49bc3bc"
      unitRef="shares">34318000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81Mi9mcmFnOjg0NDU1NTJiNGIyMzRjNGU4MDVjOWY5OWYyM2Y4NTEzL3RhYmxlOjViMGM3ZDc0Njk5OTRiMDViMjA5NDQzMWEzM2QyMzA5L3RhYmxlcmFuZ2U6NWIwYzdkNzQ2OTk5NGIwNWIyMDk0NDMxYTMzZDIzMDlfNi04LTEtMS0xNzQxMA_c19a25d9-a94b-40c5-a805-beefd493682a"
      unitRef="shares">34318000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="id6ada2596cf84b118b49af7a6561fb79_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81Mi9mcmFnOjg0NDU1NTJiNGIyMzRjNGU4MDVjOWY5OWYyM2Y4NTEzL3RhYmxlOjViMGM3ZDc0Njk5OTRiMDViMjA5NDQzMWEzM2QyMzA5L3RhYmxlcmFuZ2U6NWIwYzdkNzQ2OTk5NGIwNWIyMDk0NDMxYTMzZDIzMDlfOS0yLTEtMS0xNzQxMA_430cea00-78a9-40ab-9d13-3cb0a30214df"
      unitRef="usdPerShare">-0.17</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="id6ada2596cf84b118b49af7a6561fb79_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81Mi9mcmFnOjg0NDU1NTJiNGIyMzRjNGU4MDVjOWY5OWYyM2Y4NTEzL3RhYmxlOjViMGM3ZDc0Njk5OTRiMDViMjA5NDQzMWEzM2QyMzA5L3RhYmxlcmFuZ2U6NWIwYzdkNzQ2OTk5NGIwNWIyMDk0NDMxYTMzZDIzMDlfOS0yLTEtMS0xNzQxMA_6983b76a-0aa6-4b3e-89d0-df62ced41be3"
      unitRef="usdPerShare">-0.17</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ic9b0b6a3c69447bf8f151dfd98c14ac9_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81Mi9mcmFnOjg0NDU1NTJiNGIyMzRjNGU4MDVjOWY5OWYyM2Y4NTEzL3RhYmxlOjViMGM3ZDc0Njk5OTRiMDViMjA5NDQzMWEzM2QyMzA5L3RhYmxlcmFuZ2U6NWIwYzdkNzQ2OTk5NGIwNWIyMDk0NDMxYTMzZDIzMDlfOS00LTEtMS0xNzQxMA_207b2936-6a05-422a-8b53-a3bfad0e7e2c"
      unitRef="usdPerShare">-0.12</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="ic9b0b6a3c69447bf8f151dfd98c14ac9_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81Mi9mcmFnOjg0NDU1NTJiNGIyMzRjNGU4MDVjOWY5OWYyM2Y4NTEzL3RhYmxlOjViMGM3ZDc0Njk5OTRiMDViMjA5NDQzMWEzM2QyMzA5L3RhYmxlcmFuZ2U6NWIwYzdkNzQ2OTk5NGIwNWIyMDk0NDMxYTMzZDIzMDlfOS00LTEtMS0xNzQxMA_50e1a700-1446-4171-85e0-3f209c9cbac1"
      unitRef="usdPerShare">-0.12</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81Mi9mcmFnOjg0NDU1NTJiNGIyMzRjNGU4MDVjOWY5OWYyM2Y4NTEzL3RhYmxlOjViMGM3ZDc0Njk5OTRiMDViMjA5NDQzMWEzM2QyMzA5L3RhYmxlcmFuZ2U6NWIwYzdkNzQ2OTk5NGIwNWIyMDk0NDMxYTMzZDIzMDlfOS02LTEtMS0xNzQxMA_0cdfae6c-c765-4b59-be65-df91281219ec"
      unitRef="usdPerShare">-0.50</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81Mi9mcmFnOjg0NDU1NTJiNGIyMzRjNGU4MDVjOWY5OWYyM2Y4NTEzL3RhYmxlOjViMGM3ZDc0Njk5OTRiMDViMjA5NDQzMWEzM2QyMzA5L3RhYmxlcmFuZ2U6NWIwYzdkNzQ2OTk5NGIwNWIyMDk0NDMxYTMzZDIzMDlfOS02LTEtMS0xNzQxMA_10523e10-af4b-4c4a-afcf-38d26c1b5144"
      unitRef="usdPerShare">-0.50</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81Mi9mcmFnOjg0NDU1NTJiNGIyMzRjNGU4MDVjOWY5OWYyM2Y4NTEzL3RhYmxlOjViMGM3ZDc0Njk5OTRiMDViMjA5NDQzMWEzM2QyMzA5L3RhYmxlcmFuZ2U6NWIwYzdkNzQ2OTk5NGIwNWIyMDk0NDMxYTMzZDIzMDlfOS04LTEtMS0xNzQxMA_129f8030-4ae2-4ea2-9dca-837a0ff1a867"
      unitRef="usdPerShare">-0.38</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81Mi9mcmFnOjg0NDU1NTJiNGIyMzRjNGU4MDVjOWY5OWYyM2Y4NTEzL3RhYmxlOjViMGM3ZDc0Njk5OTRiMDViMjA5NDQzMWEzM2QyMzA5L3RhYmxlcmFuZ2U6NWIwYzdkNzQ2OTk5NGIwNWIyMDk0NDMxYTMzZDIzMDlfOS04LTEtMS0xNzQxMA_4f320c74-1566-453f-916d-4ba561d349b3"
      unitRef="usdPerShare">-0.38</us-gaap:EarningsPerShareBasic>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia08951cf06e540858ba8bf177ab2b743_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81Mi9mcmFnOjg0NDU1NTJiNGIyMzRjNGU4MDVjOWY5OWYyM2Y4NTEzL3RhYmxlOjViMGM3ZDc0Njk5OTRiMDViMjA5NDQzMWEzM2QyMzA5L3RhYmxlcmFuZ2U6NWIwYzdkNzQ2OTk5NGIwNWIyMDk0NDMxYTMzZDIzMDlfMTMtMi0xLTEtMTc0MTA_7bf47bc5-5696-497c-88fa-da4d0d61e15f"
      unitRef="shares">6635000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i42b97828049d4ebdaf08135fff616832_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81Mi9mcmFnOjg0NDU1NTJiNGIyMzRjNGU4MDVjOWY5OWYyM2Y4NTEzL3RhYmxlOjViMGM3ZDc0Njk5OTRiMDViMjA5NDQzMWEzM2QyMzA5L3RhYmxlcmFuZ2U6NWIwYzdkNzQ2OTk5NGIwNWIyMDk0NDMxYTMzZDIzMDlfMTMtNC0xLTEtMTc0MTA_80a147fb-56db-4d3b-a4d8-710d2d98f04d"
      unitRef="shares">5534000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ib5e3c2254a1e4a9db8e760889439789b_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81Mi9mcmFnOjg0NDU1NTJiNGIyMzRjNGU4MDVjOWY5OWYyM2Y4NTEzL3RhYmxlOjViMGM3ZDc0Njk5OTRiMDViMjA5NDQzMWEzM2QyMzA5L3RhYmxlcmFuZ2U6NWIwYzdkNzQ2OTk5NGIwNWIyMDk0NDMxYTMzZDIzMDlfMTMtNi0xLTEtMTc0MTA_2c207726-99a1-44be-a7c0-e03678946036"
      unitRef="shares">6635000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i87a2f188443846f38dac55f8e2d32c45_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81Mi9mcmFnOjg0NDU1NTJiNGIyMzRjNGU4MDVjOWY5OWYyM2Y4NTEzL3RhYmxlOjViMGM3ZDc0Njk5OTRiMDViMjA5NDQzMWEzM2QyMzA5L3RhYmxlcmFuZ2U6NWIwYzdkNzQ2OTk5NGIwNWIyMDk0NDMxYTMzZDIzMDlfMTMtOC0xLTEtMTc0MTA_3ab9685b-923b-4a58-8013-c5ea80c652b2"
      unitRef="shares">5534000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81NS9mcmFnOjhiZmNkOGRlMWFlODQwNzc4YzM3NTNjNDllMjc2NWMxL3RleHRyZWdpb246OGJmY2Q4ZGUxYWU4NDA3NzhjMzc1M2M0OWUyNzY1YzFfMTY5MA_0962a108-3f04-45e9-a88d-7c73dbb5753c">STOCK-BASED COMPENSATION &lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Company&#x2019;s stock option plans, the Board of Directors may grant restricted stock and options to purchase common shares to the Company's employees, officers, directors and consultants. The Company accounts for stock options in accordance with FASB ASC Topic 718, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Compensation - Stock Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, with stock-based compensation expense recognized over the vesting period based on the fair value on the grant date utilizing the Black-Scholes model, which includes a number of estimates that affect the grant date fair value and the amount of expense to recognize.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized approximately $1,692,000 and $5,056,000, respectively, in stock-based compensation expense during the three and nine months ended September 30, 2022, as compared with $1,184,000 and $3,747,000, respectively, for the three and nine months ended September 30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock option activity is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted average exercise price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,397,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,692,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(299,006)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled and forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(155,697)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at September&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,635,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company allows stock option holders to exercise stock-based awards by surrendering stock-based awards with an intrinsic value equal to the cumulative exercise price of the stock-based awards being exercised, referred to as net settlements. These surrenders are included in stock options exercised in the options rollforward above. For the three months ended September&#160;30, 2022 and 2021, respectively, we received 55,853 and 37,049 options as payment in the exercise of 33,313 and 13,285 options. For the nine months ended September 30, 2022 and 2021, respectively, we received 92,520 and 59,104 options as payment in the exercise of 72,313 and 39,312 options.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Common shares required to be issued upon the exercise of stock options would be issued from authorized and unissued shares. The Company calculated the grant date fair value of options granted in 2022 (&#x201c;2022 Grants&#x201d;) utilizing a Black-Scholes model.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:58.771%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.815%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.825%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.133%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.827%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022 Grants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Strike price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$5.10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$10.56&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.9%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69.6%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.5%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81NS9mcmFnOjhiZmNkOGRlMWFlODQwNzc4YzM3NTNjNDllMjc2NWMxL3RleHRyZWdpb246OGJmY2Q4ZGUxYWU4NDA3NzhjMzc1M2M0OWUyNzY1YzFfMTY5OA_fed5cfcd-6565-4d7b-b8d5-c2afd1905ad9">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Company&#x2019;s stock option plans, the Board of Directors may grant restricted stock and options to purchase common shares to the Company's employees, officers, directors and consultants. The Company accounts for stock options in accordance with FASB ASC Topic 718, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Compensation - Stock Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, with stock-based compensation expense recognized over the vesting period based on the fair value on the grant date utilizing the Black-Scholes model, which includes a number of estimates that affect the grant date fair value and the amount of expense to recognize.&lt;/span&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id6ada2596cf84b118b49af7a6561fb79_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81NS9mcmFnOjhiZmNkOGRlMWFlODQwNzc4YzM3NTNjNDllMjc2NWMxL3RleHRyZWdpb246OGJmY2Q4ZGUxYWU4NDA3NzhjMzc1M2M0OWUyNzY1YzFfNjUw_dbb803ce-ea65-4e2d-a960-0c421e3a3605"
      unitRef="usd">1692000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81NS9mcmFnOjhiZmNkOGRlMWFlODQwNzc4YzM3NTNjNDllMjc2NWMxL3RleHRyZWdpb246OGJmY2Q4ZGUxYWU4NDA3NzhjMzc1M2M0OWUyNzY1YzFfNjU3_941d98ce-8065-424b-88db-185b418bd0a1"
      unitRef="usd">5056000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic9b0b6a3c69447bf8f151dfd98c14ac9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81NS9mcmFnOjhiZmNkOGRlMWFlODQwNzc4YzM3NTNjNDllMjc2NWMxL3RleHRyZWdpb246OGJmY2Q4ZGUxYWU4NDA3NzhjMzc1M2M0OWUyNzY1YzFfNzUz_e2712c6b-9e70-4b4b-8b41-d4c299706133"
      unitRef="usd">1184000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81NS9mcmFnOjhiZmNkOGRlMWFlODQwNzc4YzM3NTNjNDllMjc2NWMxL3RleHRyZWdpb246OGJmY2Q4ZGUxYWU4NDA3NzhjMzc1M2M0OWUyNzY1YzFfNzYw_652bda87-ed9e-4c7f-9732-0ad3908eee53"
      unitRef="usd">3747000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81NS9mcmFnOjhiZmNkOGRlMWFlODQwNzc4YzM3NTNjNDllMjc2NWMxL3RleHRyZWdpb246OGJmY2Q4ZGUxYWU4NDA3NzhjMzc1M2M0OWUyNzY1YzFfMTY5Mg_546ddaa2-b426-42ec-91c9-351d12edfe1c">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock option activity is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted average exercise price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,397,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,692,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(299,006)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled and forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(155,697)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at September&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,635,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81NS9mcmFnOjhiZmNkOGRlMWFlODQwNzc4YzM3NTNjNDllMjc2NWMxL3RhYmxlOjNmNmVlZDZmMTQ4NDQ1YjU5NDVhYzNhNzg3MDMwZjliL3RhYmxlcmFuZ2U6M2Y2ZWVkNmYxNDg0NDViNTk0NWFjM2E3ODcwMzBmOWJfNS0xLTEtMS0xNzQxMA_bee7d836-2725-46b3-b343-28e0ed8df902"
      unitRef="shares">5397691</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i6366ccfc5be94d939469c44eee70e010_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81NS9mcmFnOjhiZmNkOGRlMWFlODQwNzc4YzM3NTNjNDllMjc2NWMxL3RhYmxlOjNmNmVlZDZmMTQ4NDQ1YjU5NDVhYzNhNzg3MDMwZjliL3RhYmxlcmFuZ2U6M2Y2ZWVkNmYxNDg0NDViNTk0NWFjM2E3ODcwMzBmOWJfNS0zLTEtMS0xNzQxMA_6d564b70-6a3f-425a-8d04-0eb5a972cd11"
      unitRef="usdPerShare">5.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81NS9mcmFnOjhiZmNkOGRlMWFlODQwNzc4YzM3NTNjNDllMjc2NWMxL3RhYmxlOjNmNmVlZDZmMTQ4NDQ1YjU5NDVhYzNhNzg3MDMwZjliL3RhYmxlcmFuZ2U6M2Y2ZWVkNmYxNDg0NDViNTk0NWFjM2E3ODcwMzBmOWJfNi0xLTEtMS0xNzQxMA_e2fe6c5d-1afb-45aa-9a8b-b5f07e7788d6"
      unitRef="shares">1692419</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81NS9mcmFnOjhiZmNkOGRlMWFlODQwNzc4YzM3NTNjNDllMjc2NWMxL3RhYmxlOjNmNmVlZDZmMTQ4NDQ1YjU5NDVhYzNhNzg3MDMwZjliL3RhYmxlcmFuZ2U6M2Y2ZWVkNmYxNDg0NDViNTk0NWFjM2E3ODcwMzBmOWJfNi0zLTEtMS0xNzQxMA_cc0d11d0-8670-46cd-a8af-f83499fc4bf9"
      unitRef="usdPerShare">10.64</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81NS9mcmFnOjhiZmNkOGRlMWFlODQwNzc4YzM3NTNjNDllMjc2NWMxL3RhYmxlOjNmNmVlZDZmMTQ4NDQ1YjU5NDVhYzNhNzg3MDMwZjliL3RhYmxlcmFuZ2U6M2Y2ZWVkNmYxNDg0NDViNTk0NWFjM2E3ODcwMzBmOWJfNy0xLTEtMS0xNzQxMA_54986b89-6345-4b21-a357-253761704a0d"
      unitRef="shares">299006</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81NS9mcmFnOjhiZmNkOGRlMWFlODQwNzc4YzM3NTNjNDllMjc2NWMxL3RhYmxlOjNmNmVlZDZmMTQ4NDQ1YjU5NDVhYzNhNzg3MDMwZjliL3RhYmxlcmFuZ2U6M2Y2ZWVkNmYxNDg0NDViNTk0NWFjM2E3ODcwMzBmOWJfNy0zLTEtMS0xNzQxMA_5ae75b1d-2fe9-492d-823e-f23fca17456e"
      unitRef="usdPerShare">4.57</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81NS9mcmFnOjhiZmNkOGRlMWFlODQwNzc4YzM3NTNjNDllMjc2NWMxL3RhYmxlOjNmNmVlZDZmMTQ4NDQ1YjU5NDVhYzNhNzg3MDMwZjliL3RhYmxlcmFuZ2U6M2Y2ZWVkNmYxNDg0NDViNTk0NWFjM2E3ODcwMzBmOWJfOC0xLTEtMS0xNzQxMA_d2173c40-b45b-44c7-9af3-c274ce5ff46c"
      unitRef="shares">155697</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81NS9mcmFnOjhiZmNkOGRlMWFlODQwNzc4YzM3NTNjNDllMjc2NWMxL3RhYmxlOjNmNmVlZDZmMTQ4NDQ1YjU5NDVhYzNhNzg3MDMwZjliL3RhYmxlcmFuZ2U6M2Y2ZWVkNmYxNDg0NDViNTk0NWFjM2E3ODcwMzBmOWJfOC0zLTEtMS0xNzQxMA_7dd5da29-4483-4837-b061-d36ab229522a"
      unitRef="usdPerShare">9.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81NS9mcmFnOjhiZmNkOGRlMWFlODQwNzc4YzM3NTNjNDllMjc2NWMxL3RhYmxlOjNmNmVlZDZmMTQ4NDQ1YjU5NDVhYzNhNzg3MDMwZjliL3RhYmxlcmFuZ2U6M2Y2ZWVkNmYxNDg0NDViNTk0NWFjM2E3ODcwMzBmOWJfOS0xLTEtMS0xNzQxMA_571213d1-8164-4555-939d-290fdb8654ad"
      unitRef="shares">6635409</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81NS9mcmFnOjhiZmNkOGRlMWFlODQwNzc4YzM3NTNjNDllMjc2NWMxL3RhYmxlOjNmNmVlZDZmMTQ4NDQ1YjU5NDVhYzNhNzg3MDMwZjliL3RhYmxlcmFuZ2U6M2Y2ZWVkNmYxNDg0NDViNTk0NWFjM2E3ODcwMzBmOWJfOS0zLTEtMS0xNzQxMA_ae4ea06c-a2e2-42e2-9a0a-7baa3fadc9b8"
      unitRef="usdPerShare">7.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <apyx:StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived
      contextRef="id6ada2596cf84b118b49af7a6561fb79_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81NS9mcmFnOjhiZmNkOGRlMWFlODQwNzc4YzM3NTNjNDllMjc2NWMxL3RleHRyZWdpb246OGJmY2Q4ZGUxYWU4NDA3NzhjMzc1M2M0OWUyNzY1YzFfMTI1MQ_077e1d69-cb60-4b0e-a988-66a9a64e1558"
      unitRef="shares">55853</apyx:StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived>
    <apyx:StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived
      contextRef="ic9b0b6a3c69447bf8f151dfd98c14ac9_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81NS9mcmFnOjhiZmNkOGRlMWFlODQwNzc4YzM3NTNjNDllMjc2NWMxL3RleHRyZWdpb246OGJmY2Q4ZGUxYWU4NDA3NzhjMzc1M2M0OWUyNzY1YzFfMTI1OA_346a2cc5-d48c-4994-92f6-8c49ad016efb"
      unitRef="shares">37049</apyx:StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived>
    <apyx:StockIssuedDuringPeriodSharesStockSwaps
      contextRef="id6ada2596cf84b118b49af7a6561fb79_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81NS9mcmFnOjhiZmNkOGRlMWFlODQwNzc4YzM3NTNjNDllMjc2NWMxL3RleHRyZWdpb246OGJmY2Q4ZGUxYWU4NDA3NzhjMzc1M2M0OWUyNzY1YzFfMTI5OQ_5342ceb9-46ce-4da5-8b74-96b7c6b5e396"
      unitRef="shares">33313</apyx:StockIssuedDuringPeriodSharesStockSwaps>
    <apyx:StockIssuedDuringPeriodSharesStockSwaps
      contextRef="ic9b0b6a3c69447bf8f151dfd98c14ac9_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81NS9mcmFnOjhiZmNkOGRlMWFlODQwNzc4YzM3NTNjNDllMjc2NWMxL3RleHRyZWdpb246OGJmY2Q4ZGUxYWU4NDA3NzhjMzc1M2M0OWUyNzY1YzFfMTMwNg_3ae273e7-ad08-44a9-9981-3a9d8557c78a"
      unitRef="shares">13285</apyx:StockIssuedDuringPeriodSharesStockSwaps>
    <apyx:StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81NS9mcmFnOjhiZmNkOGRlMWFlODQwNzc4YzM3NTNjNDllMjc2NWMxL3RleHRyZWdpb246OGJmY2Q4ZGUxYWU4NDA3NzhjMzc1M2M0OWUyNzY1YzFfMTM2Mw_5a006506-c145-4642-908b-edd512d77ba0"
      unitRef="shares">92520</apyx:StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived>
    <apyx:StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived
      contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81NS9mcmFnOjhiZmNkOGRlMWFlODQwNzc4YzM3NTNjNDllMjc2NWMxL3RleHRyZWdpb246OGJmY2Q4ZGUxYWU4NDA3NzhjMzc1M2M0OWUyNzY1YzFfMTM3MA_fa139795-7019-4c5d-a4b2-0460e307c932"
      unitRef="shares">59104</apyx:StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived>
    <apyx:StockIssuedDuringPeriodSharesStockSwaps
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81NS9mcmFnOjhiZmNkOGRlMWFlODQwNzc4YzM3NTNjNDllMjc2NWMxL3RleHRyZWdpb246OGJmY2Q4ZGUxYWU4NDA3NzhjMzc1M2M0OWUyNzY1YzFfMTQxMQ_d991c690-140c-437e-89b1-08d1fe28378f"
      unitRef="shares">72313</apyx:StockIssuedDuringPeriodSharesStockSwaps>
    <apyx:StockIssuedDuringPeriodSharesStockSwaps
      contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81NS9mcmFnOjhiZmNkOGRlMWFlODQwNzc4YzM3NTNjNDllMjc2NWMxL3RleHRyZWdpb246OGJmY2Q4ZGUxYWU4NDA3NzhjMzc1M2M0OWUyNzY1YzFfMTQxOA_c9f86f26-5092-4037-bf10-7d90b29afc5d"
      unitRef="shares">39312</apyx:StockIssuedDuringPeriodSharesStockSwaps>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81NS9mcmFnOjhiZmNkOGRlMWFlODQwNzc4YzM3NTNjNDllMjc2NWMxL3RleHRyZWdpb246OGJmY2Q4ZGUxYWU4NDA3NzhjMzc1M2M0OWUyNzY1YzFfMTcwMQ_4dbef092-ad80-42c4-911a-757b3113e5db">The Company calculated the grant date fair value of options granted in 2022 (&#x201c;2022 Grants&#x201d;) utilizing a Black-Scholes model.&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:58.771%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.815%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.825%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.133%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.827%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022 Grants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Strike price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$5.10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$10.56&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.9%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69.6%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.5%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="iee9cabca77f2439a98f1d745e8aa8fbf_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81NS9mcmFnOjhiZmNkOGRlMWFlODQwNzc4YzM3NTNjNDllMjc2NWMxL3RhYmxlOjYyMTUzMTA2YjM3MTQ2MjNhOWY0Yjc3N2M0MzUwOTQ0L3RhYmxlcmFuZ2U6NjIxNTMxMDZiMzcxNDYyM2E5ZjRiNzc3YzQzNTA5NDRfMS0xLTEtMS0xNzQxMA_b7f77e1b-a333-42ae-bd30-2891df66cc5f"
      unitRef="usdPerShare">5.10</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i569c520a81a0408e8dcae24590fd7f45_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81NS9mcmFnOjhiZmNkOGRlMWFlODQwNzc4YzM3NTNjNDllMjc2NWMxL3RhYmxlOjYyMTUzMTA2YjM3MTQ2MjNhOWY0Yjc3N2M0MzUwOTQ0L3RhYmxlcmFuZ2U6NjIxNTMxMDZiMzcxNDYyM2E5ZjRiNzc3YzQzNTA5NDRfMS0zLTEtMS0xNzQxMA_3724c2f2-31a5-463e-8155-c06aa2b7c362"
      unitRef="usdPerShare">10.56</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="iee9cabca77f2439a98f1d745e8aa8fbf_D20220101-20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81NS9mcmFnOjhiZmNkOGRlMWFlODQwNzc4YzM3NTNjNDllMjc2NWMxL3RhYmxlOjYyMTUzMTA2YjM3MTQ2MjNhOWY0Yjc3N2M0MzUwOTQ0L3RhYmxlcmFuZ2U6NjIxNTMxMDZiMzcxNDYyM2E5ZjRiNzc3YzQzNTA5NDRfMi0xLTEtMS0xNzQxMA_d53fef75-492e-4949-8812-726efecaddec"
      unitRef="number">0.016</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i569c520a81a0408e8dcae24590fd7f45_D20220101-20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81NS9mcmFnOjhiZmNkOGRlMWFlODQwNzc4YzM3NTNjNDllMjc2NWMxL3RhYmxlOjYyMTUzMTA2YjM3MTQ2MjNhOWY0Yjc3N2M0MzUwOTQ0L3RhYmxlcmFuZ2U6NjIxNTMxMDZiMzcxNDYyM2E5ZjRiNzc3YzQzNTA5NDRfMi0zLTEtMS0xNzQxMA_02205b0a-3c93-4e47-b906-119b5fe0cb63"
      unitRef="number">0.039</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81NS9mcmFnOjhiZmNkOGRlMWFlODQwNzc4YzM3NTNjNDllMjc2NWMxL3RhYmxlOjYyMTUzMTA2YjM3MTQ2MjNhOWY0Yjc3N2M0MzUwOTQ0L3RhYmxlcmFuZ2U6NjIxNTMxMDZiMzcxNDYyM2E5ZjRiNzc3YzQzNTA5NDRfMy0xLTEtMS0xNzQxMA_024d421a-2599-41e7-b3e7-fc0626055095"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="iee9cabca77f2439a98f1d745e8aa8fbf_D20220101-20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81NS9mcmFnOjhiZmNkOGRlMWFlODQwNzc4YzM3NTNjNDllMjc2NWMxL3RhYmxlOjYyMTUzMTA2YjM3MTQ2MjNhOWY0Yjc3N2M0MzUwOTQ0L3RhYmxlcmFuZ2U6NjIxNTMxMDZiMzcxNDYyM2E5ZjRiNzc3YzQzNTA5NDRfNC0xLTEtMS0xNzQxMA_62d3043c-d72a-4d26-a390-d2e12cf21933"
      unitRef="number">0.696</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i569c520a81a0408e8dcae24590fd7f45_D20220101-20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81NS9mcmFnOjhiZmNkOGRlMWFlODQwNzc4YzM3NTNjNDllMjc2NWMxL3RhYmxlOjYyMTUzMTA2YjM3MTQ2MjNhOWY0Yjc3N2M0MzUwOTQ0L3RhYmxlcmFuZ2U6NjIxNTMxMDZiMzcxNDYyM2E5ZjRiNzc3YzQzNTA5NDRfNC0zLTEtMS0xNzQxMA_cf16d789-f69b-4b8c-98bf-4be7c66c5e44"
      unitRef="number">0.785</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81NS9mcmFnOjhiZmNkOGRlMWFlODQwNzc4YzM3NTNjNDllMjc2NWMxL3RhYmxlOjYyMTUzMTA2YjM3MTQ2MjNhOWY0Yjc3N2M0MzUwOTQ0L3RhYmxlcmFuZ2U6NjIxNTMxMDZiMzcxNDYyM2E5ZjRiNzc3YzQzNTA5NDRfNS0xLTEtMS0xNzQxMA_c8eca355-11fd-487f-9393-956494b2817e">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i569c520a81a0408e8dcae24590fd7f45_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81NS9mcmFnOjhiZmNkOGRlMWFlODQwNzc4YzM3NTNjNDllMjc2NWMxL3RhYmxlOjYyMTUzMTA2YjM3MTQ2MjNhOWY0Yjc3N2M0MzUwOTQ0L3RhYmxlcmFuZ2U6NjIxNTMxMDZiMzcxNDYyM2E5ZjRiNzc3YzQzNTA5NDRfNS0zLTEtMS0xNzQxMA_65d7fde4-8716-4ca6-b1c1-bfcf3547b82f">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81OC9mcmFnOjhlNGI2OTRhOTAzYTQ5ZDY5ZGYxNzk5MjA2ODI0ZDk0L3RleHRyZWdpb246OGU0YjY5NGE5MDNhNDlkNjlkZjE3OTkyMDY4MjRkOTRfMTgzNw_35081693-6efc-4d66-ab6a-ff3c69b230f3">INCOME TAXES Income tax expense was approximately $50,000 and $73,000 with effective tax rates of (0.9)% and (1.8)% for the three months ended September&#160;30, 2022 and 2021, respectively. Income tax expense was approximately $216,000 and $246,000 with effective tax rates of (1.3)% and (1.9)% for the nine months ended September 30, 2022 and 2021, respectively. For the three and nine months ended September&#160;30, 2022 and 2021, the effective rates differ from the statutory rate primarily due to the full valuation allowance recorded on the net operating loss (&#x201c;NOL&#x201d;) generated during the period, combined with interest and penalties on uncertain tax positions. The Company has gross unrecognized tax benefits of approximately $1,313,000 at September&#160;30, 2022. It recognized accrued interest and penalties related to unrecognized tax benefits in the provision for income taxes in the condensed consolidated financial statements. As of September&#160;30, 2022, the Company had approximately $711,000 in accrued interest and penalties related to unrecognized tax benefits. Included in the income tax expense for the three months ended September&#160;30, 2022 and 2021, respectively, are approximately $54,000 and $52,000 of interest and penalties on the Company's uncertain tax positions. Included in the income tax expense for the nine months ended September 30, 2022 and 2021, respectively, are approximately $160,000 and $152,000 of interest and penalties on the Company's uncertain tax positions. If the Company were to prevail on all uncertain tax positions, the resulting impact will be material as the Company will recognize approximately $2,024,000 of income tax benefits in the consolidated statement of operations. During June 2022, the Company was notified by the Internal Revenue Service (&#x201c;IRS&#x201d;) that it is examining the Company&#x2019;s 2018, 2019 and 2020 federal income tax returns. The examination is expected to be completed no later than May 2023. It is expected that all of the uncertain tax positions should be resolved with the completion of the IRS examination.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="id6ada2596cf84b118b49af7a6561fb79_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81OC9mcmFnOjhlNGI2OTRhOTAzYTQ5ZDY5ZGYxNzk5MjA2ODI0ZDk0L3RleHRyZWdpb246OGU0YjY5NGE5MDNhNDlkNjlkZjE3OTkyMDY4MjRkOTRfNjc_3af1d98a-1a69-4972-afc1-937034c7d66c"
      unitRef="usd">50000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ic9b0b6a3c69447bf8f151dfd98c14ac9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81OC9mcmFnOjhlNGI2OTRhOTAzYTQ5ZDY5ZGYxNzk5MjA2ODI0ZDk0L3RleHRyZWdpb246OGU0YjY5NGE5MDNhNDlkNjlkZjE3OTkyMDY4MjRkOTRfNzQ_465642b7-fd7e-46de-bb20-d672486577fa"
      unitRef="usd">73000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="id6ada2596cf84b118b49af7a6561fb79_D20220701-20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81OC9mcmFnOjhlNGI2OTRhOTAzYTQ5ZDY5ZGYxNzk5MjA2ODI0ZDk0L3RleHRyZWdpb246OGU0YjY5NGE5MDNhNDlkNjlkZjE3OTkyMDY4MjRkOTRfMTA1_82389a41-a4a2-4891-ab24-5f396fdcb3ed"
      unitRef="number">-0.009</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="ic9b0b6a3c69447bf8f151dfd98c14ac9_D20210701-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81OC9mcmFnOjhlNGI2OTRhOTAzYTQ5ZDY5ZGYxNzk5MjA2ODI0ZDk0L3RleHRyZWdpb246OGU0YjY5NGE5MDNhNDlkNjlkZjE3OTkyMDY4MjRkOTRfMTEy_90420106-3203-438f-ac46-0b5b90a032fd"
      unitRef="number">-0.018</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81OC9mcmFnOjhlNGI2OTRhOTAzYTQ5ZDY5ZGYxNzk5MjA2ODI0ZDk0L3RleHRyZWdpb246OGU0YjY5NGE5MDNhNDlkNjlkZjE3OTkyMDY4MjRkOTRfMjA0_e79a2880-7410-4b9f-84f2-e6d5abcb4e58"
      unitRef="usd">216000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81OC9mcmFnOjhlNGI2OTRhOTAzYTQ5ZDY5ZGYxNzk5MjA2ODI0ZDk0L3RleHRyZWdpb246OGU0YjY5NGE5MDNhNDlkNjlkZjE3OTkyMDY4MjRkOTRfMjEx_d87dfbe7-bf9d-481d-a66f-0a4bdbff16f5"
      unitRef="usd">246000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81OC9mcmFnOjhlNGI2OTRhOTAzYTQ5ZDY5ZGYxNzk5MjA2ODI0ZDk0L3RleHRyZWdpb246OGU0YjY5NGE5MDNhNDlkNjlkZjE3OTkyMDY4MjRkOTRfMjQy_6097ccbc-5848-42fd-afd1-7c6e7df9b434"
      unitRef="number">-0.013</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81OC9mcmFnOjhlNGI2OTRhOTAzYTQ5ZDY5ZGYxNzk5MjA2ODI0ZDk0L3RleHRyZWdpb246OGU0YjY5NGE5MDNhNDlkNjlkZjE3OTkyMDY4MjRkOTRfMjQ5_9cc69296-d5a5-45ec-b423-805d48a4f748"
      unitRef="number">-0.019</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81OC9mcmFnOjhlNGI2OTRhOTAzYTQ5ZDY5ZGYxNzk5MjA2ODI0ZDk0L3RleHRyZWdpb246OGU0YjY5NGE5MDNhNDlkNjlkZjE3OTkyMDY4MjRkOTRfNjIz_90ccdd0d-11aa-478f-bd69-984e5d8d5f88"
      unitRef="usd">1313000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81OC9mcmFnOjhlNGI2OTRhOTAzYTQ5ZDY5ZGYxNzk5MjA2ODI0ZDk0L3RleHRyZWdpb246OGU0YjY5NGE5MDNhNDlkNjlkZjE3OTkyMDY4MjRkOTRfODQx_d16685a2-71c8-4128-98b1-a8d04bb51109"
      unitRef="usd">711000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="id6ada2596cf84b118b49af7a6561fb79_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81OC9mcmFnOjhlNGI2OTRhOTAzYTQ5ZDY5ZGYxNzk5MjA2ODI0ZDk0L3RleHRyZWdpb246OGU0YjY5NGE5MDNhNDlkNjlkZjE3OTkyMDY4MjRkOTRfMTAyMQ_a1b4c59b-162e-4320-8efe-53d803a99138"
      unitRef="usd">54000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="ic9b0b6a3c69447bf8f151dfd98c14ac9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81OC9mcmFnOjhlNGI2OTRhOTAzYTQ5ZDY5ZGYxNzk5MjA2ODI0ZDk0L3RleHRyZWdpb246OGU0YjY5NGE5MDNhNDlkNjlkZjE3OTkyMDY4MjRkOTRfMTAyOA_e27c656d-c98c-4223-aa49-9a8d3889d90f"
      unitRef="usd">52000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81OC9mcmFnOjhlNGI2OTRhOTAzYTQ5ZDY5ZGYxNzk5MjA2ODI0ZDk0L3RleHRyZWdpb246OGU0YjY5NGE5MDNhNDlkNjlkZjE3OTkyMDY4MjRkOTRfMTE4NQ_5c26a4c7-2148-415e-b65b-9466eb506e8c"
      unitRef="usd">160000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81OC9mcmFnOjhlNGI2OTRhOTAzYTQ5ZDY5ZGYxNzk5MjA2ODI0ZDk0L3RleHRyZWdpb246OGU0YjY5NGE5MDNhNDlkNjlkZjE3OTkyMDY4MjRkOTRfMTE5Mg_5daf5587-2b12-48a6-ad51-e4bee2a3606e"
      unitRef="usd">152000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV81OC9mcmFnOjhlNGI2OTRhOTAzYTQ5ZDY5ZGYxNzk5MjA2ODI0ZDk0L3RleHRyZWdpb246OGU0YjY5NGE5MDNhNDlkNjlkZjE3OTkyMDY4MjRkOTRfMTQwOA_c66ac85a-51b2-4c0a-89c6-640bdff72f1e"
      unitRef="usd">2024000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82MS9mcmFnOmQ5MzUyMGI2YmIyYjQxYjdiYzQ0MDAwN2Y1NmM2OGZkL3RleHRyZWdpb246ZDkzNTIwYjZiYjJiNDFiN2JjNDQwMDA3ZjU2YzY4ZmRfNTQxNA_c2a0731d-116f-4b54-a7de-a4c8e526eaf7">COMMITMENTS AND CONTINGENCIES&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Litigation &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The medical device industry is characterized by frequent claims and litigation, and the Company may become subject to various claims, lawsuits and proceedings in the ordinary course of our business. Such claims may include claims by current or former employees, distributors and competitors, claims concerning the marketing and promotion of our products and product liability claims.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is involved in a number of legal actions relating to the use of our Helium Plasma technology. The outcomes of these legal actions are not within the Company&#x2019;s control and may not be known for prolonged periods of time. It believes that such claims are adequately covered by insurance; however, in the case of one of the Company&#x2019;s carriers, the Company is in a dispute regarding the total level of coverage available. Notwithstanding the foregoing, in the opinion of management, the Company has meritorious defenses, and such claims are not expected, individually or in the aggregate, to result in a material, adverse effect on its financial condition, results of operations and cash flows. However, in the event that damages exceed the aggregate coverage limits of the Company&#x2019;s policies or if its insurance carriers disclaim coverage, management believes it is possible that costs associated with these claims could have a material adverse impact on the consolidated financial condition, results of operations and cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During December 2021, the Company provided notice of contract termination to an international distributor of the Company. In March 2022, the Company received a letter from the former distributor citing improper contract termination and alleging damages. While the matter is still in the early stages, management has determined that a loss is probable and that a range of estimated losses is approximately $250,000 to $1,000,000. The Company has recorded an estimated loss of $250,000 in professional services in the accompanying Condensed Consolidated Statement of Operations for the nine months ended September 30, 2022. It is at least possible that a change in the actual amount of loss will occur in the near term, though management expects the actual amount of loss will be within the estimated range of losses.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, as previously disclosed with the U.S. Securities and Exchange Commission on the Company&#x2019;s Current Report on Form 8-K filed June 7, 2022, on June 6, 2022, a complaint (the &#x201c;Complaint&#x201d;) was filed in the United States District Court for the Middle District of Florida by plaintiff William E. Hattaway, individually and on behalf of all others similarly situated against the Company, Charles D. Goodwin (&#x201c;Goodwin&#x201d;), the Company&#x2019;s President and Chief Executive Officer and a member of the Company&#x2019;s Board of Directors, and Tara Semb (&#x201c;Semb&#x201d;), the Company&#x2019;s Chief Financial Officer, Treasurer and Secretary, alleging violations by the Company, Goodwin and Semb of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder, primarily related to certain public statements and disclosures concerning the off-label usage of certain of the Company&#x2019;s Advanced Energy products and the impact such usage would have on the Company&#x2019;s business, operations and prospects. The Complaint seeks an unspecified amount of damages. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Although the ultimate outcome of this matter cannot be determined with certainty, the Company believes that the allegations stated in the Complaint are without merit. The Company, Goodwin and Semb intend to defend themselves vigorously in the suit. In the opinion of management, such claims are adequately covered by insurance, however, in the event that damages exceed the aggregate coverage limits of our policy or if our insurance carriers disclaim coverage, we believe it is possible that costs associated with this claim could have a material adverse impact on our consolidated results of operations, financial &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;position or cash flows. While the matter is still in the early stages, management has determined that a loss is probable and that a range of estimated losses is approximately $475,000 to $2,500,000. The Company has recorded an estimated loss of $475,000 in professional services in the accompanying Condensed Consolidated Statement of Operations for the nine months ended September 30, 2022. It is at least possible that a change in the actual amount of loss will occur in the near term, though management expects the actual amount of loss will be within the estimated range of losses.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accrues a liability in its consolidated financial statements for these actions when a loss is known or considered probable and the amount can be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is recorded. If a loss is reasonably possible, but not known or probable, and can be reasonably estimated, the estimated loss or range of loss is disclosed in the notes to the condensed consolidated financial statements. In most cases, significant judgment is required to estimate the amount and timing of a loss to be recorded, actual results may differ from these estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Purchase Commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At September&#160;30, 2022, the Company had purchase commitments totaling approximately $3.1&#160;million, substantially all of which is expected to be purchased within the next fifteen months.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LossContingencyEstimateOfPossibleLoss
      contextRef="ifb875bc28ba541afbdc97bd369d0b276_I20220930"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82MS9mcmFnOmQ5MzUyMGI2YmIyYjQxYjdiYzQ0MDAwN2Y1NmM2OGZkL3RleHRyZWdpb246ZDkzNTIwYjZiYjJiNDFiN2JjNDQwMDA3ZjU2YzY4ZmRfMTg4OQ_e5fa8f7d-5038-4e65-bad1-4af6ae87ba4b"
      unitRef="usd">250000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <us-gaap:LossContingencyEstimateOfPossibleLoss
      contextRef="i0e86764ca7f24ce6a39afdcc54d3ea31_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82MS9mcmFnOmQ5MzUyMGI2YmIyYjQxYjdiYzQ0MDAwN2Y1NmM2OGZkL3RleHRyZWdpb246ZDkzNTIwYjZiYjJiNDFiN2JjNDQwMDA3ZjU2YzY4ZmRfMTg5NQ_2f0c7ff9-60c2-4fe8-9731-be04b4264ecf"
      unitRef="usd">1000000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="i1887856679e9469f916771312e57a2e9_I20220930"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82MS9mcmFnOmQ5MzUyMGI2YmIyYjQxYjdiYzQ0MDAwN2Y1NmM2OGZkL3RleHRyZWdpb246ZDkzNTIwYjZiYjJiNDFiN2JjNDQwMDA3ZjU2YzY4ZmRfMTY0OTI2NzQ1NzUzMQ_9d990f02-091a-4f15-b01c-2af7a9184c29"
      unitRef="usd">250000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyEstimateOfPossibleLoss
      contextRef="icc81989264bf4729990e5332a7d926ff_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82MS9mcmFnOmQ5MzUyMGI2YmIyYjQxYjdiYzQ0MDAwN2Y1NmM2OGZkL3RleHRyZWdpb246ZDkzNTIwYjZiYjJiNDFiN2JjNDQwMDA3ZjU2YzY4ZmRfNDEyMQ_134b34d4-2540-4ddb-a3ad-1b44d37b27f3"
      unitRef="usd">475000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <us-gaap:LossContingencyEstimateOfPossibleLoss
      contextRef="i47884c866bfd4b0bb5978e741a32ff7a_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82MS9mcmFnOmQ5MzUyMGI2YmIyYjQxYjdiYzQ0MDAwN2Y1NmM2OGZkL3RleHRyZWdpb246ZDkzNTIwYjZiYjJiNDFiN2JjNDQwMDA3ZjU2YzY4ZmRfNDEyNw_a65a3dfb-3277-4f8e-90cf-a04d24ac51aa"
      unitRef="usd">2500000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="i5d8aee9372fb4f169e0a8eb66390bb67_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82MS9mcmFnOmQ5MzUyMGI2YmIyYjQxYjdiYzQ0MDAwN2Y1NmM2OGZkL3RleHRyZWdpb246ZDkzNTIwYjZiYjJiNDFiN2JjNDQwMDA3ZjU2YzY4ZmRfNDE3Nw_ae64c9a8-cda0-42e5-9e1f-6f64b0619986"
      unitRef="usd">475000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:PurchaseObligation
      contextRef="ic42af16cc8974cebbc452370076f22e5_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82MS9mcmFnOmQ5MzUyMGI2YmIyYjQxYjdiYzQ0MDAwN2Y1NmM2OGZkL3RleHRyZWdpb246ZDkzNTIwYjZiYjJiNDFiN2JjNDQwMDA3ZjU2YzY4ZmRfNTMyMA_573a30d2-e7c9-4aa2-9d97-d62e3177bb09"
      unitRef="usd">3100000</us-gaap:PurchaseObligation>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82NC9mcmFnOjcwYzZhYjdjMTM3NjRiMDNiZTg2ZDVhNzY5M2MwNzhiL3RleHRyZWdpb246NzBjNmFiN2MxMzc2NGIwM2JlODZkNWE3NjkzYzA3OGJfODQ0_4423d130-97e4-40ee-a60a-e4b74adfa235">RELATED PARTY TRANSACTIONS&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Several relatives of Nikolay Shilev, Apyx Bulgaria&#x2019;s Managing Director, are considered related parties. Teodora Shileva, Mr. Shilev&#x2019;s spouse, is an employee of the Company working in the accounting department. Antoaneta Dimitrova Shileva-Toromanova, Mr. Shilev&#x2019;s sister, is the manager of human resources. Svetoslav Shilev, Mr. Shilev&#x2019;s son, is a quality manager in the quality assurance department.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The partner in the Company's China joint venture is also a supplier to the Company. For the three months ended September&#160;30, 2022 and 2021, the Company made purchases from this supplier of approximately $85,000 and $456,000, respectively. For the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;nine months ended September 30, 2022&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and 2021, the Company made purchases from this supplier of approximately $455,000 and $1,102,000, respectively. At September&#160;30, 2022 and December&#160;31, 2021, respectively, the Company owed this supplier approximately $41,000 and $1,000.&lt;/span&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty
      contextRef="if06767f062cc44ada17fa9800b45b707_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82NC9mcmFnOjcwYzZhYjdjMTM3NjRiMDNiZTg2ZDVhNzY5M2MwNzhiL3RleHRyZWdpb246NzBjNmFiN2MxMzc2NGIwM2JlODZkNWE3NjkzYzA3OGJfNjI5_173d27a8-398f-4916-91e6-58494a4e3eaf"
      unitRef="usd">85000</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty
      contextRef="if24822e015bf406fa7a58fe352a3de87_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82NC9mcmFnOjcwYzZhYjdjMTM3NjRiMDNiZTg2ZDVhNzY5M2MwNzhiL3RleHRyZWdpb246NzBjNmFiN2MxMzc2NGIwM2JlODZkNWE3NjkzYzA3OGJfNjM2_bd1e5f34-e57a-45ea-96e4-0549f7a5b3da"
      unitRef="usd">456000</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty
      contextRef="i1cce60115e9e4b31be367f868dcccb14_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82NC9mcmFnOjcwYzZhYjdjMTM3NjRiMDNiZTg2ZDVhNzY5M2MwNzhiL3RleHRyZWdpb246NzBjNmFiN2MxMzc2NGIwM2JlODZkNWE3NjkzYzA3OGJfNzM2_6adbc7d8-1faf-47e4-b30e-19019d935795"
      unitRef="usd">455000</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty
      contextRef="i10d9cc88ef7f4a2cb54fd0ce01238148_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82NC9mcmFnOjcwYzZhYjdjMTM3NjRiMDNiZTg2ZDVhNzY5M2MwNzhiL3RleHRyZWdpb246NzBjNmFiN2MxMzc2NGIwM2JlODZkNWE3NjkzYzA3OGJfNzQz_a076e5a2-eb50-4bfe-9a72-52e27bdef60d"
      unitRef="usd">1102000</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="if76fe4dedddf40aca527d7e4b7a2654c_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82NC9mcmFnOjcwYzZhYjdjMTM3NjRiMDNiZTg2ZDVhNzY5M2MwNzhiL3RleHRyZWdpb246NzBjNmFiN2MxMzc2NGIwM2JlODZkNWE3NjkzYzA3OGJfODM0_579539c7-850a-409f-a4a7-7fab29aef7d7"
      unitRef="usd">41000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="ib8f8d460633b499797d344045f093397_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82NC9mcmFnOjcwYzZhYjdjMTM3NjRiMDNiZTg2ZDVhNzY5M2MwNzhiL3RleHRyZWdpb246NzBjNmFiN2MxMzc2NGIwM2JlODZkNWE3NjkzYzA3OGJfODQx_46b10c6e-e2cf-4196-a3e3-f5649c10424a"
      unitRef="usd">1000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RleHRyZWdpb246YTQzN2Q5YmQxMWFiNGVlYjg3ODFhYzFmZWUyODdiYTNfMTY3OA_d85a1981-6888-4e11-a02d-4583dc653c4c">GEOGRAPHIC AND SEGMENT INFORMATION &lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating segments are aggregated into reportable segments only if they exhibit similar economic characteristics. In addition to similar economic characteristics, the Company also considers the following factors in determining the reportable segments: the nature of business activities, the management structure directly accountable to its chief operating decision maker for operating and administrative activities, availability of discrete financial information and information presented to the Board of Directors and investors. Asset information is not reviewed by the chief operating decision maker by segment and is not available by segment, accordingly, the Company has not presented a measure of assets by segment.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2019;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s reportable segments are disclosed as principally organized and managed as two operating segments: Advanced Energy and OEM. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201c;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate &amp;amp; Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; includes certain unallocated corporate and administrative costs which were not specifically attributed to any reportable segment. The OEM segment is primarily development and manufacturing contract and product driven, all related expenses are recorded as cost of sales, therefore no segment specific operating expenses are incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Summarized financial information with respect to reportable segments is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.811%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.696%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Advanced Energy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;OEM&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Corporate &amp;amp; Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income (loss) from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,174)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,964)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,782)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other loss, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.811%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.696%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Advanced Energy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;OEM&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Corporate &amp;amp; Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income (loss) from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,348)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,968)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other loss, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(192)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(192)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.811%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.696%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Advanced Energy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;OEM&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Corporate &amp;amp; Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income (loss) from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,765)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,006)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,629)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.811%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.696%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Advanced Energy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;OEM&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Corporate &amp;amp; Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income (loss) from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(224)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,120)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,756)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other loss, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(188)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(188)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;International sales represented approximately 23.2% and 29.5% of total revenues for the three and nine months ended September 30, 2022, respectively, as compared with approximately 33.1% and 34.2% of total revenues for the three and nine months ended September 30, 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue by geographic region, based on the customer's &#x201c;ship to&#x201d; location on the invoice, are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Sales by Domestic and International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RleHRyZWdpb246YTQzN2Q5YmQxMWFiNGVlYjg3ODFhYzFmZWUyODdiYTNfODYy_3dab7a3e-a86e-4244-bd9a-aa458c87103f"
      unitRef="segment">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RleHRyZWdpb246YTQzN2Q5YmQxMWFiNGVlYjg3ODFhYzFmZWUyODdiYTNfODYy_86893244-2d05-4a2c-90c6-976590558044"
      unitRef="segment">2</us-gaap:NumberOfReportableSegments>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RleHRyZWdpb246YTQzN2Q5YmQxMWFiNGVlYjg3ODFhYzFmZWUyODdiYTNfMTY4Mw_7a26e60e-45ea-4ce0-8c7d-88ae423cc6c9">Summarized financial information with respect to reportable segments is as follows:&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.811%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.696%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Advanced Energy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;OEM&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Corporate &amp;amp; Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income (loss) from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,174)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,964)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,782)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other loss, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.811%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.696%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Advanced Energy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;OEM&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Corporate &amp;amp; Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income (loss) from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,348)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,968)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other loss, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(192)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(192)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.811%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.696%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Advanced Energy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;OEM&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Corporate &amp;amp; Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income (loss) from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,765)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,006)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,629)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.811%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.696%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Advanced Energy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;OEM&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Corporate &amp;amp; Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income (loss) from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(224)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,120)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,756)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other loss, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(188)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(188)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib86c17a29ad64fff8b4f5645ccc11575_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmE5OWEwMGU5ODkwNTQ5N2VhZGFiYTU4ZjQ4YzU1YmVjL3RhYmxlcmFuZ2U6YTk5YTAwZTk4OTA1NDk3ZWFkYWJhNThmNDhjNTViZWNfMi0zLTEtMS0xNzQxMA_59d46f9d-1580-4129-beee-902148e43a57"
      unitRef="usd">7080000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaaa11755febd4f87a4971e2cdb19bccd_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmE5OWEwMGU5ODkwNTQ5N2VhZGFiYTU4ZjQ4YzU1YmVjL3RhYmxlcmFuZ2U6YTk5YTAwZTk4OTA1NDk3ZWFkYWJhNThmNDhjNTViZWNfMi01LTEtMS0xNzQxMA_728ea0ea-892a-4dc0-b172-d7840ef35027"
      unitRef="usd">2034000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i12ee9d61be8f4dc6a652027fc6bd93b9_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmE5OWEwMGU5ODkwNTQ5N2VhZGFiYTU4ZjQ4YzU1YmVjL3RhYmxlcmFuZ2U6YTk5YTAwZTk4OTA1NDk3ZWFkYWJhNThmNDhjNTViZWNfMi03LTEtMS0xNzQxMA_d37acec1-5939-4018-80bd-a3a4936a6b1e"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id6ada2596cf84b118b49af7a6561fb79_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmE5OWEwMGU5ODkwNTQ5N2VhZGFiYTU4ZjQ4YzU1YmVjL3RhYmxlcmFuZ2U6YTk5YTAwZTk4OTA1NDk3ZWFkYWJhNThmNDhjNTViZWNfMi05LTEtMS0xNzQxMA_e0264de1-92cf-40a8-9d47-323e63bf2c8a"
      unitRef="usd">9114000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:OperatingIncomeLoss
      contextRef="ib86c17a29ad64fff8b4f5645ccc11575_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmE5OWEwMGU5ODkwNTQ5N2VhZGFiYTU4ZjQ4YzU1YmVjL3RhYmxlcmFuZ2U6YTk5YTAwZTk4OTA1NDk3ZWFkYWJhNThmNDhjNTViZWNfMTQtMy0xLTEtMTc0MTA_485695f7-11d6-44a4-8d8b-59014f1b4735"
      unitRef="usd">-1174000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="iaaa11755febd4f87a4971e2cdb19bccd_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmE5OWEwMGU5ODkwNTQ5N2VhZGFiYTU4ZjQ4YzU1YmVjL3RhYmxlcmFuZ2U6YTk5YTAwZTk4OTA1NDk3ZWFkYWJhNThmNDhjNTViZWNfMTQtNS0xLTEtMTc0MTA_a4dbbc5c-026f-45f8-85d7-d7e1aa75dfd9"
      unitRef="usd">356000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i12ee9d61be8f4dc6a652027fc6bd93b9_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmE5OWEwMGU5ODkwNTQ5N2VhZGFiYTU4ZjQ4YzU1YmVjL3RhYmxlcmFuZ2U6YTk5YTAwZTk4OTA1NDk3ZWFkYWJhNThmNDhjNTViZWNfMTQtNy0xLTEtMTc0MTA_48f67360-adb1-4c3a-9c1f-2d144a3da957"
      unitRef="usd">-4964000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="id6ada2596cf84b118b49af7a6561fb79_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmE5OWEwMGU5ODkwNTQ5N2VhZGFiYTU4ZjQ4YzU1YmVjL3RhYmxlcmFuZ2U6YTk5YTAwZTk4OTA1NDk3ZWFkYWJhNThmNDhjNTViZWNfMTQtOS0xLTEtMTc0MTA_ae51e453-77ad-405c-be3c-cf7e0fd70e95"
      unitRef="usd">-5782000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeOperating
      contextRef="ib86c17a29ad64fff8b4f5645ccc11575_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmE5OWEwMGU5ODkwNTQ5N2VhZGFiYTU4ZjQ4YzU1YmVjL3RhYmxlcmFuZ2U6YTk5YTAwZTk4OTA1NDk3ZWFkYWJhNThmNDhjNTViZWNfMTYtMy0xLTEtMTc0MTA_489deba4-d90b-4b1d-ab97-6e748d3d6cfb"
      unitRef="usd">0</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="iaaa11755febd4f87a4971e2cdb19bccd_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmE5OWEwMGU5ODkwNTQ5N2VhZGFiYTU4ZjQ4YzU1YmVjL3RhYmxlcmFuZ2U6YTk5YTAwZTk4OTA1NDk3ZWFkYWJhNThmNDhjNTViZWNfMTYtNS0xLTEtMTc0MTA_3072867d-fbf2-4185-b494-f1acf3668b14"
      unitRef="usd">0</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="i12ee9d61be8f4dc6a652027fc6bd93b9_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmE5OWEwMGU5ODkwNTQ5N2VhZGFiYTU4ZjQ4YzU1YmVjL3RhYmxlcmFuZ2U6YTk5YTAwZTk4OTA1NDk3ZWFkYWJhNThmNDhjNTViZWNfMTYtNy0xLTEtMTc0MTA_d3f66ded-3c2c-451d-958d-e27c2c855540"
      unitRef="usd">73000</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="id6ada2596cf84b118b49af7a6561fb79_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmE5OWEwMGU5ODkwNTQ5N2VhZGFiYTU4ZjQ4YzU1YmVjL3RhYmxlcmFuZ2U6YTk5YTAwZTk4OTA1NDk3ZWFkYWJhNThmNDhjNTViZWNfMTYtOS0xLTEtMTc0MTA_9f40a70b-01da-4a17-bf4b-2f330efbfca8"
      unitRef="usd">73000</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestExpense
      contextRef="ib86c17a29ad64fff8b4f5645ccc11575_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmE5OWEwMGU5ODkwNTQ5N2VhZGFiYTU4ZjQ4YzU1YmVjL3RhYmxlcmFuZ2U6YTk5YTAwZTk4OTA1NDk3ZWFkYWJhNThmNDhjNTViZWNfMTctMy0xLTEtMTc0MTA_d4264f3d-951a-45b7-bc2a-4234db7ef9f6"
      unitRef="usd">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="iaaa11755febd4f87a4971e2cdb19bccd_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmE5OWEwMGU5ODkwNTQ5N2VhZGFiYTU4ZjQ4YzU1YmVjL3RhYmxlcmFuZ2U6YTk5YTAwZTk4OTA1NDk3ZWFkYWJhNThmNDhjNTViZWNfMTctNS0xLTEtMTc0MTA_2383f9d1-f075-4da1-b04e-01b1a6dd40e8"
      unitRef="usd">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i12ee9d61be8f4dc6a652027fc6bd93b9_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmE5OWEwMGU5ODkwNTQ5N2VhZGFiYTU4ZjQ4YzU1YmVjL3RhYmxlcmFuZ2U6YTk5YTAwZTk4OTA1NDk3ZWFkYWJhNThmNDhjNTViZWNfMTctNy0xLTEtMTc0MTA_1a1640e7-a400-4b1c-838a-d6a3af25d919"
      unitRef="usd">1000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="id6ada2596cf84b118b49af7a6561fb79_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmE5OWEwMGU5ODkwNTQ5N2VhZGFiYTU4ZjQ4YzU1YmVjL3RhYmxlcmFuZ2U6YTk5YTAwZTk4OTA1NDk3ZWFkYWJhNThmNDhjNTViZWNfMTctOS0xLTEtMTc0MTA_ea18db85-8fc9-400b-b516-61d14b3b2f90"
      unitRef="usd">1000</us-gaap:InterestExpense>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="ib86c17a29ad64fff8b4f5645ccc11575_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmE5OWEwMGU5ODkwNTQ5N2VhZGFiYTU4ZjQ4YzU1YmVjL3RhYmxlcmFuZ2U6YTk5YTAwZTk4OTA1NDk3ZWFkYWJhNThmNDhjNTViZWNfMTgtMy0xLTEtMTc0MTA_720d50b1-961b-48d5-9ed8-d0ec08d21c3e"
      unitRef="usd">0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="iaaa11755febd4f87a4971e2cdb19bccd_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmE5OWEwMGU5ODkwNTQ5N2VhZGFiYTU4ZjQ4YzU1YmVjL3RhYmxlcmFuZ2U6YTk5YTAwZTk4OTA1NDk3ZWFkYWJhNThmNDhjNTViZWNfMTgtNS0xLTEtMTc0MTA_471374ce-a0e1-4c45-89bb-32a0f399a304"
      unitRef="usd">0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i12ee9d61be8f4dc6a652027fc6bd93b9_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmE5OWEwMGU5ODkwNTQ5N2VhZGFiYTU4ZjQ4YzU1YmVjL3RhYmxlcmFuZ2U6YTk5YTAwZTk4OTA1NDk3ZWFkYWJhNThmNDhjNTViZWNfMTgtNy0xLTEtMTc0MTA_3e08346a-488b-4b61-a7a0-af5831e78f2e"
      unitRef="usd">-35000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="id6ada2596cf84b118b49af7a6561fb79_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmE5OWEwMGU5ODkwNTQ5N2VhZGFiYTU4ZjQ4YzU1YmVjL3RhYmxlcmFuZ2U6YTk5YTAwZTk4OTA1NDk3ZWFkYWJhNThmNDhjNTViZWNfMTgtOS0xLTEtMTc0MTA_9aed8336-23d6-402d-940e-982428978ea9"
      unitRef="usd">-35000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ib86c17a29ad64fff8b4f5645ccc11575_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmE5OWEwMGU5ODkwNTQ5N2VhZGFiYTU4ZjQ4YzU1YmVjL3RhYmxlcmFuZ2U6YTk5YTAwZTk4OTA1NDk3ZWFkYWJhNThmNDhjNTViZWNfMjItMy0xLTEtMTc0MTA_672daaa4-7d59-493a-b2a7-0512a763d898"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="iaaa11755febd4f87a4971e2cdb19bccd_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmE5OWEwMGU5ODkwNTQ5N2VhZGFiYTU4ZjQ4YzU1YmVjL3RhYmxlcmFuZ2U6YTk5YTAwZTk4OTA1NDk3ZWFkYWJhNThmNDhjNTViZWNfMjItNS0xLTEtMTc0MTA_32493819-7b00-4682-8f8d-bf10ea95789b"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i12ee9d61be8f4dc6a652027fc6bd93b9_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmE5OWEwMGU5ODkwNTQ5N2VhZGFiYTU4ZjQ4YzU1YmVjL3RhYmxlcmFuZ2U6YTk5YTAwZTk4OTA1NDk3ZWFkYWJhNThmNDhjNTViZWNfMjItNy0xLTEtMTc0MTA_73d82e61-b5d2-45b0-9bcc-040a22097d78"
      unitRef="usd">50000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="id6ada2596cf84b118b49af7a6561fb79_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmE5OWEwMGU5ODkwNTQ5N2VhZGFiYTU4ZjQ4YzU1YmVjL3RhYmxlcmFuZ2U6YTk5YTAwZTk4OTA1NDk3ZWFkYWJhNThmNDhjNTViZWNfMjItOS0xLTEtMTc0MTA_6b1036de-5489-4a7c-8efb-cb172765b51a"
      unitRef="usd">50000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i14808dab5a9a44dda4de75eaaebf7f2c_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOjMyZDQ5NDQyNWZiZDQwMjBhMzRlNjg2ZTlhZGFiMzdlL3RhYmxlcmFuZ2U6MzJkNDk0NDI1ZmJkNDAyMGEzNGU2ODZlOWFkYWIzN2VfMi0zLTEtMS0xNzQxMA_087dde11-485a-4ed2-92ec-665b1350c931"
      unitRef="usd">10313000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i35bc95fa11524622b8a7f5abe7f7a8d0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOjMyZDQ5NDQyNWZiZDQwMjBhMzRlNjg2ZTlhZGFiMzdlL3RhYmxlcmFuZ2U6MzJkNDk0NDI1ZmJkNDAyMGEzNGU2ODZlOWFkYWIzN2VfMi01LTEtMS0xNzQxMA_92844b93-c1ec-4131-a72e-e75ecc1c20f1"
      unitRef="usd">1518000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id24ea483328641d39abd6bbf5097a73b_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOjMyZDQ5NDQyNWZiZDQwMjBhMzRlNjg2ZTlhZGFiMzdlL3RhYmxlcmFuZ2U6MzJkNDk0NDI1ZmJkNDAyMGEzNGU2ODZlOWFkYWIzN2VfMi03LTEtMS0xNzQxMA_d521b0af-53ce-4940-af99-e9053417408e"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic9b0b6a3c69447bf8f151dfd98c14ac9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOjMyZDQ5NDQyNWZiZDQwMjBhMzRlNjg2ZTlhZGFiMzdlL3RhYmxlcmFuZ2U6MzJkNDk0NDI1ZmJkNDAyMGEzNGU2ODZlOWFkYWIzN2VfMi05LTEtMS0xNzQxMA_c89aa9f3-9926-4f98-9ce1-3f9e18b5261f"
      unitRef="usd">11831000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:OperatingIncomeLoss
      contextRef="i14808dab5a9a44dda4de75eaaebf7f2c_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOjMyZDQ5NDQyNWZiZDQwMjBhMzRlNjg2ZTlhZGFiMzdlL3RhYmxlcmFuZ2U6MzJkNDk0NDI1ZmJkNDAyMGEzNGU2ODZlOWFkYWIzN2VfMTQtMy0xLTEtMTc0MTA_6ee975af-dc0b-4729-b225-2897a0a945c4"
      unitRef="usd">52000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i35bc95fa11524622b8a7f5abe7f7a8d0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOjMyZDQ5NDQyNWZiZDQwMjBhMzRlNjg2ZTlhZGFiMzdlL3RhYmxlcmFuZ2U6MzJkNDk0NDI1ZmJkNDAyMGEzNGU2ODZlOWFkYWIzN2VfMTQtNS0xLTEtMTc0MTA_5bfb1653-1824-4650-8e8b-d2772b81db20"
      unitRef="usd">328000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="id24ea483328641d39abd6bbf5097a73b_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOjMyZDQ5NDQyNWZiZDQwMjBhMzRlNjg2ZTlhZGFiMzdlL3RhYmxlcmFuZ2U6MzJkNDk0NDI1ZmJkNDAyMGEzNGU2ODZlOWFkYWIzN2VfMTQtNy0xLTEtMTc0MTA_1595f1a1-225d-43da-bb7e-9c21311c206b"
      unitRef="usd">-4348000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ic9b0b6a3c69447bf8f151dfd98c14ac9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOjMyZDQ5NDQyNWZiZDQwMjBhMzRlNjg2ZTlhZGFiMzdlL3RhYmxlcmFuZ2U6MzJkNDk0NDI1ZmJkNDAyMGEzNGU2ODZlOWFkYWIzN2VfMTQtOS0xLTEtMTc0MTA_43444b64-641e-4fc0-97bf-bda77e64f5f2"
      unitRef="usd">-3968000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeOperating
      contextRef="i14808dab5a9a44dda4de75eaaebf7f2c_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOjMyZDQ5NDQyNWZiZDQwMjBhMzRlNjg2ZTlhZGFiMzdlL3RhYmxlcmFuZ2U6MzJkNDk0NDI1ZmJkNDAyMGEzNGU2ODZlOWFkYWIzN2VfMTYtMy0xLTEtMTc0MTA_8ba539f1-717b-4573-a2a4-f4dcb1a8d260"
      unitRef="usd">0</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="i35bc95fa11524622b8a7f5abe7f7a8d0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOjMyZDQ5NDQyNWZiZDQwMjBhMzRlNjg2ZTlhZGFiMzdlL3RhYmxlcmFuZ2U6MzJkNDk0NDI1ZmJkNDAyMGEzNGU2ODZlOWFkYWIzN2VfMTYtNS0xLTEtMTc0MTA_9669ee3d-eafe-46cd-96f5-af0640459408"
      unitRef="usd">0</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="id24ea483328641d39abd6bbf5097a73b_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOjMyZDQ5NDQyNWZiZDQwMjBhMzRlNjg2ZTlhZGFiMzdlL3RhYmxlcmFuZ2U6MzJkNDk0NDI1ZmJkNDAyMGEzNGU2ODZlOWFkYWIzN2VfMTYtNy0xLTEtMTc0MTA_9baefdd2-f269-4e93-8255-70dabfe8407e"
      unitRef="usd">2000</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="ic9b0b6a3c69447bf8f151dfd98c14ac9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOjMyZDQ5NDQyNWZiZDQwMjBhMzRlNjg2ZTlhZGFiMzdlL3RhYmxlcmFuZ2U6MzJkNDk0NDI1ZmJkNDAyMGEzNGU2ODZlOWFkYWIzN2VfMTYtOS0xLTEtMTc0MTA_8d9e7a48-3e27-4905-bf82-c0327853a534"
      unitRef="usd">2000</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestExpense
      contextRef="i14808dab5a9a44dda4de75eaaebf7f2c_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOjMyZDQ5NDQyNWZiZDQwMjBhMzRlNjg2ZTlhZGFiMzdlL3RhYmxlcmFuZ2U6MzJkNDk0NDI1ZmJkNDAyMGEzNGU2ODZlOWFkYWIzN2VfMTgtMy0xLTEtMTc0MTA_efd786f1-218c-4c5d-ac01-992af17495a1"
      unitRef="usd">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i35bc95fa11524622b8a7f5abe7f7a8d0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOjMyZDQ5NDQyNWZiZDQwMjBhMzRlNjg2ZTlhZGFiMzdlL3RhYmxlcmFuZ2U6MzJkNDk0NDI1ZmJkNDAyMGEzNGU2ODZlOWFkYWIzN2VfMTgtNS0xLTEtMTc0MTA_dbb43a7b-4762-4f8f-aeaa-e2998ddc3779"
      unitRef="usd">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="id24ea483328641d39abd6bbf5097a73b_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOjMyZDQ5NDQyNWZiZDQwMjBhMzRlNjg2ZTlhZGFiMzdlL3RhYmxlcmFuZ2U6MzJkNDk0NDI1ZmJkNDAyMGEzNGU2ODZlOWFkYWIzN2VfMTgtNy0xLTEtMTc0MTA_6e373303-e209-4f27-9a76-02a047965ee1"
      unitRef="usd">3000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ic9b0b6a3c69447bf8f151dfd98c14ac9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOjMyZDQ5NDQyNWZiZDQwMjBhMzRlNjg2ZTlhZGFiMzdlL3RhYmxlcmFuZ2U6MzJkNDk0NDI1ZmJkNDAyMGEzNGU2ODZlOWFkYWIzN2VfMTgtOS0xLTEtMTc0MTA_3f3107bf-9225-44a7-8164-3dafbe585835"
      unitRef="usd">3000</us-gaap:InterestExpense>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i14808dab5a9a44dda4de75eaaebf7f2c_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOjMyZDQ5NDQyNWZiZDQwMjBhMzRlNjg2ZTlhZGFiMzdlL3RhYmxlcmFuZ2U6MzJkNDk0NDI1ZmJkNDAyMGEzNGU2ODZlOWFkYWIzN2VfMTktMy0xLTEtMTc0MTA_3eb52121-0681-4b1d-a779-7de1c4cf881d"
      unitRef="usd">0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i35bc95fa11524622b8a7f5abe7f7a8d0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOjMyZDQ5NDQyNWZiZDQwMjBhMzRlNjg2ZTlhZGFiMzdlL3RhYmxlcmFuZ2U6MzJkNDk0NDI1ZmJkNDAyMGEzNGU2ODZlOWFkYWIzN2VfMTktNS0xLTEtMTc0MTA_db6d5e61-dee0-4426-a075-baee1e6dd2f4"
      unitRef="usd">0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="id24ea483328641d39abd6bbf5097a73b_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOjMyZDQ5NDQyNWZiZDQwMjBhMzRlNjg2ZTlhZGFiMzdlL3RhYmxlcmFuZ2U6MzJkNDk0NDI1ZmJkNDAyMGEzNGU2ODZlOWFkYWIzN2VfMTktNy0xLTEtMTc0MTA_b6954d4d-b371-4b45-b254-ef107576a36f"
      unitRef="usd">-192000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="ic9b0b6a3c69447bf8f151dfd98c14ac9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOjMyZDQ5NDQyNWZiZDQwMjBhMzRlNjg2ZTlhZGFiMzdlL3RhYmxlcmFuZ2U6MzJkNDk0NDI1ZmJkNDAyMGEzNGU2ODZlOWFkYWIzN2VfMTktOS0xLTEtMTc0MTA_21143455-6c98-43e2-9593-071fd721def4"
      unitRef="usd">-192000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i14808dab5a9a44dda4de75eaaebf7f2c_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOjMyZDQ5NDQyNWZiZDQwMjBhMzRlNjg2ZTlhZGFiMzdlL3RhYmxlcmFuZ2U6MzJkNDk0NDI1ZmJkNDAyMGEzNGU2ODZlOWFkYWIzN2VfMjMtMy0xLTEtMTc0MTA_18395edf-cbe5-4887-97ea-06cc1e439428"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i35bc95fa11524622b8a7f5abe7f7a8d0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOjMyZDQ5NDQyNWZiZDQwMjBhMzRlNjg2ZTlhZGFiMzdlL3RhYmxlcmFuZ2U6MzJkNDk0NDI1ZmJkNDAyMGEzNGU2ODZlOWFkYWIzN2VfMjMtNS0xLTEtMTc0MTA_2379d217-2950-4fee-8300-90e0a97bed54"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="id24ea483328641d39abd6bbf5097a73b_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOjMyZDQ5NDQyNWZiZDQwMjBhMzRlNjg2ZTlhZGFiMzdlL3RhYmxlcmFuZ2U6MzJkNDk0NDI1ZmJkNDAyMGEzNGU2ODZlOWFkYWIzN2VfMjMtNy0xLTEtMTc0MTA_b2436174-ba99-4776-940e-f9e0e1966b50"
      unitRef="usd">73000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ic9b0b6a3c69447bf8f151dfd98c14ac9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOjMyZDQ5NDQyNWZiZDQwMjBhMzRlNjg2ZTlhZGFiMzdlL3RhYmxlcmFuZ2U6MzJkNDk0NDI1ZmJkNDAyMGEzNGU2ODZlOWFkYWIzN2VfMjMtOS0xLTEtMTc0MTA_e027fd43-032e-447c-8ac9-2eaed117b138"
      unitRef="usd">73000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic79a2007f9024641a9822f1b84d5f8cd_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmNiYTNlYmM0NzNkOTRlZGZhMjBjMjA0NzA3M2MxYjM2L3RhYmxlcmFuZ2U6Y2JhM2ViYzQ3M2Q5NGVkZmEyMGMyMDQ3MDczYzFiMzZfMi0zLTEtMS0xNzQxMA_034c4cfd-2867-4cca-9320-3ba74e3be0c3"
      unitRef="usd">26258000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i859943e8321b4443a613d8938534494e_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmNiYTNlYmM0NzNkOTRlZGZhMjBjMjA0NzA3M2MxYjM2L3RhYmxlcmFuZ2U6Y2JhM2ViYzQ3M2Q5NGVkZmEyMGMyMDQ3MDczYzFiMzZfMi01LTEtMS0xNzQxMA_667cde3a-4266-4ce9-a0d3-597993fa70c3"
      unitRef="usd">5641000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i042c28c1eeda4c15bb204324175550d5_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmNiYTNlYmM0NzNkOTRlZGZhMjBjMjA0NzA3M2MxYjM2L3RhYmxlcmFuZ2U6Y2JhM2ViYzQ3M2Q5NGVkZmEyMGMyMDQ3MDczYzFiMzZfMi03LTEtMS0xNzQxMA_f286a121-f663-48bc-b1fc-da52bf089ec7"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmNiYTNlYmM0NzNkOTRlZGZhMjBjMjA0NzA3M2MxYjM2L3RhYmxlcmFuZ2U6Y2JhM2ViYzQ3M2Q5NGVkZmEyMGMyMDQ3MDczYzFiMzZfMi05LTEtMS0xNzQxMA_7cc2b930-3051-409e-9744-df728ccf05de"
      unitRef="usd">31899000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:OperatingIncomeLoss
      contextRef="ic79a2007f9024641a9822f1b84d5f8cd_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmNiYTNlYmM0NzNkOTRlZGZhMjBjMjA0NzA3M2MxYjM2L3RhYmxlcmFuZ2U6Y2JhM2ViYzQ3M2Q5NGVkZmEyMGMyMDQ3MDczYzFiMzZfMTQtMy0xLTEtMTc0MTA_f2f0bc28-c87a-4e7c-8fea-db66ebe86b07"
      unitRef="usd">-3765000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i859943e8321b4443a613d8938534494e_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmNiYTNlYmM0NzNkOTRlZGZhMjBjMjA0NzA3M2MxYjM2L3RhYmxlcmFuZ2U6Y2JhM2ViYzQ3M2Q5NGVkZmEyMGMyMDQ3MDczYzFiMzZfMTQtNS0xLTEtMTc0MTA_cb00662f-430f-4988-b98b-b253c5c0f08a"
      unitRef="usd">1142000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i042c28c1eeda4c15bb204324175550d5_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmNiYTNlYmM0NzNkOTRlZGZhMjBjMjA0NzA3M2MxYjM2L3RhYmxlcmFuZ2U6Y2JhM2ViYzQ3M2Q5NGVkZmEyMGMyMDQ3MDczYzFiMzZfMTQtNy0xLTEtMTc0MTA_e3013a23-df9e-4419-9476-6b9ae2219626"
      unitRef="usd">-15006000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmNiYTNlYmM0NzNkOTRlZGZhMjBjMjA0NzA3M2MxYjM2L3RhYmxlcmFuZ2U6Y2JhM2ViYzQ3M2Q5NGVkZmEyMGMyMDQ3MDczYzFiMzZfMTQtOS0xLTEtMTc0MTA_df579936-3377-42f0-b816-8df8a66613b8"
      unitRef="usd">-17629000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeOperating
      contextRef="ic79a2007f9024641a9822f1b84d5f8cd_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmNiYTNlYmM0NzNkOTRlZGZhMjBjMjA0NzA3M2MxYjM2L3RhYmxlcmFuZ2U6Y2JhM2ViYzQ3M2Q5NGVkZmEyMGMyMDQ3MDczYzFiMzZfMTYtMy0xLTEtMTc0MTA_799a664c-91c0-45d0-ba6d-62b4313c2d0d"
      unitRef="usd">0</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="i859943e8321b4443a613d8938534494e_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmNiYTNlYmM0NzNkOTRlZGZhMjBjMjA0NzA3M2MxYjM2L3RhYmxlcmFuZ2U6Y2JhM2ViYzQ3M2Q5NGVkZmEyMGMyMDQ3MDczYzFiMzZfMTYtNS0xLTEtMTc0MTA_acdbf349-ccbf-4aa6-be56-59cacdc97594"
      unitRef="usd">0</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="i042c28c1eeda4c15bb204324175550d5_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmNiYTNlYmM0NzNkOTRlZGZhMjBjMjA0NzA3M2MxYjM2L3RhYmxlcmFuZ2U6Y2JhM2ViYzQ3M2Q5NGVkZmEyMGMyMDQ3MDczYzFiMzZfMTYtNy0xLTEtMTc0MTA_dd46e0d1-a48e-4850-9dea-6a68a9a6f1ee"
      unitRef="usd">93000</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmNiYTNlYmM0NzNkOTRlZGZhMjBjMjA0NzA3M2MxYjM2L3RhYmxlcmFuZ2U6Y2JhM2ViYzQ3M2Q5NGVkZmEyMGMyMDQ3MDczYzFiMzZfMTYtOS0xLTEtMTc0MTA_ebea55c7-2172-4d1c-8782-6a9c202e0325"
      unitRef="usd">93000</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestExpense
      contextRef="ic79a2007f9024641a9822f1b84d5f8cd_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmNiYTNlYmM0NzNkOTRlZGZhMjBjMjA0NzA3M2MxYjM2L3RhYmxlcmFuZ2U6Y2JhM2ViYzQ3M2Q5NGVkZmEyMGMyMDQ3MDczYzFiMzZfMTctMy0xLTEtMTc0MTA_dddaed07-4881-4406-9227-ab5edb3be858"
      unitRef="usd">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i859943e8321b4443a613d8938534494e_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmNiYTNlYmM0NzNkOTRlZGZhMjBjMjA0NzA3M2MxYjM2L3RhYmxlcmFuZ2U6Y2JhM2ViYzQ3M2Q5NGVkZmEyMGMyMDQ3MDczYzFiMzZfMTctNS0xLTEtMTc0MTA_94695743-983f-4305-8a5b-8523a6d28e89"
      unitRef="usd">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i042c28c1eeda4c15bb204324175550d5_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmNiYTNlYmM0NzNkOTRlZGZhMjBjMjA0NzA3M2MxYjM2L3RhYmxlcmFuZ2U6Y2JhM2ViYzQ3M2Q5NGVkZmEyMGMyMDQ3MDczYzFiMzZfMTctNy0xLTEtMTc0MTA_e3d770c7-47c8-4150-925f-fff957327bd9"
      unitRef="usd">12000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmNiYTNlYmM0NzNkOTRlZGZhMjBjMjA0NzA3M2MxYjM2L3RhYmxlcmFuZ2U6Y2JhM2ViYzQ3M2Q5NGVkZmEyMGMyMDQ3MDczYzFiMzZfMTctOS0xLTEtMTc0MTA_ee4abb5c-eb48-45d9-bace-7f83e5da2137"
      unitRef="usd">12000</us-gaap:InterestExpense>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="ic79a2007f9024641a9822f1b84d5f8cd_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmNiYTNlYmM0NzNkOTRlZGZhMjBjMjA0NzA3M2MxYjM2L3RhYmxlcmFuZ2U6Y2JhM2ViYzQ3M2Q5NGVkZmEyMGMyMDQ3MDczYzFiMzZfMTgtMy0xLTEtMTc0MTA_df59871f-fbaa-4058-893f-fd72854b9bd9"
      unitRef="usd">0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i859943e8321b4443a613d8938534494e_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmNiYTNlYmM0NzNkOTRlZGZhMjBjMjA0NzA3M2MxYjM2L3RhYmxlcmFuZ2U6Y2JhM2ViYzQ3M2Q5NGVkZmEyMGMyMDQ3MDczYzFiMzZfMTgtNS0xLTEtMTc0MTA_2e130893-a5e7-4f4f-b455-e43f005fc301"
      unitRef="usd">0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i042c28c1eeda4c15bb204324175550d5_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmNiYTNlYmM0NzNkOTRlZGZhMjBjMjA0NzA3M2MxYjM2L3RhYmxlcmFuZ2U6Y2JhM2ViYzQ3M2Q5NGVkZmEyMGMyMDQ3MDczYzFiMzZfMTgtNy0xLTEtMTc0MTA_b23374d2-f5a6-4261-98ca-f7cf242643ab"
      unitRef="usd">551000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmNiYTNlYmM0NzNkOTRlZGZhMjBjMjA0NzA3M2MxYjM2L3RhYmxlcmFuZ2U6Y2JhM2ViYzQ3M2Q5NGVkZmEyMGMyMDQ3MDczYzFiMzZfMTgtOS0xLTEtMTc0MTA_fbb0f409-cd5d-4b24-a721-6cc3cb6bec79"
      unitRef="usd">551000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ic79a2007f9024641a9822f1b84d5f8cd_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmNiYTNlYmM0NzNkOTRlZGZhMjBjMjA0NzA3M2MxYjM2L3RhYmxlcmFuZ2U6Y2JhM2ViYzQ3M2Q5NGVkZmEyMGMyMDQ3MDczYzFiMzZfMjItMy0xLTEtMTc0MTA_62e21d26-3c5f-428a-b5b6-fb62a3d18e48"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i859943e8321b4443a613d8938534494e_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmNiYTNlYmM0NzNkOTRlZGZhMjBjMjA0NzA3M2MxYjM2L3RhYmxlcmFuZ2U6Y2JhM2ViYzQ3M2Q5NGVkZmEyMGMyMDQ3MDczYzFiMzZfMjItNS0xLTEtMTc0MTA_e438430f-56df-4e8f-aefa-12b4150509ec"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i042c28c1eeda4c15bb204324175550d5_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmNiYTNlYmM0NzNkOTRlZGZhMjBjMjA0NzA3M2MxYjM2L3RhYmxlcmFuZ2U6Y2JhM2ViYzQ3M2Q5NGVkZmEyMGMyMDQ3MDczYzFiMzZfMjItNy0xLTEtMTc0MTA_ddafa99d-f21e-4b6b-a969-205351de6508"
      unitRef="usd">216000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmNiYTNlYmM0NzNkOTRlZGZhMjBjMjA0NzA3M2MxYjM2L3RhYmxlcmFuZ2U6Y2JhM2ViYzQ3M2Q5NGVkZmEyMGMyMDQ3MDczYzFiMzZfMjItOS0xLTEtMTc0MTA_c8011edf-2c25-4ed4-8007-b3c2759ca86f"
      unitRef="usd">216000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iab38511a317c44aa9f0dc79521e2a6d5_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOjk5NTliMzg5MzQwYTRjNTA4ZjBmMTYyZTBmOGMyOTFjL3RhYmxlcmFuZ2U6OTk1OWIzODkzNDBhNGM1MDhmMGYxNjJlMGY4YzI5MWNfMi0zLTEtMS0xNzQxMA_3d72f8aa-2a24-48c4-8cdb-6187c265873d"
      unitRef="usd">27951000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7bfacb65a9e6459ea08bf4947d3b9c2b_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOjk5NTliMzg5MzQwYTRjNTA4ZjBmMTYyZTBmOGMyOTFjL3RhYmxlcmFuZ2U6OTk1OWIzODkzNDBhNGM1MDhmMGYxNjJlMGY4YzI5MWNfMi01LTEtMS0xNzQxMA_487f7040-d345-4466-a8fa-245c7c8d62f6"
      unitRef="usd">3742000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6944c3767530469d9f26618cb4e807e6_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOjk5NTliMzg5MzQwYTRjNTA4ZjBmMTYyZTBmOGMyOTFjL3RhYmxlcmFuZ2U6OTk1OWIzODkzNDBhNGM1MDhmMGYxNjJlMGY4YzI5MWNfMi03LTEtMS0xNzQxMA_f12ba92f-3223-4aee-95ab-ffec04fe585e"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOjk5NTliMzg5MzQwYTRjNTA4ZjBmMTYyZTBmOGMyOTFjL3RhYmxlcmFuZ2U6OTk1OWIzODkzNDBhNGM1MDhmMGYxNjJlMGY4YzI5MWNfMi05LTEtMS0xNzQxMA_cdc25023-a7fc-4eae-89a9-21d9b272b410"
      unitRef="usd">31693000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:OperatingIncomeLoss
      contextRef="iab38511a317c44aa9f0dc79521e2a6d5_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOjk5NTliMzg5MzQwYTRjNTA4ZjBmMTYyZTBmOGMyOTFjL3RhYmxlcmFuZ2U6OTk1OWIzODkzNDBhNGM1MDhmMGYxNjJlMGY4YzI5MWNfMTQtMy0xLTEtMTc0MTA_cfac1446-dd45-4419-a5aa-978cffcf7939"
      unitRef="usd">-224000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i7bfacb65a9e6459ea08bf4947d3b9c2b_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOjk5NTliMzg5MzQwYTRjNTA4ZjBmMTYyZTBmOGMyOTFjL3RhYmxlcmFuZ2U6OTk1OWIzODkzNDBhNGM1MDhmMGYxNjJlMGY4YzI5MWNfMTQtNS0xLTEtMTc0MTA_702fbbd6-4e6e-4b58-9c20-dc733cbdb90d"
      unitRef="usd">588000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i6944c3767530469d9f26618cb4e807e6_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOjk5NTliMzg5MzQwYTRjNTA4ZjBmMTYyZTBmOGMyOTFjL3RhYmxlcmFuZ2U6OTk1OWIzODkzNDBhNGM1MDhmMGYxNjJlMGY4YzI5MWNfMTQtNy0xLTEtMTc0MTA_a585e005-cc63-4e6a-a34d-67eda98bccc7"
      unitRef="usd">-13120000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOjk5NTliMzg5MzQwYTRjNTA4ZjBmMTYyZTBmOGMyOTFjL3RhYmxlcmFuZ2U6OTk1OWIzODkzNDBhNGM1MDhmMGYxNjJlMGY4YzI5MWNfMTQtOS0xLTEtMTc0MTA_b5703f9f-22f4-4a3a-a661-1a88373df3f3"
      unitRef="usd">-12756000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeOperating
      contextRef="iab38511a317c44aa9f0dc79521e2a6d5_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOjk5NTliMzg5MzQwYTRjNTA4ZjBmMTYyZTBmOGMyOTFjL3RhYmxlcmFuZ2U6OTk1OWIzODkzNDBhNGM1MDhmMGYxNjJlMGY4YzI5MWNfMTYtMy0xLTEtMTc0MTA_4b0a1c83-6aa0-4140-9f43-c7cf40b05355"
      unitRef="usd">0</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="i7bfacb65a9e6459ea08bf4947d3b9c2b_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOjk5NTliMzg5MzQwYTRjNTA4ZjBmMTYyZTBmOGMyOTFjL3RhYmxlcmFuZ2U6OTk1OWIzODkzNDBhNGM1MDhmMGYxNjJlMGY4YzI5MWNfMTYtNS0xLTEtMTc0MTA_9310dc32-5db0-43ab-97df-53511fbc6e64"
      unitRef="usd">0</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="i6944c3767530469d9f26618cb4e807e6_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOjk5NTliMzg5MzQwYTRjNTA4ZjBmMTYyZTBmOGMyOTFjL3RhYmxlcmFuZ2U6OTk1OWIzODkzNDBhNGM1MDhmMGYxNjJlMGY4YzI5MWNfMTYtNy0xLTEtMTc0MTA_35042933-a1d4-407a-ab3a-0df53fd7dbbd"
      unitRef="usd">9000</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOjk5NTliMzg5MzQwYTRjNTA4ZjBmMTYyZTBmOGMyOTFjL3RhYmxlcmFuZ2U6OTk1OWIzODkzNDBhNGM1MDhmMGYxNjJlMGY4YzI5MWNfMTYtOS0xLTEtMTc0MTA_7d2a609b-5a10-4a79-8c0f-a72b81310d51"
      unitRef="usd">9000</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestExpense
      contextRef="iab38511a317c44aa9f0dc79521e2a6d5_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOjk5NTliMzg5MzQwYTRjNTA4ZjBmMTYyZTBmOGMyOTFjL3RhYmxlcmFuZ2U6OTk1OWIzODkzNDBhNGM1MDhmMGYxNjJlMGY4YzI5MWNfMTctMy0xLTEtMTc0MTA_c550b2bb-8ec0-4588-96e2-c9a2a2c2fa3b"
      unitRef="usd">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i7bfacb65a9e6459ea08bf4947d3b9c2b_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOjk5NTliMzg5MzQwYTRjNTA4ZjBmMTYyZTBmOGMyOTFjL3RhYmxlcmFuZ2U6OTk1OWIzODkzNDBhNGM1MDhmMGYxNjJlMGY4YzI5MWNfMTctNS0xLTEtMTc0MTA_6c3fa659-7f32-4eba-babb-adfb29dffd03"
      unitRef="usd">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i6944c3767530469d9f26618cb4e807e6_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOjk5NTliMzg5MzQwYTRjNTA4ZjBmMTYyZTBmOGMyOTFjL3RhYmxlcmFuZ2U6OTk1OWIzODkzNDBhNGM1MDhmMGYxNjJlMGY4YzI5MWNfMTctNy0xLTEtMTc0MTA_5ac558d3-7a68-49ca-b2f4-29bffbb9c5dc"
      unitRef="usd">9000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOjk5NTliMzg5MzQwYTRjNTA4ZjBmMTYyZTBmOGMyOTFjL3RhYmxlcmFuZ2U6OTk1OWIzODkzNDBhNGM1MDhmMGYxNjJlMGY4YzI5MWNfMTctOS0xLTEtMTc0MTA_529b0988-e155-4f87-ad4a-e386ec90811b"
      unitRef="usd">9000</us-gaap:InterestExpense>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="iab38511a317c44aa9f0dc79521e2a6d5_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOjk5NTliMzg5MzQwYTRjNTA4ZjBmMTYyZTBmOGMyOTFjL3RhYmxlcmFuZ2U6OTk1OWIzODkzNDBhNGM1MDhmMGYxNjJlMGY4YzI5MWNfMTgtMy0xLTEtMTc0MTA_bb06a8cb-50a5-43a6-b9bb-70bce28dc2fd"
      unitRef="usd">0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i7bfacb65a9e6459ea08bf4947d3b9c2b_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOjk5NTliMzg5MzQwYTRjNTA4ZjBmMTYyZTBmOGMyOTFjL3RhYmxlcmFuZ2U6OTk1OWIzODkzNDBhNGM1MDhmMGYxNjJlMGY4YzI5MWNfMTgtNS0xLTEtMTc0MTA_5cceb087-55df-4e14-a368-de24b498d44d"
      unitRef="usd">0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i6944c3767530469d9f26618cb4e807e6_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOjk5NTliMzg5MzQwYTRjNTA4ZjBmMTYyZTBmOGMyOTFjL3RhYmxlcmFuZ2U6OTk1OWIzODkzNDBhNGM1MDhmMGYxNjJlMGY4YzI5MWNfMTgtNy0xLTEtMTc0MTA_d0d2db93-a252-4df5-86c3-881bcd7dfb86"
      unitRef="usd">-188000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOjk5NTliMzg5MzQwYTRjNTA4ZjBmMTYyZTBmOGMyOTFjL3RhYmxlcmFuZ2U6OTk1OWIzODkzNDBhNGM1MDhmMGYxNjJlMGY4YzI5MWNfMTgtOS0xLTEtMTc0MTA_2e02826d-c59b-4dd4-be30-a1ab47fcb12f"
      unitRef="usd">-188000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="iab38511a317c44aa9f0dc79521e2a6d5_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOjk5NTliMzg5MzQwYTRjNTA4ZjBmMTYyZTBmOGMyOTFjL3RhYmxlcmFuZ2U6OTk1OWIzODkzNDBhNGM1MDhmMGYxNjJlMGY4YzI5MWNfMjItMy0xLTEtMTc0MTA_b5bcc937-3aaa-43c3-aa69-657cc71face9"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i7bfacb65a9e6459ea08bf4947d3b9c2b_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOjk5NTliMzg5MzQwYTRjNTA4ZjBmMTYyZTBmOGMyOTFjL3RhYmxlcmFuZ2U6OTk1OWIzODkzNDBhNGM1MDhmMGYxNjJlMGY4YzI5MWNfMjItNS0xLTEtMTc0MTA_3601496a-59b1-4131-b6d3-e30cf59d9c1d"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i6944c3767530469d9f26618cb4e807e6_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOjk5NTliMzg5MzQwYTRjNTA4ZjBmMTYyZTBmOGMyOTFjL3RhYmxlcmFuZ2U6OTk1OWIzODkzNDBhNGM1MDhmMGYxNjJlMGY4YzI5MWNfMjItNy0xLTEtMTc0MTA_99061aab-9491-4fb8-91e2-6352bef2e5f8"
      unitRef="usd">246000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOjk5NTliMzg5MzQwYTRjNTA4ZjBmMTYyZTBmOGMyOTFjL3RhYmxlcmFuZ2U6OTk1OWIzODkzNDBhNGM1MDhmMGYxNjJlMGY4YzI5MWNfMjItOS0xLTEtMTc0MTA_473fb86d-620f-4517-a7f3-8ccd9bb76cae"
      unitRef="usd">246000</us-gaap:IncomeTaxExpenseBenefit>
    <apyx:TotalRevenuePercent
      contextRef="id6ada2596cf84b118b49af7a6561fb79_D20220701-20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RleHRyZWdpb246YTQzN2Q5YmQxMWFiNGVlYjg3ODFhYzFmZWUyODdiYTNfMTQwNg_473664c5-b908-4e7b-8628-77a39c92d973"
      unitRef="number">0.232</apyx:TotalRevenuePercent>
    <apyx:TotalRevenuePercent
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RleHRyZWdpb246YTQzN2Q5YmQxMWFiNGVlYjg3ODFhYzFmZWUyODdiYTNfMTQxMw_86c11696-5df3-4939-beea-9bcfead0b46d"
      unitRef="number">0.295</apyx:TotalRevenuePercent>
    <apyx:TotalRevenuePercent
      contextRef="ic9b0b6a3c69447bf8f151dfd98c14ac9_D20210701-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RleHRyZWdpb246YTQzN2Q5YmQxMWFiNGVlYjg3ODFhYzFmZWUyODdiYTNfMTUwMQ_8c01f0a5-3314-44d2-9832-eed5a9f426a7"
      unitRef="number">0.331</apyx:TotalRevenuePercent>
    <apyx:TotalRevenuePercent
      contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RleHRyZWdpb246YTQzN2Q5YmQxMWFiNGVlYjg3ODFhYzFmZWUyODdiYTNfMTUwOA_1d830657-4f62-48dc-a100-68a706a680dd"
      unitRef="number">0.342</apyx:TotalRevenuePercent>
    <us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RleHRyZWdpb246YTQzN2Q5YmQxMWFiNGVlYjg3ODFhYzFmZWUyODdiYTNfMTY4MQ_3d13faaa-ee63-44e0-bb5f-760b93f3a378">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue by geographic region, based on the customer's &#x201c;ship to&#x201d; location on the invoice, are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Sales by Domestic and International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8c92311eeeba414cba8eeea9eae36a73_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmI5YzQ3Yjk4OTEwZTQwYTZhZDE2YTQzOWRkMjEyMjZiL3RhYmxlcmFuZ2U6YjljNDdiOTg5MTBlNDBhNmFkMTZhNDM5ZGQyMTIyNmJfMy0xLTEtMS0xNzQxMA_748dd521-2d1c-4584-9ef5-920fadf5a8ac"
      unitRef="usd">6997000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1cbcf0bb6950436780b8711457cab3c0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmI5YzQ3Yjk4OTEwZTQwYTZhZDE2YTQzOWRkMjEyMjZiL3RhYmxlcmFuZ2U6YjljNDdiOTg5MTBlNDBhNmFkMTZhNDM5ZGQyMTIyNmJfMy0zLTEtMS0xNzQxMA_42ee38f7-526f-4e10-a4d1-01671b4f3c62"
      unitRef="usd">7911000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i36f2a37affac45d0a14e5ea2173cf5e1_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmI5YzQ3Yjk4OTEwZTQwYTZhZDE2YTQzOWRkMjEyMjZiL3RhYmxlcmFuZ2U6YjljNDdiOTg5MTBlNDBhNmFkMTZhNDM5ZGQyMTIyNmJfMy01LTEtMS0xNzQxMA_3883a4e0-cb4c-4556-8942-65f18ab5b954"
      unitRef="usd">22492000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4cf11e8a8ad24223ab309b02dcedcecb_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmI5YzQ3Yjk4OTEwZTQwYTZhZDE2YTQzOWRkMjEyMjZiL3RhYmxlcmFuZ2U6YjljNDdiOTg5MTBlNDBhNmFkMTZhNDM5ZGQyMTIyNmJfMy03LTEtMS0xNzQxMA_c066a7ba-e50c-42f2-a04f-e969313dbe86"
      unitRef="usd">20860000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifd22960d67cd4d7fadc9314e44177757_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmI5YzQ3Yjk4OTEwZTQwYTZhZDE2YTQzOWRkMjEyMjZiL3RhYmxlcmFuZ2U6YjljNDdiOTg5MTBlNDBhNmFkMTZhNDM5ZGQyMTIyNmJfNC0xLTEtMS0xNzQxMA_a41819e2-3c10-43a9-b699-d0ad4b998edb"
      unitRef="usd">2117000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6227c7fe3e8c479d92f2f099128bd674_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmI5YzQ3Yjk4OTEwZTQwYTZhZDE2YTQzOWRkMjEyMjZiL3RhYmxlcmFuZ2U6YjljNDdiOTg5MTBlNDBhNmFkMTZhNDM5ZGQyMTIyNmJfNC0zLTEtMS0xNzQxMA_779d4511-617f-4cec-80dc-20e336003a34"
      unitRef="usd">3920000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1d94b2111aef41dfb83851bf1579dc6e_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmI5YzQ3Yjk4OTEwZTQwYTZhZDE2YTQzOWRkMjEyMjZiL3RhYmxlcmFuZ2U6YjljNDdiOTg5MTBlNDBhNmFkMTZhNDM5ZGQyMTIyNmJfNC01LTEtMS0xNzQxMA_696f4e5d-ba1e-44b8-af35-75f72276713c"
      unitRef="usd">9407000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idbb33a02347e4099b5d0a31dcb304fdb_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmI5YzQ3Yjk4OTEwZTQwYTZhZDE2YTQzOWRkMjEyMjZiL3RhYmxlcmFuZ2U6YjljNDdiOTg5MTBlNDBhNmFkMTZhNDM5ZGQyMTIyNmJfNC03LTEtMS0xNzQxMA_3293f5d7-e420-4f6e-ae37-747e98da0b53"
      unitRef="usd">10833000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id6ada2596cf84b118b49af7a6561fb79_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmI5YzQ3Yjk4OTEwZTQwYTZhZDE2YTQzOWRkMjEyMjZiL3RhYmxlcmFuZ2U6YjljNDdiOTg5MTBlNDBhNmFkMTZhNDM5ZGQyMTIyNmJfNS0xLTEtMS0xNzQxMA_21c46bb0-6eaa-4a28-aed4-0290e21eff54"
      unitRef="usd">9114000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic9b0b6a3c69447bf8f151dfd98c14ac9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmI5YzQ3Yjk4OTEwZTQwYTZhZDE2YTQzOWRkMjEyMjZiL3RhYmxlcmFuZ2U6YjljNDdiOTg5MTBlNDBhNmFkMTZhNDM5ZGQyMTIyNmJfNS0zLTEtMS0xNzQxMA_638db13e-99fc-4d31-a4fb-6074615db920"
      unitRef="usd">11831000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4050f508f36d4034b97cc23dac96956a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmI5YzQ3Yjk4OTEwZTQwYTZhZDE2YTQzOWRkMjEyMjZiL3RhYmxlcmFuZ2U6YjljNDdiOTg5MTBlNDBhNmFkMTZhNDM5ZGQyMTIyNmJfNS01LTEtMS0xNzQxMA_536a1ec6-176f-4f33-893d-79f47f22761e"
      unitRef="usd">31899000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifa69d3b7e9cd48418d1cd94c8227f772_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5Nzg4YzcyZjQ4NzRlZGNhNzhjMWM0ZjMwN2ZlYzA1L3NlYzplOTc4OGM3MmY0ODc0ZWRjYTc4YzFjNGYzMDdmZWMwNV82Ny9mcmFnOmE0MzdkOWJkMTFhYjRlZWI4NzgxYWMxZmVlMjg3YmEzL3RhYmxlOmI5YzQ3Yjk4OTEwZTQwYTZhZDE2YTQzOWRkMjEyMjZiL3RhYmxlcmFuZ2U6YjljNDdiOTg5MTBlNDBhNmFkMTZhNDM5ZGQyMTIyNmJfNS03LTEtMS0xNzQxMA_97c6d48a-438e-4e84-9786-e4373e129559"
      unitRef="usd">31693000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>60
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M2*BJ(5*O0.K50_J8<:6%BE[)DUA)I6UXN)56F>VA>*BJ(5Z_P.O7PYL(%<K
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MA8I[Y=;X2]E*EX)OD-XVEPGG!4R:6N.?>T%(3-( C$9^:)(&8#CPB<4:PI'
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M&XOZR*V^47Q;G2G-N%)\4UVN6:JK70G0_U]RKMYNR@&:@\_QWU!+ P04
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M6<3"R1@ZT+54&/JY\+)I&Z#$+\IU5H@FM_6':-)%:$J%HY&#5,*6 T,_"4J
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MC+Y^Z$EP207.Z._7,6X[$AD;!_W1^K'0HNM2.K"6R%E*ES1Q?IQ#)O?&47=
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M#W/V\FVQZE]//2LU'&NI3>XZAL?259I<6Q>_HUM#]CZ9W>S<^AR*9#OG.<]
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M;"]W;W)K<VAE971S+W-H965T,3,N>&ULE5;;;N,V$/V5@39=)$!@W>S$B2^
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M9?K\J1]%P< :&7Q[=<-P< 6;C-*_W!VMEC%-"_7"WX WN].!%VMOP,YAB2B
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M4XM6T-5U^VJ@GJ(-$PZ2VI$+5EA*9>P,$>0RZ<(#SQV!_TX@:3Q/4]A1C]"
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MQ!@+&3$-C(&R@"'35I62WNCDL%M:W;8I:3!@@85B< R#2X#JT" *QP*XKY>
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M5,A5(3A(W$V=>3!>Q.:]??!7@0=U)H/Q9"O$D]E\SJ:.;PAAB:DV"(R69_R
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MXNMPIF_&JF8I3AUJ#(7R&9W9K[\$0_^W&V3C$]GX%OILP521 N,99$79:,P
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M_MT%YKTC\]XE]/&B;AT0*Z#*2+8@2E/;"EB1-A*V8S)5YXA?A#Y/?'%R2=U
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M=KFA%Q:E4:#SE1#ZL#$7'-_L\;]02P,$%     @ B'IJ56;Y-GR0!   XPP
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M3&+:V=R/8+F>X5M<1_^7FFGHT,"0&SBA3UZ1["')<7Q(SY[3"U%"*&L?09'
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M#! 1 ?SY#F-VJH@$];79Z#]02P,$%     @ B'IJ53X_5[II!   :14  !D
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M&F+8@G?U^-M_PWMZO.UH"$PI6JV<<U!N[F@99_FF!WWK"AS+OFD31 _W,3O
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MVU,Y>'FL6#8DRXN3N3F3DJ7%Y8;@)>&Z@WJ^8DR^-/1A7W6X._H/4$L#!!0
M   ( (AZ:E5<IX/&. 0  .$0   9    >&PO=V]R:W-H965T<R]S:&5E=#,T
M+GAM;*U8;6_B.!#^*U9N==J5KDV<-Z '2!0X;4^[703T[J33?3!A &N=.&N;
MTO[[LT,:( E9D/JEQ(EGGGD>VS/C=G=<?)<; (5>8I;(GK51*KVS;1EM(";R
MEJ>0Z"\K+F*B]%"L;9D*(,O,*&:VZSBA'1.:6/UN]FXB^EV^58PF,!%(;N.8
MB-=[8'S7L[#U]F)*UQME7MC];DK6, /UE$Z$'MF%ER6-(9&4)TC JF<-\-T(
M^\8@F_$7A9T\>D:&RH+S[V;PL.Q9CHD(&$3*N"#ZYQF&P)CQI./XD3NU"DQC
M>/S\YOV/C+PFLR 2AIS]39=JT[/:%EK"BFR9FO+=9\@)!<9?Q)G,_J)=/M>Q
M4+25BL>YL8X@ILG^E[SD0AP9:*+U!FYNX%YJX.4&WJ4&?FZ026WOJ60ZC(@B
M_:[@.R3,;.W-/&1B9M::/DW,NL^4T%^IME/]P7 X?1J/T/B?R?AQ-IZAP>,(
M?9M_'D_1\&DZ'3_.T9>'P?W#EX?Y@_[Z<02*4"8_H1OT-!NACQ\^H0^()FB^
MX5M)DJ7LVDJ'99S;41["_3X$]TP(,TAOD>?\AES'=6O,A\WF@U0TFH^:S4<0
M:7.<F>-3<UMK60CJ%H*ZF3_OC+\)>24+!A)I,= @BL26,(G^'2RD$GJ3_U>G
MS]ZC7^_1G/P[F9((>I8^VA+$,UC]7W_!H?-[G5KOZ6ST3LY.E/0*);TF[_U,
M/%BBE+P*SEB=<'L'8>; 9+CG?KO5Z=K/QWHT@ERK1Q4P\,,"\(2F7]#T+Z*Y
MX,E60NWYV3L(CE"=$LE&B&M)5N%<C%OU+(."97 1RXC',96F:M0R#2K0[5:K
MQ+41Z%JN54 <!F=6-"RXAI=M7,&7VTBA'1&")(K6+VY8B2#$88ER(]ZUE*N
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M76\$W>EHU!M,X+Z?W/;O^Y.^WCV' 1&"F'<%IRDJ0ID\TZO3<0JG)V=P K2
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M3*K-M[F,U0$,N Y0]S>,R?U "U1'NME_4$L#!!0    ( (AZ:E6QU4T3> ,
M /8/   9    >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;+57;6_3,!#^*Z>
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M!3#'><PG9/4%ROVH!'T2,_6+5D7L14=#?LXX24JPR"")TN(?/Y4^;  $3SW
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M(%P\V6H8BCX/J P0W^>$\/5$"E2=H_,'4$L#!!0    ( (AZ:E5*UO4=  ,
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M"UCB#9%3MKN'/)^&YHL8$>:)=IEO\]I"T49(EN1@M8(DIMD;/^<Z'  43SG
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MUZK(/&N5LHEDJ>D%YDRJSL(,UZJ[!*X=U/<E8W(_T0&*?C7X U!+ P04
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M^&WZ](75@=S";Y%&>?D7/=5::X 6#SE/X[I8M"#>)-7_\+GNB)T"X0,7D+J
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M70!E]903CVPIJ"J1NB)0%;YD0@$)G&W49!L=EHT]"_;)P7 CH%>E<(!$:GH
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M$^CMJ+<3Z.VHMQ/H[:BW/U+OE$^[F&X]US6^_Y%4Y_.S\?;ZR_*ZV6/G@G.
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M8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " "'>FI5@'0=[NT    K @  $0
M            @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " "'
M>FI5F5R<(Q &  "<)P  $P              @ '+ 0  >&PO=&AE;64O=&AE
M;64Q+GAM;%!+ 0(4 Q0    ( (=Z:E5ZFV@^P04  *T>   8
M  " @0P(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " "'
M>FI5X8T8K'0&  "U&@  &               @($##@  >&PO=V]R:W-H965T
M<R]S:&5E=#(N>&UL4$L! A0#%     @ AWIJ51-PJ-)= P  F0D  !@
M         ("!K10  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0
M   ( (AZ:E5!->R%108   0=   8              " @4 8  !X;"]W;W)K
M<VAE971S+W-H965T-"YX;6Q02P$"% ,4    " "(>FI5[:4K,T((   61P
M&               @(&['@  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L!
M A0#%     @ B'IJ51W:6)?D!@   1\  !@              ("!,R<  'AL
M+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( (AZ:E4O6E*<+ \
M )0I   8              " @4TN  !X;"]W;W)K<VAE971S+W-H965T-RYX
M;6Q02P$"% ,4    " "(>FI5XB@T2*<$  !!"@  &               @(&O
M/0  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ B'IJ52,D
M686W!   E0L  !@              ("!C$(  'AL+W=O<FMS:&5E=',O<VAE
M970Y+GAM;%!+ 0(4 Q0    ( (AZ:E6_Z25:3P,  /T&   9
M  " @7E'  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @
MB'IJ504*<_";!   U!(  !D              ("!_TH  'AL+W=O<FMS:&5E
M=',O<VAE970Q,2YX;6Q02P$"% ,4    " "(>FI5ICCL[M\#  "9"   &0
M            @('13P  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4
M Q0    ( (AZ:E7>D)(LN0,  %$(   9              " @>=3  !X;"]W
M;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ B'IJ58K3!0#" P
ME@@  !D              ("!UU<  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX
M;6Q02P$"% ,4    " "(>FI5GJ=<#L,%  " #0  &0              @('0
M6P  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( (AZ:E59
M1FI4O00  ,H,   9              " @<IA  !X;"]W;W)K<VAE971S+W-H
M965T,38N>&UL4$L! A0#%     @ B'IJ59"QJ*_*"0  :QH  !D
M     ("!OF8  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( (AZ:E7RG:I'=@,  "H*   9              "
M@9^%  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ B'IJ
M50F!U9IV P  ?@<  !D              ("!3(D  'AL+W=O<FMS:&5E=',O
M<VAE970R,RYX;6Q02P$"% ,4    " "(>FI5N6+]T=4"   Z!@  &0
M        @('YC   >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0
M   ( (AZ:E4*2W5L+@,  .<&   9              " @060  !X;"]W;W)K
M<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ B'IJ5:I87"2? P  OP<
M !D              ("!:I,  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q0
M2P$"% ,4    " "(>FI59ODV?) $  #C#   &0              @(% EP
M>&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( (AZ:E4E?18&
M]@,  $(3   9              " @0><  !X;"]W;W)K<VAE971S+W-H965T
M,C@N>&UL4$L! A0#%     @ B'IJ53X_5[II!   :14  !D
M ("!-*   'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    " "(
M>FI5],P6P=X"   2"   &0              @('4I   >&PO=V]R:W-H965T
M<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( (AZ:E4*GL!E'0(  $$%   9
M          " @>FG  !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#
M%     @ B'IJ57.X8U^A @  9 @  !D              ("!/:H  'AL+W=O
M<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    " "(>FI5X=U9 C@$  #H
M%0  &0              @($5K0  >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM
M;%!+ 0(4 Q0    ( (AZ:E5<IX/&. 0  .$0   9              " @82Q
M  !X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ B'IJ56<%
MYEQZ @  &08  !D              ("!\[4  'AL+W=O<FMS:&5E=',O<VAE
M970S-2YX;6Q02P$"% ,4    " "(>FI5HS\;QZ$"   1"   &0
M    @(&DN   >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    (
M (AZ:E4]8,3P!@0  "D3   9              " @7R[  !X;"]W;W)K<VAE
M971S+W-H965T,S<N>&UL4$L! A0#%     @ B'IJ5>;S=Q)J!   F10  !D
M             ("!N;\  'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"
M% ,4    " "(>FI5IV>O_RH#  #@"0  &0              @(%:Q   >&PO
M=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( (AZ:E5MOEOX4 ,
M  8+   9              " @;O'  !X;"]W;W)K<VAE971S+W-H965T-# N
M>&UL4$L! A0#%     @ B'IJ5=%C.?9H P  E0P  !D              ("!
M0LL  'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"% ,4    " "(>FI5
M?DPH4)8#  #>#0  &0              @('AS@  >&PO=V]R:W-H965T<R]S
M:&5E=#0R+GAM;%!+ 0(4 Q0    ( (AZ:E6QU4T3> ,  /8/   9
M      " @:[2  !X;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%
M  @ B'IJ5:$8Z\[U @  10H  !D              ("!7=8  'AL+W=O<FMS
M:&5E=',O<VAE970T-"YX;6Q02P$"% ,4    " "(>FI52M;U'0 #  "["@
M&0              @(&)V0  >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+
M 0(4 Q0    ( (AZ:E5OP8(90P8  ',F   9              " @<#<  !X
M;"]W;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @ B'IJ54@7)%QV
M P  X@\  !D              ("!.N,  'AL+W=O<FMS:&5E=',O<VAE970T
M-RYX;6Q02P$"% ,4    " "(>FI5Q4"#G4(#  #*%   #0
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:+GAM;%!+!08     -P W /@.  !R\P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>107</ContextCount>
  <ElementCount>228</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>20</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="apyx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="apyx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="apyx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="apyx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="apyx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="apyx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="apyx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Disclosure - BASIS OF PRESENTATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/BASISOFPRESENTATION</Role>
      <ShortName>BASIS OF PRESENTATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="apyx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/RECENTACCOUNTINGPRONOUNCEMENTS</Role>
      <ShortName>RECENT ACCOUNTING PRONOUNCEMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="apyx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - DISPOSAL OF BUSINESS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/DISPOSALOFBUSINESS</Role>
      <ShortName>DISPOSAL OF BUSINESS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="apyx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - INVENTORIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/INVENTORIES</Role>
      <ShortName>INVENTORIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="apyx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - LEASES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/LEASES</Role>
      <ShortName>LEASES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="apyx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES</Role>
      <ShortName>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="apyx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - CHINA JOINT VENTURE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/CHINAJOINTVENTURE</Role>
      <ShortName>CHINA JOINT VENTURE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="apyx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - EARNINGS (LOSS) PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/EARNINGSLOSSPERSHARE</Role>
      <ShortName>EARNINGS (LOSS) PER SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="apyx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - STOCK-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/STOCKBASEDCOMPENSATION</Role>
      <ShortName>STOCK-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="apyx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/INCOMETAXES</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="apyx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIES</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="apyx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONS</Role>
      <ShortName>RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="apyx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATION</Role>
      <ShortName>GEOGRAPHIC AND SEGMENT INFORMATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="apyx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - BASIS OF PRESENTATION (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/BASISOFPRESENTATIONPolicies</Role>
      <ShortName>BASIS OF PRESENTATION (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="apyx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - INVENTORIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/INVENTORIESTables</Role>
      <ShortName>INVENTORIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://apyxmedical.com/role/INVENTORIES</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="apyx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - LEASES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/LEASESTables</Role>
      <ShortName>LEASES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://apyxmedical.com/role/LEASES</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="apyx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables</Role>
      <ShortName>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="apyx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - CHINA JOINT VENTURE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/CHINAJOINTVENTURETables</Role>
      <ShortName>CHINA JOINT VENTURE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://apyxmedical.com/role/CHINAJOINTVENTURE</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="apyx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - EARNINGS (LOSS) PER SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/EARNINGSLOSSPERSHARETables</Role>
      <ShortName>EARNINGS (LOSS) PER SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://apyxmedical.com/role/EARNINGSLOSSPERSHARE</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="apyx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - STOCK-BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONTables</Role>
      <ShortName>STOCK-BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://apyxmedical.com/role/STOCKBASEDCOMPENSATION</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="apyx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONTables</Role>
      <ShortName>GEOGRAPHIC AND SEGMENT INFORMATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATION</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="apyx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - BASIS OF PRESENTATION - NARRATIVE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/BASISOFPRESENTATIONNARRATIVEDetails</Role>
      <ShortName>BASIS OF PRESENTATION - NARRATIVE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="apyx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - DISPOSAL OF BUSINESS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/DISPOSALOFBUSINESSDetails</Role>
      <ShortName>DISPOSAL OF BUSINESS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://apyxmedical.com/role/DISPOSALOFBUSINESS</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="apyx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - INVENTORIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/INVENTORIESDetails</Role>
      <ShortName>INVENTORIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://apyxmedical.com/role/INVENTORIESTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="apyx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - LEASES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/LEASESNarrativeDetails</Role>
      <ShortName>LEASES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="apyx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - LEASES - Lease Terms and Discount Rates (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/LEASESLeaseTermsandDiscountRatesDetails</Role>
      <ShortName>LEASES - Lease Terms and Discount Rates (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="apyx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - LEASES - Maturities of Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails</Role>
      <ShortName>LEASES - Maturities of Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="apyx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails</Role>
      <ShortName>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="apyx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESNarrativeDetails</Role>
      <ShortName>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="apyx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - CHINA JOINT VENTURE - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/CHINAJOINTVENTURENarrativeDetails</Role>
      <ShortName>CHINA JOINT VENTURE - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="apyx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - CHINA JOINT VENTURE - Rollforward of Joint Venture (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/CHINAJOINTVENTURERollforwardofJointVentureDetails</Role>
      <ShortName>CHINA JOINT VENTURE - Rollforward of Joint Venture (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="apyx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - EARNINGS (LOSS) PER SHARE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails</Role>
      <ShortName>EARNINGS (LOSS) PER SHARE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://apyxmedical.com/role/EARNINGSLOSSPERSHARETables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="apyx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="apyx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - STOCK-BASED COMPENSATION - Summary of Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONSummaryofStockOptionsDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Summary of Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="apyx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - STOCK-BASED COMPENSATION - Fair Value Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONFairValueAssumptionsDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Fair Value Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="apyx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - INCOME TAXES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/INCOMETAXESDetails</Role>
      <ShortName>INCOME TAXES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://apyxmedical.com/role/INCOMETAXES</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="apyx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - COMMITMENTS AND CONTINGENCIES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="apyx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - RELATED PARTY TRANSACTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSDetails</Role>
      <ShortName>RELATED PARTY TRANSACTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONS</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="apyx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONNarrativeDetails</Role>
      <ShortName>GEOGRAPHIC AND SEGMENT INFORMATION - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="apyx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION - Reportable Segment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails</Role>
      <ShortName>GEOGRAPHIC AND SEGMENT INFORMATION - Reportable Segment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="apyx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION - Geographic (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails</Role>
      <ShortName>GEOGRAPHIC AND SEGMENT INFORMATION - Geographic (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="apyx-20220930.htm">apyx-20220930.htm</File>
    <File>a2022q310-qexhibit311.htm</File>
    <File>a2022q310-qexhibit312.htm</File>
    <File>a2022q310-qexhibit321.htm</File>
    <File>a2022q310-qexhibit322.htm</File>
    <File>apyx-20220930.xsd</File>
    <File>apyx-20220930_cal.xml</File>
    <File>apyx-20220930_def.xml</File>
    <File>apyx-20220930_lab.xml</File>
    <File>apyx-20220930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>apyx-20220930_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="586">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>65
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "apyx-20220930.htm": {
   "axisCustom": 0,
   "axisStandard": 10,
   "contextCount": 107,
   "dts": {
    "calculationLink": {
     "local": [
      "apyx-20220930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "apyx-20220930_def.xml"
     ]
    },
    "inline": {
     "local": [
      "apyx-20220930.htm"
     ]
    },
    "labelLink": {
     "local": [
      "apyx-20220930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "apyx-20220930_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "apyx-20220930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 327,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 5
   },
   "keyCustom": 20,
   "keyStandard": 208,
   "memberCustom": 7,
   "memberStandard": 13,
   "nsprefix": "apyx",
   "nsuri": "http://apyxmedical.com/20220930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20220930.htm",
      "contextRef": "i4050f508f36d4034b97cc23dac96956a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover",
     "role": "http://apyxmedical.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20220930.htm",
      "contextRef": "i4050f508f36d4034b97cc23dac96956a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20220930.htm",
      "contextRef": "i4050f508f36d4034b97cc23dac96956a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - INVENTORIES",
     "role": "http://apyxmedical.com/role/INVENTORIES",
     "shortName": "INVENTORIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20220930.htm",
      "contextRef": "i4050f508f36d4034b97cc23dac96956a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LesseeFinanceLeasesTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20220930.htm",
      "contextRef": "i4050f508f36d4034b97cc23dac96956a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - LEASES",
     "role": "http://apyxmedical.com/role/LEASES",
     "shortName": "LEASES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LesseeFinanceLeasesTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20220930.htm",
      "contextRef": "i4050f508f36d4034b97cc23dac96956a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20220930.htm",
      "contextRef": "i4050f508f36d4034b97cc23dac96956a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES",
     "role": "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES",
     "shortName": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20220930.htm",
      "contextRef": "i4050f508f36d4034b97cc23dac96956a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20220930.htm",
      "contextRef": "i4050f508f36d4034b97cc23dac96956a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MinorityInterestDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - CHINA JOINT VENTURE",
     "role": "http://apyxmedical.com/role/CHINAJOINTVENTURE",
     "shortName": "CHINA JOINT VENTURE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20220930.htm",
      "contextRef": "i4050f508f36d4034b97cc23dac96956a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MinorityInterestDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20220930.htm",
      "contextRef": "i4050f508f36d4034b97cc23dac96956a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - EARNINGS (LOSS) PER SHARE",
     "role": "http://apyxmedical.com/role/EARNINGSLOSSPERSHARE",
     "shortName": "EARNINGS (LOSS) PER SHARE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20220930.htm",
      "contextRef": "i4050f508f36d4034b97cc23dac96956a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20220930.htm",
      "contextRef": "i4050f508f36d4034b97cc23dac96956a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - STOCK-BASED COMPENSATION",
     "role": "http://apyxmedical.com/role/STOCKBASEDCOMPENSATION",
     "shortName": "STOCK-BASED COMPENSATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20220930.htm",
      "contextRef": "i4050f508f36d4034b97cc23dac96956a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20220930.htm",
      "contextRef": "i4050f508f36d4034b97cc23dac96956a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - INCOME TAXES",
     "role": "http://apyxmedical.com/role/INCOMETAXES",
     "shortName": "INCOME TAXES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20220930.htm",
      "contextRef": "i4050f508f36d4034b97cc23dac96956a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20220930.htm",
      "contextRef": "i4050f508f36d4034b97cc23dac96956a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "role": "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20220930.htm",
      "contextRef": "i4050f508f36d4034b97cc23dac96956a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20220930.htm",
      "contextRef": "i4050f508f36d4034b97cc23dac96956a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - RELATED PARTY TRANSACTIONS",
     "role": "http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONS",
     "shortName": "RELATED PARTY TRANSACTIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20220930.htm",
      "contextRef": "i4050f508f36d4034b97cc23dac96956a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20220930.htm",
      "contextRef": "i4050f508f36d4034b97cc23dac96956a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION",
     "role": "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATION",
     "shortName": "GEOGRAPHIC AND SEGMENT INFORMATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20220930.htm",
      "contextRef": "i4050f508f36d4034b97cc23dac96956a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20220930.htm",
      "contextRef": "ic42af16cc8974cebbc452370076f22e5_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS",
     "role": "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20220930.htm",
      "contextRef": "ic42af16cc8974cebbc452370076f22e5_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20220930.htm",
      "contextRef": "i4050f508f36d4034b97cc23dac96956a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PriorPeriodReclassificationAdjustmentDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - BASIS OF PRESENTATION (Policies)",
     "role": "http://apyxmedical.com/role/BASISOFPRESENTATIONPolicies",
     "shortName": "BASIS OF PRESENTATION (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20220930.htm",
      "contextRef": "i4050f508f36d4034b97cc23dac96956a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PriorPeriodReclassificationAdjustmentDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20220930.htm",
      "contextRef": "i4050f508f36d4034b97cc23dac96956a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - INVENTORIES (Tables)",
     "role": "http://apyxmedical.com/role/INVENTORIESTables",
     "shortName": "INVENTORIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20220930.htm",
      "contextRef": "i4050f508f36d4034b97cc23dac96956a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20220930.htm",
      "contextRef": "i4050f508f36d4034b97cc23dac96956a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - LEASES (Tables)",
     "role": "http://apyxmedical.com/role/LEASESTables",
     "shortName": "LEASES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20220930.htm",
      "contextRef": "i4050f508f36d4034b97cc23dac96956a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20220930.htm",
      "contextRef": "i4050f508f36d4034b97cc23dac96956a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)",
     "role": "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables",
     "shortName": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20220930.htm",
      "contextRef": "i4050f508f36d4034b97cc23dac96956a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20220930.htm",
      "contextRef": "i4050f508f36d4034b97cc23dac96956a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "apyx:NoncontrollingInterestTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - CHINA JOINT VENTURE (Tables)",
     "role": "http://apyxmedical.com/role/CHINAJOINTVENTURETables",
     "shortName": "CHINA JOINT VENTURE (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20220930.htm",
      "contextRef": "i4050f508f36d4034b97cc23dac96956a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "apyx:NoncontrollingInterestTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20220930.htm",
      "contextRef": "i4050f508f36d4034b97cc23dac96956a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - EARNINGS (LOSS) PER SHARE (Tables)",
     "role": "http://apyxmedical.com/role/EARNINGSLOSSPERSHARETables",
     "shortName": "EARNINGS (LOSS) PER SHARE (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20220930.htm",
      "contextRef": "i4050f508f36d4034b97cc23dac96956a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20220930.htm",
      "contextRef": "i4050f508f36d4034b97cc23dac96956a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - STOCK-BASED COMPENSATION (Tables)",
     "role": "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONTables",
     "shortName": "STOCK-BASED COMPENSATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20220930.htm",
      "contextRef": "i4050f508f36d4034b97cc23dac96956a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20220930.htm",
      "contextRef": "i4050f508f36d4034b97cc23dac96956a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION (Tables)",
     "role": "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONTables",
     "shortName": "GEOGRAPHIC AND SEGMENT INFORMATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20220930.htm",
      "contextRef": "i4050f508f36d4034b97cc23dac96956a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20220930.htm",
      "contextRef": "i10095f0cb8c949fbb4f3d9e2b6c90b20_D20180830-20180830",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromDivestitureOfBusinesses",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - BASIS OF PRESENTATION - NARRATIVE (Details)",
     "role": "http://apyxmedical.com/role/BASISOFPRESENTATIONNARRATIVEDetails",
     "shortName": "BASIS OF PRESENTATION - NARRATIVE (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20220930.htm",
      "contextRef": "i10095f0cb8c949fbb4f3d9e2b6c90b20_D20180830-20180830",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromDivestitureOfBusinesses",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - DISPOSAL OF BUSINESS (Details)",
     "role": "http://apyxmedical.com/role/DISPOSALOFBUSINESSDetails",
     "shortName": "DISPOSAL OF BUSINESS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20220930.htm",
      "contextRef": "i8c47d3c9d755423bac06c8de9bc6733a_D20180830-20180830",
      "decimals": null,
      "lang": "en-US",
      "name": "apyx:AssetPurchaseAgreementTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20220930.htm",
      "contextRef": "ic42af16cc8974cebbc452370076f22e5_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20220930.htm",
      "contextRef": "ic42af16cc8974cebbc452370076f22e5_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20220930.htm",
      "contextRef": "ic42af16cc8974cebbc452370076f22e5_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - INVENTORIES (Details)",
     "role": "http://apyxmedical.com/role/INVENTORIESDetails",
     "shortName": "INVENTORIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20220930.htm",
      "contextRef": "ic42af16cc8974cebbc452370076f22e5_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20220930.htm",
      "contextRef": "ic42af16cc8974cebbc452370076f22e5_I20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseRenewalTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - LEASES - Narrative (Details)",
     "role": "http://apyxmedical.com/role/LEASESNarrativeDetails",
     "shortName": "LEASES - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20220930.htm",
      "contextRef": "ic42af16cc8974cebbc452370076f22e5_I20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseRenewalTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20220930.htm",
      "contextRef": "ic42af16cc8974cebbc452370076f22e5_I20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - LEASES - Lease Terms and Discount Rates (Details)",
     "role": "http://apyxmedical.com/role/LEASESLeaseTermsandDiscountRatesDetails",
     "shortName": "LEASES - Lease Terms and Discount Rates (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20220930.htm",
      "contextRef": "ic42af16cc8974cebbc452370076f22e5_I20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20220930.htm",
      "contextRef": "ic42af16cc8974cebbc452370076f22e5_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - LEASES - Maturities of Lease Liabilities (Details)",
     "role": "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails",
     "shortName": "LEASES - Maturities of Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20220930.htm",
      "contextRef": "ic42af16cc8974cebbc452370076f22e5_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20220930.htm",
      "contextRef": "ic42af16cc8974cebbc452370076f22e5_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccruedSalariesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)",
     "role": "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails",
     "shortName": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20220930.htm",
      "contextRef": "ic42af16cc8974cebbc452370076f22e5_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccruedSalariesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20220930.htm",
      "contextRef": "ic42af16cc8974cebbc452370076f22e5_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "apyx:JointAndSeveralPayrollLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES - Narrative (Details)",
     "role": "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESNarrativeDetails",
     "shortName": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20220930.htm",
      "contextRef": "i84408c5278f544ccb03b5314b28177f5_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "apyx:NoncontrollingInterestRequiredCapitalContribution",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - CHINA JOINT VENTURE - Narrative (Details)",
     "role": "http://apyxmedical.com/role/CHINAJOINTVENTURENarrativeDetails",
     "shortName": "CHINA JOINT VENTURE - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20220930.htm",
      "contextRef": "i84408c5278f544ccb03b5314b28177f5_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "apyx:NoncontrollingInterestRequiredCapitalContribution",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20220930.htm",
      "contextRef": "i6366ccfc5be94d939469c44eee70e010_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MinorityInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - CHINA JOINT VENTURE - Rollforward of Joint Venture (Details)",
     "role": "http://apyxmedical.com/role/CHINAJOINTVENTURERollforwardofJointVentureDetails",
     "shortName": "CHINA JOINT VENTURE - Rollforward of Joint Venture (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "apyx:NoncontrollingInterestTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20220930.htm",
      "contextRef": "i8d492a2b0cb940b3a3efba0a8c74f3b2_I20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:MinorityInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted",
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20220930.htm",
      "contextRef": "id6ada2596cf84b118b49af7a6561fb79_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - EARNINGS (LOSS) PER SHARE (Details)",
     "role": "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails",
     "shortName": "EARNINGS (LOSS) PER SHARE (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted",
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20220930.htm",
      "contextRef": "id6ada2596cf84b118b49af7a6561fb79_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20220930.htm",
      "contextRef": "id6ada2596cf84b118b49af7a6561fb79_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details)",
     "role": "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
     "shortName": "STOCK-BASED COMPENSATION - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20220930.htm",
      "contextRef": "id6ada2596cf84b118b49af7a6561fb79_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20220930.htm",
      "contextRef": "id6ada2596cf84b118b49af7a6561fb79_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "role": "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20220930.htm",
      "contextRef": "id6ada2596cf84b118b49af7a6561fb79_D20220701-20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20220930.htm",
      "contextRef": "i6366ccfc5be94d939469c44eee70e010_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - STOCK-BASED COMPENSATION - Summary of Stock Options (Details)",
     "role": "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONSummaryofStockOptionsDetails",
     "shortName": "STOCK-BASED COMPENSATION - Summary of Stock Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20220930.htm",
      "contextRef": "i6366ccfc5be94d939469c44eee70e010_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20220930.htm",
      "contextRef": "i4050f508f36d4034b97cc23dac96956a_D20220101-20220930",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - STOCK-BASED COMPENSATION - Fair Value Assumptions (Details)",
     "role": "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONFairValueAssumptionsDetails",
     "shortName": "STOCK-BASED COMPENSATION - Fair Value Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20220930.htm",
      "contextRef": "i4050f508f36d4034b97cc23dac96956a_D20220101-20220930",
      "decimals": "3",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20220930.htm",
      "contextRef": "id6ada2596cf84b118b49af7a6561fb79_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - INCOME TAXES (Details)",
     "role": "http://apyxmedical.com/role/INCOMETAXESDetails",
     "shortName": "INCOME TAXES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20220930.htm",
      "contextRef": "id6ada2596cf84b118b49af7a6561fb79_D20220701-20220930",
      "decimals": "3",
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20220930.htm",
      "contextRef": "ic42af16cc8974cebbc452370076f22e5_I20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PurchaseObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - COMMITMENTS AND CONTINGENCIES - Narrative (Details)",
     "role": "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
     "shortName": "COMMITMENTS AND CONTINGENCIES - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20220930.htm",
      "contextRef": "ic42af16cc8974cebbc452370076f22e5_I20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PurchaseObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20220930.htm",
      "contextRef": "if06767f062cc44ada17fa9800b45b707_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - RELATED PARTY TRANSACTIONS (Details)",
     "role": "http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSDetails",
     "shortName": "RELATED PARTY TRANSACTIONS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20220930.htm",
      "contextRef": "if06767f062cc44ada17fa9800b45b707_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:NumberOfOperatingSegments",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20220930.htm",
      "contextRef": "i4050f508f36d4034b97cc23dac96956a_D20220101-20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION - Narrative (Details)",
     "role": "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONNarrativeDetails",
     "shortName": "GEOGRAPHIC AND SEGMENT INFORMATION - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:NumberOfOperatingSegments",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20220930.htm",
      "contextRef": "i4050f508f36d4034b97cc23dac96956a_D20220101-20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20220930.htm",
      "contextRef": "id6ada2596cf84b118b49af7a6561fb79_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION - Reportable Segment (Details)",
     "role": "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails",
     "shortName": "GEOGRAPHIC AND SEGMENT INFORMATION - Reportable Segment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20220930.htm",
      "contextRef": "ib86c17a29ad64fff8b4f5645ccc11575_D20220701-20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20220930.htm",
      "contextRef": "id6ada2596cf84b118b49af7a6561fb79_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION - Geographic (Details)",
     "role": "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails",
     "shortName": "GEOGRAPHIC AND SEGMENT INFORMATION - Geographic (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20220930.htm",
      "contextRef": "i8c92311eeeba414cba8eeea9eae36a73_D20220701-20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20220930.htm",
      "contextRef": "iac6178b585a24bdd9c611d8f43b21488_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY",
     "role": "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20220930.htm",
      "contextRef": "iac6178b585a24bdd9c611d8f43b21488_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20220930.htm",
      "contextRef": "i4050f508f36d4034b97cc23dac96956a_D20220101-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20220930.htm",
      "contextRef": "i4050f508f36d4034b97cc23dac96956a_D20220101-20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20220930.htm",
      "contextRef": "i4050f508f36d4034b97cc23dac96956a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000007 - Disclosure - BASIS OF PRESENTATION",
     "role": "http://apyxmedical.com/role/BASISOFPRESENTATION",
     "shortName": "BASIS OF PRESENTATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20220930.htm",
      "contextRef": "i4050f508f36d4034b97cc23dac96956a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20220930.htm",
      "contextRef": "i4050f508f36d4034b97cc23dac96956a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000008 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS",
     "role": "http://apyxmedical.com/role/RECENTACCOUNTINGPRONOUNCEMENTS",
     "shortName": "RECENT ACCOUNTING PRONOUNCEMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20220930.htm",
      "contextRef": "i4050f508f36d4034b97cc23dac96956a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20220930.htm",
      "contextRef": "i4050f508f36d4034b97cc23dac96956a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - DISPOSAL OF BUSINESS",
     "role": "http://apyxmedical.com/role/DISPOSALOFBUSINESS",
     "shortName": "DISPOSAL OF BUSINESS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20220930.htm",
      "contextRef": "i4050f508f36d4034b97cc23dac96956a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 20,
   "tag": {
    "apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Liabilities and Other Liabilities, Current",
        "label": "Accrued Liabilities and Other Liabilities, Current",
        "terseLabel": "Accrued expenses and other current liabilities",
        "totalLabel": "Total accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesAndOtherLiabilitiesCurrent",
     "nsuri": "http://apyxmedical.com/20220930",
     "presentation": [
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails",
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_AdvancedEnergyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Advanced Energy [Member]",
        "label": "Advanced Energy [Member]",
        "terseLabel": "Advanced Energy"
       }
      }
     },
     "localname": "AdvancedEnergyMember",
     "nsuri": "http://apyxmedical.com/20220930",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "apyx_AssetPurchaseAgreementTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Purchase Agreement, Term",
        "label": "Asset Purchase Agreement, Term",
        "terseLabel": "Asset purchase agreement, term"
       }
      }
     },
     "localname": "AssetPurchaseAgreementTerm",
     "nsuri": "http://apyxmedical.com/20220930",
     "presentation": [
      "http://apyxmedical.com/role/DISPOSALOFBUSINESSDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "apyx_CapitalizationOfLeaseExecution": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capitalization Of Lease, Execution",
        "label": "Capitalization Of Lease, Execution",
        "terseLabel": "Right-of-use assets capitalized and finance lease liabilities recognized upon execution of lease"
       }
      }
     },
     "localname": "CapitalizationOfLeaseExecution",
     "nsuri": "http://apyxmedical.com/20220930",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_CapitalizationOfLeaseNonCash": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capitalization Of Lease, Non Cash",
        "label": "Capitalization Of Lease, Non Cash",
        "terseLabel": "Right-of-use assets capitalized and operating lease liabilities recognized upon lease modification"
       }
      }
     },
     "localname": "CapitalizationOfLeaseNonCash",
     "nsuri": "http://apyxmedical.com/20220930",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_ChineseSupplierMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Chinese Supplier",
        "label": "Chinese Supplier [Member]",
        "terseLabel": "Chinese Supplier"
       }
      }
     },
     "localname": "ChineseSupplierMember",
     "nsuri": "http://apyxmedical.com/20220930",
     "presentation": [
      "http://apyxmedical.com/role/CHINAJOINTVENTURENarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "apyx_ContractWithInternationalDistributorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract with International Distributor",
        "label": "Contract with International Distributor [Member]",
        "terseLabel": "Contract with International Distributor"
       }
      }
     },
     "localname": "ContractWithInternationalDistributorMember",
     "nsuri": "http://apyxmedical.com/20220930",
     "presentation": [
      "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "apyx_ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Electro Surgical Disposables And Accessories, Cauteries And Other Products Supply Agreement [Member]",
        "label": "Electro Surgical Disposables And Accessories, Cauteries And Other Products Supply Agreement [Member]",
        "terseLabel": "Electro Surgical Disposables and Accessories, Cauteries and Other Products Supply Agreement"
       }
      }
     },
     "localname": "ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember",
     "nsuri": "http://apyxmedical.com/20220930",
     "presentation": [
      "http://apyxmedical.com/role/DISPOSALOFBUSINESSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "apyx_FinanceLeaseCostsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance Lease, Costs [Abstract]",
        "label": "Finance Lease, Costs [Abstract]",
        "terseLabel": "Finance"
       }
      }
     },
     "localname": "FinanceLeaseCostsAbstract",
     "nsuri": "http://apyxmedical.com/20220930",
     "presentation": [
      "http://apyxmedical.com/role/LEASESLeaseTermsandDiscountRatesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "apyx_FinanceLeaseLiabilityToBePaidDueAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance Lease, liability, To Be Paid, Due After Year Four",
        "label": "Finance Lease, liability, To Be Paid, Due After Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityToBePaidDueAfterYearFour",
     "nsuri": "http://apyxmedical.com/20220930",
     "presentation": [
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_JointAndSeveralPayrollLiability": {
     "auth_ref": [],
     "calculation": {
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": {
       "order": 7.0,
       "parentTag": "apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Joint And Several Payroll Liability",
        "label": "Joint And Several Payroll Liability",
        "negatedLabel": "Joint and several payroll liability",
        "terseLabel": "Joint and several payroll liability"
       }
      }
     },
     "localname": "JointAndSeveralPayrollLiability",
     "nsuri": "http://apyxmedical.com/20220930",
     "presentation": [
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails",
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, to be Paid, Due after Year Four",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Due after Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour",
     "nsuri": "http://apyxmedical.com/20220930",
     "presentation": [
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_NoncontrollingInterestRequiredCapitalContribution": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncontrolling Interest, Required Capital Contribution",
        "label": "Noncontrolling Interest, Required Capital Contribution",
        "terseLabel": "Required capital contribution"
       }
      }
     },
     "localname": "NoncontrollingInterestRequiredCapitalContribution",
     "nsuri": "http://apyxmedical.com/20220930",
     "presentation": [
      "http://apyxmedical.com/role/CHINAJOINTVENTURENarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_NoncontrollingInterestTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncontrolling Interest",
        "label": "Noncontrolling Interest [Table Text Block]",
        "terseLabel": "Schedule of China Joint Venture"
       }
      }
     },
     "localname": "NoncontrollingInterestTableTextBlock",
     "nsuri": "http://apyxmedical.com/20220930",
     "presentation": [
      "http://apyxmedical.com/role/CHINAJOINTVENTURETables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "apyx_OEMMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "OEM [Member]",
        "terseLabel": "OEM"
       }
      }
     },
     "localname": "OEMMember",
     "nsuri": "http://apyxmedical.com/20220930",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "apyx_OperatingLeaseCostsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, Costs [Abstract]",
        "label": "Operating Lease, Costs [Abstract]",
        "terseLabel": "Operating"
       }
      }
     },
     "localname": "OperatingLeaseCostsAbstract",
     "nsuri": "http://apyxmedical.com/20220930",
     "presentation": [
      "http://apyxmedical.com/role/LEASESLeaseTermsandDiscountRatesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "apyx_OtherAccruedExpensesAndLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": {
       "order": 10.0,
       "parentTag": "apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Accrued Expenses And Liabilities, Current",
        "label": "Other Accrued Expenses And Liabilities, Current",
        "terseLabel": "Other accrued expenses and current liabilities"
       }
      }
     },
     "localname": "OtherAccruedExpensesAndLiabilitiesCurrent",
     "nsuri": "http://apyxmedical.com/20220930",
     "presentation": [
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised": {
     "auth_ref": [],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Stock Options Exercised And Warrants Exercised",
        "label": "Proceeds From Stock Options Exercised And Warrants Exercised",
        "terseLabel": "Proceeds from stock option exercises"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercisedAndWarrantsExercised",
     "nsuri": "http://apyxmedical.com/20220930",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_ProvisionForInventoryObsolescence": {
     "auth_ref": [],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Provision For Inventory Obsolescence",
        "label": "Provision For Inventory Obsolescence",
        "terseLabel": "Provision for inventory obsolescence"
       }
      }
     },
     "localname": "ProvisionForInventoryObsolescence",
     "nsuri": "http://apyxmedical.com/20220930",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_ProvisionForObsolescenceInventory": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Provision For Obsolescence, Inventory",
        "label": "Provision For Obsolescence, Inventory",
        "terseLabel": "Inventories, provision for obsolescence"
       }
      }
     },
     "localname": "ProvisionForObsolescenceInventory",
     "nsuri": "http://apyxmedical.com/20220930",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_RepaymentOfFinanceLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Repayment Of Finance Lease Liabilities",
        "label": "Repayment Of Finance Lease Liabilities",
        "negatedTerseLabel": "Repayment of finance lease liabilities"
       }
      }
     },
     "localname": "RepaymentOfFinanceLeaseLiabilities",
     "nsuri": "http://apyxmedical.com/20220930",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_ShortTermContractLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": {
       "order": 11.0,
       "parentTag": "apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short-Term Contract Liabilities",
        "label": "Short-Term Contract Liabilities",
        "terseLabel": "Short-term contract liabilities"
       }
      }
     },
     "localname": "ShortTermContractLiabilities",
     "nsuri": "http://apyxmedical.com/20220930",
     "presentation": [
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_StockIssuedDuringPeriodSharesStockSwaps": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Stock Swaps",
        "label": "Stock Issued During Period, Shares, Stock Swaps",
        "terseLabel": "Stock swaps (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockSwaps",
     "nsuri": "http://apyxmedical.com/20220930",
     "presentation": [
      "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Stock Swaps Equity Instruments Received",
        "label": "Stock Issued During Period, Shares, Stock Swaps Equity Instruments Received",
        "terseLabel": "Stock swaps equity instruments received (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived",
     "nsuri": "http://apyxmedical.com/20220930",
     "presentation": [
      "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "apyx_StockSwapToAcquireOptionsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock swap to acquire options shares.",
        "label": "Stock swap to acquire options, Shares",
        "terseLabel": "Shares issued on net settlement of stock options (in shares)"
       }
      }
     },
     "localname": "StockSwapToAcquireOptionsShares",
     "nsuri": "http://apyxmedical.com/20220930",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "apyx_SuitAgainstGoodwinAndSimbMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Suit against Goodwin and Simb",
        "label": "Suit against Goodwin and Simb [Member]",
        "terseLabel": "Suit Against Goodwin and Simb"
       }
      }
     },
     "localname": "SuitAgainstGoodwinAndSimbMember",
     "nsuri": "http://apyxmedical.com/20220930",
     "presentation": [
      "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "apyx_SymmetrySurgicalInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Symmetry Surgical Inc. [Member]",
        "label": "Symmetry Surgical Inc. [Member]",
        "terseLabel": "Symmetry Surgical Inc."
       }
      }
     },
     "localname": "SymmetrySurgicalInc.Member",
     "nsuri": "http://apyxmedical.com/20220930",
     "presentation": [
      "http://apyxmedical.com/role/DISPOSALOFBUSINESSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "apyx_TotalRevenuePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total Revenue, Percent",
        "label": "Total Revenue, Percent",
        "terseLabel": "International sales, percent of total revenue"
       }
      }
     },
     "localname": "TotalRevenuePercent",
     "nsuri": "http://apyxmedical.com/20220930",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "apyx_UncertainTaxPositionsLiability": {
     "auth_ref": [],
     "calculation": {
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": {
       "order": 8.0,
       "parentTag": "apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Uncertain Tax Positions Liability",
        "label": "Uncertain Tax Positions Liability",
        "terseLabel": "Uncertain tax positions"
       }
      }
     },
     "localname": "UncertainTaxPositionsLiability",
     "nsuri": "http://apyxmedical.com/20220930",
     "presentation": [
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "Domestic"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_ConsolidationItemsAxis": {
     "auth_ref": [
      "r92",
      "r139",
      "r152",
      "r153",
      "r154",
      "r155",
      "r157",
      "r159",
      "r163",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r232",
      "r233",
      "r235",
      "r237",
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Axis]",
        "terseLabel": "Consolidation Items [Axis]"
       }
      }
     },
     "localname": "ConsolidationItemsAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidationItemsDomain": {
     "auth_ref": [
      "r92",
      "r139",
      "r152",
      "r153",
      "r154",
      "r155",
      "r157",
      "r159",
      "r163",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r232",
      "r233",
      "r235",
      "r237",
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Domain]",
        "terseLabel": "Consolidation Items [Domain]"
       }
      }
     },
     "localname": "ConsolidationItemsDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r215",
      "r217",
      "r218",
      "r219",
      "r240",
      "r241",
      "r253",
      "r254",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r421",
      "r423",
      "r445",
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r215",
      "r217",
      "r218",
      "r219",
      "r240",
      "r241",
      "r253",
      "r254",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r421",
      "r423",
      "r445",
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]",
        "terseLabel": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://apyxmedical.com/role/CHINAJOINTVENTURENarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]",
        "terseLabel": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://apyxmedical.com/role/CHINAJOINTVENTURENarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r206",
      "r215",
      "r217",
      "r218",
      "r219",
      "r240",
      "r241",
      "r251",
      "r253",
      "r254",
      "r270",
      "r271",
      "r272",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r421",
      "r423",
      "r445",
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONFairValueAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r206",
      "r215",
      "r217",
      "r218",
      "r219",
      "r240",
      "r241",
      "r251",
      "r253",
      "r254",
      "r270",
      "r271",
      "r272",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r421",
      "r423",
      "r445",
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r167",
      "r168",
      "r248",
      "r250",
      "r422",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r167",
      "r168",
      "r248",
      "r250",
      "r422",
      "r434",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r46",
      "r371"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r172",
      "r173"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Trade accounts receivable, net of allowance of $634 and $430"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedBonusesCurrent": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": {
       "order": 2.0,
       "parentTag": "apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Bonuses, Current",
        "terseLabel": "Accrued bonuses"
       }
      }
     },
     "localname": "AccruedBonusesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedInsuranceCurrent": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": {
       "order": 5.0,
       "parentTag": "apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable to insurance entities to mitigate potential loss from various risks or to satisfy a promise to provide certain coverage's to employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Insurance, Current",
        "terseLabel": "Accrued product liability claim insurance deductibles"
       }
      }
     },
     "localname": "AccruedInsuranceCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": {
       "order": 6.0,
       "parentTag": "apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accrued professional fees and legal related contingent liabilities"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedSalariesCurrent": {
     "auth_ref": [
      "r23",
      "r49"
     ],
     "calculation": {
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": {
       "order": 1.0,
       "parentTag": "apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Salaries, Current",
        "verboseLabel": "Accrued payroll"
       }
      }
     },
     "localname": "AccruedSalariesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedSalesCommissionCurrent": {
     "auth_ref": [
      "r23",
      "r49"
     ],
     "calculation": {
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": {
       "order": 3.0,
       "parentTag": "apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for sales commissions. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Sales Commission, Current",
        "terseLabel": "Accrued commissions"
       }
      }
     },
     "localname": "AccruedSalesCommissionCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r26",
      "r200"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "terseLabel": "Accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Cash Flow Elements and Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Non cash activities:"
       }
      }
     },
     "localname": "AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r32",
      "r371"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r93",
      "r94",
      "r95",
      "r279",
      "r280",
      "r281",
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r255",
      "r283",
      "r284"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "verboseLabel": "Stock based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r274"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Stock based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "auth_ref": [
      "r37",
      "r174",
      "r182",
      "r183",
      "r185"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable.",
        "label": "Accounts Receivable, Allowance for Credit Loss",
        "terseLabel": "Allowance for doubtful accounts receivable"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Anti-dilutive instruments (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r28",
      "r88",
      "r147",
      "r154",
      "r161",
      "r178",
      "r225",
      "r226",
      "r227",
      "r229",
      "r230",
      "r231",
      "r232",
      "r234",
      "r236",
      "r238",
      "r239",
      "r312",
      "r319",
      "r332",
      "r369",
      "r371",
      "r398",
      "r409"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r21",
      "r45",
      "r88",
      "r178",
      "r225",
      "r226",
      "r227",
      "r229",
      "r230",
      "r231",
      "r232",
      "r234",
      "r236",
      "r238",
      "r239",
      "r312",
      "r319",
      "r332",
      "r369",
      "r371"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r19",
      "r25",
      "r84"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r77",
      "r84",
      "r86"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents, end of period",
        "periodStartLabel": "Cash and cash equivalents, beginning of period",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/BASISOFPRESENTATIONNARRATIVEDetails",
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r77",
      "r336"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net change in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CoVenturerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other venturer from the perspective of the entity in the corporate joint venture.",
        "label": "Co-venturer [Member]",
        "terseLabel": "Co-venturer"
       }
      }
     },
     "localname": "CoVenturerMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r209",
      "r210",
      "r211",
      "r220",
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r93",
      "r94",
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r30",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r30",
      "r371"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value; 75,000,000 shares authorized; 34,588,398 issued and outstanding as of September\u00a030, 2022, and 34,409,912 issued and outstanding as of December 31, 2021"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r245",
      "r246",
      "r249"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Long-term contract liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateJointVentureMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporation owned and operated by a small group of ventures to accomplish a mutually beneficial venture or project.",
        "label": "Corporate Joint Venture [Member]",
        "terseLabel": "Corporate Joint Venture"
       }
      }
     },
     "localname": "CorporateJointVentureMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CHINAJOINTVENTURENarrativeDetails",
      "http://apyxmedical.com/role/CHINAJOINTVENTURERollforwardofJointVentureDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateNonSegmentMember": {
     "auth_ref": [
      "r152",
      "r153",
      "r154",
      "r155",
      "r157",
      "r163",
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.",
        "label": "Corporate, Non-Segment [Member]",
        "terseLabel": "Corporate &amp; Other"
       }
      }
     },
     "localname": "CorporateNonSegmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r69",
      "r381"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of sales"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Other costs and expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r82",
      "r142"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DilutiveSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "DilutiveSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r256",
      "r257",
      "r275",
      "r276",
      "r277",
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "STOCK-BASED COMPENSATION"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/STOCKBASEDCOMPENSATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discontinued Operations and Disposal Groups [Abstract]",
        "terseLabel": "Discontinued Operations and Disposal Groups [Abstract]"
       }
      }
     },
     "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold": {
     "auth_ref": [
      "r12",
      "r16"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Costs of Goods Sold",
        "terseLabel": "Cost of sales"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/DISPOSALOFBUSINESSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense": {
     "auth_ref": [
      "r12"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating expense attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Operating Expense",
        "terseLabel": "Operating expenses"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/DISPOSALOFBUSINESSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss": {
     "auth_ref": [
      "r12"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating income (loss) attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Operating Income (Loss)",
        "negatedTerseLabel": "Net other loss"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/DISPOSALOFBUSINESSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue": {
     "auth_ref": [
      "r12",
      "r16"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Revenue",
        "terseLabel": "Sales"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/DISPOSALOFBUSINESSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": {
     "auth_ref": [
      "r17",
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]",
        "terseLabel": "DISPOSAL OF BUSINESS"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/DISPOSALOFBUSINESS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r91",
      "r228",
      "r230",
      "r231",
      "r237",
      "r238",
      "r239",
      "r364",
      "r402",
      "r414"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties.",
        "label": "Due to Related Parties",
        "terseLabel": "Due to related parties"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Loss per share:"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r62",
      "r102",
      "r103",
      "r104",
      "r105",
      "r106",
      "r113",
      "r116",
      "r123",
      "r124",
      "r125",
      "r129",
      "r130",
      "r327",
      "r328",
      "r405",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic [Abstract]",
        "terseLabel": "Loss per share:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r62",
      "r102",
      "r103",
      "r104",
      "r105",
      "r106",
      "r116",
      "r123",
      "r124",
      "r125",
      "r129",
      "r130",
      "r327",
      "r328",
      "r405",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted [Abstract]",
        "terseLabel": "Anti-dilutive instruments excluded from diluted loss per common share:"
       }
      }
     },
     "localname": "EarningsPerShareDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share Reconciliation [Abstract]",
        "terseLabel": "Earnings Per Share Reconciliation [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r126",
      "r127",
      "r128",
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "EARNINGS (LOSS) PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/EARNINGSLOSSPERSHARE"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r336"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "terseLabel": "Effect of exchange rates on cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r56",
      "r57",
      "r58",
      "r93",
      "r94",
      "r95",
      "r99",
      "r107",
      "r109",
      "r133",
      "r179",
      "r242",
      "r243",
      "r279",
      "r280",
      "r281",
      "r296",
      "r297",
      "r326",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r359",
      "r424",
      "r425",
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, to be Paid [Abstract]",
        "terseLabel": "Finance Lease, Liability, Payment, Due [Abstract]"
       }
      }
     },
     "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinanceLeaseLiability": {
     "auth_ref": [
      "r348",
      "r355"
     ],
     "calculation": {
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.",
        "label": "Finance Lease, Liability",
        "totalLabel": "Present value of lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r348"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Finance Lease, Liability, Current",
        "negatedLabel": "Less current portion of lease liabilities",
        "terseLabel": "Current portion of finance lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.",
        "label": "Finance Lease, Liability, Fiscal Year Maturity [Table Text Block]",
        "terseLabel": "Maturities of Finance Lease Liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/LEASESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r348"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "Finance Lease, Liability, Noncurrent",
        "terseLabel": "Long-term finance lease liabilities",
        "verboseLabel": "Long-term portion of lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r355"
     ],
     "calculation": {
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r355"
     ],
     "calculation": {
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r355"
     ],
     "calculation": {
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r355"
     ],
     "calculation": {
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r355"
     ],
     "calculation": {
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r355"
     ],
     "calculation": {
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year.",
        "label": "Finance Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r355"
     ],
     "calculation": {
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Less imputed interest"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "auth_ref": [
      "r347"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization",
        "terseLabel": "Finance lease right-of-use assets"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r353",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for finance lease calculated at point in time.",
        "label": "Finance Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/LEASESLeaseTermsandDiscountRatesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r352",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Finance Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/LEASESLeaseTermsandDiscountRatesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedLabel": "Loss on disposal of property and equipment"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r67",
      "r88",
      "r147",
      "r153",
      "r157",
      "r160",
      "r163",
      "r178",
      "r225",
      "r226",
      "r227",
      "r230",
      "r231",
      "r232",
      "r234",
      "r236",
      "r238",
      "r239",
      "r332"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "Gross profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r60",
      "r147",
      "r153",
      "r157",
      "r160",
      "r163",
      "r397",
      "r403",
      "r407",
      "r418"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/DISPOSALOFBUSINESSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": {
     "auth_ref": [
      "r4",
      "r6",
      "r7",
      "r8",
      "r9",
      "r10",
      "r11",
      "r13",
      "r14",
      "r15",
      "r16",
      "r203",
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table]",
        "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/DISPOSALOFBUSINESSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r89",
      "r290",
      "r294",
      "r295",
      "r301",
      "r303",
      "r305",
      "r306",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r90",
      "r108",
      "r109",
      "r145",
      "r288",
      "r302",
      "r304",
      "r419"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails",
      "http://apyxmedical.com/role/INCOMETAXESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r79",
      "r85"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income Taxes Paid",
        "terseLabel": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesReceivable": {
     "auth_ref": [
      "r31",
      "r401",
      "r415"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.",
        "label": "Income Taxes Receivable, Current",
        "terseLabel": "Income tax receivables"
       }
      }
     },
     "localname": "IncomeTaxesReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Trade receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInIncomeTaxesReceivable": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid.",
        "label": "Increase (Decrease) in Income Taxes Receivable",
        "negatedLabel": "Income tax receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInIncomeTaxesReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedTerseLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedTerseLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r59",
      "r141",
      "r343",
      "r344",
      "r406"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedTerseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeOperating": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities.",
        "label": "Interest Income, Operating",
        "terseLabel": "Interest income",
        "verboseLabel": "Interest income"
       }
      }
     },
     "localname": "InterestIncomeOperating",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r75",
      "r78",
      "r85"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]",
        "terseLabel": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "INVENTORIES"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/INVENTORIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://apyxmedical.com/role/INVENTORIESDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Inventory, Finished Goods, Gross",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/INVENTORIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryGross": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://apyxmedical.com/role/INVENTORIESDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Inventory, Gross",
        "totalLabel": "Gross inventories"
       }
      }
     },
     "localname": "InventoryGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/INVENTORIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r20",
      "r44",
      "r371"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://apyxmedical.com/role/INVENTORIESDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "totalLabel": "Inventories, net",
        "verboseLabel": "Inventories, net of provision for obsolescence of $379 and $263"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://apyxmedical.com/role/INVENTORIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r24",
      "r42",
      "r87",
      "r132",
      "r186",
      "r187",
      "r189",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/BASISOFPRESENTATIONPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterials": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://apyxmedical.com/role/INVENTORIESDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Raw Materials, Gross",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterials",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/INVENTORIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryValuationReserves": {
     "auth_ref": [
      "r44",
      "r188"
     ],
     "calculation": {
      "http://apyxmedical.com/role/INVENTORIESDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation reserve for inventory.",
        "label": "Inventory Valuation Reserves",
        "negatedLabel": "Less: provision for obsolescence"
       }
      }
     },
     "localname": "InventoryValuationReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/INVENTORIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcess": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://apyxmedical.com/role/INVENTORIESDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.",
        "label": "Inventory, Work in Process, Gross",
        "terseLabel": "Work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcess",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/INVENTORIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Lease Costs"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/LEASESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeFinanceLeaseTermOfContract1": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Finance Lease, Term of Contract",
        "terseLabel": "Finance lease, term of contract"
       }
      }
     },
     "localname": "LesseeFinanceLeaseTermOfContract1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeFinanceLeasesTextBlock": {
     "auth_ref": [
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.",
        "label": "Lessee, Finance Leases [Text Block]",
        "terseLabel": "LEASES"
       }
      }
     },
     "localname": "LesseeFinanceLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/LEASES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Maturities of Operating Lease Liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/LEASESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r355"
     ],
     "calculation": {
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r355"
     ],
     "calculation": {
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r355"
     ],
     "calculation": {
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r355"
     ],
     "calculation": {
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r355"
     ],
     "calculation": {
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r355"
     ],
     "calculation": {
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r355"
     ],
     "calculation": {
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "auth_ref": [
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "terseLabel": "Operating lease extension"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Operating lease, extension"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "LEASES"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/LEASES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r48",
      "r88",
      "r155",
      "r178",
      "r225",
      "r226",
      "r227",
      "r230",
      "r231",
      "r232",
      "r234",
      "r236",
      "r238",
      "r239",
      "r313",
      "r319",
      "r320",
      "r332",
      "r369",
      "r370"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r36",
      "r88",
      "r178",
      "r332",
      "r371",
      "r400",
      "r412"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r22",
      "r50",
      "r88",
      "r178",
      "r225",
      "r226",
      "r227",
      "r230",
      "r231",
      "r232",
      "r234",
      "r236",
      "r238",
      "r239",
      "r313",
      "r319",
      "r320",
      "r332",
      "r369",
      "r370",
      "r371"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r212",
      "r214",
      "r215",
      "r216",
      "r217",
      "r222",
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "auth_ref": [
      "r212",
      "r213"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss contingency liability.",
        "label": "Loss Contingency Accrual",
        "terseLabel": "Costs accrued"
       }
      }
     },
     "localname": "LossContingencyAccrualAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyEstimateOfPossibleLoss": {
     "auth_ref": [
      "r215",
      "r217",
      "r222"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.",
        "label": "Loss Contingency, Estimate of Possible Loss",
        "terseLabel": "Loss Contingency, Estimate of Possible Loss"
       }
      }
     },
     "localname": "LossContingencyEstimateOfPossibleLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r53",
      "r88",
      "r178",
      "r225",
      "r230",
      "r231",
      "r232",
      "r238",
      "r239",
      "r332",
      "r399",
      "r411"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending interest in China JV",
        "periodStartLabel": "Beginning interest in China JV",
        "terseLabel": "Non-controlling interest"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CHINAJOINTVENTURERollforwardofJointVentureDetails",
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestDisclosureTextBlock": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for noncontrolling interest in consolidated subsidiaries, which could include the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.",
        "label": "Noncontrolling Interest Disclosure [Text Block]",
        "terseLabel": "CHINA JOINT VENTURE"
       }
      }
     },
     "localname": "MinorityInterestDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CHINAJOINTVENTURE"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MinorityInterestLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Noncontrolling Interest [Line Items]",
        "terseLabel": "Noncontrolling Interest [Line Items]"
       }
      }
     },
     "localname": "MinorityInterestLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CHINAJOINTVENTURENarrativeDetails",
      "http://apyxmedical.com/role/CHINAJOINTVENTURERollforwardofJointVentureDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.",
        "label": "Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners",
        "terseLabel": "Ownership interest"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CHINAJOINTVENTURENarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_MinorityInterestTable": {
     "auth_ref": [
      "r53",
      "r68",
      "r309",
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of noncontrolling interest disclosure which includes the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.",
        "label": "Noncontrolling Interest [Table]",
        "terseLabel": "Noncontrolling Interest [Table]"
       }
      }
     },
     "localname": "MinorityInterestTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CHINAJOINTVENTURENarrativeDetails",
      "http://apyxmedical.com/role/CHINAJOINTVENTURERollforwardofJointVentureDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MovementInMinorityInterestRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]",
        "terseLabel": "Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]"
       }
      }
     },
     "localname": "MovementInMinorityInterestRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CHINAJOINTVENTURERollforwardofJointVentureDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r77",
      "r80",
      "r83"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "negatedTerseLabel": "Cash used in operations",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/BASISOFPRESENTATIONNARRATIVEDetails",
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r16",
      "r54",
      "r55",
      "r58",
      "r61",
      "r83",
      "r88",
      "r98",
      "r102",
      "r103",
      "r104",
      "r105",
      "r108",
      "r109",
      "r121",
      "r147",
      "r153",
      "r157",
      "r160",
      "r163",
      "r178",
      "r225",
      "r226",
      "r227",
      "r230",
      "r231",
      "r232",
      "r234",
      "r236",
      "r238",
      "r239",
      "r328",
      "r332",
      "r404",
      "r416"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net loss attributable to stockholders"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r54",
      "r55",
      "r58",
      "r108",
      "r109",
      "r315",
      "r322"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss attributable to non-controlling interest",
        "verboseLabel": "Net loss attributable to Apyx"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CHINAJOINTVENTURERollforwardofJointVentureDetails",
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r102",
      "r103",
      "r104",
      "r105",
      "r113",
      "r114",
      "r122",
      "r125",
      "r147",
      "r153",
      "r157",
      "r160",
      "r163"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "terseLabel": "Net loss attributable to stockholders, basic"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "auth_ref": [
      "r115",
      "r117",
      "r118",
      "r119",
      "r120",
      "r122",
      "r125"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "terseLabel": "Net loss attributable to stockholders, diluted"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update and Change in Accounting Principle [Abstract]",
        "terseLabel": "Accounting Standards Update and Change in Accounting Principle [Abstract]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "auth_ref": [
      "r2",
      "r96",
      "r97",
      "r100",
      "r101",
      "r110",
      "r111",
      "r112",
      "r176",
      "r177",
      "r180",
      "r181",
      "r298",
      "r299",
      "r300",
      "r325",
      "r329",
      "r330",
      "r331",
      "r333",
      "r334",
      "r335",
      "r345",
      "r346",
      "r358",
      "r360",
      "r382",
      "r383",
      "r384",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Text Block]",
        "terseLabel": "RECENT ACCOUNTING PRONOUNCEMENTS"
       }
      }
     },
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/RECENTACCOUNTINGPRONOUNCEMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/BASISOFPRESENTATIONPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "terseLabel": "International"
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncontrolling Interest [Abstract]"
       }
      }
     },
     "localname": "NoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance": {
     "auth_ref": [
      "r244",
      "r311",
      "r317"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders.",
        "label": "Noncontrolling Interest, Increase from Subsidiary Equity Issuance",
        "terseLabel": "Contributions from non-controlling interest",
        "verboseLabel": "Contributions"
       }
      }
     },
     "localname": "NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CHINAJOINTVENTURERollforwardofJointVentureDetails",
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r93",
      "r94",
      "r95",
      "r243",
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Non-controlling Interest"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total other costs and expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r147",
      "r153",
      "r157",
      "r160",
      "r163"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "negatedTerseLabel": "Loss from operations",
        "terseLabel": "Loss from operations",
        "verboseLabel": "Income (loss) from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/BASISOFPRESENTATIONNARRATIVEDetails",
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid [Abstract]",
        "terseLabel": "Operating"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r348"
     ],
     "calculation": {
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "totalLabel": "Present value of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r348"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "negatedLabel": "Less current portion of lease liabilities",
        "terseLabel": "Current portion of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r348"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Long-term operating lease liabilities",
        "verboseLabel": "Long-term portion of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r347"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r353",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/LEASESLeaseTermsandDiscountRatesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r352",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/LEASESLeaseTermsandDiscountRatesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingSegmentsMember": {
     "auth_ref": [
      "r152",
      "r153",
      "r154",
      "r155",
      "r157",
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Operating Segments [Member]",
        "terseLabel": "Operating Segments"
       }
      }
     },
     "localname": "OperatingSegmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r18",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "BASIS OF PRESENTATION"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/BASISOFPRESENTATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "totalLabel": "Total other income (loss), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingIncomeExpenseNet": {
     "auth_ref": [],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.",
        "label": "Other Operating Income (Expense), Net",
        "terseLabel": "Other (loss) income, net",
        "verboseLabel": "Other income (loss), net"
       }
      }
     },
     "localname": "OtherOperatingIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.",
        "label": "Other Receivables, Net, Current",
        "terseLabel": "Other receivables"
       }
      }
     },
     "localname": "OtherReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]",
        "terseLabel": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.",
        "label": "Reclassification, Comparability Adjustment [Policy Text Block]",
        "terseLabel": "Reclassifications"
       }
      }
     },
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/BASISOFPRESENTATIONPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ProceedsFromDivestitureOfBusinesses": {
     "auth_ref": [
      "r72"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.",
        "label": "Proceeds from Divestiture of Businesses",
        "terseLabel": "Proceeds from the disposition of Core business"
       }
      }
     },
     "localname": "ProceedsFromDivestitureOfBusinesses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/BASISOFPRESENTATIONNARRATIVEDetails",
      "http://apyxmedical.com/role/DISPOSALOFBUSINESSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMinorityShareholders": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from a noncontrolling interest. Includes, but is not limited to, purchase of additional shares or other increase in noncontrolling interest ownership.",
        "label": "Proceeds from Noncontrolling Interests",
        "terseLabel": "Contributions from non-controlling interests"
       }
      }
     },
     "localname": "ProceedsFromMinorityShareholders",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductWarrantyAccrualClassifiedCurrent": {
     "auth_ref": [
      "r49",
      "r221",
      "r224"
     ],
     "calculation": {
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": {
       "order": 4.0,
       "parentTag": "apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers. For classified balance sheets, represents the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Product Warranty Accrual, Current",
        "terseLabel": "Accrued product warranties"
       }
      }
     },
     "localname": "ProductWarrantyAccrualClassifiedCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfessionalFees": {
     "auth_ref": [
      "r432",
      "r433"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.",
        "label": "Professional Fees",
        "terseLabel": "Professional services"
       }
      }
     },
     "localname": "ProfessionalFees",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r16",
      "r54",
      "r55",
      "r58",
      "r76",
      "r88",
      "r98",
      "r108",
      "r109",
      "r147",
      "r153",
      "r157",
      "r160",
      "r163",
      "r178",
      "r225",
      "r226",
      "r227",
      "r230",
      "r231",
      "r232",
      "r234",
      "r236",
      "r238",
      "r239",
      "r310",
      "r314",
      "r316",
      "r322",
      "r323",
      "r328",
      "r332",
      "r407"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY",
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r201",
      "r371",
      "r408",
      "r413"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net of accumulated depreciation and amortization of $5,335 and $5,316"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r64",
      "r184"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "terseLabel": "Provision for allowance for doubtful accounts"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PurchaseObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.",
        "label": "Purchase Obligation",
        "terseLabel": "Purchase obligation"
       }
      }
     },
     "localname": "PurchaseObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r252",
      "r363",
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CHINAJOINTVENTURENarrativeDetails",
      "http://apyxmedical.com/role/CHINAJOINTVENTURERollforwardofJointVentureDetails",
      "http://apyxmedical.com/role/DISPOSALOFBUSINESSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r252",
      "r363",
      "r364",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/DISPOSALOFBUSINESSDetails",
      "http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/DISPOSALOFBUSINESSDetails",
      "http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Related Party Transaction, Purchases from Related Party",
        "terseLabel": "Purchases from related party"
       }
      }
     },
     "localname": "RelatedPartyTransactionPurchasesFromRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]",
        "terseLabel": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r252",
      "r363",
      "r366",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CHINAJOINTVENTURENarrativeDetails",
      "http://apyxmedical.com/role/CHINAJOINTVENTURERollforwardofJointVentureDetails",
      "http://apyxmedical.com/role/DISPOSALOFBUSINESSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r361",
      "r362",
      "r364",
      "r367",
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "RELATED PARTY TRANSACTIONS"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r286",
      "r380",
      "r447"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r33",
      "r243",
      "r371",
      "r410",
      "r427",
      "r431"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r93",
      "r94",
      "r95",
      "r99",
      "r107",
      "r109",
      "r179",
      "r279",
      "r280",
      "r281",
      "r296",
      "r297",
      "r326",
      "r424",
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r138",
      "r139",
      "r152",
      "r158",
      "r159",
      "r166",
      "r167",
      "r170",
      "r247",
      "r248",
      "r381"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Sales"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails",
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": {
     "auth_ref": [
      "r351",
      "r356"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability",
        "terseLabel": "Right-of-use assets and finance lease liabilities derecognized upon execution of lease modification"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SalariesAndWages": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.",
        "label": "Salary and Wage, NonOfficer, Excluding Cost of Good and Service Sold",
        "terseLabel": "Salaries and related costs"
       }
      }
     },
     "localname": "SalariesAndWages",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SalesAndExciseTaxPayableCurrent": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": {
       "order": 9.0,
       "parentTag": "apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred through that date and payable for statutory sales and use taxes, including value added tax. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Sales and Excise Tax Payable, Current",
        "terseLabel": "Sales tax payable"
       }
      }
     },
     "localname": "SalesAndExciseTaxPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accounts Payable and Accrued Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Basic and diluted earnings (loss) per share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/EARNINGSLOSSPERSHARETables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r24",
      "r41",
      "r42",
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/INVENTORIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r365",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock": {
     "auth_ref": [
      "r66",
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the names of foreign countries from which revenue is material and the amount of revenue from external customers attributed to those countries. An entity may also provide subtotals of geographic information about groups of countries.",
        "label": "Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]",
        "terseLabel": "Schedule of revenue by geographic area"
       }
      }
     },
     "localname": "ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r147",
      "r150",
      "r156",
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails",
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "auth_ref": [
      "r147",
      "r150",
      "r156",
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "terseLabel": "Schedule of reporting information by segment"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Details comprising a table providing supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table]",
        "terseLabel": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONFairValueAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r259",
      "r265",
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of stock options and stock awards"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of option fair value assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r134",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r152",
      "r153",
      "r154",
      "r155",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r163",
      "r170",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r207",
      "r208",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]",
        "terseLabel": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]",
        "terseLabel": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r134",
      "r136",
      "r137",
      "r147",
      "r151",
      "r157",
      "r161",
      "r162",
      "r163",
      "r164",
      "r166",
      "r169",
      "r170",
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "GEOGRAPHIC AND SEGMENT INFORMATION"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails",
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedTerseLabel": "Canceled and forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONSummaryofStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Canceled and forfeited (in dollars per shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONSummaryofStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONSummaryofStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r260",
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding, end of period (in shares)",
        "periodStartLabel": "Outstanding, beginning of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONSummaryofStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONSummaryofStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r260",
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding, end of period (in dollars per share)",
        "periodStartLabel": "Outstanding, beginning of period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONSummaryofStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted average exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONSummaryofStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONSummaryofStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)",
        "verboseLabel": "Strike price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONFairValueAssumptionsDetails",
      "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONSummaryofStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r258",
      "r267",
      "r268",
      "r269",
      "r270",
      "r273",
      "r282",
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Share based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/BASISOFPRESENTATIONPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]",
        "terseLabel": "Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONFairValueAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONFairValueAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r5",
      "r134",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r152",
      "r153",
      "r154",
      "r155",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r163",
      "r170",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r202",
      "r207",
      "r208",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]",
        "terseLabel": "Segments [Axis]"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r52",
      "r56",
      "r57",
      "r58",
      "r93",
      "r94",
      "r95",
      "r99",
      "r107",
      "r109",
      "r133",
      "r179",
      "r242",
      "r243",
      "r279",
      "r280",
      "r281",
      "r296",
      "r297",
      "r326",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r359",
      "r424",
      "r425",
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r93",
      "r94",
      "r95",
      "r133",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r29",
      "r30",
      "r242",
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Shares issued on stock options exercises for cash (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r29",
      "r30",
      "r242",
      "r243",
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONSummaryofStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r52",
      "r242",
      "r243"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Shares issued on stock options exercises for cash"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r30",
      "r34",
      "r35",
      "r88",
      "r175",
      "r178",
      "r332",
      "r371"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r0",
      "r1",
      "r57",
      "r88",
      "r93",
      "r94",
      "r95",
      "r99",
      "r107",
      "r178",
      "r179",
      "r243",
      "r279",
      "r280",
      "r281",
      "r296",
      "r297",
      "r308",
      "r309",
      "r321",
      "r326",
      "r332",
      "r337",
      "r338",
      "r342",
      "r359",
      "r425",
      "r426"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Cash paid for:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r287",
      "r292"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "terseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r291"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "terseLabel": "Accrued interest and penalties"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": {
     "auth_ref": [
      "r291"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense",
        "terseLabel": "Interest and penalties included in income tax expense"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "auth_ref": [
      "r293"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.",
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "terseLabel": "Uncertain tax positions that would impact effective tax rate"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r115",
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average shares outstanding - diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r113",
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average shares outstanding - basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=SL108384541-122693"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "250",
   "URI": "https://asc.fasb.org/topic&trid=2122394"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e543-108305"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8475-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/subtopic&trid=2122178"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "https://asc.fasb.org/topic&trid=2134510"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(1)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(2)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.BB)",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "https://asc.fasb.org/topic&trid=2126998"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=126907644&loc=d3e11281-110244"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12524-110249"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569655-111683"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org/topic&trid=2122745"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(1)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(2)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(3)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.10)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(3),(4))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.17)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.5(c))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Subparagraph": "(k)",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=124433917&loc=SL114874205-224268"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07.2(a),(b),(c),(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r448": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r449": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r451": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r452": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r453": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1(e))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.19)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>66
<FILENAME>0000719135-22-000091-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000719135-22-000091-xbrl.zip
M4$L#!!0    ( (AZ:E4,5QY45P@  )4J   9    83(P,C)Q,S$P+7%E>&AI
M8FET,S$Q+FAT;>U::V_;.!;]OK^"XV#Z /R0;">N[31 FJ0[!F::;L:+[GP:
M4")E<T.)&I*RX_WU>R\I^9'$C;/I=IQ@"M2QQ$ORDO?PW$.:QS^<7YZ-?_M\
M0:8VE>3S/S_\/#HCM4:K]:5SUFJ=C\_)3^-??B;=9A"2L::9$5:HC,I6Z^)3
MC=2FUN:#5FL^GS?GG:;2D];XJH5-=5M2*<.;S++:R3&^@4].V<G?CG]H-,BY
MBHN49Y;$FE/+&2F,R";D"^/FFC0:I=69RA=:3*:6M(-VFWQ1^EK,J"^WPDI^
M4K5SW/+/QRW7R7&DV.+DF(D9$>Q]302]HZ,X.3KLA5&O&W6C/@UYT.%)/P@I
M/:+Q[R$XV0)S7\?8A>3O:ZG(&E.._0^Z[6;O,+?#N6!V.@B#X,?:AJGE-[9!
MI9AD ^?PT+T0&0/?JLI0(U$PY+)*K*32@X/ _1MB22.AJ9"+P>NQ2+DAG_B<
M7*F49J_K!B:^8;@6B3<TXC\<O "'W./<.]F#=J3(>.5TV$8W+_[UT^C#:$PZ
M83,\;J']VE"]2S!?^F2S[,YDK(TPAD%Q_2<-YXQK*Q(1 VK(YT*;@H(/5I%?
M>8S(?'40'@7#3M"^,]1]&XA*R*]41S2#)E\=O&N'X9!<WDB^(*>Q)5#:#I[!
M*,XNKL:CCZ.ST_'H\A.Y_$C.+BYW<?K?A8$P+FI; ;A+M?_?8+OW#G94)V=3
MJB6T>$[^KA2;BXR,X*V=<G+%)\)8H$C[VH"9X FYN.%Q8<6,D\L$(,MUG<0.
MO@NH0>VK@\-WPV\]62G5$^"M2%FK4C^PG#(&[-J0/+&#SE%>LM-&VQN$U4"C
M/VF.PV8UM._?^^9,M=\U'6N/R)1""#6?"3Z'5&6GPI _"JIAU<D%O,^5A@6;
MD8]*IR0,&O_ U7N:+V[(+YP!4TE(9!J,J">HP_[VH#_WZ+7W+GH?J(&80732
M!;G.U%QR-N%U'\0R=$R!"YD",0(]4%C2-%N0(K.ZX# "2#1.J4!,*4GA20N(
M:$*1I#51J7#IQ]G=,<AXS(VA>H$F*;WFCBF6;1IXQ\ 9Z%(ZF0-]H$$L-,@:
M,,N@.GC"N";SJ8BGQ!3XL:H_YYJ7C>  4F$DZ!^44G-AIS! DT->Q-ZQW1Q<
M4PR&.8-JC$2+]6EXV<#L/!]@<I*(#$*/*%H+-<W &DKU6K'($N <QROP/98%
M@R8!3>OH3JA FLH!"PACA+>4*YR6$#&W.H:EP)S4KZ-%(<$ P*D 0:XW[TY,
MS90D4LU-A5R]3(*$XLNZLP,GZVL -)4S=YQ]V1CL[AT&QQLA<RJT-S0ES$JI
M@F2BO'QQP1P1JKF##<! 1))C> D'I$92F"F:HUD*1(IDBL],F%@J4T ]I%BM
MI,=/KE7,&;PVY W A7' G\?$Q4T\I=F$.RU\5:#B"CNT$1Z^X6]=U?"0^2?_
M*% "9QZWV#Y!BEN#LX<7^K)S1\E&1PETA..\#7*P0'7P=2GW$'![[?T&+MT?
MX/:;00_GX9P;F"F(H<N(#P.LCLDZIH79O0IFS8@#6,J>?!Y6A88&@,AFPCAZ
M!"N>N790TZ^(=9V;-9?4H:],Q"L$U4O>QD(!) N^&"4%<X<BIHB,8()J@0,0
M7BZX9)%A2X7!%.X6JW'YWI&I,AP<LD#>6"D'F2KB0E+, 3 LY\1*"D -+RS6
M,P9\BS@: DU#?<Z>1LO[CNYH?]!=TO(FN'?FMCL8WYT5=X8Z+(^98(A@:E1&
MD?ZI ?2C5$584\TJB 'H!8V$%':!\N"^;G'!.30ZH/FULF&ZIG]<EKDI!Y07
ML*$R$ 64,W&L-',..-$[X1FH% EXAQ*>XT)"$Q#T'M.PX$0.1/^R41WO#ZHK
MSKZ845DX8L.8\R3!([L91,O<HQ^78F0'HO:/]TM*AV*H""1KO'"-5&&W>[!+
M*J%+:XZB/'EX<T6B2NV[A<G]3%3' =C!BP4BVQ\@5O3J0WP7*KCO+^6@*[D7
MCX\@5=0#*HX+C8!82[[WM)HJ8^$]GN5"6P8/C<HC)O)FL\IKI,)" ]'=LBM=
MADT9=X<5>(Z1%4N/WGI_IM0L-0I2I%L#"$U-W$24M+X@4EQS61Y<W#)_\M0\
M'?7[OM<[W#O4_V][/7?TR:H%4U_Q&-+J.FA7E(;@>X1FN2.)EZY1D,56:;.4
M">X%-)FFPEK.OY(T(@5"!,N9 /]<(V\ X<#1!G, _$5Q7JU'_D<AP'VW]HK,
M_8YDWOZUI?O.\N!4@MZ#N7*_[H%/N$N/!0? E"E^N;6:<WJ-.=OK/Y>UG7)U
M![+5$=6C8%CN@OS)QCT42!E4-/Q!!JST+E0!W($LK7OA8$ UF"(%U, LN<%4
MIW/WG>6]?%&P?WNN4\C]B0:&J0,6N"-%0),[5"]A5_<)5&0S)6<<LVA&)^5O
M [KD49[F4BTXE,ZGRI,GW0 U@/ QXL)L16SS(6Q8E0_\K0/KMFEE:02@Y+H!
M4RUI;OB@^C($DL\E70Q$YB;,51INX@QO0,PP4X#L*('E .6+R\L1_7ZS%_3P
M?H35\)]5'9=7)YKNZD3+LKMEW:-FO]_96APTPZUE7VNVTSSLM[]]JYUF<-3]
MYLV&8;-_N+WJ>K,M-[]^CB&*)J?9^UJG5E4H43YHYS<DW&0#!/[M0/H8?G\Z
M<%=ISF&)N7Q+/@'>TP@@'P9U=^MG"?-R.AXWTHKW]FFP'Q:;TN(Y#<RU.! 6
M>HMW&.JK@RZPFOM<W9QHKEV=>,0D!#@%C\3^1ITGFY;4B<0*ML2=TY)J6O<O
M5E^-S/./QC.;\,\:)"KJ+J?^MMP/>E( 6BYEWR,(;MUAS)6_Q#GPOTK,^-9;
MC67:#U95: 2H+^SV*MONI6V]8EA^^@N;[NKHR7\!4$L#!!0    ( (AZ:E4J
M3?^J5 @  (4J   9    83(P,C)Q,S$P+7%E>&AI8FET,S$R+FAT;>U::V\;
MN17]WE_!E=$\ +T?L2TY!AS9Q@K8C;..%FD_%9PA1V+-&<Z2',G37]][R1D]
M+,F1ZVXJ&PT063.\E[PD#\\]I'CVT^7-</SW+U=D:F-)OOS^Z9?1D%1JC<:W
MSK#1N!Q?DI_'O_Y"NO5FBXPU38RP0B54-AI7GRND,K4V[3<:\_F\/N_4E9XT
MQK<-K*K;D$H97F>65<[/\ U\<LK._W+V4ZU&+E68Q3RQ)-2<6LY(9D0R(=\8
M-W>D5BNLABK-M9A,+6DWVVWR3>D[,:.^W HK^7E9SUG#/Y\U7"-G@6+Y^1D3
M,R+8QXJ@O6ZO%76Z4?.$=4].VD$8])KA,3MILEYXT@W^T8(@&V#N?8S-)?]8
MB452FW)LO]]MUX][J1W,!;/3?JO9_&MES=3R>UNC4DR2O@MXX%Z(A$%LI3-X
M1 JZ7+B$2BK=/VJZ?P,LJ44T%C+OOQV+F!ORF<_)K8II\K9J8.!KAFL1>4,C
M_L4A"@C(/<Y]D,=0CQ0)+X-NM3',J[_]//HT&I-.J]X^:Z#]2E=]2#!>^GR]
M;&,P5GH80J>X_A]U9\BU%9$( 37D2Z9-1B$&J\A7'B(RWQRU/C0'G>9F5P^M
M(RHB7ZD.: )5OCDZ:;=: W)S+WE.+D)+H+3=? &]&%[=CD?7H^'%>'3SF=Q<
MD^'US3Y!_S,S,(UY92< %^#\\WK4W=JC496,J:8 J#BH$COEY)9/A+% ?O:M
M(<.IX!&Y%@E-0D$EN8D C%Q72>B F8,'M6^.>B>#_1?;*N=0/0':"92U*O8A
MIY0Q(,>:Y)'M=SZD!;FLC>,:W]30Z$_'P_;1:]7+KOWXUM='JGU2=Z0[(E,Z
MXT3SF>!SR#1V*@SY(Z,:%HW,X7VJ-*RWA%PK'9-6L_8;+KZ+-+\GOW(&1",A
M#VDPHIY?>J>;,_M:9J]]<+/WB1J8,YB=."=WB9I+SB:\ZB>QF#JF((1$@9:
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M+H.'1L41$WFW[O(6J3#30'0/[(J085/&W6$%GF,DV2*B]SZ>*34+C8(4Z=8
M0E,3-Q %K>=$BCLNBX.+!^;/'IKGH_[0]WJ]@T/]?[;7<T>?K%PPU26/(:VN
M@G9):0B^)VB6#4F\"(V"++9*FX5,<"^@RC@6UG+^2-((% @1+&<"XG.5O .$
M T<;S 'P%\5YN1[Y'YF \-W:RQ+W,Y!Y__\MW0^6!Q<2]!Z,E?MQ#F+"77HH
M. "F2/&+K=6<TSO,V5[_N:SME*L[D"V/J)X$PV(7Y$\VME @9>!H^'<9L-2[
MX *X UE:]<+!@&HP60RH@5%RG2E/Y[:=Y;U^47!X>ZX+R/V1!H:I A:X(T5
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M5J\.#SXTJP?5P34?X%FB=71PUJS2*MO=W+C<W8;G-M_APX\?3@Y//3TLGM^
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M-/B]V6[M]]K^<_]>?[ZX\Q'?9NW;2!ZK.+#\935\BS16NB"XPE90RCG61EJ
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M?2@UP5AOA,Q9M]1:(WP41&G#I8W:+ U]9N/ICFMEP$L@B1/@XU(P'H.![R2
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MS$W@T06;L 9RI90DD7JA5LF7E"UFTQA 1.8I%=R2F'M".1V5S,F@G &[&+=
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MSO4)UY0\RRF:<!V0H'MF06;8RO4I9S:$>NOX):Z0XJSK1TS@U,</;L!" Z:
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M1_ADDZ)R)\_YK(C\NMVI]$YBY3_7D%3I1U JL15B^(DD/'V.QFNGXP>]\A0
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M?RL@MM+N5-J]D]BIG)YWZMU0+^H#@\WRI^N\6*_?A.3BU,ZQ;=6OBN^_SQ@
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M,^F+F+DQ/N[>>7[0[MG&..R,Q^SO7T[4&ELB>(E/$\&GT2PPBBTVGA)$A$B
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M@U]9'\,">IFH-[^B.K9]2J6HCE-4A^P$YPVQT4ADL*2(>R61YI@C%ZS"*EF
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MB$0C<D$;X"ECDA$QRI#+1Z]*-JZXPQQM EH@6Z]S'G]8>O.&B5^FSDRTO<*
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MQ OS816+<77WG(_DS#%&)9ZKL$\@.;,4]K$*^W#"A+($? *#!,FYF%*)'),
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M6?7B$YT\WY+\^+SG<]DQ$Y@ZB*."5$LAU9^+E?,Z*.$\1U*E/ 9/>61D]"B
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MQKNB *X.#!>Z9>03#H8CTB)$Q!F/N6FL04)+Q8*FRC&YL:7(IN2K:GQ3 +$
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M$L>1%"DB3JQ#UON #-<2$Y/S=-C&EMC$XLZNY8(*!;SO1J8RUK$<[<<W9HO
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MQ$ _(K@4N?NBN+-VTN+^B\^>9U>FG12>O0^>G==+8F0,$\J1B"HA[H)%AJ:
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M%2"N1)6>7C+E*%I#Z"/,N)C91 ;;%/ICUXT+N_C8DSA6MLIB!]W*#CJSP$H
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MA]1?QA2N8T @01IGC7(R0W)X%6>G49[Z(,\X64%E&/MO"-S\XAC4W$FP<2J
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M_7N0['"/S8F0LSF6!V(?N!EV(;N5^F,WFFS;==;M3-#Q&Q!5"Z0+)+E0_F>
M9!G@O,27#'V <Y.=R(<U]&L5"!9K/\;&<39][*F1#T*JG[/F\ETGDCHO=2+*
MLI9WL=$7CYE]A!/<K&$[?T,-W4TDKI-]/?D#V2LXJ!>8K\@*W]0\Z7?G' 1Y
MFR:O3/?AAW?AKQ-8RB+9XI?.$*Z<IC1D&0XGI1]JB7_E0$W/TG#V,%V_.].P
M9%:J<XY#UFV[.43<!;NBOL7JST\CXI8BUF9UTO^<5?3-G''0[W7/KYQ_D!9]
MT,9_(O_(QFJGCF&Y1D)-A6/SD%/IU7PC6+-SY)[0^&8Q.;G;=VC8F$H_T>\L
M9S/3IS>[@,UFA5=4SD&=)P%DO0X';LOI\2I"WI+1YW()YY*9GG=ZMKPY/;MD
M6I=,ZY)I_4.9UA6Z4-E"ZQ_PQJSK^ZOVN>YCW\@T7=/,T16)X2<<>6C\6TW2
M0)V,,*%][6[HU]'O[^0)Y#S7[%CJ7WCNKP\*]3]=9-#"31(L/Y.DCG_[[GC8
M9,=>JPWFU5V^-YMT-(SO:T45OOSH_!34V,%Y=32-6DUB6SE':+.)/=39O>-!
MD] XC=[VXJ@"PW X=2GDX16@[:3:0UP;)9<1_0O/]66$8Q(GG_I/)G=:<)TT
M'M1)JO&+:J=96_TJ/$IU"I>>@,E2>\./XMEHDJZ!KPNK7#R$[<W.1L@Y5TNF
M6MVU/Y38J,/B\-M"$<-T7<TPHS]@<27'ZOLY5GNY=(%CXQFV":7$&.*$**1M
M,DA8BZ5@$@N=IXJI%_+;65:-?S?;C>TX$P=QE-N7OVIBY>'7\S?#W)SGXJAL
M7R1HE*-RBZ,B#O_\&V,&%F@N< '1C+C7&#E+ DHN*,&9B"PR."KBQ4U]P:9'
M)><D9>2;]?+F/)D:4KX'2#FJVPS]F0)H]C]^ B)-_(_+G#_/J4U$>M W%,^3
MNSP7E('BI&2B-(J_]VXZ=E=/6SYJ^?_=RZ6\CL,<8@,]*[^QW0M77YBYLAS
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M(7^0_8KCRXJX.K!PR9]-:#KO58A=.Y<UF:/8O9.:W_+'ZVCE8);8M6"Z4I0
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M!C66P_=/HR&;&97&I^.F_"S$G-(SRL9-OJ!V\=6.Y<YL!.*RP.X":J8@=?&
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MQ][4=7PSJ?AO+CZ6OQH1UK8L_,M]V.MEUW+-$I/Q'R_!3 8=XX\F@^*GIIB
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MJ;^ZR-MYW=+-4C;W94J,,]<I,6FLJ=;/L(6\[$:$[Y64N 51CRM.Y[<$4$H
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M>%)YB'#+,$<&()OW@V0$:(8=($$R([RR(>BD/*@[2TN^!@?_\IZ'SWGMUK$
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MD$X^/P84B7^@)01+S+QD+/$#6B8_+*)RO6>>6B0KJ90RK\A5<(*K-#',:::
M,SARE8882*D%P%132;2 @OFU3;0!2RGS4AQ12ID7Y <TF>\,N9:ILI4*"D:M
MRT9^$,P!;1BVQG(5/%S;A!OR7GYX6_T-%[/';NT,O.'NA@MFXK;ZR9VWE'(&
MN]5/"TG![<&,[\4)_^([:=9&2;D EWS^,)]/E\)&"AE&4CPT9PQ0[RA0GEC
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M0:"("4#K*%@"P<;"D)0+1)95Z*;T6JP@)R]9N;B3DTMF7819)W4,Y;70F!K
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MQ__9K6YE?]5VJ_7LGYUJ_=O>SK*[^#XXI-64E[NMB!Y(W9:2_LK;?BHJH@?
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M7EM3 <;5[[N7!S?NK'KS%=?J9RP^\S+^=EW9/HOCJ%P=U"LWA]N[<:PS6UE
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M_9[_7,S K9*L^>_QS\2N#TUNEHMVMY&N_M#Q39V8XX_+ANN=#)EV[*KBM3_
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MB7?]IA_4&)XBMMQF&,2 ;J4):?2N<\_SNW8L'1\QRIW3&@-#,8\RSEN@D%6
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MTVL"S[1T?TGU[HE[E,^@Y^6+T]UM?<DC*#YWVMUNJ>DM#<(:4YJ>Q\%SRQQ
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MY$JCR+1I__ ;V:=;:>BSL\]O&^SY+D.*A)[,:+_,ZRKY^,UEBYFH3ZRX,TI
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MOX2WB\[4R.7UUH>J,;CN+)@71::*\K9E:V$-(#:G3"=C8\J=<<,]%=&.\S%
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M%"D-V IC<!(CT^:3W<WLNO-"6\&YCWA>R''N.CEW/D808$P)#4,4"98@2E2
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M#X;>^#R?P*RRO%.3]D0Z;I4[YS><NG;E!1\*(*K]H2K.KI< Z%*;7Z8I\_8
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MJT4C7T(]8MW%[B=SZ<?/GB[R@9=7S6SSX9/4*4Y'NB;%:ZC/NZ])\>W^Q'\
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M>F6<CUZ;M 7X#IGT&FBTB[IVY04?"B"J_:$JSJZ7 .A2FU^F0_KV /%HO^<
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M0*5C24'!JDR;8\$GYJ\5\KQQ[H%%+!3,("?*X#4#C"O3(+F<B/-O@,&@]#N
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M1R1=7I!R=VYFR\L6[_[VN&!_$BVV%NZ;IK;X1K7%M=Y?&)06/D2]5FTO<2*
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M]STL9_(WZPOE<&(U82P#^?+]7LLSU;]9) SOI1!@78//JDYCUDX)!",8I&S
M/\RV7>NG49#WR0O"1*6_1A:CEF2B#*[(G,671#GD6)7IQP?'48@=XA*LB8K_
M3*-Q&'/96<L193JQ#T!DV765N:M56LO[VS4*_>VH\QA\1"=KR?B6?;9@X"<[
MZ%%Q5*SR,\%"L? ]_%"<]O[$HI=4;%15N<PZF\%SL9Q3V=O=/U6\8[LE=AHS
MH<?-2NS8IH&PJ9E3KIHY92&_>_7'=>?NQ^UE=W]WO^_:O4=6%3F2_6-6W1#$
MBQF0!/O'NJD_M1R6BG+065=*63Y>=H7%#10^T^-#YO=%_THN-@KQ (T<\32
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M@$A9^;S-2@P(UHA@$[)!!%WKUM"PU+YQ<_7 GR=655)R!*5$G&T3D8#P$9+
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MDS*3H(FU$A(#:S@3WF-60J+VHC$]'H&T##G4#T:.EEIH1HV]R7@^A33_@YS
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M&F<7&"VV)4/*7N76*]&Z!=M/NS7[X]-S4_4WH^>YB ?EJM@'XXT&>!""]!%
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M?>D6M,%F,'O3P63O'&9:3SY45?AS,-H;A=[@TMV8&/FPK%8"-K-LJ"2CD9/
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MX5'<^@&;S+U\W^,OC"L_ZI_XYG,L-+-#Z2#TI%LM'K5Q&!?#W9GJ\T'%X'E
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MV_Q'9(<SY:UC/>&N'=5W*Z\.+&9+2\]O_ETCW@<9T KF"%QU%7S,YW!56E?
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M?5[*277-Z*>U8A],P,C"J/S9>K_A4H()?)TQMC/!8 '>]GV:>XI9HP2G630
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M?9,]S90*9MJ^V=J?&9&;B/FGU3+,D,?&,=15X"XJ![* '1]CWK [SP*4J+(
M5/X$(@B^TB)77Y#  C2P -E*>.WS^D[$8@:6(7TX -L1L_]0QA./-:D.U]H;
M#=VH0M?UGV:/48"!PG#X[FW(\F7EL^&95T&J<4\H/?(2_M9XE)%_!1.WHQV^
MR50ERS!/0M]/?HDT7B]+1H^Y:@3<U6\DF?Y S*@T6^RD2[S!CSCJYA#<0SIV
MT>+UE^_;VZ4/ZJ/V,_9?WF)C348B["_G)(@:8&))5G>PCK5+'#^]#LA,W!UE
M 5Z.38]0D##?X,.$KX3JE@>*<WK8("?MMA=K#8 #,2.WD?DJ5 ].A\K\U_',
M;3IRF;FS/:W<^,"TXSK"A^E&A'DN[U/L5[C)?YZ!Q^3"5G/F*?QT=M$#Y!^K
MQJ%+?1>OS>K]4.=8@Z6+5.5[EK@FI43]IB19F"IO5Q=>EF+FH-,9)?5N)#%!
M0WSK"<W?HS2SGZ&='TZ<!#^B0$F_T.:HCIHZL0V"<8O.RG&V"T#@,ANGQ5Y2
MT7R6^7*N6EJ"E#KF_HLV3<BOA[UAP& 9F6A-EZSEV+#?/NI\943+CIX-LJS*
MK[$A:!GP-2FG<"[U/<5C5]2DI?JX))#^W'GB;9"P+@_MINC==P935+8S=Q)>
M1/J1?(]D^S04-=A%T)EZ@^8DPL3OMD.R$N$J7.\S#]P_!H!R)X9#J*?<>>D+
MZ"(V^3SZ+VMF%GTI6+F*_&56N(CK%E'HA5Q""^+09UH6"^!3"VXD@?X,6%I\
M,SIU^[YK8?OMGN66N0OVKNV5,BXZ4^ 4:ACR13;,R#F Y_>43>>  7_HL<C]
M6JL%BNTTKD9O,.Y5'D(K]UB K!O??(0RP2& QM35>HZ-T/&Q[@0Z"Y#B2%3L
MN9-G]"RFEEF] \WP*OJ9[O(V6D)T?<QY!)&TOXUE/KW&8A11#FS#D&\IM^%S
M\E5]($([SI+I3F\0G'5GZ&/+AL')%LKNC[9:J,4EV?9*-M/6G=+A.JM""*-G
MQ/6%*Y^VZV\7BYGW^L&6Q@DO@LO2W=XF''61FZ-!MS?AL4J'#\6_O)I"+B>%
MD;_#SY!3:=K-#R9/I*R7@CP2Y^Y&*0SEP9XBY]I\8?Q0EUOU.OC)GRUZ<NZ%
MJY[\PS?F0Y+U3H0C?J\C:HU>P*Y8C'K*!QR[(_FF^2?!URN$FDW%:%U5PI%A
M9],%O-H?X5P@>253H@S!Q(9[;,,H U3V'T-'9^W,@,/9189:/9NE.GS'RDO5
M 4 30^54W^L9%LX6^,+97FQKGZ#-RO/-\ %H4,!S3FK>JR7PAGCH'RH'+&#E
MJEG.NYS)%=*EXH8O%6[\QKDZ]RY!HLE7\#^!8>)\T9T;\?=K6L>&4 3]:'[P
M9MX,7*;!KY*6!%R R+7LW(?5)S(?)%$HR->>XL]W[AC)J=%JW)>F6("_QYZH
MU_4_OK#P7YJ%),&T/7\&>' UI5UO4C*FN\J4;JIVE")N]%TERO7[M[MFKAJR
MA9C82A&E5K,H$=?M>/W@OD2H2\QI1+,5@<]-%N83'7T\RU]36"G99JV.3:,
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M-M02LU B"O1N36R-1$0=,-ZX2"U77>."C'K.@$KD7B'P)\C^I^G$%<S _JJ
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MM]W=+,$(4Z;SAL/*Z.D/_@$R7V/]>D>Z68!8>G<RVZC6H]+V^D-7T--(LEZ
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M<P<+\,0U#$% UUQXNF(_4NATRS;0D9*&S.A<T=->\QC$2<CQ@[FOFX>A;[(
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MV!9VC'P@J\T7E%SHXQ,IL>-A]]%(+_8L5O*%O[9DGAANNA:FPN:.%'*7ULD
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M%L#WL/C\$)T%4(]@K^H<;\[!'=XAY%0V_5S=&;94]3!*?A:;TZX1[]&LP@T
M/AB]N#.R;@/4N[5>/RWU0/Y8\[TQN'0N)45PA5^CB5=#V1HU205%4Q_J^()7
M*$0P\Z3DFY:RK8:R'THR$"&04@==@:G)6[G#O]3/X'[38MQZ-](//):P[1I-
MGXUH[*_'I8H6EZ:S -F<UDU5/R__S0[;G5J4._+$SWH\S8=I6I!OJ(1>R#T
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ML/" X,K<-\8";,C"/QM9L@#.4]7H2N0*]70BQ8$%.%),1K, -[@#$80KZRQ
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M/<-C]SS_NG&_GR==F0*T;?P6TE>TE(*J-AZ#UP(GLKO()/:J-/.._681Y2R
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MD:>?U_+LQXS!^>M7;F+/7DUYZ8&TC>K?25$+ZGJ^+:,E=3)X<4Q=*T^OA,X
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MA9/S+&_)6ULD3H*XEA!':W1<,QVCY_2/V"6^&N*!C2$_,>YP^]&P#77'OA)
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M1Y[P^;;NI)[>W^(A8HNZ7+TMLE,8:[C22]7(<2284W+],T?O$$Z5%E:VKBM
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M!?N<'C]CM_AR@D=U0OZ/@'7K%0,M(I2"LF?:Q7[HG<KX66K'!G-$UL@B3K%
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M?^H+HU_!U0"**%;%#^CF4^2XUM\;K#,UW/S]<.U,BH>_)+*Y:K(9,&&Q3$X
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M1H'.VBS"&*?D$8:$P2D6:&7T&KS*EHZ,6D'GK]*3H/C5G9U$%D@[ SNP0W_
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MQK1]+__(5Q&QX)LS^H^]]3_/4XXUD;J J_SH+^D"Y?D7.PCY\U,+_ 5V<T,
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M^IAHE@:Z$=(TNA2J[_/6R1Q7#AU:CO4 \</G)D%<\)5V*O$VQE =!A"WB8@
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M_/AU$25QDNS^=OX7&M,,*\D!53(!F$((:)&E((T5X:C@ M'LZO$OF10I(ZH
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M^;)K,]VH\(,J2Z565/O!]/AAS/AXHKOYQ%XJWGZW5"/]=0K]#P:0T!Q@B7)
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MDDJRJ#2BN?O .:%M<;0? ,/01S\5?+7(42WS*D%5+?957< TJB0/ *O#W4
M>'NZ+_ %L]M%@B->)R\7;-OJ[\+!4;NM2PC7=[O&1CP]S>KRL-6!U$A!B"OO
M/44H!9@P""@K<OT3@CE/XR253A[.NQT,C9QK^:+2"'@5_5/\YSB&T3.;UWO
M?XGR]"J.8_-/Z]S,EHNOL_GX'TK^2X3P54K(%:(D&M<SQ[A^;;H_L[)RR]5?
M2I6>Y/_\[S"+_P7%5Y'Y?FM/,=T(CND5A<GI1MXI4;41(5B]#EW#-G:&VL[L
MO&0  Z\,S=C=UV-727?5,)C/\(S#^GL+RMAION=0C,/*[0=@''G.:Z:N41XG
M,LZ$T.:AU-9B'%- 28:!,'5K"@J5WG9ZR-$U- [:R#3UW&2:$AZS<UV6EVM
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M%W??IYH$OXZ?/RD]M[0LC^K-RT<-H=Z9:CAU2X_U(R.N).44QD#R. %ZUT@
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M&5'ZL*%R 5B><OVG!"4L29/8K7'$X09CHX%/BSG8S;B8GLNXL(/1E*13&:<
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MRF5R;J.Q631U,N&.L)&1]NQ84C=TNU_PD)CU_*;[PN61>MF-Q079ERT+#YR
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MX>PFCE @]4P6SO@X96N? ^""Y.W6I0?+Y3ZGW&YJ]]EK@Z9VK+8CK[>#8Y#
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MN]7?>.'769?CMN)P]3I>FN[5\?BMX-^9^5?]=:&S:D'^MIHHD10TEAS('$N
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MQ3W5OU7S4,G]QQL,F\[?JN!1 G_[E1>Z#.[5[L>A^C1LK&=8*/UN$PI@6DB
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M<K9>X]E&HXKEK9X7U_S_O$V74G_J7^5R_>-!/[CU]5R8 MI7<\F$2)%G&"F
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M@A%&E1&-&6SPI9<P)3D;SW.LWU9N!<*V[[IW]9*S18<8(@4U.6@HUS^1.>/
MX?X/3# C+6=,Z=H)H?L4--.HIQ(6'C?$VUC>#>QL-]0O);(_.?\Z&>.7L[WO
MP]G 670-?:) '>[0@E(/)CJTO-I$0IFC@L:NP/,408U@:0--/P>:K<7> (8>
M\/!^<NZ&XP$GQ"@F+&[XY;YY$!1\B 1,2#0)[Z*4M4>Z/$E((YC97M$/W:.M
MI=X =.X4F_^:SGV:#D3F(2GFP"95QHH8 IZA9>:*1'3P9":Q]G[UB(B>P[#M
M%?M\2?\&4FX )L_T\;]BQA$G0M9(O9.Y'&&CD#RN)VI\&62D;:Y^:_)%@GJ.
MQ:K#IY[T&X#2P_;]5UQ(9325R$540H!(Y18RD1)DDDEGEYFFM0_"GJ:DW^*1
M^N"I(.\&4//TR<H5+S0EEX*00'A:]+*VX%-):W'&#6&E,WOU@[ 7Z.FW5J0^
M@JK)O@$<W;B#'W%-+*ZC##!2H,&J!-%3#",2]QA&& ]*D4RXHM14OU+YF(I&
M^J%6#*PV$W #$#D<AVD9-OL^+?][.'Z<N#C!M?!A,OW#3>, ';FH!6Z]1DC$
M/2,)/*4)5X!3AI(L!*O=:FU-$AN)P#9$Q.,[0)VIIP'TW6LBQUP@D>8 N0PX
M1I,JRBA0#MGXH 3QRIGJ@Q'7;=W7Y06R[A3]T&IM*O6-$?,U38>3B&MC.F]I
MUHL(BE#& T:C0L%BAI9C3D,.WNOLG5*Q?L)Q9[->NKS*MCNL[E[3S:#\:5ZN
MI5\N)9]>^-DP#MWT\DHVN*9+&_^!X&7BCD@08K8H\C+DBU@.S- 4HL)MIWKO
M\<VI[;TKT\[0O".-MK"S%QDNMYCW%].R6I>+8['U7%_-2+%$;FD\6RA[@+L-
M$LLY1$8Q2J>J##)$\4KJ!;&2.UV]+?0&9/;>$FJWMK=#';8+TT7G]<7/CK\N
M*CT.OJ=I&"*S VD4=5)P2-H0$#8G%*WG0'D*N)5D&GDG\^'6(;+WDOJ^(5I)
M?PT ="_^GXO9O 24L[/),ZGQQ5+T#Y?B24))SX;S=-4Z<BF9DQ0FG\>+IRQ'
M6Y.L.%&X5IUALK3NSN 7;4^\RCFR3)FLW3"D:YYZ;PVP,_@WA8Y>>P\L9A$M
MVXC_X;ZB, +R-TU7RW^Y90ULE$FP,NLVE/E5,@4P*AC0E!.7M!.1/*C_?6;B
MTRLOZKW=0.< K"[N!DSMG6HJ?+SDG'A@@I<\/RX NZA7("HEPC@)H?8-[34+
MU;IL,K S\[6AQ!O RKT4FB3&4&D=4%<F:J=R)EVFG"EKT,E@2N54_=+CNHG+
M+IL(]).X7$?J6Z9T#L:QI;0EY=9HACYK2 O.#4=AH@BS4SXJ+CB2_W;3EITV
M"7AK><MU5%T5Y+NN0-@[_=N'C\>_=S,$Y?;INZDZ>)J9^O4&^V[VY<-H\L=M
MCT,$B%0J>HA&E.D2A(+1*4.TI1T\P<B7U^YP\Q(]%8ISRS,7,T91<N\N?\,P
MYG!\TZ]H+\R'WY8#N:\EX-%_"#1*,(3@HG4^8NR" M&!9V\#=R+7CF?7I[*1
M,^IM$?1$J6^7ZFK [[OCL5K#F2&E;$.94(93$?").) 8+\=@E=>T=K9ZW686
M70&H:ST_'R:L(_0F>B'>R]"4],HX#$?I7DW\V61=86H4%HL:V684I6!"!D<H
M 6Y8Y(QY@CY"ESF[2GST>XJ]8Q#W#H0&K.<JPY8'7C/";3 @HLD@+,$ECGL1
MY.2=]]9RF6I7.:]"5[\6MW_T3#I698_P?#3'_F9V_=V!]@-AC1?9F'(_:A&+
MR7*_. -1%@$5HJ%<O!:JK/:J?@UC,UCK0"\-&,%?W'!<9'@\/G6C=)SO39>_
M,UH^&JFH#KA8-+H[M SS$B0#]Y*G$&@.O/;=M-4HZ_>V3C/@[%"=V_9GKI?A
M?GR_([*4I7&LE/+%XH!GL)XJ2-DYDZ.@5-6>S=;B-9SF8%A!70W8QKO&_OWD
MPL_SQ6@OA,D%RGD@L[%<"P::JM+BT$OP7"B@E@2A='*&UL[LO$1/OY=LF@-@
M-=4U ,/'!P4W4KNZ5'$C,I.X)HD[X%0Z$$P%<,$%(-+1D%1(C'30Q7E%ZOJ]
M"-,<1#M2:Y. O5YZ*/<T_+8H=,LARFA\&7VD?+F.0<%Q52X4!^)##BG(VA[E
M*G2U5G=3!Q.O0F]+!37A(S[FZM,T?77#^/Z*HJO.U7OCN)@+4.:@XVY >18T
M9PG)ESG%-ECPR!K(&#@K32-9]1EEFU':6IG-CJ!978GM#)QYS.R=[OUWEJ((
MFL>$#@NW293K2!1LB J8I<+&[#G?@:U\DK36BF5VA,GMU=2HQ;S.:0W+A4DJ
MN&;4 G49V3%)X9HBZ# SHX7R4H7JW8A>)*BU4I>=86TSE;1LYJ[=C4_N\LK7
MT('K<I!JD#GA8P*O3 )!+$TB&<W,[IS!*Z):*UO9L2>XB6I:C3VF%TC'T/GA
M:!&^#;*V+(5 (*LRN,24BH)$#.@L7<PJ,B*[#Y,?T]5:I<CN$+>-@AH W>J'
M]P.2=')*)[3@IHB.6#!$AG(FR8AFB>=4O11Z9>KZ]>9V? 6B(Z4U,";B&<Z*
M(S%[1I!9V8@\:K"D]!5/5H.CZ+H2KWV(.4A%:M>1KD]E(XV:=G1/L9:Z&K"/
MZ$M<5P4N*[/N'4N6Z>@W)Y/.4F]*7\Z4+7*F! K26P5!!F>83EK5/U99F;HF
M[SE6P\G#(Y1NE-9$X+NZ*$L+ 2E)M*")\Z4].O(FF0,:'*6"<L)][=!D=>J:
MO+/8%2 [4EJ[&_:'X=B-P]."3%$1&W&-,<H*ARR!%8F!%UD2_-):U<$ NC6I
M[->?W/6&74M=#=P]#"G%Q9S9)[M6H.W_W4VGN O<Z63!% 9F) C 3R0(DG%E
M\T2!<9X\\\9*_^ JSO/W$==_?9,[<S5 3':JG;[Q=Y*^+EV/X[R48/I8$@5W
M\P-HW8760D*2C(/ E0S>>0Z.V4@RIUDRLQ+87G]7DUML)\BJ+/=V\L]WE\RO
MP_%D.IQ?+FZH757$#F24,AA-0)G2CP^W!K :71/FO*0\>]5)@X47:6HR%5,;
M=ITHJ(%X=W7Q#1+C-CKT0W(@ 41( IPP&:B0(L3DG68[R@<^05V_)VX[!F%'
M2FL@O#C(.06TZ@??PQ<W_IQ.T+P>CPNSY=\2QG]SH[2X_8-R' 8TON4'Z$C<
M_\:=WQSX0$T*R6(@I]"A$ Z%S#"DB]P$0A)N"*IV:7<';/0+\,X"E+X5WH )
MWHK99?NQQR=55RTS[HIU*>J!D3;2Y"T$5T8QN*C &,_0W?;4"4XY&J7*RV&W
M'/9[&M[92FD8)@UL'-M9#&Z3M-I@I(FQ)P@J(W[&"!!F'76XA:KZT\PZWPPZ
M.WYO$^)K*;&95N7;L2RC,X8@H^CDE3IAE< ;8\%(GV5B#GFN[9)WC]O.^CLV
MBMMUE-A*/[:+KU]'"U&ZT;4H#\=Y,CU?*O-:J,Z5>PW&(R\9HP]'/7@:)"@7
MM*):I^1K#Q==D;1^>T5VAL0N%-. BWS=UJWTY\7@=X A<K#>$F!:<(QJ,P>7
M#4-3[S4)F8G :P_C>D!"SXVHNE#SH]MOF\N\"<C<W'LO' R(1ADD7$L\)UQ5
MZ,."\S0!5S+&++BAMG;B] $)/=\)V@ED-I=Y Y"Y[0-^+:"#I<1FN'^O*C_/
MDE62)[!^T8^W>*'E Y/&.TE5UK'V];0:=/?;"[>S_7#G*NW[1/+J_O-5(Z'C
MO#@7.YHL,FJ#F$D.242@*1$0A#)PG!C(1%$E0S'G#RX(/7,6^=);^N[WM&N%
M3[J0?I,P.OB>PL6B.X9,FC,J<)/P+H+@N#@M15:8E]8P$6UZ.,QR'2#=O*?O
M=D[-06DS#32PM9X,/W]!X_[;+"VJ8(_]<MKTX?@Z\_AA,GWJ)/]R$-',HS]2
MVE4&]$>HH>!L1KZU38IZ1^L?>&],;-\=GGK"ZVZ57 W-=3MUO]L[/3P]_O#I
MY.#TX.AL[^SP^.@^Q:NUY'[J,35Z;[]*7J4FV\?3SVY\9;3V)^/99#2,[JK%
MX:<[Q%]?W!FZT8WS=^OR*9JR8-: U0Y1&&)&Z^8RI*APKPQHX7CM*Z-5"-_6
M3&Y%Q/OA+(PFLXMI.D-EOL/G_G- ,78+4F50I(PA2BA(E)V"&$.B1BE!3.VN
M8[5YZ->?W#V>'UK57C'1J+$].=@O5FQ___BWH[/#HU\^G1P?X:?[RT$"F]C=
M5YY8PP2O0W0E:WR4_K@JDB[C,Z:3,7X:;GR"_<6F/+LII%[\SA 1A/*Z@UWG
M.4M40PR6@<CE()AA^)TYDYD3[8BH7V^W-=G;WXO;F(3;E:8H\X0I"E')Q1DZ
M+2>2'E1BS&5D6XGZ(Q6VI[OO&^J[Q>SCRW4[UGRC-O;]X>FGX].]C\<?WOUV
M>GAT<+J177WB*35LZ6O$5;*?9?N<%"5?I'A5;8T[,,( ?_!U,G.C7Z:3BZ^W
MN"/.<8_Q"FC.*4;ENDQ+UQ0,\3YPS:S/M;LUK$GBUIWH[SWUY@+1TU0\Y7TP
M)JDM 9X53(%0WH#)#(,^X:V,3AEO:D__V);F?NUAEQA\U)Q^E]IMU.X='OT=
M_;'CD\.#C0S>W3^O8>F>):>2B;MI#7^KSALHL<RS+A,E95+EY$4P<%1%R%&@
M0H/GOOI0K!?(V?Y$^-&C[P1%+CE:5HWR& J)9#FXE#U0SBU3QJ84Z[=U>IZ>
MOGM[UL'$X_/A2AIHU'1\/-@[W<QJ7/UE#8/Q%!&5;,4B:WN[TQ@?A'(V A/2
M@K",@,O) +?<.*H9]ZSV+9S[%&QK$3ZFV2REFS8ZRX??(E*89&,V&8BF93-C
M#IP) ;S3HN1PM NU;U>^3%&_5F$+[3\T!!4%W\#AUI*;NR<;=WBQR1 FB(*,
M_AB(DG*S,DO(DE.3:58QU$Z?O$1/OT>JU2%40>B-[B5[^_LGOQV\/_C'IS(R
M]73OZ/WQV=\.3O9_.SE!?_#CX=Z[PX^'9QLZJ:L_O,:.M"$KE3:MJ^Z0)6):
MM.]SHUL !NZU=SP@.JPH/=(0@(E*B"PC?KCS4=3>P5X@9^O[:_?[85Z_X5Z_
MPJ<\+YXD=44*-+H,@F6,&*.3(&T61)8J55O]RMIFI/:[ =9"TJ-+:CO06Z-6
M;O]OAT=[_WY\>'16HMS?3@XVL6:/'U)E6O7+I-4ZH7ER?/EM$RJOB9 F0)34
MES%$"5"Y&:(F22K\4NO:!10O4[2MC;KNF7#]W">32 [W:5N8)J7TD#D-AF@+
MVADE"#=)5,^BKD!6SZ<B]7#RT/S45DFCIN9@[^3H\.B7TX_'IZ>?#DY._[:W
MF;5Y\CDU#,[K!%:R.0=N.D80E:+@1>N2VTW,H]NL=0"G."E3 2Q@V!4A:"(S
M]=)D4[U3PC.T;-U(XL%S;Z$<7/)&1 XZ2=PUI5%@*4:8@7.9K3"4B-JUOL\2
MTZ]-J8*#1PT=J@B^41MR>G:\_Q_O]DX/WN\?_UJBF8WO^3WSI!IV9!4B*YZ/
M+K>*XWQW?.))&I6^6/N3V7RV0($O Q:OV[3>[EJ.!NVD )U=:5%M$1'E,Y:4
M5R)XIV+M\&L[BBN<GJ[V]G=WWWZ[A(CT5"1J("=C0;C P$A'(#B-T(I.A5#;
M0&])<O]GISO"YQ-'J3M3=:/6\O (#=#!V=X_-CU)O?WS.B>ISY!3[23UJOKQ
MB5.S)!(G04I@D480@@CP/&CTGSGJT07!?.VF.R^04ZVV]JE0P4E2[C<9H#E(
M7#2)@)>2 J>4$V^Y4J'VW>V7Z.G[)+4.)IZMM-U6 XV:#ERIOQZ>+2[&[AVA
M'[.X,'MPM+]AOONEQU7)%:U*;B53@QO*^7!^<R=Q<3?G<QJ'>XG"&Z!9C4]0
MN('$,G!$:$[!*NO!1(SI121"L-I7KM8B<.L>.JN\['9Y9)\\E\(@U;D,AT*9
M^)3*Q!3KG7#9:5([I[8>A?V:K.ZP]:AM3G=Z:]2LG1Q\W#L[>/]I[^3L/\].
M]C TVR^QV885"\\\JTZMPBJ$5K)F5R[Q)S>=7YY-'3K*87G'\>8ZMZ6!JW(Z
M3+(L0[PX.",#*)8<45(X8FJ[%*_1M'5![#//?PKXR2D:!(^@@F0@*/'@ L\@
MM2?)&N--M#MBOSEK514[CPI:.U)2H];IEX/C7T[V/OWM<!^=F-.#7XH_<WCT
MX?CDUXW37*\]LH:M6HOL2B;K-'TN^]9)^CJ9+@:ZW, MT!0XS1"8R""\%&!2
M.9.-Q")$(O>\]EI]CI:MF[P]>.Z3YT)$8L@B(IBR'0O')'BA)? D0U#6.*)K
M7QU8@:R>FW/5P,:CQFZ5E=&H"7JB3/W39#0L+N$FYN>EQW545?\TN4U5UU/.
M--'!0"F#6Z86$7\<LN*&9FNCD+7OM3917?]I.IQ,EYV03U(8N=ELF%&?"S+B
M_[F8+4*1]VD6IL/%H)I!E(I+=!$@,2I04!P%Q183P9*4L4Q*)[6KY]>E\4>H
MCE\'CX_G<72HTP;N%K]0C;JP-)?+C[>;@*=H_(.BD'P96V<8;C(<99N403$G
M-([5^^6L2V._=Y#[QVRG.FT LS=E/@_YD,A#\C*#Y[Z,5&06?'8)#*7&)Z6M
MI+43D<_1TF^KIOXQ6$5'#6#M]@CU[B'K<M <"O,0%Q8NLV^I3(*]6ET#1DW4
MOM3E9\T!+3Y%9C6#TDB2)VI]RM5CM/7)['?@2_\([5JSC49 =^I]SQ:WS3<[
M.G_XD,JER$^1MH."9*]MP##9X!YHRQ% F6YO,.#UA*&:/5>L^OV7#@N23\.7
M%"]&Z3C?O&3_8EI6YT*\MS;99$JHC@I<UKB,6+HJ+I!6.:JUI;SZOKDJ;7T?
MK]?!RB/;TX5F&C4XRWKAS6W-O;^O5\#<H85Y4(6(2& Y1(WPT!@1X@8%+N0,
M1 DK1!3>Q-I1?NTR9GQ:N5#V )R4\TA2F2DH)>Z&-.-&B-@'12/+0F='4^WV
M4\^0TE3A\CKZ?EQUNKVH&_":GZJ_ONG&^JN;7Y1ZD <L9NJMM:P,!,L6A"^)
M$^$D:%'<*B5]KGYM8@,RFZIOW@YIW:JH 10^V0OX&=8DS]QJHL!;W%X%?@66
M. <B9D5%9,+94!E]:Y#7;S:A(NJZ4DFCOL_*E>F;NT?KOF*G!?<=.EDO%4N;
MI-%240-$$,2+9P1L4 XR(L<R$D.TM1V3#LON;X.%50JY'RPBF\J('./ :)1"
M&6@"UE,.DCH=J&$FV=IG<=O0VVX!_CJ8>C[<ZUB#C9K!1Z7NFYN[YQ[5245^
MA^;KE7IK%@G)+GM Y?)2(>G A[(+:LN8%LZ3AY-T&JW+7\P:>?K1#T,<+SBG
M0H%U(8)( 8,=JSA0[7"=":],8J^A8^6W-5ULOX[R[\UTJ2[G1NW)4Y7LFYN4
M%Y[65=E]AX;EV:+KI)FESFL@%GUJ85A)(2@"VN:D?<B4I-KQ=5?%][?[Z<,W
MO'.S85CTKAU=S%-\ 'U"A5.,4 B^=+'0I=Z2) LQ2TVX9U&1VO7 &Y+::.'^
M.AAZW@GJ3FF-VJNG*^8WMU@O/J^[$O\.K=:6A=1,24^(,<"X*_WXM0;#60;$
M3I14:D-X[4M)_1;ZWRZFIX^Q3^>X=)9GV;.],!]^>YQ>P>5$G*,"HBA'2Y$&
M7,NB]$KD2G%!E72U@^3MJ7[3Y?[KH/1YZ[D3A3>0O7V*XRN1[OWAIO$NQW]W
MHXLE"F:SB_/E]QYPSUCA&.-W'LMX:8,B<%:A,*PD)-BLE*P=4=7EH-^3A\:@
MOR,@-.I/O%*1M+ECL=J#=U!4U:&K\6SYC--&,.LRN(S(%,FB<ZN)AH0?&8;B
MQH3: 5)GI56W2^;!&^[,Y'QW>?7#V[4150H,I0!"*OQ@E01OLH6DN22"1TUY
M]7*KS4AMM 1K'0R]8.<Z4UI3^_I)^I;&%^D#BO< U_:T3):]F,TGY_BNO?E\
M.O2+<'#R83)-P\_C_9(YGP[3[-WE+VGR>>J^?L&P<9K<'1>'B6PY"^C3)(Q/
M+1IX%XQ '<3@''Y/5^^HWR$[_>[X'6.\7^4WNK$_4>]WM'=R@I_\_>!]FKOA
MJ%:9XJ/'=E2N^#+Y394M,N-5,"9#H)J6?DD6+,L>@O+9.$0W5;7W_T;*%B<A
MI3@K2_']\%N:S8?SA9__[F(V')=K0K-!(%YDC!!!,R% 4,_ E*HV]-VE#$9G
M3FOW%UN!K!^A.'$=U#TN3JRKN0:\@YL+:<L.9!\GL]G !\^8$A&<=!%9B!+0
MOPD@B;12JV!9K+XP'Y/Q(U05;@.V;36S/KCL$ESC]+FD&,ZJ86S?S;Z4?P_^
MZV+XS8V*A$YP[4R'H60R\ <HT_O?N/.; _0PK*0Y X\Y@#!9@>7"@B:.21VI
MS;SV=>ZM"/X1*A&WP>WNM-V ^3Q*\\(!;@S?ANA7O;O\;9;BX?AF[5ZEAM&/
M'NB@(M'6@):LS#"2$AP)%*RUP46FM':UJQ17I^Y'*$[<!K0=Z;&V#>YZ(O06
M,<_S#^MF/G27\<VZ(WJ93)X;4PK2 D;"SE-PR?A2G\8UHT%K6ONL8\=CHI<^
MR,VB>^=&Y5KYZ9>4YN5.98S#\GXWNCVVF+V[7&OZ\"(#/= N&N>YP,6ER%5N
M3= $,G@3/2>>IOIC6W?"6O\GJ5TA^NE>QFUAI0%7X;GF@^\N[_YD[_MP-G!)
M*T]C!A*BN2I[)RY#9I%(GV@RL?:QP.K4]5TAW""X5FPSN:6F&\/P^\FY&XX'
MP=*0G?2@F"_].&4$ZY"-)#/Z8CHG(VMGJAY3T6;/TFWU_0*L-A!^C_!97)8^
MO3P_3_/IY>G%]'-Q[G 9_OG7=.[3=. ,%Y)R#LZ54>&AE%R0)$&GF'.D7DA!
M7O,_7WE'.PC91'63^G)LS)K<63?+A6)1(H(EB"[8<FM$@..&@W?<N<QI4-5[
M&KY 3K^YR#>\YZVMRW9A>;5NF6.9<:9!+::>$1O0,\YHP8FQEBH2'-E1\^Z&
MM[[UU;X:G#;00=_;WL$HA?ET<FVMKY;E;=5CFLTFY9Q]WUW@&X>+;Q_/OZ3I
MI^DD7H3Y[/3BZ]?1Y=[G:5JL_BM3+[2T,5L%4BU,/2F'[X(#C3'*H"R+3J^T
M979#7Y.HW 0]D[94V8!Y['XW^C@<IT-\^FQ &3$^" \AJP B$PG.E'G<BE$K
MJ'?4UC[[V2%[_9X4O06OHE6L-; ,5[F+0&(FT5(&@8I2>JH-E#YI0# 0$%*+
MC/OQ_]]ND30+J0WNFJRCW[[]H#VD>/[I8AJ^N%FZV0+/TO1\H&@)3E. ()PO
M;8XR.$$BQ" 2(XE[&L-*OLSS[_C1 [CM,%=300V8QGN2>UEP5[=B!TXJX84U
MP()&J=E,P3&/O$9O13)9D(<9J!HG>&M2^:/["W4,9\?:?UOX7M2)'>=?)I,X
M.YV,XL!8SJ(-!)*PI<E7U&#+] 3/K/()E[.,'53N;DINO]=2?D#$;X6'MP7]
MF[L[!]]+]60:Q"2B(C0 LY:!,*)T^0T.. M))V9,?6]X"W)7@K[\'^CO!@]O
M%/IWK@X3DZ1A)(#290X$*:U$E,U@!3>X^1$:^_1P-KW_K?YG >P,%6U?9KPS
MS&"+6XQ//*7RI(4N[RV^U#Z?^\RS5QQ28FEYL=I%[B 2[TU.QD=6N_U(AZ,6
M;AY]XO[XU95LNQO-!BG2G)S5H%UIWV99 "\-A:!99$+&8&GNBL>[A/2=X:J#
M@F='#&TL\P9VT1LF?I],_WDX7F39T X&+1SARH)R%DTP3^@&L\7(7Y:$YD+9
M6'LB]=.4])VHZA@ZFTN])>Q\&(Z'LR\I+L*H@934$(6!4W#E3E<99N\2C1 ,
MX\YH2BRM'5<\34G?^:&.L;.YU%O"#CIJB'QC0G3)9=#,E+L1)>Q.7(!/QN9H
MN/6L=HGE?0KZSJQTC)7UI;PY1B9S-ZJ+D9NN2B>HENFW156Q3J5E6!G]4.82
M$0?62 Y,ZL"XBBZ+VK>.GJ>F[]1$Q]C93OK;1DEUD724Y@,1B:$Q.B!%,KBI
MEJ)A-)>!>1N3MUJGVC>T[[Z_[SB^8[2L*^%J=J:+J6%';EI2!-_2%B'T,T^J
M-TGL92*[F2E&#:>".@U11HQRC!/@A"E-[%@BAJ1 :.WKR+5GBCT>/W22QND/
M-UH<\085N(R(WAA2Z6R%)@Z#.@O)44J2RHZQ^@R^2%)3,\;6T?\JDY\V%7T#
MGNS3[)2;E==?+;CRS%*)]G#9[%X80\'RJ(#':+.E+!!6VV-9C;*F)HK5Q]56
MBF@&7G?G5A4N2A/4\4)D=% D9E7VD%-I@I(- :N5@"!8MHX+%WW],8BO$-74
MP+#M055+_(VV?5OZ$3?<S=RB#GHQ*>@$??#9UM[/ZX^NYPZMR48W_E&REF3!
M X32"D,X[<&6]A@VLD@9#Y+'VCFP.O[1XNK;?1NZN"-QRQF1GAH;@*L2)&3D
MS$@?@ 9<6(P()Y)[#12OO:0I5V<=5=Z[0%A+B@UL0O=9^3T-/W_!T'SO&W[W
M\Q-[+!K%8)V*94HL+Z<@))1,4S"@?0[.<"63KWU^L"Z-_8"L+C*>:Y'6A9I:
MA^%=4_\I30,J84 8;OU9$MST4P!!T>&SB98:<Z-(QI^EZCVFUJ6Q'_>[/QAN
MJZ:^[^W?=07OBXQSYJWW9:"%4R"\E>"4P3@C>AMCD(K8U7;&9U_15*BV\;Y8
M1X(-F*.[C*Q@;(ERQ(HBJRC+92:JBME5$#BSQ!8&3>V4TGH4]K@C5L+$"].>
M*RNH;?@]9619J5F),8'TI:Q6A0A6$0[)D!A9\CJ:VD>LZU'8XTZX<_AMJZ"F
M$PE7\]2':3;)]R:M#RND$E9Y>+UDPMJL=)-."%%%]+H,Q%P*&RWZZ2[B!R:)
M2_A9%KEVW7?=XY;[+N$=(5Y/:GI_<7L.R3AB7W&Z2-"!T.A9>)_0L\!0Q68N
M$DVA4Z_]9?J:RDZL@XR7_?2*2FE@<WSJ,.":P\MK_I9. .JK--*=X?+_S^2F
M \=\\B@X8+P,/)?<@:<E/,Y1<REHC&87)S6K4=OS"(+.$+3"V4X'ZGPKP$6Q
M'N%.<_9'&GU+OT[&\R^S@:2$6^D<<%O:"P4AP>C$P&1GC,LFQ[B+$^M5:.UY
ME$%3H-U6E6\(LF4YGOTQ&<B08B8F@@IE@!/#[<I$2H'PX$)*5G)3N_1J31)[
MGEG0&D W4=Q;PR4"+0TH-X8+3L"+C,*4#(491(; B#"RC!"UM6/DM8GL>31!
MD]A<6WEO#)T?)A?3 5,I:RD\6)TH[@HQ@75<(W]6:\:\I[%^$+@>C?W>A&X2
MFVNKKN\#CA>9.YN\2Y_<,!9)9GSA#8=..:\\+CZFLBG-+1T8&1E8:90R3#FC
M'_31>.;P8Z/7]WNGNG/<[4@O;\@H#M 1EM$H7%&D#),/B8!C68,2PDN)8I2N
MKYUZ)3#J-PO&3E750-71BWS]-HY7F?L4#[Z7HLV]\_+5(&CGN>(.E#1E$ATO
MM1,I@7>><>>CT$3N$H_/$;H2.,V/#<XJ2FRBKND9!@?*:$(8^AO96!2=-0*,
MIQR"4B$K0HTUM5W%9TA9"6_VS>.MAB(:L'W/L+%_,2W2'H08DRS.!#%,HB4O
M4Y $=: M#YY[]')5[7X2+U.T6O:;_*CPVD0O+=NMH\DX7+%$B2RW+B0DYFPY
MUQ*E$0\O/H0G2GEF>>V^?*\2M1K:WOYA2UWM;&S6OJ6IGW1P5^85R5D;L^*,
M0K"XA$0P&?=_YB!P'ZRE,H;J5_=7IZZI&X#;G#UWI) &0MBG.'OEB)*5HK.,
MBP@-M0 A!,?E1 @L[J-%EE-(M4^<UZ>RWY/FKO"R BPK*J]U>#YU&&E4YBQI
MY \YQ: H9S",:2#(*?'&6F/T+L'9W'ER"]#<5G%O )C7AY F*47* J/44A#2
M)3#E9@>C42LCRRV/VJ5%*Y+6[ZEQ(S#<1$UO!7V+8T9'J)5:4^"&<!2>1L86
M=S5\SL$%4FX8]8&__L^&6T+@VJIZ(QA<'.I@!!<4LP%,+!GU6*:F1H[.!R&&
M>1^"E;6G@J]*6[\GP TA<&U%]7WN^R13SYXK>J^B<!CV:2DM""XC& SZ49J9
M$1I(U/S5"_WKO[;?<]Z.T=6Q%MZ @1N80 75 LTT"2@V$1VXQ!CP8!.&4XJ3
M7+N5R6LT]7N:VXA!6TLQ#9QC/,G/L\=^2D:O$PW@T5\ X:0 CY($FXG/FC#)
MU4ZVTS;/;/N$8!65U>[37QF6 ZVT-8&[TD H89SN(R _&;3.O*PKSW+M?I1/
M$M+O46V?,%M+!:V:MYO#0,L->@4:O*&EBEER\$)'H$P+;32::KL3.+5Q1-LG
MK#;12!/'LT]R<_?X#\VKTZ+T=V6F%$67*2E&@J(F2R,--][O F+-',WVB;(-
M]5+Q6+:G&O+!@QJHRE7D [K;.O*'[-Q4DO^\H2#W]O=/?CMX?_"/3P='2,+>
MT?OCL[\=G.S_=G)R<'3V\7#OW>''P[/MY@.M_8X:(MV.L4H5^KBV[XRZGUZX
MT>W!N,@DZ) DKFS-03#*P5E',3:7/#,F4WC8(V]K^_@".=ON!HOGI7CJ1FZ*
M<+W>U9+0R1J*GI+3)<&O K@@+%CF6&+1EUK%RDP^34F_!].U</#0UE>0>A,W
M;Z[X>#<97\QNV1"$F=)L%R15R$;"T,T9;< ZJ5,TSI-0^_K^DX3T>W+<,7:V
MD'D#R<+;!8 L3,[/A[-9&=AZQ8P/+D?C'4@9"3*C.)@H2VJ*QAR8-XS5CG)>
M)*C?L]_NC="V.F@ 4)^FDW@1YK^7<0GC^>65H/9'#IG*PQ2OV6)H0Q5'"=$2
MLXF<,7 +QH%)A)N0G?"Y=ON9%4GK]WBW*Y!UH9<&X':U=@['LXMIB=JNV2"*
M2>=,@,QYZ1=N,QC.%?)2YIIZ*S2K[1P^0TJ_9[4=VZRMY-X.?'!QY+2PNF[T
M(=UNYLX'I#L;R#Z54B7'R[!F= NI250H@S^L;:1>IJC?H]F.P51#"WV?[__[
M9#@NLYI/4VE!.$*)X=-'=TJ52-*J-'_F'"VKL): )82"D\I8JVB(_$'_H&=.
M]%]Y4;\'JK6!4EVT?</D],MD.B_]4*\G7-S)5 V\<9PQ9R QA8P8'\$03T%[
MYH@WAEL:5\+(2V_I][BS$X!4$VK?Z/@--]3IW W'9^[[I\EL>#6Y_1KH(F7\
MQRYFZV!$X+4#I[P"QPQ-4AKIV&KX>/D]_9Y4=H*0BH)MP'E9!(PHGX/O83A+
MA:6ES*[W36N8ULDF8!8E)#AZ\<[C"LA4:.T(R^BI5?9>7B&IYV/*KOR7FHKH
MV_8<S[^DZ95#=O#]:QK/%JS=,:4W7*'(')<.&!49A"A)+FTX9":X-=2PX,A*
M9FCE5_9\_MB)2>I&WGVCZ(JA.UP@3PM6GV#,2ZJ2T1(8TZ5\GV=D+#CP.<7H
ME/7>A)6 M,Y;5\/2FTE*=ROU1L?'KGQ$66/"[.8OV^EI[$[FU+Z$7I6E)R9P
MH*D,%@V)@D^E:-DHGF76ULGJB=WZQ[(K19SXZX8JQ4!Q7SK(%E>QI+TLRJ#8
M9T8>SAKI,)CO9=M;1]EK!?/KB+;B;:ZZ]FG_;X='>_]^?'AT]G=<I+_A2JU@
MAUY_: U[LR;IE>Q*N6558G>$PG#\^7",WDB:S6_0IGW*2@8&#./UD@@L'9L]
M;EXD,IIMC$K4;E?R,D7;1G"_#L>3*<+]^KEG9:$-N+3:4I8!&2Q'R)Z#7:34
ME4@A",-%K'WQ[TE"^C4[%;'P,%[;7NP-1/\G:52,UR<WG5^>3=UXAE(IZ8QW
MEW=_LO=].!MD+B@5-)>.:P0C!XL&FCN,')0D3$N=ZL_$6IVZ?E%6 0J3G>BE
M,<2]GY0N'0.J*%>22Z LX-H3*H+7VD$BTA*EM<5=JT-D+:GH%T%=Z?L%6&T@
M_ ;@LS^9?IV@#Y$6OM_?4;07T_1K.O=I.C!:D1Q+.EZ7 6!6)'#HIH'T4BBN
M3#:Z]DVU%\AI!U";:'K2C=A[1-!L.A\<_S'&YWP9?EVL)*MBRD90R!ZC#0P/
MRDA=$4"ZQ WQ*A"S4@DK/OD.5O"K6YP\>FF_MQCK;53;2;,5&%RMC.B,)Q39
M-N5BG!"9@//$@Z*(7^$H%W*EIEZK J'/'6=+Q3VE_@VDV'=J>?_+<(SR/KWX
M^G4T3-,K2T8"HV@'%7 1T)(Y&A?I4O")<!XT"S&O=B;ZY.,;T/<FFII4%5L#
M+L1#(_@1>3J<IW-TK6C2(N'^9:-&1LI 64<<A<B2E);[&%)M1_198OJ]I5P_
MHJDC]0;A<[.XKH;#NL_IW>7]O,/R5P:1<.6R*)<9;0;AN09#F"I\)\Z59Z)Z
M>[Z-B6TKH-X0+*] L!O-];VU/9WR.DG_=3%$2O;=U^'<C1:7FX;^HBATX(1@
MEFH/DB;<#GQP8 EE*%V/G(K O7(K;7MKO[HM;W@[E.U ^(V.DGZ4YC]!]O-D
M^H>;QDF^&S'6/+%X]26=G&"LQ]IN3C1(]CEK)2!YZD$03\!RC//16!D3G&8L
MU"ZPZN-$(U)I;;(4>."X/K)08!QA$- 4,\,)JW^/_NV=:*R#A=5.--81>P/N
MV1J95"X(C2HYR);$9=SB.%KBA(ZLS"XRF6L/ GK;)QIK06'S$XUU]-(8XJX"
M;).9%:6/)'H-!H0E%FP(O$R5X280D9RJ[>F_X1.-M?3]^HG&.L)O #XOI=9M
MHBR6IJ1>R'@5=Y22E"2R9<HDR4/M:0-OZ41C+4VO<:*QCM@;0-#S<8P7BOE@
M!0AF$JZLA!&-(AF<(52Q9%WPM8>+;9?0VO')QS8;6AVIMP"?R;=4>E\=CA^R
M5(*=#\M@9\"#8MHX";@NRNDA+6M-"S"2:)XH&O!8^]K42H2UY2=M"(*'T*JN
MD19@]H"506)6<<X=;O8H'*$4 :\H YV$(!+7(>5=IT-[!D]]-;]BH]:2^<:8
M^9JFPTD\G>-.704Y3X>\A^,P+>W9/J!<3R_\;!B';GIY\%\7A=_9[*(T%!A0
M28E+S$.(%L/AD!W8G"A8E%X,V9J8:U]:VYS:GG?(SM&X(STVT4OK*!7&)N?I
MXV0VVYLO\[W%YSB;/"V&0;*"428)<%=8Y,* (8*!"X&0+'@ROOJ]Y'6)[/E0
MLGN$=JJU)H#Y:$L(PF7NDH),E%FVO+7*&"!2.>=Y]DK7SH)MM UWUBRIAVUX
M'9EON0T?C+LK33G8.SDZ//KE]./QZ>FG@Y/3O^V='&QQQ//2XVH<YJQ,;J5C
MFP,W':.MF'U*T],O",6;)'UT)EB3!3#G,>QT1(.AJ'ZOD]59$!)$[27W'"U;
MMP\(7U*\&*7CO#>>X]8]NBCE/:<I7/70/?@>1A<HRK*[[T_.OUXL]7:<'Q*T
M#,@9I\I1PX"%*%$R68$O]1D&(W'-&$M&UHX)ZG+0;T11!7&/&A/TI^(&PM8M
M>7YW^?0#%HGO9)4.+AIP-I>K_#&B%'@&+2PUG/$D8VT[T"$[_4*_3Y0^[$36
M"&2:73U'[CQ=I?!=<E:7<=2*<>3'H?_L2ULE] J8(,BJ?WCEMJ,E<$M3OSAN
M!CPK@7I#33: S /T2">7*9W.)^&?QU^+-*_K63CE69?&DT(I$%2G,KJ(@G2:
MJ"2L#]7[%3]+3(M8W%3GDRX4T "2MERQMT<&*5/D.GD@R9=;ILR"X[A:593"
M"*N\#K6OG]>BO=_4Y8^S]V\&A@86P4-&3E*8C,-P-%R"X#H.<3E;JTD$:469
MB4!P:1N'_&43.,U<J%"[F]QJE+5H:+M&S4.#7%^%#0#S?DKWFQN.EOG<TB-_
M,EYL/E\F(U3O[)V;#<- 1>-QZS(@=7: CI% ]G("386F46H=>.V8;$T2VTHQ
MU$#)BUGXNBI[4XA\7TQ"B@.GN,/%JR#+4J&9-#+H(@=G#(O$E@Z0M:WFVD3V
MZP$TA<I-U-8 +M\_#AJOY>:ML(S*#,DL2E-$ "<D _2&"!,Z)$MJ _!Y:OI%
M6A-;=255-0"ZW]/P\Q=<+'NE@]OG='11(L#CO)#5[/AB/IN[<40!+BU]E%8R
MBT*RIDQDI-R#<5$@KR0H*JR6O'93J[4(['=KKH6*R:Y4U"[^KDSX(QX'V1,3
M52K3.IW 59LBVG1K@"@OC4N2<EM[[/V:)/9K'G>+P2IJ:@"%C[*X92G="BY0
M96C.$+R4*#BNP'B;0)7V#5Q2%V7MFT$O$M3O+: F-N!Z"FL5?0-K0W9:*!"D
M+"&-R]4JEB!H;7Q(.>CJ?3*?)*2M<'<+1:\"H;6DWB!TKD,?'X/)QBJ(&.N
MB+Y,6XH.C-'."D>XS+6WR6=(:2LN[0X^FTB^70#=UC,;SZ7@!)3 R%E(+<&6
MV-TRXJ,T-!G9=<+X 4G]7E9L<O?;1FD-8'!+F>Z=3R[&\P%-P7,G-&@;3&FC
MYL QFX%DSA+CD3-9N]:N"N%M[:];0:GN6=P&>FVT0<OIV?'^?[S;.SUXOW_\
M:YG]L'=V>'Q4HX_\BD^N<7MW$R8J7>1]/YR%T61V,4W'N4 FC6<+^J]*DO<G
ML_EL 1GO9J5"^;)<)[\SWX#PJ!3"E^12=$65*K>]&41$MO0AE&QP]>SI-A1O
M;5!'B]^Y"LS?E5?<)>)J0M$@1ZUDHAZLL.C^1(GN#Q($$1>UX)0)ZJM??UR)
MLK[3>#M#VR.+65]Q?;=#6QS,E#JR%-_C#C#^_&E9G;A(&2U^>/J'^SJ[JC<;
MHQ O%O(\22&A68F#B.ZSSQ;E:6R9"(H1F8]> 7KHZ&%3%U2TKYG)*I3TG=C;
M.2IWK[\W M:!\\1J3A0&CA@]"I(X&$LH2)(DU9YP:E;KV+?B"_O-^#4.O;6T
M\:8\Q-.+\W,WO9SD.W<T9]6]Q1??TIWGN#IS;7B1-$N>N68@C2E78[,!H\O\
M3\*2E<1SYLP/Y44^[8/LH;\__KPHV'QW>?LK5R_?*[6:5[J\<QYTMY#3L:24
MQ:U 6H_."PD)O$L9@G!,:)^H";EVB5DGG+QI+W4=-#\J2.L?& UDK2I*87F<
M.DA<DZLD-*<@6-;@J0T@4N;&&Q^H;GAE+)GHN0BM 61VMU@V@$DS/62V%<,O
M^(OSV>%XZ0+^,IW,9@/B"$5OD@-JIX3!UH.7+H"EW%)IC7?5)Z)UP$;/I1L_
MWHK9%BHM["VO1CY7O!Y\3],RKCX.)"Y^PD4$+1@!84HKO< )A!P(]\Z67E.U
M%\/:5/8;Q[:(]6X5O>U0W;-FO"44=D[#TB.TC# ^^/YU.%T\X6:=#W(*,0M>
MYB:I,AQ%.G!.2K!")J>#"E167P!=,]7O67>+ZZ4I&/TXR^NQERE58IQP"ZJT
M]17.2'!9"Z J^2@(M:)Z<_9^@A'Y/\MG1S"IVDFKB;7RX%KT]2;]:3H,Z>1V
M4LE .^9(C(NK^"@EJS/X:!+@CIT]=2SF4'LRZNZY?-/G8XWDP[H 5 OQS&XD
M-$@F:^>*,^S*%=X8(Z"15"!SU-G&H*BOW3ID1ZS],'FU3A#>SX)<"VYO)Q,W
M6RN_\K* M+!9TP@^A #"6PE^,35=>NNUD5*QG6>TZ['WPV3NFEB3/<'N+>R.
MKXGFFOO5I&.RH%)C<)L9!K="I00F*P*$,)T2D\I6[\F^6PY_F"SCFUB7W8'O
M+2S-;?--+PJ+$<U5&7QD,\.@Q-H +C)5:D1B2$8RR5H+&[=B^(=)=S:Q<)N!
MY@^PCE>."#BU03J)]BRAYT&8 Q-8!AY$IL$Z:D7M(J26 M"WD$M]"VNS"[@U
M/,?@Z0NB']QP^G<WNDA[L]G%>4>77U]Z27=W7U=FK8VKKXYS+JWB()4ITW^,
M+I,9&<0H30@N4BUKC\'L^>KK34/3IU?R\GQ^[V+^93(=_G>*OZ&.IG>.ZS^-
M7)FT>M^VE+5_-?8P&DUL0B?825+JSC,X2PU838S041 ?:Q=5=\O1F[X*NPZZ
MGY_-T#M0>O2R9M/Y8$'UHLLY"5I$Y4K+ V] L.3!.6%!2LVURLHXL5+O"7SJ
M'63C5[>HOO?"5N8>](^ R;;J: %#5TW(L[&B],4'%D69*%SN8<C(0/*0+(N$
M$+728()54-1GK_<ME/50W1M(KF>%_SH<#\\OSJ\(#YQE%HB$THD,L6[0XPXR
M@<A)9RE\9JM=87Q%Y?=>VK/2-U'9I(;\^E:\^WZ'<!N<LZ5L+V=*06A&<0=F
M&A=!1IX2E4*&&HJ_^])^#F^J*7YC^36;C%EIHWR\37Z\Z:@3A,S">@_,*0V"
M4@N>EZ&0VB(7GF1G:Q?H=<-)*\,<FG%H&@).L\NGFY/4P!PO%QE 4T*+?<I@
M+'.0K?8QFZ0U:>ZLL/(!_HXOU>P6S3T>TJ\#K28F]VZ<U'TJVW<RG/WSPS2E
MFU&W;IX&//D8$SIP3KA8>@<R,%QSL(P&R;AD#=VY7I6I%B_)M+W&=@JCM["?
MK2.0TB(IH,EY/_PVC&D<%P()-' J/($HM<)P2!?_V&B@/F>I \F&U,Y?=\Y4
MBY=<?IQUM36,?M1U]??)"!\S&LXO%R)Q3-+,(P%TWM'4Z(5(4H*L)6.6>T5#
M[?&A.V"KQ7LH/][:V@)*K:PN_[I(_#HB.4O3<SHPQLN$O .SAH,(.H(+CH'W
MV03C#4&ON8M%U0DW+=X;Z7\M]0^<1ANA'1[M'_]Z<+;WCX/3+>YZ//&4&I<Y
M7B.NTFV-Y9BS,_?]]F#[YK Z,T-T-A:2*[Z]8Z61A1'@DN;"$D()KWW![ 5R
MMC6B-X^^ZFSZ+HU3'LX'S%LN(J<0%W/BO!10!C, M[BP# );NMH77Y\AI=\4
M42TD/+1!->3>P!Y\D#-:O^&W=,-/\23V)^/Y<'PQ''\^_IJN[K0.LHK4$N.
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M$>_<\EH"25SF&!*(,N@P!ZM-[9/J1\L/5TA6%PN'2K8!4&P5BBKJ9,Q*$(#
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M4$L! A0#%     @ B'IJ5;5D[9S_!   _18  !D              ( !&1$
M &$R,#(R<3,Q,"UQ97AH:6)I=#,R,2YH=&U02P$"% ,4    " "(>FI5>-$@
M7?0$  "(%@  &0              @ %/%@  83(P,C)Q,S$P+7%E>&AI8FET
M,S(R+FAT;5!+ 0(4 Q0    ( (AZ:E6)O2+6%VT! &69$@ 1
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G+3(P,C(P.3,P7W!R92YX;6Q02P4&      L "P#H @  @<X#

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
